<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://safernicotine.wiki/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Richardpruen</id>
	<title>Safer nicotine wiki - User contributions [en-gb]</title>
	<link rel="self" type="application/atom+xml" href="https://safernicotine.wiki/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=Richardpruen"/>
	<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php/Special:Contributions/Richardpruen"/>
	<updated>2026-04-18T22:13:59Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.44.0</generator>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85248</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85248"/>
		<updated>2026-03-29T12:25:38Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.&lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
T create a new page, simply type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, please see the link at the bottom of each page for it&#039;s licence.   &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum, but it might be slow or unavailable for a time due to database optimisations.  Thank you for your understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85240</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85240"/>
		<updated>2026-03-23T11:47:58Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.&lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
T create a new page, simply type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, please see the link at the bottom of each page for it&#039;s licence.   &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum, but it might be slow or unavailable for a time due to database optimisations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=MediaWiki:Titleblacklist&amp;diff=85233</id>
		<title>MediaWiki:Titleblacklist</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=MediaWiki:Titleblacklist&amp;diff=85233"/>
		<updated>2026-03-07T19:30:59Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: add rule to prevent urls in usernames&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;br /&gt;
# This is a disallowed titles list. Titles and usernames that match a regular expression here cannot be created.&lt;br /&gt;
# Use &amp;quot;#&amp;quot; for comments.&lt;br /&gt;
# This is case-insensitive by default&lt;br /&gt;
&lt;br /&gt;
# Examples:&lt;br /&gt;
# Foo &amp;lt;autoconfirmed|noedit|errmsg=blacklisted-testpage&amp;gt; # This page name is not allowed&lt;br /&gt;
# [Bb]ar # No one should create article about it&lt;br /&gt;
# .*pandora.* # This word is not allowed in any part of a page name&lt;br /&gt;
.*porn.*&lt;br /&gt;
.*nude.*&lt;br /&gt;
.*\.+.*&lt;br /&gt;
&lt;br /&gt;
# Each entry may also contain optional attributes, enclosed in &amp;lt;&amp;gt; and separated with |.&lt;br /&gt;
&lt;br /&gt;
# autoconfirmed - also allows autoconfirmed users to perform such actions&lt;br /&gt;
# casesensitive - do not ignore case when checking title for being put on the block list&lt;br /&gt;
# noedit - also forbid editing the page (if it already exists)&lt;br /&gt;
# moveonly - forbid moves but allow ordinary creation (rev:35163)&lt;br /&gt;
# newaccountonly - forbid creation of matching usernames, but allow page creation (rev:38977)&lt;br /&gt;
# reupload - allow reuploads of existing blocked files (rev:33656)&lt;br /&gt;
# errmsg - the name of the message that should be displayed instead of standard&lt;br /&gt;
# If the AntiSpoof extension is installed, you can also use the ‎&amp;lt;antispoof&amp;gt; attribute.&lt;br /&gt;
&lt;br /&gt;
# What is referred to here as regular expressions are not proper regular expressions, but rather subpatterns that are inserted into a hard-coded regular expression. i.e. the subpattern Foo from above would create a # regular expression like /^Foo$/usi.&lt;br /&gt;
&lt;br /&gt;
# Underscores (&amp;quot;_&amp;quot;) in regular expressions will be converted to spaces by the extension, because titles are matched against its text form (&amp;quot;Page title&amp;quot; instead of &amp;quot;Page_title&amp;quot;).&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85218</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85218"/>
		<updated>2026-02-08T16:19:25Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.&lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
T create a new page, simply type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, please see the link at the bottom of each page for it&#039;s licence.   &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85205</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=85205"/>
		<updated>2026-01-26T13:08:54Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: test&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.&lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
T create a new page, simply type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, please see the link at the bottom of each page for it&#039;s licence.   &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84768</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84768"/>
		<updated>2025-12-08T13:51:25Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
T create a new page, simply type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, please see the link at the bottom of each page for it&#039;s licence.   &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Environmental_Impact_of_Vaping_Devices:_A_Global_Approach_to_Sustainability&amp;diff=84745</id>
		<title>Environmental Impact of Vaping Devices: A Global Approach to Sustainability</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Environmental_Impact_of_Vaping_Devices:_A_Global_Approach_to_Sustainability&amp;diff=84745"/>
		<updated>2025-10-23T09:36:45Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Added categories&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[File:Portada.png|thumb|Environmental Impact of Vaping Devices: A Global Approach to Sustainability.]]&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;Abstract&#039;&#039;&#039; ===&lt;br /&gt;
This document investigates the environmental impact of vaping devices, focusing on the waste they generate, such as plastics, lithium batteries, and electronic components, and their inadequate management. It analyses the adverse effects of this waste on the environment and public health, and presents recycling approaches with examples from different parts of the world. Additionally, it addresses environmental ethics and individual responsibility in waste management, emphasising bioethics and harm reduction related to smoking. The composition and hazardousness of the waste are examined, promoting a circular economy and environmental education to transform attitudes towards recycling. An international survey reveals the environmental risk perception among users and the demand for recycling policies. While limitations in the research are acknowledged, opportunities for innovation and sustainable development in the management of this waste are highlighted. &lt;br /&gt;
 &lt;br /&gt;
Van Isseldyk, Aylen and Teme, Juan Facundo, &#039;&#039;&#039;Environmental Impact of Vaping Devices:&#039;&#039;&#039; A Global Approach to Sustainability. (May 14, 2025). Available at SSRN: https://ssrn.com/abstract=5287029 &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;Note:&#039;&#039;&#039; Downloadable document is in Spanish.&lt;br /&gt;
&lt;br /&gt;
== &#039;&#039;&#039;Declaration of Interest&#039;&#039;&#039; ==&lt;br /&gt;
Aylen Van Isseldyk received the Scholarship for Tobacco Harm Reduction from Knowledge-Action-Change (KAC), a UK-based public health organization focused on promoting tobacco harm reduction. Juan Facundo Teme has contributed as an author of this document on an ad honorem basis, meaning that his participation has been made without receiving any monetary compensation or establishing contractual links with the scholarships from KAC (Knowledge Action Change), which are managed through the THRSP (Tobacco Harm Reduction Scholarship Programme). His collaboration with the project &amp;quot;Circular Vape Recycle&amp;quot; stems from his altruism and strong commitment to reducing harm caused by smoking and protecting the environment.&lt;br /&gt;
[[Category:Paper]]&lt;br /&gt;
[[Category:Vaping devices]]&lt;br /&gt;
[[Category:Environmental impact]]&lt;br /&gt;
[[Category:Sustainability]]&lt;br /&gt;
[[Category:Recycling]]&lt;br /&gt;
[[Category:Circular economy]]&lt;br /&gt;
[[Category:Pollution]]&lt;br /&gt;
[[Category:Waste management]]&lt;br /&gt;
[[Category:Environmental policies]]&lt;br /&gt;
[[Category:Environmental bioethics]]&lt;br /&gt;
[[Category:Environmental education]]&lt;br /&gt;
[[Category:Vaping waste]]&lt;br /&gt;
[[Category:Public health]]&lt;br /&gt;
[[Category:Environmental legislation]]&lt;br /&gt;
[[Category:Circular Vape Recycle]]&lt;br /&gt;
[[Category:Studies, Surveys, and Papers]]&lt;br /&gt;
[[Category:Scientist]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Circular_Vape_Recycle&amp;diff=84740</id>
		<title>Circular Vape Recycle</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Circular_Vape_Recycle&amp;diff=84740"/>
		<updated>2025-10-23T09:33:04Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Added some categories&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[File:8f6eeb02-55b8-4277-a3ac-8e18a9bf6df6.jpg|thumb|258x258px]]&lt;br /&gt;
Circular Vape Recycle is a project founded by Aylen Van Isseldyk and Juan Facundo Teme that conducts exhaustive, global research on the environmental impact of vaping devices. Given their growing popularity and the attention of millions of users, it is essential to critically evaluate how these devices affect the environment. This analysis incorporates bioethics, harm reduction in tobacco use, and environmental education, and includes a survey on engagement and perceptions of environmental recycling.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The relevance of the initiative lies in addressing the environmental consequences of the use and disposal of vape devices. As they expand globally, it is crucial to investigate not only the waste and pollution associated with their production and disposal but also to identify sustainable practices that mitigate these effects.&lt;br /&gt;
&lt;br /&gt;
This study is based on the premise that environmental harm reduction and tobacco harm reduction are interrelated objectives that require a systematic and collaborative approach. Circular Vape Recycle aims to offer a critical and detailed analysis of the environmental impacts of vaping devices and to contribute to the formulation of informed policies for environmental education, regulation, and management of these products.&lt;br /&gt;
&lt;br /&gt;
The research will cover the lifespan of the devices, their components, their end-of-life disposal, and the cumulative effects of pollution. It will also explore sustainable alternatives for production and recycling, promoting a more responsible future. Circular Vape Recycle seeks to be a reference in solutions that foster sustainability and environmental stewardship, promoting community and user engagement toward more conscious consumption practices. Through collaborations and dissemination of findings, the project aims to generate positive impact and facilitate a cultural shift in waste management and consumer devices.&lt;br /&gt;
&lt;br /&gt;
The result of sustained effort and institutional dedication, the Circular Vape Recycle project has generated a worldwide-scoped investigation, developed over one year, that establishes a close link between harm reduction associated with tobacco use and harm reduction for the environment. This work argues that the circular economy and sustainability are essential conditions for the proper management and recycling of vaping devices, as well as for the adoption of appropriate waste disposal practices.&lt;br /&gt;
&lt;br /&gt;
The analytical inquiry exhaustively covered disposable vaping devices, closed systems, and open systems. Each component was evaluated to determine its degree of biodegradability, its potential for recyclability, and the strategies to promote good recycling practices, in addition to analyzing its use and end-of-life disposition.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Additionally, batteries, liquid containers, and absorption materials (cotton) used in different devices were examined to measure their recyclability and environmental sustainability. The study integrated environmental bioethics considerations throughout the document aimed at promoting a philosophy of life that encourages habits beneficial to the health of the planet.&lt;br /&gt;
&lt;br /&gt;
The research rigorously explored the feasibility of applying a circular economy to these devices, proposing design, production, selective collection, and recycling strategies that reduce environmental impact and foster a culture of environmental responsibility among users, manufacturers, and regulators.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
The document [[snw:index.php/Environmental_Impact_of_Vaping_Devices:_A_Global_Approach_to_Sustainability|«Environmental Impact of Vaping Devices: A Global Approach to Sustainability»]] is available on SSRN, where findings, methodologies, and recommendations are presented to advance a more sustainable and ethical use of vaping technology on a global scale.&lt;br /&gt;
&lt;br /&gt;
Thank you for supporting this THR project (Tobacco Harm Reduction); it was made possible thanks to the grant from the Tobacco Harm Reduction Scholarships Program (THRSP), implemented by Knowledge•Action•Change (K•A•C).&lt;br /&gt;
[[Category:Paper]]&lt;br /&gt;
[[Category:Environmental impact]]&lt;br /&gt;
[[Category:Sustainability]]&lt;br /&gt;
[[Category:Recycling]]&lt;br /&gt;
[[Category:Circular economy]]&lt;br /&gt;
[[Category:Pollution]]&lt;br /&gt;
[[Category:Waste management]]&lt;br /&gt;
[[Category:Environmental policies]]&lt;br /&gt;
[[Category:Environmental bioethics]]&lt;br /&gt;
[[Category:Environmental education]]&lt;br /&gt;
[[Category:Vaping waste]]&lt;br /&gt;
[[Category:Public health]]&lt;br /&gt;
[[Category:Environmental legislation]]&lt;br /&gt;
[[Category:RAEE]]&lt;br /&gt;
[[Category:WEEE]]&lt;br /&gt;
[[Category:THR Advocacy Group]]&lt;br /&gt;
[[Category:Harm-reduction]]&lt;br /&gt;
[[Category:Scientist]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84643</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84643"/>
		<updated>2025-10-05T16:51:32Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
T create a new page, simply type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, please see the link at the bottom of each page for it&#039;s licence.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84623</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84623"/>
		<updated>2025-09-24T11:32:45Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
T create a new page, simply type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84616</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84616"/>
		<updated>2025-09-21T23:11:27Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]] (please try to join if you can, donate if possible, consumers need to be heard)&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84600</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84600"/>
		<updated>2025-08-12T09:40:41Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred with smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84599</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84599"/>
		<updated>2025-08-11T21:27:39Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to information on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84587</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84587"/>
		<updated>2025-08-04T11:00:24Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
For example; who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Snus&amp;diff=84579</id>
		<title>Snus</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Snus&amp;diff=84579"/>
		<updated>2025-07-26T16:52:23Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: /* Potential benefits of Snus */ Edit passage for clarity&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;__TOC__&lt;br /&gt;
[[File:323B3915-10EF-4945-AAA2-3EED42737C04.jpeg|alt=A can of Siberia Snus, showing the contained pouches and container lid|right|frameless|300x300px]]&lt;br /&gt;
&lt;br /&gt;
== Description ==&lt;br /&gt;
Snus is a tobacco product (pouch) which the user places  in the mouth between the gum and cheek. No combustion is involved. Once in place, the saliva and general moistness of the mouth work to release the nicotine into the system. This process does not require any form of combustion. For other smokeless tobacco products try the [[SLT]] page.&lt;br /&gt;
&lt;br /&gt;
=== Properties ===&lt;br /&gt;
* It&#039;s mostly portioned into convenient pouches (like teabags). These are available in differing portions, from mini, slim, and up to ordinary sizes.&lt;br /&gt;
* Whereas &amp;quot;loose snus&amp;quot; tobacco powder has to be squeezed into spherical/cylindrical shape before use.&lt;br /&gt;
* Not chewed, but usually placed behind the upper lip.&lt;br /&gt;
* It is available in a range of flavours and strengths to suit any palate / nicotine requirement.&lt;br /&gt;
*Produced to a high standard, the processing including pasteurization, results in ultra low levels of nitrosamines and other known carcinogens that occur naturally in tobacco.&lt;br /&gt;
*Common ingredients added are 20-60% water, 1.5-3.5% sodium chloride, 1.5- 3.5% humectants, 1.2-3.5% sodium bicarbonate, and less than 1% flavours.&lt;br /&gt;
* Can be used for 20-60 min usually, or as long as it still emits flavours or until it liquifies too much.&lt;br /&gt;
* Often available for around 5 euro for a tin of 20 (sizing varies).&lt;br /&gt;
* Lower nicotine likely implies lower dependency profile than cigarettes, because of slower nicotine absorption (akin to gums).&lt;br /&gt;
&lt;br /&gt;
* Should be stored in the fridge, if infrequently used. This is to prevent microbes, these can result in nitrosamines from metabolic processes. Dry Snus is more suitable/stable if refrigeration is not available.&lt;br /&gt;
&lt;br /&gt;
=== Potential benefits of Snus ===&lt;br /&gt;
&lt;br /&gt;
* Snus is considered by scientists to be 95%, and possibly closer to 99%, less risky than smoking&lt;br /&gt;
* Snus poses no respiratory risk. It cannot cause respiratory diseases, predominantly lung cancer, chronic obstructive pulmonary disease tobacco smoke does, nothing is inhaled.&lt;br /&gt;
* Low risk oral nicotine product.&lt;br /&gt;
* Highly effective way of quitting cigarettes.&lt;br /&gt;
* Eliminates second-hand smoke.&lt;br /&gt;
* Snus poses no risk to others, such as work colleagues and family members as there is no combustion and consequently no ‘second hand’ smoke and no risk of fire.&lt;br /&gt;
&lt;br /&gt;
=== Potential risks of Snus ===&lt;br /&gt;
&lt;br /&gt;
* Snus may cause irritation of the oral mucosa and a stinging/tingling sensation, however &#039;Sting free Snus&#039; is one approach to help solve this. The other is to place the pouches in different locations each time. Note there is &#039;&#039;&#039;no link to disease or cancer,&#039;&#039;&#039; merely discomfort at worst. &lt;br /&gt;
&lt;br /&gt;
=== Is snus an appropriate and acceptable harm reduction product? ===&lt;br /&gt;
Snus fulfils the criteria for a tobacco harm reduction product. It is a low risk nicotine product and delivers acceptable doses to those who use it. In countries in which it is allowed it is popular and has contributed to declines in smoking and smoking related diseases.&lt;br /&gt;
&lt;br /&gt;
=== The human cost of the ban on snus ===&lt;br /&gt;
Using data on tobacco-related mortality across the EU, and applying the Swedish mortality data to other EU countries, it has been calculated that among men over the age of 30, 355,000 lives per year could have been saved if the other EU countries had matched Sweden’s tobacco-related mortality rate.&lt;br /&gt;
&lt;br /&gt;
== [[History of Snus]] Follow this link to the history page. ==&lt;br /&gt;
&lt;br /&gt;
== Legal Status ==&lt;br /&gt;
&lt;br /&gt;
=== Africa ===&lt;br /&gt;
Snus may be banned in some locations, legal in others. It&#039;s use is not common, other more harmful oral tobacco [[SLT|(see SLT)]] is used more often.&lt;br /&gt;
&lt;br /&gt;
=== Europe ===&lt;br /&gt;
Illegal to sell in the EU (excluding Sweden), but purchase and use is not illegal (unclear if just due to tobacco industry track record, general opposition to proliferation of further tobacco products, preempting regulation for geographically restrained appeal, or even pharma influence).&lt;br /&gt;
&lt;br /&gt;
=== Sweden ===&lt;br /&gt;
Snus is legally on the market only in Sweden. The minimum age to purchase is 18 years of age.&lt;br /&gt;
&lt;br /&gt;
=== UK ===&lt;br /&gt;
Illegal in the UK, but calls have been made by [[Appgvaping]] to legalise it&#039;s sale. Snus is reasonably easy to obtain in the UK, from sources on social media, and can be ordered online. Little to no enforcement appears to be carried out to block it&#039;s transit through customs, or to stop it&#039;s use.&lt;br /&gt;
&lt;br /&gt;
=== North America ===&lt;br /&gt;
The US FDA has authorized the marketing of products through the modified risk tobacco product (MRTP) pathway. The authorizations are for eight Swedish Match USA, Inc. snus smokeless tobacco products sold under the “General” brand name.&lt;br /&gt;
&lt;br /&gt;
FDA authorizes the manufacturer to market these specific products with the claim &#039;&#039;“Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
The FDA’s review determined that the claim proposed by the company in its application is supported by scientific evidence, that consumers understand the claim and appropriately perceive the relative risk of these products compared to cigarettes, and that the modified risk products, as actually used by consumers, will significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole.&lt;br /&gt;
&lt;br /&gt;
==== Related Information ====&lt;br /&gt;
&lt;br /&gt;
* [https://www.fda.gov/tobacco-products/advertising-and-promotion/modified-risk-tobacco-products Modified Risk Tobacco Products]&lt;br /&gt;
* [https://www.fda.gov/tobacco-products/advertising-and-promotion/modified-risk-granted-orders Modified Risk Orders]&lt;br /&gt;
* [https://www.fda.gov/tobacco-products/advertising-and-promotion/swedish-match-usa-inc-mrtp-applications Swedish Match USA, Inc. MRTP Applications]&lt;br /&gt;
&lt;br /&gt;
== Snus and Stopping/Displacing Smoking ==&lt;br /&gt;
The most popular source  of Nicotine consumed globally is still combustion cigarettes. Cigarettes make up 92% of all tobacco and nicotine products sold.&lt;br /&gt;
&lt;br /&gt;
Smoke from combustion cigarettes  up of over thousands of chemicals, including at least 70 known to cause cancer. These cancer-causing chemicals are referred to as carcinogens. &lt;br /&gt;
&lt;br /&gt;
Safer Nicotine  Products  like Snus make tobacco  use safer by eliminating  all these carcinogens and only  delivering  Nicotine  without  necessary  the process  of combustion.&lt;br /&gt;
&lt;br /&gt;
Some of the carcinogens Snus eliminates include Hydrogen cyanide, Formaldehyde, Lead, Arsenic, Ammonia, Radioactive elements,Benzene, Carbon monoxide, Tobacco-specific nitrosamines (TSNAs), Polycyclic aromatic hydrocarbons (PAHs) among  others.&lt;br /&gt;
&lt;br /&gt;
== Studies general information ==&lt;br /&gt;
&lt;br /&gt;
==== 2024:[https://link.springer.com/epdf/10.1186/s12954-024-01095-7?sharing_token=_1R3Pf6IlmYuu1rCO8WKR2_BpE1tBhCbnbw3BuzI2ROn4zJn13QApxXLzZ1Nm2EMUkgR9kBcTUj-17Nn5d2sQs8mLy3R96OBBGptbTCRJIWB4pPY-WWLKJ0DqqKOq-LBdg_MBr5Q2Y15L5xIyeK8sAjjshzb6jigkC1RlZKharE%3D If there had been no snus in Sweden: the impact of snus on mortality attributable to smoking] ====&lt;br /&gt;
&lt;br /&gt;
* It is made up by comparisons between observed Swedish data and two scenarios without snus: a group of comparable countries, and, a hypothetical Sweden with no snus use.&lt;br /&gt;
* Both comparisons suggest that around 3000 lives per year have been saved by the use of snus in Sweden.&lt;br /&gt;
* The potential of snus to reduce smoking-attributable mortality can be elucidated by comparing Swedish data on smoking-attributable mortality with corresponding data from comparable countries with virtually no snus. Switzerland and most EU countries outside Sweden&lt;br /&gt;
&lt;br /&gt;
==== &#039;&#039;&#039;2022:&#039;&#039;&#039; [https://onlinelibrary.wiley.com/doi/10.1111/eos.12885 The effect of a non-tobacco-based nicotine pouch on mucosal lesions caused by Swedish smokeless tobacco (snus)] (Sara Alizadehgharib, Anna Lehrkinder, Ali Alshabeeb, Anna-Karin Östberg, Peter Lingström) ====&lt;br /&gt;
&amp;quot;Oral mucosal lesions are commonly found in Swedish smokeless tobacco (snus) users where the pouch is placed. These lesions are reversible, that is, clinical and histological tissue changes return to normal following cessation.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
&amp;quot;The main aim of this study was to investigate how the oral mucosa was affected if users substituted their regular Swedish snus with non-tobacco-based nicotine products (investigational products).&amp;quot;&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Because of these circumstances, the extent to which the use of the investigational non-tobacco-based nicotine pouch may cause mucosal lesions similar to those produced by regular, tobacco-based snus is unclear. &amp;quot;&lt;br /&gt;
&lt;br /&gt;
==== &#039;&#039;&#039;2022:&#039;&#039;&#039; [https://pubmed.ncbi.nlm.nih.gov/35840660/ Swedish snuff (snus) dipping, cigarette smoking, and risk of peripheral artery disease: a prospective cohort study]  (Shuai Yuan, Olga E Titova, Scott M Damrauer,  Agneta Åkesson, Susanna C Larsson) ====&lt;br /&gt;
&amp;quot;Cigarette smoking but not Swedish snus dipping was associated with an increased risk of PAD (peripheral artery disease).&amp;quot; &lt;br /&gt;
&lt;br /&gt;
==== 2021: [https://pubmed.ncbi.nlm.nih.gov/32466721/ No association between moist oral snuff (snus) use and oral cancer: pooled analysis of nine prospective observational studies] ====&lt;br /&gt;
&lt;br /&gt;
* We used pooled individual data from the Swedish Collaboration on Health Effects of Snus Use to assess the association between snus use and oral cancer.&lt;br /&gt;
&lt;br /&gt;
* Snus use was not associated with oral cancer among never smokers&lt;br /&gt;
* During 9,201,647 person-years of observation, 628 men developed oral cancer. Compared to never-snus use, ever-snus use was not associated with oral cancer&lt;br /&gt;
* There were no clear trends in risk with duration or intensity of snus use, although lower intensity use (⩽ 4 cans/week) was associated with a reduced risk&lt;br /&gt;
&lt;br /&gt;
==== &#039;&#039;&#039;2019&#039;&#039;&#039;: [https://doi.org/10.1186/s12954-019-0335-1 Snus: a compelling harm reduction alternative to cigarettes] (E Clarke / K Thompson / S Weaver / J Thompson / G O’Connell) ====&lt;br /&gt;
* &amp;quot;The available scientific data, including long-term population studies conducted by independent bodies, demonstrates that the health risks associated with snus are considerably lower than those associated with cigarette smoking.&amp;quot;&lt;br /&gt;
&#039;&#039;&#039;2016:&#039;&#039;&#039; [https://academic.oup.com/ije/article/46/3/872/2656164?login=false Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease]  &#039;&#039;&#039;(Fei Yang, Nancy L Pedersen, Weimin Ye, Zhiwei Liu, Margareta Norberg, Lars Forsgren, Ylva Trolle Lagerros, Rino Bellocco, Lars Alfredsson, Anders Knutsson)&#039;&#039;&#039;&lt;br /&gt;
* &amp;quot;Among men who never smoked, ever-snus users had about 60% lower Parkinson&#039;s disease risk compared with never-snus users&amp;quot;&lt;br /&gt;
&lt;br /&gt;
==== &#039;&#039;&#039;2015:&#039;&#039;&#039; T[https://doi.org/10.1093/ntr/ntu224 ime to First Use Among Daily Smokers and Smokeless Tobacco Users] (B Rodu / N Plurphanswat / K Fagerström) ====&lt;br /&gt;
* &amp;quot;[…] offering some support for the Fagerström-Eissenberg hypothesis that the dependence level of cigarettes is higher than that of ST.&amp;quot; (certainly applies to Snus as well)&lt;br /&gt;
&lt;br /&gt;
==== &#039;&#039;&#039;2013&#039;&#039;&#039;: [https://doi.org/10.1093/ntr/nts185 Patterns of dual use of snus and cigarettes in a mature snus market] (K E Lund / A McNeill), n=3524 ====&lt;br /&gt;
* Dual use is relatively small. Large percentage of users have stopped smoking, or are planning to by using snus. […]&lt;br /&gt;
&lt;br /&gt;
==== &#039;&#039;&#039;2012&#039;&#039;&#039;: [https://doi.org/10.1186/1477-7517-9-10 Contrasting snus and NRT as methods to quit smoking. an observational study] (J Scheffels / K E Lund / A McNeill) ====&lt;br /&gt;
&lt;br /&gt;
* &amp;quot;Norwegian men frequently use snus as a method for quitting smoking whereas women are more likely to use NRT. The findings indicate that switching to snus can be an effective method for quitting smoking&lt;br /&gt;
&lt;br /&gt;
==== &#039;&#039;&#039;2003:&#039;&#039;&#039; [https://doi.org/10.1136/tc.12.4.349 Effect of smokeless tobacco (snus) on smoking and public health in Sweden] (J Foulds / L Ramstrom / M Burke / K Fagerström) ====&lt;br /&gt;
* &amp;quot;Snus availability in Sweden appears to have contributed to the unusually low rates of smoking among Swedish men by helping them transfer to a notably less harmful form of nicotine dependence.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
== Studies Norway ==&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* Snus for a long time has been the most preferred method for quitting smoking among successful quitters&#039;&#039;&#039; (see figure 2) in this report: ===&lt;br /&gt;
&lt;br /&gt;
==== [https://www.fhi.no/nettpub/tobakkinorge/bruk-av-tobakk/roykeslutt/?term=&amp;amp;h=1 2022: hadde halvparten av den voksne befolkningen aldri røykt mens den andre halvparten utgjøres av nåværende og tidligere røykere. Litt over halvparten av nåværende og forhenværende røykere har brukt en eller annen form for hjelpemidler ved det siste sluttforsøket.]  [https://www-fhi-no.translate.goog/nettpub/tobakkinorge/bruk-av-tobakk/roykeslutt/?term&amp;amp;h=1&amp;amp;_x_tr_sl=auto&amp;amp;_x_tr_tl=en&amp;amp;_x_tr_hl=en-US&amp;amp;_x_tr_pto=wapp Google machine translation in english] ====&lt;br /&gt;
&lt;br /&gt;
* Those who have never smoked make up an equal proportion of the population as those who smoke or have smoked in the past.&lt;br /&gt;
* About half of daily smokers want to quit smoking&lt;br /&gt;
* One in four daily smokers has tried to quit in the past 12 months&lt;br /&gt;
* Snus use is a more common method of quitting smoking than using nicotine replacement products&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* Former smokers make up a large segment among snus users&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
==== Lund KE, Vedøy TF, Bauld L. [https://www.stir.ac.uk/research/hub/publication/542404 Do never smokers make up an increasing share of snus users as cigarette smoking declines? Changes in smoking status among male snus users in Norway 2003-15.] Addiction. 2017 Feb;112(2):340-348. doi: 10.1111/add.13638. Epub 2016 Dec 5. PMID: 27741374; PMCID: PMC5248595. ====&lt;br /&gt;
&lt;br /&gt;
* Among men who reported life-time experience with both products, a large majority had initiated their tobacco use with cigarettes.&lt;br /&gt;
* The average number of cigarettes smoked weekly was lower among dual users compared with current smokers who were former snus users or had never used snus.&lt;br /&gt;
* During the period 2003–15 in Norway, which has a mature snus market, even though smoking has declined and the relative size of the category of never-smokers among male users of snus has increased, the majority of snus users are still former or current smokers.&lt;br /&gt;
&lt;br /&gt;
==== Kvaavik E, Lund I, Nygård M, Hansen BT. [https://europepmc.org/article/med/26069033 Lifestyle Correlates of Female Snus Use and Smoking: A Large Population-Based Survey of Women in Norway.] Nicotine Tob Res. 2016 Apr;18(4):431-6. doi: 10.1093/ntr/ntv126. Epub 2015 Jun 11. PMID: 26069033. ====&lt;br /&gt;
&lt;br /&gt;
* While most snus users among older women were former or current smokers, this was not the case among younger women.&lt;br /&gt;
* The correlates of female snus use and smoking were not identical, and were similar to those previously documented for men.&lt;br /&gt;
* Female snus use was positively associated with intermediate education, alcohol consumption, number of sexual partners, and hard physical activity.&lt;br /&gt;
* Smoking was also positively associated with alcohol consumption and number of sexual partners, but negatively associated with physical activity and education.&lt;br /&gt;
&lt;br /&gt;
==== Lund KE, McNeill A. [https://pubmed.ncbi.nlm.nih.gov/22990221/ Patterns of dual use of snus and cigarettes in a mature snus market.] Nicotine Tob Res. 2013 Mar;15(3):678-84. doi: 10.1093/ntr/nts185. Epub 2012 Sep 18. PMID: 22990221; PMCID: PMC3572872. ====&lt;br /&gt;
&lt;br /&gt;
* In the mature snus market of Norway, the magnitude of dual use of cigarettes and snus is relatively small.&lt;br /&gt;
* Dual users consume fewer cigarettes, and a higher proportion portray themselves as smoke-free in the future than do exclusive cigarette smokers.&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* The quit ratio for cigarette smoking is higher among snus users than non-users&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
==== Lund KE, Scheffels J, McNeill A. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021722/ The association between use of snus and quit rates for smoking: results from seven Norwegian cross-sectional studies.] Addiction. 2011 Jan;106(1):162-7. doi: 10.1111/j.1360-0443.2010.03122.x. Epub 2010 Sep 30. PMID: 20883459; PMCID: ====&lt;br /&gt;
&lt;br /&gt;
==== Scheffels J, Lund KE, McNeill A. [https://harmreductionjournal.biomedcentral.com/articles/10.1186/1477-7517-9-10 Contrasting snus and NRT as methods to quit smoking. an observational study]. Harm Reduct J. 2012 Feb 29;9:10. doi: 10.1186/1477-7517-9-10. PMID: 22376006; PMCID: PMC3311082. ====&lt;br /&gt;
&lt;br /&gt;
==== Lund KE, Vedøy TF, Bauld L. [https://www.stir.ac.uk/research/hub/publication/542404 Do never smokers make up an increasing share of snus users as cigarette smoking declines? Changes in smoking status among male snus users in Norway 2003-15.] Addiction. 2017 Feb;112(2):340-348. doi: 10.1111/add.13638. Epub 2016 Dec 5. PMID: 27741374; PMCID: PMC5248595. ====&lt;br /&gt;
&lt;br /&gt;
==== Lund I, Lund KE. [https://www.mdpi.com/1660-4601/11/11/11705 How has the availability of snus influenced cigarette smoking in Norway?] Int J Environ Res Public Health. 2014 Nov 13;11(11):11705-17. doi: 10.3390/ijerph111111705. PMID: 25402565; PMCID: PMC4245639. ====&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* Dual users of snus and cigarettes consume fewer cigarettes, and a higher proportion portray themselves as smoke-free in the future than do exclusive cigarette smokers.&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
==== Lund KE, McNeill A. [https://pubmed.ncbi.nlm.nih.gov/22990221/ Patterns of dual use of snus and cigarettes in a mature snus market.] Nicotine Tob Res. 2013 Mar;15(3):678-84. doi: 10.1093/ntr/nts185. Epub 2012 Sep 18. PMID: 22990221; PMCID: PMC3572872. ====&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* Snus is associated with higher likelihood in of quitting smoking within the first 5 years after snus initiation&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
==== Lund I, Christiansen SG. [https://onlinelibrary.wiley.com/doi/abs/10.1111/add.14809 Association between snus use over time and smoking cessation in Norwegian smokers.] Addiction. 2020 Jan;115(1):170-174. doi: 10.1111/add.14809. Epub 2019 Oct 23. PMID: 31502348. ====&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* Snus is used as a quitting method by smokers who do not want to use NRTs&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
==== Lund KE, McNeill A, Scheffels J. [https://pubmed.ncbi.nlm.nih.gov/20622023/ The use of snus for quitting smoking compared with medicinal products.] Nicotine Tob Res. 2010 Aug;12(8):817-22. doi: 10.1093/ntr/ntq105. Epub 2010 Jul 9. PMID: 20622023; PMCID: PMC2910876. ====&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* Among current snus users who had quit smoking, 83% reported that snus was used in their final quit attempt&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
==== Lund KE, Vedøy TF, Bauld L. [https://www.stir.ac.uk/research/hub/publication/542404 Do never smokers make up an increasing share of snus users as cigarette smoking declines? Changes in smoking status among male snus users in Norway 2003-15.] Addiction. 2017 Feb;112(2):340-348. doi: 10.1111/add.13638. Epub 2016 Dec 5. PMID: 27741374; PMCID: PMC5248595. ====&lt;br /&gt;
&lt;br /&gt;
=== &#039;&#039;&#039;* Snus use was found to be a “stand-alone” cessation aid, and only weakly associated with the use of other cessation aids.&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
==== Lund M, Lund I. [https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-13032-z Smoking cessation aids and strategies: a population-based survey of former and current smokers in Norway.] BMC Public Health. 2022 Mar 31;22(1):631. doi: 10.1186/s12889-022-13032-z. PMID: 35361172; PMCID: PMC8973793. ====&lt;br /&gt;
&lt;br /&gt;
== Other references ==&lt;br /&gt;
* http://www.smokersonly.org/ on smokeless tobacco as quitting option. Mentions an estimate of ST being 98% less harmful than cigarettes.&lt;br /&gt;
* https://snusforumet.se/en/snus-science-database/ - Encompassing research list on Snus Forum.&lt;br /&gt;
* https://www.snuson.com/ - Consumer forum.&lt;br /&gt;
* https://nnalliance.org/snus-facts &lt;br /&gt;
* https://www.tobaccoharmreduction.net/thr-products&lt;br /&gt;
&lt;br /&gt;
== Suggestions to Add to This Page ==&lt;br /&gt;
&lt;br /&gt;
====2021: [https://journals.sagepub.com/doi/full/10.1177/1455072520980219 Smoking and snus use among Norwegian students: Demographic, personality and substance use characteristics] ====&lt;br /&gt;
&lt;br /&gt;
===2015: [https://www.sciencedirect.com/science/article/abs/pii/S0955395914002175 The incentives created by a harm reduction approach to smoking cessation: Snus and smoking in Sweden and Finland]===&lt;br /&gt;
&lt;br /&gt;
[[Category:THR product]]&lt;br /&gt;
[[Category:Smoking cessation]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Symbol&amp;diff=84575</id>
		<title>Symbol</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Symbol&amp;diff=84575"/>
		<updated>2025-07-23T07:38:32Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: redirect&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;#REDIRECT [[Universal THR symbol]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Universal_THR_symbol&amp;diff=84571</id>
		<title>Universal THR symbol</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Universal_THR_symbol&amp;diff=84571"/>
		<updated>2025-07-23T07:36:20Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: make page&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Page for universal THR symbol.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
A symbol to represent harm reduction of all kinds that helps cigarette smokers reduce their risk by applying Harm Reduction principals and using safer alternative products.&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84564</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84564"/>
		<updated>2025-07-21T11:21:04Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
  &lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84042</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=84042"/>
		<updated>2025-06-29T15:02:46Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Type the page name into the search box if it doesn&#039;t exist, click the red link to create that page!  &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Lindsey_Stroud&amp;diff=83846</id>
		<title>Lindsey Stroud</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Lindsey_Stroud&amp;diff=83846"/>
		<updated>2025-06-17T15:56:40Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Add page for Lindsey Stroud&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;== Lindsey Stroud ==&lt;br /&gt;
Provides the 50 state data at THR-101 site, advocate for vaping and harm reduction.&lt;br /&gt;
&lt;br /&gt;
=== For data and blog posts please visit THR-101 ===&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Tobacco Harm Reduction, Inc. (THR101) is a registered Florida 501(c)(3) nonprofit organization (with pending federal status) dedicated to promoting public health through science-based education, research, and advocacy.&lt;br /&gt;
&lt;br /&gt;
Our mission is to reduce the devastating health impacts of combustible tobacco by advancing awareness and understanding of tobacco harm reduction (THR) strategies.&lt;br /&gt;
&lt;br /&gt;
Link to [https://www.thr101.org/ THR-101] Email [mailto:info@thr101.org info@thr101.org]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Lindsay_Stroud&amp;diff=83842</id>
		<title>Lindsay Stroud</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Lindsay_Stroud&amp;diff=83842"/>
		<updated>2025-06-17T15:49:49Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Add redirect for wrong spelling&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;#REDIRECT [[Lindsey Stroud]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=83778</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=83778"/>
		<updated>2025-05-18T17:06:08Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]]. &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Briefing:_Nicotine_for_Policymakers_pt&amp;diff=83775</id>
		<title>Briefing: Nicotine for Policymakers pt</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Briefing:_Nicotine_for_Policymakers_pt&amp;diff=83775"/>
		<updated>2025-05-14T09:13:41Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Add page in the correct lang&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Documento produzido por [[Clive Bates]], The Counterfactual, Maio 2025 www.clivebates.com&lt;br /&gt;
&lt;br /&gt;
Traduzido para o português por Alexandro Lucian, Maio 2025&lt;br /&gt;
&lt;br /&gt;
www.vaporaqui.net&lt;br /&gt;
&lt;br /&gt;
=== Briefing: Nicotina para formuladores de políticas ===&lt;br /&gt;
&lt;br /&gt;
==== Resumo e principais percepções ====&lt;br /&gt;
●​A nicotina é o principal agente psicoativo no tabaco e nos sistemas alternativos de fornecimento de&lt;br /&gt;
&lt;br /&gt;
nicotina (ANDS do inglês Alternative Nicotine Delivery Systems) – vapes, sachês, tabaco aquecido e sem&lt;br /&gt;
&lt;br /&gt;
combustão). É um estimulante que produz sensações subjetivas de prazer, reduz o estresse e a&lt;br /&gt;
&lt;br /&gt;
ansiedade e melhora aspectos da função cognitiva. Seu uso pode fazer com que as pessoas se sintam&lt;br /&gt;
&lt;br /&gt;
melhor e sintam que funcionam melhor. A nicotina não causa efeitos típicos de drogas como&lt;br /&gt;
&lt;br /&gt;
intoxicação, torpor, alucinações ou violência. Ela também pode ter benefícios terapêuticos, mostrando&lt;br /&gt;
&lt;br /&gt;
potencial para algumas doenças inflamatórias, TDAH e doença de Parkinson, entre outras.&lt;br /&gt;
&lt;br /&gt;
●​Os aspectos subjetivamente percebidos como positivos do uso da nicotina explicam em grande parte&lt;br /&gt;
&lt;br /&gt;
por que as pessoas a utilizam. No entanto, essas recompensas podem se consolidar em dependência.&lt;br /&gt;
&lt;br /&gt;
Com o tempo, a abstinência e o desejo reforçam o uso da nicotina. Embora a nicotina possa&lt;br /&gt;
&lt;br /&gt;
proporcionar alívio imediato do estresse, seu impacto geral pode aumentar os níveis de estresse&lt;br /&gt;
&lt;br /&gt;
fisiológica e psicologicamente devido ao ciclo de uso, alívio e abstinência.&lt;br /&gt;
&lt;br /&gt;
●​O uso de nicotina é desproporcionalmente prevalente entre sub-populações mais pobres,&lt;br /&gt;
&lt;br /&gt;
marginalizadas ou de outra forma desfavorecidas. A nicotina provavelmente interage com níveis&lt;br /&gt;
&lt;br /&gt;
elevados de estresse nesses grupos.&lt;br /&gt;
&lt;br /&gt;
●​Não há uma resposta simples para a pergunta: A nicotina é viciante? Isso depende das características do&lt;br /&gt;
&lt;br /&gt;
usuário, da via de administração e da definição de “vício”, que é um termo impreciso e estigmatizante.&lt;br /&gt;
&lt;br /&gt;
O vício geralmente se refere a um comportamento compulsivo que persiste mesmo diante de danos&lt;br /&gt;
&lt;br /&gt;
significativos ao usuário. O tabagismo se encaixa nessa definição, mas o uso de ANDS pode não se&lt;br /&gt;
&lt;br /&gt;
encaixar. É melhor pensar na dependência ou vício em nicotina como uma constelação emergente de&lt;br /&gt;
&lt;br /&gt;
comportamentos com consequências para o indivíduo, em vez de uma propriedade intrínseca de uma&lt;br /&gt;
&lt;br /&gt;
molécula, dispositivo ou líquido.&lt;br /&gt;
&lt;br /&gt;
●​A nicotina não é uma causa direta significativa de doenças relacionadas ao tabagismo. Dezenas de&lt;br /&gt;
&lt;br /&gt;
outras substâncias químicas perigosas e potencialmente perigosas que se formam no processo de&lt;br /&gt;
&lt;br /&gt;
combustão e constituem as partículas e gases da fumaça do tabaco são, em grande parte, as&lt;br /&gt;
&lt;br /&gt;
responsáveis pelas doenças causadas pelo fumo.&lt;br /&gt;
&lt;br /&gt;
●​A nicotina isolada é muito menos prejudicial do que o tabagismo, mas não é totalmente inofensiva. Ela&lt;br /&gt;
&lt;br /&gt;
não causa câncer, doenças cardíacas ou pulmonares, mas pode aumentar riscos em pessoas com&lt;br /&gt;
&lt;br /&gt;
tumores ou condições cardiovasculares preexistentes. O tabagismo causa desfechos gestacionais&lt;br /&gt;
&lt;br /&gt;
negativos, mas a nicotina provavelmente não é a principal causa. A nicotina causa vasoconstrição&lt;br /&gt;
&lt;br /&gt;
periférica, o que pode levar à redução do peso ao nascer e à doença arterial periférica em adultos.&lt;br /&gt;
&lt;br /&gt;
●​A nicotina é o principal motivo pelo qual as pessoas usam tabaco ou ANDS, e o uso desses produtos&lt;br /&gt;
&lt;br /&gt;
deve ser compreendido como um comportamento de busca de nicotina. Dentro de limites amplos, é ousuário, não o produto, quem determina a dose. Os usuários geralmente regulam sua ingestão para&lt;br /&gt;
&lt;br /&gt;
corresponder a um nível preferido de absorção de nicotina. Esquemas regulatórios que tentam&lt;br /&gt;
&lt;br /&gt;
controlar a ingestão de nicotina por meio de restrições no design do produto provavelmente não terão&lt;br /&gt;
&lt;br /&gt;
sucesso, pois os usuários ajustam sua ingestão para atingir os níveis desejados, resultando em&lt;br /&gt;
&lt;br /&gt;
“compensação” (uso mais intenso do produto) ou troca de produtos de nicotina caso a compensação&lt;br /&gt;
&lt;br /&gt;
não seja possível.&lt;br /&gt;
&lt;br /&gt;
●​Assim como outras substâncias psicoativas – álcool, cafeína, cannabis etc. – a demanda por nicotina&lt;br /&gt;
&lt;br /&gt;
provavelmente não desaparecerá, mesmo com leis punitivas. A demanda é impulsionada&lt;br /&gt;
&lt;br /&gt;
principalmente pelos benefícios reais ou percebidos experimentados pelos usuários e, para algumas&lt;br /&gt;
&lt;br /&gt;
pessoas, pelo esforço necessário para parar.&lt;br /&gt;
&lt;br /&gt;
●​O principal fator dissuasivo do uso da nicotina, os múltiplos danos à saúde e ao bem-estar decorrentes&lt;br /&gt;
&lt;br /&gt;
do tabagismo, é significativamente reduzido nos sistemas alternativos de fornecimento de nicotina sem&lt;br /&gt;
&lt;br /&gt;
fumaça. O fator dissuasivo secundário são os efeitos de políticas destinadas a controlar o tabagismo,&lt;br /&gt;
&lt;br /&gt;
como altos impostos. Para alternativas substancialmente mais seguras, esse fator dissuasivo também&lt;br /&gt;
&lt;br /&gt;
deve ser significativamente reduzido. É possível, portanto, que o uso de nicotina pela sociedade como&lt;br /&gt;
&lt;br /&gt;
um todo aumente, embora os danos totais associados ao uso da nicotina diminuam substancialmente.&lt;br /&gt;
&lt;br /&gt;
O que é nicotina?&lt;br /&gt;
&lt;br /&gt;
O que é nicotina? A nicotina¹ é um alcaloide de ocorrência natural presente na planta do tabaco, na qual&lt;br /&gt;
&lt;br /&gt;
atua como um inseticida botânico. Também pode ser produzida sinteticamente. A nicotina também está&lt;br /&gt;
&lt;br /&gt;
presente em chá, pimentões, tomates, batatas, couve-flor e berinjela², embora a exposição dietética seja&lt;br /&gt;
&lt;br /&gt;
muito menor do que por meio do uso do tabaco e não tenha um efeito psicoativo perceptível³. Os humanos&lt;br /&gt;
&lt;br /&gt;
consomem deliberadamente a nicotina, seja através de cachimbos, charutos, mastigação, aspiração ou&lt;br /&gt;
&lt;br /&gt;
cigarros, há mais de 12.000 anos⁴. Nos níveis intencionalmente consumidos por usuários de tabaco ou ANDS,&lt;br /&gt;
&lt;br /&gt;
a nicotina não é venenosa. Para os humanos, ela funciona como uma substância psicoativa⁵, atuando tanto&lt;br /&gt;
&lt;br /&gt;
como estimulante quanto como ansiolítico (isto é, com efeitos calmantes sobre a ansiedade).&lt;br /&gt;
&lt;br /&gt;
Diferentemente de muitas drogas de abuso, a nicotina não leva a efeitos agudos e frequentemente&lt;br /&gt;
&lt;br /&gt;
prejudiciais como intoxicação, violência, torpor, paranoia, desorientação, perda de controle ou alucinações.&lt;br /&gt;
&lt;br /&gt;
No entanto, o uso da nicotina proporciona recompensa psicoativa e efeitos reforçadores. A tolerância aos&lt;br /&gt;
&lt;br /&gt;
efeitos aversivos iniciais em usuários inexperientes se desenvolve rapidamente, o que frequentemente leva à&lt;br /&gt;
&lt;br /&gt;
dependência e a sintomas desagradáveis de abstinência após a interrupção do uso.&lt;br /&gt;
&lt;br /&gt;
Como a nicotina funciona como droga? Quando o tabaco é fumado, sugado ou mascado, a nicotina é&lt;br /&gt;
&lt;br /&gt;
liberada do tabaco e entra no sangue por meio da cavidade oral, vias aéreas, pulmões ou passagens nasais, e&lt;br /&gt;
&lt;br /&gt;
depois segue para o cérebro através da circulação arterial. A nicotina se liga a receptores no cérebro para&lt;br /&gt;
&lt;br /&gt;
liberar vários neurotransmissores, mais notavelmente a dopamina⁶ e a adrenalina⁷. Essas interações&lt;br /&gt;
&lt;br /&gt;
produzem sensações de prazer⁸, aumento do estado de alerta⁹, melhora da função cognitiva¹⁰ ¹¹ e regulação&lt;br /&gt;
&lt;br /&gt;
do humor, como redução do estresse e da ansiedade¹² ¹³. Por exemplo, uma pesquisa conduzida pelo&lt;br /&gt;
&lt;br /&gt;
Programa Intramural de Pesquisa do Instituto Nacional de Abuso de Drogas dos EUA concluiu:¹⁴&lt;br /&gt;
&lt;br /&gt;
Encontramos efeitos positivos significativos da nicotina ou do tabagismo em seis domínios:&lt;br /&gt;
&lt;br /&gt;
motricidade fina, atenção de alerta, precisão e tempo de resposta (RT) da atenção, orientação&lt;br /&gt;
&lt;br /&gt;
da atenção RT, precisão da memória episódica de curto prazo e tempo de resposta da memória&lt;br /&gt;
&lt;br /&gt;
de trabalho.&lt;br /&gt;
&lt;br /&gt;
Essa gama de efeitos positivos subjetivos é importante para explicar por que há demanda pela nicotina —&lt;br /&gt;
&lt;br /&gt;
para algumas pessoas, o uso da nicotina pode fazê-las se sentir ou funcionar melhor. Essa observação não&lt;br /&gt;
&lt;br /&gt;
deve ser entendida como um endosso ao uso da nicotina ou uma recomendação, mas sim como umaexplicação. Essa variedade de efeitos também forma a base da recompensa e reforço que leva alguns&lt;br /&gt;
&lt;br /&gt;
usuários a experimentar dependência e sintomas adversos de abstinência quando param¹⁵ ¹⁶.&lt;br /&gt;
&lt;br /&gt;
Efeitos terapêuticos da nicotina. Em algumas circunstâncias, a nicotina pode ter efeitos anti-inflamatórios ou&lt;br /&gt;
&lt;br /&gt;
regulatórios com potenciais benefícios terapêuticos na prevenção, tratamento ou alívio dos sintomas de&lt;br /&gt;
&lt;br /&gt;
certas doenças. Esses casos podem incluir doença de Parkinson¹⁷ ¹⁸, colite ulcerativa¹⁹ ²⁰, TDAH²¹ ²² ²³ ²⁴ e&lt;br /&gt;
&lt;br /&gt;
psicose²⁵ ²⁶ ²⁷ ²⁸ ²⁹. Fumantes apresentaram menor probabilidade de contrair COVID-19, sugerindo um&lt;br /&gt;
&lt;br /&gt;
possível efeito protetor³⁰ ³¹. No entanto, não está claro se isso se deve à nicotina, a algum outro componente&lt;br /&gt;
&lt;br /&gt;
da fumaça ou a um artefato estatístico. Grande parte da discussão sobre os efeitos terapêuticos tem sido&lt;br /&gt;
&lt;br /&gt;
feita com cautela, devido à preocupação justificável de que isso possa incentivar o tabagismo, e muitas vezes&lt;br /&gt;
&lt;br /&gt;
as pesquisas são sugestivas, mas não conclusivas, ou apresentam uma direção ambígua de causalidade. O&lt;br /&gt;
&lt;br /&gt;
tabaco e os ANDS não são medicamentos e não devem ser usados para tratar essas condições como&lt;br /&gt;
&lt;br /&gt;
alternativa à supervisão médica. No entanto, algumas pessoas podem estar usando nicotina&lt;br /&gt;
&lt;br /&gt;
subconscientemente para automedicação ou para aliviar sintomas decorrentes dessas condições. Esta é uma&lt;br /&gt;
&lt;br /&gt;
explicação, não uma recomendação.&lt;br /&gt;
&lt;br /&gt;
Quem usa nicotina? O uso de tabaco ou nicotina não é uniformemente distribuído em toda a população em&lt;br /&gt;
&lt;br /&gt;
qualquer faixa etária. Ele é impulsionado por vários fatores genéticos e psicossociais (características do&lt;br /&gt;
&lt;br /&gt;
indivíduo e de seu contexto familiar e social)³². Um estudo identificou noventa e oito preditores distintos&lt;br /&gt;
&lt;br /&gt;
para o início do tabagismo³³:&lt;br /&gt;
&lt;br /&gt;
Um risco aumentado de início do tabagismo foi consistentemente (ou seja, em quatro ou mais&lt;br /&gt;
&lt;br /&gt;
estudos) associado à idade/série escolar mais elevada, menor status socioeconômico, baixo&lt;br /&gt;
&lt;br /&gt;
desempenho acadêmico, busca de sensações ou rebeldia, intenção de fumar no futuro,&lt;br /&gt;
&lt;br /&gt;
receptividade a esforços de promoção do tabaco, suscetibilidade ao tabagismo, familiares&lt;br /&gt;
&lt;br /&gt;
fumantes, ter amigos que fumam e exposição a filmes.&lt;br /&gt;
&lt;br /&gt;
O uso de nicotina é desproporcionalmente prevalente entre aqueles que enfrentam algum tipo de estresse,&lt;br /&gt;
&lt;br /&gt;
desvantagem, pertencem a minorias, estão marginalizados ou têm histórico desafiador, como negligência ou&lt;br /&gt;
&lt;br /&gt;
abuso³⁴ ³⁵ ³⁶ ³⁷ ³⁸ ³⁹ ⁴⁰. O uso sustentado de nicotina nessas populações pode ser uma resposta ao estresse&lt;br /&gt;
&lt;br /&gt;
vivido como consequência dessas disparidades⁴¹. Com o tempo, o cérebro se adapta ao uso de nicotina,&lt;br /&gt;
&lt;br /&gt;
exigindo doses mais altas para alcançar o mesmo efeito calmante, o que pode levar à dependência. Além&lt;br /&gt;
&lt;br /&gt;
disso, os sintomas de abstinência associados à nicotina, como desejo intenso, irritabilidade, ansiedade e&lt;br /&gt;
&lt;br /&gt;
dificuldade de concentração, contribuem ainda mais para o estresse quando os níveis de nicotina no sangue&lt;br /&gt;
&lt;br /&gt;
caem. Assim, embora a nicotina possa proporcionar alívio imediato do estresse, seu impacto geral é o de&lt;br /&gt;
&lt;br /&gt;
aumentar os níveis de estresse fisiológica e psicologicamente devido ao ciclo de dependência e abstinência.&lt;br /&gt;
&lt;br /&gt;
Nicotina e vício&lt;br /&gt;
&lt;br /&gt;
A nicotina é viciante? Nem sempre. O vício em nicotina é um comportamento com consequências adversas&lt;br /&gt;
&lt;br /&gt;
para o indivíduo, em vez de uma propriedade universal da molécula de nicotina. A maior parte do que&lt;br /&gt;
&lt;br /&gt;
sabemos sobre a nicotina vem de estudos sobre o comportamento de fumar. No caso do tabagismo, existe&lt;br /&gt;
&lt;br /&gt;
uma justificativa clara para parar, a fim de evitar prejuízos significativos à saúde e ao bem-estar. No entanto,&lt;br /&gt;
&lt;br /&gt;
quando há muito menos dano, a motivação para parar é provavelmente menor, e as consequências de não&lt;br /&gt;
&lt;br /&gt;
parar são reduzidas. Por isso, as definições de vício tendem a enfatizar o uso compulsivo e prejudicial, e é&lt;br /&gt;
&lt;br /&gt;
necessário cuidado ao definir termos como “vício” (ver abaixo). É por isso que tratamos a cafeína e nossa&lt;br /&gt;
&lt;br /&gt;
necessidade de café pela manhã de forma diferente — podemos ser dependentes, mas ela não causa muito&lt;br /&gt;
&lt;br /&gt;
dano⁴². Se a nicotina é viciante depende da definição usada, das características do usuário (por exemplo,&lt;br /&gt;
&lt;br /&gt;
genética, estresse ou outros fatores que aumentam a intensidade do uso), do padrão de uso do usuário, e dométodo de administração da nicotina.&lt;br /&gt;
&lt;br /&gt;
Definições de vício. Se a nicotina é “viciante” também depende, crucialmente, da definição escolhida para o&lt;br /&gt;
&lt;br /&gt;
termo “vício”. Este é um termo carregado e estigmatizante, e frequentemente usado de forma imprecisa⁴³. A&lt;br /&gt;
&lt;br /&gt;
maioria das definições formais de vício exige não apenas uso dependente e compulsivo, mas também danos&lt;br /&gt;
&lt;br /&gt;
significativos ao usuário⁴⁴. Por exemplo, a definição de vício usada na Addiction Ontology é a seguinte⁴⁵:&lt;br /&gt;
&lt;br /&gt;
Uma disposição mental para episódios repetidos de níveis anormalmente altos de motivação&lt;br /&gt;
&lt;br /&gt;
para se engajar em um comportamento, adquirida como resultado do engajamento no&lt;br /&gt;
&lt;br /&gt;
comportamento, onde esse comportamento resulta em risco ou ocorrência de dano líquido&lt;br /&gt;
&lt;br /&gt;
grave.&lt;br /&gt;
&lt;br /&gt;
O Instituto Nacional de Abuso de Drogas dos EUA (NIDA) também inclui consequências adversas em sua&lt;br /&gt;
&lt;br /&gt;
definição⁴⁶ ⁴⁷:&lt;br /&gt;
&lt;br /&gt;
O vício é uma doença crônica caracterizada pela busca e uso compulsivo de drogas, ou difícil de&lt;br /&gt;
&lt;br /&gt;
controlar, apesar das consequências prejudiciais.&lt;br /&gt;
&lt;br /&gt;
A Associação Psiquiátrica Americana prefere o título mais clinicamente preciso de transtorno por uso de&lt;br /&gt;
&lt;br /&gt;
substâncias (SUD) em vez de vício⁴⁸:&lt;br /&gt;
&lt;br /&gt;
O transtorno por uso de substâncias (SUD) é uma condição complexa na qual há uso&lt;br /&gt;
&lt;br /&gt;
descontrolado de uma substância, apesar das consequências prejudiciais. Pessoas com SUD&lt;br /&gt;
&lt;br /&gt;
têm um foco intenso – às vezes chamado de vício – no uso de uma ou mais substâncias, como&lt;br /&gt;
&lt;br /&gt;
álcool, tabaco ou outras substâncias psicoativas, a ponto de sua capacidade de funcionar no&lt;br /&gt;
&lt;br /&gt;
dia a dia ficar comprometida.&lt;br /&gt;
&lt;br /&gt;
Transtorno por uso de substâncias. Na psiquiatria, o termo “vício” foi amplamente substituído pelo conceito&lt;br /&gt;
&lt;br /&gt;
mais nuançado de transtorno por uso de substâncias, que considera diferentes dimensões do dano. O&lt;br /&gt;
&lt;br /&gt;
Manual Diagnóstico e Estatístico de Transtornos Mentais, Quinta Edição (DSM-5), da Associação Psiquiátrica&lt;br /&gt;
&lt;br /&gt;
Americana, refere-se ao transtorno por uso de substâncias (SUD), incluindo o transtorno por uso de tabaco⁴⁹.&lt;br /&gt;
&lt;br /&gt;
Os transtornos por uso de substâncias são avaliados com base em onze critérios⁵⁰, que cobrem quatro&lt;br /&gt;
&lt;br /&gt;
categorias gerais de problema: controle prejudicado, problemas sociais, uso arriscado e dependência física. O&lt;br /&gt;
&lt;br /&gt;
transtorno por uso de substâncias é classificado de leve a grave, de acordo com o número de critérios&lt;br /&gt;
&lt;br /&gt;
atendidos. O transtorno por uso de substâncias grave, envolvendo seis ou mais critérios, às vezes é&lt;br /&gt;
&lt;br /&gt;
considerado equivalente, em termos clínicos, ao termo mais coloquial “vício”⁵¹ ⁵². O uso da nicotina&lt;br /&gt;
&lt;br /&gt;
geralmente não causa controle prejudicado ou problemas sociais, e sua periculosidade depende fortemente&lt;br /&gt;
&lt;br /&gt;
do tipo de produto utilizado.&lt;br /&gt;
&lt;br /&gt;
A importância do dano na saúde pública. A menos que haja dano significativo ao usuário, à sua família, a&lt;br /&gt;
&lt;br /&gt;
terceiros ou à sociedade em geral, o argumento para uma intervenção de saúde pública para lidar com&lt;br /&gt;
&lt;br /&gt;
qualquer forma de uso de substâncias ou comportamento compulsivo é bastante reduzido. Em sua definição&lt;br /&gt;
&lt;br /&gt;
de “vício”, a Addiction Ontology fornece o seguinte raciocínio:&lt;br /&gt;
&lt;br /&gt;
Esta entidade foca na motivação anormal para se engajar em um comportamento e inclui dano&lt;br /&gt;
&lt;br /&gt;
líquido grave como característica. A razão é limitar a classificação a coisas que justificam um&lt;br /&gt;
&lt;br /&gt;
tratamento e resposta de saúde pública. É uma entidade quantitativa e um conjunto difuso,&lt;br /&gt;
&lt;br /&gt;
pois podem haver diferentes limiares para o grau de dano e intensidade da motivação. Como&lt;br /&gt;
&lt;br /&gt;
resultado, é essencial operacionalizar o termo para que ele seja significativo.&lt;br /&gt;
&lt;br /&gt;
Esse entendimento deve direcionar recursos para a cessação do tabagismo, e também o reconhecimento deque a “cessação do vaping” provavelmente não é um uso custo-efetivo de fundos públicos ou filantrópicos.&lt;br /&gt;
&lt;br /&gt;
Todos os sistemas de saúde fazem racionamento de alguma forma, e gastar os recursos marginais com&lt;br /&gt;
&lt;br /&gt;
cessação do tabagismo ou outras intervenções com melhor custo-benefício em termos de resultados de&lt;br /&gt;
&lt;br /&gt;
saúde por dólar gasto sempre será melhor.&lt;br /&gt;
&lt;br /&gt;
Outros reforçadores. Embora a nicotina seja o agente psicoativo essencial na fumaça do cigarro, existem&lt;br /&gt;
&lt;br /&gt;
outros, incluindo, por exemplo, inibidores da monoamina oxidase (IMAO) encontrados na fumaça. Os IMAOs&lt;br /&gt;
&lt;br /&gt;
inibem a ação da enzima monoamina oxidase, que degrada dopamina e outras monoaminas como a&lt;br /&gt;
&lt;br /&gt;
serotonina, fazendo com que elas se acumulem e persistam por mais tempo, aumentando os efeitos&lt;br /&gt;
&lt;br /&gt;
psicoativos da nicotina⁵³. Isso pode ser uma consideração importante para explicar as diferenças no potencial&lt;br /&gt;
&lt;br /&gt;
de formação de dependência entre diferentes produtos de tabaco e nicotina. O reforço não é apenas&lt;br /&gt;
&lt;br /&gt;
químico; ele também pode ser impulsionado por rituais comportamentais e gatilhos ambientais⁵⁴ ⁵⁵, ou&lt;br /&gt;
&lt;br /&gt;
marketing⁵⁶ ⁵⁷.&lt;br /&gt;
&lt;br /&gt;
Nicotina e potencial de abuso – o dilema do regulador. O uso da nicotina tende a ser mais fortemente&lt;br /&gt;
&lt;br /&gt;
reforçador quando os níveis de nicotina aumentam rapidamente e atingem um nível alto no cérebro, criando&lt;br /&gt;
&lt;br /&gt;
um pico ou “bolus”. O transporte da nicotina à medida que ela é absorvida pelo corpo e levada ao cérebro é&lt;br /&gt;
&lt;br /&gt;
conhecido como farmacocinética, frequentemente abreviado como PK. O perfil PK (a velocidade com que&lt;br /&gt;
&lt;br /&gt;
aumenta, o nível máximo atingido) é determinado principalmente por três fatores interativos:&lt;br /&gt;
&lt;br /&gt;
1.​ a via de administração (por exemplo, por inalação, absorção pela boca ou através da pele);&lt;br /&gt;
&lt;br /&gt;
2.​ as características do produto ou dispositivo (por exemplo, concentração de nicotina, tamanho da&lt;br /&gt;
&lt;br /&gt;
partícula, pH);&lt;br /&gt;
&lt;br /&gt;
3.​ as características individuais do usuário (por exemplo, frequência e profundidade das tragadas para&lt;br /&gt;
&lt;br /&gt;
produtos inalados ou tempo de uso para produtos orais, que podem refletir a força de sua&lt;br /&gt;
&lt;br /&gt;
motivação para usar nicotina).&lt;br /&gt;
&lt;br /&gt;
Potencial de abuso é um conceito usado por reguladores para lidar com a preocupação de que os usuários&lt;br /&gt;
&lt;br /&gt;
possam se tornar dependentes de um produto terapêutico. Para a nicotina, os estudos de farmacocinética&lt;br /&gt;
&lt;br /&gt;
são frequentemente utilizados para caracterizar o potencial de abuso. No entanto, isso pode representar um&lt;br /&gt;
&lt;br /&gt;
dilema ao avaliar alternativas de risco reduzido baseadas no consumo, como vapes ou sachês. O perfil PK&lt;br /&gt;
&lt;br /&gt;
também pode refletir sua eficácia como substitutos do cigarro, correspondendo ao perfil PK experimentado&lt;br /&gt;
&lt;br /&gt;
como recompensa pelos fumantes. Reguladores farmacêuticos geralmente exigiram que os fabricantes de&lt;br /&gt;
&lt;br /&gt;
terapias de reposição de nicotina (NRT) mantivessem o potencial de abuso baixo, mas isso provavelmente&lt;br /&gt;
&lt;br /&gt;
tornou os NRT menos eficazes para a cessação do tabagismo⁵⁸ ⁵⁹ ⁶⁰.&lt;br /&gt;
&lt;br /&gt;
O desafio de regular a exposição à nicotina&lt;br /&gt;
&lt;br /&gt;
Os usuários controlam sua exposição à nicotina, e isso pode levar a efeitos contra intuitivos. Não é&lt;br /&gt;
&lt;br /&gt;
surpresa que os consumidores de álcool controlem a quantidade que consomem, bebendo volumes maiores&lt;br /&gt;
&lt;br /&gt;
de cerveja e volumes menores de uísque para atingir a mesma ingestão de álcool. Os bebedores fazem isso&lt;br /&gt;
&lt;br /&gt;
por meio de goles mais profundos e frequentes de cerveja e de goles pequenos de uísque. Para facilitar isso,&lt;br /&gt;
&lt;br /&gt;
a cerveja é servida em copos maiores e geralmente sem canudo, para não restringir o fluxo. Há equivalentes&lt;br /&gt;
&lt;br /&gt;
para a nicotina: os usuários controlam ou “titulam” sua ingestão de nicotina variando a profundidade e&lt;br /&gt;
&lt;br /&gt;
frequência das tragadas (conhecido como “topografia de tragadas”) e escolhendo produtos que facilitem a&lt;br /&gt;
&lt;br /&gt;
exposição desejada sem esforço excessivo. Isso cria um efeito conhecido como “compensação”, no qual os&lt;br /&gt;
&lt;br /&gt;
usuários ajustam seu comportamento em resposta a mudanças na disponibilidade da nicotina⁶¹ ⁶². Por&lt;br /&gt;
&lt;br /&gt;
exemplo, reduzir a concentração de nicotina pode levar a uma maior inalação de aerossol para alcançar a&lt;br /&gt;
&lt;br /&gt;
mesma exposição.Tentativas de medir e regular a entrega de nicotina. Várias abordagens para caracterizar e regular a&lt;br /&gt;
&lt;br /&gt;
exposição à nicotina foram propostas. Como discutido abaixo, elas podem ser ineficazes, enganosas ou até&lt;br /&gt;
&lt;br /&gt;
contraproducentes.&lt;br /&gt;
&lt;br /&gt;
●​ Rendimento de nicotina. Essa abordagem foi comum até os anos 2000, quando se tornou&lt;br /&gt;
&lt;br /&gt;
impossível ignorar suas falhas. O rendimento de nicotina é uma medida da quantidade de nicotina&lt;br /&gt;
&lt;br /&gt;
emitida pelo produto durante o uso, sob regimes padronizados de fumo com uma máquina de&lt;br /&gt;
&lt;br /&gt;
fumar⁶³. O rendimento é a massa de nicotina retida em um filtro, relatada em mg por cigarro,&lt;br /&gt;
&lt;br /&gt;
normalmente entre 0,1 e 3,0 mg por unidade⁶⁴. O desafio é que as pessoas ajustam seu&lt;br /&gt;
&lt;br /&gt;
comportamento de fumar (“compensação”) para obter a nicotina desejada (“titulação”)⁶⁵ ⁶⁶, e isso&lt;br /&gt;
&lt;br /&gt;
varia enormemente entre indivíduos e por fatores como raça⁶⁷, genética⁶⁸ e condição&lt;br /&gt;
&lt;br /&gt;
socioeconômica⁶⁹. Além disso, as indústrias de tabaco projetaram cigarros para apresentar baixa&lt;br /&gt;
&lt;br /&gt;
emissão de alcatrão e nicotina nas máquinas, mas com facilidade de compensação pelo usuário, por&lt;br /&gt;
&lt;br /&gt;
exemplo, incluindo orifícios de ventilação no filtro que podiam ser bloqueados facilmente. Isso levou&lt;br /&gt;
&lt;br /&gt;
à falsa sensação de segurança dos cigarros “light” e “mild”, que exploravam preocupações de saúde&lt;br /&gt;
&lt;br /&gt;
dos fumantes sem reduzir de fato o risco⁷⁰ ⁷¹.&lt;br /&gt;
&lt;br /&gt;
●​ Teor de nicotina no tabaco. Existem propostas para controlar o potencial de dependência dos&lt;br /&gt;
&lt;br /&gt;
cigarros ou do tabaco limitando a concentração de nicotina presente no próprio tabaco⁷² ⁷³. A&lt;br /&gt;
&lt;br /&gt;
desnicotinização é viável e pode ser alcançada por meio de modificação genética ou pela redução&lt;br /&gt;
&lt;br /&gt;
química da nicotina a um nível “sub-dependente”, ou a níveis tão baixos que inviabilizam a&lt;br /&gt;
&lt;br /&gt;
compensação. A principal questão de saúde é como os usuários responderão aos padrões&lt;br /&gt;
&lt;br /&gt;
obrigatórios de baixo teor de nicotina: Eles vão parar de fumar, passarão a fumar cigarros de nicotina&lt;br /&gt;
&lt;br /&gt;
muito baixa, vão migrar para produtos de nicotina mais seguros, buscarão cigarros de nicotina no&lt;br /&gt;
&lt;br /&gt;
mercado ilegal ou encontrarão formas de contornar as regras? Remover a maior parte da nicotina&lt;br /&gt;
&lt;br /&gt;
dos cigarros equivale, na prática, a proibir os cigarros — tal como a maioria das pessoas os utilizam.&lt;br /&gt;
&lt;br /&gt;
Essa proibição de fato apresentaria uma série de desafios que reguladores e legisladores precisam&lt;br /&gt;
&lt;br /&gt;
considerar com cuidado. Isso inclui aceitação pública, especialmente entre os afetados,impacto na&lt;br /&gt;
&lt;br /&gt;
agricultura e nas cadeias de suprimento, aplicação da lei, corrupção e efeitos comunitários, comércio&lt;br /&gt;
&lt;br /&gt;
ilícito e perda de arrecadação tributária.&lt;br /&gt;
&lt;br /&gt;
●​ Concentração de nicotina em e-líquidos. A União Europeia estabelece uma concentração máxima&lt;br /&gt;
&lt;br /&gt;
de nicotina para e-líquidos de 20 mg/ml (cerca de 2% em volume)⁷⁴, e essa abordagem regulatória&lt;br /&gt;
&lt;br /&gt;
foi adotada em outras jurisdições⁷⁵. A questão envolve tanto a aceitação pelos consumidores quanto&lt;br /&gt;
&lt;br /&gt;
a compensação pelo usuário: as pessoas consomem volumes maiores de líquidos mais fracos para&lt;br /&gt;
&lt;br /&gt;
atingir a dose de nicotina preferida. No entanto, isso pode aumentar a exposição a contaminantes e&lt;br /&gt;
&lt;br /&gt;
a produtos tóxicos da decomposição térmica — sem alterar significativamente sua exposição à&lt;br /&gt;
&lt;br /&gt;
nicotina⁷⁶ ⁷⁷.&lt;br /&gt;
&lt;br /&gt;
●​ Fluxo de nicotina. Essa medida avalia a taxa de fluxo de nicotina emitida por um produto (por&lt;br /&gt;
&lt;br /&gt;
exemplo, microgramas de nicotina por segundo de tragada)⁷⁸ ⁷⁹. Embora seja destinada a servir&lt;br /&gt;
&lt;br /&gt;
como um indicador da entrega de nicotina, os parâmetros que definem o fluxo de nicotina não&lt;br /&gt;
&lt;br /&gt;
capturam todos os fatores que determinam a entrega efetiva de nicotina ao usuário. O principal&lt;br /&gt;
&lt;br /&gt;
desafio é que o usuário controla esse fluxo ao variar a frequência, profundidade e duração das&lt;br /&gt;
&lt;br /&gt;
tragadas. Os proponentes desse método sugerem limitar o efeito do comportamento do usuário&lt;br /&gt;
&lt;br /&gt;
tornando os dispositivos de ENDS (sistemas eletrônicos de entrega de nicotina) semelhantes a&lt;br /&gt;
&lt;br /&gt;
produtos com dose medida, entregando uma dose fixa ou limitada de nicotina⁸⁰. No entanto, isso&lt;br /&gt;
&lt;br /&gt;
deve ser visto como uma admissão de que a ideia é inviável. Se essa dose for muito baixa ou se o uso&lt;br /&gt;
&lt;br /&gt;
do produto for frustrante ou insatisfatório, os usuários buscarão alternativas, incluindo cigarros ou&lt;br /&gt;
&lt;br /&gt;
produtos de vape que forneçam a dose desejada de nicotina.●​ “Potencial de abuso” da nicotina. Isso envolveria a imposição de limites à farmacocinética (PK) —&lt;br /&gt;
&lt;br /&gt;
ou seja, ao pico (“bolus”) da exposição à nicotina no cérebro — o nível máximo (“Cmax”) e o tempo&lt;br /&gt;
&lt;br /&gt;
até atingir esse pico (“Tmax”), ou a razão Cmax/Tmax⁸¹. Mais uma vez, esses fatores estão&lt;br /&gt;
&lt;br /&gt;
majoritariamente sob o controle do usuário, embora possam ser influenciados por restrições do&lt;br /&gt;
&lt;br /&gt;
dispositivo. Para produtos de baixo risco, há uma ambiguidade sobre a finalidade regulatória.&lt;br /&gt;
&lt;br /&gt;
Deveria ser reduzir o potencial de abuso para impedir que os produtos gerem dependência ou&lt;br /&gt;
&lt;br /&gt;
deveria ser igualar o perfil PK dos cigarros e, assim, fornecer uma alternativa satisfatória, viável e de&lt;br /&gt;
&lt;br /&gt;
baixo risco ao fumo, que funcione para pessoas que fumam?&lt;br /&gt;
&lt;br /&gt;
O ponto geral é que tentar controlar o uso de nicotina limitando os dispositivos ou líquidos pelos quais ela é&lt;br /&gt;
&lt;br /&gt;
consumida provavelmente falhará. Os usuários acabarão acessando a nicotina que desejam. Seria como&lt;br /&gt;
&lt;br /&gt;
tentar controlar o uso de álcool limitando o tamanho dos copos de vinho ou obrigando as pessoas a beber&lt;br /&gt;
&lt;br /&gt;
com canudo.&lt;br /&gt;
&lt;br /&gt;
Efeitos da nicotina na saúde&lt;br /&gt;
&lt;br /&gt;
Efeitos da nicotina na saúde. Citar a observação de Michael Russell, de 1976 — *“As pessoas fumam pela&lt;br /&gt;
&lt;br /&gt;
nicotina, mas morrem pelo alcatrão”*⁸² — tornou-se comum para transmitir a ideia de que não é a nicotina a&lt;br /&gt;
&lt;br /&gt;
principal causa direta de doenças e mortes relacionadas ao tabagismo. É o motivo pelo qual as pessoas&lt;br /&gt;
&lt;br /&gt;
fumam e, como consequência, se expõem a milhares de substâncias tóxicas presentes na fumaça do cigarro.&lt;br /&gt;
&lt;br /&gt;
Essa percepção ainda se mantém verdadeira hoje. A liderança da Food and Drug Administration (FDA) dos&lt;br /&gt;
&lt;br /&gt;
EUA reiterou esse ponto em 2017, ao definir uma abordagem estratégica para a nicotina⁸³:&lt;br /&gt;
&lt;br /&gt;
“A nicotina, embora não seja inofensiva, não é diretamente responsável pelos cânceres,&lt;br /&gt;
&lt;br /&gt;
doenças pulmonares e doenças cardíacas causadas pelo tabaco que matam centenas de&lt;br /&gt;
&lt;br /&gt;
milhares de americanos todos os anos.”&lt;br /&gt;
&lt;br /&gt;
Mas se a própria nicotina não é a responsável direta pelas principais doenças relacionadas ao tabagismo,&lt;br /&gt;
&lt;br /&gt;
quais são os riscos residuais? Estudos epidemiológicos sobre tabaco sem combustão⁸⁴ ⁸⁵ ⁸⁶ ⁸⁷ ou uso&lt;br /&gt;
&lt;br /&gt;
prolongado de terapias de reposição de nicotina (nicotina farmacêutica)⁸⁸ ⁸⁹ sugerem que os riscos de&lt;br /&gt;
&lt;br /&gt;
doenças graves atribuíveis à nicotina são baixos ou surgem apenas em circunstâncias limitadas, quando o&lt;br /&gt;
&lt;br /&gt;
consumo de nicotina é dissociado da inalação da fumaça.&lt;br /&gt;
&lt;br /&gt;
●​ Mortalidade por todas as causas. Pesquisas contínuas com usuários exclusivamente de tabaco sem&lt;br /&gt;
&lt;br /&gt;
combustão (SLT) nos EUA não demonstram aumento no risco de mortalidade: “Usuários de SLT, em&lt;br /&gt;
&lt;br /&gt;
geral, não apresentaram risco significativamente aumentado de mortalidade por todas as causas,&lt;br /&gt;
&lt;br /&gt;
mortalidade por câncer em geral ou doenças cardíacas em comparação com pessoas que nunca&lt;br /&gt;
&lt;br /&gt;
usaram tabaco [...] Além disso, o uso de SLT não teve efeito adverso discernível em nenhuma das&lt;br /&gt;
&lt;br /&gt;
nove principais causas de morte, nem aumentou o risco de mortalidade por nenhum dos principais&lt;br /&gt;
&lt;br /&gt;
cânceres frequentemente associados ao uso de SLT.”⁹⁰&lt;br /&gt;
&lt;br /&gt;
●​ Doença cardiovascular. Não há evidência de risco cardiovascular generalizado atribuível à nicotina,&lt;br /&gt;
&lt;br /&gt;
mas pode haver risco específico da nicotina para pessoas com doenças cardiovasculares&lt;br /&gt;
&lt;br /&gt;
preexistentes⁹¹:&lt;br /&gt;
&lt;br /&gt;
“Os riscos da nicotina sem os produtos da combustão do tabaco (fumaça do cigarro) são baixos&lt;br /&gt;
&lt;br /&gt;
em comparação com o tabagismo, mas ainda assim são motivo de preocupação para pessoas&lt;br /&gt;
&lt;br /&gt;
com doenças cardiovasculares.”&lt;br /&gt;
&lt;br /&gt;
Estudos sobre o uso de nicotina sem exposição à fumaça, por exemplo, o uso de snus, não&lt;br /&gt;
&lt;br /&gt;
demonstram aumento no risco cardiovascular, indicando que “componentes tóxicos diferentesda nicotina parecem estar implicados na fisiopatologia da doença cardíaca isquêmica&lt;br /&gt;
&lt;br /&gt;
relacionada ao tabagismo”⁹² e “O uso de snus não foi associado ao risco de AVC. Assim, é&lt;br /&gt;
&lt;br /&gt;
improvável que a nicotina contribua de forma significativa para a fisiopatologia do acidente&lt;br /&gt;
&lt;br /&gt;
vascular cerebral.”⁹³&lt;br /&gt;
&lt;br /&gt;
●​ Câncer. O Relatório do Cirurgião-Geral dos EUA de 2014 concluiu⁹⁴:&lt;br /&gt;
&lt;br /&gt;
“As evidências são insuficientes para inferir a presença ou ausência de uma relação causal&lt;br /&gt;
&lt;br /&gt;
entre exposição à nicotina e risco de câncer.”&lt;br /&gt;
&lt;br /&gt;
Entretanto, o relatório menciona estudos em animais indicando que a nicotina “é um promotor&lt;br /&gt;
&lt;br /&gt;
tumoral em alguns modelos experimentais”, mas cita dados epidemiológicos sugerindo que&lt;br /&gt;
&lt;br /&gt;
“em humanos a nicotina pode não ter um forte efeito promotor tumoral”. Na medida em que o&lt;br /&gt;
&lt;br /&gt;
tabaco sem combustão apresenta qualquer risco de câncer, as evidências sugerem que isso se&lt;br /&gt;
&lt;br /&gt;
deve à exposição a compostos que não a nicotina⁹⁵ ⁹⁶.&lt;br /&gt;
&lt;br /&gt;
●​ Doença respiratória. As evidências não apoiam uma ligação entre exposição sistêmica à nicotina e&lt;br /&gt;
&lt;br /&gt;
doenças respiratórias. Embora não haja evidência conclusiva, é possível que a exposição direta de&lt;br /&gt;
&lt;br /&gt;
células pulmonares à nicotina⁹⁷, ou a agentes perigosos além da nicotina em aerossóis inalados de&lt;br /&gt;
&lt;br /&gt;
nicotina, possa gerar risco respiratório.&lt;br /&gt;
&lt;br /&gt;
●​ Gravidez. O tabagismo está claramente associado a uma série de desfechos negativos na gravidez⁹⁸.&lt;br /&gt;
&lt;br /&gt;
No entanto, grande parte disso provavelmente se deve à exposição a toxinas presentes na fumaça&lt;br /&gt;
&lt;br /&gt;
do tabaco, que não são a nicotina. O Cirurgião-Geral dos EUA concluiu⁹⁹:&lt;br /&gt;
&lt;br /&gt;
“Evidências de estudos sobre interações gene-ambiente apoiam a hipótese de que&lt;br /&gt;
&lt;br /&gt;
componentes do tabaco além da nicotina podem contribuir para os desfechos adversos&lt;br /&gt;
&lt;br /&gt;
relacionados ao tabaco na gravidez.”&lt;br /&gt;
&lt;br /&gt;
Um ensaio clínico com mais de 1.000 gestantes fumantes descobriu que “O uso regular de cigarros&lt;br /&gt;
&lt;br /&gt;
eletrônicos ou adesivos de nicotina por gestantes fumantes não parece estar associado a quaisquer desfechos&lt;br /&gt;
&lt;br /&gt;
adversos.”¹⁰⁰ Embora a maioria dos estudos não encontre riscos decorrentes do uso de vapes durante a&lt;br /&gt;
&lt;br /&gt;
gravidez, as evidências podem ser de baixa qualidade ou contraditórias.¹⁰¹&lt;br /&gt;
&lt;br /&gt;
Impactos no cérebro adolescente. Houve alto nível de preocupação política, midiática e pública em relação&lt;br /&gt;
&lt;br /&gt;
aos efeitos da nicotina sobre o cérebro em desenvolvimento. O Cirurgião-Geral dos EUA destacou isso como&lt;br /&gt;
&lt;br /&gt;
uma descoberta significativa no relatório de 2016 E-Cigarette Use Among Youth and Young Adults.¹⁰² No&lt;br /&gt;
&lt;br /&gt;
entanto, a base de evidência subjacente é fraca, baseada em modelos animais ou sujeita a confusões como&lt;br /&gt;
&lt;br /&gt;
fatores genéticos e socioeconômicos, uso de outras substâncias e presença prévia de problemas&lt;br /&gt;
&lt;br /&gt;
neuropsiquiátricos associados ao tabagismo na juventude.¹⁰³ Se houvesse prejuízos perceptíveis relacionados&lt;br /&gt;
&lt;br /&gt;
ao uso de nicotina na adolescência, eles seriam observáveis nas gerações de adultos que fumaram durante a&lt;br /&gt;
&lt;br /&gt;
juventude. No entanto, não há evidência convincente disso: um estudo constatou que “O tabagismo anterior&lt;br /&gt;
&lt;br /&gt;
não foi associado a desempenho significativamente inferior em qualquer domínio cognitivo, em comparação&lt;br /&gt;
&lt;br /&gt;
com pessoas que nunca fumaram.”¹⁰⁴ Evidências recentes indicam ainda outro desafio a esse argumento: há&lt;br /&gt;
&lt;br /&gt;
indícios de que diferenças na estrutura cerebral podem anteceder e prever o início do uso de substâncias¹⁰⁵,&lt;br /&gt;
&lt;br /&gt;
com a exposição à poluição ambiental como possível causa subjacente.¹⁰⁶&lt;br /&gt;
&lt;br /&gt;
Saúde mental. Há índices significativamente mais altos de uso de nicotina em populações com transtornos&lt;br /&gt;
&lt;br /&gt;
mentais, como TDAH, transtornos de ansiedade e depressão. É plausível que o uso de nicotina por essas&lt;br /&gt;
&lt;br /&gt;
populações seja uma tentativa, consciente ou inconsciente, de automedicação ou regulação desses&lt;br /&gt;
&lt;br /&gt;
transtornos.¹⁰⁷ ¹⁰⁸ Também é possível que o uso de nicotina possa causar ou intensificar esses transtornos, ouque a relação causal seja bidirecional.¹⁰⁹ ¹¹⁰ É intrinsecamente difícil isolar a direção da causalidade nessa&lt;br /&gt;
&lt;br /&gt;
associação, e as evidências atuais são contraditórias e incertas.¹¹¹ ¹¹²&lt;br /&gt;
&lt;br /&gt;
Percepções públicas e profissionais sobre os riscos da nicotina são profundamente imprecisas. Existe um&lt;br /&gt;
&lt;br /&gt;
corpo extenso de literatura que apoia a análise de que “as pessoas fumam pela nicotina, mas morrem pelo&lt;br /&gt;
&lt;br /&gt;
alcatrão” ou suas muitas variações. No entanto, o conhecimento público sobre os conceitos básicos de risco&lt;br /&gt;
&lt;br /&gt;
relacionados à nicotina é muito deficiente. Por exemplo, nos Estados Unidos, um estudo de 2022 constatou&lt;br /&gt;
&lt;br /&gt;
que 61,2% dos fumantes acreditam que a nicotina causa câncer ou não sabem; os autores pediram&lt;br /&gt;
&lt;br /&gt;
mensagens corretivas.¹¹³ Na Nova Zelândia, propostas para reduzir o teor de nicotina dos cigarros foram mal&lt;br /&gt;
&lt;br /&gt;
interpretadas como medidas para tornar os produtos mais seguros.¹¹⁴ No Reino Unido, em 2021, apenas 11%&lt;br /&gt;
&lt;br /&gt;
dos fumantes reconheceram que ‘nenhum’ ou ‘uma quantidade muito pequena’ dos riscos à saúde do&lt;br /&gt;
&lt;br /&gt;
tabagismo vêm da nicotina presente nos cigarros de tabaco.¹¹⁵ Diversas pesquisas mostram que mesmo&lt;br /&gt;
&lt;br /&gt;
profissionais de saúde compartilham essas percepções equivocadas. Por exemplo, um estudo nos EUA de&lt;br /&gt;
&lt;br /&gt;
2021 constatou:¹¹⁶&lt;br /&gt;
&lt;br /&gt;
No geral, a maioria dos médicos “concordava fortemente” que a nicotina contribui diretamente&lt;br /&gt;
&lt;br /&gt;
para o desenvolvimento de doenças cardiovasculares (83,2%), DPOC (80,9%) e câncer (80,5%).&lt;br /&gt;
&lt;br /&gt;
Essas percepções errôneas sobre a nicotina também sustentam equívocos sobre os riscos do vaping e outras&lt;br /&gt;
&lt;br /&gt;
opções de nicotina sem fumaça, criando uma barreira à substituição do cigarro por alternativas menos&lt;br /&gt;
&lt;br /&gt;
nocivas. O problema é que crenças falsas sobre riscos influenciam o comportamento e inibem mudanças&lt;br /&gt;
&lt;br /&gt;
benéficas, tanto na intenção quanto na ação.&lt;br /&gt;
&lt;br /&gt;
Conclusão&lt;br /&gt;
&lt;br /&gt;
Quando usada como pretendido, a nicotina é uma substância psicoativa relativamente benigna e não causa&lt;br /&gt;
&lt;br /&gt;
overdose, intoxicação, alucinações, torpor ou outros efeitos extremos típicos de drogas. As pessoas usam&lt;br /&gt;
&lt;br /&gt;
nicotina porque ela as faz se sentirem melhor e acreditarem que funcionam melhor, e isso sustenta a&lt;br /&gt;
&lt;br /&gt;
demanda pela substância. A nicotina em si não causa a vasta maioria dos danos relacionados ao tabaco,&lt;br /&gt;
&lt;br /&gt;
embora tenha alguns efeitos adversos e riscos à saúde. O uso da nicotina pode criar dependência, tanto pelo&lt;br /&gt;
&lt;br /&gt;
reforço positivo (efeitos prazerosos) quanto pelos efeitos negativos da abstinência e do desejo. Pode ser&lt;br /&gt;
&lt;br /&gt;
difícil parar de usá-la. Podemos considerar a dependência de nicotina como um vício se o usuário não&lt;br /&gt;
&lt;br /&gt;
consegue parar apesar de sofrer danos significativos, como acontece no tabagismo contínuo.&lt;br /&gt;
&lt;br /&gt;
Durante os últimos 100 anos, a nicotina foi consumida principalmente por meio da inalação de fumaça tóxica&lt;br /&gt;
&lt;br /&gt;
de tabaco. No entanto, isso está mudando à medida que o mundo inicia uma transição para formas de&lt;br /&gt;
&lt;br /&gt;
nicotina sem fumaça (vapes, sachês, tabaco aquecido e sem combustão). Isso abre uma série de desafios e&lt;br /&gt;
&lt;br /&gt;
oportunidades para políticas públicas. Esses produtos podem atender à demanda por nicotina com danos&lt;br /&gt;
&lt;br /&gt;
significativamente reduzidos em comparação com o tabaco fumado. Mas isso também significa a perda do&lt;br /&gt;
&lt;br /&gt;
principal fator dissuasivo ao uso da nicotina: os danos causados pelo fumo. A emergência da nicotina como&lt;br /&gt;
&lt;br /&gt;
uma droga relativamente benigna, sem grandes danos associados ao seu uso, exige uma reavaliação&lt;br /&gt;
&lt;br /&gt;
profunda da posição da nicotina como substância legal (assim como a cafeína, o álcool e, cada vez mais, os&lt;br /&gt;
&lt;br /&gt;
canabinóides) na sociedade.&lt;br /&gt;
&lt;br /&gt;
Regulamentar o uso da nicotina é um desafio, porque os usuários em grande parte controlam sua própria&lt;br /&gt;
&lt;br /&gt;
ingestão por meio de mudanças de comportamento, de produto ou, em última instância, buscando&lt;br /&gt;
&lt;br /&gt;
fornecedores ilícitos dos produtos desejados. Os formuladores de políticas devem aceitar que a demanda&lt;br /&gt;
&lt;br /&gt;
por nicotina é inevitável e provavelmente persistirá indefinidamente. Nesse caso, o desafio regulatório é&lt;br /&gt;
&lt;br /&gt;
tornar a nicotina disponível em mercados regulados, com fornecedores legais atendendo à demanda adulta,&lt;br /&gt;
&lt;br /&gt;
com garantias para aumentar a conscientização, controlar marketing e branding, e limitar o acesso.Referências&lt;br /&gt;
&lt;br /&gt;
1&lt;br /&gt;
&lt;br /&gt;
National Library of Medicine (US), PubChem. Nicotine C10H14N2.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://pubchem.ncbi.nlm.nih.gov/compound/89594&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
2&lt;br /&gt;
&lt;br /&gt;
Siegmund, B., Leitner, E., &amp;amp; Pfannhauser, W. (1999). Determination of the nicotine content of various edible nightshades&lt;br /&gt;
&lt;br /&gt;
(Solanaceae) and their products and estimation of the associated dietary nicotine intake. Journal of Agricultural and&lt;br /&gt;
&lt;br /&gt;
Food Chemistry, 47(8), 3113–3120. &amp;lt;nowiki&amp;gt;https://doi.org/10.1021/jf990089w&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
3Benowitz, N. L., &amp;amp; Jacob, P. (1984). Daily intake of nicotine during cigarette smoking. Clinical Pharmacology and&lt;br /&gt;
&lt;br /&gt;
Therapeutics, 35(4), 499–504. [link]. Smokers average 37.6mg/day nicotine intake, but dietary intake typically&lt;br /&gt;
&lt;br /&gt;
2.25µg/day (Sigmund et al. op cit) suggesting an approximately 17,000-fold difference.&lt;br /&gt;
&lt;br /&gt;
4Duke, D., Wohlgemuth, E., Adams, K. R., Armstrong-Ingram, A., Rice, S. K., &amp;amp; Young, D. C. (2022). Earliest evidence for&lt;br /&gt;
&lt;br /&gt;
human use of tobacco in the Pleistocene Americas. Nature Human Behaviour, 6(2), 183–192.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1038/s41562-021-01202-9&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
5National Cancer Institute. Definition of psychoactive substance (2011, February 2) [link]&lt;br /&gt;
&lt;br /&gt;
6&lt;br /&gt;
&lt;br /&gt;
Balfour, D. J. K. (2004). The neurobiology of tobacco dependence: A preclinical perspective on the role of the&lt;br /&gt;
&lt;br /&gt;
dopamine projections to the nucleus. Nicotine &amp;amp; Tobacco Research, 6(6), 899–912.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1080/14622200412331324965&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
7&lt;br /&gt;
&lt;br /&gt;
National Institute on Drug Abuse (US). How does tobacco deliver its effects?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://nida.nih.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/how-does-tobacco-deliver-its&amp;lt;/nowiki&amp;gt; effects&lt;br /&gt;
&lt;br /&gt;
8&lt;br /&gt;
&lt;br /&gt;
Benowitz, N. L. (2008). Neurobiology of nicotine addiction: Implications for smoking cessation treatment. The American&lt;br /&gt;
&lt;br /&gt;
Journal of Medicine, 121(4 Suppl 1), S3-10. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.amjmed.2008.01.015&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
9&lt;br /&gt;
&lt;br /&gt;
Beer, A. L. (2016). Chapter 27 - Nicotine and Cognition: Effects of Nicotine on Attention and Memory Systems in Humans. In&lt;br /&gt;
&lt;br /&gt;
V. R. Preedy (Ed.), Neuropathology of Drug Addictions and Substance Misuse (pp. 282–290). Academic Press. [link]&lt;br /&gt;
&lt;br /&gt;
10Valentine, G., &amp;amp; Sofuoglu, M. (2018). Cognitive Effects of Nicotine: Recent Progress. Current Neuropharmacology, 16(4),&lt;br /&gt;
&lt;br /&gt;
403–414. [link]&lt;br /&gt;
&lt;br /&gt;
11Alhowail, A. (2021). Molecular insights into the benefits of nicotine on memory and cognition (Review). Molecular&lt;br /&gt;
&lt;br /&gt;
Medicine Reports, 23(6), 1–6. &amp;lt;nowiki&amp;gt;https://doi.org/10.3892/mmr.2021.12037&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
12Choi, D., Ota, S., &amp;amp; Watanuki, S. (2015). Does cigarette smoking relieve stress? Evidence from the event-related&lt;br /&gt;
&lt;br /&gt;
potential (ERP). International Journal of Psychophysiology, 98(3, Part 1), 470–476.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.ijpsycho.2015.10.005&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
13&lt;br /&gt;
&lt;br /&gt;
Kutlu, M. G., &amp;amp; Gould, T. J. (2015). Nicotine Modulation of Fear Memories and Anxiety: Implications for Learning and&lt;br /&gt;
&lt;br /&gt;
Anxiety Disorders. Biochemical Pharmacology, 97(4), 498–511. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.bcp.2015.07.029&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
14&lt;br /&gt;
&lt;br /&gt;
Heishman, S. J., Kleykamp, B. A., &amp;amp; Singleton, E. G. (2010). Meta-analysis of the acute effects of nicotine and smoking on&lt;br /&gt;
&lt;br /&gt;
human performance. Psychopharmacology, 210(4), 453–469.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151730/&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
15Benowitz, N. L. (2009). Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annual Review&lt;br /&gt;
&lt;br /&gt;
of Pharmacology and Toxicology, 49, 57. [link]&lt;br /&gt;
&lt;br /&gt;
16Benowitz, N. L. (2010). Nicotine Addiction. The New England Journal of Medicine, 362(24), 2295–2303. [link][NCBI]&lt;br /&gt;
&lt;br /&gt;
17&lt;br /&gt;
&lt;br /&gt;
Mappin-Kasirer, B., Pan, H., Lewington, S., Kizza, J., Gray, R., Clarke, R., &amp;amp; Peto, R. (2020). Tobacco smoking and the risk of&lt;br /&gt;
&lt;br /&gt;
Parkinson disease. Neurology, 10.1212/WNL.0000000000009437.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1212/WNL.0000000000009437&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
18Yang, F., Pedersen, N. L., Ye, W., Liu, Z., Norberg, M., Forsgren, L., Trolle Lagerros, Y., Bellocco, R., Alfredsson, L., Knutsson,&lt;br /&gt;
&lt;br /&gt;
A., Jansson, J.-H., Wennberg, P., Galanti, M. R., Lager, A. C., Araghi, M., Lundberg, M., Magnusson, C., &amp;amp; Wirdefeldt, K.&lt;br /&gt;
&lt;br /&gt;
(2017). Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease. International Journal of Epidemiology, 46(3),&lt;br /&gt;
&lt;br /&gt;
872–880. &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ije/dyw294&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
19Zhang, W., Lin, H., Zou, M., Yuan, Q., Huang, Z., Pan, X., &amp;amp; Zhang, W. (2022). Nicotine in Inflammatory Diseases:&lt;br /&gt;
&lt;br /&gt;
Anti-Inflammatory and Pro-Inflammatory Effects. Frontiers in Immunology, 13.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.3389/fimmu.2022.826889&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
20Kastratovic, N., Markovic, V., Arsenijevic, A., Volarevic, A., Zdravkovic, N., Zdravkovic, M., Brankovic, M., Gmizic, T., Harrell,&lt;br /&gt;
&lt;br /&gt;
C. R., Jakovljevic, V., Djonov, V., &amp;amp; Volarevic, V. (2024). The effects of combustible cigarettes and electronic nicotine&lt;br /&gt;
&lt;br /&gt;
delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis. Nicotine &amp;amp; Tobacco&lt;br /&gt;
&lt;br /&gt;
Research, ntae193. &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntae193&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
21van Amsterdam, J., van der Velde, B., Schulte, M., &amp;amp; van den Brink, W. (2018). Causal Factors of Increased Smoking in&lt;br /&gt;
&lt;br /&gt;
ADHD: A Systematic Review. Substance Use &amp;amp; Misuse, 53(3), 432–445.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1080/10826084.2017.133406622&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Liebrenz, M., Frei, A., Fisher, C. E., Gamma, A., Buadze, A., &amp;amp; Eich, D. (2014). Adult attention-deficit/hyperactivity&lt;br /&gt;
&lt;br /&gt;
disorder and nicotine use: A qualitative study of patient perceptions. BMC Psychiatry, 14(1), 141.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1186/1471-244X-14-141&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
23&lt;br /&gt;
&lt;br /&gt;
Potter, A. S., &amp;amp; Newhouse, P. A. (2008). Acute nicotine improves cognitive deficits in young adults with attention&lt;br /&gt;
&lt;br /&gt;
deficit/hyperactivity disorder. Pharmacology Biochemistry and Behavior, 88(4), 407–417.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.pbb.2007.09.014&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
24&lt;br /&gt;
&lt;br /&gt;
Shytle, R. D., Silver, A. A., Wilkinson, B. J., &amp;amp; Sanberg, P. R. (2002). A Pilot Controlled Trial of Transdermal Nicotine in the&lt;br /&gt;
&lt;br /&gt;
Treatment of Attention Deficit Hyperactivity Disorder. The World Journal of Biological Psychiatry.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.3109/15622970209150616&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
25&lt;br /&gt;
&lt;br /&gt;
Waterhouse, U., Brennan, K. A., &amp;amp; Ellenbroek, B. A. (2018). Nicotine self-administration reverses cognitive deficits in a rat&lt;br /&gt;
&lt;br /&gt;
model for schizophrenia. Addiction Biology, 23(2), 620–630. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/adb.12517&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
26&lt;br /&gt;
&lt;br /&gt;
Morisano, D., Wing, V. C., Sacco, K. A., Arenovich, T., &amp;amp; George, T. P. (2013). Effects of Tobacco Smoking on&lt;br /&gt;
&lt;br /&gt;
Neuropsychological Function in Schizophrenia in Comparison to Other Psychiatric Disorders and Non-psychiatric Controls. The&lt;br /&gt;
&lt;br /&gt;
American Journal on Addictions, 22(1), 46–53. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/j.1521-0391.2013.00313.x&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
27&lt;br /&gt;
&lt;br /&gt;
Sacco, K. A., Termine, A., Seyal, A., Dudas, M. M., Vessicchio, J. C., Krishnan-Sarin, S., Jatlow, P. I., Wexler, B. E., &amp;amp; George, T.&lt;br /&gt;
&lt;br /&gt;
P. (2005). Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in Schizophrenia: Involvement of&lt;br /&gt;
&lt;br /&gt;
Nicotinic Receptor Mechanisms. Archives of General Psychiatry, 62(6), 649–659. &amp;lt;nowiki&amp;gt;https://doi.org/10.1001/archpsyc.62.6.649&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
28Featherstone, R. E., &amp;amp; Siegel, S. J. (2015). Chapter Two—The Role of Nicotine in Schizophrenia. In M. De Biasi (Ed.),&lt;br /&gt;
&lt;br /&gt;
International Review of Neurobiology (Vol. 124, pp. 23–78). Academic Press.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1016/bs.irn.2015.07.002&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
29Featherstone, R. E., &amp;amp; Siegel, S. J. (2015). Chapter Two—The Role of Nicotine in Schizophrenia. In M. De Biasi (Ed.),&lt;br /&gt;
&lt;br /&gt;
International Review of Neurobiology (Vol. 124, pp. 23–78). Academic Press.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1016/bs.irn.2015.07.002&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
30Simons, D., Shahab, L., Brown, J., &amp;amp; Perski, O. (2021). The association of smoking status with SARS-CoV-2 infection,&lt;br /&gt;
&lt;br /&gt;
hospitalisation and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (version 12).&lt;br /&gt;
&lt;br /&gt;
Qeios. &amp;lt;nowiki&amp;gt;https://doi.org/10.32388/UJR2AW.15&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
31Farsalinos, K., Niaura, R., Le Houezec, J., Barbouni, A., Tsatsakis, A., Kouretas, D., Vantarakis, A., &amp;amp; Poulas, K. (2020).&lt;br /&gt;
&lt;br /&gt;
Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicology&lt;br /&gt;
&lt;br /&gt;
Reports, 7, 658–663. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.toxrep.2020.04.012&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
32&lt;br /&gt;
&lt;br /&gt;
Tyas, S., &amp;amp; Pederson, L. (1998). Psychosocial factors related to adolescent smoking: A critical review of the literature.&lt;br /&gt;
&lt;br /&gt;
Tobacco Control, 7(4), 409–420. &amp;lt;nowiki&amp;gt;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751465/&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
33&lt;br /&gt;
&lt;br /&gt;
Wellman, R. J., Dugas, E. N., Dutczak, H., O’Loughlin, E. K., Datta, G. D., Lauzon, B., &amp;amp; O’Loughlin, J. (2016). Predictors of&lt;br /&gt;
&lt;br /&gt;
the Onset of Cigarette Smoking: A Systematic Review of Longitudinal Population-Based Studies in Youth. American Journal&lt;br /&gt;
&lt;br /&gt;
of Preventive Medicine, 51(5), 767–778. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.amepre.2016.04.003&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
34&lt;br /&gt;
&lt;br /&gt;
Siddiqi, K., Jawad, M., Mushtaq, N., Ali, S., &amp;amp; Khan, J. A. (2015). Tobacco and Health Disparities. BioMed Research&lt;br /&gt;
&lt;br /&gt;
International, 2015(1), 570173. &amp;lt;nowiki&amp;gt;https://doi.org/10.1155/2015/570173&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
35&lt;br /&gt;
&lt;br /&gt;
Leventhal, A. M., Bello, M. S., Galstyan, E., Higgins, S. T., &amp;amp; Barrington-Trimis, J. L. (2019). Association of Cumulative&lt;br /&gt;
&lt;br /&gt;
Socioeconomic and Health-Related Disadvantage With Disparities in Smoking Prevalence in the United States, 2008 to&lt;br /&gt;
&lt;br /&gt;
2017. JAMA Internal Medicine, 179(6), 777–785. &amp;lt;nowiki&amp;gt;https://doi.org/10.1001/jamainternmed.2019.0192&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
36&lt;br /&gt;
&lt;br /&gt;
Kastaun, S., Brose, L. S., Scholz, E., Viechtbauer, W., &amp;amp; Kotz, D. (2022). Mental Health Symptoms and Associations with&lt;br /&gt;
&lt;br /&gt;
Tobacco Smoking, Dependence, Motivation, and Attempts to Quit: Findings from a Population Survey in Germany (DEBRA&lt;br /&gt;
&lt;br /&gt;
Study). European Addiction Research, 28(4), 287–296. &amp;lt;nowiki&amp;gt;https://doi.org/10.1159/000523973&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
37Glasser, A. M., Hinton, A., Wermert, A., Macisco, J., &amp;amp; Nemeth, J. M. (2022). Characterizing tobacco and marijuana use&lt;br /&gt;
&lt;br /&gt;
among youth combustible tobacco users experiencing homelessness – considering product type, brand, flavor, frequency,&lt;br /&gt;
&lt;br /&gt;
and higher-risk use patterns and predictors. BMC Public Health, 22(1), 820.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1186/s12889-022-13244-3&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
38Ganz, O., Schulz, J. A., Ehlke, S. J., King Jensen, J. L., &amp;amp; Villanti, A. C. (2024). Cigarette smoking behaviors and nicotine&lt;br /&gt;
&lt;br /&gt;
dependence at the intersection of sexual identity and sex in the United States: Findings from the National Survey on&lt;br /&gt;
&lt;br /&gt;
Drug Use and Health. Preventive Medicine Reports, 38, 102593.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.pmedr.2024.102593&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
39Arrazola, R. A. (2023). US Cigarette Smoking Disparities by Race and Ethnicity—Keep Going and Going! Preventing Chronic&lt;br /&gt;
&lt;br /&gt;
Disease, 20. &amp;lt;nowiki&amp;gt;https://doi.org/10.5888/pcd20.220375&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
40&lt;br /&gt;
&lt;br /&gt;
Hiscock, R., Bauld, L., Amos, A., Fidler, J. A., &amp;amp; Munafò, M. (2012). Socioeconomic status and smoking: A review. Annals of&lt;br /&gt;
&lt;br /&gt;
the New York Academy of Sciences, 1248(1), 107–123. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/j.1749-6632.2011.06202.x&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
41&lt;br /&gt;
&lt;br /&gt;
Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E., Schmeichel, B., Vendruscolo, L. F., Wade, C. L.,&lt;br /&gt;
&lt;br /&gt;
Whitfield, T. W., &amp;amp; George, O. (2014). Addiction as a Stress Surfeit Disorder. Neuropharmacology, 76(0 0),&lt;br /&gt;
&lt;br /&gt;
10.1016/j.neuropharm.2013.05.024. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.neuropharm.2013.05.024&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
42&lt;br /&gt;
&lt;br /&gt;
Fagerstrom, K. (2018). A Comparison of Dependence across Different Types of Nicotine Containing Products and Coffee.&lt;br /&gt;
&lt;br /&gt;
International Journal of Environmental Research and Public Health, 15(8).&amp;lt;nowiki&amp;gt;https://doi.org/10.3390/IJERPH15081609&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
43&lt;br /&gt;
&lt;br /&gt;
National Institute on Drug Abuse (NIDA). (2021). Words Matter: Preferred Language for Talking About Addiction.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://nida.nih.gov/research-topics/addiction-science/words-matter-preferred-language-talking-about-addiction&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
44&lt;br /&gt;
&lt;br /&gt;
West, R., Cox, S., Notley, C. J., Plessis, G. D., &amp;amp; Hastings, J. (n.d.). Achieving consensus, coherence, clarity and consistency&lt;br /&gt;
&lt;br /&gt;
when talking about addiction. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/add.16393&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
45&lt;br /&gt;
&lt;br /&gt;
AddictO Vocab. Addiction. Accessed 10 September 2024, from &amp;lt;nowiki&amp;gt;https://addictovocab.org/ADDICTO:0000349&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
46&lt;br /&gt;
&lt;br /&gt;
National Institute on Drug Abuse (NIDA). Drug Misuse and Addiction, What is drug addiction?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
47&lt;br /&gt;
&lt;br /&gt;
National Institute on Drug Abuse (NIDA). Understanding Drug Use and Addiction DrugFacts, accessed 10 September&lt;br /&gt;
&lt;br /&gt;
2024. &amp;lt;nowiki&amp;gt;https://nida.nih.gov/publications/drugfacts/understanding-drug-use-addiction&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
48&lt;br /&gt;
&lt;br /&gt;
American Psychiatric Association.. Addiction and Substance Use Disorders. Retrieved 11 September 2024, from&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.psychiatry.org:443/patients-families/addiction-substance-use-disorders&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
49&lt;br /&gt;
&lt;br /&gt;
Diagnostic and Statistical Manual of Mental Disorders | Psychiatry Online. (2023.). DSM Library. Retrieved 10 September&lt;br /&gt;
&lt;br /&gt;
2024, from &amp;lt;nowiki&amp;gt;https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
50&lt;br /&gt;
&lt;br /&gt;
Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry,&lt;br /&gt;
&lt;br /&gt;
N. M., Schuckit, M., &amp;amp; Grant, B. F. (2013). DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. The&lt;br /&gt;
&lt;br /&gt;
American Journal of Psychiatry, 170(8), 834–851.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1176/appi.ajp.2013.12060782&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
51Gateway Foundation, G. (2021, June 15). DSM-5 Criteria for Substance Use Disorders.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.gatewayfoundation.org/addiction-blog/dsm-5-substance-use-disorder/&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
52Addiction Policy Forum. (2020, August 17). DSM-5 Criteria for Addiction Simplified.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.addictionpolicy.org/post/dsm-5-facts-and-figures&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
53&lt;br /&gt;
&lt;br /&gt;
Hong, S. W., et al. (2022). Biologically Active Compounds Present in Tobacco Smoke: Potential Interactions Between&lt;br /&gt;
&lt;br /&gt;
Smoking and Mental Health. Frontiers in Neuroscience, 16. &amp;lt;nowiki&amp;gt;https://doi.org/10.3389/fnins.2022.885489&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
54&lt;br /&gt;
&lt;br /&gt;
Shiffman, S., Dunbar, M., Kirchner, T., Li, X., Tindle, H., Anderson, S., &amp;amp; Scholl, S. (2013). Smoker reactivity to cues: Effects&lt;br /&gt;
&lt;br /&gt;
on craving and on smoking behavior. Journal of Abnormal Psychology, 122(1), 264–280. &amp;lt;nowiki&amp;gt;https://doi.org/10.1037/a0028339&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
55&lt;br /&gt;
&lt;br /&gt;
Chiamulera, C. (2005). Cue reactivity in nicotine and tobacco dependence: A “multiple-action” model of nicotine as a&lt;br /&gt;
&lt;br /&gt;
primary reinforcement and as an enhancer of the effects of smoking-associated stimuli. Brain Research Reviews, 48(1),&lt;br /&gt;
&lt;br /&gt;
74–97. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.brainresrev.2004.08.005&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
56&lt;br /&gt;
&lt;br /&gt;
Saad, C., Cheng, B. (Hsu-C., Takamizawa, R., Thakur, A., Lee, C.-W., Leung, L., Veerman, J. L., &amp;amp; Aminde, L. N. (2025).&lt;br /&gt;
&lt;br /&gt;
Effectiveness of tobacco advertising, promotion and sponsorship bans on smoking prevalence, initiation and cessation: A&lt;br /&gt;
&lt;br /&gt;
systematic review and meta-analysis. Tobacco Control. &amp;lt;nowiki&amp;gt;https://doi.org/10.1136/tc-2024-058903&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
57&lt;br /&gt;
&lt;br /&gt;
Lovato, C., Watts, A., &amp;amp; Stead, L. F. (n.d.). Impact of tobacco advertising and promotion on increasing adolescent smoking&lt;br /&gt;
&lt;br /&gt;
behaviours—Lovato, C - 2011 | Cochrane Library. Retrieved 11 May 2025, from&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003439.pub2/full&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
58&lt;br /&gt;
&lt;br /&gt;
Le Houezec, J. (2003). Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: A review.&lt;br /&gt;
&lt;br /&gt;
The International Journal of Tuberculosis and Lung Disease, 7(9), 811–819.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.ingentaconnect.com/content/iuatld/ijtld/2003/00000007/00000009/art00002&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
59&lt;br /&gt;
&lt;br /&gt;
Schneider, N. G., Olmstead, R. E., Franzon, M. A., &amp;amp; Lunell, E. (2001). The Nicotine Inhaler. Clinical&lt;br /&gt;
&lt;br /&gt;
Pharmacokinetics, 40(9), 661–684. &amp;lt;nowiki&amp;gt;https://doi.org/10.2165/00003088-200140090-00003&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
60&lt;br /&gt;
&lt;br /&gt;
Azzopardi, D., Ebajemito, J., McEwan, M., Camacho, O. M., Thissen, J., Hardie, G., Voisine, R., Mullard, G., Cohen, Z., &amp;amp;&lt;br /&gt;
&lt;br /&gt;
Murphy, J. (2022). A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two&lt;br /&gt;
&lt;br /&gt;
nicotine replacement therapy products. Scientific Reports, 12(1), 6949. &amp;lt;nowiki&amp;gt;https://doi.org/10.1038/s41598-022-&amp;lt;/nowiki&amp;gt; 10544-x&lt;br /&gt;
&lt;br /&gt;
61&lt;br /&gt;
&lt;br /&gt;
Ashton, H., Stepney, R., &amp;amp; Thompson, J. W. (1979). Self-titration by cigarette smokers. British Medical Journal,&lt;br /&gt;
&lt;br /&gt;
2(6186), 357–360. &amp;lt;nowiki&amp;gt;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1596095/&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
62Soar, K., Kimber, C., McRobbie, H., &amp;amp; Dawkins, L. E. (2019). Nicotine absorption from e-cigarettes over 12 months.&lt;br /&gt;
&lt;br /&gt;
Addictive Behaviors, 91, 102–105. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.addbeh.2018.07.019&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
63International Standards Organisation. (2021, June). ISO 10315:2021 Cigarettes—Determination of nicotine in total&lt;br /&gt;
&lt;br /&gt;
particulate matter from the mainstream smoke—Gas-chromatographic method. ISO.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.iso.org/standard/79002.html&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
64Kuiper, N., Coats, E. M., Crawford, T. N., Gammon, D. G., Loomis, B., Watson, C. H., Melstrom, P. C., Lavinghouze, R., Rogers,&lt;br /&gt;
&lt;br /&gt;
T., &amp;amp; King, B. A. (2020). Trends in Manufacturer-Reported Nicotine Yields in Cigarettes Sold in the United States,&lt;br /&gt;
&lt;br /&gt;
2013–2016. Preventing Chronic Disease, 17, E148. &amp;lt;nowiki&amp;gt;https://doi.org/10.5888/pcd17.200205&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
65Jarvis, M. J., Boreham, R., Primatesta, P., Feyerabend, C., &amp;amp; Bryant, A. (2001). Nicotine Yield From Machine-Smoked&lt;br /&gt;
&lt;br /&gt;
Cigarettes and Nicotine Intakes in Smokers: Evidence From a Representative Population Survey. JNCI: Journal of the&lt;br /&gt;
&lt;br /&gt;
National Cancer Institute, 93(2), 134–138. &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/jnci/93.2.134&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
66Maron, D. J., &amp;amp; Fortmann, S. P. (1987). Nicotine yield and measures of cigarette smoke exposure in a largepopulation: Are lower-yield cigarettes safer? American Journal of Public Health, 77(5), 546–549.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.2105/ajph.77.5.546&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
67MacKillop, J., Obasi, E., Amlung, M. T., McGeary, J. E., &amp;amp; Knopik, V. S. (2010). The Role of Genetics in Nicotine&lt;br /&gt;
&lt;br /&gt;
Dependence: Mapping the Pathways from Genome to Syndrome. Current Cardiovascular Risk Reports, 4(6), 446– 453.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1007/s12170-010-0132-6&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
68St Helen, G., Dempsey, D., Wilson, M., Jacob, P., &amp;amp; Benowitz, N. L. (2013). Racial differences in the relationship between&lt;br /&gt;
&lt;br /&gt;
tobacco dependence and nicotine and carcinogen exposure. Addiction (Abingdon, England), 108(3), 607– 617.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1111/j.1360-0443.2012.04077.x&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
69Pan, C., Qi, X., Cheng, S., Chen, Y., Li, C., Zhang, H., Zhang, J., Zhang, Z., Yang, X., Meng, P., Yao, Y., Wen, Y., Jia, Y., &amp;amp; Zhang, F.&lt;br /&gt;
&lt;br /&gt;
(2024). The Comprehensive Effect of Socioeconomic Deprivation on Smoking Behavior: An Observational and&lt;br /&gt;
&lt;br /&gt;
Genome-Wide by Environment Interaction Analyses in UK Biobank. International Journal of Mental Health and&lt;br /&gt;
&lt;br /&gt;
Addiction, 22(1), 344–360. &amp;lt;nowiki&amp;gt;https://doi.org/10.1007/s11469-022-00876-0&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
70Mutti, S., Hammond, D., Borland, R., Cummings, K. M., O’Connor, R. J., &amp;amp; Fong, G. T. (2011). Beyond Light &amp;amp; Mild: Cigarette&lt;br /&gt;
&lt;br /&gt;
Brand Descriptors and Perceptions of Risk in the International Tobacco Control (ITC) Four Country Survey. Addiction&lt;br /&gt;
&lt;br /&gt;
(Abingdon, England), 106(6), 1166–1175. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/j.1360-0443.2011.03402.x&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
71Mutti, S., Hammond, D., Borland, R., Cummings, K. M., O’Connor, R. J., &amp;amp; Fong, G. T. (2011). Beyond Light &amp;amp; Mild: Cigarette&lt;br /&gt;
&lt;br /&gt;
Brand Descriptors and Perceptions of Risk in the International Tobacco Control (ITC) Four Country Survey. Addiction&lt;br /&gt;
&lt;br /&gt;
(Abingdon, England), 106(6), 1166–1175. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/j.1360-0443.2011.03402.x&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
72Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products, 90 FR 5032&lt;br /&gt;
&lt;br /&gt;
5032 (2025). &amp;lt;nowiki&amp;gt;https://www.federalregister.gov/d/2025-00397&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
73WHO Study Group on Tobacco Product Regulation (TobReg). (2015). Advisory note: Global nicotine reduction strategy.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.who.int/publications/i/item/advisory-note-global-nicotine-reduction-strategy-who-study&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
group-on-tobacco-product-regulation&lt;br /&gt;
&lt;br /&gt;
74European Union. (2014, April 3). Tobacco Products Directive 2014/40/EU. EUR-Lex. &amp;lt;nowiki&amp;gt;https://eur&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
lex.europa.eu/eli/dir/2014/40/oj/eng&lt;br /&gt;
&lt;br /&gt;
75Institute for Global Tobacco Control. Product regulation | Global Tobacco Control. Johns Hopkins School of Global Public&lt;br /&gt;
&lt;br /&gt;
Health. Retrieved 11 May 2025, from &amp;lt;nowiki&amp;gt;https://www.globaltobaccocontrol.org/en/policy-scan/e&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
cigarettes/product-regulation&lt;br /&gt;
&lt;br /&gt;
76Dawkins, L., Cox, S., Goniewicz, M., McRobbie, H., Kimber, C., Doig, M., &amp;amp; Kośmider, L. (2018). ‘Real-world’&lt;br /&gt;
&lt;br /&gt;
compensatory behaviour with low nicotine concentration e-liquid: Subjective effects and nicotine, acrolein and&lt;br /&gt;
&lt;br /&gt;
formaldehyde exposure. Addiction, 113(10), 1874–1882. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/add.14271&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
77Kośmider, L., Kimber, C. F., Kurek, J., Corcoran, O., &amp;amp; Dawkins, L. E. (2018). Compensatory Puffing With Lower Nicotine&lt;br /&gt;
&lt;br /&gt;
Concentration E-liquids Increases Carbonyl Exposure in E-cigarette Aerosols. Nicotine &amp;amp; Tobacco Research, 20(8),&lt;br /&gt;
&lt;br /&gt;
998–1003. &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntx162&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
78&lt;br /&gt;
&lt;br /&gt;
Shihadeh, A., &amp;amp; Eissenberg, T. (2015). Electronic Cigarette Effectiveness and Abuse Liability: Predicting and&lt;br /&gt;
&lt;br /&gt;
Regulating Nicotine Flux. Nicotine &amp;amp; Tobacco Research, 17(2), 158–162. &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntu175&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
79&lt;br /&gt;
&lt;br /&gt;
El-Hellani, A., Hanna, E., Sharma, M., Blohowiak, R., Joseph, P., Eid, T., Nadim, H., El-Hage, R., Salman, R.,&lt;br /&gt;
&lt;br /&gt;
Karaoghlanian, N., Adeniji, A., Salam, S., Talih, F., Elbejjani, M., Breland, A., Eissenberg, T., Shihadeh, A., Baldassarri, S.&lt;br /&gt;
&lt;br /&gt;
R., &amp;amp; Talih, S. (2023). Nicotine flux as a powerful tool for regulating nicotine delivery from e cigarettes: Protocol of&lt;br /&gt;
&lt;br /&gt;
two complimentary randomized crossover clinical trials. PLOS ONE, 18(9), e0291786.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1371/journal.pone.0291786&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
80Patev, A. J., Combs, M., Gaitan, N., Karaoghlanian, N., Lipato, T., Eissenberg, T., &amp;amp; Breland, A. (2024). Constraining&lt;br /&gt;
&lt;br /&gt;
electronic nicotine delivery systems (ENDS) nicotine dose by controlling nicotine flux at a limited puff duration.&lt;br /&gt;
&lt;br /&gt;
Experimental and Clinical Psychopharmacology, 32(5), 604–614. &amp;lt;nowiki&amp;gt;https://doi.org/10.1037/pha0000719&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
81Kolli, A. R., Veljkovic, E., Calvino-Martin, F., Esposito, M., Kuczaj, A. K., Koumal, O., Rose, J. E., &amp;amp; Peitsch, M. C. (2024).&lt;br /&gt;
&lt;br /&gt;
Nicotine flux and pharmacokinetics-based considerations for early assessment of nicotine delivery systems. Drug and&lt;br /&gt;
&lt;br /&gt;
Alcohol Dependence Reports, 11, 100245. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.dadr.2024.100245&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
82Russell, M. A. (1976). Low-tar medium-nicotine cigarettes: A new approach to safer smoking. British Medical&lt;br /&gt;
&lt;br /&gt;
Journal, 1(6023), 1430–1433. 10.1136/bmj.1.6023.1430&lt;br /&gt;
&lt;br /&gt;
83Gottlieb, S., &amp;amp; Zeller, M. (2017) A Nicotine-Focused Framework for Public Health The New England Journal of&lt;br /&gt;
&lt;br /&gt;
Medicine; Massachusetts Medical Society. &amp;lt;nowiki&amp;gt;https://doi.org/10.1056/NEJMp1707409&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
84Fisher, M. T., Tan-Torres, S. M., Gaworski, C. L., Black, R. A., &amp;amp; Sarkar, M. A. (2019). Smokeless tobacco mortality risks: An&lt;br /&gt;
&lt;br /&gt;
analysis of two contemporary nationally representative longitudinal mortality studies. Harm Reduction Journal, 16, 27.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1186/s12954-019-0294-6&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
85Rodu, B., &amp;amp; Plurphanswat, N. (2019). Mortality among male smokers and smokeless tobacco users in the USA. Harm&lt;br /&gt;
&lt;br /&gt;
Reduction Journal, 16(1), 50. &amp;lt;nowiki&amp;gt;https://doi.org/10.1186/s12954-019-0321-7&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
86Lee, P. N. (2011). Summary of the epidemiological evidence relating snus to health. Regulatory Toxicology and&lt;br /&gt;
&lt;br /&gt;
Pharmacology, 59(2), 197–214. [link]&lt;br /&gt;
&lt;br /&gt;
87Lee, P. N. (2013). Epidemiological evidence relating snus to health – an updated review based on recentpublications. Harm Reduction Journal, 10(1), 36. [link]&lt;br /&gt;
&lt;br /&gt;
88&lt;br /&gt;
&lt;br /&gt;
Food and Drug Administration (United States) Modifications To Labeling of Nicotine Replacement Therapy Products for&lt;br /&gt;
&lt;br /&gt;
Over-the-Counter Human Use. (2013, April 2). Federal Register. 78 FR 19718&lt;br /&gt;
&lt;br /&gt;
89&lt;br /&gt;
&lt;br /&gt;
Murray, R. P., Connett, J. E., &amp;amp; Zapawa, L. M. (2009). Does nicotine replacement therapy cause cancer? Evidence from&lt;br /&gt;
&lt;br /&gt;
the Lung Health Study. Nicotine &amp;amp; Tobacco Research, 11(9), 1076–1082. &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntp104&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
90&lt;br /&gt;
&lt;br /&gt;
Fisher, M. T., Tan-Torres, S. M., Gaworski, C. L., Black, R. A., &amp;amp; Sarkar, M. A. (2019). Smokeless tobacco mortality&lt;br /&gt;
&lt;br /&gt;
risks: An analysis of two contemporary nationally representative longitudinal mortality studies. Harm Reduction&lt;br /&gt;
&lt;br /&gt;
Journal, 16(1), 27. &amp;lt;nowiki&amp;gt;https://doi.org/10.1186/s12954-019-0294-6&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
91&lt;br /&gt;
&lt;br /&gt;
Benowitz, N. L., &amp;amp; Burbank, A. D. (2016). Cardiovascular Toxicity of Nicotine: Implications for Electronic Cigarette Use.&lt;br /&gt;
&lt;br /&gt;
Trends in Cardiovascular Medicine, 26(6), 515–523. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.tcm.2016.03.001&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
92&lt;br /&gt;
&lt;br /&gt;
Hansson, J., Galanti, M. R., Hergens, M.-P., Fredlund, P., Ahlbom, A., Alfredsson, L., Bellocco, R., Eriksson, M., Hallqvist, J.,&lt;br /&gt;
&lt;br /&gt;
Hedblad, B., Jansson, J.-H., Nilsson, P., Pedersen, N., Trolle Lagerros, Y., Östergren, P.-O., &amp;amp; Magnusson, C. (2012). Use of&lt;br /&gt;
&lt;br /&gt;
snus and acute myocardial infarction: Pooled analysis of eight prospective observational studies. European Journal of&lt;br /&gt;
&lt;br /&gt;
Epidemiology, 27(10), 771–779. &amp;lt;nowiki&amp;gt;https://doi.org/10.1007/s10654-012-&amp;lt;/nowiki&amp;gt; 9704-8&lt;br /&gt;
&lt;br /&gt;
93&lt;br /&gt;
&lt;br /&gt;
Hansson, J., Galanti, M. R., Hergens, M.-P., Fredlund, P., Ahlbom, A., Alfredsson, L., Bellocco, R., Engström, G., Eriksson, M.,&lt;br /&gt;
&lt;br /&gt;
Hallqvist, J., Hedblad, B., Jansson, J.-H., Pedersen, N. L., Trolle Lagerros, Y., Östergren, P.-O., &amp;amp; Magnusson, C. (2014). Snus&lt;br /&gt;
&lt;br /&gt;
(Swedish smokeless tobacco) use and risk of stroke: Pooled analyses of incidence and survival. Journal of Internal&lt;br /&gt;
&lt;br /&gt;
Medicine, 276(1), 87–95. &amp;lt;nowiki&amp;gt;https://doi.org/10.1111/joim.12219&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
94&lt;br /&gt;
&lt;br /&gt;
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. (2014).&lt;br /&gt;
&lt;br /&gt;
Nicotine (Chapter 5). In The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General.&lt;br /&gt;
&lt;br /&gt;
Centers for Disease Control and Prevention (US). &amp;lt;nowiki&amp;gt;https://www.ncbi.nlm.nih.gov/books/NBK294308/&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
95Valen, H., Becher, R., Vist, G. E., Holme, J. A., Mdala, I., Elvsaas, I.-K. Ø., Alexander, J., Underland, V., Brinchmann, B. C., &amp;amp;&lt;br /&gt;
&lt;br /&gt;
Grimsrud, T. K. (2023). A systematic review of cancer risk among users of smokeless tobacco (Swedish snus) exclusively,&lt;br /&gt;
&lt;br /&gt;
compared with no use of tobacco. International Journal of Cancer, 153(12), 1942–1953.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1002/ijc.34643&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
96Warnakulasuriya, S., &amp;amp; Straif, K. (2018). Carcinogenicity of smokeless tobacco: Evidence from studies in humans &amp;amp;&lt;br /&gt;
&lt;br /&gt;
experimental animals. The Indian Journal of Medical Research, 148(6), 681–686.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.4103/ijmr.IJMR_149_18&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
97&lt;br /&gt;
&lt;br /&gt;
Mo, R., Zhang, J., Chen, Y., &amp;amp; Ding, Y. (2022). Nicotine promotes chronic obstructive pulmonary disease via inducing&lt;br /&gt;
&lt;br /&gt;
pyroptosis activation in bronchial epithelial cells. Molecular Medicine Reports, 25(3), 92.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.3892/mmr.2022.12608&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
98&lt;br /&gt;
&lt;br /&gt;
Tarasi, B., Cornuz, J., Clair, C., &amp;amp; Baud, D. (2022). Cigarette smoking during pregnancy and adverse perinatal outcomes: A&lt;br /&gt;
&lt;br /&gt;
cross-sectional study over 10 years. BMC Public Health, 22(1), 2403. &amp;lt;nowiki&amp;gt;https://doi.org/10.1186/s12889-&amp;lt;/nowiki&amp;gt; 022-14881-4&lt;br /&gt;
&lt;br /&gt;
99&lt;br /&gt;
&lt;br /&gt;
National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. (2014).&lt;br /&gt;
&lt;br /&gt;
Reproductive Outcomes. In The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon&lt;br /&gt;
&lt;br /&gt;
General. Centers for Disease Control and Prevention (US). &amp;lt;nowiki&amp;gt;https://www.ncbi.nlm.nih.gov/books/NBK294307/&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
100Pesola, F., Smith, K. M., Phillips-Waller, A., Przulj, D., Griffiths, C., Walton, R., McRobbie, H., Coleman, T., Lewis, S.,&lt;br /&gt;
&lt;br /&gt;
Whitemore, R., Clark, M., Ussher, M., Sinclair, L., Seager, E., Cooper, S., Bauld, L., Naughton, F., Sasieni, P., Manyonda, I., &amp;amp;&lt;br /&gt;
&lt;br /&gt;
Hajek, P. (2024). Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the&lt;br /&gt;
&lt;br /&gt;
Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. Addiction, 119(5), 875–884.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1111/add.16422&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
101Ussher, M., Fleming, J., &amp;amp; Brose, L. (2024). Vaping during pregnancy: A systematic review of health outcomes. BMC&lt;br /&gt;
&lt;br /&gt;
Pregnancy and Childbirth, 24(1), 435. &amp;lt;nowiki&amp;gt;https://doi.org/10.1186/s12884-024-06633-6&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
102National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. (2016). Health&lt;br /&gt;
&lt;br /&gt;
Effects of E-Cigarette Use Among U.S. Youth and Young Adults. In E-Cigarette Use Among Youth and Young Adults: A&lt;br /&gt;
&lt;br /&gt;
Report of the Surgeon General [Internet]. Centers for Disease Control and Prevention (US).&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://www.ncbi.nlm.nih.gov/books/NBK538688/&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
103Balfour, D. J. K., Benowitz, N. L., Colby, S. M., Hatsukami, D. K., Lando, H. A., Leischow, S. J., Lerman, C., Mermelstein, R. J.,&lt;br /&gt;
&lt;br /&gt;
Niaura, R., Perkins, K. A., Pomerleau, O. F., Rigotti, N. A., Swan, G. E., Warner, K. E., &amp;amp; West, R. (2021). Balancing&lt;br /&gt;
&lt;br /&gt;
Consideration of the Risks and Benefits of E-Cigarettes. American Journal of Public Health, 111(9), 1661–1672.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.2105/AJPH.2021.306416&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
104&lt;br /&gt;
&lt;br /&gt;
Corley, J., Gow, A. J., Starr, J. M., &amp;amp; Deary, I. J. (2012). Smoking, childhood IQ, and cognitive function in old age. Journal of&lt;br /&gt;
&lt;br /&gt;
Psychosomatic Research, 73(2), 132–138. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.jpsychores.2012.03.006&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
105&lt;br /&gt;
&lt;br /&gt;
Miller, A. P., Baranger, D. A. A., Paul, S. E., Garavan, H., Mackey, S., Tapert, S. F., LeBlanc, K. H., Agrawal, A., &amp;amp; Bogdan, R.&lt;br /&gt;
&lt;br /&gt;
(2024). Neuroanatomical Variability and Substance Use Initiation in Late Childhood and Early Adolescence. JAMA Network&lt;br /&gt;
&lt;br /&gt;
Open, 7(12), e2452027. &amp;lt;nowiki&amp;gt;https://doi.org/10.1001/jamanetworkopen.2024.52027&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
106&lt;br /&gt;
&lt;br /&gt;
Kardan, O., Weigard, A. S., Cope, L. M., Martz, M. M., Angstadt, M., McCurry, K. L., Michael, C., Hardee, J. E., Hyde, L. W.,&lt;br /&gt;
&lt;br /&gt;
Sripada, C., &amp;amp; Heitzeg, M. M. (2024). Functional Brain Connectivity Predictors of Prospective Substance Use Initiation andTheir Environmental Correlates. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.bpsc.2024.10.002&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
107&lt;br /&gt;
&lt;br /&gt;
Newhouse, P., And, A. S., &amp;amp; Potter, A. (n.d.). Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders.&lt;br /&gt;
&lt;br /&gt;
Current Topics in Medicinal Chemistry, 4(3), 267–282. &amp;lt;nowiki&amp;gt;https://doi.org/10.2174/1568026043451401&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
108&lt;br /&gt;
&lt;br /&gt;
Mihailescu, S., &amp;amp; Drucker-Colı́ n, R. (2000). Nicotine, Brain Nicotinic Receptors, and Neuropsychiatric Disorders. Archives of&lt;br /&gt;
&lt;br /&gt;
Medical Research, 31(2), 131–144. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/S0188-4409(99)00087-9&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
109&lt;br /&gt;
&lt;br /&gt;
Lechner, W. V., Janssen, T., Kahler, C. W., Audrain-McGovern, J., &amp;amp; Leventhal, A. M. (2017). Bi-directional associations of&lt;br /&gt;
&lt;br /&gt;
electronic and combustible cigarette use onset patterns with depressive symptoms in adolescents. Preventive Medicine, 96,&lt;br /&gt;
&lt;br /&gt;
73–78. &amp;lt;nowiki&amp;gt;https://doi.org/10.1016/j.ypmed.2016.12.034&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
110Kutlu, M. G., Parikh, V., &amp;amp; Gould, T. J. (2015). Chapter Seven—Nicotine Addiction and Psychiatric Disorders. In M. De Biasi&lt;br /&gt;
&lt;br /&gt;
(Ed.), International Review of Neurobiology (Vol. 124, pp. 171–208). Academic Press.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1016/bs.irn.2015.08.004&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
111Fluharty, M., Taylor, A. E., Grabski, M., &amp;amp; Munafò, M. R. (2017). The Association of Cigarette Smoking With&lt;br /&gt;
&lt;br /&gt;
Depression and Anxiety: A Systematic Review. Nicotine &amp;amp; Tobacco Research, 19(1), 3–13.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntw140&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
112Farooqui, M., Shoaib, S., Afaq, H., Quadri, S., Zaina, F., Baig, A., Liaquat, A., Sarwar, Z., Zafar, A., &amp;amp; Younus, S. (2023).&lt;br /&gt;
&lt;br /&gt;
Bidirectionality of smoking and depression in adolescents: A systematic review. Trends in Psychiatry and&lt;br /&gt;
&lt;br /&gt;
Psychotherapy, 45, e20210429. &amp;lt;nowiki&amp;gt;https://doi.org/10.47626/2237-6089-2021-0429&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
113Weiger, C., Moran, M. B., Kennedy, R. D., Limaye, R., &amp;amp; Cohen, J. (2022). Beliefs and Characteristics Associated With&lt;br /&gt;
&lt;br /&gt;
Believing Nicotine Causes Cancer: A Descriptive Analysis to Inform Corrective Message Content and Priority Audiences.&lt;br /&gt;
&lt;br /&gt;
Nicotine &amp;amp; Tobacco Research, 24(8), 1264–1272. &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntac060&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
114&lt;br /&gt;
&lt;br /&gt;
Gendall, P., Popova, L., Thrasher, J., &amp;amp; Hoek, J. (2024). Nicotine beliefs and perceptions of low nicotine labels and&lt;br /&gt;
&lt;br /&gt;
mitigating statements among people who do and do not smoke: A cross-sectional study from Aotearoa New Zealand.&lt;br /&gt;
&lt;br /&gt;
Tobacco Control, tc-2023-058353. &amp;lt;nowiki&amp;gt;https://doi.org/10.1136/tc-2023-058353&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
115&lt;br /&gt;
&lt;br /&gt;
McNeill, A, Simonavičius, E, Brose, LS, Taylor, E, East, K, Zuikova, E, Calder, R and Robson, D (2022). Nicotine vaping in&lt;br /&gt;
&lt;br /&gt;
England: an evidence update including health risks and perceptions, September 2022. A report commissioned by the&lt;br /&gt;
&lt;br /&gt;
Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://bit.ly/3Gj5NhV&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
116&lt;br /&gt;
&lt;br /&gt;
Steinberg, M. B., Bover Manderski, M. T., Wackowski, O. A., Singh, B., Strasser, A. A., &amp;amp; Delnevo, C. D. (2021).&lt;br /&gt;
&lt;br /&gt;
Nicotine Risk Misperception Among US Physicians. Journal of General Internal Medicine, 36(12), 3888–3890.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;nowiki&amp;gt;https://doi.org/10.1007/s11606-020-06172-8&amp;lt;/nowiki&amp;gt;&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_/_THR_-_Guides_for_Policymakers_%26_Advocates&amp;diff=83771</id>
		<title>Nicotine / THR - Guides for Policymakers &amp; Advocates</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_/_THR_-_Guides_for_Policymakers_%26_Advocates&amp;diff=83771"/>
		<updated>2025-05-14T09:11:28Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: /* 2025: Briefing: Nicotine for Policymakers */&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[file:Policymakers &amp;amp; Advocates.png|center]]&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
=More Information=&lt;br /&gt;
&lt;br /&gt;
===[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Guides_for_Healthcare_and_Social_Services_Professionals Nicotine / THR - Guides for Healthcare and Social Services Professionals]===&lt;br /&gt;
*This related page will provide helpful information for anyone interested in the use of reduced risk nicotine products.&lt;br /&gt;
&lt;br /&gt;
=Advocates= &amp;lt;!--T:1--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===[https://healthdiplomats.com/THR_Downloads/Tobacco_Harm_Reduction_2020.pdf Saving Lives - An Advocates Guide To Tobacco Harm Reduction]=== &amp;lt;!--T:2--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:3--&amp;gt;&lt;br /&gt;
*Written by AHRA - Africa Harm Reduction Alliance - 2020&lt;br /&gt;
&lt;br /&gt;
=Educational Materials= &amp;lt;!--T:4--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===2025: [https://clivebates.com/papers-and-letters/breifing-nicotine-for-policymakers/ Briefing: Nicotine for Policymakers]===&lt;br /&gt;
* Evidence Briefing 5: Nicotine for Policymakers, a narrative discussion with 100+ supporting citations.&lt;br /&gt;
* [[Briefing: Nicotine for Policymakers pt|Briefing: Nicotine for Policymakers (Translated Into Portuguese)]]&lt;br /&gt;
&lt;br /&gt;
===[https://www.clivebates.com/vaping-tobacco-harm-reduction-nicotine-science-and-policy-q-a/ Nicotine science and policy Q &amp;amp; A]=== &amp;lt;!--T:5--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
*By: Clive Bates / The counterfactual&lt;br /&gt;
*&amp;quot;Welcome, this is my (Clive) 2020 Q &amp;amp; A on nicotine science and policy. It mostly focusses on nicotine vaping as an alternative to smoking, but most of the argument also applies to heated tobacco products, modern smokeless tobacco and new oral nicotine products.  It consists of about 60 questions and builds on a brief [https://www.clivebates.com/vaping-policy-rapid-questions-and-answers/ Q &amp;amp; A that I submitted to a consultation], a critique of an absurd [https://www.clivebates.com/world-health-organisation-fails-at-science-and-fails-at-propaganda-the-sad-case-of-whos-anti-vaping-qa/ anti-vaping Q &amp;amp; A by the WHO] and my [https://www.clivebates.com/vaping-risk-compared-to-smoking-challenging-false-dangerous-claim-by-stanton-glantz/ critique of numerous false and misleading claims made by Professor Stanton Glantz].&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===[https://t.co/Lk8XrZ6KRI?amp=1 E-CIGARETTE POLICY BRIEF:  Seven Things Policy Makers Need to Know]=== &amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
*Quick 1 page guide&lt;br /&gt;
*All references are hyperlinked to official WHO and government reports, and peer-reviewed studies&lt;br /&gt;
&lt;br /&gt;
===[https://mailchi.mp/5165e20d33ee/trprblueprint A Blueprint for Better Regulation]=== &amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
*Written by UKVIA - [https://www.ukvia.co.uk/ UK Vaping Industry Association] - 2021&lt;br /&gt;
&lt;br /&gt;
===TPA Series: [https://www.protectingtaxpayers.org/thr-101/ THR 101]===&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Cessation.pdf Cessation]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Dual-Use.pdf Dual Use]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Role-of-Flavors.pdf Flavors]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-THR.pdf Harm Reduction]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Heated-Tobacco.pdf Heated Tobacco (aka: HTP, HnB)]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Popcorn-Lung.pdf Popcorn Lung]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/Tobacco-Vaping-101-Nicotine-Pouches.pdf Nicotine Pouches]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Snus.pdf Snus]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Vaping-Injuries.pdf Vaping Lung Injuries (aka: EVALI)]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Youth-Reasons.pdf Youth Use Reasons]&lt;br /&gt;
&lt;br /&gt;
===[https://www.thr101.org/tobacco-harm-reduction-101-guideboo TOBACCO HARM REDUCTION 101: A GUIDEBOOK FOR POLICYMAKERS]=== &amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
*Written by Lindsey Stroud - Webmaster of [https://www.thr101.org/ Tobacco Harm Reduction 101]&lt;br /&gt;
&lt;br /&gt;
===[https://www.atr.org/tholos-foundation-releases-vaping-tobacco-harm-reduction-the-path-to-saving-millions-of-lives-2023-report/ Vaping &amp;amp; Tobacco Harm Reduction: The Path to Saving Millions of Lives]===&lt;br /&gt;
&lt;br /&gt;
=Why= &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===[https://innco.org/wp-content/uploads/2021/03/INNCO-LMIC-English.pdf 10 reasons why blanket bans of e-cigarettes and HTPs in low- and middle-income countries (LMICs) are not fit for purpose]=== &amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
*Written by INNCO - [https://innco.org/ International Network of Nicotine Consumer Organisations] - 2021&lt;br /&gt;
&lt;br /&gt;
===[https://cei.org/studies/fear-profiteers/ Fear Profiteers: How E-cigarette Panic Benefits Health Activists]=== &amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:17--&amp;gt;&lt;br /&gt;
*Written by Michelle Minton - Competitive Enterprises Institute - 2018&lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=Promoting Harm Reduction Policies=&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/ Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study]===&lt;br /&gt;
*The simulation suggests that the promotion of e-cigarettes as a harm-reduction policy is a viable strategy, given current evidence that e-cigarettes offset or divert from smoking. Given the strong effects of implementation challenges on policy effectiveness in the short term, accurately modeling such obstacles can usefully inform policy design. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/pdf/12954_2021_Article_484.pdf PDF Version]&lt;br /&gt;
*Citation: Selya AS. Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study. Harm Reduct J. 2021;18(1):36. Published 2021 Mar 20. doi:10.1186/s12954-021-00484-6&lt;br /&gt;
*Acknowledgement: This work was supported by the National Institute for General Medical Sciences (NIGMS) within the National Institutes of Health (NIH), grant number P20GM121341; by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education (DIKU), grant number NNA-2016/10023. After the initial submission of this manuscript, AS became employed by Pinney Associates, Inc. which provides consulting services on tobacco harm minimization to JUUL Labs, Inc. The content presented here precedes this competing interest, and JUUL Labs, Inc. and PinneyAssociates, Inc. had any role in the conceptualization, design, analysis, interpretation, or presentation of data, nor in the decision to publish.&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_/_THR_-_Guides_for_Policymakers_%26_Advocates&amp;diff=79083</id>
		<title>Nicotine / THR - Guides for Policymakers &amp; Advocates</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_/_THR_-_Guides_for_Policymakers_%26_Advocates&amp;diff=79083"/>
		<updated>2025-05-14T08:40:46Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: /* Educational Materials */ added translation to clives briefing&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[file:Policymakers &amp;amp; Advocates.png|center]]&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
=More Information=&lt;br /&gt;
&lt;br /&gt;
===[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Guides_for_Healthcare_and_Social_Services_Professionals Nicotine / THR - Guides for Healthcare and Social Services Professionals]===&lt;br /&gt;
*This related page will provide helpful information for anyone interested in the use of reduced risk nicotine products.&lt;br /&gt;
&lt;br /&gt;
=Advocates= &amp;lt;!--T:1--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===[https://healthdiplomats.com/THR_Downloads/Tobacco_Harm_Reduction_2020.pdf Saving Lives - An Advocates Guide To Tobacco Harm Reduction]=== &amp;lt;!--T:2--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:3--&amp;gt;&lt;br /&gt;
*Written by AHRA - Africa Harm Reduction Alliance - 2020&lt;br /&gt;
&lt;br /&gt;
=Educational Materials= &amp;lt;!--T:4--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===2025: [https://clivebates.com/papers-and-letters/breifing-nicotine-for-policymakers/ Briefing: Nicotine for Policymakers]===&lt;br /&gt;
* Evidence Briefing 5: Nicotine for Policymakers, a narrative discussion with 100+ supporting citations.&lt;br /&gt;
* [[Briefing: Nicotine for Policymakers|Briefing: Nicotine for Policymakers (Translated Into Portuguese)]] &lt;br /&gt;
&lt;br /&gt;
===[https://www.clivebates.com/vaping-tobacco-harm-reduction-nicotine-science-and-policy-q-a/ Nicotine science and policy Q &amp;amp; A]=== &amp;lt;!--T:5--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
*By: Clive Bates / The counterfactual&lt;br /&gt;
*&amp;quot;Welcome, this is my (Clive) 2020 Q &amp;amp; A on nicotine science and policy. It mostly focusses on nicotine vaping as an alternative to smoking, but most of the argument also applies to heated tobacco products, modern smokeless tobacco and new oral nicotine products.  It consists of about 60 questions and builds on a brief [https://www.clivebates.com/vaping-policy-rapid-questions-and-answers/ Q &amp;amp; A that I submitted to a consultation], a critique of an absurd [https://www.clivebates.com/world-health-organisation-fails-at-science-and-fails-at-propaganda-the-sad-case-of-whos-anti-vaping-qa/ anti-vaping Q &amp;amp; A by the WHO] and my [https://www.clivebates.com/vaping-risk-compared-to-smoking-challenging-false-dangerous-claim-by-stanton-glantz/ critique of numerous false and misleading claims made by Professor Stanton Glantz].&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===[https://t.co/Lk8XrZ6KRI?amp=1 E-CIGARETTE POLICY BRIEF:  Seven Things Policy Makers Need to Know]=== &amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
*Quick 1 page guide&lt;br /&gt;
*All references are hyperlinked to official WHO and government reports, and peer-reviewed studies&lt;br /&gt;
&lt;br /&gt;
===[https://mailchi.mp/5165e20d33ee/trprblueprint A Blueprint for Better Regulation]=== &amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
*Written by UKVIA - [https://www.ukvia.co.uk/ UK Vaping Industry Association] - 2021&lt;br /&gt;
&lt;br /&gt;
===TPA Series: [https://www.protectingtaxpayers.org/thr-101/ THR 101]===&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Cessation.pdf Cessation]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Dual-Use.pdf Dual Use]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Role-of-Flavors.pdf Flavors]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-THR.pdf Harm Reduction]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Heated-Tobacco.pdf Heated Tobacco (aka: HTP, HnB)]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Popcorn-Lung.pdf Popcorn Lung]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/Tobacco-Vaping-101-Nicotine-Pouches.pdf Nicotine Pouches]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Snus.pdf Snus]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Vaping-Injuries.pdf Vaping Lung Injuries (aka: EVALI)]&lt;br /&gt;
*[https://www.protectingtaxpayers.org/wp-content/uploads/THR-101-Youth-Reasons.pdf Youth Use Reasons]&lt;br /&gt;
&lt;br /&gt;
===[https://www.thr101.org/tobacco-harm-reduction-101-guideboo TOBACCO HARM REDUCTION 101: A GUIDEBOOK FOR POLICYMAKERS]=== &amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
*Written by Lindsey Stroud - Webmaster of [https://www.thr101.org/ Tobacco Harm Reduction 101]&lt;br /&gt;
&lt;br /&gt;
===[https://www.atr.org/tholos-foundation-releases-vaping-tobacco-harm-reduction-the-path-to-saving-millions-of-lives-2023-report/ Vaping &amp;amp; Tobacco Harm Reduction: The Path to Saving Millions of Lives]===&lt;br /&gt;
&lt;br /&gt;
=Why= &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===[https://innco.org/wp-content/uploads/2021/03/INNCO-LMIC-English.pdf 10 reasons why blanket bans of e-cigarettes and HTPs in low- and middle-income countries (LMICs) are not fit for purpose]=== &amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
*Written by INNCO - [https://innco.org/ International Network of Nicotine Consumer Organisations] - 2021&lt;br /&gt;
&lt;br /&gt;
===[https://cei.org/studies/fear-profiteers/ Fear Profiteers: How E-cigarette Panic Benefits Health Activists]=== &amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:17--&amp;gt;&lt;br /&gt;
*Written by Michelle Minton - Competitive Enterprises Institute - 2018&lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=Promoting Harm Reduction Policies=&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/ Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study]===&lt;br /&gt;
*The simulation suggests that the promotion of e-cigarettes as a harm-reduction policy is a viable strategy, given current evidence that e-cigarettes offset or divert from smoking. Given the strong effects of implementation challenges on policy effectiveness in the short term, accurately modeling such obstacles can usefully inform policy design. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981929/pdf/12954_2021_Article_484.pdf PDF Version]&lt;br /&gt;
*Citation: Selya AS. Reducing the smoking-related health burden in the USA through diversion to electronic cigarettes: a system dynamics simulation study. Harm Reduct J. 2021;18(1):36. Published 2021 Mar 20. doi:10.1186/s12954-021-00484-6&lt;br /&gt;
*Acknowledgement: This work was supported by the National Institute for General Medical Sciences (NIGMS) within the National Institutes of Health (NIH), grant number P20GM121341; by the Norwegian Agency for International Cooperation and Quality Enhancement in Higher Education (DIKU), grant number NNA-2016/10023. After the initial submission of this manuscript, AS became employed by Pinney Associates, Inc. which provides consulting services on tobacco harm minimization to JUUL Labs, Inc. The content presented here precedes this competing interest, and JUUL Labs, Inc. and PinneyAssociates, Inc. had any role in the conceptualization, design, analysis, interpretation, or presentation of data, nor in the decision to publish.&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=79072</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=79072"/>
		<updated>2025-05-11T15:02:19Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT]demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=79041</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=79041"/>
		<updated>2025-05-05T09:16:18Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry/NGO (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=UserWiki:Richardpruen&amp;diff=78865</id>
		<title>UserWiki:Richardpruen</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=UserWiki:Richardpruen&amp;diff=78865"/>
		<updated>2025-04-13T15:31:13Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: add letter to DHSC 13 april&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;__TOC__&lt;br /&gt;
&lt;br /&gt;
{{#babel: en-N | de-2 }}&lt;br /&gt;
&lt;br /&gt;
= The Site admin =&lt;br /&gt;
&lt;br /&gt;
Richard Pruen &lt;br /&gt;
&lt;br /&gt;
Electrical and electronic engineer&lt;br /&gt;
&lt;br /&gt;
Favorite band: [https://www.rush.com/band/ Rush]&lt;br /&gt;
&lt;br /&gt;
Why spend so much time on this? It’s a fact that nicotine harm reduction (vaping and Snus) saved my life, this is my way to pay that forward, and pass along information on safer nicotine. &lt;br /&gt;
&lt;br /&gt;
Running a site from the ground up, has proved interesting and worthwhile. Some of the things I have learned about Linux, and configuration of software for servers is only stuff you learn by doing. &lt;br /&gt;
&lt;br /&gt;
I suspect the site will stick around, at least as long as it is required to provide links and info.&lt;br /&gt;
&lt;br /&gt;
I might well put more info of my vaping / thr story here soon, this is just a test edit. &lt;br /&gt;
&lt;br /&gt;
More test edit, and added some features, like babel to indicate users languages.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Site admin at Safer nicotine wiki.&lt;br /&gt;
[[File:2020-10-28-092657.jpg|thumb|Richard Pruen]]&lt;br /&gt;
&lt;br /&gt;
=ABOUT=&lt;br /&gt;
&lt;br /&gt;
Ecig user since 2008, consumer advocate for vaping and THR  #VapingSavedMyLife #VapingSavesLives&lt;br /&gt;
&lt;br /&gt;
Twitter [http://twitter.com/pruenrichard @pruenrichard]&lt;br /&gt;
&lt;br /&gt;
Below are letters and documents sent in advocacy efforts as a record and should anyone wish to use them for ideas. These are my efforts and do not necessarily reflect the views of the wiki or other users.&lt;br /&gt;
&lt;br /&gt;
[[File:FDA comment.pdf|thumb|alt=Comment on R-U FDA review |Comment on R-U FDA review ]]&lt;br /&gt;
&lt;br /&gt;
[[File:My response TGA request for comment.pdf|thumb|alt=My response TGA request for comment|My response TGA request for comment]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email to appg vaping 28th Feb 2023.pdf|thumb|alt=Hi Mark,  I am a consumer advocate for vaping, and do not use disposables beyond experimenting to see what they are like. I am also an engineer.  I have worked in the vaping industry previously testing against the standards for vaping products, and owned a now closed company BTC Battery Testing LTD (closed 2016).  Currently I care for my mother who suffers vascular dementia, and as such volunteer my spare time to the cause of THR.  The disposable vaping problem is not an easy one, because the product is in demand, a black market will form. A black market will be less regulated, even less concerned with the environment, and have no reuse or recycling plan, due to there being no incentives. Please see the situation in Australia if you have any doubts.  I would suggest the following rule changes to start. All disposable devices should be rechargeable, and either contain enough liquid to last the lifetime of the atomiser (roughly 15-20ml), or be required to have a fill method (there are many ways to do this, including community &#039;hacks&#039; that are available on the internet). If a refilling method was designed in, the extra cost is minimal to include a bung or device to allow re-fill). This would mean the atomiser is used for it&#039;s lifetime, and the battery recharged and used for much longer. Waste reduction by 1/10 (assuming 2ml  devices now, 10 such would be replaced by a single 20ml device)   My preferred solution is rechargeable and large capacity, for the following reasons. Large size, it becomes difficult to conceal a device with 20ml capacity, this will help reduce stealth use. As the lifetime is greater, plus content, the initial outlay will be higher putting the devices out of the purchacing power of youth, and doing so without adding to the cost per puff for the legitimate smoker wanting safer options.  Smaller re-fillable and rechargeable devices have many of the same advantages, but remain easy to hide, and lower price. That might be problematic.  This would depend on the lifting of the 2ml tank size, for a sealed for life device requiring tools to open, the 2 ml tank provides no protection to anyone. Even for refillable devices, in reality it increases fiddle and numbers of re-fills, and provides little protection (if any). Indeed it may be that the most dangerous time for ecigs is during filling, where child proof caps are removed etc, it might be argued that larger tanks would reduce risky refilling operations and be safer. At least a quick &#039;thought experiment&#039; says that is quite possible and warrants further investigation.  I have further suggestions, and would be happy to help if you would like, this is simply a start.  I would imagine manufacturers will be reluctant to see rules that force them to be responsible about waste, disposables are highly profitable and allow walking away from disposal and environmental costs. This should be addressed however. As a consumer my thoughts are &#039;oh dear how very sad&#039; but I am sure they will still manage to find a way to make a profit.  Thanks for your time  |Email to APPG Vaping 28th Feb 2023 ]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter to PM.pdf|thumb|alt=I heard your comment regarding the targeting of youth by possibly &#039;big tobacco&#039;, the vaping industry or some perceived, yet non-existent morph of the two. The same points are being made in the US, you are being fed a line Sir!  I am a vaping consumer myself, well aware as an early adopter of vaping (2008), more than 15 years ago, that youth are not targeted. I have seen the industry develop flavours for adults to use, it gives the edge to make a complete switch, dissociating from the taste of tobacco. It is unfortunate that there is no flavour puberty, humans&#039; basic taste preference is developed early, so targeting adults only is sadly not possible.  Please see the graph linked here, showing the insanity of youth targeting, it just doesn&#039;t make any sense. https://safernicotine.wiki/mediawiki/index.php/Old_farts_vaping (this uses US data, the UK numbers are lower).  I suggest you run things by someone who understands vaping and harm reduction before making a comment, to save embarrassment|Letter to PM re: Youth vaping]]&lt;br /&gt;
&lt;br /&gt;
[[File:Lord Markham letter.pdf|thumb|alt=Subject: Smoking Harm Reduction: support safer alternatives – save lives  Dear Lord Markham,   I am sure you are aware that vaping has been a great success in reducing smoking, the NHS finding that with support 2/3 smokers successfully stop smoking with e-cigs. This is vastly more effective than NRT products that at best where 6% successful. Sweden has had longer with Snus as a harm reduction product, thus are looking at becoming effectively smoke free (&amp;lt; 5% smokers) this year or next.  I see worrying signs in the media, and with the WHO both seem to be extremely hostile to vaping, when in fact it is doing immense good, not to mention saving the NHS vast sums (smoking is the leading cause of cancer) in preventing cancer and smoking related disease. A cancer prevented will require no detection, diagnosis or treatment; a triple saving in cost to the NHS and public.  I would like to make my view known and hope you would support it, that the UK must hold it’s nerve, it must stay true to the scientific evidence from the Royal Collage Physicians, NHS Smokefree, Cochrane etc as detailed in the reports commissioned by PHE/OHID. We must also be aware of the situation in Australia where effective prohibition (the recommendation of the WHO) has been tried, and as predicted by myself and many others, seems to have resulted in an illicit market, with worse figures for youth uptake of smoking. Youth smoking in the UK, NZ and USA where vaping is available have all fallen (in the USA youth vaping became popular as a result youth smoking became all but non existent (&amp;lt;1% regular smokers).  While youth vaping is not desirable, it remains more desirable than youth smoking, an important point to remember. Vaping is unlikely to result in deaths, open system vaping provides and off ramp in lowering nicotine and stopping (not so for smoking). If youth take up smoking and continue, then it is known at least half will die early because of it. This is also complicated by the fact that nicotine provides therapeutic benefits, thus I would like you to see this single link https://safernicotine.wiki/mediawiki/index.php/Nicotine_therapeutic_benefits it contains a lot of information, but it is important I feel to consider the benefits of safer sources of nicotine, without the harms of smoking. The following is my personal story, I do not insist you read it beyond knowing vaping saved my life.  I am primarily a user of Electronic Cigarettes, and of Snus, as well as tobacco free nicotine pouches. I am also a consumer advocate for Tobacco Harm Reduction products (hereafter referred to as THR) for the simple reason that I firmly believe these products saved my life, and have a desire to pass that opportunity on to other smokers, many of whom will not be aware.   I started vaping in 2008, primarily to vape where I could not smoke, I had no intention of giving up smoking, I had already tried every available method, some several times to no effect, and had given up any hope of stopping. However by early 2009 I discovered by happy accident, that I had not bought any tobacco for several weeks (at least 4) and thus had gained some funds budgeted for, but not spent. Unlike most folks who give up smoking I have no firm quit date, and don’t recall any difficulty in slowly switching from a vastly harmful product to a vastly safer one. The exact opposite of previous quit attempts. I learned on internet forums that this is not uncommon with vaping, but never happens to my knowledge with NRT. As part of my advocacy work I run the site https://safernicotine.wiki the intention to provide a repository of information on THR and links to science, resources for advocates, policy makers, doctors and indeed anyone interested in reducing the harm caused by smoking.  I am not paid in any way for my advocacy, and in fact pay for the bandwidth and time required to maintain the site. Much of the content is provided by volunteers around the world.  Please do not hesitate to contact me if you would like any further information, including the vast database of knowledge contained in the wiki site, or any assistance using the site.  Sincerely    Richard Pruen|Lord Markham letter]]&lt;br /&gt;
&lt;br /&gt;
[[File:My response NZ request for comment.pdf|thumb|alt=Submitted to Proposal to clarify how nicotine levels for vaping products are expressed in the Smokefree Environments and Regulated Products Regulations 2021 Submitted on 2023-06-14 23:07:05 Your details 1 What is your name? Name: Richard Pruen 2 What is your email address? Email: richard@pruen.co.uk 3 Are you submitting on behalf of an organisation? Yes If so, what is your organisation?: Safer Nicotine wiki 4 What ethnicity/ethnicities do you identify with? Other European, Not applicable (eg, I&#039;m submitting of behalf of an organisation or group) 5 What Iwi do you affiliate to? What Iwi do you affiliate to?: 6 I am, or I represent, the following category or categories (select all that apply) Other (please specify) Other: Citizen science project (wikipedia clone on tobacco harm reduction) Proposal questions 7 Do you agree with our proposal to set the maximum allowable nicotine concentration at 28.5mg/mL for reusable vaping products that contain nicotine salts? No 8 Please explain your reasoning. If No, please explain.: Based on the available science, the limit should be set at a level that provides protection from poisoning, while allowing sufficient for a heavy smoker to DIY mix liquid that will satisfy their needs. Having reviewed the recent science, it is only nicotine concentrations at or above 100mg/ml that have resulted in very few fatal poisonings with orally ingested nicotine. Concentrations below 80mg/ml have as far as can be found, never resulted in death or serious harm. Therefore a limit of 75mg/ml would provide protection from poisoning while being high enough to allow DIY mixing of liquid to suit a low-power pod vaping device, which would satisfy even a heavy smoker. This provides maximum safety in that 75mg/ml will cause the body to vomit before damaging amounts of nicotine can be ingested. Even suicide attempts by simply drinking the liquid would fail. Yet allows even heavy smokers to obtain sufficient nicotine, and thus switch more easily to a vastly safer product. 9 Is there anything else you would like to tell us at this time? Is there anything else you would like to tell us at this time?: Issues have been found with the UK limit of 20mg/ml, heavy smokers find switching difficult, this requires the use of a nicotine patch and vaping, which significantly increases friction to switching, this costs the lives of smokers who would otherwise stop smoking. The UK 20mg limit was based on poor science (an estimated LD50 based on one scientist&#039;s self-administration of nicotine IV) and the assumption that all the ingested nicotine would be instantly absorbed. Looking at real data and better LD50 data gives a better understanding. Declarations and privacy 10 Publishing submissions You may publish this submission 11 Do you have commercial interests? I do not have any commercial interests in smoked tobacco or other regulated products (vaping products, other notifiable products) 12 Commercially sensitive information This submission does not contain commercially sensitive information 13 Protection from commercial and other vested interests of the tobacco industry Please provide details of any tobacco company links or vested interests below.: No links to any industry, government, or commercial interest of any kind, and no funding from any tobacco or vaping industry nor taxes or fees collected from tobacco or other companies. All funding is from the individual volunteers who contribute to the project.|My response NZ request for comment.pdf]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter Steve Barclay 6th jul.pdf|thumb|alt=Subject: Health Select Committee meeting on Vaping   Dear Steve Barclay,  I am a consumer advocate, with no ties to industry at present (for full details see the APPG letter linked below).  I note that industry was present at this meeting but no one representing consumers of the product, why was this? As the people most likely to be impacted, why are we not included? I have further comments below and a suggestion to include at least one consumer org.  Vaping is less dependence forming than smoking, science says so. See:  https://safernicotine.wiki/mediawiki/index.php/ENDS_Public_Health#Dependence_(Addiction,_Abuse)_vs_Harm_/_Harm_Reduction_-_Ecigs_and_Nicotine   Youth brain harms are reversible and only found in rats. Human youth smokers never experienced such harms. A huge number of people smoked in the 60s-80s, many from a young age the population is huge, any effect would have been seen (yes, people have looked, negative research is rarely published, but nothing was found). I can however provide evidence in the form of quotes from experts in tobacco and nicotine, please feel free to request such information.   No UK legal vape delivers more nicotine than a cigarette, some of the illegal disposables do and are attractive to hardened smokers. Legal vapes should be allowed to use more than 20 mg/ml, see also my letter to APPG Vaping on the 28th Feb this year https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb_2023.pdf . The US Juul product (containing 58 mg salt nicotine) produces blood plasma concentrations lower than a cigarette, but closer to the same level (This is why it worked so well in adults who smoke). Estimating that all nicotine is absorbed by the vaper by the amount exhaled is flawed, nicotine is destroyed by heating and oxidation while in the device and vapour. Cigarettes are delivering 1-2 mg per cigarette, but start out with 250 mg per pack of 20 (delivering only 20-40 mg to the user). Far better to stick with measured blood plasma levels in comparison to cigarettes, since this data is available.  e.g. https://pubmed.ncbi.nlm.nih.gov/33486526/  I Agree with points on advertising to children, industry should not target the product at them, but targeting their smoking parents is absolutely going to save lives. Children must be told the truth, the product is not for them, but might mean they do not lose their parents to cancer. We know with absolute certainty that vaping is safer than smoking, there is no doubt; the only doubt is the magnitude of the difference (the lowest estimate 60% the highest 99.5%, current science says 95%+ and is climbing each year, as well as gaining certainty).  Was it necessary to brow-beat the industry representatives? They where asked if they targeted children, and responded that they did not, with good reasons for the answer, including that the owner of one business wanted to help existing smokers, as vaping helped him, not gain youth customers.   I have not seen legitimate businesses from the UK targeting underage users, that has been rouge overseas traders, and some Chinese companies.  Those selling genuinely child appealing products or advertising to youth on social media, where any influence can be had, since they are not UK based, then yes, they should be stopped as far as possible.   Taxation is not going to help, illicit markets will avoid the tax and make the environmental situation worse, as well a safety. The illicit market exploded in Australia with 90% of the 1.1 million vapers buying from the illicit market.  Flavours targeted at adults, including their memories of sweets available when they where young. Human flavour preference is done by age 2 approximately, targeting flavours at youth is not actually reasonable, humans like nice flavours. Please see: https://safernicotine.wiki/mediawiki/index.php/ENDS_Cardiovascular_System#Flavors_(Flavours)  The illicit market vapes are not regulated and may contain contaminants, this is not a surprise, and would suggest that regulation that works to reduce the illicit trade (not increase it) would be beneficial.   The loophole that allows giving vapes to kids (not selling them) is not used, no reputable company does this, or would do so. It is actually a complete non issue, since no one does it. I have never heard of this, and I asked and no one else has either. Please can you forward to me the data that shows this is happening, and where? As advocates we would like to know of problems, and if possible help, thanks for your assistance.   Popcorn lung is not caused by vaping see: https://safernicotine.wiki/mediawiki/index.php/ENDS_Flavors including the risk of inhaling flavours. No regulated UK product contains the chemical, it is banned. Another reason not to expand the black market, unregulated products would not be tested for banned flavours. That this was brought up, and seriously considered shows that the ministers failed to research the subject. You should include a purely user organisation such as the UK Charity NNA (New Nicotine Alliance) https://nnalliance.org/ , they have no industry affiliation and work for the users of the product. You might also consider INNCO (International Network Nicotine Consumer Organizations) https://innco.org/    As a user of these products; I would request MPs be better informed, before considering legislation that could impact my health, thank you!  If you want to price youngsters out of the market without detriment to adult smokers see the letter to APPG vaping mentioned above. It contains some ideas that would reduce waste 10 fold, and increase the initial outlay without increasing cost per puff, a win for the environment and adult smokers with less spending power.   Yours sincerely,     Richard Pruen  Cc: APPG-Vaping   P.S.   I await your reply with the requested information, including reasoning for not including representatives of consumers in the enquiry. I would also like to know if the MPs where briefed on vaping or the vaping industry, if so by whom?|Letter Steve Barclay 6th JUL]]&lt;br /&gt;
&lt;br /&gt;
[[File:TGA consult 8-sept-2023 my response.pdf|thumb|alt=Response ID ANON-EJTE-W3QH-B Submitted to Proposed reforms to the regulation of vapes Submitted on 2023-09-08 21:15:44 Survey contents Privacy and your personal information I consent to the TGA collecting the information requested in this survey about me, including any sensitive information, for the purposes indicated above. Agree: Yes Acknowledgement I agree. Yes.: Yes Introduction 1 What is your name? Name: Richard Pruen 2 What is your email address? Email: richard@pruen.co.uk 3 What is your organisation name? Organisation name or N/A: n/a 4 Please choose a stakeholder group that best describes you or your organisation. Others* *If other, please specify:: Consumer 5 Which best describes your response? I am responding as an individual. 6 Are you an authorised prescriber? No (please go to next page Conflicts of interest (actual or perceived) 1 Have you or your organisation ever received services, assistance or support (whether monetary or non-monetary in nature) from the tobacco industry and/or e-cigarette industry? If this scenario applies to you or your organisation, please provide relevant details in the textbox. Yes If you have selected yes, please provide details here. Otherwise, please state &#039;Not Applicable&#039;:: I owned a company testing electronic cigarettes for compliance with UK and other standards, as well as carried out investigations of failures including battery failure. I also worked on R&amp;amp;D and provided consulting services on for example battery protection circuits, chargers etc. Payment was from user fees for testing, government agencies (trading standards), trade associations, and sometimes individuals or companies carrying out due diligence testing or failure mode analysis. Ended 2016 since then I have been a consumer only and have not received any funding from any company (of any sort), government agency, or researchinstitution. 2 Have you or your organisation ever provided services, assistance or support (whether monetary or non-monetary in nature) to the tobacco industry and/or the e-cigarette industry? If this scenario applies to you or your organisation, please provide further information in the textbox. Yes If you have selected &#039;yes&#039;, please provide details here. Otherwise, please state &#039;Not Applicable&#039;: I assisted in writing standards for UK vaping products (PAS 54115 A guide for the importation and sale of electronic cigarettes and directly related products, with product safety testing methods) and proposed an IEEE standard project number P2800. Several sampling machines were supplied to others testing electronic cigarettes, and other custom test equipment, the supplied equipment presumably used to carry out tests on electronic cigarettes as designed. As academic and test houses purchased this equipment it is assumed this was paid for by test fees, or grants to carry out tests on electronic cigarettes, again possibly linked to taxes etc from tobacco and or electronic cigarette sales. The same funding source as government agencies, politicians and others working in the field. Again since 2016 I have been a consumer only. Proposal 1 -Restrictions on importation, manufacture and supply of all vapes . 1 Do you support the proposed approach to ban disposable single use vapes absolutely and all other vapes, except those for legitimate therapeutic use in compliance with the TG Act? No 2 How would you anticipate industry and consumers to respond to a ban on the importation, manufacture and supply of non-therapeutic vapes? * Please provide answer here. : Demand will remain, along with the risk of vaping being seen as cool because it is something disallowed. The tightening of rules is unlikely to be enforceable, so illicit supply will continue to be the primary supply to the population. The population know vaping is safer than smoking, thus it will be very difficult to curb demand. Prohibiting drugs such as cocaine and cannabis fails, vaping prohibition will almost certainly follow the same pattern. 3 Do you support removal of the personal importation scheme exception for vapes? If not, what would be the impact on you? No (* if not, what would be the impact on you?) * What would be the impact on you?: Vaping products that are acceptable and usable are likely to only be available via illicit sales, and criminal gangs. Particularly as research shows flavours to be vital for the prevention of release to smoking. These products will not be tested or regulated in any way, importing allows users who have a prescription to import what they need to stay smoke-free, thus not relapse to smoking and potentially death. Importantly importing from somewhere with a regulated legal market, they can be sure of the quality and contents of the products they buy. The one-size-fits-all approved vapes that consumers will find at pharmacy outlets is unlikely to be effective since most of the features that make an effective substitute for cigarettes will be regulated out. 4 Do you agree with the proposal to retain a traveller’s exemption, including the proposed limits? Yes 5 Do you support the proposed approach to prohibiting the advertisement of all vapes (subject to limited exceptions)? No 6 [If applicable] Suppliers, what part of supply chain do you occupy? Not applicable * Other -specify your role in supply chain.: Consumer 6 (a) What proportion of your sales volumes is attributable to vape sales [i.e. quantity of vapes sold]? Please provide details here: (or mark Not applicable).: N/A6 (b) What proportion of your sales revenue is attributable to vape sales [i.e. revenue earned from sales]? Please provide details here: (or mark Not applicable).: N/A 6 (c) What impact would the proposed measures have on your sales volumes? Please provide details here: (or mark Not applicable).: not a vendor, none 6 (d) What impact would the proposed measures have on your sales revenues? Please provide details here: (or mark Not applicable).: none not a vendor 6 (e) What proportion of your vapes sales is attributable to disposable single use vapes versus refillable products? Please provide details here: (or mark Not applicable).: not a vendor 6 (f) How would restricting the importation, manufacture and supply of disposable single use, and non-therapeutic, vapes in Australia impact you? Please provide details here: (or mark Not applicable).: not a vendor N/A 6 (g) How much stock do you have in Australia currently and how long would it take to sell that stock? Please provide details here: (or mark Not applicable).: not a vendor N/A 6 (h) What would be the cost to you if you were required to dispose or otherwise move on existing stock? Please provide details here: (or mark Not applicable).: N/A Proposal 2 -Changes to market accessibility requirements, including better regulation of device components. 7 Do you support the approach to require a pre-market notification of compliance with TGO 110? No 8 [If applicable] For suppliers of therapeutic vapes, what impact would the proposed notification system have on your supply model and what transition period would you require to comply with the new notification requirement? Please provide details here: (or mark Not applicable).: not a vendor 9 Do you support the proposed access to vapes under the SAS C notification system? No 9 (a) What impact would this pathway have on facilitating patient access to therapeutic vapes? Please provide details here: (or mark Not applicable).: Vaping works in the rest of the world as a product substitute, providing a safer alternative to a deadly (cigarettes) product. In the UK and NZ smoking decline has accelerated significantly past that in Australia, due to the adoption of consumer vaping, slightly less so in the US where the regulator is not so certain. The prescription model in Australia has failed, smoking has not continued to decline and may have increased possibly. Vaping is also higher in Australian youth than UK and NZ, the current policy has backfired and should be reversed. It is absolutely obvious at this point that unless you have unlimited resources for enforcement, the current policy is not workable, and never will be. The time has come to use what has worked elsewhere and start again.10 [If applicable] For prescribers, would the proposed new pathway likely change your approach to prescribing therapeutic vapes? How? Not a prescriber of vapes * How new pathway will change your approach to prescribing ttherapeutic vapes?: 11 [If applicable] For prescribers, which access pathway (SAS B, SAS C, or AP) would you envisage using to prescribe therapeutic vapes? Why? Not a prescriber of vapes Please tell us why: 12 [If applicable] For prescribers, would integration of SAS or AP applications or notifications into existing clinical software systems ease the administrative burden and/or encourage you to use the new pathway? Not a prescriber of vapes 13 Do you agree with the proposal to regulate both e-liquid and device components of unapproved vapes under the same part of the TG Act for simplicity? No 14 Will these changes have direct or indirect impact on you? Please provide details. Yes (please provide details below) Please provide details here:: As a consumer I want safer options to be available to me and to every person who smokes tobacco or would smoke tobacco for lack of a viable alternative. Sadly some kids will do adult things even if you try to stop them (for example drinking alcohol, unsafe sex, taking drugs, smoking) while they should not be encouraged to vape, it still offers a harm reduction if it diverts them from smoking, like it or not, this is true because safer is safer. 15 Do you require time to adjust to these requirements? If yes, how long? Yes 15 (a) How long do you require to adjust to these requirements? More than 12 months Proposal 3 - Improving quality standard for unapproved (unregistered) vapes) 16 Are the definitions of nicotine and mint flavours appropriate? If not, please provide reasons. No (* please provide reason below) * Please provide reason here.: Nicotine itself does not have a flavour, the flavour should be correctly referred to as &amp;quot;artificial tobacco flavour&amp;quot; There is no evidence that human flavour preference varies by age and none particularly that it changes at 18. It is therefore impossible to target age groups with specific flavours, thus limiting flavours on this basis has no merit whatsoever. 17 Do you agree with the proposed upper limit on the concentration of menthol in vapes? If not, please provide reasons. No (* please provide reason below) * Please provide reason here: It is trivial to add menthol to vapes, this simply encourages users to add more if they prefer, opening a can of worms and the potential for contamination or incompatible ingredients. This seem unwise for very little if any benefit. 18 [If applicable] Importers, manufacturers and suppliers, would the restrictions on flavour proposed above impact you? Not applicable 19 Do you agree with the proposal to require pharmaceutical-like packaging and presentation for vapes, e.g., vapes manufactured in black, white or grey coloured materials, predominantly white background on packaging, clear warning statements and other restrictions on labels in addition to other selective TGO 91 requirements for vapes? No (* please provide reason below)20 [If applicable] What impact will the labelling and packaging changes have on you? * Please provide detail here.: It will probably backfire, making legal products undesirable is likely to increase the number of people using illicit products, particularly if access remains easy, without enforcement that is most likely to be the case. 20 (a) How long would you need to transition your product to comply with the proposed requirements? More than 12 months 21 Do you agree with our approach to allow only permitted ingredients in vapes, instead of trying to prohibit individual chemical entities from use in e-liquids? No 22 [If applicable] Importers, manufacturers and suppliers, will your therapeutic vapes need any re-formulation or other changes to comply with the permitted ingredients and ingredient quality requirements? Not applicable 22 (a) If product re-formulation is required, how long will you need to make these changes? More than 12 months 22 (b) If product re-formulation is required, what financial or business impacts would be associated with them? Provide detail here or put &#039;Not Applicable&#039;: Not a vendor 23 Do you support applying the same regulatory controls to zero-nicotine therapeutic vapes, as for NVPs? No 24 What is the overall business cost on you to comply with a strengthened TGO 110? Please provide details here: (or mark Not applicable).: not a vendor 25 Do you agree with the proposed requirements under TGO 110 that will apply to unapproved device components of vapes? No 26 [If applicable] Suppliers, do you intend to register any vaping device on the register as an approved medical device? No (if no, why not?) If no, why not?: not a vendor 27 [If applicable] Importers, manufacturers and suppliers, are you familiar with relevant US FDA, or MHRA guidance and/or EU standards covering vaping devices? Not applicable 27 (a) Do your vapes currently comply with relevant US FDA, or MHRA guidance and/or EU standards covering vaping devices? Not applicable 27 (b) If not, what requirements do you meet? What requirements you currently comply with?: not a vendor 27 (c) How long would it take to achieve compliance with relevant standards? More than 12 months28 [If applicable] Importers, manufacturers and suppliers, are your vapes manufactured at facilities that hold relevant international standards for Quality Management Systems, such as ISO9001 or ISO 13485? Not applicable Proposal 4 - Strengthening domestic compliance and enforcement mechanisms 29 Do you have any other comments in relation to this proposal? Yes (* provide your comments below) Comments: I reiterate that Australian policy has failed, and further moves in the same direction are likely to fail. Other countries have shown much more desirable results, the best results on smoking have been where vaping has been accepted as a consumer alternative to smoking, but the prescription model, unfortunately, has proven unworkable. Realistically you should review the past responses to enquiries, select a number of people who have successfully predicted the results of current regulations, and ask them for solutions. At least they have a track record, and proven knowledge of the real world and likely outcomes. Supplementary questions 30 [If applicable] Suppliers, please confirm if you intend to continue to supply therapeutic vapes under the proposed reforms described? Not applicable * Product range : Not a vendor, but as a consumer, I can see vendors dropping out. This will benefit the criminals and gangs who supply illicit markets, more trade for them. 30 (a) How long would it take to meet the new requirements? More than 12 months 31 [If applicable] Suppliers, please confirm if you intend to register your therapeutic vapes in the next 2 years? Not applicable What guidance and/or clarity of supporting data requirements do you need from TGA: not a vendor Publication of submissions To proceed, please select from the options below how you would like the TGA to deal with your submissions: I agree to the TGA publishing my response in full. I request the TGA to consider redacting sensitive commercial information from my response before publication: No Please specify sensitive commercial inforation you want redatced :|TGA consult 8-sept-2023 my response]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter to pm 16 sept 2023.pdf|thumb|alt=Sent to The Prime Ministers office FAO The Prime Minister No10 downing street (via official contact form) 14:30 on 16th Sept 2023   Subject: The continuing debate around banning disposable vaping and flavoured vaping.  This is continuing from my note of the 25th May 2023, I hear worrying noises around an outright ban on disposable vapes. As a consumer myself, who would surely be dead now without vaping, 15 years more smoking (I started 2008) would have seen me off, but not a user of disposables. Please however consider the following.  First; evidence from Australia where vaping is prescription only and prescriptions are hard to obtain (a de-facto ban), shows that illicit markets step in to fill demand, and have done so with the cheapest and least safe disposable devices. It is entirely probable bans here would result in more disposable vapes than less.  Second; There are disposable vapes designed for high security locations, such as prisons and mental health units, particularly secure ones. Please do not inadvertently ban a much safer than smoking option in such places, some of these people are suffering enough, and require our assistance.  Third; Prohibition is not effective, please see the situation in Australia again, the failed implementation of alcohol prohibition, and more than 6 decades of drug war. Not one of these things has reduced the supply of the substances trying to be controlled, and there is no reason to assume it will be effective for disposable or flavoured vaping.  Fourth; There are measures, some that I suggested to APPG Vaping on 28th Feb this year, the link is safernicotine.wiki/mediawiki/index.php?Title=File:Email_to_appg_vaping_28th_Feb_2023.pdf Should you wish to read it. These measures would significantly reduce the environmental impact (by a factor of 10), and place the legal devices better able to compete with illicit imports (these generally have more puffs than the UK rules currently allow), has the effect of increasing the initial cost of the device but not the cost per puff. By such changes to legal devices three main goals can be achieved   1) Compete out the illicit and illegal products that are not safety tested and approved.  2) Reduce the environmental cost, and quantity of vapes in need of recycling.  3) Reduce the affordability of such devices to young people particularly children.  Legal devices could then be mandated to contain information on refillable devices that are just as easy to use, cheaper and more environmentally responsible. Measures to drive consumers to more environmentally sound products should absolutely be considered, such as paying more initially and receiving a repayment on return for recycling. This should be done with care for unintended consequences.  I have kept this short as you are busy, but if there is any further information you would like please feel free to contact me by email richard@pruen.co.uk.  Thank you for your time.|Letter to pm 16 sept 2023]]&lt;br /&gt;
&lt;br /&gt;
[[File:NSW Consult 30 sept.pdf|thumb|alt=Vaping is a direct substitute for smoking that is able to compete with cigarettes on the open market, it is unbeatable on cost compared to subsidised NRT, and far more effective, the UK NHS find 2/3 (66%) effective with support.  With regulated vaping in UK youth: 0.5% use &amp;gt; once weekly and are never smokers (see ASHuk graph attached). Driving the product to illicit markets and criminal gangs seems to have resulted in greater access for Australian youth.  While vaping is not entirely risk-free, it is known now that it poses a fraction of the risk of smoking (please see the attached risk map). Waiting for a perfect solution that may never be found is counterproductive, the reduction in risk is known to be large that much is proven (the unknown part is, is it 90% reduction in risk or 99%, to be sure will take time)  While youth should not vape or smoke, some will end up doing both. If there is no safer alternative available they will all be smoking. It is also worth remembering dependence on nicotine while not desirable can be reversed, death is final, and it is smoking that kills.  Like it or not vaping has a built-in off-ramp. Use an open-system vape, and use the liquid you need to prevent cravings. Then slowly reduce the nicotine strength at your own pace. On reaching zero nicotine, stop. This is also ample evidence it was developed by smokers, to help stop smoking, and then to stop vaping if that is desired. Would a tobacco company ensure a way out was built in?  The population has resoundingly refused the prescription model, any of the many reasons pointed out repeatedly or all of them are to blame. They deserve a fair regulated market they can trust, if you cannot provide a better solution than criminal gangs, then that is a failure on your part. |NSW Vaping submission 30 september 2023]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter Steve Barclay 19th oct.pdf|thumb|alt=Subject: ‘Ton of bricks’ regulation of vaping and flavours   Dear Steve Barclay,  I am a consumer advocate, with no ties to industry at present (for full details see my previous letter).  I await your reply to my last letter on 6th July, with the requested information, including reasoning for not including representatives of consumers in the enquiry. I would also like to know if the MPs where briefed on vaping or the vaping industry, if so by whom?  The point itself is brief, two short paragraphs.  After your comments on regulations, I would like to draw your attention to the following peer reviewed paper https://www.mdpi.com/1660-4601/20/20/6936 this strongly suggests that young people are being diverted from smoking, vaping is at least 95% safer than them smoking, thus while not ideal vaping reduces harm. Dependence to nicotine is also not ideal, but only 0.5% youth regularly use vapes who did not first smoke. Meanwhile you risk stopping millions of adult smokers switching to vapes by eliminating flavours, these are an important thing for adults. Please read this from Clive Bates (ex ASH Director) https://clivebates.com/documents/FlavoursBriefingV1July2022.pdf. You should of course ban candyfloss and sweet flavoured alcohol, as such flavours are aimed only at children?   One last point Vaping is already illegal for children, if the existing rules cannot be enforced, then further legislation will presumably not be enforced either, how would that help?   Yours sincerely,     Richard Pruen|Letter Steve Barclay 19th oct]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter to cop 10 repersentitives.pdf|thumb|alt=Subject: COP 10 WHO FCTC    Dear Rosanna O’Connor,  I am a consumer advocate for vaping, and do not use disposables beyond experimenting to see what they are like. I am also an engineer. I have worked in the vaping industry previously testing compliance with the standards for vaping products, and owned a now closed company BTC Battery Testing LTD (closed 2016). Currently I care for my mother who suffers vascular dementia, and as such volunteer my spare time to the cause of Tobacco Harm Reduction.  I believe that consumers should be present at the COP 10 meeting, it is consumers who have the most to gain from stopping the use of combustible tobacco, and the lived experience of trying to do so. Many millions have found a way to eliminate almost all the risk via THR products. The phrase ‘Nothing about us without us’ springs to mind. Why then are the public and press excluded. I would like to see the proceedings live streamed, so those effected can see what is being done. In no way could this effect the discussions, thus is reasonable transparency. I would like an answer regarding the possibility, please.   Many countries already found harm reduction useful, critical even. Be that low risk Snus (Sweden has the lowest cancer rate in Europe, and will be smoking free this year (&amp;gt;5%)). Vaping that the UK NHS finds almost 66% effective with support, as stated on their website. New Zealand has seen similar results, especially in native populations, reducing disparities. Japan has seen huge drops in cigarette sales due to reduced harm heated tobacco products.  Please see the letter from the Lancet from Robert Beaglehole and Ruth Bonita. They were both senior officials at WHO and are now at the University of Auckland. Robert was formerly Director of the Department of Chronic Disease and Health Promotion at WHO. Ruth was formerly the Director of Surveillance in the Noncommunicable Disease Cluster at WHO.  I wish to add my support for their recommendations, the article is attached (also link here https://doi.org/10.1016/S0140-6736(24)00140-5) please make sure these points are discussed at the COP 10 meeting.   Yours sincerely,     Richard Pruen  P.S Please ensure the representatives listed on the next page can discuss before the metting and forward more widely if you agree with the sentiment.   Katherine Sands Tobacco Control Team Leader Department for Health and Social Care  Martin Dockrell Tobacco Control Programme Lead Department for Health and Social Care  Alison Walker Senior Tobacco Control Policy Lead Department of Health and Social Care  Esther Lawrence Deputy Head of Global Health UK Mission to the UN, Geneva  Please find attached a letter from   [THELANCET-D-24-00371] S0140-6736(24)00140-5|Letter to cop 10 representatives]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter PM 16th Feb 2024-draft.pdf|thumb|alt=Subject: The ban on disposable cigarettes   Dear Prime Minister,  I am a consumer advocate for vaping (15 years and vaper for 16), and do not use disposables beyond experimenting to see what they are like. I am also an engineer. I have worked in the vaping industry previously testing against the standards for vaping products, and owned a now closed company BTC Battery Testing LTD (closed 2016). Currently I care for my mother who suffers vascular dementia, and as such volunteer my spare time to the cause of THR.  Regarding the subject. Might I remind you that Australia has already taken this path, over 50 fire bombings, at least 3 gang style murders, and a rampant illegal trade has resulted.  I am aware you have children, and they are potentially at the age to start experimenting with adult products. The prohibitionist faction may have played on this, and convinced you that a ban is enforceable, sadly if Australia cannot do it, the proximity of Europe means less chance here.  This is simply being realistic. The best, perhaps only, way to control the illicit trade to to make sure there is a legal trade that makes it less profitable,the US abandoned alcohol prohibition in favour of this.    Please however remain focused on preventing harm, having the only source of disposable vapes (sorry to say this but it is true) that your children could possibly buy, being from a ‘dealer’ who might supply other illicit substances, that is not safer! At least if they are from a shop selling tested, safe devices, then that is a huge reduction in harm already, avoiding interaction with drug dealers. I would prefer the shop followed the law, but as we know not everyone will. Your children might also sample smoking, especially if they sensibly avoid illicit substance dealers, this too is not exactly a win, smoking being deadly and carcinogenic.   You are not the only one being pressured, please see the tweet linked here:  https://x.com/ASHNZ2025/status/1757930273751363892?s=20  “Disappointing that @HealthCoA lump ASH in with tobacco industry in an OIA request rather than ask us. Is a smear campaign coming our way? On the record ASH has no $$ or COI with tobacco, vape, alcohol, gambling, pharmaceutical, retail, food, or billionaire philanthropist” &amp;lt;a letter from the NZ government is attached to the tweet&amp;gt;  I apologise for the somewhat robust and direct letter, but I feel you are about to make a huge mistake. I would regret it on behalf of current cigarette smokers, some of whom will die, and those who return to smoking because they use a banned product, some of those too will die. Meanwhile it will not help your children, or anyone else&#039;s to drive all sales to illicit/criminal markets.  Please see the attached graph, so far regular use is not high and may be displacing cigarettes, sensible regulations to keep it that way, those would be welcome.  A few truths to bear in mind:   Infrequent trial use isn’t the best indicator of dependence, vaping doesn’t kill children nor is it likely ever to do so, smoking cigarettes does kill adults, reasonable regulation results in overall lowest harm.    I would like to hear your thoughts, I will be happy to provide evidence to support what I have said, if required for any point please let me know.  Thank you for your time, and please do not take this lightly!  Yours sincerely,  Richard Pruen |Letter PM 16th Feb 2024-draft]]&lt;br /&gt;
&lt;br /&gt;
[[File:For Attention APPG Smoking and health.pdf|thumb|alt=Dear Rt. Hon. Bob Blackman,  I am contacting you as you are the contact for APPG Smoking and Health. There have been worrying sudden changes in government policy, primarily related to vaping and talk of taxes and bans on a vastly safer product, vaping, that has been successfully displacing smoking.  Please see my previous letter to APPG vaping on why the disposable ban is likely to backfire; simply put, it will hand the entire market to illicit sales (these are already a problem, with oversized and higher-than-legal nicotine content). Illegal sales will likely increase sales to youth since they are already ignoring the law, and the situation in Australia with more than 50 fire bombings and three murders so far in the &#039;Nicotine turf wars&#039; might be repeated here.  As per my letter above, the best way to deal with illegal disposables is to have the legal market out-compete them; at least shops and retailers have fixed premises, and trading standards can take action if they don&#039;t follow the law. It is much harder to police some bloke at the pub or other informal sales. You also lose out on VAT charged on legal sales.  Whatever you think about vaping, it saved my life; I started 16 years ago, very early when it was a new thing, and since then, there has been a vast amount of science (some good, some sadly terrible). Last week, 51 peer-reviewed papers and over 8,000 total papers were published. By now, vaping/nicotine is likely the most studied consumer drug ever. I had an MRI 15 years vaping (stopping smoking) of my head and upper torso. The doctors were able to confirm all the smoking damage had healed, and on explicitly asking if they could see any sign I vape, they could not (despite having found previously healed fractured ribs). Such experiences are not uncommon. A list of links to approximately 100,000 people reporting in their own words how vaping helped them.   Tobacco control has a problem; please do not let that upset the government&#039;s plans to help people stop smoking with the best available harm-reduced product to date. The NHS finds it 2/3 (66%) effective, far better than NRT at around 15% with the same support (easily found on their vaping to stop smoking web page).  Please ensure that the UK policy isn&#039;t derailed by click bait media, or the following:   Extract from Clive Bates (former director ASH) essay:Tobacco Control&#039;s Nervous Breakdown     Fourth, the existential threat to the tobacco control complex. The public discussion of the emerging landscape of low-risk consumer products seldom focuses on the interest group that is most vulnerable to disruption: the mainstream of tobacco control. It is a complex of interests comprising nonprofit activists, academics, medical and health societies, major institutions (such as the World Health Organization or the U.S. Food and Drug Administration), philanthropists and research-funding bodies. The problem for the mainstream of tobacco control is that without serious harm, the whole movement loses its purpose and its reason to exist. When it comes to low-risk alternatives to smoking, this complex is profoundly confronted by the threat of having nothing to control, no case for intervention and no reason to be. It is a powerful incumbent interest group challenged by new technology, new suppliers and new consumer confidence. As a result, the mainstream of this interest group has rejected tobacco harm reduction as a strategy for addressing its own notional goals of reducing death and disease from tobacco use. Instead, it has mounted a rear-guard defense based on a range of strategies, including the following: Falsely implying that noncombustible products are no less risky than cigarettes, that data is too uncertain or short-term, or asserting that reduced risk is no more than a marketing claim of tobacco companies. Asserting that harm reduction is merely a commercial strategy of tobacco companies. The aim here is to attach the reputational baggage of “Big Tobacco” to these new developments. Yet, many independent experts support tobacco harm reduction, and it is good if tobacco companies adopt a business model aligned with reducing health impacts. Excluding or stigmatizing contrarian opinions and creating sealed bubbles open to groupthink. The WHO Framework Convention on Tobacco Control has taken this to new extremes. Shifting emphasis to problematize nicotine rather than the “tar” of cigarette smoke that is the cause of nearly all tobacco-related disease. We are hearing more about “addiction” and less about cancer. Yet, a dependence only meets the definition of addiction if there is serious net harm to the user. A relentless focus on the supposed interests of children without recognizing that would-be smokers among adolescents also benefit from low-risk products and that the demand for nicotine has persisted across generations for hundreds of years. Young people have an interest in the health of the significant adults in their lives as carers, breadwinners and role models. Pressing for prohibitions or equivalent regulation to cigarettes, often with manipulation of language to imply equivalent risk, for example, by stating that heated-tobacco products produce “smoke” or that all tobacco products should be treated the same even though they have very different risks. A blunt refusal to face trade-offs (for example, between the interests of youth and adults) or unintended consequences (for example, increases in smoking) arising from favored policy positions. I have watched on in horror as the leadership in tobacco control, albeit with many honorable exceptions, has dogmatically denied and suppressed the opportunity to radically reshape the recreational nicotine market to cause vastly reduced harm and avoid hundreds of millions of premature deaths. It looks like a nervous breakdown is developing in tobacco control in response to profound disruptive innovation. I doubt they will survive it.  See also my Letter PM 16th Feb 2024 particularly the graph that shows frequent youth use is not increasing, trials and infrequent use have, for perspective however, vaping has been far less popular and less harmful than youth drinking.  Please do what you can to ensure legislation is well thought out, measured and does not result in people being forced back to deadly smoking. Thank you for your time and urgent attention!|Email APPG Smoking and health-4 March 2024]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter sec state health and social care 14 March 2024.pdf|thumb|alt=Subject: Youth vaping    Please see the above graph, so far regular use (greater than once a week) is not high and may be displacing cigarettes, cigarettes are the worlds most deadly consumer product. Infrequent and trial use (once in 30 days, or ever use) while undesirable does not lead to dependence, only those in the graph above can possibly be ‘hooked’, but not all will be.   I do not think young people should be encouraged to vape, but I would like to know your answer to one question, please.  If a young person is determined to use nicotine, would you advise them to smoke cigarettes instead of safer alternatives, and a what age should harm reduction products like vaping be made available.  I look forward to receiving your answer. Please feel free to ask others what they think should be done.  Personally I feel the situation in Sweden is close to the best balance, accepting some use of low risk Snus, in order to reduce the uptake of deadly smoking. This will take effect far faster than the generational tobacco ban, Sweden will be a non smoking nation this year, although nicotine use remains, they have the lowest cancer rate in Europe. The UK can easily and quickly achieve the same with vaping. I note also Sweden reduced the tax on Snus to accelerate uptake.  Yours sincerely,  Richard Pruen|Letter sec state health and social care 14 March 2024]]&lt;br /&gt;
[[File:Letter sec state health and social care 11 May 2024.pdf|thumb|alt=Subject: Tobacco and vapes bill Dear Victoria Atkins,  I am contacting you as a vaping consumer, and advocate for saving lives, vaping saved my life (happy to share medical records to prove that) and I aim to pass that on to as many as possible, I am not paid in any way by anyone to do so.  I was disturbed to hear some of the testimony given in parliament, much of the information was incorrect, or deliberately misleading. This is not good enough when debating a serious matter of health, accurate and science backed information is critical to saving lives.  I would like an answer to the following question: What was the reason to justify excluding stakeholders, the users of vaping products, other safer tobacco products, and even people who smoke?  User funded charities such as New Nicotine Alliance, who take no money from the tobacco or vaping industry should have been consulted. Users themselves or NNA would have been able to counter some of the poor information given and also to provide a view from those directly affected by the legislation being discussed.    Much of the information could have been corrected, quickly and easily. The main issues with the unopposed debate (no stakeholder representative, or consideration given to stakeholders, it seems); the conflation of illegal/criminal imports of untested and illegal drug products, and legal UK nicotine vaping; the lack of separation between the independent vaping industry and tobacco multinationals (they are not the same thing); the potential to harm the UK government stop to swap scheme (saving lives of people who smoke now, not a future population, years from now)… I could go on, but others like UK Vaping Industry Association have pointed out the issues, no need for a repeat.  My most important question; What is being done to ensure that stakeholders are heard, and the users of these products are not swept aside? Particularly what is being done to ensure false/misleading statements are not made to parliament by the experts, or that at least someone is included on behalf of users to set the record straight?  I look forward to your responses.   Yours sincerely,  Richard Pruen|Letter sec state health and social care 11 May 2024]]&lt;br /&gt;
&lt;br /&gt;
[[File:Draft redact address letter PM 8th Jul 2024.pdf|thumb|alt=Subject: The ban on disposable cigarettes / vaping in general&lt;br /&gt;
Dear Prime Minister,&lt;br /&gt;
I am a consumer advocate for vaping (15 years and a vaper for 16), and I do not use disposables beyond experimenting to see what they are like. I am also an engineer. I have previously worked in the vaping industry, testing against the standards for vaping products, and owned a now-closed company, BTC Battery Testing LTD (closed 2016). I am a consumer now and take no money from any industry, charity, or government scheme. Currently, I care for my mother, who suffers from vascular dementia, and as such, I volunteer my spare time to the cause of THR. I also advocate for smoking cessation in sufferers of severe mental health conditions. ASH UK funds the group, but I do not take any payment for my time. Regarding the subject. Might I remind you that Australia has already taken this path? An effective ban, over 80 fire bombings, at least three gang-style murders, and a rampant illegal trade have resulted? It simply won’t work. The prohibitionist faction has played on children starting using these products, and may have convinced you that a ban is enforceable; sadly, if Australia cannot do it, the proximity of Europe means less chance here. I am simply being realistic. The best, perhaps only, way to control the illicit trade is to make sure there is a legal trade that makes it less profitable; the US abandoned alcohol prohibition in favour of this. Please, however, remain focused on preventing harm; having the only source of disposable vapes (sorry to say this, but it is true) that adolescents could buy, being from a ‘dealer’ who might supply other illicit substances, is not safer! At least if they are from a shop selling tested, safe devices, then that is a vast reduction in harm already, avoiding interaction with drug dealers. I prefer every shop to follow the law, but as we know, not everyone will. Adolescents might also sample smoking, especially if they sensibly avoid illicit substance dealers; this, too, is not exactly a win, smoking being deadly and carcinogenic. Those diverted from cigarettes face a much lower risk of cancer and other smoking-related diseases. It is a fact that zero deaths have been caused by vaping a regulated nicotine product; among around 82 million users worldwide, the EVALI deaths all resulted from an illegal trade in THC vaping in the US (different chemistry and devices, incompatible with nicotine vapes). I favour regulations to encourage the use of rechargeable vapes. However, even disposables can be recycled; these are far superior to cigarette filters; filter tips are nearly impossible to recycle and will be in the environment for years. Exceptions should be made for disabled people (unable to fill or use pods) in secure mental health care/prisons; here, disposable tamper-resistant devices are safer. However, legislation should favour the refillable and reusable vapes that are most environmentally sound; disposables can be discouraged without a ban. Please see the graph. So far, regular use is not high and may be displacing cigarettes. Sensible regulations to keep it that way would be welcome. A few truths to bear in mind: The use of the word ‘children’ is a deliberate tactic to tug on heart strings, more correctly teens particularly adolescents are at risk from experimenting with vapes and other adult things, harm reduction still applies, beer is safer than vodka, vapes are vastly safer than cigarettes. Infrequent trial use isn’t the best indicator of dependence (once in 30 days), better is once a week or more. To risk dependence you need to be regularly vaping. The harm from vaping is low enough it is right to argue against the use of addiction, since the DSM-5 definition requires significant harm, dependence is more correct because it can be hard to stop. Vaping allows users to taper nicotine so less than cigarettes. Millions of lives are at stake, billions of pounds the NHS spend on cancer and other smoking related treatments that could be eliminated, smoking is the leading cause of preventable death, vaping regulated nicotine products, zero deaths in 20 years. The less popular you make vaping, the more popular smoking will become, they are substitutes. When you ban things; illicit markets form, they have no reason to follow age of sale or other rules, this risks making things worse not better (Australia demonstrates this). The generational ban while it sounds good, kicks the can into the future, vaping is reducing smoking right now, and more effort is required to target older adults, they are the ones facing smoking related diseases imminently, switching them to vapes is a huge immediate benefit the generational ban could never deliver. I would like to hear your thoughts, I will be happy to provide evidence to support what I have said, if required for any point please let me know. You promised your government would work for us, and would look after our health and well-being, here is a way to prove you will listen, many lives can be saved.  If there is one single study I think most important: Comparison of biomarkers of exposure among US adult smokers, users of electronic nicotine delivery systems, dual users and nonusers, 2018–2019. For every harmful or potentially harmful compound, vapers look exactly like non-users. Thank you for your time, I have tried to be brief as you must be busy, but welcome questions should you have any.  Yours sincerely, Richard Pruen P.S. My story: Why I do this? I started vaping in 2008 when it was relatively new, I had at this point given up trying to stop smoking, having tried everything. I intended to vape where I was unable to smoke. To my surprise in March of 2009 I discovered I had money budgeted for cigarettes that was unspent, this was how I discovered I had accidentally given up smoking. In 2010 I watched my father die from cancer, smoking 20/day didn’t help, although as a firefighter there is occupational risk also. My health improved substantially over the first 5 years, and at 15 years vaping I had an MRI due to aortic aneurysms running in the family (my father had one repaired), my lungs where those of a non smoker, doctors where unable to find any sign I vape. Put simply vaping saved my life and I would like pass that forward, partly in memory of my father, he was a firefighter and lived to save lives.  |draft letter to new PM for 8th JUL]]&lt;br /&gt;
[[File:Draft redact address letter wes sweeting 15th Jul 2024.pdf|thumb|alt=Subject: Tobacco and vapes bill&lt;br /&gt;
Dear Wes Sweeting,&lt;br /&gt;
&lt;br /&gt;
I am contacting you as a vaping consumer and advocate for saving lives; vaping saved my life (I am happy to share medical records to prove that), and I aim to pass that on to as many as possible. I am not paid in any way by anyone to do so. I have worked in the vaping industry, helping to develop standards and testing against them (I ran BTC battery testing until 2016). This was good for consumer safety, but the industry did not necessarily favour it. I am also part of a group funded by ASH advocating for smoking cessation in people living with severe mental illness; 40% smoke cigarettes, double the national number. &lt;br /&gt;
&lt;br /&gt;
I was disturbed to hear some of the testimony given in parliament, mainly by the previous government. Much of the information was incorrect or deliberately misleading. You must do better when debating a serious health matter; accurate and science-backed information is critical to saving lives. You should be using the research OHID paid for using taxpayers&#039; money, not anecdotal (often second-hand) accounts from teaching staff or parents frightened by the media (more on that below).&lt;br /&gt;
 &lt;br /&gt;
Before proceeding with further legislation, you must pause and ensure stakeholders (particularly end users) are appropriately consulted. Without accurate and proper information, bad legislation will result, like Australia and the prescription model (now dropped, and pharmacy only, also likely to fail)  Will Australia&#039;s tightened prescription system reduce nicotine vaping among young people? wiley.com and others show the policy failed, and instead 90% supply was from illegal sales controlled by organised crime. At the time of writing this, there have been more than 80 fire-bombings, three murders, and many gang ‘turf-wars’ in Australia. We do not need to bring that here. &lt;br /&gt;
&lt;br /&gt;
Sadly, there is a lot of misinformation being pushed in the media regarding children using these products; the use of ‘children’ is deceptive, even using the over-wide definitions that are often cited; children are not the population at risk. Sales are already illegal to those under 18; advertising to such age groups is also banned, and advertising is generally restricted. Please see my letter to the PM available from my wiki user page (direct link) https://safernicotine.wiki/mediawiki/index.php/File:Draft_redact_address_letter_PM_8th_Jul_2024.pdf. Adolescents are the population who might take up vaping, they might also take up smoking (far more deadly), or experiment with other adult things. It is a part of growing up, and if you prevent the less harmful options, adolescents will probably do more risky things.&lt;br /&gt;
 &lt;br /&gt;
I agree that you should keep a close eye on frequent vaping among adolescents; thankfully, that remains low and does not show worrying trends (please see the graph in the letter to PM above). Experimentation with vaping is preferable to cigarettes, and still, too many are starting to smoke tobacco. Vaping is unlikely to cause deaths, at least, unlike tobacco, and has (with open devices) the off-ramp of tapering nicotine slowly (around a third of folks quitting smoking with vapes also stop vaping this way; see ONS data).&lt;br /&gt;
 &lt;br /&gt;
It is essential to accept the vastly lower risk when considering legislation that will steer adolescents in a particular direction. Assuming they will do extra homework if they can’t experiment is faulty. They will likely do something more risky instead, such as alcohol. Alcohol, for example, results in accidents, intoxication and deaths. This is sadly human nature, and harm reduction at least keeps the risks as low as possible.&lt;br /&gt;
It is also vital to ensure that illicit vapes and illegal sales are kept to a minimum; buying vapes from ‘dealers’ opens all manner of unwanted possibilities, including other more harmful illegal drugs being offered. Thus, great care is needed to avoid a ban on a product type resulting in supply shifting to criminal-controlled illicit sales. There is already too much of this with over-strength/over-capacity disposable vapes; outright bans on disposables will make this far worse. This will require some subtlety and care in regulations to address the issue. Instead of a ban, having the price include the cost of disassembly recovery and recycling might better direct sales to refillable and, thus, much more environmentally friendly devices. The extra complexity of using a pod device is slight, so a small nudge is likely required for most consumers to shift to a more environmentally responsible product. You need to consider things carefully before doing anything and look at the unintended consequences that might occur.  &lt;br /&gt;
 &lt;br /&gt;
In only five years, New Zealand halved its smoking rate (now approaching 5%). https://www.scoop.co.nz/stories/WO2407/S00138/caphra-calls-on-asia-pacific-governments-to-allow-sale-of-oral-nicotine-products.htm The government there promoted vaping more than the UK government. For comparison, Canada taxes and does not promote vaping, and the smoking rate has remained stable. Sweden recently reduced the tax on Snus in a bid to increase switching (they are about to drop below 5% also) and has had great success with a THR product in Snus.&lt;br /&gt;
 &lt;br /&gt;
In Sweden, the use of nicotine is about the same as in the EU as a whole, but the rates of cancer are lower, particularly in men, since they switched earlier, and the trend is now apparent in the data. It is worth looking at Sweden because it has had a harm-reduction product for a long time, and trends and population data are readily available. It is obvious that nicotine is not a problem; it is combusted tobacco, particularly cigarettes; switching existing users to safer products is the priority; you can save vast numbers of lives and treatment costs. I suggest you research the history of THR in Sweden, allowing users to initiate nicotine use with a safer product works; they have the lowest cancer rates in the EU by a good margin. &lt;br /&gt;
&lt;br /&gt;
It is essential to be honest when looking at nicotine; it has benefits for some people; for ADHD, it is an effective treatment. I can help with other things, schizophrenia and depression. There is a list of peer-reviewed science here: https://safernicotine.wiki/mediawiki/index.php/Nicotine_therapeutic_benefits. Not to mention that every military in the world included nicotine in rations and snuff for submariners (since smoking was not possible due to hydrogen from batteries); they would not have gone to such expense if it was not beneficial to highly stressed young soldiers. These reasons mean that some people will use nicotine, so safer options are a win. Nicotine cannot be eradicated as some would wish. Trying to do so will result in uncontrolled illegal sales and crime (please see Australia if you have any doubts). To do the right thing and reduce harm as far as possible, you must look at all this and do your best. There is no clear path; there are always unintended consequences (thankfully, safer nicotine products are very non-deadly compared to cigarettes, so the remaining risk equates to being dependent (this happens with caffeine/coffee/energy drinks with little fuss)). So you have a chance to do what is right by the people you work for, and the NHS, even if it doesn’t fit entirely with popular opinion (partly due to worldwide campaigns by Mike Bloomberg and associated NGOs, they were caught trying to influence government https://mb.com.ph/2021/08/30/local-anti-vaping-groups-also-received-millions-of-grant-money-from-bloomberg/ Bloomberg has also stated “I don’t care if vapes are safer. I want them shut down no matter what” Public health heavyweights and scientists alike have offered to present evidence proving the good from vaping/THR, but have been ignored (repeatedly), Bloomberg’s view seems based not on data, but ideology.&lt;br /&gt;
&lt;br /&gt;
Needless to say, the tobacco and vapes bill is generational prohibition; by the modelling done, it will not do anything until it restricts sales (2040 before results are seen); it risks creating an illegal market and other prohibition-related problems; we can look to Australia to see the sorts of things to expect. Getting vapes out to older adult cigarette users will give results from day one; as soon as someone switches to vaping, the risk of cancer and disease begins to fall. That relieves pressure for treatment from the NHS, which can only be good.&lt;br /&gt;
&lt;br /&gt;
As I see it, you need to stop and take a hard look at the sin tax (it will put folks off switching and give the impression vapes are as bad as smoking) and the tobacco and vapes bill, then it shouldn’t be challenging to find something better. I think vapes should remain tax-free to encourage switching. However, users might put up with a small amount to improve enforcement of underage sales and illegal vapes. (Though there are things that can be done to reduce the waste from disposables by a factor of 10) some ideas in this letter https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb_2023.pdf&lt;br /&gt;
&lt;br /&gt;
One last point, the UN considers harm reduction for drug users to be a human right, and nicotine is a drug. This means that because harm reduction options exist, all with vastly lower risk than cigarettes, you must try to make them available to those at risk from the more harmful combusted tobacco.  &lt;br /&gt;
Please feel free to ask questions. I will always try to help if possible. Likewise, if you require evidence to support anything I have said, please ask. Alternatively, you can verify with your own research if you wish. Yours sincerely,Richard Pruen|Draft letter Wes Sweeting]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email 6th sept DHSC reply.pdf|thumb|alt=Sirs, Please find my reply inline in answer to your comments below. It is rather long, but a great deal of misinformation needs correcting.   On Fri, 2024-09-06 at 10:51 +0000, Department of Health and Social Care wrote:   Our ref: DE-1524319   Dear Mr Pruen,   Thank you for your correspondence of 5 August about vaping. I have been asked to reply.  I appreciate your concerns.  The Government recognises the role that vapes can play as a smoking quit aid and it is not its intention to restrict the accessibility of vapes to adults in the upcoming Bill.  Any measures brought forward through the upcoming Bill will be designed to curb youth vaping whilst having a minimal impact on adult vapers. The number of children vaping has tripled in the last three years, with one in five having used a vape in 2023, and the Government’s aim is to stop future generations from becoming hooked on nicotine.   Regarding the number vaping, very small number tripled is a very small number, for comparison please see the following graph (30 day use for various places) this includes a lot of experimental use that does not lead to dependence, and is sadly a part of growing up, adolescents try adult things (including alcohol at higher rates than vaping, causing deaths). Vaping won&#039;t cause any deaths at least, unlike cigarettes (few but fires do happen).    As can be seen the rates of infrequent use are the lowest in the UK, and highest in Australia (excluding the blip in the USA). I do not believe this is a coincidence, it reflects the regulation and illegal sales, the UK and Australia being at opposite extremes.  Here in the UK vaping is regulated and most sales are legal, from shops that have every reason to restrict sales to adolescents. In Australia the product is illegal without prescription, and 92% of the supply is via illegal sales, leading to firebombings and gang warfare. Illegal sales have every incentive to break the law, and sell to anyone with the cash. Illegal products are entirely unregulated.  We need to remain in control of sales, since it is working, the UK has the lowest use among adolescents. Changes risk sending more sales to the illegal market, and reducing control over sales. This will have the opposite effect to the one you intend and result in more sales being illegal and thus more sales to underage.  More enforcement of the existing rules, and work to reduce illegal sales would be welcome, and I suggest more useful than further restrictions in remaining in control.        Absolutely do not follow Australia, that method/type of control is proven a failure.     In the data above from ASH, we can see that 0.8% young people are vaping regularly having not also been a smoker, vaping is vastly safer than smoking, diverting them from cigarettes is a highly positive outcome.  Given the data, and we must rely on data and facts here, all but 0.8% are diverted from cigarettes, and that means virtually no smoking naive youth are going on to regularly vape. This quite near to the ideal situation, changes in legislation that might make this worse (by increasing illegal sales) should be avoided.  If it is working, don&#039;t fix it?   While it is certainly true that adults prefer fruit and sweet flavours, many flavours on the market are overly appealing to children.Evidence shows that children are attracted to the fruit and sweet flavours of vapes, both in their taste and smell, as well as how they are described. Many flavours have attractive wording and names that entice children to try vaping, such as ‘gummy bear’ and ‘rainbow burst’.  Nonsense, gummy bears are a sweet from my childhood, they may exist still, but I would buy that, I contest that is targeted at memories of adults. You might have more information on this, you should speak to the actual consumers of the product before jumping to easy sounding conclusions. New Nicotine Alliance are a charity funded exclusively by consumers and represent them, they would be a great point of contact. A consumer only org eliminates possible issues with manufacturer or even tobacco company influence.    The Government is aware that vape flavours are an important consideration for adult smokers when seeking to quit smoking and it will carefully consider any restrictions to avoid unintended consequences. The primary purpose of the Tobacco and Vapes Bill is to reduce smoking rates by bringing forward a generational ban on the sale of tobacco, making it an offence for anyone to sell tobacco products to anyone born on or after 1 January 2009. This policy is not being implemented for vapes because the health advice is clear that vaping is less harmful than smoking; however, vaping is not risk-free and nor is the consumption of nicotine.  https://x.com/JonathanFoulds/status/1829195343780819169    The tobacco part of the bill is irrelevant according to this, and economists everywhere, cigarettes are going away. By the time the generational ban has any effect, there will have been no uptake of smoking for some years, and thankfully that will result in faster reductions in death and disease. The Generational ban is too slow, no effect for more than 20 years, but thankfully, THR (tobacco harm reduction) will have more effect and way faster, it has already begun as above.      Nicotinecauses addiction rapidly and can increase the risk of developing conditions such as cardiovascular disease, gastrointestinal disorder and more rapid development of some cancers. Giving up nicotine is very difficult, and withdrawal symptoms can include cravings, irritability, anxiety, trouble concentrating, headaches and other mental symptoms. Evidence also suggests that the brain in adolescence is more sensitive to the effects of nicotine, so there could be additional risks for young people. That is why it is vital that vapes are only used as a smoking cessation tool.    Vapes are an effective quit tool for smokers, particularly when combined with behavioural support. Therefore, it is important that vapes remain accessible to adult smokers. The Government remains fully committed to the Swap to Stop scheme, which involves swapping cigarettes for vapes.    This part is shocking, and awful both at the same time. The misinformation presented to government is terrible. There is no good evidence that nicotine outside smoking increases the risk of cardiovascular disease, in fact long term studies in Sweden show nicotine from Snus is not associated with increase in cardiovascular risk, nor with any sort of cancer. Since Snus has been popular for a long time the evidence is based on studies of the actual population, much more reliable than e.g. extrapolation from cell or animal studies.  Would you provide the source of this disinformation (Cardiovascular desease, gastrointestinal desease, cancer risk), and who presented it, please? This is important, the government needs true and up to date information, and sources of poor/disinformation need to be tackled.   Further there is good evidence that nicotine can treat some gastrointestinal problems, please may I have the source for your claim it is a cause. I present some peer reviewed papers below, none are industry funded. I can present more if you would like?   https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntae193/7727428 &amp;quot;Despite different mechanisms of action, both ENDS and CCs attenuated on-going colon inflammation, enhanced healing and ameliorated recovery of injured intestines of DSS-treated mice and UC patients.&amp;quot; Citation: Kastratovic N, Markovic V, Arsenijevic A, Volarevic A, Zdravkovic N, Zdravkovic M, Brankovic M, Gmizic T, Harrell CR, Jakovljevic V, Djonov V, Volarevic V. The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis. Nicotine Tob Res. 2024 Aug 5:ntae193. doi: 10.1093/ntr/ntae193. Epub ahead of print. PMID: 39101540.  https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Analysis of several studies - some animal. In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity. Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889 Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.  https://www.hindawi.com/journals/grp/2008/237185/ Smoking has a detrimental effect in Crohn&#039;s disease (CD), but this may be due to factors in smoking other than nicotine. Given that transdermal nicotine benefits ulcerative colitis (UC), and there is a considerable overlap in the treatment of UC and CD, the possible beneficial effect of nicotine has been examined in patients with Crohn&#039;s colitis. In this relatively small study of patients with active Crohn&#039;s colitis, 6 mg nicotine enemas appeared to be of clinical benefit in most patients. They were well tolerated and safe. PDF Version Citation: J. R. Ingram, J. Rhodes, B. K. Evans, and G. A. O. Thomas, Hindawi Publishing Corporation, Gastroenterology Research and Practice, Volume 2008, Article ID 237185, 6 pages, doi:10.1155/2008/237185 Acknowledgements: J. R. Ingram was supported by the Gastrointestinal Foundation Trust. SLA Pharma gave financial support to the project. The authors are indebted to Dr. J. T. Green (of Cardiff and Vale Hospitals Trust) who referred patients, and to Professor G. T. Williams (GTW) who performed all histological assessments.   Regarding nicotine addiction, the DSM requires significant harm as well as the difficulty in stopping use, the safer forms of nicotine do not pose sufficient risk/harm by that definition. Tobacco when smoked certainly does pose sufficient risk, thus addiction is justified. Loss of autonomy is not sufficient harm, though it does require consideration, if it where caffine in coffee would be addictive, not the more reasonable dependency forming.  For the dependency of nicotine, your information appears out of date, I will deffer to Karl Fagerstrom, world leading expert and inventor of the most used dependency test for nicotine.   Karl Fagerstrom | 14 December 2013 &amp;quot;We used to believe that nicotine is very dependence producing, but the evidence suggests that there are a number of problems with this statement. For example, animals do not self-administer nicotine as readily as they do other dependence producing drugs such as amphetamine, cocaine, and heroin (Villegier et al. 2003); nicotine is a relatively weak reinforcer in human laboratory studies (Perkins et al. 2001); abstinent smokers seem to prefer a much reduced or nicotine free e-cigarette rather than other - often stronger - nicotine-containing products like gum; and although nicotine replacement treatment is an effective aid for quitting smoking, its efficacy is moderate even in doses that replace most or all nicotine from the cigarettes formerly used (Dale et al. 1995). There is very little to no evidence for the abuse of nicotine when not delivered in a tobacco vehicle.&amp;quot;  https://nicotinepolicy.net/authors/karl-fagerstrom/dependence-on-tobacco-and-nicotine/  The above link contains more information expanding on the above, with references.   The Vaping Products Duty did not form part of the previous Government’s Tobacco and Vapes Bill. Taxation is the responsibility of HM Treasury, which ran a public consultation on the proposals for the duty from 6 March to 29 May. HM Treasury and HM Revenue and Customs are currently considering responses to that consultation. There are no plans to introduce any tax changes as part of the upcoming Bill. I hope this reply is helpful.  Thank you for the reply, it remains to be seen how useful this conversation is, it depends on your willingness to accept the evidence. Evidence is changing rapidly in tobacco and nicotine, this was not always the case, for a long time tobacco was the only source of nicotine in popular use, now that has changed (for the better with safer products, mostly not from the tobacco industry of old, I would argue).    Regarding the tax, it need to be considered alongside policy, it as proposed is a &#039;sin tax&#039; and will result in significant increase in illegal sales as tax avoidance adds to profitability, thus crime and sales to youth, as well as dissuading adults who smoke cigarettes from switching to a product that is likely to save their life. I would remind you that 30% of vape sales are illegal, I have previously written to explain some ways to reduce the impact of vapes on the environment (by a significant ten fold) and at the same time allow regulated products to out-compete the illegal products (making illegal sales nonprofitable is the easiest/cheapest control). A link o my previous letter https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb_2023.pdf  Yours sincerely,   Correspondence Officer Ministerial Correspondence and Public Enquiries Department of Health and Social Care  --------------------------------------------------------------------- ----------------------------------------------------  Please do not reply to this email. To contact the Department of Health and Social Care, please visit theContact DHSC section on GOV.UK To receive news about DHSC: sign up to our monthly newsletter This e-mail and any attachments is intended only for the attention of the addressee(s). Its unauthorised use, disclosure, storage or copying is not permitted. If you are not the intended recipient, please destroy all copies and inform the sender by return e-mail. Any views expressed in this message are not necessarily those of the Department of Health and Social Care. Please note: Incoming and outgoing email messages are routinely monitored for compliance with our policy on the use of electronic communications.  --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|reply from DHSC and reply sent]]&lt;br /&gt;
&lt;br /&gt;
[[File:20240908122716 FAO- Wes Streeting, Potential risk reductions.pdf|thumb|alt=Dear Wes Streeting,  Given the abundance of poor information circulating in Parliament, I thought I should provide an easy to understand example of what a 95% reduction is risk product can do to cancer rates. Unlike the modelling and assumptions that appear to prop up the tobacco and vapes bill, I will provide real population data from Sweden (they started using a harm reduction strategy with snus years ago, enough that real world data is available).    You can verify these graphs by visiting https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Main_Page  The use of nicotine in Sweden is roughly the EU average at 22%, but much of that is a product that is similar in risk to vaping, snus is also 95% or better less risky than cigarettes. Sweden in allowing some uptake by young people has seen the reductions above, snus has substituted for a much more harmful product and overall risk has fallen dramatically as seen above. The &#039;not without risk&#039; aspect of nicotine and vaping is massively overplayed, it is certainly less risky than alcohol.      As you can see above so far the UK has avoided the surge in adolescent vaping seen elsewhere, there has been a rise, but according to the latest ASH data 0.8% of frequent (&amp;gt; once per week) users are tobacco naive, so most of the increase is diversion from smoking (a good thing since if you never inhale tobacco smoke, it cannot harm you).   This begs the question; if it seems to be working, why fix it? Further restrictions will drive the product to illegal sales, and like has been seen in Australia, that results in more sales to youth, and less access for adults, exactly the opposite of the desired outcome. We already have an illegal market in oversized/over strength products roughly 30% of the market, changes will cause it to step up and supply more if it becomes profitable. Big hint here that the proposed &#039;sin tax&#039; on nicotine is guaranteed to increase illegal sales. Is the tax take in the short term favourable, with the increase in illegal sales it will prompt, compared to maximising the savings to the NHS? I would strongly suggest not!  Extending the swap to stop scheme, particularly to target older cigarette users will have a huge effect on the NHS, reductions like those in the Sweden graph above, would save more than 500 million a year (up to 1 billion, if we can match Sweden in 50% reduction in lung cancer). https://www.brunel.ac.uk/news-and-events/news/articles/How-much-could-the-NHS-save-if-people-had-healthier-lifestyles-Hundreds-of-millions-according-to-research#:~:text=One%20of%20my%20studies%20indicates,mouth%20cancer%20and%20heart%20disease.  The reduction would help cut waiting lists by 2029 as you have promised, especially if targeting the older at risk population with swap to stop. The tobacco part of the tobacco and vapes bill, that won&#039;t have had any effect by that point, and it is likely by the time it does the cigarette market will have collapsed/changed beyond recognition.    I am not sure about it collapsing, but it is becoming obvious that big changes are afoot, and it will not be good for Big Tobacco of old.  I would like to ask you to be cautious of changing regulations that we already have, and that appear to be working. Also to ensure that any further measures are well though out. The tobacco generational ban, I don&#039;t think will do any vast harm at least, it might have been a really good idea if implemented 20 years ago.  I would also draw your attention to this regarding misinformation https://safernicotine.wiki/mediawiki/index.php/File:Email_6th_sept_DHSC_reply.pdf  I have to wonder if misinformation on vaping is from tobacco companies, since as above vaping is doing a number on them? It seems this misinformation is stated without evidence usually or highly speculative evidence (rodent studies that are unsupported by the real world data). However I am happy to provide evidence for what I have said, and welcome any questions you may have, please feel free to ask.  Thank you for your time.   --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|Email FAO- Wes Streeting, Potential risk reductions]]&lt;br /&gt;
&lt;br /&gt;
[[File:APPG for Responsible Vaping Call for Evidence Form - 10 October 2024.pdf|thumb|alt=APPG for Responsible Vaping Inquiry on Vaping – Autumn 2024 CALL FOR EVIDENCE Those wishing to submit evidence to the inquiry should use this form. Submissions should be sent by email to info@responsiblevapingappg.org by 31 October 2024. Responses to individual questions should be kept to 500 words. Supporting information and evidence will also be accepted (see section 6). The APPG for Responsible Vaping is committed to transparency. The names of those organisations providing evidence, together with their submission, will be acknowledged in the final report and made available on the APPG for Responsible Vaping website. Personal information will not be released. All information gathered will be treated in accordance with the APPG’s GDPR policies. The APPG for Responsible Vaping has no links, connections or other engagement with the tobacco industry. If any tobacco company provides a submission to the APPG inquiry, as per guidance on requirements of article 5.3 of the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC), it will not be considered. About your organisation Q. Please provide your name and the name of the organisation that you are representing including contact details. Please indicate if you are responding in a personal capacity. I am representing myself as a consumer Q. Please outline your organisation’s field of interest/area of expertise in vaping including the relevant sector you represent e.g. public health, retail, manufacturer, regulator etc. I am a consumer of vaping products, I wish to present a consumer view Key Lines of Inquiry 1. The health impact of vaping including current application and usage 1a. Please provide comment and evidence to show the health impact of vaping including how, when and by whom such products are used, and their effectiveness or otherwise. Vaping provides a vastly safer alternative to combustible tobacco, both for current cigarette users, and for anyone who would start using riskier forms of tobacco. 1b. How should the government and others in public health treat vaping as part of the Smoke Free 2030 strategy and other health interventions? Vaping has a vastly lower and different risk profile to tobacco, the rules for tobacco are suitable for tobacco only (due to the extreme harm, and long lead time to that harm). Vaping must be treated separately and law must reflect the fact that it is at least twenty times safer than cigarettes. The risk is actually substantially lower, given use over 15 years has shown little problem. Vaping is capable of displacing cigarettes from the market, this has already begun.1c. And what are the barriers to this happening at present and in the future? focus on the generational ban as the go to policy, this will not do anything in time for the 2030 strategy, and the vapes part of it needs to avoid preventing switching, and any further restrictions favour expanding the illegal market. 2. Challenges facing the vape sector, including youth access and the environment 2a. How should we tackle issues relating to youth vaping? Please provide details of your experiences and supporting evidence including examples of effective interventions or other work, including from other sectors or countries. What else should the government, regulators, retail and vape sectors be doing in this regard and what does an effective strategy look like? Youth are already prevented from legally purchasing vapes, and the uptake of regular use &amp;gt; 1 time a week is 0.8% and not trending quickly in any direction. Keeping legal vapes on the market and available more freely than illegal ones is key, illegal vapes will only be sold if profitable, the cheapest control for illegal sales is to have legal products that prevent illegal products being profitable. Vaping is at least 20 times safer than cigarettes, and has an off ramp in tapering, while use is undesirable, it is still very much better than cigarettes for those determined to use nicotine. 2b. How should we tackle issues relating to the environmental impact of vaping. Please provide comment and evidence on the effectiveness of the current environmental legislative regime, such as the WEEE Directive, whether this is fit for purpose or what changes need to occur. I wrote to APPGVaping before with some ideas here is the letter from 28th feb 2023 this would also help suppress the illegal oversize devices, and reduce waste by a factor of ten times. https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb _2023.pdf 2c. What other measures or schemes could be considered to improve the environmental impact of vaping? Is there, for example, a need to consider innovative take-back schemes together with financial penalties or incentives on the consumer, retailer and manufacturer, and what is the role for government and regulators? disposables should be discouraged, having a rewarded return scheme, and improving the design. For example I released a metal free pod that the part thrown away is entirely safe to throw away, the two tiny graphite contacts are the only parts that do not biodegrade quickly https://x.com/PruenRichard/status/1729128256329154749 It is dedicated to public domain so anyone can use for any purpose. 2d. Will the government’s likely proposal to ban single use or disposable vapes be beneficial in tackling youth vaping and the environmental impact of vaping? Are there potential consequences that need to be understood and explored? Please explain and evidence yourcomments. No it will likely drive all disposable sales to illegal markets (30% is already oversized/strength disposables) This will result in easier availability to underage due to no age of sale law being followed and greater risk due to untested products. This needs to be considered, a ban will increase danger. 2e. How can challenges relating to the growth of the illicit vape market be addressed and what role is there for government, regulators, law enforcement, retail, vape manufacturers etc? The regulated legal market is the best way to ensure it is not profitable to sell illegally, this has zero cost to implement. Ensure legal products are desirable and useable enough and there is no profit in illegal products. 2f. In recent years, there has been a significant increase among smokers believing that vaping is as harmful as tobacco use. Why has this come about, what are the risks with this and how can such misconceptions be addressed and corrected? Media focus on harms. This needs media and facts targeted particularly at older adults to get them facts and encourage then to switch as soon as possible. There is no other policy that can reach the most at risk population, older adults facing smoking related issues, the sooner they switch the better. 3. The economic impact of vaping towards public health, retail sector and wider economy 3a. What evidence can you share that highlights the economic impact of vaping, both positive and negative, towards the various sectors listed above. Having it be cheaper for the consumer is another reason to switch, the risk reduction is enormous so a large incentive is warrented to incentivise switching. 3b. What impact will the government’s likely course of legislative action (proposed ban on single-use vapes, banning advertising and branding as well as potential restrictions on vape flavours and retail display) on vaping have on the economic impact of vaping? Youth regular vaping is 0.8% and it might reduce that to 0.5% at best, meanwhile it will prevent many adults from switching, the adults still smoking face death 50% of the time. None of the youth starting will face death from vaping in the short or medium term, and unlikely to face death in the long term. The youth gain little for a lot of adult death. An annoying dependence VS 50% chance of death, these need to be weighted properly. 4. Proposed government legislative measures including flavours, packaging, display, excise and a ban on certain vaping products 4a. Please comment on the government’s likely proposed measures for regulating the vapesector including a ban on single-use vapes and a graduated excise regime – please indicate where you support or oppose such steps and your views on their likely consequences. as above the risk to youth and adults must be propperly considered. The risk of increasing illegal sales as well, it can be seen from Australia that demand exists and supply will meet it. Far better legal regulated vapes than illegasl ones. Flavours are vital for adults and any youth determined to try vapes will use whatever is available, it is unlikely to change the decision they make. 4b. Please comment on the government’s potential measures around packaging, display and flavours – please indicate where you support or oppose such steps including your views on their likely consequences (the APPG recognises that the government is still to publish full details around a number of these measures). Packaging/flavours should be no more restricted than the far worse alcohol, or other adult goods, if age of sale is acceptable for alcohol, and yet deaths occur in under 18s then a product without deaths and unlikely in the extreme to cause any, it doesn’t make logical sense. one puff in 30 days but 0.8% regular use indicates vapes are not as sticky as cigarettes, as most trials do not proceed to regular use. Risk reduction, because risk elimination is not possible. 4c. What are the risks, if any, to achieving the government’s Smoke Free 2030 ambition with its likely course of legislative action? The potential to increase the share of illegal sales, thus increasing availabity to youth, while causing adults to thing vaping is as harmful as cigarettes. Restrictions have a huge potential to cause harm, and little to do good on a whole population basis. 5. Better regulating the vape sector in the UK 5a. Please set out what in your view what would constitute a better regulated vape sector, with reference to examples from other sectors or countries. Where available, provide evidence to highlight how a particular route or measure has achieved its goals in delivering better regulation and the desired outcome. This could include responsibilities for government, regulators, retail and manufactures and both legislative and non-legislative routes. The existing rules are not too bad, they have led to the lowest youth vaping in the world and no spike in use as seen in the USA. Better enforcement of age of sale and keeping the illigal market suppressd, it would be very easy to do worse than continue as things are. 5b. Would a licensing scheme for vaping provide a better regulated sector and how could such a model work? Please provide any evidence to substantiate your comments including examples from other sectors or countries, and what would specifically need to occur to make this a feasible &amp;amp; effective scheme? 500 words No vapes should be available wherever cigarettes are available and with preferably less restrictions. The existing laws are good as they are, slightly favouring display of vapes over tobacco. Restrictions on vapes will make tobaccomore appealing in comparison, and tobacco is 20 times worse. 6. Other 6a. Please use this space to set out any other information or comments that you like to submit that you do not feel have been adequately covered by the above. Respondents can also submit an attachment. 500 words general supporting evidence attached Youth vaping is well under control and there are no sudden or worying trends or fad use. This is possibly as good as it gets, more restrictions are lilkey to make things worse (increasing illegal markets) Regular use very low and has been the same for several years|Response to APPG call for evidence]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email-response-reply-DHSC-26-oct-2024-draft2.pdf.pdf|thumb|alt=Thank you for the reply, please find my response inline.   On Thu, 2024-10-24 at 17:26 +0000, Department of Health and Social Care wrote: &amp;gt; Our ref: DE-1529395 &amp;lt;cut&amp;gt;  We also remain fully committed to our Swap to Stop scheme, which sees up to one million adult smokers being encouraged to ‘swap to stop’, swapping cigarettes for vapes under the national scheme – the first of its kind in the world.   Very glad to hear this, as suggested before I hope you would consider putting extra focus on reaching older cigarette users, they are the group most directly facing health harms, and the generational ban does nothing for them ever. The possibility exists to eliminate a huge amount of disease and death. With savings to the NHS year on year because cancer treatments are expensive.   On the subject of the tobacco and vapes bill, I don&#039;t see the big rush the likes of ASHuk promote, by the time the legislation has any effect the 2030 smoke free deadline will have passed. IMHO it is better to take the time and get it right, than to rush through damaging regulations. Clive Bates provides good reasons here: https://clivebates.com/uk-tobacco-and-vapes-bill-a-misfire-and-a-backfire/    In addition, NHS programmes delivering nicotine replacement therapy are helping thousands of adults each year to live healthier lives with adult smoking rates dropping by more than half in the last three decades.  Good, the more low risk options available the more likely people will find an acceptable one, and thus not die.   Whilst vapes can be an effective quit aid for adult smokers, we are concerned about the worrying rise in vaping among children, and there are legitimate concerns about the unknown long-term harms from vaping.  There has not been a significant rise in regular use of vapes (once a week or more) certainly nothing sudden or panic worthy. The Please see this graph:      With 20 years of use, biomarker data, 16 years of popular use mostly in ex cigarette users, you are vastly overstating the remaining risk. Vaping is not likely to cause cancer of any kind (cancer potential 0.004% of smoking, a robust body of evidence https://safernicotine.wiki/mediawiki/index.php/Nicotine_-_Myth_-_Nicotine_Causes_Cancer)   At this stage any possible risks are sure to be minor, the type that may cause discomfort or be annoying, but extremely unlikely to be life threatening. Science has moved on since cigarettes where found harmful, there is also real world population data from Sweden on reduced risk products and the effect. No need for modelling, there has been enough time to see the results in the eurobarometer.     Vapes can do the same in the UK, or legalise Snus and copy Sweden, either way would work. As long as the you do not ban the good, while trying to achieve the perfect (resulting the disaster of more cigarettes). Ideally legalise Suns alongside vapes and transition those who will not vape to that, and cut deaths faster.  Disposable vapes play a significant role in driving youth vaping with 54 per cent of current vapers aged 11-to-17 in Great Britain using them. They are easily available, cheaply priced and come in enticing colours and flavours. Additionally, they cause significant environmental harm with five million disposable vapes being either littered or thrown away in general waste every week. Given the level of environmental harm, the Department for Environment, Food and Rural Affairs is reviewing proposals to restrict the sale and supply of disposable vapes and will shortly outline its plans. Reusable and refillable products will remain available to help support smokers to switch and we do not have any plans to restrict vapes, for instance, to prescription only channels.  There is absolutely no reason to punish the thousands of adults who will be put off from vaping, for 54% of 0.8% (youth vapers who never used cigarettes). Half of those adults not switching will die, while the youth will need to taper off nicotine using refillable vapes built in off ramp, cigarettes do not have that.  Meanwhile according to NHS digital 2022 (graph below) 8% of 11-16 year old&#039;s have been drunk 3 or more times, vape are very effectively kept out of young peoples hands compared to that. There is no mass moral panic about alcohol, alcohol is far more deadly than vapes  You need to sort priorities out, because the evidence doesn&#039;t support the focus on vapes.      Enforcement of our regulations is vital. This is why we will ensure that the Tobacco and Vapes Bill contains new powers for trading standards, to take more immediate action to prevent the sale of vape to children and stop illicit products.  That is great, underage sales need to be kept low, so does the illegal sale of unregulated vapes.  In addition to local enforcement action, we are also providing £3million of funding over two years for Operation Joseph to reduce the sale of illegal vapes and nicotine containing vapes to under 18s. Operation Jospeh has been increasing funding at ports to ensure trading standards can conduct large seizures of illicit vapes before they enter the country.  Great, but ensuring a legal market of products people want and find acceptable will mean illegal sales are unprofitable, there is also no cost to the government to enforce that. Restricting adults choices of flavours and full plain packaging will result in demand, the proposed sin tax will increase profitability, Australia at the time of writing has had 130 firebombings in the vapes turf war, do not bring that sort of insanity here, learn from their mistakes.  Marketing is already restricted, and no reputable company targets underage users, they would be boycotted out of existence by consumers because they will not put up with youth targeting (I have seen this several times and it is very effective).  Any genuinely youth appealing marketing or packaging can be dealt with under existing rules against advertising the product. It is while consumers are on side you can rely on this, if like Australia restrictions mean the public support the illegal market, then things will go badly here, just like Australia.   I also worry the focus on vaping will detract from youth alcohol and drug prevention. Both these cause significant deaths, vaping doesn&#039;t even intoxicate, nor will it cause young people to die.   The Department has previously published a call for evidence, a policy paper and a response to the public consultation on tobacco and vaping measures. All of these contain published links to evidence the Government has used in formulating policy and are relevant to many of the points you have raised. In addition to this, we work closely with organisations such as Action on Smoking and Health, public health bodies, academics, local organisations and other relevant parties to ensure that policy is based on the most reliable evidence.  With respect it would be best to rely more heavily on the reports that where done for OHID, and less on hearsay or anecdotal evidence that may be brought up in parliament. Views should be heard, but must never take precedence over a report based on evidence and backed by science.   We will be undertaking further consultations before the introduction of vaping regulations once the Tobacco and Vapes Bill has completed its parliamentary stages, and I would encourage you to respond to those consultations when they launch.   Yes thank you. You can be sure I will be taking part in such consultations where possible. I am however just a consumer and care for my Mum who has vascular dementia,   I hope this reply is helpful.   Yes thank you, it makes it clear that risk is not an easy concept, and I hope the information presented helps to provide better perspective. Please feel free to ask any questions I will do my best to clarify any points or provide extra evidence if needed.   Yours sincerely,   Correspondence Officer Ministerial Correspondence and Public Enquiries Department of Health and Social Care   --------------------------------------------------------------------- ----------------------------------------------------  Please do not reply to this email. To contact the Department of Health and Social Care, please visit theContact DHSC section on GOV.UK  To receive news about DHSC: sign up to our monthly newsletter     This e-mail and any attachments is intended only for the attention of the addressee(s). Its unauthorised use, disclosure, storage or copying is not permitted. If you are not the intended recipient, please destroy all copies and inform the sender by return e-mail. Any views expressed in this message are not necessarily those of the Department of Health and Social Care. Please note: Incoming and outgoing email messages are routinely monitored for compliance with our policy on the use of electronic communications.  --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|Email response to DHSC draft 2]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email-dhsc-20-nov-2024.pdf|thumb|alt=Hi folks,  Since the government promised to be evidence led, I thought this new evidence was vital for vaping policy.  In this paper the authors examined respiratory symptoms in e-cigarette users without a history of smoking from the VERITAS cohort. While vapers reported slightly more frequent symptoms than non-vapers on the Respiratory Symptom Experience Scale, the difference was not clinically significant. Disposable e-cigarettes were the most common device type, with fruit flavors preferred by most users.  https://www.nature.com/articles/s41598-024-80221-8  The VERITAS cohort https://veritascohort.coehar.org/ aims to provide long term data on vaping in never cigarette users &amp;lt;100 cigarettes in their life, and is important because most vapers are past cigarette smokers and significant confounding exists due to this.  The first data above shows &#039;the difference between groups was not clinically significant&#039;, further proof that in the long term, vaping is vastly safer than smoking, and the effects on non-smokers are tiny, not clinically significant.  It is vital that you factor this information into policy because adults who are convinced not to switch face death 50% of the time. Adolescent nicotine use is falling, and if they do use any product, then smoking should be the least available to them, as it is the most harmful. Vaping in adolescents is lower than alcohol use, and alcohol is far more toxic in both the short and long term.  The current age of sale laws means the UK has the lowest regular use of vapes in underage in the world; we should keep doing that, but be aware that there is little harm from vaping when you compare that to the death faced by cigarette smokers.  The tax and ban policy will not work; it will lead to illegal markets, just like Australia has seen; once control is lost, it will be harder to regain. Sweden, on the other hand, did not reduce nicotine use, which is average for the EU, but has seen reductions in smoking-related diseases and cancer. They have also achieved the smoke-free goal 17 years early:    The UK will reduce death and disease more rapidly being more like Sweden than like Australia.  I would like you to focus on reducing death and disease quickly, and without sacrificing the older cigarettes smoking population, this is possible, if Sweden can do it, so can the UK.   Thank for your time.  --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|Email to DHSC 20 nov 2024]]&lt;br /&gt;
&lt;br /&gt;
DRAFT: [[File:Letter minister for health 11th Feb 2025.pdf|thumb|alt=Subject: Ongoing Vaping Policy Dear Ashley Dalton,  I am contacting you as a vaping consumer and advocate for saving lives; vaping saved my life (I am happy to share medical records to prove that), and I aim to pass that on to as many as possible. I am not paid in any way by anyone to do so. I have worked in the vaping industry, helping to develop standards and testing against them (I ran BTC battery testing until 2016). This was good for consumer safety, but the industry did not necessarily favour it. I am also part of a group funded by ASH advocating for smoking cessation in people living with severe mental illness; 40% smoke cigarettes, double the national number.  I was disturbed to hear some of the testimony given in parliament. Much of the information was incorrect or deliberately misleading. You must do better when debating a serious health matter; accurate and science-backed information is critical to saving lives. You should use the research OHID paid for using taxpayers&#039; money, not anecdotal (often second-hand) accounts from teaching staff or parents frightened by the media. Consumers are not represented; I would ask you to consider involving NNA (New Nicotine Alliance) as they are a consumer-only group that is not funded by the industry. info@nnalliance.org Charity Registration Number: 1160481. It seems fair since UKVIA (industry trade association) and tobacco control NGOs were involved, but there was no one for consumers.    Sadly, the media is almost all negative and presents harm because that sells papers; the truth is that in 12 years of monitoring by the MHRA yellow card early warning system, not one single disease/symptom has been detected as linked to vaping nicotine. There have been less than 20 admissions to hospital per year, and none fatal, compared to 15 per day for household cleaners (some sadly fatal).    I agree that you should keep a close eye on frequent vaping among adolescents; thankfully, that remains low and does not show worrying trends (see graphs below). Experimentation with vaping is preferable to cigarettes, and still, too many are starting to smoke tobacco. Unlike tobacco, vaping is unlikely to cause deaths since 20 years of study shows no such issue. Vaping has (with open devices) the off-ramp of tapering nicotine slowly (around a third of folks quitting smoking with vapes also stop vaping this way; see ONS data that you must have access to).   It is essential to accept the vastly lower risk from vaping when considering legislation that will steer adolescents in a particular direction. Assuming they will do extra homework if they can’t experiment is faulty. They will likely do something more risky instead, such as alcohol. Alcohol, for example, results in accidents, intoxication and deaths. This is sadly human nature, and harm reduction at least keeps the risks as low as possible. It is also vital to ensure that illicit vapes and illegal tobacco sales are kept to a minimum; buying vapes from ‘dealers’ opens all manner of unwanted possibilities, including other more harmful illegal drugs offered at the same time. Thus, great care is needed to avoid a ban on a product type resulting in supply shifting to criminal-controlled illicit sales. Australia is a perfect example of open gang war and fire bombings. A legally regulated market that renders illegal supply unprofitable is the best solution; there is no enforcement cost in that case, and consumers should be protected against entirely unregulated products.    In Sweden, the use of nicotine is about the same as in the EU as a whole, but the rates of cancer are lower, particularly in men, since they switched earlier, and the trend is now apparent in the data. It is worth looking at Sweden because it has had a harm-reduction product for a long time, and trends and population data are readily available. It is obvious that nicotine is not the problem; combusted tobacco is the killer, particularly cigarettes; switching existing users to safer products is the priority; you can save vast numbers of lives and treatment costs.   I suggest you research the history of THR in Sweden, allowing users to initiate nicotine use with a safer product works; they have the lowest cancer rates in the EU by a good margin. (see the following graphs) The UK can still do the same with vaping by not restricting it too much.     Yours sincerely,  Richard Pruen|Letter minister for health 11th Feb 2025]]&lt;br /&gt;
[[File:20250413114422 Cigarettes and Big tobacco.pdf|thumb|alt=I thought this Sobering analysis of the US cigarette market might be interesting. It looks like Big Tobacco is winning, while the only successful commercial alternative (vaping and other THR (tobacco harm reduction) products like tobacco-free pouches) are being further restricted.  The UK is falling into the same trap.    &amp;quot;Last August Barclays analysts updated the data to show how US cigarettes had become massively more profitable. Based on that Goldman Sachs report this week, the ever-accelerating price increases since last August will bring the gross profit on a pack of Marlboros to $4.50 and the operating profit to around $3.64. More than doubling profits per pack in less than five years, and on a product that costs a mere 40 cents to make.&amp;quot; The entire report by David Sweanor, a well-known tobacco control expert from Canada, is attached.  While no one wants young people to take up vaping, it is far more vital that they do not start smoking cigerettes. Youth vaping once a week or more is low and remains so (please see graph)      The current government plans for a smoke-free generation will not help anyone currently smoking cigarettes; they also have the significant downside of forcing any young people insisting on using nicotine into the illegal market; the sin tax on legal vaping will mean the cheapest/most available product they encounter will be illegal cigarettes, likely they will use those. As we are well aware, cigarettes are not safe, and they are not better than vaping.  Despite the ridiculous claims of the press and the rubbish spouted in Parliament, vaping has not been linked to any disease or syndrome. Twelve years of MHRA early warning monitoring would have detected anything serious (that is the reason for its existence). The data is available here: https://safernicotine.wiki/mediawiki/index.php/MHRA_yellow_card (or ask the MHRA). This government promised to be evidence-led, so please look at the evidence and do that.   The overabundance of caution to prevent youth vaping will cause more youth to start smoking cigarettes, and that cannot be a good thing; it will cost lives. I would ask you to consider carefully because THR can save at least some of those lives. It may not be perfect or easy to regulate, but lives are important.  I do not want to be able to say &#039;I told you so&#039;, I would much rather you did better and saved more lives, please! |Letter to DHSC 13 April 2024]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=File:20250413114422_Cigarettes_and_Big_tobacco.pdf&amp;diff=78860</id>
		<title>File:20250413114422 Cigarettes and Big tobacco.pdf</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=File:20250413114422_Cigarettes_and_Big_tobacco.pdf&amp;diff=78860"/>
		<updated>2025-04-13T15:29:52Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Letter to DHSC 13 April 2025&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78780</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78780"/>
		<updated>2025-03-23T16:12:54Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thank you! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_therapeutic_benefits&amp;diff=78779</id>
		<title>Nicotine therapeutic benefits</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_therapeutic_benefits&amp;diff=78779"/>
		<updated>2025-03-23T09:36:14Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: /* ADD / ADHD / Attention / Cognition */ add nicotine improves memory study&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;big&amp;gt;&#039;&#039;&#039;&#039;&#039;Safer Nicotine Wiki does NOT endorse smoking for any potential therapeutic benefits. Smoking has too many severe consequences. Studies showing that fewer people who smoke end up with a specific ailment are included to show the potential benefits of the nicotine. Some of these studies show a potential benefit, not proof of a benefit. Some of the studies are animal studies, not human studies.&#039;&#039;&#039;&#039;&#039;&amp;lt;/big&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
[[File:Nic Ther Ben.png|alt=Nicotine Therapeutic benefits banner|center]]&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;big&amp;gt;&#039;&#039;&#039;Note: Some topics are subgroups under the main topic of &amp;quot;Mental Health.&amp;quot; &#039;&#039;&#039;&amp;lt;/big&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Acne&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2010 [https://ijphjournal.it/article/view/5708 Evaluation of the association between acne and smoking: systematic review and meta-analysis of cross-sectional studies]===&lt;br /&gt;
*Acne vulgaris is one of the most common skin diseases with a multifactorial pathogenesis. &lt;br /&gt;
*Our meta-analysis underlines that there is no evidence to support an association between smoking habits and acne, although in three of the good quality papers a significant protection in the current smoker was found. It necessary to be cautious in declaring that smoking may provide a protective effect in the pathogenesis of acne because the analysis was based on only a small number of studies.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.sciencedirect.com/science/article/pii/S0022202X15330153 Severe Acne Vulgaris and Tobacco Smoking in Young Men]===&lt;br /&gt;
*It is crucial to emphasize that any positive effects found must be traced to specific tobacco components that can be therapeutically used without smoking (e.g., nicotine patches or gums), to avoid any “legitimatizing” of smoking based on its beneficial effects on health.&lt;br /&gt;
*Active smokers showed a significantly lower prevalence of severe acne (0.71%) than nonsmokers (1.01%) (P=0.0078). &lt;br /&gt;
*Previous in vitro and clinical studies strongly support an association with nicotine. We suggest a trial with topical nicotine treatment for acne to further investigate this association.&lt;br /&gt;
&lt;br /&gt;
===1993 [https://academic.oup.com/ced/article-abstract/18/2/100/6629365 Does smoking influence acne?]===&lt;br /&gt;
*[https://sci-hub.se/10.1111/j.1365-2230.1993.tb00986.x PDF of full study]&lt;br /&gt;
*The findings of this study support the hypothesis that some component of cigarette smoke, possibly nicotine, has an anti‐inflammatory action on acne.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;ADD / ADHD / Attention / Cognition&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
=== 2025 &#039;&#039;&#039;[https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntaf060/8078909 Nicotine improves working memory via augmenting BDNF levels through α7 nAChR: evidence from clinical and pre-clinical studies]&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
* While smoking has been associated with many negative consequences to human health, one possible benefit is that nicotine could improve cognitive functions. Previous studies have suggested that smoking may influence brain-derived neurotrophic factor (BDNF) levels.&lt;br /&gt;
* Our research revealed that tobacco product use led to an increase in working memory and human plasma BDNF levels. Furthermore, nicotine was responsible for the elevation in BDNF levels, which showed dose-dependent increases in both serum and the hippocampus, and improved memory performance.&lt;br /&gt;
* Animal study (rat) &lt;br /&gt;
* &#039;&#039;Yingyan Li, PhD, Xin Li, Yaning Fu, PhD, Wenjun Mou, Zuxin Chen, PhD, Ping Wu, PhD, Fanglin Liu, PhD, Huan Chen, PhD, Hongwei Hou, PhD, Qingyuan Hu, PhD: Nicotine &amp;amp; Tobacco Research&#039;&#039;, ntaf060, &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntaf060&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.845646/full Tobacco and ADHD: A Role of MAO-Inhibition in Nicotine Dependence and Alleviation of ADHD Symptoms]===&lt;br /&gt;
*&amp;quot;Our review of evidence supports the finding that individuals with ADHD are at greater vulnerability for both initiation and continuation of smoking (both cigarettes, e-cigarettes).&amp;quot;&lt;br /&gt;
*&amp;quot;Greater support for a “self-medication” model of ADHD and smoking includes not only nicotine but also MAO-inhibitors as dopamine agonists contained in cigarettes and e-cigarettes.&amp;quot;&lt;br /&gt;
*Taylor, M. R., Carrasco, K., Carrasco, A., &amp;amp; Basu, A. (2022). Tobacco and ADHD: A Role of MAO-Inhibition in Nicotine Dependence and Alleviation of ADHD Symptoms. Frontiers in Neuroscience, 16, 845646. https://doi.org/10.3389/fnins.2022.845646&lt;br /&gt;
*Funds for open access publication fees are contributed by the Faculty of Health, University of Canterbury and University of Canterbury library.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== &lt;br /&gt;
*Preclinical models and human studies have demonstrated that nicotine has cognitive-enhancing effects. Attention, working memory, fine motor skills and episodic memory functions are particularly sensitive to nicotine’s effects. &lt;br /&gt;
*High rates of smoking are observed among individuals with psychiatric disorders including schizophrenia, bipolar disorder, major depression, attention deficit hyperactivity disorder (ADHD) and comorbid substance use disorders (SUD). Because these psychiatric disorders are associated with various cognitive impairments, including deficits in attention, working memory, and response inhibition functions, the cognitive enhancing effects of nicotine may be especially important determinants of the initation and maintenance of smoking in this comorbid population. Growing evidence suggest that cognitive enhancing effects of nicotine may also contribute to the difficulty in quitting smoking, especially in individuals with psychiatric disorders.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/pdf/CN-16-403.pdf PDF Version]&lt;br /&gt;
*Citation: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Curr Neuropharmacol. 2018;16(4):403-414. doi: 10.2174/1570159X15666171103152136. PMID: 29110618; PMCID: PMC6018192.&lt;br /&gt;
&lt;br /&gt;
===2017: [https://www.tandfonline.com/doi/full/10.1080/10826084.2017.1334066 Causal Factors of Increased Smoking in ADHD: A Systematic Review]===&lt;br /&gt;
*One of the most striking comorbidities of ADHD is nicotine dependence. Youth diagnosed with ADHD are 2–3 times more likely to smoke than their peers without ADHD, initiate smoking earlier in life and progress more quickly and more frequently to regular use and dependence. Possible explanations for these increased risks are: (a) self-medication of ADHD symptoms with the stimulant nicotine; (b) ADHD symptoms like inattention and hyperactivity/impulsivity predispose for smoking initiation and impede smoking cessation; (c) peer pressure; and/or (d) common genetic or environmental determinants for ADHD and smoking.&lt;br /&gt;
*In contrast, the positive relation between ADHD and nicotine dependence is currently best explained by the self-medication hypothesis. This hypothesis has a clear pharmacological rationale and is supported by ample evidence, but awaits confirmation from longitudinal naturalistic studies.&lt;br /&gt;
*Citation: Jan van Amsterdam, Bauke van der Velde, Mieke Schulte &amp;amp; Wim van den Brink (2018) Causal Factors of Increased Smoking in ADHD: A Systematic Review, Substance Use &amp;amp; Misuse, 53:3, 432-445, DOI: 10.1080/10826084.2017.1334066 &lt;br /&gt;
&lt;br /&gt;
===2014: [https://www.medscape.com/viewarticle/827544_1 Adult Attention-Deficit/Hyperactivity Disorder and Nicotine Use: A Qualitative Study of Patient Perceptions]===&lt;br /&gt;
*Participants had different views about the link between cigarette smoking and ADHD. While the majority thought of nicotine as a sort of therapy, viewing smoking as a way to self-medicate symptoms of ADHD, motivations for nicotine use were also related to self-image, desire to belong to a peer-group, and a drive to undermine perceived social norms. Ultimately, these findings can be used by clinicians to improve treatment alliance and collaboration.&lt;br /&gt;
*[https://sci-hub.se/10.1186/1471-244x-14-141 Alternative Link]&lt;br /&gt;
*Citation: Liebrenz, M., Frei, A., Fisher, C. E., Gamma, A., Buadze, A., &amp;amp; Eich, D. (2014). Adult attention-deficit/hyperactivity disorder and nicotine use: a qualitative study of patient perceptions. BMC Psychiatry, 14(1). doi:10.1186/1471-244x-14-141 &lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150/ Cognitive enhancers for the treatment of ADHD]===&lt;br /&gt;
*Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, affecting approximately 8–9% of school-aged children and 4–5% of adults (Froehlich et al., 2007; Kessler et al., 2006; Visser et al., 2007). Although formally the disorder is characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity (APA, 2000), myriad phenotypic features—many of which are related to cognition broadly defined—have been shown to distinguish those with ADHD from those without the disorder.&lt;br /&gt;
*Together, these findings have led to the hypothesis that individuals with ADHD may smoke in order to alleviate requisite symptoms of the disorder and further suggest nicotine and/or nicotinic agonists can be used to improve aspects of cognitive function in these patients (McClernon and Kollins, 2008). Some support for this hypothesis has been provided by studies which have shown positive effects of nicotine on ADHD symptoms (Gehricke et al., 2009; Shytle et al., 2002) and cognitive performance (Levin et al., 1996; Potter and Newhouse, 2004) in non-smokers with ADHD. Whereas there are currently no FDA-approved nicotinic agonists to treat ADHD, laboratory and small-scale clinical trials have been conducted in recent years, and novel nicotinic pharmacotherapies are on the horizon.&lt;br /&gt;
*Citation: Bidwell LC, McClernon FJ, Kollins SH. Cognitive enhancers for the treatment of ADHD. Pharmacol Biochem Behav. 2011 Aug;99(2):262-74. doi: 10.1016/j.pbb.2011.05.002. Epub 2011 May 10. PMID: 21596055; PMCID: PMC3353150.&lt;br /&gt;
&lt;br /&gt;
===2009 [https://pubmed.ncbi.nlm.nih.gov/20025370/ Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder]===&lt;br /&gt;
*Nicotine reduced reports of ADHD symptoms by 8% and negative moods by 9%, independent of smoking status. In addition, nicotine increased cardiovascular activity during the first 3 to 6 hours after nicotine patch administration. The results support the self-medication hypothesis for nicotine in adults with ADHD and suggest that smoking cessation and prevention efforts for individuals with ADHD will need to address both the symptom reducing and mood enhancing effects of nicotine.&lt;br /&gt;
*Citation: Gehricke, J. G., Hong, N., Whalen, C. K., Steinhoff, K., &amp;amp; Wigal, T. L. (2009). Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 23(4), 644–655. https://doi.org/10.1037/a0017441&lt;br /&gt;
&lt;br /&gt;
===2009 [https://www.tandfonline.com/doi/abs/10.3109/15622970209150616 A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder]===&lt;br /&gt;
*All 10 subjects enrolled (six males, four females; mean age = 10 years, SEM = 0.8) completed the study. As assessed by the 48-item Conners Parent Rating Scale at endpoint and during the trial, there was a significantly greater reduction in ADHD symptoms on “Learning Problems” and “Hyperactivity” subfactors. Nausea, stomach ache, itching under patch and dizziness were the most frequently reported adverse effects associated with transdermal nicotine.&lt;br /&gt;
*Citation: R. Douglas Shytle, Archie A. Silver, Berney J. Wilkinson &amp;amp; Paul R. Sanberg (2002) A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder, The World Journal of Biological Psychiatry, 3:3, 150-155, DOI: 10.3109/15622970209150616&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.sciencedirect.com/science/article/abs/pii/S0091305707003048?via%3Dihub Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder]=== &lt;br /&gt;
*Non-smoking young adults with ADHD-C showed improvements in cognitive performance following nicotine administration in several domains that are central to [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ADHD&#039;&#039;&#039;]].&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.pbb.2007.09.014 PDF Version]&lt;br /&gt;
*Citation: Alexandra S. Potter, Paul A. Newhouse, Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder, Pharmacology Biochemistry and Behavior, Volume 88, Issue 4, 2008, Pages 407-417, ISSN 0091-3057, doi: 10.1016/j.pbb.2007.09.014.&lt;br /&gt;
*Acknowledgements: This work was supported by: GCRC M01-00109 and Targacept Inc.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://pmc.ncbi.nlm.nih.gov/articles/PMC2446482/ Transdermal Nicotine in Adult ADHD With Depression and Anxiety]===&lt;br /&gt;
*&amp;quot;This case report neither rules out the placebo effect, nor does it prove that transdermal nicotine is useful in managing adult ADHD with depression and anxiety. However, it does suggest that the beneficial effect of transdermal nicotine may be attributed to biobehavioral pathways common to chronic nicotine withdrawal and ADHD with depression and anxiety. Nicotine agonists and delivery systems may be new treatments for adult ADHD. Larger well-designed studies are warranted to evaluate the therapeutic potential of nicotine delivery systems in otherwise medically stable adults with ADHD accompanied by depression and anxiety. Further exploration of the nicotinic-cholinergic system may also expand our understanding of the neuropsychiatry underlying ADHD.&amp;quot;&lt;br /&gt;
*Citation: Cocores JA. Transdermal nicotine in adult ADHD with depression and anxiety. Prim Care Companion J Clin Psychiatry. 2008;10(3):253-4. doi: 10.4088/pcc.v10n0312f. PMID: 18615164; PMCID: PMC2446482.&lt;br /&gt;
*Dr. Cocores reports no financial affiliations or other relationships relevant to the subject of this letter.&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.academia.edu/2412620/Smoking_to_self_medicate_attentional_and_emotional_dysfunctions Smoking to self-medicate attentional and emotional dysfunctions]===&lt;br /&gt;
*The data from diverse studies are generally consistent with the self-medication hypothesis and suggest that individuals with ADHD may smoke to alleviate symptoms associated with attention deficit, impulsivity, and hyperactivity. More studies on larger samples are necessary to assess the differential risks for adolescent smoking initiation that are associated with ADHD subtypes and with ODD and CD comorbidities.&lt;br /&gt;
*Citation: Gehricke, J.-G., Loughlin, S., Whalen, C., Potkin, S., Fallon, J., Jamner, L., … Leslie, F. (2007). Smoking to self-medicate attentional and emotional dysfunctions. Nicotine  Tobacco Research, 9, 523–536. https://doi.org/10.1080/14622200701685039&lt;br /&gt;
&lt;br /&gt;
===2007: [https://www.academia.edu/18995031/Smoking_to_self_medicate_attentional_and_emotional_dysfunctions Smoking to self-medicate attentional and emotional dysfunctions]===&lt;br /&gt;
*(Note: Need to add summary)&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.academia.edu/17983526/The_reinforcing_effects_of_nicotine_and_stimulant_medication_in_the_everyday_lives_of_adult_smokers_with_ADHD_A_preliminary_examination The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination]===&lt;br /&gt;
*The findings suggest that smokers with ADHD experience nicotine-related reductions in ADHD symptoms during their everyday lives.&lt;br /&gt;
*Citation: Gehricke, J. G., Whalen, C., Jamner, L., Wigal, T., &amp;amp; Steinhoff, K. (2006). The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination. Nicotine  Tobacco Research, 8(1), 37–47. https://doi.org/10.1080/14622200500431619&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.sciencedirect.com/science/article/abs/pii/S0031938405005627?via%3Dihub Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits]===&lt;br /&gt;
*The results showed nicotine-induced improvement on some measures of sustained attention in the low attention group and some decrement in working memory in the high attention group, which suggests that nicotine tends to optimize rather than improve performance on cognitive tasks.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.physbeh.2005.12.011 PDF Version]&lt;br /&gt;
*Citation: D.V. Poltavski, T. Petros, Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits, Physiology &amp;amp; Behavior, Volume 87, Issue 3, 2006, Pages 614-624, ISSN 0031-9384, doi: 10.1016/j.physbeh.2005.12.011.&lt;br /&gt;
&lt;br /&gt;
===2004: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
* Yet few of the horrendous health effects of smoking are traceable to nicotine itself—cigarettes contain nearly 4,000 other compounds that play a role. Until recently, nicotine research has been driven primarily by nicotine&#039;s unparalleled power to keep people smoking, rather than its potential therapeutic uses.&lt;br /&gt;
* There&#039;s a cheap, common, and mostly safe drug, in daily use for centuries by hundreds of millions of people, that only lately has been investigated for its therapeutic potential for a long list of common ills. The list includes Alzheimer disease, Parkinson disease, depression and anxiety, schizophrenia, attention deficit hyperactivity disorder (ADHD), and even pain and obesity.&lt;br /&gt;
* People with depressive-spectrum disorders, schizophrenia, and adult ADHD tend to smoke heavily, which suggested to researchers that nicotine may soothe their symptoms. Common to all these disorders is a failure of attention, an inability to concentrate on particular stimuli and screen out the rest. Nicotine helps.&lt;br /&gt;
* Researchers at the National Institute on Drug Abuse have shown via functional magnetic resonance imaging that nicotine activates specific brain areas during tasks that demand attention&lt;br /&gt;
*Citation: Powledge TM. Nicotine as therapy. PLoS Biol. 2004 Nov;2(11):e404. doi: 10.1371/journal.pbio.0020404. Epub 2004 Nov 16. PMID: 15547644; PMCID: PMC526783&lt;br /&gt;
&lt;br /&gt;
===2003: [https://www.academia.edu/2412608/Is_There_a_Link_Between_Adolescent_Cigarette_Smoking_and_Pharmacotherapy_for_ADHD   Is There a Link Between Adolescent Cigarette Smoking and pharmacotherapy for ADHD?]===&lt;br /&gt;
*Self-report surveys, electronic diaries, and salivary cotinine all indicated that adolescents treated with pharmacotherapy for ADHD smoked less than their untreated counterparts over 2 years of high school. These convergent findings from 3 disparate indicators lend support to the self-medication hypothesis over the gateway hypothesis, although alternative explanations need further study. The findings also suggest that early treatment of psychological and behavioral problems may prevent or delay smoking initiation&lt;br /&gt;
*Citation: Whalen, C. K., Jamner, L. D., Henker, B., Gehricke, J.-G., &amp;amp; King, P. S. (2003). Is There a Link Between Adolescent Cigarette Smoking and Pharmacotherapy for ADHD? Psychology of Addictive Behaviors, 17(4), 332–335. https://doi.org/10.1037/0893-164X.17.4.332&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
*Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&lt;br /&gt;
===2001 [https://psycnet.apa.org/record/2001-14365-012 Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder.]===&lt;br /&gt;
*This small study (40 participants) provided evidence that nicotine treatment can reduce severity of attentional deficit symptoms and produce improvement on an objective computerized attention task.&lt;br /&gt;
*Citation: Levin, E. D., Conners, C. K., Silva, D., Canu, W., &amp;amp; March, J. (2001). Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Experimental and Clinical Psychopharmacology, 9(1), 83–90. https://doi.org/10.1037/1064-1297.9.1.83&lt;br /&gt;
&lt;br /&gt;
===1998 [https://pubmed.ncbi.nlm.nih.gov/9860103/ Transdermal nicotine effects on attention]=== &lt;br /&gt;
*This study shows that, in addition to reducing attentional impairment, nicotine administered via transdermal patches can improve attentiveness in normal adult non-smokers.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s002130050750 PDF Version]&lt;br /&gt;
*Citation: Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J, Rose JE. Transdermal nicotine effects on attention. Psychopharmacology (Berl). 1998 Nov;140(2):135-41. doi: 10.1007/s002130050750. PMID: 9860103&lt;br /&gt;
*Acknowledgement: The authors thank R.J. Reynolds for financial support of the project. Work on this article was partially supported by Career Science Award (K05MH0122903) to Dr. Conners and Research Scientist Development Award (K02MH0098102) to Dr. March&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/8741955/ Nicotine effects on adults with attention-deficit/hyperactivity disorder]=== &lt;br /&gt;
*Nicotine caused a significant overall nicotine-induced improvement on the CGI. This effect was significant when only the nonsmokers were considered, which indicated that it was not due merely to withdrawal relief. Nicotine caused significantly increased vigor as measured by the POMS test. Nicotine caused an overall significant reduction in reaction time (RT) on the CPT, as well as, with the smokers, a significant reduction in another index of inattention, variability in reaction time over trial blocks. Nicotine improved accuracy of time estimation and lowered variability of time-estimation response curves. Because improvements occurred among nonsmokers, the nicotine effect appears not to be merely a relief of withdrawal symptoms. It is concluded that nicotine deserves further clinical trials with ADHD.&lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02246281 PDF Version]&lt;br /&gt;
*Citation: Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996 Jan;123(1):55-63. doi: 10.1007/BF02246281. PMID: 8741955.&lt;br /&gt;
*Acknowledgement: The authors thank Dr. Allen Frances, Chairman of the Department of Psychiatry, Duke University Meidcal Center for his finanical support of the project. Work on this article was partially supported by Career Science Award (K05MH01229-03) to Dr. Conners and Research Scientist Development Award (K20MH00981-02) to Dr. March and a Young Investigator Award from the National Alliance for Research Schizophenia and Depression to Dr. Levin.&lt;br /&gt;
&lt;br /&gt;
===1996: [https://pubmed.ncbi.nlm.nih.gov/8927677/ Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)]===&lt;br /&gt;
*The present study is an acute double-blind crossover administration of nicotine and placebo with smokers (n = 6) and nonsmokers (n = 11) diagnosed with adult ADHD. The drug was delivered via a transdermal patch at a dosage of 7 mg/day for nonsmokers and 21 mg/day for smokers. Results indicate significant clinician-rated global improvement, self-rated vigor and concentration, and improved performance on chronometric measures of attention and timing accuracy. Side effects were minimal. These acute results indicate the need for a longer clinical trial and a comparison with other stimulants in adult ADHD treatment.&lt;br /&gt;
*Citation: Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67-73. PMID: 8927677.&lt;br /&gt;
&lt;br /&gt;
===Year Unknown: Article: [https://www.adxs.org/en/page/192/nicotine-as-a-medication-for-adhd Nicotine as a medication for ADHD]===&lt;br /&gt;
*Lists references&lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Aging&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.nature.com/articles/s41467-023-36543-8 Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity]===&lt;br /&gt;
*Abstract &amp;quot;Imbalances in NAD+ homeostasis have been linked to aging and various diseases. Nicotine, a metabolite of the NAD+ metabolic pathway, has been found to possess anti-inflammatory and neuroprotective properties, yet the underlying molecular mechanisms remained unknown. Here we find that, independent of nicotinic acetylcholine receptors, low-dose nicotine can restore the age-related decline of NAMPT activity through SIRT1 binding and subsequent deacetylation of NAMPT, thus increasing NAD+ synthesis. 18F-FDG PET imaging revealed that nicotine is also capable of efficiently inhibiting glucose hypermetabolism in aging male mice. Additionally, nicotine ameliorated cellular energy metabolism disorders and deferred age-related deterioration and cognitive decline by stimulating neurogenesis, inhibiting neuroinflammation, and protecting organs from oxidative stress and telomere shortening. Collectively, these findings provide evidence for a mechanism by which low-dose nicotine can activate NAD+ salvage pathways and improve age-related symptoms.&amp;quot;&lt;br /&gt;
**Citation: Yang, L., Shen, J., Liu, C. et al. Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity. Nat Commun 14, 900 (2023). https://doi.org/10.1038/s41467-023-36543-8&lt;br /&gt;
***Acknowledgement: This work was supported by grants from Shenzhen Science and Technology Program (KQTD20210811090117032), Shenzhen Key Laboratory of Viral Vectors for Biomedicine (ZDSYS20200811142401005), CAS Key Laboratory of Brain Connectome and Manipulation (2019DP173024) and Guangdong Provincial Key Laboratory of Brain Connectome and Behavior (2017B030301017).&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Akathisia&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===1997: [https://pubmed.ncbi.nlm.nih.gov/9399378/ Treatment of neuroleptic-induced akathisia with nicotine patches]===&lt;br /&gt;
*We administered 14 mg nicotine patches to 16 patients, all non-smokers, who displayed akathisia from antipsychotic drugs. On single-blind ratings, akathisia appeared significantly reduced on days when patients were wearing the patches as compared to the baseline day. These findings, if confirmed, may help to explain the high rates of tobacco use among psychotic patients, and may suggest avenues for the treatment of akathisia.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s002130050436 PDF Version]&lt;br /&gt;
**Citation: Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl). 1997 Nov;134(2):153-6. doi: 10.1007/s002130050436. PMID: 9399378.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Alcohol Use Disorder&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://onlinelibrary.wiley.com/doi/10.1111/acer.15103 Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco]===&lt;br /&gt;
*Our findings may indicate that nicotine has anti-inflammatory effects in patients with AUD.&lt;br /&gt;
**Citation: Bolstad I, Lien L, Moe JS, Pandey S, Toft H, Bramness JG. Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco. Alcohol Clin Exp Res (Hoboken). 2023 Jul;47(7):1352-1363. doi: 10.1111/acer.15103. Epub 2023 May 30. PMID: 37208927.&lt;br /&gt;
***Acknowledgement: This work was financially supported by The Research Council of Norway, grant FRIPRO 251140.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Allergies / Hayfever / Histamines&#039;&#039;&#039; (See also: Hypersensitivity Pneumonitis / Extrinsic Allergic Alveolitis)=&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203434/ Suppressive effect of environmental tobacco smoke on murine Th2 cell-mediated nasal eosinophilic inflammation]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*In this study, the effect of environmental tobacco smoke (ETS) on allergen-immunized and allergen-specific Th2 cell-transferred murine eosinophilic inflammation models and that of cigarette smoke extract (CSE) and nicotine on allergen-induced Th2 cell proliferation and interleukin (IL)-4 production were investigated.&lt;br /&gt;
*In summary, ETS suppressed allergen-induced nasal responses including NHR by inhibiting allergen-specific Th2 cell responses. Although our present findings do not deny harmful effects of cigarette smoking, nicotine as a component of ETS may be a target to treat Th2-mediated allergic diseases, including allergic rhinitis (AR).&lt;br /&gt;
**Citation: Nishimura T, Kaminuma O, Saeki M, Kitamura N, Mori A, Hiroi T. Suppressive effect of environmental tobacco smoke on murine Th2 cell-mediated nasal eosinophilic inflammation. Asia Pac Allergy. 2020 Apr 27;10(2):e18. doi: 10.5415/apallergy.2020.10.e18. PMID: 32411583; PMCID: PMC7203434.&lt;br /&gt;
***Acknowledgement: This work was supported in part by funding from the Smoking Research Foundation provided to Osamu Kaminuma.&lt;br /&gt;
&lt;br /&gt;
===2017: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440386/ Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium]===&lt;br /&gt;
*Our results suggest that smoking may be causally related to a higher risk of asthma and a slightly lower risk of hay fever. However, the adverse events associated with smoking limit its clinical significance.&lt;br /&gt;
**Citation: Skaaby T, Taylor AE, Jacobsen RK, et al. Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium. Sci Rep. 2017 May 22;7(1):2224. doi: 10.1038/s41598-017-01977-w. PMID: 28533558; PMCID: PMC5440386.&lt;br /&gt;
***Acknowledgement: This work was supported by the Medical Research Council (grant numbers: MR/J01351X/1, MC_UU_12013/6). The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk).&lt;br /&gt;
&lt;br /&gt;
===2014: [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085888 Anti-allergic role of cholinergic neuronal pathway via α7 nicotinic ACh receptors on mucosal mast cells in a murine food allergy model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*In this study, nicotine treatment significantly ameliorated FA [Food Allergy], mainly due to the suppression of upregulated mucosal immune responses via α7 nAChRs on immune cells. Therefore, the therapeutic effects of nicotine and GTS-21 on the FA model raise the possibility that a strategy for drug discovery against FA by targeting α7 nAChRs could potentially have therapeutic benefits.&lt;br /&gt;
**Citation: Yamamoto T, Kodama T, Lee J, Utsunomiya N, Hayashi S, Sakamoto H, Kuramoto H, Kadowaki M. Anti-allergic role of cholinergic neuronal pathway via α7 nicotinic ACh receptors on mucosal mast cells in a murine food allergy model. PLoS One. 2014 Jan 16;9(1):e85888. doi: 10.1371/journal.pone.0085888. PMID: 24454942; PMCID: PMC3894205.&lt;br /&gt;
&lt;br /&gt;
===2008: [https://journals.aai.org/jimmunol/article/180/11/7655/84640/Nicotine-Primarily-Suppresses-Lung-Th2-but-Not Nicotine Primarily Suppresses Lung Th2 but Not Goblet Cell and Muscle Cell Responses to Allergens]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*hese results suggest that nicotine modulates allergy/asthma primarily by suppressing eosinophil trafficking and suppressing Th2 cytokine/chemokine responses without reducing goblet cell metaplasia, mucous production, and may explain the lower risk of allergic diseases in smokers. To our knowledge this is the first direct evidence that nicotine modulates allergic responses.&lt;br /&gt;
**Citation: Neerad C. Mishra, Jules Rir-sima-ah, Raymond J. Langley, Shashi P. Singh, Juan C. Peña-Philippides, Takeshi Koga, Seddigheh Razani-Boroujerdi, Julie Hutt, Matthew Campen, K. Chul Kim, Yohannes Tesfaigzi, Mohan L. Sopori; Nicotine Primarily Suppresses Lung Th2 but Not Goblet Cell and Muscle Cell Responses to Allergens1. J Immunol 1 June 2008; 180 (11): 7655–7663. https://doi.org/10.4049/jimmunol.180.11.7655&lt;br /&gt;
***Acknowledgement: This work was supported in part by grants from the National Institutes of Health (R01-DA017003, R01-DA04208-15, and R01-DA042087S).&lt;br /&gt;
&lt;br /&gt;
===2004: [https://link.springer.com/article/10.1007/s00011-004-1249-1 The effect of nicotine on basophil histamine release]===&lt;br /&gt;
*This study has demonstrated that nicotine agonists inhibit histamine release from human basophils.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s00011-004-1249-1 PDF Full Version]&lt;br /&gt;
**Citation: Thompson-Cree, M.E.M., Stevenson, M.R., Shields, M.D. et al. The effect of nicotine on basophil histamine release. Inflamm. res. 53, 211–214 (2004). https://doi.org/10.1007/s00011-004-1249-1&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Alzheimer / Dementia / Mild Cognitive Imparement (MCI)&#039;&#039;&#039;= &lt;br /&gt;
===2013 [https://link.springer.com/article/10.1007/s12017-013-8242-1 Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these results demonstrate that nicotine prevents memory deficits and synaptic impairment induced by Aβ oligomers. In addition, nicotine improves memory in young APP/PS1 transgenic mice before extensive amyloid deposition and senile plaque development, and also in old mice where senile plaques have already formed.&lt;br /&gt;
*[https://sci-hub.st/https://link.springer.com/article/10.1007/s12017-013-8242-1 PDF Version]&lt;br /&gt;
*Citation: Inestrosa, N.C., Godoy, J.A., Vargas, J.Y. et al. Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation. Neuromol Med 15, 549–569 (2013). doi: 10.1007/s12017-013-8242-1&lt;br /&gt;
*Acknowledgements: We thank Dr. Rodrigo Varas for his help with the electrophysiological studies of the α7-nAChR. This work was supported by a grant from FONDECYT No 120156 to N.C.I; predoctoral fellowships from CONICYT to G.G.F., M.S.A. F.G.S., J.A.R. and from Fundación Gran Mariscal de Ayacucho to J.Y.V. The Basal Center of Excellence in Science and Technology CARE was funded by CONICYT/PFB 12/2007.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/ Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== &lt;br /&gt;
*The secondary outcome measures showed significant nicotine-associated improvements in attention, memory, and psychomotor speed, and improvements were seen in patient/informant ratings of cognitive impairment. &lt;br /&gt;
*Safety and tolerability for transdermal nicotine were excellent. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/pdf/znl91.pdf PDF Version]&lt;br /&gt;
*Citation: Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb. PMID: 22232050; PMCID: PMC3466669.&lt;br /&gt;
&lt;br /&gt;
===2010 [https://www.tandfonline.com/doi/abs/10.1080/13607860220126808 Nicotine&#039;s effect on neural and cognitive functioning in an aging population]=== &lt;br /&gt;
*Recent advances in nicotine research have pointed to a number of cognitive and neurological benefits that have been linked to the ingestion of nicotine.&lt;br /&gt;
*This article examines cognitive decline in the elderly and looks at nicotine&#039;s potential role in ameliorating this decline.&lt;br /&gt;
*Nicotine’s effects on cognitive functioning have shown it to increase perception, visual attention,and arousal as well as improving the speed and accuracy of motor functioning while decreasing reaction time and inhibiting declines in efficiency. In addition, research has shown nicotine to improve long-term and short-term memory, and to increase the ability to withhold inappropriate responses.&lt;br /&gt;
*Research has revealed that chronic exposure to nicotine produces an unusual up-regulation of the nicotinic receptor sites. This increase in receptor sites is thought to provide some protection against neuro-degenerative disorders such as Alzheimer’s disease.&lt;br /&gt;
*[https://sci-hub.st/10.1080/13607860220126808 PDF Version]&lt;br /&gt;
*Citation: K. N. Murray &amp;amp; N. Abeles (2002) Nicotine&#039;s effect on neural and cognitive functioning in an aging population, Aging &amp;amp; Mental Health, 6:2, 129-138, DOI: 10.1080/13607860220126808&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12436427/ Nicotinic receptors in aging and dementia]=== &lt;br /&gt;
*Nicotine and nicotinic agonists have been shown to improve cognitive function in aged or impaired subjects.&lt;br /&gt;
*Acute nicotine administration can improve performance of patients with AD on cognitive tasks, including verbal learning and memory, attention in a continuous performance task, and accuracy in a visual attention task.&lt;br /&gt;
*In addition to its ability to reverse cognitive deficits following aging, nicotine has been shown to protect against neurotoxic insult in vitro and in vivo. This suggests that nicotine has a dual effect on brain function following aging or injury, such that it can rescue function of remaining neurons, as well as saving neurons that might otherwise undergo cell death.&lt;br /&gt;
*[https://sci-hub.st/10.1002/neu.10102 PDF Version]&lt;br /&gt;
*Citation: Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol. 2002 Dec;53(4):641-55. doi: 10.1002/neu.10102. PMID: 12436427.&lt;br /&gt;
*Keywords: nAChR; neuroprotection; Alzheimer’s disease; Parkinson’s disease; acetylcholine&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
*Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Alzheimer&#039;s disease (AD)&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1410164/ Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer&#039;s disease]=== &lt;br /&gt;
*Nicotine significantly improved sustained visual attention (in both RVIP and DRMLO tasks), reaction time (in both FT and RVIP tasks), and perception (CFF task--both ascending and descending thresholds). &lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02247426 PDF Version]&lt;br /&gt;
*Citation: Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer&#039;s disease. Psychopharmacology (Berl). 1992;108(4):485-94. doi: 10.1007/BF02247426. PMID: 1410164.&lt;br /&gt;
*Acknowledgements. This research was supported by British-American Tobacco Co. Ltd. BJS thanks the Wellcome Trust and the Eleanor Peel Foundation for support. &lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in enhancement of performance, and protection against  Alzheimer&#039;s disease (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1989 [https://pubmed.ncbi.nlm.nih.gov/2597885/ The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type]=== &lt;br /&gt;
*Nicotine in patients with dementia of the Alzheimer type (DAT) produced a significant and marked improvement in discriminative sensitivity and reaction times on a computerised test of attention and information processing. Nicotine also improved the ability of DAT patients to detect a flickering light in a critical flicker fusion test. These results suggest that nicotine may be acting on cortical mechanisms involved in visual perception and attention, and support the hypothesis that acetylcholine transmission modulates vigilance and discrimination. Nicotine may therefore be of some value in treating deficits in attention and information processing in DAT patients. &lt;br /&gt;
*[https://sci-hub.st/10.1192/bjp.154.6.797 PDF Version]&lt;br /&gt;
*Citation: Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989 Jun;154:797-800. doi: 10.1192/bjp.154.6.797. PMID: 2597885.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Aphthous ulcers&#039;&#039;&#039; (See also: Behcet&#039;s disease)= &lt;br /&gt;
&lt;br /&gt;
===2015: [https://pmc.ncbi.nlm.nih.gov/articles/PMC4387635/ Use of pure nicotine for the treatment of aphthous ulcers]===&lt;br /&gt;
*The theory that nicotine is known as the protective factor is also supported by three case reports, in which aphthous ulcers were prevented or healed while the patients used nicotine replacement materials.&lt;br /&gt;
*To summarize, the use of pure nicotine in therapeutic forms, seems to be a proper alternative to treat aphthous ulcers; however, there has not been any evidence-based case-control study to prove such claim.&lt;br /&gt;
**Citation: Motamedi MR, Golestannejad Z. Use of pure nicotine for the treatment of aphthous ulcers. Dent Res J (Isfahan). 2015 Mar-Apr;12(2):197-8. PMID: 25878688; PMCID: PMC4387635.&lt;br /&gt;
&lt;br /&gt;
===2014: [https://pubmed.ncbi.nlm.nih.gov/25584320/ Recurrent aphthous ulcers among tobacco users- hospital based study]===&lt;br /&gt;
*The tobacco consumers have less frequency of aphthous ulceration compared non users.&lt;br /&gt;
**Citation: Mohamed S, Janakiram C. Recurrent aphthous ulcers among tobacco users- hospital based study. J Clin Diagn Res. 2014 Nov;8(11):ZC64-LC66. doi: 10.7860/JCDR/2014/10368.5145. Epub 2014 Nov 20. PMID: 25584320; PMCID: PMC4290331.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.sciencedirect.com/science/article/abs/pii/S0306987711001691?via%3Dihub Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis]=== &lt;br /&gt;
*In addition, nicotine or its metabolites can result in decrease of pro-inflammatory cytokines like tumor necrosis factor-α, interleukins 1 and 6, and increase of anti-inflammatory cytokine interleukin-10. Consequently, there is reduced susceptibility to RAS due to immunosuppression and/or reduction in inflammatory response.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2011.04.006 PDF Version]&lt;br /&gt;
**Citation: Subramanyam, R. V. (2011). Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis. Medical Hypotheses, 77(2), 185–187. doi:10.1016/j.mehy.2011.04.006&lt;br /&gt;
&lt;br /&gt;
===2004: [https://pubmed.ncbi.nlm.nih.gov/15370162/ The relationship between smoking cessation and mouth ulcers]===&lt;br /&gt;
*Our results confirm that mouth ulcers are a common result of stopping smoking, affecting two in five quitters. Patients should be reassured that the lesions are a result of stopping smoking and not a side-effect of smoking cessation medication.&lt;br /&gt;
**Citation: McRobbie H, Hajek P, Gillison F. The relationship between smoking cessation and mouth ulcers. Nicotine Tob Res. 2004 Aug;6(4):655-9. doi: 10.1080/14622200410001734012. PMID: 15370162.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12108762/ Minor recurrent aphthous stomatitis and smoking: an epidemiological study measuring plasma cotinine]=== &lt;br /&gt;
*This study shows that a group of RAS patients is significantly less likely to contain smokers than a matched control population, and among smokers the level of cigarette use was significantly lower in RAS patients than the control population. The perceived negative association between RAS and smoking was supported by this epidemiological study.&lt;br /&gt;
*[https://sci-hub.st/10.1034/j.1601-0825.2002.01826.x PDF Version]&lt;br /&gt;
**Citation: Atkin PA, Xu X, Thornhill MH. Minor recurrent aphthous stomatitis and smoking: an epidemiological study measuring plasma cotinine. Oral Dis. 2002 May;8(3):173-6. doi: 10.1034/j.1601-0825.2002.01826.x. PMID: 12108762.&lt;br /&gt;
&lt;br /&gt;
===2000: [https://www.nejm.org/doi/10.1056/NEJM200012143432418?url_ver=Z39.88-2003&amp;amp;rfr_id=ori%3Arid%3Acrossref.org&amp;amp;rfr_dat=cr_pub++0pubmed Nicotine Patches for Aphthous Ulcers Due to Behçet&#039;s Syndrome]=== &lt;br /&gt;
*We describe a woman with Behçet&#039;s syndrome characterized by recurrent oral and genital aphthous ulcers, severe eye involvement, and the onset of arthritis at the age of 29 years. At the age of 35 several large and extremely painful buccal aphthous ulcers developed. Therapy with a nicotine patch led to a regression of all aphthous ulcers within a few days. A month later, after the patient had stopped using the nicotine patches, four aphthous ulcers developed within a week. These ulcers rapidly regressed once she resumed using the nicotine patches.&lt;br /&gt;
*[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section)&lt;br /&gt;
**Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418&lt;br /&gt;
&lt;br /&gt;
===1992: [https://pubmed.ncbi.nlm.nih.gov/1408021/ Smokeless tobacco use prevents aphthous stomatitis]===&lt;br /&gt;
*In (contrast to cigarette smoking, however, few components other than nicotine are systemically absorbed by ST users. Thus if the mechanism that protects ST users against aphthous ulcers is systemic, then nicotine is the likely protective factor. &lt;br /&gt;
*[https://sci-hub.se/10.1016/0030-4220(92)90296-3 PDF Version]&lt;br /&gt;
**Citation: Grady D, Ernster VL, Stillman L, Greenspan J. Smokeless tobacco use prevents aphthous stomatitis. Oral Surg Oral Med Oral Pathol. 1992 Oct;74(4):463-5. doi: 10.1016/0030-4220(92)90296-3. PMID: 1408021.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://onlinelibrary.wiley.com/doi/abs/10.5694/j.1326-5377.1991.tb121180.x?sid=nlm%3Apubmed Recurrent aphthous ulcers and nicotine]=== &lt;br /&gt;
*The aim of this study was to investigate the effect of nicotine, in the form of Nicorette tablets, on aphthous ulcers in non-smoking patients. This preliminary trial shows that nicotine may have a beneficial effect on aphthous ulcers.&lt;br /&gt;
*[https://sci-hub.st/10.5694/j.1326-5377.1991.tb121180.x PDF Version]&lt;br /&gt;
**Citation: Bittoun, R. (1991), Recurrent aphthous ulcers and nicotine. Medical Journal of Australia, 154: 471-472. https://doi.org/10.5694/j.1326-5377.1991.tb121180.x&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Arthritis/Skeletal&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
==Osteoarthritis==&lt;br /&gt;
&lt;br /&gt;
===2019 [https://journals.aai.org/jimmunol/article/203/2/485/107400/Nicotine-Attenuates-Osteoarthritis-Pain-and-Matrix Nicotine Attenuates Osteoarthritis Pain and Matrix Metalloproteinase-9 Expression via the α7 Nicotinic Acetylcholine Receptor]===&lt;br /&gt;
*In conclusion, stimulation of α7-nAChRs by nicotine attenuates MIA-induced OA pain and cartilage degradation. This protective effect of nicotine can be associated with the inhibition of MMP-9 overexpression through the PI3K/Akt/NF-κB signaling pathway. Although the use of nicotine is limited by its nonspecific effects, this study provides novel evidence supporting the future development of therapeutic strategies for inflammatory diseases via the cholinergic anti-inflammatory pathway.&lt;br /&gt;
**Citation: Teng P, Liu Y, Dai Y, Zhang H, Liu WT, Hu J. Nicotine Attenuates Osteoarthritis Pain and Matrix Metalloproteinase-9 Expression via the α7 Nicotinic Acetylcholine Receptor. J Immunol. 2019 Jul 15;203(2):485-492. doi: 10.4049/jimmunol.1801513. Epub 2019 May 31. PMID: 31152077.&lt;br /&gt;
***This work was supported by grants from the National Natural Science Foundation of China (81373397, 81672218, and 81603092) and the Department of Science, Education, and Health Program of Jiangsu Province (QNRC 2016606 and QNRC 2016604).&lt;br /&gt;
&lt;br /&gt;
==Rheumatoid arthritis (collagen-induced arthritis CIA in mice)==&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.spandidos-publications.com/mmr/14/6/5057 Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Taken together, the present results indicated that nicotine‑induced activation of the CAP in mice with CIA may reduce the number of macrophages in the synovium, which may serve a role in alleviating arthritis in mice.&lt;br /&gt;
**Citation: Li S, Zhou B, Liu B, Zhou Y, Zhang H, Li T, Zuo X. Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration. Mol Med Rep. 2016 Dec;14(6):5057-5064. doi: 10.3892/mmr.2016.5904. Epub 2016 Oct 31. PMID: 27840928; PMCID: PMC5355730.&lt;br /&gt;
***Acknowledgement: The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81571602).&lt;br /&gt;
&lt;br /&gt;
===2014 [https://pubmed.ncbi.nlm.nih.gov/24313917/ Regulatory effect of nicotine on collagen-induced arthritis and on the induction and function of in vitro-cultured Th17 cells]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine stimulation attenuated signs and severity of arthritis in mice. Activation of nicotine acetylcholine receptors on in vitro-cultured Th17 cells decreased their pro-inflammatory function, which may play a potential role in alleviating arthritis in mice.&lt;br /&gt;
*[https://sci-hub.st/10.3109/14397595.2013.862352 PDF Full paper]&lt;br /&gt;
**Citation: Yang Y, Yang Y, Yang J, Xie R, Ren Y, Fan H. Regulatory effect of nicotine on collagen-induced arthritis and on the induction and function of in vitro-cultured Th17 cells. Mod Rheumatol. 2014 Sep;24(5):781-7. doi: 10.3109/14397595.2013.862352. Epub 2013 Dec 9. PMID: 24313917.&lt;br /&gt;
***Acknowledgement: This work was supported by The Shanghai Committee of Science and Technology Project, China (Grant No. 12GWZX0201,11140902900).&lt;br /&gt;
&lt;br /&gt;
===2014 [https://www.sciencedirect.com/science/article/abs/pii/S0014299914003033 Attenuation of collagen induced arthritis via suppression on Th17 response by activating cholinergic anti-inflammatory pathway with nicotine]===&lt;br /&gt;
*Activating the cholinergic anti-inflammatory pathway with nicotine can inhibit Th17 cell responses, may improve the Th1/Th2 imbalance in CIA, and provide a new justification for its application in the clinical treatment of RA.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.ejphar.2014.04.019 PDF Full paper]&lt;br /&gt;
**Citation: Wu S, Luo H, Xiao X, Zhang H, Li T, Zuo X. Attenuation of collagen induced arthritis via suppression on Th17 response by activating cholinergic anti-inflammatory pathway with nicotine. Eur J Pharmacol. 2014 Jul 15;735:97-104. doi: 10.1016/j.ejphar.2014.04.019. Epub 2014 Apr 19. PMID: 24755145.&lt;br /&gt;
***Acknowledgement: This work was supported by a grant from the National Natural Science Foundation of China, People&#039;s Republic of China [81102261] and the Innovative Research Funds for the Central South University, People&#039;s Republic of China. [CX2012B088].&lt;br /&gt;
&lt;br /&gt;
===2009 [https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.24177 Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Clinical arthritis was exacerbated by vagotomy and ameliorated by oral nicotine administration. Moreover, oral nicotine inhibited bone degradation and reduced TNFalpha expression in synovial tissue. Both IP-injected nicotine and AR-R17779 ameliorated clinical arthritis and reduced synovial inflammation. This was accompanied by a reduction of TNFalpha levels in both plasma and synovial tissue. The effect of AR-R17779 was more potent compared with that of nicotine and was associated with delayed onset of the disease as well as with protection against joint destruction.&lt;br /&gt;
**Citation: van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009 Jan;60(1):114-22. doi: 10.1002/art.24177. PMID: 19116908.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Auditory&#039;&#039;&#039; =&lt;br /&gt;
===2021 [https://www.nature.com/articles/s41598-021-92588-z Task-dependent effects of nicotine treatment on auditory performance in young-adult and elderly human nonsmokers]=== &lt;br /&gt;
*The present study evaluated acute effects of oral nicotine treatment on three auditory tasks in young adult and elderly, healthy, non-smoking individuals. All had normal hearing within the frequency range of the stimuli presented for the three tasks. Compared to pre-treatment performance, nicotine improved frequency discrimination. Compared to placebo, nicotine produced no overall effects on the two frequency related tasks, but significantly improved intensity discrimination, with more improvement obtained for those who had lower baseline performance. The present results support the hypothesis that nicotine enhances auditory processing, but this enhancement is task-dependent.&lt;br /&gt;
*[https://www.nature.com/articles/s41598-021-92588-z.pdf PDF Version]&lt;br /&gt;
*Citation: Sun, S., Kapolowicz, M.R., Richardson, M. et al. Task-dependent effects of nicotine treatment on auditory performance in young-adult and elderly human nonsmokers. Sci Rep 11, 13187 (2021). doi: 10.1038/s41598-021-92588-z&lt;br /&gt;
&lt;br /&gt;
===2019 [https://pubmed.ncbi.nlm.nih.gov/31832719/ Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers]=== &lt;br /&gt;
*Nicotine improves auditory performance in difficult listening situations. The present results support future investigation of nicotine effects in clinical populations with auditory processing deficits or reduced cholinergic activation.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s00213-019-05421-x PDF Version]&lt;br /&gt;
*Citation: Pham CQ, Kapolowicz MR, Metherate R, Zeng FG. Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers. Psychopharmacology (Berl). 2020 Mar;237(3):833-840. doi: 10.1007/s00213-019-05421-x. Epub 2019 Dec 12. PMID: 31832719; PMCID: PMC7039769.&lt;br /&gt;
*Acknowledgements: This research was supported by grants from the National Institutes of Health to FGZ (5R01DC015587), to RM (4R01-DC013200) and a pre-doctoral fellowship to CQP (UL1-TR000153).&lt;br /&gt;
*Keywords: Acetylcholinergic systems; Auditory processing; Nicotine; Selective attention; Spectral ripple discrimination; Temporal gap detection; Tone in noise detection.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Atopic Dermatitis&#039;&#039;&#039; =&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37454697/ Association of Atopic Dermatitis with Substance Use Disorders: A Case-Control Study in the All of Us Research Program.] ===&lt;br /&gt;
&lt;br /&gt;
* Joshi TP, Bancroft A, DeLeon D, Garcia D, Kunisetty B, Truong P, Kim SJ. J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01361-0. doi: 10.1016/j.jaad.2023.06.051. Online ahead of print. PMID: 37454697 No abstract available.&lt;br /&gt;
* Patients with AD, compared to controls, were more likely to use cannabis (4.4% vs 2.7%, 60 P &amp;lt;0.01), hallucinogens (3.2% vs 1.8%, P &amp;lt;0.01), opioids (3.5% vs 1.3%, P &amp;lt;0.01), and 61 stimulants (2.3% vs 1.5%, P &amp;lt;0.01) and less likely to use e-cigarettes (10.8% vs 15.6%, P &amp;lt;0.01) 62 and regular cigarettes (39.0% vs 56.0%, P &amp;lt;0.01). &lt;br /&gt;
* In multivariable analysis adjusted for age, 63 income, insurance type, race, sex, depression, and anxiety, only the associations with cannabis 64 (aOR 1.49, 95% CI 1.24-1.80), e-cigarette (aOR 0.71, 95% CI 0.65-0.77), and regular cigarette 65 use (aOR 0.65, 95% CI 0.63-0.68) persisted (Table I)&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Autism&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
=== 2020: [https://pubmed.ncbi.nlm.nih.gov/32691528/ The Role of Nicotinic Receptors in the Attenuation of Autism-Related Behaviors in a Murine BTBR T + tf/J Autistic Model] ===&lt;br /&gt;
&lt;br /&gt;
* Nicotinic receptors are distributed throughout the central and peripheral nervous system. Postmortem studies have reported that some nicotinic receptor subtypes are altered in the brains of autistic people.&lt;br /&gt;
* Recent studies have demonstrated the importance of nicotinic acetylcholine receptors (nAChRs) in the autistic behavior of BTBR T + tf/J mouse model of autism. This study was undertaken to examine the behavioral effects of targeted nAChRs using pharmacological ligands, including nicotine and mecamylamine in BTBR T + tf/J and C57BL/6J mice in a panel of behavioral tests relating to autism.&lt;br /&gt;
* Overall, the findings indicate that the pharmacological modulation of nicotinic receptors is involved in modulating core behavioral phenotypes in the BTBR T + tf/J mouse model.&lt;br /&gt;
* LAY SUMMARY: The involvement of brain nicotinic neurotransmission system plays a crucial role in regulating autism-related behavioral features. In addition, the brain of the autistic-like mouse model has a low acetylcholine level. Here, we report that nicotine, at certain doses, improved sociability and reduced repetitive behaviors in a mouse model of autism, implicating the potential therapeutic values of a pharmacological intervention targeting nicotinic receptors for autism therapy.&lt;br /&gt;
* Mouse study, may not explain human response&lt;br /&gt;
* Autism Research 2020 Aug;13(8):1311-1334  doi: 10.1002/aur.2342. Epub 2020 Jul 21.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]=== &lt;br /&gt;
*Taken together, our study provides evidence for the feasibility and tolerability of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine (TN/TNP)&#039;&#039;&#039;]] in a small sample of adults with severe [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Autism Spectrum Disorder (ASD)&#039;&#039;&#039;]] symptoms and pathological chronic aggression and irritability. &lt;br /&gt;
*Our results also suggest that TN may have a beneficial effect on aggression, irritability, and sleep in ASD, though the sample size of this study is too small to make definitive conclusions. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/pdf/nihms-950880.pdf PDF Version]&lt;br /&gt;
*Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.&lt;br /&gt;
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).&lt;br /&gt;
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Behcet&#039;s disease&#039;&#039;&#039; (See also: Aphthous ulcers)= &lt;br /&gt;
*Post on [https://healthunlocked.com/behcetsuk/posts/138632782/nicotine-and-it%E2%80%99s-effects-on-my-beh%C3%A7et%E2%80%99s-for-the-positive Behçet&#039;s UK]. A person started smoking seeking relief from the pain they suffered because of Behcet&#039;s disease.&lt;br /&gt;
&lt;br /&gt;
===2010 [https://academic.oup.com/rheumatology/article/49/3/501/1786816 Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series]=== &lt;br /&gt;
*In this report, we describe five ex-smoker [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;BD&#039;&#039;&#039;]] patients with active mucocutaneous lesions, not responsive to standard pharmacological treatments and treated with transdermal nicotine patches. Four out of five patients quickly responded to nicotine-patch therapy and experienced a complete regression of all mucocutaneous lesions within 6 months of observation.&lt;br /&gt;
**Citation: Giovanni Ciancio, Matteo Colina, Renato La Corte, Andrea Lo Monaco, Francesco De Leonardis, Francesco Trotta, Marcello Govoni, Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series, Rheumatology, Volume 49, Issue 3, March 2010, Pages 501–504, doi: 10.1093/rheumatology/kep401&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.jidonline.org/article/S0022-202X(15)33112-2/fulltext Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet&#039;s disease]===&lt;br /&gt;
*&amp;quot;In conclusion, we observed substantial inhibitory effects of CSE and nicotine on IL-8 and to a lesser extent on IL-6 release by human keratinocytes and HMEC-1 endothelial cells. These findings may explain the beneficial effect of smoking in BD, also because IL-8, and to some extent IL-6, are likely to induce pivotal proinflammatory signals in this disease (Lee et al., 1993). Nicotine may cause immunoregulation by affecting chemokine/cytokine production. This study also demonstrates the different behavior of cells in terms of cytokine release when stimulated with BD patients&#039; sera compared to those of healthy individuals. The in vitro evidence of beneficial effects of nicotine in BD is fundamental to our ongoing clinical trial with nicotine transdermal patches in BD. In addition, the detected beneficial effect of biochanin A implicates this compound as a candidate for future developments in aphthae treatment. The development of topical nicotinic cholinergic receptor subtype-specific agonists is likely to exhibit beneficial effects on skin and mucosae without inducing systemic adverse effects.&amp;quot;&lt;br /&gt;
**Citation: Kalayciyan A, Orawa H, Fimmel S, Perschel FH, González JB, Fitzner RG, Orfanos CE, Zouboulis CC. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet&#039;s disease. J Invest Dermatol. 2007 Jan;127(1):81-9. doi: 10.1038/sj.jid.5700492. Epub 2006 Sep 28. PMID: 17008886.&lt;br /&gt;
***Acknowledgement: Dr Kalayciyan was supported by a grant of the Berlin Foundation for Dermatology. The research project was supported by the Deutsches Register Morbus Adamantiades–Behçet e.V.&lt;br /&gt;
&lt;br /&gt;
===2000 [https://www.nejm.org/doi/10.1056/NEJM200012143432418?url_ver=Z39.88-2003&amp;amp;rfr_id=ori%3Arid%3Acrossref.org&amp;amp;rfr_dat=cr_pub++0pubmed Nicotine Patches for Aphthous Ulcers Due to Behçet&#039;s Syndrome]=== &lt;br /&gt;
*We describe a woman with Behçet&#039;s syndrome characterized by recurrent oral and genital aphthous ulcers, severe eye involvement, and the onset of arthritis at the age of 29 years. At the age of 35 several large and extremely painful buccal aphthous ulcers developed. Therapy with a nicotine patch led to a regression of all aphthous ulcers within a few days. A month later, after the patient had stopped using the nicotine patches, four aphthous ulcers developed within a week. These ulcers rapidly regressed once she resumed using the nicotine patches.&lt;br /&gt;
*[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section)&lt;br /&gt;
**Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Brain Injury / Disease&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2024: [https://pubmed.ncbi.nlm.nih.gov/38698493/ Nicotine inhalant via E-cigarette facilitates sensorimotor function recovery by upregulating neuronal BDNF-TrkB signalling in traumatic brain injury]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Conclusioin: &amp;quot;Post-injury chronic nicotine exposure via vaping facilitates recovery of sensorimotor function by upregulating neuroprotective mBDNF/TrkB/Akt/Erk signalling. These findings suggest potential neuroprotective properties of nicotine despite its highly addictive nature. Thus, understanding the multifaceted effects of chronic nicotine exposure on TBI-associated symptoms is crucial for paving the way for informed and properly managed therapeutic interventions.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15681815/ Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease]=== &lt;br /&gt;
*Several studies have shown that nicotine treatment can attenuate cognitive deficits produced by medial septal lesions, lesions of the nucleus basalis, and traumatic brain injury.&lt;br /&gt;
*[https://sci-hub.st/10.1196/annals.1332.019 PDF Version]&lt;br /&gt;
*Citation: Pauly JR, Charriez CM, Guseva MV, Scheff SW. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Ann N Y Acad Sci. 2004 Dec;1035:316-34. doi: 10.1196/annals.1332.019. PMID: 15681815.&lt;br /&gt;
*Acknowledgements: This work was supported by grants from the National Institutes of Health (NS42196 to J.R.P. and NS39828 to S.W.S.) and the Kentucky Tobacco Research and Development Center. We acknowledge the technical assistance of Melissa Yingling and Khaled Tanwir.&lt;br /&gt;
*KEYWORDS: nicotine; neurodegeneration; neuroprotection&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cancer / Cancer Treatments&#039;&#039;&#039;= &lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S001448272030416X?via%3Dihub Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells]=== &lt;br /&gt;
*Nicotine inhibits ovarian cancer cell ERK and p38 [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;MAPK&#039;&#039;&#039;]] signaling.&lt;br /&gt;
*Nicotine inhibits ovarian cancer proliferation and spheroid invasion.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.yexcr.2020.112167 PDF Version]&lt;br /&gt;
*Citation: Sarah J. Harmych, Jay Kumar, Mesa E. Bouni, Deborah N. Chadee, Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells, Experimental Cell Research, Volume 394, Issue 1, 2020, 112167, ISSN 0014-4827, doi: 10.1016/j.yexcr.2020.112167.&lt;br /&gt;
*Acknowledgements: This work was supported by the National Institutes of Health [R15 CA199164] and [R15 CA241898] to D.N.C. &lt;br /&gt;
*Keywords: Nicotine, Ovarian cancer, Spheroid, MAPK, Invasion&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.sciencedirect.com/science/article/abs/pii/S0014299913003270?via%3Dihub Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models]=== &lt;br /&gt;
*Nicotine significantly reduced antiviral-dependent alterations of the nociceptive threshold. &lt;br /&gt;
*Moreover, nicotine decreased neuropathic pain induced by repeated intraperitoneal administration of the anticancer agent oxaliplatin (2.4 mg/kg), lowering the hypersensitivity to mechanical and thermal stimuli. &lt;br /&gt;
*Intraperitoneal nicotine administration controls neuropathic pain evoked by traumatic or toxic nervous system alterations. These results support the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] modulation as a possible therapeutic approach to the complex, undertreated chemotherapy-induced neuropathies. &lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.ejphar.2013.04.022 PDF Version]&lt;br /&gt;
*Citation: Lorenzo Di Cesare Mannelli, Matteo Zanardelli, Carla Ghelardini, Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models, European Journal of Pharmacology, Volume 711, Issues 1–3, 2013, Pages 87-94, ISSN 0014-2999, doi: 10.1016/j.ejphar.2013.04.022.&lt;br /&gt;
*Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research.&lt;br /&gt;
*Keywords: nAChR; Dideoxycytidine; Oxaliplatin; Antiviral; Anticancer, pain, chemotherapy, nicotine, neuropathy&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cannabis / THC&#039;&#039;&#039;= &lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32034447/ Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial]=== &lt;br /&gt;
*The findings provide the first evidence that [[Special:MyLanguage/Abbreviations|NP (Nicotine Patch)]] may be able to attenuate NA (negative affect) - related withdrawal symptoms in individuals with cannabis use disorder who are not heavy users of tobacco or nicotine.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s00213-020-05476-1 PDF Version]&lt;br /&gt;
*Citation: Gilbert DG, Rabinovich NE, McDaniel JT. Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial. Psychopharmacology (Berl). 2020 May;237(5):1507-1519. doi: 10.1007/s00213-020-05476-1. Epub 2020 Feb 7. PMID: 32034447.&lt;br /&gt;
*Acknowledgement: The study was supported by NIH grant R01DA031006 awarded to David Gilbert.&lt;br /&gt;
*Keywords: Cannabis; Marijuana; Negative affect; Nicotine; Smoking; THC; Testing effect; Withdrawal symptoms.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Cardiovascular&#039;&#039;&#039; =&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/pii/S0014488624002723 Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these findings indicate that acute nicotine exposure enhances functional stroke recovery. Future studies will have to evaluate the effects of (1) chronic nicotine exposure, a clinically relevant vascular risk factor, and (2) the cessation of nicotine exposure, which is widely recommended post-stroke, but might have detrimental effects in the early stroke recovery phase.&lt;br /&gt;
**Citation: Abbaspour S, Fahanik-Babaei J, Adeli S, Hermann DM, Sardari M. Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state. Exp Neurol. 2024 Sep 13;382:114946. doi: 10.1016/j.expneurol.2024.114946. Epub ahead of print. PMID: 39278587.&lt;br /&gt;
***Funding: None&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://pubmed.ncbi.nlm.nih.gov/38529793/ Transdermal Nicotine Patch Increases the Number and Function of Endothelial Progenitor Cells in Young Healthy Nonsmokers without Adverse Hemodynamic Effects] ===&lt;br /&gt;
* This study aimed to explore the influence of TNPs on circulating EPCs with surface markers of CD34, CD133, and/or KDR, and colony-forming function plus migration activity of early EPCs derived from cultured peripheral blood mononuclear cells before and after TNP treatments in young healthy nonsmokers.&lt;br /&gt;
* PWA analyses on day 7, compared with pretreatment, did not show significant change except diastolic pressure time index, which was prolonged and implied potential vascular benefit. In conclusion, 7-day TNP treatments could be a practical strategy to enhance angiogenesis of circulating EPCs to alleviate tissue ischemia without any hemodynamic concern.&lt;br /&gt;
* Nicotine patches appear to promote blood vessel formation, without adverse effects.&lt;br /&gt;
&lt;br /&gt;
=== 2015 [https://www.nature.com/articles/srep15895 Dose-dependent protective effect of nicotine in a murine model of viral myocarditis induced by coxsackievirus B3] ===&lt;br /&gt;
&lt;br /&gt;
* The alpha 7 nicotinic acetylcholine receptor (alpha7 nAChR) was recently described as an anti-inflammatory target in various inflammatory diseases. The aim of this study was to investigate the dose-related effects of nicotine, an alpha7 nAChR agonist, in murine model of viral myocarditis.&lt;br /&gt;
* The survival rate on day 14 increased in a dose-dependent fashion and was markedly higher in the 0.2 and 0.4 mg/kg nicotine groups than in the infected untreated group.&lt;br /&gt;
* The findings suggest that alpha7 nAChR agonists may be a promising new strategy for patients with viral myocarditis.&lt;br /&gt;
* Animal study (mice)&lt;br /&gt;
* Ge Li-Sha, Zhao Jing-Lin, Chen Guang-Yi, Liu Li, Zhou De-Pu &amp;amp; Li Yue-Chun &#039;&#039;Scientific Reports&#039;&#039; volume 5, Article number: 15895 (2015) &lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Chlamydia Pneumoniae&#039;&#039;&#039;=&lt;br /&gt;
*Chlamydia pneumoniae is a type of bacteria that can cause respiratory tract infections, such as pneumonia. C. pneumoniae is one cause of community-acquired pneumonia or lung infections developed outside of a healthcare setting. However, not everyone exposed to C. pneumoniae will develop pneumonia. [https://www.cdc.gov/pneumonia/atypical/cpneumoniae/index.html Source: US CDC]&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection...&lt;br /&gt;
*Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cognitive / IQ / Memory&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10998423/ An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence] ===&lt;br /&gt;
*Conclusion: Overall, the nicotine containing products improved sustained attention and mood while reducing smoking urges, with the studied e-cigarettes having comparable effects to combustible cigarettes across the assessed cognitive parameters and mood measures. These results demonstrate the potential role of e-cigarettes to provide an acceptable alternative for combustible cigarettes among people who would otherwise continue to smoke.&lt;br /&gt;
*Citation: Harry J. Green, Olivia K. O’Shea, Jack Cotter, Helen L. Philpott, and Nik Newland. Harm Reduct J. 2024; 21: 78. Published online 2024 Apr 6. doi: 10.1186/s12954-024-00993-0 PMCID: PMC10998423&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://www.frontiersin.org/articles/10.3389/fnins.2023.1252705/full Editorial: Nicotine and its derivatives in disorders of cognition: a challenging new topic of study] ===&lt;br /&gt;
&lt;br /&gt;
* Front. Neurosci., 18 July 2023 Sec. Neurodegeneration Volume 17 - 2023 | &amp;lt;nowiki&amp;gt;https://doi.org/10.3389/fnins.2023.1252705&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
* Albert Gjedde, Department of Neuroscience, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark&lt;br /&gt;
* Nicotine is a compound of considerable interest to neuroscience, in contexts of physiology as well as pathology of brain functions related to neurotransmitter mechanisms. Nicotine is an alkaloid that exists naturally in plants such as tomatoes and potatoes, with the highest levels in the tobacco plant.&lt;br /&gt;
* In mammalian brains, nicotine has multiple actions that appear to be accidents of evolution, as no specific relation springs to mind between the functions of nicotine in plants and animals.&lt;br /&gt;
* The following discussion expands upon the three topics of biology, therapy, and possible prevention, as related to cognition, in the three reviews and the three original studies included in the collection.&lt;br /&gt;
** Conclusion: Questions remain of how nicotine treatment in normal aging should proceed, including length of treatment, dose of nicotine, handling of smokers, effects of AD risk factors, and many others. While data from studies of psychiatric and memory-impaired subjects indicate that nicotine may relieve cognitive symptoms, it is mandatory to test the benefits of nicotine in normal aging in order to fill gaps in the literature and to verify the extent to which nicotine is useful as a pharmacologic agent that prevents pathological aging.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36736944/ Nicotine&#039;s effect on cognition, a friend or foe?] ===&lt;br /&gt;
* In this review, we first introduce the beneficial effect of nicotine on cognition including attention, short-term memory and long-term memory. We next summarize the beneficial effect of nicotine on cognition under pathological conditions, including Alzheimer&#039;s disease, Parkinson&#039;s disease, Schizophrenia, Stress-induced Anxiety, Depression, and drug-induced memory impairment.&lt;br /&gt;
* We can only access the abstract, but would be interested to read the whole thing if anyone can help?&lt;br /&gt;
* Human study&lt;br /&gt;
* Qian Wang, Weihong Du, Hao Wang, Panpan Geng, Yanyun Sun, Junfang Zhang, Wei Wang, Xinchun Jin, PMID: 36736944 DOI: 10.1016/j.pnpbp.2023.110723&lt;br /&gt;
&lt;br /&gt;
=== 2021: [https://www.spandidos-publications.com/10.3892/mmr.2021.12037# Molecular insights into the benefits of nicotine on memory and cognition] ===&lt;br /&gt;
&lt;br /&gt;
* Published online on: March 25, 2021 Molecular Medicine Reports  &amp;lt;nowiki&amp;gt;https://doi.org/10.3892/mmr.2021.12037&amp;lt;/nowiki&amp;gt; Article Number: 398&lt;br /&gt;
* Author: Ahmad Alhowail&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0306452220304723?via%3Dihub Effects of Nicotine on Task Switching and Distraction in Non-smokers. An fMRI Study]=== &lt;br /&gt;
*Nicotine improves sustained attention and reduces distractor interference, promoting cognitive stability. Nicotine enhances response times without differential impact on task switching or distraction.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.neuroscience.2020.07.029 PDF Version]&lt;br /&gt;
*Citation: Stefan Ahrens, Christiane M. Thiel, Effects of Nicotine on Task Switching and Distraction in Non-smokers. An fMRI Study, Neuroscience, Volume 444, 2020, Pages 43-53, ISSN 0306-4522, doi: 10.1016/j.neuroscience.2020.07.029.&lt;br /&gt;
*Acknowledgements: This work was supported by a grant from the German Research Foundation DFG TH766/8-1.&lt;br /&gt;
*Key words: nicotine, cholinergic, cognitive control, distraction, task switching, neuroimaging&lt;br /&gt;
&lt;br /&gt;
===2019: [https://www.frontiersin.org/articles/10.3389/fnins.2018.01002/full#B5 Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review]===&lt;br /&gt;
*Nicotine lowers learning and memory impairment in some neurological disorders.&lt;br /&gt;
*Citation: Majdi, A., Kamari, F., &amp;amp; Gjedde, A. (2019). Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review. Frontiers in Neuroscience, 12. https://doi.org/10.3389/fnins.2018.01002&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== &lt;br /&gt;
*Preclinical models and human studies have demonstrated that nicotine has cognitive-enhancing effects. Attention, working memory, fine motor skills and episodic memory functions are particularly sensitive to nicotine’s effects. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/pdf/CN-16-403.pdf PDF Version]&lt;br /&gt;
*Citation: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Curr Neuropharmacol. 2018;16(4):403-414. doi: 10.2174/1570159X15666171103152136. PMID: 29110618; PMCID: PMC6018192.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2013: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/ A fresh look at tobacco harm reduction: the case for the electronic cigarette]===&lt;br /&gt;
*Smokers of any age can reap substantial health benefits by quitting. In fact, no other single public health effort is likely to achieve a benefit comparable to large-scale smoking cessation.&lt;br /&gt;
*E-cigs might be the most promising product for tobacco harm reduction to date, because, besides delivering nicotine vapour without the combustion products that are responsible for nearly all of smoking’s damaging effect, they also replace some of the rituals associated with smoking behaviour.&lt;br /&gt;
*Nicotine’s beneficial effects include correcting problems with concentration, attention and memory, as well as improving symptoms of mood impairments. Keeping such disabilities at bay right now can be much stronger motivation to continue using nicotine than any threats of diseases that may strike &lt;br /&gt;
*Nicotine’s beneficial effects can be controlled, and the detrimental effects of the smoky delivery system can be attenuated, by providing the drug via less hazardous delivery systems. Although more research is needed, e-cigs appear to be effective cigarette substitutes for inveterate smokers, and the health improvements enjoyed by switchers do not differ from those enjoyed by tobacco/nicotine abstainers.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/pdf/1477-7517-10-19.pdf PDF Version]&lt;br /&gt;
&lt;br /&gt;
===2012: [https://pubmed.ncbi.nlm.nih.gov/22503574/ The electronic-cigarette: Effects on desire to smoke, withdrawal symptoms and cognition]=== &lt;br /&gt;
*The e-cigarette can reduce desire to smoke and nicotine withdrawal symptoms 20 minutes after use.&lt;br /&gt;
*The nicotine content in this respect may be more important for males.&lt;br /&gt;
*The first study to demonstrate that the nicotine e-cigarette can improve working memory.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.addbeh.2012.03.004 PDF Version]&lt;br /&gt;
*Citation: Dawkins, L., Turner, J., Hasna, S., &amp;amp; Soar, K. (2012). The electronic-cigarette: Effects on desire to smoke, withdrawal symptoms and cognition. Addictive Behaviors, 37(8), 970–973. doi:10.1016/j.addbeh.2012.03.004 &lt;br /&gt;
*Electronic Cigarette Company (TECC) supplied the e-cigarettes and cartridges for this study. TECC had no involvement in the design or conduct of the study.&lt;br /&gt;
&lt;br /&gt;
===2003 [https://www.nature.com/articles/1300202 Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects]=== &lt;br /&gt;
*Compared to placebo, nicotine and donepezil significantly improved, while alcohol significantly impaired overall flight performance. Both cholinergic drugs showed the largest effects on flight tasks requiring sustained visual attention.&lt;br /&gt;
*[https://www.nature.com/articles/1300202.pdf PDF Version]&lt;br /&gt;
*Citation: Mumenthaler, M., Yesavage, J., Taylor, J. et al. Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects. Neuropsychopharmacol 28, 1366–1373 (2003). doi: 10.1038/sj.npp.1300202&lt;br /&gt;
*Acknowledgements: This research was supported in part by NIMH Grant 40041; NIA Grant AG17824; the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); the Alcohol Beverage Medical Research Foundation; the Swiss Foundation for Alcohol Research; the Swiss National Science Foundation; and the Medical Research Service of the Department of Veterans Affairs.&lt;br /&gt;
*Keywords: cholinergic agents, ethanol, cognition, psychomotor performance, psychopharmacology, aerospace medicine&lt;br /&gt;
&lt;br /&gt;
===1996 [https://link.springer.com/article/10.1007/BF02805972 Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers]===&lt;br /&gt;
*These results are consistent with other recent research suggesting a primary effect of nicotine in enhancing cognitive performance.&lt;br /&gt;
*Citation: Foulds, J., Stapleton, J., Swettenham, J. et al. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology 127, 31–38 (1996). https://doi.org/10.1007/BF02805972&lt;br /&gt;
&lt;br /&gt;
===1994 [https://link.springer.com/article/10.1007/BF02245346 Smoking and raven IQ]=== &lt;br /&gt;
*Nicotine has recently been shown to enhance measures of information processing speed including the decision time (DT) component of simple and choice reaction time and the string length measure of evoked potential waveform complexity. Both (DT and string length) have been previously demonstrated to correlate with performance on standard intelligence tests ([[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;IQ&#039;&#039;&#039;]]).&lt;br /&gt;
*In this experiment we used the Raven [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Advanced Progressive Matrices (APM)&#039;&#039;&#039;]] test. APM scores were significantly higher in the smoking session compared to the non-smoking session, suggesting that nicotine acts to enhance physiological processes underlying performance on intellectual tasks.&lt;br /&gt;
*[https://sci-hub.st/https://link.springer.com/article/10.1007/BF02245346 PDF Version]&lt;br /&gt;
*Citation: Stough, C., Mangan, G., Bates, T. et al. Smoking and raven IQ. Psychopharmacology 116, 382–384 (1994). doi: 10.1007/BF02245346&lt;br /&gt;
*Key words: Intelligence, APM, Nicotine, Smoking Cholinergic system&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1579636/ Nicotine as a cognitive enhancer]=== &lt;br /&gt;
*Nicotine improves attention in a wide variety of tasks in healthy volunteers. &lt;br /&gt;
*Nicotine improves immediate and longer term memory in healthy volunteers. &lt;br /&gt;
*Nicotine improves attention in patients with probable Alzheimer&#039;s Disease. &lt;br /&gt;
*While some of the memory effects of nicotine may be due to enhanced attention, others seem to be the result of improved consolidation as shown by post-trial dosing. &lt;br /&gt;
*[https://sci-hub.st/10.1016/0278-5846(92)90069-q PDF Version]&lt;br /&gt;
*Citation: Warburton DM. Nicotine as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1992 Mar;16(2):181-91. doi: 10.1016/0278-5846(92)90069-q. PMID: 1579636.&lt;br /&gt;
*Keywords: acetylcholine, Alzheimer&#039;s Disease, attention, cholinergic, memory, nicotine, scopolamine.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;COVID / Long COVID / Post-COVID Syndrome / Long-Haul COVID (SARS-CoV-2)&#039;&#039;&#039;=&lt;br /&gt;
*See Also: The Inflamation Section &lt;br /&gt;
&lt;br /&gt;
===2025: [https://bioelecmed.biomedcentral.com/articles/10.1186/s42234-025-00167-8 Long COVID – a critical disruption of cholinergic neurotransmission?]===&lt;br /&gt;
*Conclusions: &amp;quot;A review of the literature indicates that a significant disruption of cholinergic neurotransmission might be a central issue for both LC/ME/CFS and PVS. The hypothesis of a viral blockade of nAChRs and the possibility of a competitive reversal of this blockade by LDTN has been corroborated by highly promising results in the broad application of this method to numerous patients. Randomized controlled trials are necessary to determine whether these preliminary results can be substantiated by evidence. However, LDTN application provides many patients with a method that offers a high probability of symptom relief with only minor side effects and represents an affordable therapeutic intervention for the majority of people affected worldwide. Furthermore, dose-finding studies are required to develop individually adapted therapy regimens with regard to dosage and duration of therapy.&amp;quot;&lt;br /&gt;
*Citation: Leitzke, M., Roach, D.T., Hesse, S. et al. Long COVID – a critical disruption of cholinergic neurotransmission?. Bioelectron Med 11, 5 (2025). https://doi.org/10.1186/s42234-025-00167-8&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37264452/ The controversial effect of smoking and nicotine in SARS-CoV-2 infection.] ===&lt;br /&gt;
* States the obvious: the exposure (smoke vs. nicotine and dose need to be characterised correctly).&lt;br /&gt;
* Considering that the effects of nicotine and cigarette smoke are different from each other, it is necessary to be careful in generalizing the effects of nicotine and cigarette to each other in the conducted researches. The generalization and the undifferentiation of nicotine from smoke is a significant bias. Moreover, different doses of nicotine stimulate different effects (dose-dependent response). In addition to further assessing the role of nicotine in COVID-19 infection and any other cases, a clever assessment of underlying diseases should also be considered to achieve a guideline for health providers and a personalized approach to treatment.&lt;br /&gt;
* Salehi Z, Motlagh Ghoochani BFN, Hasani Nourian Y, Jamalkandi SA, Ghanei M. Allergy Asthma Clin Immunol. 2023 Jun 1;19(1):49. doi: 10.1186/s13223-023-00797-0. PMID: 37264452 Review.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36650574/ Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?] ===&lt;br /&gt;
* Nicotine COVID/SARS-CoV-2 interaction mystery takes another turn.&lt;br /&gt;
* Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh).&lt;br /&gt;
* We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.&lt;br /&gt;
*In all four of the cases we studied, transcutaneous use of nicotine led to a near immediate improvement in symptoms and rapid restitutio ad integrum. The course of symptom improvement was as distinct as the clinical presentation of post-COVID-19 syndrome in each patient.&lt;br /&gt;
*Citation: Leitzke M. Bioelectron Med. 2023 Jan 18;9(1):2. doi: 10.1186/s42234-023-00104-7. PMID: 36650574 Free PMC article.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.nature.com/articles/s41598-023-45072-9 Treatment of 95 post-Covid patients with SSRIs]===&lt;br /&gt;
*To stick nicotine patches helps PCS (post-COVID syndrome) patients. This may be not only because nicotine is a nicotinic receptor agonist and therefore an opponent of these poisonous metabolites, but nicotine is a strong acetylcholine (ACh) agonist as well.&lt;br /&gt;
*Citation: Rus, C.P., de Vries, B.E.K., de Vries, I.E.J. et al. Treatment of 95 post-Covid patients with SSRIs. Sci Rep 13, 18599 (2023). https://doi.org/10.1038/s41598-023-45072-9&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183099/ Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials]===&lt;br /&gt;
* Studies show that the penetration of SARS-CoV-2 into upper respiratory tract, bronchial and pulmonary cells involve transmembrane receptor ACE2, which probably interacts with acetylcholine nicotinic receptors of the α7 subtype. The mechanism of the interactions remains hypothetical.&lt;br /&gt;
* Despite a relatively safe tolerance profile, transdermal nicotine therapy in non-smokers can only be used in clinical trials. There is a lack of formal assessment of the potential risk of developing a tobacco addiction. This review offers baseline data to set a transdermal nicotine protocol for non-smokers with a new purpose.&lt;br /&gt;
* Analyses of nicotine administration protocols and safety were conducted after reviewing Medline and Science Direct databases performing a search using the words [transdermal nicotine] AND [non-smoker] AND selected diseases.&lt;br /&gt;
* Excessive secondary cytokine reaction plays a role in the mortality associated with COVID. One of the hypotheses to explain the effect of nicotine on the occurrence of severe forms of COVID and death is based on the loss of the downregulation of the parasympathetic nervous system, which exerts an inhibitory effect on cytokine storm, especially in the lung and digestive tract. The α 7-type nicotinic receptors are part of this chain of reaction.&lt;br /&gt;
* B. Dautzenberg, A. Levi, M. Adler, and R. Gaillardc. Respir Med Res. 2021 Nov; 80: 100844. Published online 2021 Jun 7. doi: 10.1016/j.resmer.2021.100844 PMCID: PMC8183099 PMID: 34153704&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704168/ Does Nicotine Prevent Cytokine Storms in COVID-19?]===&lt;br /&gt;
*Case study of one individual&lt;br /&gt;
*Nicotine, an α7-nACh receptor agonist, may boost the cholinergic anti-inflammatory pathway and hinder the uncontrolled overproduction of pro-inflammatory cytokines triggered by the SARS-CoV-2 virus, which is understood to be the main pathway to poor outcomes and death in severe COVID-19.&lt;br /&gt;
*In the absence of any effective treatment for COVID-19, further research as to whether nicotine replacement offers protection against severe SAR-CoV-2 infection in smokers is clearly essential. If the mechanisms through which nicotine may interact with the virus remain speculative, the effects of route of administration, duration, dosing and frequency of use of nicotine on any such interaction are unknown. Should NRT be found to be of help in the management of COVID-19, it would be yet another strong reason to persuade smokers to switch to NRT and ultimately quit smoking.&lt;br /&gt;
*Citation: Dratcu L, Boland X. Does Nicotine Prevent Cytokine Storms in COVID-19? Cureus. 2020 Oct 28;12(10):e11220. doi: 10.7759/cureus.11220. PMID: 33269148; PMCID: PMC7704168.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300218/ Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm]===&lt;br /&gt;
*Abstract: &amp;quot;SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.&amp;quot;&lt;br /&gt;
*Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218.&lt;br /&gt;
&lt;br /&gt;
===2020: [https://www.sciencedirect.com/science/article/pii/S2214750020302924 Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system]===&lt;br /&gt;
*Nicotine could maintain or restore the function of the cholinergic anti-inflammatory system and thus control the release and activity of pro-inflammatory cytokines. This could prevent or suppress the cytokine storm. This hypothesis needs to be examined in the laboratory and the clinical setting.&lt;br /&gt;
*Citation: Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, Vantarakis A, Poulas K. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020 Apr 30;7:658-663. doi: 10.1016/j.toxrep.2020.04.012. PMID: 32355638; PMCID: PMC7192087.&lt;br /&gt;
&lt;br /&gt;
=== 2019: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679833/ Mitochondria as a possible target for nicotine action] ===&lt;br /&gt;
&lt;br /&gt;
* See also this twitter thread for detailed information on possible mechanisms. https://x.com/angryhacademic/status/1741968457296490977?s=20&lt;br /&gt;
* This review presents a comprehensive overview of the present knowledge of nicotine action on mitochondrial function. Observed effects of nicotine exposure on the mitochondrial respiratory chain, oxidative stress, calcium homeostasis, mitochondrial dynamics, biogenesis, and mitophagy are discussed, considering the context of the experimental design.&lt;br /&gt;
* The potential action of nicotine on cellular adaptation and cell survival is also examined through its interaction with mitochondria. Although a large number of studies have demonstrated the impact of nicotine on various mitochondrial activities, elucidating its mechanism of action requires further investigation.&lt;br /&gt;
* J Bioenerg Biomembr. 2019; 51(4): 259–276. Published online 2019 Jun 13. doi: 10.1007/s10863-019-09800-z PMCID: PMC6679833 PMID: 31197632&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Digestive Tract / Bowel&#039;&#039;&#039;= &lt;br /&gt;
===2024: [https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntae193/7727428 The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis]===&lt;br /&gt;
*&amp;quot;Despite different mechanisms of action, both ENDS and CCs attenuated on-going colon inflammation, enhanced healing and ameliorated recovery of injured intestines of DSS-treated mice and UC patients.&amp;quot;&lt;br /&gt;
**Citation: Kastratovic N, Markovic V, Arsenijevic A, Volarevic A, Zdravkovic N, Zdravkovic M, Brankovic M, Gmizic T, Harrell CR, Jakovljevic V, Djonov V, Volarevic V. The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis. Nicotine Tob Res. 2024 Aug 5:ntae193. doi: 10.1093/ntr/ntae193. Epub ahead of print. PMID: 39101540.&lt;br /&gt;
***Paywalled, unable to view funding/COI&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects]===&lt;br /&gt;
*Analysis of several studies - some animal.&lt;br /&gt;
*In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity.&lt;br /&gt;
**Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889&lt;br /&gt;
***Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S000927971931734X Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Conclusion: &amp;quot;Taken together, we demonstrated that nicotine inhibits apoptosis and proliferation by modulating AMPK/mTOR pathway-mediated autophagy and improves colitis severity in the DSS-induced UC mouse model. These findings provide new insights into the mechanism of nicotine treatment on UC autophagy. Further exploration of the mechanism of nicotine in autophagy and targeting factors might be considered a new approach for ulcerative colitis treatment.&amp;quot;&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.cbi.2020.108943 PDF Full paper]&lt;br /&gt;
**Citation: Gao Q, Bi P, Luo D, Guan Y, Zeng W, Xiang H, Mi Q, Yang G, Li X, Yang B. Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model. Chem Biol Interact. 2020 Feb 1;317:108943. doi: 10.1016/j.cbi.2020.108943. Epub 2020 Jan 10. PMID: 31926917.&lt;br /&gt;
***Acknowledgement: This work was supported by the Yunnan Key Laboratory of Tobacco Chemistry Project [Grant No. 2017539200340397].&lt;br /&gt;
&lt;br /&gt;
===2018 [https://academic.oup.com/jleukbio/article-abstract/104/5/1013/6935503 Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment]===&lt;br /&gt;
*Animal/Cell study&lt;br /&gt;
*These results supported our hypothesis that nicotine treatment ameliorated colitis through the suppression of MAdCAM-1 expression on the microvessels in the inflamed colon. Further investigation is warranted on the role of nicotine in the treatment of UC.&lt;br /&gt;
*[https://sci-hub.st/10.1002/JLB.3A0717-304R PDF Full paper]&lt;br /&gt;
**Citation: Maruta K, Watanabe C, Hozumi H, Kurihara C, Furuhashi H, Takajo T, Okada Y, Shirakabe K, Higashiyama M, Komoto S, Tomita K, Nagao S, Ishizuka T, Miura S, Hokari R. Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment. J Leukoc Biol. 2018 Nov;104(5):1013-1022. doi: 10.1002/JLB.3A0717-304R. Epub 2018 Jun 14. PMID: 29901817.&lt;br /&gt;
***Acknowledgement: This research was supported by grants from the National Defense Medical College, by Grants-in-aid for the Intractable Diseases Project of the Ministry of Health, Labour, and Welfare of Japan, and by Grantsin-aid for Scientific Research from the Japanese Ministry of Education (2646080).&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533410/ Novel Insights on the Effect of Nicotine in a Murine Colitis Model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Administration of low, but not high, doses of oral nicotine in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of tumor necrosis factor-α.&lt;br /&gt;
**Citation: AlSharari SD, Akbarali HI, Abdullah RA, Shahab O, Auttachoat W, Ferreira GA, White KL, Lichtman AH, Cabral GA, Damaj MI. Novel insights on the effect of nicotine in a murine colitis model. J Pharmacol Exp Ther. 2013 Jan;344(1):207-17. doi: 10.1124/jpet.112.198796. Epub 2012 Oct 31. PMID: 23115221; PMCID: PMC3533410.&lt;br /&gt;
***Acknowledgement: This work was supported by National Institutes of Health [Grants DA-019377; (to M.I.D.) and DK 046367] (to H.I.A.).&lt;br /&gt;
&lt;br /&gt;
===2012 [https://journals.physiology.org/doi/full/10.1152/ajpgi.00411.2011 Nicotine suppresses hyperexcitability of colonic sensory neurons and visceral hypersensivity in mouse model of colonic inflammation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*&amp;quot;In summary, in an acute and postinflammatory model of colitis, we demonstrated that nAChRs mediate suppression of hyperexcitability of colonic sensory. The present study also highlights the potential of in vivo treatment with nicotine towards its antinociceptive effects in colonic inflammation.&amp;quot;&lt;br /&gt;
**Citation: Abdrakhmanova GR, Kang M, Imad Damaj M, Akbarali HI. Nicotine suppresses hyperexcitability of colonic sensory neurons and visceral hypersensivity in mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol. 2012 Apr;302(7):G740-7. doi: 10.1152/ajpgi.00411.2011. Epub 2012 Jan 12. PMID: 22241859; PMCID: PMC3330777.&amp;quot;&lt;br /&gt;
***Acknowledgement: This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-046367 (to H. I. Akbarali).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
**Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
***Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.hindawi.com/journals/grp/2008/237185/ Nicotine Enemas for Active Crohn&#039;s Colitis: An Open Pilot Study]=== &lt;br /&gt;
*Smoking has a detrimental effect in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Crohn&#039;s disease (CD)&#039;&#039;&#039;]], but this may be due to factors in smoking other than nicotine. Given that transdermal nicotine benefits [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ulcerative colitis (UC)&#039;&#039;&#039;]], and there is a considerable overlap in the treatment of UC and CD, the possible beneficial effect of nicotine has been examined in patients with Crohn&#039;s colitis.&lt;br /&gt;
*In this relatively small study of patients with active Crohn&#039;s colitis, 6 mg nicotine enemas appeared to be of clinical benefit in most patients. They were well tolerated and safe.&lt;br /&gt;
*[http://downloads.hindawi.com/journals/grp/2008/237185.pdf PDF Version]&lt;br /&gt;
**Citation: J. R. Ingram, J. Rhodes, B. K. Evans, and G. A. O. Thomas, Hindawi Publishing Corporation, Gastroenterology Research and Practice, Volume 2008, Article ID 237185, 6 pages, doi:10.1155/2008/237185&lt;br /&gt;
***Acknowledgements: J. R. Ingram was supported by the Gastrointestinal Foundation Trust. SLA Pharma gave financial support to the project. The authors are indebted to Dr. J. T. Green (of Cardiff and Vale Hospitals Trust) who referred patients, and to Professor G. T. Williams (GTW) who performed all histological assessments.&lt;br /&gt;
&lt;br /&gt;
===2004 [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004722.pub2/full Transdermal nicotine for induction of remission in ulcerative colitis]=== &lt;br /&gt;
*Ulcerative colitis is largely a disease of nonsmokers and patients who have quit smoking. Randomised controlled trials were therefore developed to test the hypothesis that nicotine patches can induce remission of a flare of ulcerative colitis. This review provides evidence that transdermal nicotine is superior to placebo (fake patch) for the treatment of active ulcerative colitis.&lt;br /&gt;
*[https://sci-hub.st/https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004722.pub2/full PDF Version]&lt;br /&gt;
**Citation: McGrath, J., McDonald, J. W., &amp;amp; MacDonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004722.pub2&lt;br /&gt;
***Acknowledgements: Funding for the IBD/FBD Review Group (October 1, 2005 - September 30, 2010) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch; the Canadian Agency for Drugs and Technologies in Health (CADTH); and the CIHR Institutes of Health Services and Policy Research; Musculoskeletal Health and Arthritis; Gender and Health; Human Development, Child and Youth Health; Nutrition, Metabolism and Diabetes; and Infection and Immunity. Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12072594/ Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Conclusions: (1) Two weeks of nicotine administration leads to contrasting effects on jejunal and colonic inflammation in IL-10 -/- mice. (2) Nicotine ameliorated inflammation in the colon, which was associated with enhanced expression of two protective peptides.&lt;br /&gt;
*[https://sci-hub.st/10.1097/00042737-200206000-00005 PDF of full paper]&lt;br /&gt;
**Citation: Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. Eur J Gastroenterol Hepatol. 2002 Jun;14(6):607-14. doi: 10.1097/00042737-200206000-00005. PMID: 12072594.&lt;br /&gt;
&lt;br /&gt;
===1999 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/ Nicotine treatment for ulcerative colitis]=== &lt;br /&gt;
*No withdrawal symptoms suggesting nicotine addiction have been reported either after 4–6 weeks of therapy in short-term studies, or after a period of up to 6 months in the only long-term study available&lt;br /&gt;
*It can be concluded from these data that transdermal nicotine alone has limited efficacy in active ulcerative colitis and is ineffective as maintenance treatment. On the other hand, if administered in combination with mesalazine, nicotine is superior to placebo in promoting clinical remission of ulcerative colitis of mild to moderate degree, may represent an efficacious alternative to steroids in selected cases and, when effective, seems to exert a longer-lasting therapeutic effect than prednisone.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/pdf/bcp0048-0481.pdf PDF Version]&lt;br /&gt;
**Citation: Guslandi M. Nicotine treatment for ulcerative colitis. Br J Clin Pharmacol. 1999 Oct;48(4):481-4. doi: 10.1046/j.1365-2125.1999.00039.x. PMID: 10583016; PMCID: PMC2014383.&lt;br /&gt;
***No funding/COI information&lt;br /&gt;
&lt;br /&gt;
===1996 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2398677/ The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis.]=== &lt;br /&gt;
*Nicotine is believed to be the pharmacological ingredient of tobacco that is responsible for this beneficial deterrent of UC and several clinical trials using nicotine have demonstrated it to be an effective therapeutic agent in the treatment of ulcerative colitis. Although the aetiology of ulcerative colitis is unclear, current research using nicotine-based products has produced some interesting clues, together with the possibility of some form of therapeutic treatment based on nicotine administration.&lt;br /&gt;
*[https://sci-hub.st/10.1136/pgmj.72.854.714 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J. The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Postgrad Med J. 1996 Dec;72(854):714-8. doi: 10.1136/pgmj.72.854.714. PMID: 9015463; PMCID: PMC2398677.&lt;br /&gt;
&lt;br /&gt;
===1996: [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*Nicotine may have therapeutic uses in the treatment of ulcerative colitis.&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1994: [https://pubmed.ncbi.nlm.nih.gov/8114833/ Transdermal nicotine for active ulcerative colitis]===&lt;br /&gt;
*The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.&lt;br /&gt;
**Citation: Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994 Mar 24;330(12):811-5. doi: 10.1056/NEJM199403243301202. PMID: 8114833.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against ulcerative colitis (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Down&#039;s Syndrome&#039;&#039;&#039;= &lt;br /&gt;
===2001: [https://link.springer.com/chapter/10.1007/978-3-7091-6262-0_19 Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome]===&lt;br /&gt;
*To explore the potential for cognitive enhancement utilizing nicotinic stimulation, 8 patients with Down syndrome (aged 18.5–31 years) received placebo and a single dose of transdermal nicotine (5mg patch) over 2h in a single-blind, within-subjects repeated measures design. &lt;br /&gt;
*Neuropsychological tests exhibited improvements in digit symbol performance subtest in 4 of 8 subjects and 7 of 8 subjects in the Frankfurt Attention Inventory. These results suggest that stimulating central nicotinic receptors might have an acute cognitive benefit in young adult Down syndrome subjects.&lt;br /&gt;
*Citation: Bernert G., Sustrova M., Sovcikova E., Seidl R., Lubec G. (2001) Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome. In: Lubec G. (eds) Protein Expression in Down Syndrome Brain. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6262-0_19&lt;br /&gt;
&lt;br /&gt;
===2000 [https://pubmed.ncbi.nlm.nih.gov/11052587/ Effects of transdermal nicotine on cognitive performance in Down&#039;s syndrome]=== &lt;br /&gt;
*We investigated the effect of nicotine-agonistic stimulation with 5 mg transdermal patches, compared with placebo, on cognitive performance in five adults with the disorder. Improvements possibly related to attention and information processing were seen for Down&#039;s syndrome patients compared with healthy controls. Our preliminary findings are encouraging, although not generalizable because of small numbers. &lt;br /&gt;
*[https://sci-hub.st/10.1016/S0140-6736(00)02848-8 PDF Version]&lt;br /&gt;
*Seidl R, Tiefenthaler M, Hauser E, Lubec G. Effects of transdermal nicotine on cognitive performance in Down&#039;s syndrome. Lancet. 2000 Oct 21;356(9239):1409-10. doi: 10.1016/S0140-6736(00)02848-8. PMID: 11052587.&lt;br /&gt;
*Acknowledgements: We thank Pharmacia-Upjohn, Uppsala, Sweden, for providing transdermal nicotine patches. This study was supported by the Red Bull Company, Salzburg.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Dyskinesia&#039;&#039;&#039;=&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
*In summary, our data show that nicotine treatment decreases haloperidol-induced VCMs [vacuous chewing movements] in an established rat model of tardive dyskinesia. The demonstration that nicotine removal leads to a return of VCMs, whereas nicotine re-exposure reduced haloperidol-induced VCMs, suggests a causal relationship. These data have clinical applications for the treatment of tardive dyskinesias associated with long-term antipsychotic treatment using nicotine.&lt;br /&gt;
*Bordia T, McIntosh JM, Quik M. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. J Pharmacol Exp Ther. 2012 Mar;340(3):612-9. doi: 10.1124/jpet.111.189100. Epub 2011 Dec 5. PMID: 22144565; PMCID: PMC3286320.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Endurance / Exercise / Athletic Performance&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2024 Article: [https://web.archive.org/web/20241002001111/https://www.golfdigest.com/story/tour-pros-little-helper-does-nicotine-create-a-competitive-advantage Tour Pro’s Little Helper: Does nicotine create a competitive advantage?]===&lt;br /&gt;
*&amp;quot;In all, we talked to nearly 100 pro golfers to learn more about the popularity and usage patterns of nicotine on the major professional tours. Some told us they turn to tobacco or nicotine products for an energy boost; others say it helps them concentrate or feel relaxed. But for many, it’s just about keeping on.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.mdpi.com/1660-4601/20/2/1009 The Effect of High Nicotine Dose on Maximum Anaerobic Performance and Perceived Pain in Healthy Non-Smoking Athletes: Crossover Pilot Study]===&lt;br /&gt;
*The lower perception of pain intensity that we reported after the 8 mg nicotine dose application might be an important factor that affects performance. However, we did not report any improvement in physical performance parameters.&lt;br /&gt;
**Citation: Bartík P, Šagát P, Pyšná J, Pyšný L, Suchý J, Trubák Z, Petrů D. The Effect of High Nicotine Dose on Maximum Anaerobic Performance and Perceived Pain in Healthy Non-Smoking Athletes: Crossover Pilot Study. Int J Environ Res Public Health. 2023 Jan 5;20(2):1009. doi: 10.3390/ijerph20021009. PMID: 36673765; PMCID: PMC9859273.&lt;br /&gt;
***Acknowledgement: The authors would like to acknowledge the support of Prince Sultan University for paying the article processing charges (APC) of this publication. This study was conducted by the SSDRL research group.&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745004/ Acute Effects of Nicotine on Physiological Responses and Sport Performance in Healthy Baseball Players]===&lt;br /&gt;
*Our HRV and salivary analysis revealed that nicotine could induce endocrine and sympathetic nerve activity in healthy male baseball players who had never smoked. Compared with the placebo group, the nicotine group exhibited enhanced cognitive function (an average decrease in motor reaction time of 11.14%; an average decrease in motor reaction time of 5.72%) and baseball-hitting performance (an average increase of 34.69%), and small effect sizes were observed for these results. However, muscle strength did not increase after nicotine intake.&lt;br /&gt;
**Citation: Fang SH, Lu CC, Lin HW, Kuo KC, Sun CY, Chen YY, Chang WD. Acute Effects of Nicotine on Physiological Responses and Sport Performance in Healthy Baseball Players. Int J Environ Res Public Health. 2022 Jan 4;19(1):515. doi: 10.3390/ijerph19010515. PMID: 35010774; PMCID: PMC8745004.&lt;br /&gt;
***Acknowledgement: Study was supported by the Ministry of Science and Technology in Taiwan (No: MOST 107-2410-H-028-002-MY2 and MOST 109-2410-H-028-009-MY3).&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.tandfonline.com/doi/full/10.1186/s12970-021-00413-9 Nicotine supplementation enhances simulated game performance of archery athletes]===&lt;br /&gt;
*In summary, these results indicated that 2-mg nicotine gum supplementation enhanced cognitive function, decreased saliva α-amylase activity and HRV through stimulating the sympathetic adrenergic system. More importantly, the archery scores were significantly increased after nicotine supplementation.&lt;br /&gt;
**Citation: Hung BL, Chen LJ, Chen YY, Ou JB, Fang SH. Nicotine supplementation enhances simulated game performance of archery athletes. J Int Soc Sports Nutr. 2021 Feb 18;18(1):16. doi: 10.1186/s12970-021-00413-9. PMID: 33602279; PMCID: PMC7890628.&lt;br /&gt;
***Acknowledgement: Funded by the Taiwan Ministry of Science and Technology (MOST104–2628-H-028-001-MY2).&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5236038/ A Randomised, Placebo-Controlled, Crossover Study Investigating the Effects of Nicotine Gum on Strength, Power and Anaerobic Performance in Nicotine-Naïve, Active Males]===&lt;br /&gt;
*The present study has demonstrated that low-dose (2 mg) nicotine gum increases leg extensor torque, but counter-movement jump and anaerobic capacity during WAnT remained unchanged when compared to a placebo, whilst there were minimal effects of the 4-mg nicotine gum on the performance parameters measured. Together with our previous observation [24], these results indicate that nicotine per se can improve exercise endurance and muscular strength, something that WADA should continue to monitor alongside patterns of (mis)use.&lt;br /&gt;
**Citation: Mündel T, Machal M, Cochrane DJ, Barnes MJ. A Randomised, Placebo-Controlled, Crossover Study Investigating the Effects of Nicotine Gum on Strength, Power and Anaerobic Performance in Nicotine-Naïve, Active Males. Sports Med Open. 2017 Dec;3(1):5. doi: 10.1186/s40798-016-0074-8. Epub 2017 Jan 13. PMID: 28092056; PMCID: PMC5236038.&lt;br /&gt;
***Acknowledgement: This study was funded in part by a grant from the World Anti-Doping Agency.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/expphysiol.2006.033373 Effect of transdermal nicotine administration on exercise endurance in men]=== &lt;br /&gt;
*Nicotine improved exercise endurance by 17 ± 7%, and in the absence of any effect on the usual peripheral markers, such as ventilation, heart rate and blood metabolites, we conclude that nicotine prolongs endurance by a central mechanism that may involve nicotinic receptor activation and/or altered activity of dopaminergic pathways.&lt;br /&gt;
*[https://physoc.onlinelibrary.wiley.com/doi/pdf/10.1113/expphysiol.2006.033373 PDF Version]&lt;br /&gt;
**Citation: Mündel T, Jones DA. Effect of transdermal nicotine administration on exercise endurance in men. Exp Physiol. 2006 Jul;91(4):705-13. doi: 10.1113/expphysiol.2006.033373. Epub 2006 Apr 20. PMID: 16627574.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Eyes - Ocular - Vision&#039;&#039;&#039;=&lt;br /&gt;
==Myopia (short-sighted, near-sighted)==&lt;br /&gt;
===2024 [https://iovs.arvojournals.org/article.aspx?articleid=2800816 Administration of Nicotine Can Inhibit Myopic Growth in Animal Models]===&lt;br /&gt;
*Nicotine, administered as an intravitreal injection or topical eye drop, significantly inhibits the development of experimental myopia.&lt;br /&gt;
**Citation: Thomson K, Karouta C, Ashby R. Administration of Nicotine Can Inhibit Myopic Growth in Animal Models. Invest Ophthalmol Vis Sci. 2024 Sep 3;65(11):29. doi: 10.1167/iovs.65.11.29. PMID: 39292451; PMCID: PMC11412605.&lt;br /&gt;
***Acknowledgement: Funded by ANU Connect Ventures through a Discovery Translation Fund grant (Project ID: DTF311). &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Huntington’s Disease&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2005: [https://pubmed.ncbi.nlm.nih.gov/16140176/ Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington&#039;s disease in rats]===&lt;br /&gt;
*These results clearly showed neuroprotective effect of nicotine in experimental model of HD. The clinical relevance of these findings in HD patients remains unclear and warrants further studies.&lt;br /&gt;
*In conclusion, nicotine significantly and dose-dependently attenuated 3-NP-induced striatal lesions and behavioral deficits in rats. The protective effect of nicotine may be attributed to its ability of restoring striatal DA levels in 3-NP intoxicated rats.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.brainresbull.2005.06.024 PDF Version]&lt;br /&gt;
**Citation: Tariq M, Khan HA, Elfaki I, Al Deeb S, Al Moutaery K. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington&#039;s disease in rats. Brain Res Bull. 2005 Sep 30;67(1-2):161-8. doi: 10.1016/j.brainresbull.2005.06.024. PMID: 16140176.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Hashimoto&#039;s disease (Hashimoto thyroiditis)&#039;&#039;&#039;=&lt;br /&gt;
*[https://www.hopkinsmedicine.org/health/conditions-and-diseases/hashimotos-thyroiditis Hashimoto&#039;s Thyroiditis] &amp;quot;is when your thyroid gland becomes irritated or inflamed. Hashimoto thyroiditis is the most common type of this health problem. It may also be called chronic autoimmune thyroiditis. This thyroiditis is an autoimmune disease. It occurs when your body makes antibodies that attack the cells in your thyroid. The thyroid gland becomes overrun with white blood cells and becomes scarred. This makes the gland feel firm and rubbery. The thyroid then can’t make enough of the thyroid hormone.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2020: [https://www.endocrine-abstracts.org/ea/0070/ea0070oc8.4?_ga=2.114580999.1434360570.1735281186-102848752.1735281184 Cigarette smoking and the risk to develop symptoms of Hashimoto’s thyroiditis]===&lt;br /&gt;
*&amp;quot;In patients who had discontinued smoking at the age of 39 years or more, the diagnosis of HT was predominantly made after the discontinuation of smoking.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2013: [https://onlinelibrary.wiley.com/doi/10.1111/cen.12222 Smoking and thyroid]===&lt;br /&gt;
*&amp;quot;Smoking has distinct associations with thyroid function and size in healthy subjects. It has remarkable and contrasting associations with thyroid function in autoimmune thyroid disease (lower risk of Hashimoto&#039;s disease and higher risk of Graves’ disease) and with thyroid size in nodular disease (lower risk of thyroid carcinoma and higher risk of nontoxic goitre and multinodularity). The observed associations likely indicate causal relationships in view of consistent associations across studies, the presence of a dose–response relationship and disappearance of the associations after cessation of smoking. Which mechanisms mediate the many effects of smoking remains largely obscure. Probably, they differ between the various effects. The divergent effects of smoking on the expression of autoimmune thyroid disease are intriguing and reminiscent on the contrasting effects of smoking on inflammatory bowel disease: protective against ulcerative colitis (OR 0·41, 0·34–0·48) but risky for Crohn&#039;s disease (OR 1·61, 1·27–2·03).&amp;quot;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Hypersensitivity Pneumonitis / Extrinsic Allergic Alveolitis&#039;&#039;&#039; (See Also: Allergies/Hayfever/Histamines)=&lt;br /&gt;
*[https://www.nhlbi.nih.gov/health/hypersensitivity-pneumonitis Hypersensitivity pneumonitis] is a rare immune system disorder that affects the lungs. This disease is also called bird or pigeon fancier’s lung, farmer’s lung, hot tub lung, cheese worker&#039;s lung, Bagassosis, mushroom worker&#039;s lung, malt worker&#039;s lung, or humidifier lung. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/books/NBK499918/ Hypersensitivity pneumonitis] (HP) classified as an interstitial lung disease is characterized by a complex immunological reaction of the lung parenchyma in response to repetitive inhalation of a sensitized allergen.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/books/NBK499918/ Hypersensitivity Pneumonitis]===&lt;br /&gt;
*Cigarette smoking seems to protect from developing clinically significant HP likely due to nicotine inhibiting macrophage activation and lymphocyte proliferation. &lt;br /&gt;
*However, smokers who develop HP have been shown to have a more severe course and higher mortality.&lt;br /&gt;
**Citation: Chandra D, Cherian SV. Hypersensitivity Pneumonitis. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499918/&lt;br /&gt;
&lt;br /&gt;
===2007: [https://academic.oup.com/qjmed/article-abstract/100/4/233/2258683?redirectedFrom=fulltext Extrinsic allergic alveolitis: incidence and mortality in the general population]===&lt;br /&gt;
*We identified 271 incident cases of EAA (mean age at diagnosis 57 years, 51% male). Between 1991 and 2003, the incident rate for EAA was stable at ∼0.9 cases per 100 000 person-years. In comparison to the 1084 general population controls, patients with EAA were less likely to smoke (odds ratio 0.56, 95%CI 0.39–0.81), but had a marked increase in the risk of death (hazard ratio 2.98, 95%CI 2.05–4.33).&lt;br /&gt;
**Citation: M. Solaymani-Dodaran, J. West, C. Smith, R. Hubbard, Extrinsic allergic alveolitis: incidence and mortality in the general population, QJM: An International Journal of Medicine, Volume 100, Issue 4, April 2007, Pages 233–237, https://doi.org/10.1093/qjmed/hcm008&lt;br /&gt;
&lt;br /&gt;
===2002: [https://www.atsjournals.org/doi/10.1164/rccm.200210-1154OC Inhibitory Effect of Nicotine on Experimental Hypersensitivity Pneumonitis In Vivo and In Vitro]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Results of this study show that nicotine reduces the alveolar inflammatory response to S. rectivirgula antigen and affects some AM (stimulated with LPS or S. rectivirgula) functions in vitro. This influence could be, at least in part, responsible for the protection that smokers have against development of HP. Because nicotine is effective in the treatment of ulcerative colitis, it could also be of interest in the treatment of HP and other pulmonary inflammatory diseases.&lt;br /&gt;
**Citation: Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am J Respir Crit Care Med. 2004 Apr 15;169(8):903-9. doi: 10.1164/rccm.200210-1154OC. Epub 2003 Dec 30. PMID: 14701707.&lt;br /&gt;
&lt;br /&gt;
===1992: [https://pubmed.ncbi.nlm.nih.gov/1344064/ Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum]===&lt;br /&gt;
*It was concluded that cigarette smoking had a suppressive effect on the outbreak of SHP, but smoking caused no further suppression after the disease was established.&lt;br /&gt;
**Citation: Arima K, Ando M, Ito K, Sakata T, Yamaguchi T, Araki S, Futatsuka M. Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum. Arch Environ Health. 1992 Jul-Aug;47(4):274-8. doi: 10.1080/00039896.1992.9938361. PMID: 1344064.&lt;br /&gt;
&lt;br /&gt;
===1987: [https://pubmed.ncbi.nlm.nih.gov/3499342/ Prevalence and incidence of chronic bronchitis and farmer&#039;s lung with respect to age, sex, atopy, and smoking]===&lt;br /&gt;
*Farmer&#039;s lung was only slightly more common among atopic than among non-atopic subjects and twice as common among non-smokers as among smokers.&lt;br /&gt;
**Citation: Terho EO, Husman K, Vohlonen I. Prevalence and incidence of chronic bronchitis and farmer&#039;s lung with respect to age, sex, atopy, and smoking. Eur J Respir Dis Suppl. 1987;152:19-28. PMID: 3499342.&lt;br /&gt;
&lt;br /&gt;
===1977: [https://pmc.ncbi.nlm.nih.gov/articles/PMC470791/ Extrinsic allergic alveolitis: a disease commoner in non-smokers.]===&lt;br /&gt;
*In the literature of extrinsic allergic alveolitis non-smokers predominate in those papers in which smoking habits are recorded (Hapke et al., 1968; Schlueter et al., 1969; Schofield et al., 1976). Studies of the prevalence of precipitating antibodies against Micropolyspora faeni in farmers have shown that they are detected significantly more often in non-smokers than in smokers (Morgan et al., 1975).&lt;br /&gt;
**Citation: Warren CP. Extrinsic allergic alveolitis: a disease commoner in non-smokers. Thorax. 1977 Oct;32(5):567-9. doi: 10.1136/thx.32.5.567. PMID: 594937; PMCID: PMC470791.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Inflammation&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871277/  Effect of Nicotine on Immune System Function]===&lt;br /&gt;
*Despite the completely destructive and harmful effects of cigarette smoke, nicotine via stimulation of the α7 receptor can promote the anti-inflammatory benefits on the immune system. However, these effects depend on the concentration, and administration methods are different and sometimes contradictory. It can be used successfully to treat or inhibit autoimmune diseases. Although the exact mechanism of this treatment is unknown, it appears to involve inhibiting downstream intracellular pathways that lead to the secretion of pre-inflammatory cytokines.&lt;br /&gt;
**Citation: Mahmoudzadeh L, Abtahi Froushani SM, Ajami M, Mahmoudzadeh M. Effect of Nicotine on Immune System Function. Adv Pharm Bull. 2023 Jan;13(1):69-78. doi: 10.34172/apb.2023.008. Epub 2022 Jan 4. PMID: 36721811; PMCID: PMC9871277.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://onlinelibrary.wiley.com/doi/10.1111/acer.15103 Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco]===&lt;br /&gt;
*Our findings may indicate that nicotine has anti-inflammatory effects in patients with AUD.&lt;br /&gt;
**Citation: Bolstad I, Lien L, Moe JS, Pandey S, Toft H, Bramness JG. Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco. Alcohol Clin Exp Res (Hoboken). 2023 Jul;47(7):1352-1363. doi: 10.1111/acer.15103. Epub 2023 May 30. PMID: 37208927.&lt;br /&gt;
***Acknowledgement: This work was financially supported by The Research Council of Norway, grant FRIPRO 251140.&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects]===&lt;br /&gt;
*Analysis of several studies - some animal.&lt;br /&gt;
*In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity.&lt;br /&gt;
**Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889&lt;br /&gt;
***Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.mdpi.com/1660-4601/18/2/483/htm Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study]===&lt;br /&gt;
*HSC-2 cell viability was not impaired by nicotine at the concentrations usually observed in smokers; increased expressions of IL-8 and ICAM-1 induced by P. gingivalis LPS or TNF-α were diminished by nicotine treatment. Additionally, an inhibitory effect on β-defensin production was also demonstrated. Apart from being the usually alleged harmful substance, nicotine probably exerted a suppressive effect on inflammatory factors production in HSC-2 cells.&lt;br /&gt;
**Citation: An, N., Holl, J., Wang, X., Rausch, M. A., Andrukhov, O., &amp;amp; Rausch-Fan, X. (2021). Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study. International Journal of Environmental Research and Public Health, 18(2), 483. https://doi.org/10.3390/ijerph18020483&lt;br /&gt;
***Acknowledgement: This research was supported by the grant from Ministry of Science and Technology of China under a contract from the International Science &amp;amp; Technology Cooperation Program Foundation Nr.1019 and the National Natural Science Foundation of China (Grant No. 81500859).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704168/ Does Nicotine Prevent Cytokine Storms in COVID-19?]===&lt;br /&gt;
*Case study of one individual&lt;br /&gt;
*Nicotine, an α7-nACh receptor agonist, may boost the cholinergic anti-inflammatory pathway and hinder the uncontrolled overproduction of pro-inflammatory cytokines triggered by the SARS-CoV-2 virus, which is understood to be the main pathway to poor outcomes and death in severe COVID-19.&lt;br /&gt;
*In the absence of any effective treatment for COVID-19, further research as to whether nicotine replacement offers protection against severe SAR-CoV-2 infection in smokers is clearly essential. If the mechanisms through which nicotine may interact with the virus remain speculative, the effects of route of administration, duration, dosing and frequency of use of nicotine on any such interaction are unknown. Should NRT be found to be of help in the management of COVID-19, it would be yet another strong reason to persuade smokers to switch to NRT and ultimately quit smoking.&lt;br /&gt;
**Citation: Dratcu L, Boland X. Does Nicotine Prevent Cytokine Storms in COVID-19? Cureus. 2020 Oct 28;12(10):e11220. doi: 10.7759/cureus.11220. PMID: 33269148; PMCID: PMC7704168.&lt;br /&gt;
***Acknowledgement: All authors have declared that no financial support was received from any organization for the submitted work.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300218/ Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm]===&lt;br /&gt;
*Abstract: &amp;quot;SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.&amp;quot;&lt;br /&gt;
**Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218.&lt;br /&gt;
***Acknowledgement: This work was supported by University of Castilla-La Mancha Research Programme 2020-GRIN-28705.&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
* This study provides evidence that nicotine alters the infiltration of proinflammatory monocytes and neutrophils into the CNS of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] mice via multiple [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChRs&#039;&#039;&#039;]], including the α7 and α9 subtypes. Nicotine appears to achieve these effects by inhibiting the expression of CCL2 and CXCL2, two cytokines involved in the chemotaxis of proinflammatory monocytes and neutrophils, respectively. The use of ligands that are selective for one or both of these nAChR subtypes may offer a beneficial clinical outcome, and thus provide a valuable therapeutic strategy for neuroinflammatory disorders such as MS.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/pdf/1501613.pdf PDF Version]&lt;br /&gt;
**Citation: Jiang W, St-Pierre S, Roy P, Morley BJ, Hao J, Simard AR. Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis. J Immunol. 2016 Mar 1;196(5):2095-108. doi: 10.4049/jimmunol.1501613. Epub 2016 Jan 25. PMID: 26810225; PMCID: PMC4760232.&lt;br /&gt;
***Acknowledgements: This work was supported by grants from the Multiple Sclerosis Society of Canada (to A.R.S.), the New Brunswick Health Research Foundation (to A.R.S.), the New Brunswick Innovation Foundation (to A.R.S.), the Nebraska Tobacco Settlement Biomedical Research Fund (to B.J.M.), and the National Institutes of Health (Grant R01DC006907 to B.J.M.). Salary support was provided by the Centre de Formation Médicale du Nouveau-Brunswick (to W.J.) and the New Brunswick Innovation Foundation (to S.S-P. and P.R.).&lt;br /&gt;
*See Also - Related article: [https://mssociety.ca/research-news/article/ms-society-funded-study-shows-that-nicotine-reduces-the-invasion-of-harmful-immune-cells-into-the-brain-in-mice-with-an-ms-like-disease MS Society-funded study shows that nicotine reduces the invasion of harmful immune cells into the brain in mice with an MS-like disease]&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila and Chlamydia pneumonia infection...&lt;br /&gt;
**Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/ Novel Therapeutic Approach by Nicotine in Experimental Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Due to the proven therapeutic effect of nicotine on AD (Alzheimer’s Disease) and PD (Parkinson’s Disease), we decided to study the role of nicotine in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] as an animal model of MS. Our treatment group showed less inflammation in histopathological evaluation along with myelin sheet protection. Moreover, prevention group showed less inflammation compared with treatment group. Thus, nicotine might be recommended as a promising drug for [[Special:MyLanguage/Abbreviations|MS]] therapy.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version]&lt;br /&gt;
**Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034.&lt;br /&gt;
***Acknowledgement: No funding was provided for the preparation of this article.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/ Can nicotine use alleviate symptoms of psoriasis?]=== &lt;br /&gt;
*In light of recent data demonstrating that psoriasis is an immune-mediated disease, the possibility that novel anti-inflammatory treatments such as nicotine replacement therapy or analogues could have a beneficial effect on patients with psoriasis should be considered. This case described one such occasion in which it appeared that nicotine had a therapeutic effect on a patient’s psoriasis. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version]&lt;br /&gt;
**Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
**Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
***Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://pubmed.ncbi.nlm.nih.gov/21691078/ Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells]===&lt;br /&gt;
*In summary, we showed that nicotine could suppress TNF-α expression mainly through activation of the α7 nAChR subunit, which inhibited the MyD88/IκBα/NFκB signaling pathway in HBE16 airway epithelial cells. These findings may provide new information on the potential pharmacological effects of nicotine and nAChR in the treatment of respiratory inflammatory diseases. Further research on nicotine and nAChRs may provide more evidence for the treatment of inflammatory diseases and the development of related drugs.&lt;br /&gt;
*[https://www.karger.com/Article/Pdf/329982 PDF Version]&lt;br /&gt;
**Citation: Li, Q., Zhou, X. D., Kolosov, V. P., &amp;amp; Perelman, J. M. (2011). Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 27(5), 605–612. https://doi.org/10.1159/000329982&lt;br /&gt;
***Acknowledgement: This work was supported by the National Natural Science Foundation of China (No.81070031), and China-Russia Cooperation Research Program (81011120108).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.sciencedirect.com/science/article/abs/pii/S0306987711001691?via%3Dihub Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis]===&lt;br /&gt;
*In addition, nicotine or its metabolites can result in decrease of pro-inflammatory cytokines like tumor necrosis factor-α, interleukins 1 and 6, and increase of anti-inflammatory cytokine interleukin-10. Consequently, there is reduced susceptibility to RAS due to immunosuppression and/or reduction in inflammatory response.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2011.04.006 PDF Version]&lt;br /&gt;
**Citation: Subramanyam, R. V. (2011). Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis. Medical Hypotheses, 77(2), 185–187. doi:10.1016/j.mehy.2011.04.006&lt;br /&gt;
&lt;br /&gt;
===2008 [https://onlinelibrary.wiley.com/doi/10.1002/jnr.21901 Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Primary impact to the spinal cord results in stimulation of secondary processes that potentiate the initial trauma. Recent evidence indicates that nicotine can exert potent antioxidant and neuroprotective effects in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;spinal cord injury (SCI)&#039;&#039;&#039;]].&lt;br /&gt;
*The results of the present study indicate that [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;iNOS&#039;&#039;&#039;]] is induced in the early stages of SCI, leading to increased nitration of protein tyrosine residues and potentiation of inflammatory responses. Microglial cells appear to be the main cellular source of iNOS in SCI. In addition, nicotine-induced anti-inflammatory effects in SCI are mediated, at least in part, by the attenuation of iNOS overexpression through the receptor-mediated mechanism. This data may have significant therapeutic implications for the targeting of nicotine receptors in the treatment of compressive spinal cord trauma.&lt;br /&gt;
*[https://sci-hub.st/10.1002/jnr.21901 PDF Version]&lt;br /&gt;
**Citation: Lee, M.‐Y., Chen, L. and Toborek, M. (2009), Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J. Neurosci. Res., 87: 937-947.doi.org/10.1002/jnr.21901&lt;br /&gt;
***Acknowledgement: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693390/ Neuronal Nicotinic Alpha7 Receptors Modulate Inflammatory Cytokine Production in the Skin Following Ultraviolet Radiation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Cytokine responses to UV in mice administered chronic oral nicotine, a nAChR agonist, were reduced... These results demonstrate that nAChRα7 can participate in modulating a local pro-inflammatory response in the absence of parasympathetic innervation.&lt;br /&gt;
**Citation: Osborne-Hereford AV, Rogers SW, Gahring LC. Neuronal nicotinic alpha7 receptors modulate inflammatory cytokine production in the skin following ultraviolet radiation. J Neuroimmunol. 2008 Jan;193(1-2):130-9. doi: 10.1016/j.jneuroim.2007.10.029. PMID: 18077004; PMCID: PMC2693390.&lt;br /&gt;
***Acknowledgement: These studies were funded by NIH grants DA015148 and DA018930 (LCG), PO1 HL72903 (LCG, SWR) and the Browning Foundation of Utah.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1809735/ Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-κB phosphorylation and nuclear factor-κB transcriptional activity through nicotinic acetylcholine receptor α7]===&lt;br /&gt;
*Macrophages/monocytes and the proinflammatory mediators, such as tumour necrosis factor (TNF)-α, prostaglandin E2 (PGE2), macrophage inflammatory protein (MIP)-1α and MIP-1α, play a critical role in the progression of immunological disorders including rheumatoid arthritis, Behçet’s disease and Crohn’s disease. In addition, the nicotinic acetylcholine receptor-α7 (α7nAChR) subunit is an essential regulator of inflammation. In this study, we evaluated the expression of the α7nAChR subunit on human peripheral monocytes and the effect of nicotine on the production of these proinflammatory mediators by activated monocytes.&lt;br /&gt;
*These suppressive effects of nicotine were caused at the transcriptional level and were mediated through α7nAChR. Nicotine suppressed the phosphorylation of I-κB, and then inhibited the transcriptional activity of nuclear factor-κB. These immunosuppressive effects of nicotine may contribute to the regulation of some immune diseases.&lt;br /&gt;
*This supports the therapeutic use of nicotine in some inflammatory diseases; the NF-κB activation pathway is one of the most critical molecular targets of nicotine therapy.&lt;br /&gt;
**Citation: Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. 2006 Oct;146(1):116-23. doi: 10.1111/j.1365-2249.2006.03169.x. PMID: 16968406; PMCID: PMC1809735.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Legionella Pneumophila (Legionnaires&#039; disease)&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection...&lt;br /&gt;
*Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome&#039;&#039;&#039;=&lt;br /&gt;
*See Also: COVID (Long COVID)&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Mental Health&#039;&#039;&#039;=&lt;br /&gt;
*See subcategories below&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Anxiety&#039;&#039;&#039;== &lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Behavior Issues&#039;&#039;&#039;== &lt;br /&gt;
*See Also: ADD/ADHD above&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0028390819305003?via%3Dihub Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies]=== &lt;br /&gt;
*Human and Animal Studies&lt;br /&gt;
*Clinical trials and case series report anti-aggressive effects of nicotine. Here we argue that the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] system, the molecular basis for the global public health problem of tobacco smoking, may also be a key target for modulation of aggressive behaviors. Future research should aim to clarify which forms of aggression are most strongly affected by nAChR modulation, identify the nAChR subtypes, circuits, and neurobiological mechanisms of nicotine action, and determine whether more selective nAChR-active agents can replicate or improve the serenic effects of nicotine, especially with chronic dosing. Given the prevalence of aggressive behaviors across neuropsychiatric disorders affecting the very young to the very old, these studies have the potential to have a significant impact on public health.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.neuropharm.2019.107929 PDF Version]&lt;br /&gt;
*Citation: Alan S. Lewis, Marina R. Picciotto, Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies, Neuropharmacology, Volume 167, 2020, 107929, ISSN 0028-3908, doi: 10.1016/j.neuropharm.2019.107929.&lt;br /&gt;
*Acknowledgements: This work was supported by National Institutes of Health grants MH116339 (A.S.L.), MH077681 and DA14241 (M.R.P.).&lt;br /&gt;
*Keywords: Nicotine, Nicotinic receptor, Aggression, Aggressive behavior, Impulsivity, Acetylcholine&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]=== &lt;br /&gt;
*Taken together, our study provides evidence for the feasibility and tolerability of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine (TN/TNP)&#039;&#039;&#039;]] in a small sample of adults with severe [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Autism Spectrum Disorder (ASD)&#039;&#039;&#039;]] symptoms and pathological chronic aggression and irritability. &lt;br /&gt;
*Our results also suggest that TN may have a beneficial effect on aggression, irritability, and sleep in ASD, though the sample size of this study is too small to make definitive conclusions. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/pdf/nihms-950880.pdf PDF Version]&lt;br /&gt;
*Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.&lt;br /&gt;
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).&lt;br /&gt;
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Depression&#039;&#039;&#039;== &lt;br /&gt;
===2022: [https://onlinelibrary.wiley.com/doi/full/10.1111/add.15950 The relationship between smokeless tobacco (snus) and anxiety and depression among adults and elderly people. A comparison to smoking in the Tromsø Study]===&lt;br /&gt;
*In Norway, current snus users differ from current smokers by having a higher socio-economic status and no detectable association with anxiety and depression. This suggests that the relationship between tobacco use and anxiety and depression is associated with the administration method.&lt;br /&gt;
*Citation: Yebo Yu, Fan Yang, Mingqi Fu, Farooq Ahmed, Muhammad Shahid, Jing Guo, Relationship Between Work-Family Conflict and Depressive Symptoms Among Male Firefighters in China, Journal of Occupational &amp;amp; Environmental Medicine, 10.1097/JOM.0000000000002759, 65, 4, (337-343), (2022).&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.sciencedirect.com/science/article/abs/pii/S0376871621005676 Adolescent depression symptoms and e-cigarette progression]=== &lt;br /&gt;
*Depression symptoms predicted more rapid e-cigarette progression in adolescents.&lt;br /&gt;
*E-cigarette use was not associated with an escalation in depression symptoms.&lt;br /&gt;
*E-cigarette use was not related to the development of depression symptoms over time.&lt;br /&gt;
*Must pay to view PDF&lt;br /&gt;
*Citation: Afaf F. Moustafa, Shannon Testa, Daniel Rodriguez, Stephen Pianin, Janet Audrain-McGovern, Adolescent depression symptoms and e-cigarette progression, Drug and Alcohol Dependence, Volume 228, 2021, 109072, ISSN 0376-8716, doi.org/10.1016/j.drugalcdep.2021.109072.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2000 [https://www.sciencedirect.com/science/article/abs/pii/S0091305700002057 The Effects of Nicotine on Neural Pathways Implicated in Depression: A Factor in Nicotine Addiction?]=== &lt;br /&gt;
*It is postulated that smokers are protected from the consequences of these changes, while they continue to smoke, by the antidepressant properties of nicotine.&lt;br /&gt;
*[https://sci-hub.st/10.1016/S0091-3057(00)00205-7 PDF Version]&lt;br /&gt;
*Citation: Balfour, D. J. ., &amp;amp; Ridley, D. L. (2000). The Effects of Nicotine on Neural Pathways Implicated in Depression. Pharmacology Biochemistry and Behavior, 66(1), 79–85. doi:10.1016/s0091-3057(00)00205-7 &lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.sciencedirect.com/science/article/abs/pii/S0149763417301793 Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression]=== &lt;br /&gt;
*Nicotine improves cognitive performance in clinical and preclinical studies.&lt;br /&gt;
*Nicotine may also benefit depressive symptoms and depressive behavior.&lt;br /&gt;
*Cognitive and mood benefits may be mediated by nicotinic effect on neural networks.&lt;br /&gt;
*Nicotine’s effects on networks may reverse network changes seen in depression.&lt;br /&gt;
*Improvement to mood and cognition may particularly benefit older depressed adults.&lt;br /&gt;
*Both preclinical and clinical studies support that nicotine and other nAChR agonists can improve depressive behavior, mood, and cognitive performance. nAChR agonists also demonstrate neuropharmacologic effects that oppose the intrinsic network alterations reported in MDD. Through modulation of intrinsic functional networks, nAChR agonists may reduce depressive symptoms, enhance emotional regulation ability, and improve cognitive deficits common in LLD. For these reasons, we propose nAChR agonists as a potential novel treatment for the mood and cognitive symptoms of LLD.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.neubiorev.2017.08.018 PDF Version]&lt;br /&gt;
*Citation: Gandelman, J. A., Newhouse, P., &amp;amp; Taylor, W. D. (2018). Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression. Neuroscience &amp;amp; Biobehavioral Reviews, 84, 289–298. doi:10.1016/j.neubiorev.2017.08.0&lt;br /&gt;
*Acknowledgement: Supported by NIH grants K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://pubmed.ncbi.nlm.nih.gov/29795403/ Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder]=== &lt;br /&gt;
*In [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;MDD&#039;&#039;&#039;]], acute nicotine administration normalized both pathways to the level of healthy controls, while having no impact on healthy controls. These results indicate that nicotine normalizes dysfunctional cortico-striatal communication in unmedicated non-smokers with MDD.&lt;br /&gt;
*[https://sci-hub.st/10.1038/s41386-018-0069-x PDF Version]&lt;br /&gt;
*Citation: Janes AC, Zegel M, Ohashi K, Betts J, Molokotos E, Olson D, Moran L, Pizzagalli DA. Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder. Neuropsychopharmacology. 2018 Nov;43(12):2445-2451. doi: 10.1038/s41386-018-0069-x. Epub 2018 Apr 19. PMID: 29795403; PMCID: PMC6180119.&lt;br /&gt;
*Acknoledgements: This project was supported by the National Institute on Drug Abuse grants K10 DA029645 and K02 DA042987 (ACJ). DAP was partially supported by National Institute of Mental Health grant R37 MH068376. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer and Posit Science, for activities unrelated to the current research.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/ Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Non-Smokers with Late-Life Depression]=== &lt;br /&gt;
*[[Special:MyLanguage/Abbreviations|Late &#039;&#039;&#039;Life Depression (LLD)&#039;&#039;&#039;]] is characterized by poor antidepressant response and cognitive dysfunction. Late life depression has no currently approved treatment that improves both its mood and cognitive symptoms.&lt;br /&gt;
*We observed robust response (86.7%) and remission rates (53.3%). There was a significant decrease in MADRS (Montgomery-Asberg Depression Rating scale) over the study, with improvement seen as early as three weeks. We also observed improvement in apathy and rumination. We did not observe improvement on the CPT (Conners Continuous Performance Test), but did observe improvement in subjective cognitive performance and signals of potential drug effects on secondary cognitive measures of working memory, episodic memory, and self-referential emotional processing.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/pdf/nihms965043.pdf PDF Version]&lt;br /&gt;
*Citation: Gandelman JA, Kang H, Antal A, Albert K, Boyd BD, Conley AC, Newhouse P, Taylor WD. Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. J Clin Psychiatry. 2018 Aug 28;79(5):18m12137. doi: 10.4088/JCP.18m12137. PMID: 30192444; PMCID: PMC6129985.&lt;br /&gt;
*Acknowledgements: This research was supported by NIH grant K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. The sponsor provided funding for the study but did not influence the design or conduct of the study.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://pubmed.ncbi.nlm.nih.gov/16977477/ Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial]=== &lt;br /&gt;
*These findings suggest a role for nicotinic receptor systems in the pathophysiology of depression and that nicotinic compounds should be evaluated for treating depression symptoms.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s00213-006-0516-y PDF Version]&lt;br /&gt;
*Citation: McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006 Nov;189(1):125-33. doi: 10.1007/s00213-006-0516-y. Epub 2006 Sep 15. PMID: 16977477.&lt;br /&gt;
*Acknowledgement: This research was supported by a Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression. Dr. Rose is an inventor named on several nicotine patch patents and receives royalties from sales of certain nicotine patches.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/11995405/ Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients]=== &lt;br /&gt;
*Acute administration of nicotine patches produced rapid eye movement sleep (REM) increases in non-smoking major depressed patients as well as clinical improvement in mood. Antidepressant effect was also observed after four continuous days of nicotine administration.&lt;br /&gt;
*Citation: Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin. 2002 Jan-Feb;54(1):36-40. PMID: 11995405.&lt;br /&gt;
&lt;br /&gt;
===1999 [https://link.springer.com/article/10.1007/s002130050879 Antidepressant effects of nicotine in an animal model of depression]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Epidemiological studies indicate a high incidence of cigarette smoking among depressed individuals. Moreover, individuals with a history of depression have a much harder time giving up smoking. It has been postulated that smoking may reflect an attempt at self-medication with nicotine by these individuals.&lt;br /&gt;
*The data strongly implicate the involvement of central nicotinic receptors in the depressive characteristics of the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;FSL&#039;&#039;&#039;]] rats, and suggest that nicotinic agonists may have therapeutic benefits in depressive disorders&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1007/s002130050879 PDF Version]&lt;br /&gt;
*Citation: Tizabi, Y., Overstreet, D., Rezvani, A. et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 142, 193–199 (1999). https://doi.org/10.1007/s002130050879&lt;br /&gt;
*Acknowledgements This work was supported in part by the Department of Pharmacology, Howard University, VAMC and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.&lt;br /&gt;
*Keywords: Key words Nicotine · Nicotinic receptor · FSL and FRL rats · Animal model of depression &lt;br /&gt;
&lt;br /&gt;
===1998 [https://pubmed.ncbi.nlm.nih.gov/9592048/ A novel effect of nicotine on mood and sleep in major depression]=== &lt;br /&gt;
*Transdermal nicotine patches increased REM sleep in normal volunteers and depressed patients during 4 days of continuous administration. In addition, a significant improvement of mood was observed in depressed patients. Nicotinic mechanisms may be involved in depression.  These findings suggest that nicotine receptor activation may be important in major depression and shows for the first time that nicotine patches may be useful in the treatment of depression.&lt;br /&gt;
*[https://sci-hub.st/10.1097/00001756-199801050-00012 PDF Version]&lt;br /&gt;
*Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 1998 Jan 5;9(1):57-60. doi: 10.1097/00001756-199801050-00012. PMID: 9592048.&lt;br /&gt;
*ACKNOWLEDGEMENT: This work has been supported by the following grants: DGAPA-UNAM IN -200895 to R.J.S-P.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9746444/ Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression]=== &lt;br /&gt;
*A high frequency of cigarette smoking has been reported among individuals with major depression.&lt;br /&gt;
*Results of the visual analog scale and [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;HAM-D&#039;&#039;&#039;]] showed a significant improvement in depression after the second day of nicotine patches.&lt;br /&gt;
*Citation: Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996 Sep;57(9):387-9. PMID: 9746444.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://psycnet.apa.org/record/1996-00468-019 Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement.]=== &lt;br /&gt;
*&lt;br /&gt;
*[https://sci-hub.st/10.1037/0022-006X.64.4.791 PDF Version]&lt;br /&gt;
*Citation:&lt;br /&gt;
&lt;br /&gt;
===1995 [https://pubmed.ncbi.nlm.nih.gov/8619011/ Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients]=== &lt;br /&gt;
*The main finding of the present study was that nicotine patches induced an increase in REM sleep time in depressed patients without any other changes in sleep variables&lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02246496 PDF Version]&lt;br /&gt;
*Citation: Salín-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colín R. Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl). 1995 Oct;121(4):476-9. doi: 10.1007/BF02246496. PMID: 8619011.&lt;br /&gt;
*Acknowledgement: This work has been supported in part by FIIRESIN, Fideicomiso-UNAM (to RD-C) and DGAPA-UNAM1N203393 (to RJS-P).&lt;br /&gt;
&lt;br /&gt;
===1993 [https://jamanetwork.com/journals/jamapsychiatry/article-abstract/496026 Nicotine Dependence and Major Depression]=== &lt;br /&gt;
*There is, then, no evidence in these data that the occurrence of MDD in persons with a prior history of nicotine dependence might have been caused directly by recent persistent smoking.&lt;br /&gt;
*[https://sci-hub.st/10.1001/archpsyc.1993.01820130033006 PDF Version]&lt;br /&gt;
*Citation: Breslau N, Kilbey MM, Andreski P. Nicotine Dependence and Major Depression: New Evidence From a Prospective Investigation. Arch Gen Psychiatry. 1993;50(1):31–35. doi:10.1001/archpsyc.1993.01820130033006&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
* When chronically taken, nicotine may result in: (1) positive reinforcement, (2) negative reinforcement (mood normalization) (other issues and diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Mental Illness&#039;&#039;&#039;==&lt;br /&gt;
&lt;br /&gt;
===2022 [https://academic.oup.com/ntr/article-abstract/24/9/1405/6562456 E-Cigarette Provision to Promote Switching in Cigarette Smokers With Serious Mental Illness—A Randomized Trial]===&lt;br /&gt;
*This was the first prospective study to compare e-cigarette provision with assessments only to evaluate the appeal and impact of e-cigarettes on smoking behavior, carbon monoxide exposure, and nicotine dependence among smokers with Severe Mental Illness (SMI) who had tried but were unable to quit and were not currently interested in cessation treatment. The finding that e-cigarette provision led to significant reductions in smoking and carbon monoxide without increasing nicotine dependence has implications for reducing harm not only among the millions of smokers with SMI who struggle to quit, but also for other vulnerable smokers who cannot achieve cessation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - OCD (Obsessive Compulsive Disorder)&#039;&#039;&#039;== &lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/ Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review]=== &lt;br /&gt;
*Nicotine may ameliorate OC symptoms in severe, treatment-refractory [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;OCD&#039;&#039;&#039;]] patients. Although encouraging, these initial positive effects should be tested in large controlled studies.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/pdf/12991_2020_Article_309.pdf PDF Version]&lt;br /&gt;
*Citation: Piacentino D, Maraone A, Roselli V, Berardelli I, Biondi M, Kotzalidis GD, Pasquini M. Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review. Ann Gen Psychiatry. 2020 Sep 30;19:57. doi: 10.1186/s12991-020-00309-z. PMID: 33014119; PMCID: PMC7528475.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - PTSD (Post Traumatic Stress Disorder)&#039;&#039;&#039;== &lt;br /&gt;
===2012 [https://www.hindawi.com/journals/aps/2012/265724/ Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study]=== &lt;br /&gt;
*Smokers with PTSD report greater NA (Negative Affects) immediately prior to smoking and greater decreases in NA following smoking, and these findings are consistent with the observed patterns of brain activation in the current study. Thus, our findings provide a neurobiological basis that helps explain why individuals with PTSD are at greater risk of smoking and also experience greater difficulty quitting. The present study is not without its limitations. Our sample size was small and was predominately represented by female smokers.&lt;br /&gt;
*[https://downloads.hindawi.com/journals/aps/2012/265724.pdf PDF Version]&lt;br /&gt;
*Citation: Froeliger, B., Crowell Beckham, J., Feldman Dennis, M., Victoria Kozink, R., &amp;amp; Joseph McClernon, F. (2012). Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study. Advances in Pharmacological Sciences, 2012, 1–6. doi:10.1155/2012/265724 &lt;br /&gt;
*Acknowledgement: Department of Veterans Affairs or the National Institutes of Health.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Schizophrenia&#039;&#039;&#039;== &lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fpsyt.2022.804055/full Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence]===&lt;br /&gt;
*Nicotine administration normalized DMN hyperconnectivity in schizophrenia. We here provide direct evidence that the biological basis of nicotine dependence is different in schizophrenia and in non-schizophrenia populations. Our results suggest the high prevalence of nicotine use in schizophrenia may be an attempt to correct a network deficit known to interfere with cognition.&lt;br /&gt;
*[https://twitter.com/hbwardMD/status/1487037135299518474 Twitter thread about this study]&lt;br /&gt;
**Citation: Ward HB, Beermann A, Nawaz U, Halko MA, Janes AC, Moran LV and Brady RO Jr (2022) Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence. Front. Psychiatry 13:804055. doi: 10.3389/fpsyt.2022.804055&lt;br /&gt;
***Acknowledgement: This work was supported by NIMH R01MH116170 (RB); NIMH R01MH111868 and NIMH R01MH117063 (MH); NIDA 1K02DA042987 and NIDA K01DA029645 (AJ); NIMH K23MH110564, NARSAD Young Investigator Award, Brain and Behavior Research Foundation, Pope-Hintz Fellowship Award, McLean Hospital, Dupont-Warren Fellowship Award, and Harvard Medical School (LM); and the Sidney R. Baer, Jr. Foundation, and the Norman E. Zinberg Fellowship in Addiction Psychiatry Research, Harvard Medical School (HW).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0149763420305042?via%3Dihub The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review]=== &lt;br /&gt;
*Cognitive and early sensory alterations are core features of [https://en.wikipedia.org/wiki/Schizophrenia &#039;&#039;&#039;schizophrenia&#039;&#039;&#039;]. A single dose of nicotine can improve those features in patients. Attention domain is the most responsive to nicotine in patients. Effects vary upon type of neuropsychological assessment and nicotine intake condition.&lt;br /&gt;
*[https://sci-hub.do/10.1016/j.neubiorev.2020.07.035 PDF Version]&lt;br /&gt;
**Citation: Clément Dondé, Jérôme Brunelin, Marine Mondino, Caroline Cellard, Benjamin Rolland, Frédéric Haesebaert, The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review, Neuroscience &amp;amp; Biobehavioral Reviews, Volume 118, 2020, Pages 121-133, ISSN 0149-7634, doi: 10.1016/j.neubiorev.2020.07.035.&lt;br /&gt;
&lt;br /&gt;
=== 2017: [https://www.nature.com/articles/nm.4274 Nicotine reverses hypofrontality in animal models of addiction and schizophrenia] ===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*“Our study provides compelling biological evidence that a specific genetic variant contributes to risk for schizophrenia, defines the mechanism responsible for the effect and validates that nicotine improves that deficit,” said Jerry Stitzel, a researcher at the Institute for Behavioral Genetics (IBG) and one of four CU Boulder researchers on the study. &lt;br /&gt;
*Previous genome-wide association studies have suggested that people with a variation in a gene called CHRNA5 are more likely to have schizophrenia, but the mechanism for that association has remained unclear. People with that variant are also more likely to smoke.&lt;br /&gt;
**Citation: Fani Koukouli, Marie Rooy, Dimitrios Tziotis, Kurt A Sailor, Heidi C O&#039;Neill, Josien Levenga, Mirko Witte, Michael Nilges, Jean-Pierre Changeux, Charles A Hoeffer, Jerry A Stitzel, Boris S Gutkin, David A DiGregorio  Uwe Maskos Nature Medicine volume 23, pages347–354 (2017)&lt;br /&gt;
&lt;br /&gt;
===2017: [https://pubmed.ncbi.nlm.nih.gov/28441884/ Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging]===&lt;br /&gt;
*This brief review discusses evidence from neurophysiological and neuroimaging studies in schizophrenia patients that nicotinic agonists may effectively target dysfunctional neuronal circuits in the illness. Evidence suggests that nicotine significantly modulates a number of these circuits, although relatively few studies have used modern neuroimaging techniques (e.g. functional magnetic resonance imaging (fMRI)) to examine the effects of nicotinic drugs on disease-related neurobiology. The neuronal effects of nicotine and other nicotinic agonists in schizophrenia remain a priority for psychiatry research.&lt;br /&gt;
**Citation: Smucny J, Tregellas JR. Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging. J Psychopharmacol. 2017 Jul;31(7):801-811. doi: 10.1177/0269881117705071. Epub 2017 Apr 26. PMID: 28441884; PMCID: PMC5963521.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
**Citation: Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2009 [https://pubmed.ncbi.nlm.nih.gov/19328631/ Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications]=== &lt;br /&gt;
*The principal reason for the markedly increased rate of cigarette smoking in people with schizophrenia: tobacco cigarette smoking represents an attempt at self-medication in schizophrenia, because the additional nicotine so provided alleviates the hypofunctional sensory gating seen in this illness.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version]&lt;br /&gt;
**Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631.&lt;br /&gt;
&lt;br /&gt;
===2007: [https://pmc.ncbi.nlm.nih.gov/articles/PMC2702723/ Nicotinic Interactions with Antipsychotic Drugs, Models of Schizophrenia and Impacts on Cognitive Function]===&lt;br /&gt;
*Human and Animal study&lt;br /&gt;
*Nicotinic receptor systems in the brain are important for a variety of aspects of cognitive function impaired in schizophrenia and aggravated by antipsychotic drugs. Nicotine and selective nicotinic α7 and α4β2 agonists can significantly improve learning, memory and attention. Nicotine and nicotine agonists can reduce some of the cognitive impairments caused by some antipsychotic drugs as well as reduce cognitive impairments seen in the NMDA glutamate blockade animal model of schizophrenia.&lt;br /&gt;
**Citation: Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007 Oct 15;74(8):1182-91. doi: 10.1016/j.bcp.2007.07.019. Epub 2007 Jul 20. PMID: 17714691; PMCID: PMC2702723.&lt;br /&gt;
***Acknowledgement: Research presented was supported by a grant from the National Institute of Mental Health grant MH64494.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
**Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Movement Disorders (not diagnosis specific)&#039;&#039;&#039;= &lt;br /&gt;
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/ Role for the nicotinic cholinergic system in movement disorders; therapeutic implications]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Several [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] subtypes appear to be involved in these beneficial effects of nicotine and nAChR drugs including α4β2*, α6β2* and α7 nAChRs (the asterisk indicates the possible presence of other subunits in the receptor). Overall, the above findings, coupled with nicotine&#039;s neuroprotective effects, suggest that nAChR drugs have potential for future drug development for movement disorders.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/pdf/nihms600497.pdf PDF Version]&lt;br /&gt;
*Citation: Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. PMID: 24836728; PMCID: PMC4149916.&lt;br /&gt;
*Acknowledgements: This work was supported by grants NS59910 and NS 65851 from the National Institutes of Health.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Multiple Sclerosis - Humans / Experimental Autoimmune Encephalomyelitis (EAE) - Animals&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
* This study provides evidence that nicotine alters the infiltration of proinflammatory monocytes and neutrophils into the CNS of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] mice via multiple [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChRs&#039;&#039;&#039;]], including the α7 and α9 subtypes. Nicotine appears to achieve these effects by inhibiting the expression of CCL2 and CXCL2, two cytokines involved in the chemotaxis of proinflammatory monocytes and neutrophils, respectively. The use of ligands that are selective for one or both of these nAChR subtypes may offer a beneficial clinical outcome, and thus provide a valuable therapeutic strategy for neuroinflammatory disorders such as MS.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/pdf/1501613.pdf PDF Version]&lt;br /&gt;
**Citation: Jiang W, St-Pierre S, Roy P, Morley BJ, Hao J, Simard AR. Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis. J Immunol. 2016 Mar 1;196(5):2095-108. doi: 10.4049/jimmunol.1501613. Epub 2016 Jan 25. PMID: 26810225; PMCID: PMC4760232.&lt;br /&gt;
***Acknowledgements: This work was supported by grants from the Multiple Sclerosis Society of Canada (to A.R.S.), the New Brunswick Health Research Foundation (to A.R.S.), the New Brunswick Innovation Foundation (to A.R.S.), the Nebraska Tobacco Settlement Biomedical Research Fund (to B.J.M.), and the National Institutes of Health (Grant R01DC006907 to B.J.M.). Salary support was provided by the Centre de Formation Médicale du Nouveau-Brunswick (to W.J.) and the New Brunswick Innovation Foundation (to S.S-P. and P.R.).&lt;br /&gt;
*See Also - Related article: [https://mssociety.ca/research-news/article/ms-society-funded-study-shows-that-nicotine-reduces-the-invasion-of-harmful-immune-cells-into-the-brain-in-mice-with-an-ms-like-disease MS Society-funded study shows that nicotine reduces the invasion of harmful immune cells into the brain in mice with an MS-like disease]&lt;br /&gt;
&lt;br /&gt;
===2015 [https://pubmed.ncbi.nlm.nih.gov/25813705/ Nicotine modulates neurogenesis in the central canal during experimental autoimmune encephalomyelitis]===&lt;br /&gt;
*Amimal study&lt;br /&gt;
*We found that reduction of ependymal cell proliferation correlated with inflammation in the same area, which was relieved by the administration of nicotine. Further, increased numbers of oligodendrocytes (OLs) were observed after nicotine treatment. These findings give a new insight into the mechanism of how nicotine functions to attenuate EAE.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.neuroscience.2015.03.031 PDF Full Study]&lt;br /&gt;
**Citation: Gao Z, Nissen JC, Legakis L, Tsirka SE. Nicotine modulates neurogenesis in the central canal during experimental autoimmune encephalomyelitis. Neuroscience. 2015 Jun 25;297:11-21. doi: 10.1016/j.neuroscience.2015.03.031. Epub 2015 Mar 23. PMID: 25813705; PMCID: PMC4428965.&lt;br /&gt;
***Acknowledgement: The work was supported by NMSS PP1815, NIH R01NS42168, NIH IRACDA K12GM102778.&lt;br /&gt;
&lt;br /&gt;
===2015 [https://pubmed.ncbi.nlm.nih.gov/26209886/ Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients]===&lt;br /&gt;
*The data obtained highlight the role of α7 receptor subtype in the modulation of anti-inflammatory cytokines also in MS. Moreover the ability of nicotine to up-regulate the expression of α7 receptor subtype in RR-MS patients, indicates that nicotinic receptor stimulation may contribute to down-modulate the inflammation occurred in MS by a positive feedback control of its expression.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.intimp.2015.06.034 PDF Full paper]&lt;br /&gt;
**Citation: Reale M, Di Bari M, Di Nicola M, D&#039;Angelo C, De Angelis F, Velluto L, Tata AM. Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients. Int Immunopharmacol. 2015 Nov;29(1):152-7. doi: 10.1016/j.intimp.2015.06.034. Epub 2015 Jul 23. PMID: 26209886.&lt;br /&gt;
***Acknowledgement: This work was supported by FISM – Fondazione Italiana Sclerosi Multipla – Cod. 2013/R/25. MDB was supported by fellowship on FISM project 2013/R/25.&lt;br /&gt;
&lt;br /&gt;
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176721/ The Experimental Autoimmune Encephalomyelitis Disease Course Is Modulated by Nicotine and Other Cigarette Smoke Components]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Our results show that nicotine reduces the severity of EAE, as shown by reduced demyelination, increased body weight, and attenuated microglial activation. Nicotine administration after the development of EAE symptoms prevented further disease exacerbation, suggesting that it might be useful as an [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE/MS&#039;&#039;&#039;]] therapeutic. In contrast, the remaining components of cigarette smoke, delivered as cigarette smoke condensate (CSC), accelerated and increased adverse clinical symptoms during the early stages of EAE.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176721/pdf/pone.0107979.pdf PDF Version]&lt;br /&gt;
**Citation: Gao Z, Nissen JC, Ji K, Tsirka SE. The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS One. 2014 Sep 24;9(9):e107979. doi: 10.1371/journal.pone.0107979. PMID: 25250777; PMCID: PMC4176721.&lt;br /&gt;
***Acknowledgements: This work was supported by National Multiple Sclerosis Society awards CA1044A1 and PP181, National Aeronautics and Space Administration NNA14AB04A and National Institutes of Health R01NS42168 (ST), and National Institutes of Health K12GM102778 to JN.&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/ Novel Therapeutic Approach by Nicotine in Experimental Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Due to the proven therapeutic effect of nicotine on AD (Alzheimer’s Disease) and PD (Parkinson’s Disease), we decided to study the role of nicotine in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] as an animal model of MS. Our treatment group showed less inflammation in histopathological evaluation along with myelin sheet protection. Moreover, prevention group showed less inflammation compared with treatment group. Thus, nicotine might be recommended as a promising drug for [[Special:MyLanguage/Abbreviations|MS]] therapy.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version]&lt;br /&gt;
**Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034.&lt;br /&gt;
***Acknowledgement: No funding was provided for the preparation of this article.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Narcolepsy&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.authorea.com/doi/full/10.22541/au.162126605.51833119 The therapeutic use of medical nicotine in narcolepsy]===&lt;br /&gt;
*PDF: [https://www.researchgate.net/profile/Carolina-Diamandis/publication/351648895_The_therapeutic_use_of_medical_nicotine_in_narcolepsy/links/60aa9cb945851522bc10a4c1/The-therapeutic-use-of-medical-nicotine-in-narcolepsy.pdf The therapeutic use of nicotine in narcolepsy]&lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3311418/ Narcolepsy with Cataplexy Masked by the Use of Nicotine]===&lt;br /&gt;
*&lt;br /&gt;
&lt;br /&gt;
===2010: [https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC2823281/ A Novel Approach to Treating Morning Sleep Inertia in Narcolepsy]===&lt;br /&gt;
*&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Nicotine Used With Other Substances&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/34119664/ Nicotine and modafinil combination protects against the neurotoxicity induced by 3,4-Methylenedioxymethamphetamine in hippocampal neurons of male rats]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*The overall results indicate that nicotine and modafinil co-administration rescued brain from MDMA-induced neurotoxicity. We suggest that nicotine and modafinil combination therapy could be considered as a possible treatment to reduce the neurological disorders induced by MDMA. (Note: AKA ecstasy)&lt;br /&gt;
*Citation: Kowsari G, Mehrabi S, Soleimani Asl S, Pourhamzeh M, Mousavizadeh K, Mehdizadeh M. Nicotine and modafinil combination protects against the neurotoxicity induced by 3,4-Methylenedioxymethamphetamine in hippocampal neurons of male rats. J Chem Neuroanat. 2021 Jun 10;116:101986. doi: 10.1016/j.jchemneu.2021.101986. Epub ahead of print. PMID: 34119664.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Oral / Jaw&#039;&#039;&#039;= &lt;br /&gt;
===2021: [https://www.mdpi.com/1660-4601/18/2/483/htm Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study]===&lt;br /&gt;
*HSC-2 cell viability was not impaired by nicotine at the concentrations usually observed in smokers; increased expressions of IL-8 and ICAM-1 induced by P. gingivalis LPS or TNF-α were diminished by nicotine treatment. Additionally, an inhibitory effect on β-defensin production was also demonstrated. Apart from being the usually alleged harmful substance, nicotine probably exerted a suppressive effect on inflammatory factors production in HSC-2 cells.&lt;br /&gt;
*Acknowledgement: This research was supported by the grant from Ministry of Science and Technology of China under a contract from the International Science &amp;amp; Technology Cooperation Program Foundation Nr.1019 and the National Natural Science Foundation of China (Grant No. 81500859).&lt;br /&gt;
*Citation: An, N., Holl, J., Wang, X., Rausch, M. A., Andrukhov, O., &amp;amp; Rausch-Fan, X. (2021). Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study. International Journal of Environmental Research and Public Health, 18(2), 483. https://doi.org/10.3390/ijerph18020483&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32381373/ Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial]=== &lt;br /&gt;
*The positive findings in the present study in surgeries performed under local anaesthesia are in agreement with data from systematic reviews that have reported the effectiveness of nicotine in the control of postoperative pain following surgery under general anaesthesia.&lt;br /&gt;
*This study establishes a new prevention and treatment modality regarding pain, [https://en.wikipedia.org/wiki/Edema oedema], and [https://en.wikipedia.org/wiki/Trismus trismus] in a versatile, convenient, safe, and effective form, thereby minimizing gastrointestinal and cardiovascular disorders caused by the use of anti-inflammatory drugs in third molar surgeries.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.ijom.2019.08.013 PDF Version]&lt;br /&gt;
*Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373.&lt;br /&gt;
*Acknowledgements: Funding - CAPES, Ministry of Education, Brazil&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444372/ Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program]===&lt;br /&gt;
*The results of this study confirm that chewing the tested nicotine replacement gum as recommended in a ‘real world’ active smoking cessation program produces a statistically significant change in the parameter of whitening as measured by change from baseline versus the negative control (Microtab) following 6 weeks in a smoking cessation programme. The Vita® Shade Guide (the secondary outcome measure) supported the trend of stain improvement. These results support the efficacy of the tested nicotine replacement gum in stain reduction, in arresting the progression of tooth stain and in shade lightening.&lt;br /&gt;
*Acknowledgement: The study was fully funded by McNeil AB who is the manufacturer of the test and control products. It was designed by McNeil AB in consultation with HW and DOM. The study was run, participants recruited, smoking cessation intervention administered and data collected by the team of research staff at the Oral Health Services Research Centre at University College Cork under the leadership of HW with consultant input from DOM. RK carried out the clinical examinations but was blinded to intervention allocation. The data were analysed by McNeil AB with input from HW and DOM. The study was externally monitored by MDS Pharma Services, UK and conducted to ICH GCP standards. The data were interpreted by HW, DOM and RK. The manuscript was drafted by HW with editorial comment from the other authors. HW decided to submit the manuscript for publication.&lt;br /&gt;
*Citation: Whelton H, Kingston R, O&#039;Mullane D, Nilsson F. Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program. BMC Oral Health. 2012 Jun 13;12:13. doi: 10.1186/1472-6831-12-13. PMID: 22695211; PMCID: PMC3444372.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pain / Analgesic&#039;&#039;&#039;= &lt;br /&gt;
===2023: [https://pubmed.ncbi.nlm.nih.gov/37132069/ Effect of perioperative high-dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study]===&lt;br /&gt;
*Perioperative high-dose nicotine replacement therapy may help to relieve postoperative pain among male smoking-abstinent patients undergoing abdominal surgery.&lt;br /&gt;
**Citation: Zhu C, Bi Y, Wei K, Tao K, Hu L, Lu Z. Effect of perioperative high-dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study. Addiction. 2023 Aug;118(8):1579-1585. doi: 10.1111/add.16224. Epub 2023 May 19. PMID: 37132069.&lt;br /&gt;
***Acknowledgement: Shanghai Municipal Science and Technology Commission. Grant Number: 17411960400&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.mdpi.com/1424-8247/16/12/1665 The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis]===&lt;br /&gt;
*Conclusion: These results help to clarify the mixed outcomes of trials and may ultimately inform the treatment of pain. We observed that acute nicotine administration prolonged the laboratory-induced pain threshold and tolerance time and may mildly relieve postoperative pain. In addition, long-term tobacco smoking may have a nociceptive effect on different types of chronic pain. More research is needed to determine the anti-nociceptive effects of nicotine in humans, and to understand the optimal timing, dose, and method of delivery of nicotine.&lt;br /&gt;
**Citation: Luo Y, Yang Y, Schneider C, Balle T. The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2023; 16(12):1665. https://doi.org/10.3390/ph16121665&lt;br /&gt;
***Acknowledgement: This work was funded by the Australian Research Council LP160100560.&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.sciencedirect.com/science/article/abs/pii/S0014299923000298?via%3Dihub Nicotine suppresses central post-stroke pain via facilitation of descending noradrenergic neuron through activation of orexinergic neuron]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine-induced antinociception was inhibited by intrathecal pre-treatment with yohimbine, an α2 adrenergic receptor antagonist. These results indicated that nicotine may suppress BCAO-induced mechanical hypersensitivity through the activation of the descending pain control system via orexin neurons.&lt;br /&gt;
**Citation: Nakamoto, K., Matsuura, W., &amp;amp; Tokuyama, S. (2023). Nicotine suppresses central post-stroke pain via facilitation of descending noradrenergic neuron through activation of orexinergic neuron. European journal of pharmacology, 175518. Advance online publication. https://doi.org/10.1016/j.ejphar.2023.175518&lt;br /&gt;
***Acknowledgement: This work was supported by the Smoking Research Foundation (FP01807092).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32381373/ Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial]=== &lt;br /&gt;
*The positive findings in the present study in surgeries performed under local anaesthesia are in agreement with data from systematic reviews that have reported the effectiveness of nicotine in the control of postoperative pain following surgery under general anaesthesia.&lt;br /&gt;
*This study establishes a new prevention and treatment modality regarding pain, oedema, and trismus in a versatile, convenient, safe, and effective form, thereby minimizing gastrointestinal and cardiovascular disorders caused by the use of anti-inflammatory drugs in third molar surgeries.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.ijom.2019.08.013 PDF Version]&lt;br /&gt;
**Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373.&lt;br /&gt;
***Acknowledgements: Funding - CAPES, Ministry of Education, Brazil&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912401/ Acute Analgesic Effects of Nicotine and Tobacco in Humans: A Meta-Analysis]=== &lt;br /&gt;
*Pain and tobacco smoking are both highly prevalent and comorbid conditions, current smoking has been associated with more severe chronic pain and physical impairment, and acute nicotine-induced analgesia could make smoking more rewarding and harder to give up.&lt;br /&gt;
*Moderation analyses further revealed that acute analgesic effects may be achieved regardless of nicotine delivery method, current smoking status, pain induction modality, study design, or control condition, and that such effects may be more robust among men than women.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912401/pdf/nihms-774195.pdf PDF Version]&lt;br /&gt;
**Citation: Ditre JW, Heckman BW, Zale EL, Kosiba JD, Maisto SA. Acute analgesic effects of nicotine and tobacco in humans: a meta-analysis. Pain. 2016;157(7):1373-1381. doi:10.1097/j.pain.0000000000000572 (viewed Oct 5, 2021)&lt;br /&gt;
***Acknowledgement: This research was supported by NIH Grant Nos. R21DA034285 and R21DA038204 awarded to Joseph W. Ditre, NIH Grant Nos. F31DA033058 and T32DA007288 awarded to Bryan W. Heckman, NIH Grant No. F31DA039628 awarded to Emily L. Zale, and NIH Grant No. 2K05 AA16928 awarded to Stephen A. Maisto.&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.sciencedirect.com/science/article/abs/pii/S0014299913003270?via%3Dihub Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models]=== &lt;br /&gt;
*Nicotine significantly reduced antiviral-dependent alterations of the nociceptive threshold. &lt;br /&gt;
*Moreover, nicotine decreased neuropathic pain induced by repeated intraperitoneal administration of the anticancer agent oxaliplatin (2.4 mg/kg), lowering the hypersensitivity to mechanical and thermal stimuli. &lt;br /&gt;
*Intraperitoneal nicotine administration controls neuropathic pain evoked by traumatic or toxic nervous system alterations. These results support the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] modulation as a possible therapeutic approach to the complex, undertreated chemotherapy-induced neuropathies. &lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.ejphar.2013.04.022 PDF Version]&lt;br /&gt;
**Citation: Lorenzo Di Cesare Mannelli, Matteo Zanardelli, Carla Ghelardini, Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models, European Journal of Pharmacology, Volume 711, Issues 1–3, 2013, Pages 87-94, ISSN 0014-2999, doi: 10.1016/j.ejphar.2013.04.022.&lt;br /&gt;
***Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://journals.lww.com/ejanaesthesiology/Fulltext/2011/08000/Randomised_trial_of_intranasal_nicotine_and.7.aspx Randomised trial of intranasal nicotine and postoperative pain, nausea and vomiting in non-smoking women]=== &lt;br /&gt;
*Intraoperative use of intranasal nicotine has a sustained opioid-sparing effect in non-smoking women undergoing gynaecological procedures and is associated with a higher frequency of nausea. &lt;br /&gt;
*[https://sci-hub.st/10.1097/EJA.0b013e328344d998 PDF Version]&lt;br /&gt;
*Citation: Jankowski, Christopher J.; Weingarten, Toby N.; Martin, David P.; Whalen, Francis X.; Gebhart, John B.; Liedl, Lavonne M.; Danielson, David R.; Nadeau, Ashley M.; Schroeder, Darrell R.; Warner, David O.; Sprung, Juraj Randomised trial of intranasal nicotine and postoperative pain, nausea and vomiting in non-smoking women, European Journal of Anaesthesiology (EJA): August 2011 - Volume 28 - Issue 8 - p 585-591 doi: 10.1097/EJA.0b013e328344d998&lt;br /&gt;
*Acknowledgements: The present work was supported solely by the Department of Anesthesiology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://journals.lww.com/anesthesia-analgesia/Fulltext/2008/09000/Transdermal_Nicotine_for_Analgesia_After_Radical.48.aspx Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy]=== &lt;br /&gt;
*The preoperative application of a 7 mg nicotine patch resulted in a significant reduction in postoperative opioid consumption in nonsmoking men undergoing [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;RRP&#039;&#039;&#039;]] in this study. Its use was generally well tolerated, but the maximum nausea scores were higher in patients who received nicotine.&lt;br /&gt;
*[https://sci-hub.se/10.1213/ane.0b013e31816f2616# PDF Version]&lt;br /&gt;
*Citation: Habib, Ashraf S., MBBCh, MSc, FRCA*; White, William D., MPH*; El Gasim, Magdi A., MD*; Saleh, Gamal, MD*; Polascik, Thomas J., MD†; Moul, Judd W., MD†; Gan, Tong J., MB, FRCA* Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy, Anesthesia &amp;amp; Analgesia: September 2008 - Volume 107 - Issue 3 - p 999-1004 doi: 10.1213/ane.0b013e31816f2616&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12131122/ Isoflurane hyperalgesia is modulated by nicotinic inhibition]=== &lt;br /&gt;
*Animal study&lt;br /&gt;
*Female mice had significant [https://en.wikipedia.org/wiki/Hyperalgesia hyperalgesia] from [https://en.wikipedia.org/wiki/Isoflurane isoflurane]. Nicotine administration prevented isoflurane-induced hyperalgesia without altering the antinociception produced by higher isoflurane concentrations.&lt;br /&gt;
**Citation: Flood P, Sonner JM, Gong D, Coates KM. Isoflurane hyperalgesia is modulated by nicotinic inhibition. Anesthesiology. 2002 Jul;97(1):192-8. doi: 10.1097/00000542-200207000-00027. PMID: 12131122.&lt;br /&gt;
***Acknowledgement: 1P01GM47818/GM/NIGMS NIH HHS/United States, K08GM00695/GM/NIGMS NIH HHS/United States&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Parkinson Disease&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/abs/pii/S0967586824003849 The effect of a nicotine-rich diet with/without redistribution of dietary protein on motor indices in patients with Parkinson&#039;s disease: A randomized clinical trial]===&lt;br /&gt;
*The results of our study indicated that nicotine consumption in an isocaloric diet, while preventing a decrease in anthropometric indices, leads to improvements in motor indices and a reduction in alpha-synuclein levels. Additional and larger controlled trials are required to validate these findings.&lt;br /&gt;
**Citation: Lorvand Amiri H, Hassan Javanbakht M, Mohammad Baghbanian S, Parsaeian M. The effect of a nicotine-rich diet with/without redistribution of dietary protein on motor indices in patients with Parkinson&#039;s disease: A randomized clinical trial. J Clin Neurosci. 2024 Sep 30;129:110845. doi: 10.1016/j.jocn.2024.110845. Epub ahead of print. PMID: 39353253.&lt;br /&gt;
***Acknowledgement: This work was supported by the Tehran University of Medical Sciences. (Project No. 53161).&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://pubmed.ncbi.nlm.nih.gov/38430248/ Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson&#039;s disease] ===&lt;br /&gt;
*Animal study (worms with humanised neurons)&lt;br /&gt;
*This study examines whether nicotine helps transgenic C. elegans PD models. According to numerous studies, nicotine enhances synaptic plasticity and dopaminergic neuronal survival. Upgrades UPS pathways, increases autophagy, and decreases oxidative stress and mitochondrial dysfunction.&lt;br /&gt;
*At 100, 150, and 200 µM nicotine levels, worms showed reduced α-Syn aggregation, repaired DA neurotoxicity after 6-OHDA intoxication, increased lifetime, and reduced lipofuscin accumulation. Furthermore, nicotine triggered autophagy and UPS. &lt;br /&gt;
*We revealed nicotine&#039;s potential as a UPS and autophagy activator to prevent PD and other neurodegenerative diseases.&lt;br /&gt;
*&#039;&#039;Note: highly technical brain biochemistry, appears to be important however (ed.)&#039;&#039; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586504/ Paper on the UPS and it&#039;s purpose] for info.&lt;br /&gt;
**Citation: Ullah I, Uddin S, Zhao L, Wang X, Li H. Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson&#039;s disease. Exp Brain Res. 2024 Apr;242(4):971-986. doi: 10.1007/s00221-023-06765-9. Epub 2024 Mar 2. PMID: 38430248.&lt;br /&gt;
***Acknowledgement: This study was supported by the Special International Cooperation Project of the Ministry of Science and Technology (2012DFA30480); National Natural Science Foundation of China (No. 81403145); Natural Science Foundation of Gansu Province (No. 20JR10RA602); Fundamental Research Funds for the Central Universities of China (lzujbky—2017-206, lzujbky-2018-136); Science and Technology Cooperation Program of Gansu Academy of Sciences (grant number 2019HZ-02); Program of Lanzhou Science and Technology Foundation (Grant number 2010-1-154). Major science and technology project of Gansu province (23ZDFA013), Natural Science Foundation of Gansu province (20JR10RA602).&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://www.frontiersin.org/articles/10.3389/fnagi.2023.1223310/full Changes in smoking, alcohol consumption, and the risk of Parkinson’s disease] ===&lt;br /&gt;
*A total of 3,931,741 patients were included.&lt;br /&gt;
*Compared to the sustained non-smokers, sustained light smokers, sustained moderate smokers, and sustained heavy smokers had a lower risk of PD. &lt;br /&gt;
*Compared to those who sustained non-drinking, sustained light drinkers, sustained moderate drinkers, and sustained heavy drinkers showed decreased risk of PD. &lt;br /&gt;
*Among non-drinkers, those who started drinking to a light level were at decreased risk of PD. Among non-smoking and non-drinking participants, those who initiated smoking only, drinking only, and both smoking and drinking showed decreased risk of PD.&lt;br /&gt;
*Smoking is associated with decreased risk of PD with a dose–response relationship. Alcohol consumption at a light level may also be associated with decreased risk of PD. Further studies are warranted to find the possible mechanisms for the protective effects of smoking and drinking on PD, which may present insights into the etiology of PD.&lt;br /&gt;
**Citation: Jung SY, Chun S, Cho EB, Han K, Yoo J, Yeo Y, Yoo JE, Jeong SM, Min JH, Shin DW. Changes in smoking, alcohol consumption, and the risk of Parkinson&#039;s disease. Front Aging Neurosci. 2023 Sep 13;15:1223310. doi: 10.3389/fnagi.2023.1223310. PMID: 37771519; PMCID: PMC10525683.&lt;br /&gt;
***Acknowledgement: J-HM received a grant from the National Research Foundation of Korea and SMC Research and Development Grant. J-HM has lectured, consulted, and received Honoria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Sanofi Genzyme, Teva-Handok, UCB, Samsung Bioepis, Mitsubishi Tanabe Pharma, and Roche.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36817162/ Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson&#039;s disease.] ===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine (Nic) has previously been proven to reduce neurodegeneration in the models of Parkinson&#039;s disease (PD). The present study is intended to investigate the detailed mechanisms related to the potential neuroprotective effects of Nic in vivo.&lt;br /&gt;
*In summary, Nic pretreatment ameliorates MPTP-induced dyskinesia and anxiety-like behavior in mice with PD. Nic was found to alleviate neuroapoptosis by improving nigrostriatal dopaminergic damage, reducing the accumulation of pathological p-α-syn, and inhibiting microglia activation and pro-inflammatory factor expression in the substantia nigra and striatal regions of mice brain under MPTP stimulation. These neuroprotective effects of Nic may be achieved by modulating the JNK and ERK signaling pathways in the nigrostriatal system, which was further confirmed by the pretreatment of 5-MOP to decline the brain metabolic activity of Nic.&lt;br /&gt;
**Citation: Ruan S, Xie J, Wang L, Guo L, Li Y, Fan W, Ji R, Gong Z, Xu Y, Mao J, Xie J. Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson&#039;s disease. Front Pharmacol. 2023 Feb 2;14:1088957. doi: 10.3389/fphar.2023.1088957. PMID: 36817162; PMCID: PMC9932206.&lt;br /&gt;
***Acknowledgement: This study received funding from the National Science Foundation of China (Grant No. 32072344, 82101506, 32272455), the Scientific and Technological Project of Henan Province of China (Grant No. 182102310157) and the Scientific and Technological Project of China Tobacco Jiangsu Industrial Co., Ltd. (No. H202002). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Authors JX, RJ, and ZG were employed by China Tobacco Jiangsu Industrial Co., Ltd.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://jamanetwork.com/journals/jamaneurology/article-abstract/2805037 Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune]===&lt;br /&gt;
*“Parkinson disease risk was substantially lower among Black veterans and EVER-SMOKERS (OR 0.49, 95% CI: 0.40-0.61).&lt;br /&gt;
**Citation: Goldman SM, Weaver FM, Stroupe KT, Cao L, Gonzalez B, Colletta K, Brown EG, Tanner CM. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. JAMA Neurol. 2023 Jul 1;80(7):673-681. doi: 10.1001/jamaneurol.2023.1168. PMID: 37184848; PMCID: PMC10186205.&lt;br /&gt;
***Acknowledgement: This research was supported by clinical science research and development merit award I01 CX002040-01 from the US Department of Veterans Affairs. Support for Veterans Administration (VA)/Centers for Medicare &amp;amp; Medicaid Services data was from the US Department of Veterans Affairs, VA Health Services Research and Development Service, and project numbers SDR 02-237 and 98-004 from the VA Information Resource Center. Dr Weaver reported receiving grants from the Edward Hines, Jr VA Hospital during the conduct of the study and outside the submitted work. Dr Brown reported receiving grants from the Michael J. Fox Foundation and the National Institute on Aging and personal fees from Gateway Consulting, LLC, outside the submitted work. Dr Tanner reported receiving personal fees from Lundbeck Pharma, CNS Ratings, Adamas, Cadent, and Evidera; serving on advisory boards for Kyowa Kirin, Acorda, Australia Parkinson’s Mission; serving on a clinical trial steering committee for Jazz Pharmaceuticals/Cavion; and receiving grants from the National Institutes of Health, Biogen Idec, Parkinson Foundation, Michael J. Fox Foundation, Department of Defense Parkinson’s Research Program, Roche, Genentech, BioElectron, and Gateway Institute for Brain Research, LLC, outside the submitted work. No other disclosures were reported.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602090/ Butyrate Protects and Synergizes with Nicotine against Iron- and Manganese-induced Toxicities in Cell Culture]===&lt;br /&gt;
*Preprint, not peer-reviewed.&lt;br /&gt;
*In summary, our results not only support neuroprotective effects of nicotine and butyrate in countering Fe and Mn toxicities but indicate a synergistic protection by combination of the two. Moreover, distinct mechanisms of action for each metal, i.e., nicotinic receptor for nicotine and FA3R for butyrate are indicated. Further exploitation of mechanisms of action of butyrate and nicotine may provide novel targets for metal toxicities and/or amelioration of neurodegenerative diseases.&lt;br /&gt;
**Citation: Tizabi Y, Getachew B, Aschner M. Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases. Res Sq [Preprint]. 2023 Oct 5:rs.3.rs-3389904. doi: 10.21203/rs.3.rs-3389904/v1. Update in: Neurotox Res. 2023 Dec 14;42(1):3. doi: 10.1007/s12640-023-00682-z. PMID: 37886507; PMCID: PMC10602090.&lt;br /&gt;
***Acknowledgement: Supported in part by: NIH/NIAAA R03 AA022479 and NIH/NIGMS (2 SO6 GM08016‐39) (YT), and NIEHS R01ES10563 and R01ES07331 (MA).&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.nature.com/articles/s41598-021-88910-4 Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels]===&lt;br /&gt;
*Insect study&lt;br /&gt;
*In conclusion our data show that the PD model by expression of Sph-1 in dopaminergic neurons provides a good opportunity to study the early prodromal stages of PD, while also the late onset symptoms such as neurodegeneration and motor impairment in aged animals. On the other hand, working on this animal model has allowed us to advance on the therapeutic effects of nicotine treatment over several PD-linked features. The protective effect of nicotine appears to be specific for the genotype predisposed to develop a parkinsonian phenotype and provide a hint on the idea that nicotine treatment even in later stages of the disease could be beneficial to patients. Our findings provide new ideas that contribute to a better understanding on the mechanisms underlying the positive effects of nicotine in PD.&lt;br /&gt;
**Citation: Carvajal-Oliveros, A., Domínguez-Baleón, C., Zárate, R.V. et al. Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Sci Rep 11, 9579 (2021). https://doi.org/10.1038/s41598-021-88910-4&lt;br /&gt;
***Acknowledgement: This work was supported by the CONACyT (Grant Number 255478) and by DGAPA-PAPIIT (Grant Number IN206517).&lt;br /&gt;
&lt;br /&gt;
=== 2020: [https://n.neurology.org/content/94/20/e2132 Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors] === &lt;br /&gt;
*In contrast to previous suggestions, the present report demonstrates a causally protective effect of current smoking on the risk of PD, which may provide insights into the etiology of PD.&lt;br /&gt;
**Citation: Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, Peto R. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology. 2020 May 19;94(20):e2132-e2138. doi: 10.1212/WNL.0000000000009437. Epub 2020 May 5. PMID: 32371450; PMCID: PMC7526668.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://academic.oup.com/ajcn/advance-article-abstract/doi/10.1093/ajcn/nqaa186/5876214?redirectedFrom=fulltext Dietary nicotine intake and risk of Parkinson disease: a prospective study]=== &lt;br /&gt;
*At 26 year follow-up, women with greater dietary nicotine intake had a lower risk of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Parkinson Disease (PD)&#039;&#039;&#039;]] than those with lower intake. Dietary nicotine intake was calculated based on consumption of peppers, tomatoes, processed tomatoes, potatoes, and tea. &lt;br /&gt;
*[https://sci-hub.st/10.1093/ajcn/nqaa186 PDF Version]&lt;br /&gt;
**Citation: Chaoran Ma, Samantha Molsberry, Yanping Li, Michael Schwarzschild, Alberto Ascherio, Xiang Gao, Dietary nicotine intake and risk of Parkinson disease: a prospective study, The American Journal of Clinical Nutrition, Volume 112, Issue 4, October 2020, Pages 1080–1087, doi: 10.1093/ajcn/nqaa186&lt;br /&gt;
***Acknowledgements: Supported by National Institute of Neurological Disorders and Stroke at the NIH grant 1R03NS093245-01A1 (to XG). The Nurses’ Health Study is supported by the NIH through grant UM1 CA186107. The Health Professionals Follow-up Study cohort is supported by the NIH through grant U01 CA167552.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-018-0625-y Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*The reduced prevalence of Parkinson’s disease in tobacco users is a fascinating phenomenon that is not understood. This study suggests a mechanistic explanation for how tobacco users are protected from Parkinson’s and how the tobacco component nicotine confers neuroprotection; more specifically, nicotine suppresses SIRT6 which confers resistance to neuron and cell death. Few effective treatments exist that prevent neuron death for those suffering from Parkinson’s and other neurodegenerative disorders. The identification of SIRT6 as potentially pathogenic and as a therapeutic target for suppression opens a novel line of research for the treatment of neurodegeneration.&lt;br /&gt;
**Citation: Nicholatos, J.W., Francisco, A.B., Bender, C.A. et al. Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6. acta neuropathol commun 6, 120 (2018). https://doi.org/10.1186/s40478-018-0625-y&lt;br /&gt;
***Acknowledgement: S.L. and J.W.N. were in part supported by a grant from American Federation for Aging Research (AFAR, grant # 2015–030). S.L. received seed grant funding from the Cornell University Center for Vertebrate Genomics. J.W.N. was supported by a Glenn/AFAR Scholarship for Research in the Biology of Aging.&lt;br /&gt;
&lt;br /&gt;
===2017 [https://academic.oup.com/ije/article/46/3/872/2656164 Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease]===&lt;br /&gt;
*Non-smoking men who used snus had a 60% lower risk of Parkinson’s disease compared with never snus users.&lt;br /&gt;
**Citation: Yang F, Pedersen NL, Ye W, Liu Z, Norberg M, Forsgren L, Trolle Lagerros Y, Bellocco R, Alfredsson L, Knutsson A, Jansson JH, Wennberg P, Galanti MR, Lager ACJ, Araghi M, Lundberg M, Magnusson C, Wirdefeldt K. Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease. Int J Epidemiol. 2017 Jun 1;46(3):872-880. doi: 10.1093/ije/dyw294. PMID: 27940486.&lt;br /&gt;
***Acknowledgement: This work was supported by the Swedish Research Council (grant number 521-2013-2488 to N.L.P.) and the regional agreement on medical training and clinical research between Stockholm County Council and Karolinska Institutet (Y.T.L.).&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
**Author/Acknowledgements: Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2046219/ Nicotinic receptors as CNS targets for Parkinson’s disease]=== &lt;br /&gt;
*Human and animal references&lt;br /&gt;
*Analyzes results showing that chronic nicotine treatment improved striatal integrity and function.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2046219/pdf/nihms32016.pdf PDF Version]&lt;br /&gt;
**Citation: Quik M, Bordia T, O&#039;Leary K. Nicotinic receptors as CNS targets for Parkinson&#039;s disease. Biochem Pharmacol. 2007 Oct 15;74(8):1224-34. doi: 10.1016/j.bcp.2007.06.015. Epub 2007 Jun 17. PMID: 17631864; PMCID: PMC2046219.&lt;br /&gt;
***Acknowledgements: This work was supported by NIH grants NS42091 and NS47162.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*Nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Parkinson&#039;s Disease&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against &#039;&#039;&#039;Parkinson&#039;s Disease&#039;&#039;&#039; (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pemphigus Vulgaris&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2001: [https://pubmed.ncbi.nlm.nih.gov/11737449/ Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire]===&lt;br /&gt;
*The risk for pemphigus vulgaris was lower for ex-smokers and current smokers than for patients who had never smoked.&lt;br /&gt;
*The beneficial effect of smoking on pemphigus might be explained by its effect on the immune system. &lt;br /&gt;
**Citation: Brenner S, Tur E, Shapiro J, Ruocco V, D&#039;Avino M, Ruocco E, Tsankov N, Vassileva S, Drenovska K, Brezoev P, Barnadas MA, Gonzalez MJ, Anhalt G, Nousari H, Ramos-e-Silva M, Pinto KT, Miranda MF. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol. 2001 Sep;40(9):562-9. doi: 10.1046/j.1365-4362.2001.01266.x. Erratum in: Int J Dermatol. 2003 Sep;42(9):760. Silva MR [corrected to Ramos-e-Silva M]. PMID: 11737449.&lt;br /&gt;
&lt;br /&gt;
===2000: [https://jamanetwork.com/journals/jamadermatology/fullarticle/189739 A Case of Pemphigus Vulgaris Improved by Cigarette Smoking]===&lt;br /&gt;
*The patient reported an inverse relationship between smoking and pemphigus flares. He observed a worsening of the pemphigus when he stopped smoking. Nicotine patches were prescribed, but he began smoking cigarettes again instead. On average, he smokes 15 cigarettes per day. One week after he began smoking again, his pemphigus rapidly started to clear.&lt;br /&gt;
**Citation: Mehta JN, Martin AG. A case of pemphigus vulgaris improved by cigarette smoking. Arch Dermatol. 2000 Jan;136(1):15-7. doi: 10.1001/archderm.136.1.15. PMID: 10632179.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Psoriasis&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/ Can nicotine use alleviate symptoms of psoriasis?]=== &lt;br /&gt;
*In light of recent data demonstrating that psoriasis is an immune-mediated disease, the possibility that novel anti-inflammatory treatments such as nicotine replacement therapy or analogues could have a beneficial effect on patients with psoriasis should be considered. This case described one such occasion in which it appeared that nicotine had a therapeutic effect on a patient’s psoriasis. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version]&lt;br /&gt;
**Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pyoderma Gangrenosum&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15204166/ Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream]=== &lt;br /&gt;
*Two patients with pyoderma gangrenosum treated with topical nicotine 0.5% w/w cetamacrogol formula A cream are described here, both of whom had dramatic clinical resolution of their pyoderma gangrenosum.&lt;br /&gt;
*[https://scihubtw.tw/10.1080/09546630310019364 PDF Version]&lt;br /&gt;
**Citations:Patel GK, Rhodes JR, Evans B, Holt PJ. Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream. J Dermatolog Treat. 2004 Apr;15(2):122-5. doi: 10.1080/09546630310019364. PMID: 15204166.&lt;br /&gt;
&lt;br /&gt;
===1998 [https://jamanetwork.com/journals/jamadermatology/fullarticle/189304?fbclid=IwAR33gpEktRMf2Q0v5Btl9C5E8gmXw-ZP8_gDFt6sebxUBpXE_WfVt-o-mSw Nicotine for Pyoderma Gangrenosum]=== &lt;br /&gt;
*Herein we describe a patient with pyoderma gangrenosum who responded twice to topical nicotine within 4 weeks and 3 months, respectively, without any adverse effects.&lt;br /&gt;
*[https://scholar.google.com/scholar_url?url=https://jamanetwork.com/journals/jamadermatology/articlepdf/189304/dce8005.pdf&amp;amp;hl=en&amp;amp;sa=T&amp;amp;oi=ucasa&amp;amp;ct=ufr&amp;amp;ei=Z2aqX4SnOc2rywTPj5aYDw&amp;amp;scisig=AAGBfm1pz6ffl3a23G__I3APgBLpY6Cofw PDF Version]&lt;br /&gt;
**Citation: Wolf R, Ruocco V. Nicotine for Pyoderma Gangrenosum. Arch Dermatol. 1998;134(9):1071–1072. doi:10.1001/archderm.134.9.1071&lt;br /&gt;
&lt;br /&gt;
===1995 [https://pubmed.ncbi.nlm.nih.gov/8537562/ Successful treatment of pyoderma gangrenosum with nicotine chewing gum]=== &lt;br /&gt;
*We used nicotine chewing gum for the treatment of pyoderma gangrenosum with remarkable results. We strongly suggest that nicotine chewing gum may not only be beneficial in treating pyoderma gangrenosum but may also be useful in treating other skin disorders with prominent neutrophilic infiltrations such as Behcet&#039;s disease, Sweet disease, allergic vasculitis, and recurrent oral aphthae, the last of which is known to respond to smoking.&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1346-8138.1995.tb03904.x PDF Version]&lt;br /&gt;
**Citation: Kanekura T, Kanzaki T. Successful treatment of pyoderma gangrenosum with nicotine chewing gum. J Dermatol. 1995 Sep;22(9):704-5. doi: 10.1111/j.1346-8138.1995.tb03904.x. PMID: 8537562.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sarcoidosis&#039;&#039;&#039;= &lt;br /&gt;
===2021 [https://journal.chestnet.org/article/S0012-3692(21)01282-4/fulltext Promise of Nicotine as a Treatment for Pulmonary Sarcoidosis]=== &lt;br /&gt;
===2021 [https://journal.chestnet.org/article/S0012-3692(21)00962-4/fulltext A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis]===&lt;br /&gt;
*Nicotine treatment was well tolerated in patients with active pulmonary sarcoidosis, and the preliminary findings of this pilot study suggest that it may reduce disease progression, based on FVC.&lt;br /&gt;
**Citation: A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis, Crouser, Elliott D. et al. CHEST, Volume 160, Issue 4, 1340 - 1349&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journal.chestnet.org/article/S0012-3692(13)60095-1/fulltext Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis]=== &lt;br /&gt;
*The immune phenotype of patients with symptomatic [[wikipedia:Sarcoidosis|&#039;&#039;&#039;sarcoidosis&#039;&#039;&#039;]] treated with nicotine closely resembled that of asymptomatic patients, supporting the notion that nicotine treatment may be beneficial in this patient population.&lt;br /&gt;
*[https://www.researchgate.net/profile/Mark_Julian/publication/230645268_Nicotine_Treatment_Improves_TLR2_and_TLR9_Responsiveness_in_Active_Pulmonary_Sarcoidosis/links/556ca4af08aeab77722318be/Nicotine-Treatment-Improves-TLR2-and-TLR9-Responsiveness-in-Active-Pulmonary-Sarcoidosis.pdf PDF Version]&lt;br /&gt;
**Citation: Mark W. Julian, MS; Guohong Shao, MD; Larry S. Schlesinger, MD; Qin Huang, MD; David G. Cosmar, BA; Nitin Y. Bhatt, MD; Daniel A. Culver, MD, FCCP; Robert P. Baughman, MD, FCCP; Karen L. Wood, MD, FCCP; and Elliott D. Crouser, MD - ORIGINAL RESEARCH DIFFUSE LUNG DISEASE| VOLUME 143, ISSUE 2, P461-470, FEBRUARY 01, 2013, DOI 10.1378/chest.12-0383&lt;br /&gt;
***Acknowledgements: This work was supported by the American Thoracic Society and the Foundation for Sarcoidosis Research. © 2013 American College of Chest Physicians&lt;br /&gt;
&lt;br /&gt;
===1988:[https://thorax.bmj.com/content/43/7/516.abstract Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.]===&lt;br /&gt;
*These finding support the possibility that smokers, particularly those with a prominent accumulation of alveolar macrophages in the lower respiratory tract, may be less likely to develop sarcoidosis.&lt;br /&gt;
**Citation: Valeyre D, Soler P, Clerici C, et alSmoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.Thorax 1988;43:516-524.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Seizures / Epilepsy&#039;&#039;&#039;=&lt;br /&gt;
*See also:&lt;br /&gt;
**Video: News 5: [https://www.youtube.com/watch?v=Ztvf45coKZk Nicotine Stops Seizures]&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.neurology.org/doi/10.1212/WNL.0000000000209790/ Pearls &amp;amp; Oy-sters: Exquisite Response of Sleep-Related Hypermotor Epilepsy to a Nicotine Patch]===&lt;br /&gt;
*&amp;quot;Sleep-related hypermotor epilepsy (SHE), previously known as nocturnal frontal lobe epilepsy, is characterized by brief (&amp;lt;2 minutes) seizures with abrupt onset and offset and stereotyped focal or generalized hypermotor events occurring predominantly (but not exclusively) from sleep.&amp;quot;&lt;br /&gt;
*&amp;quot;Our case highlights that there may be mechanisms by which nicotine assists with seizure cessation in specific populations of individuals with SHE.&amp;quot;&lt;br /&gt;
**Citation: Nam S, Von Stein EL, Meador KJ, Levy RJ, Gallentine W, Li Y. Pearls &amp;amp; Oy-sters: Exquisite Response of Sleep-Related Hypermotor Epilepsy to a Nicotine Patch. Neurology. 2024 Oct 8;103(7):e209790. doi: 10.1212/WNL.0000000000209790. Epub 2024 Sep 9. PMID: 39250747; PMCID: PMC11385953.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/34763266/ Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients]=== &lt;br /&gt;
*This is the hitherto largest observational study supporting a favorable effect of nicotine in this specific seizure disorder. Better seizure control from transdermal nicotine compared to only day-time consumption suggests benefit from exposure throughout the night. According to current clinical experience, patients with uncontrolled ADSHE harboring relevant mutations should be offered precision treatment with transdermal nicotine.&lt;br /&gt;
**Citation: Brodtkorb E, Myren-Svelstad S, Knudsen-Baas KM, Nakken KO, Spigset O. Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients. Epilepsy Res. 2021 Oct 25;178:106792. doi: 10.1016/j.eplepsyres.2021.106792. Epub ahead of print. PMID: 34763266.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.pedneur.com/article/S0887-8994(21)00147-8/fulltext Nicotine patch improved autosomal dominant sleep-related hypermotor epilepsy]=== &lt;br /&gt;
*Nevertheless, the two siblings reported here add to the small number of pediatric case reports regarding the successful use of nicotine patches in ADSHE.&lt;br /&gt;
*Journal Pre-Proof [https://www.pedneur.com/action/showPdf?pii=S0887-8994%2821%2900147-8 PDF Version]&lt;br /&gt;
**Citation: Nguyen SM, Deering L, Nelson GT, McDaniel SS, Nicotine patch improved autosomal dominant sleep-related hypermotor epilepsy, Pediatric Neurology (2021), doi:10.1016/j.pediatrneurol.2021.07.006.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/33284031/ Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]===&lt;br /&gt;
*&amp;quot;Genetic variants of the neuronal nicotinic acetylcholine receptor (nAChR) cause autosomal dominant sleep-related hypermotor epilepsy. Approximately 30% of autosomal dominant sleep-related hypermotor epilepsy patients are medically intractable.&amp;quot;&lt;br /&gt;
*&amp;quot;Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants. We propose consideration of transdermal nicotine treatment in intractable epilepsy with known nAChR variants as an experimental therapy.&amp;quot;&lt;br /&gt;
**Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/33284031/ Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]===&lt;br /&gt;
*&amp;quot;Four patients were prescribed nicotine patches for intractable seizures. Three of 4 patients had a clinical response, with &amp;gt;50% seizure reduction.&amp;quot;&lt;br /&gt;
*&amp;quot;Conclusions: Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants.&amp;quot;&lt;br /&gt;
**Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32097883/  Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy]===&lt;br /&gt;
*&amp;quot;Results: A striking seizure reduction was reported soon after treatment onset. Hypermotor seizures disappeared; only sporadic arousals, sometimes with minor motor elements, were observed. Psychometric testing documented improvement in cognitive domains such as visuospatial ability, processing speed, memory, and some areas of executive functions.&amp;quot;&lt;br /&gt;
**Citation: Lossius K, de Saint Martin A, Myren-Svelstad S, Bjørnvold M, Minken G, Seegmuller C, Valenti Hirsch MP, Chelly J, Steinlein O, Picard F, Brodtkorb E. Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy. Epilepsy Behav. 2020 Apr;105:106944. doi: 10.1016/j.yebeh.2020.106944. Epub 2020 Feb 22. PMID: 32097883.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.dovepress.com/sleep-related-hypermotor-epilepsy-prevalence-impact-and-management-str-peer-reviewed-fulltext-article-NSS Sleep-related hypermotor epilepsy: prevalence, impact and management strategies]===&lt;br /&gt;
*&amp;quot;Seizure frequency improved in a single patient with refractory ADSHE after nicotine transdermal patches treatment.(108) The favorable effect of nicotine on seizure frequency was also described in 9 of 22 patients from two European ADSHE families carrying CHRNA4 mutations.(109) Considering the role of the cholinergic system in arousal regulatory processes, these observations suggested a possible link between nicotine defect, alteration of arousal regulation and seizures in SHE/ADSHE patients. However, despite the reported positive effect of nicotine in reducing seizure frequency, a case–control family study, did not find a higher tendency to smoke tobacco in SHE patients and their relatives compared with the control cases.(110)&lt;br /&gt;
**Citation: Menghi V, Bisulli F, Tinuper P, Nobili L. Sleep-related hypermotor epilepsy: prevalence, impact and management strategies. Nat Sci Sleep. 2018 Oct 10;10:317-326. doi: 10.2147/NSS.S152624. PMID: 30349413; PMCID: PMC6186898.&lt;br /&gt;
&lt;br /&gt;
===2015 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433466/ Pearls &amp;amp; Oy-sters: A case of refractory nocturnal seizures]===&lt;br /&gt;
*&amp;quot;Due to frequent seizures, there was a paucity of slow-wave sleep and complete absence of REM sleep. On the second day of her hospital admission, a 7-mg nicotine patch was applied about 2–3 hours before bedtime. There was almost complete resolution of clinical and electrical events. The duration of slow-wave sleep increased and REM sleep was recorded. The next morning, the patient felt refreshed and less anxious.&amp;quot;&lt;br /&gt;
**Citation: Pavlakis PP, Douglass LM. Pearls &amp;amp; Oysters: A case of refractory nocturnal seizures: Putting out fires without smoke. Neurology. 2015 May 5;84(18):e134-6. doi: 10.1212/WNL.0000000000001539. PMID: 25941204; PMCID: PMC4433466.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2012.03715.x Resolution of epileptic encephalopathy following treatment with transdermal nicotine]=== &lt;br /&gt;
*We report resolution of an epileptic encephalopathy by administration of transdermal nicotine patches in an adolescent with severe nonlesional refractory frontal lobe epilepsy. The 18.5‐year‐old female patient had refractory epilepsy from the age of 11. Recurrent electroencephalography (EEG) recordings showed mostly generalized activity, albeit with right frontal predominance. Almost all antiepileptic medications failed to provide benefit. She developed an encephalopathic state with cognitive decline. The nonlesional frontal lobe epilepsy and a family history of a cousin with nocturnal epilepsy with frontal origin suggested genetic etiology. Transdermal nicotine patches brought complete resolution of the seizures, normalization of the EEG, and a significant improvement in her thinking process and speech organization. Sequencing of the CHRNB2 and CHRNA4 genes did not detect a mutation. Transdermal nicotine patches should be considered in severe pharmacoresistant frontal lobe epilepsy.&lt;br /&gt;
*[https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2012.03715.x PDF Version]&lt;br /&gt;
**Citation: Zerem, A., Nishri, D., Yosef, Y., Blumkin, L., Lev, D., Leshinsky‐Silver, E., Kivity, S. and Lerman‐Sagie, T. (2013), Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia, 54: e13-e15. doi: 10.1111/j.1528-1167.2012.03715.x&lt;br /&gt;
&lt;br /&gt;
===2006 [https://pubmed.ncbi.nlm.nih.gov/16931165/ Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy]===&lt;br /&gt;
*&amp;quot;This study indicates that nicotine consumption is an environmental factor that, in many patients with ADNFLE, may influence susceptibility to seizures. A detailed account of tobacco habits should be part of the history. Transdermal nicotine should be considered in pharmacoresistant cases.&amp;quot;&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.yebeh.2006.07.008 PDF Full study]&lt;br /&gt;
**Citation: Brodtkorb E, Picard F. Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy. Epilepsy Behav. 2006 Nov;9(3):515-20. doi: 10.1016/j.yebeh.2006.07.008. Epub 2006 Aug 22. PMID: 16931165.&lt;br /&gt;
&lt;br /&gt;
===2003 [https://onlinelibrary.wiley.com/doi/full/10.1046/j.1528-1157.2003.58102.x-i1?sid=nlm%3Apubmed Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study]=== &lt;br /&gt;
*In this individual with refractory [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ADNFLE&#039;&#039;&#039;]], nicotine had a therapeutic effect on seizures, and it may be useful to others with this disorder.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1046/j.1528-1157.2003.58102.x-i1 PDF Version]&lt;br /&gt;
**Citation: Willoughby, J.O., Pope, K.J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study. Epilepsia, 44: 1238-1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sepsis/Septic/endotoxemia/infection&#039;&#039;&#039;=&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/pii/S0014488624002723 Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these findings indicate that acute nicotine exposure enhances functional stroke recovery. Future studies will have to evaluate the effects of (1) chronic nicotine exposure, a clinically relevant vascular risk factor, and (2) the cessation of nicotine exposure, which is widely recommended post-stroke, but might have detrimental effects in the early stroke recovery phase.&lt;br /&gt;
**Citation: Abbaspour S, Fahanik-Babaei J, Adeli S, Hermann DM, Sardari M. Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state. Exp Neurol. 2024 Sep 13;382:114946. doi: 10.1016/j.expneurol.2024.114946. Epub ahead of print. PMID: 39278587.&lt;br /&gt;
***Funding: None&lt;br /&gt;
&lt;br /&gt;
===2014 [https://academic.oup.com/jid/article/209/10/1668/855517#78932729 Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*In conclusion, stimulation of α7nAChR by nicotine improves mortality rates and MODS during sepsis. This protective effect of nicotine can be associated with the inhibition of TLR4 overexpression through the PI3K/Akt signaling pathway. Although the therapeutic potential of nicotine is still limited by its nonspecific effects, this study may provide an impetus for further development of therapeutic strategies for modifying the cholinergic antiinflammatory pathway in the treatment of various inflammatory diseases.&lt;br /&gt;
**Citation: Kim TH, Kim SJ, Lee SM. Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation. J Infect Dis. 2014 May 15;209(10):1668-77. doi: 10.1093/infdis/jit669. Epub 2013 Dec 1. Erratum in: J Infect Dis. 2015 Mar 1;211(5):851. doi: 10.1093/infdis/jiu824. PMID: 24298024.&lt;br /&gt;
***Acknowledgement: This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Information and Communication Technologies (ICT) and Future Planning (NRF-2013R1A1A3008145).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://pubmed.ncbi.nlm.nih.gov/20805763/ Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*The results suggested that both carbachol and nicotine play a role in the anti-inflammatory process and organ function protection through the α7 subunit of nicotinic cholinergic receptor.&lt;br /&gt;
*[https://sci-hub.st/10.1097/TA.0b013e3181e9732d PDF Full Paper]&lt;br /&gt;
**Citation: Zhou G, Hu S, Lv Y, Song Q, Zou X, Sheng Z. Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide. J Trauma. 2011 Jul;71(1):157-62. doi: 10.1097/TA.0b013e3181e9732d. PMID: 20805763.&lt;br /&gt;
***Acknowledgement: From the Laboratory of Shock and Organ Dysfunction (G.Z., S.H., Y.L., Q.S., X.Z., Z.S.), Burn Institute, the First Hospital Affiliated to the People’s Liberation Army General Hospital, Beijing, China.&lt;br /&gt;
&lt;br /&gt;
===2005 [https://academic.oup.com/jid/article/191/12/2138/842542 The Cholinergic Anti-Inflammatory Pathway Regulates the Host Response during Septic Peritonitis]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*&amp;quot;Initial cytokine release during septic peritonitis was enhanced after previous vagotomy and was decreased after nicotine pretreatment, independently of the integrity of the vagus nerve. Further study established that vagotomy before septic peritonitis resulted in an enhanced influx of neutrophils and a marked increase in proinflammatory cytokine levels and liver damage. Conversely, nicotine pretreatment strongly decreased cell influx, proinflammatory cytokine levels, and liver damage, whereas bacterial clearance and survival were impaired.&amp;quot;&lt;br /&gt;
**Citation: van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, van der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis. 2005 Jun 15;191(12):2138-48. doi: 10.1086/430323. Epub 2005 May 10. PMID: 15898001.&lt;br /&gt;
***Acknowledgement: Financial support: Academic Medical Center, Amsterdam, The Netherlands. Potential conflicts of interest: K.J.T. is cofounder of Critical Therapeutics Inc., a pharmaceutical company developing potential future treatment modalities based on the cholinergic anti-inflammatory pathway.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sleep Apnea&#039;&#039;&#039;= &lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against sleep apnea (other diseases / issues mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1985: [https://pubmed.ncbi.nlm.nih.gov/3965253/ Nicotine: a different approach to treatment of obstructive sleep apnea]===&lt;br /&gt;
*Reduced upper airway muscle activity may contribute to the occurrence of obstructive apneas during sleep. There is no uniformly successful treatment of these apneas, and it is possible that agents which increase upper airway muscle activity could reduce the occurrence of obstruction during sleep. Nicotine, a known stimulant of breathing, also increases the activity of muscles which dilate the upper airway proportionally more than it does ventilation. Hence, we evaluated the effect of nicotine on apneas during the first two hours of sleep in eight patients with sleep apnea syndrome. It was concluded that nicotine reduces apneas during the early hours of sleep, and this effect may be caused by its stimulating action on upper airway muscles.&lt;br /&gt;
*[https://sci-hub.se/10.1378/chest.87.1.11 PDF Version]&lt;br /&gt;
**Citation: Gothe B, Strohl KP, Levin S, Cherniack NS. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest. 1985 Jan;87(1):11-7. doi: 10.1378/chest.87.1.11. PMID: 3965253.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Smoking Cessation / Preventing Relapse&#039;&#039;&#039;= &lt;br /&gt;
===Resource Doc: [https://docs.google.com/document/d/13-D2q1P0KpmZuoFBkKV4l9wUEQ-zcHfp6MAVJGoAaG4/edit?usp=sharing INNCO - Myth of the month:  Ecigs and snus don’t help smokers quit]=== &lt;br /&gt;
*Links and conclusions of studies formatted to fit the character limits on Twitter&lt;br /&gt;
&lt;br /&gt;
===[https://safernicotine.wiki/mediawiki/index.php/Myth:_Alternative_nicotine_products_don%27t_help_people_stop_smoking Myth: Alternative nicotine products don&#039;t help people stop smoking]=== &lt;br /&gt;
*This wiki page shows over 70 studies demonstrating these products help people stop smoking.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Spinal Cord Injury&#039;&#039;&#039;= &lt;br /&gt;
===2008 [https://onlinelibrary.wiley.com/doi/10.1002/jnr.21901 Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Primary impact to the spinal cord results in stimulation of secondary processes that potentiate the initial trauma. Recent evidence indicates that nicotine can exert potent antioxidant and neuroprotective effects in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;spinal cord injury (SCI)&#039;&#039;&#039;]].&lt;br /&gt;
*The results of the present study indicate that [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;iNOS&#039;&#039;&#039;]] is induced in the early stages of SCI, leading to increased nitration of protein tyrosine residues and potentiation of inflammatory responses. Microglial cells appear to be the main cellular source of iNOS in SCI. In addition, nicotine-induced anti-inflammatory effects in SCI are mediated, at least in part, by the attenuation of iNOS overexpression through the receptor-mediated mechanism. This data may have significant therapeutic implications for the targeting of nicotine receptors in the treatment of compressive spinal cord trauma.&lt;br /&gt;
*[https://sci-hub.st/10.1002/jnr.21901 PDF Version]&lt;br /&gt;
*Citation: Lee, M.‐Y., Chen, L. and Toborek, M. (2009), Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J. Neurosci. Res., 87: 937-947.doi.org/10.1002/jnr.21901&lt;br /&gt;
*Acknowledgements: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation.&lt;br /&gt;
*Key words: spinal cord injury; nicotine; neuronal nicotinic receptors; oxidative stress; inflammatory responses; nitric oxide synthase&lt;br /&gt;
&lt;br /&gt;
= Stroke =&lt;br /&gt;
&lt;br /&gt;
=== 2025: &#039;&#039;&#039;[https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntaf034/8005730?redirectedFrom=fulltext&amp;amp;login=false The protective effect of low-dose nicotine on ischemia stroke by maintaining the integrity of the blood-brain barrier]&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
* Animal study (mice)&lt;br /&gt;
* These results demonstrate that nicotine treatment could alleviates the IS-compromised integrity of BBB by regulating the Wnt signal pathway through α7 nAChR.&lt;br /&gt;
* The study demonstrates that nicotine at low concentrations exerts neuro-protective effects by supporting the integrity of BBB and subsequent endothelial viability after ischemic stroke.&lt;br /&gt;
* Qianqian Pang, Xinyang Yan, Zheng Chen, Liang Yun, Jiang Qian, Zeyi Dong, Miao Wang, Wei Deng, Yao Fu, Tao Hai, Zhichao Chen, Xianfang Rong: Nicotine &amp;amp; Tobacco Research, ntaf034, &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntaf034&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Tourette&#039;s Syndrome&#039;&#039;&#039;= &lt;br /&gt;
===2012 [https://pubmed.ncbi.nlm.nih.gov/22776623/ Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette&#039;s, depression, and beyond]=== &lt;br /&gt;
* The article presents a mini-review of studies on TS and depression over the past 25 years.&lt;br /&gt;
* It summarizes the studies on the behavioral biology of the basal ganglia and its neurotransmitters.&lt;br /&gt;
* It describes research with TS patients to evaluate the therapeutics of nicotine and mecamylamine.&lt;br /&gt;
* [https://sci-hub.se/10.1016/j.physbeh.2012.06.023 PDF Version]&lt;br /&gt;
*Citation: Sanberg, P. R., Vindrola-Padros, C., &amp;amp; Shytle, R. D. (2012). Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette’s, depression, and beyond. Physiology &amp;amp; Behavior, 107(5), 801–808. doi:10.1016/j.physbeh.2012.06.023 &lt;br /&gt;
*Acknowledgement: Paul R. Sanberg and R. Douglas Shytle are inventors on patents related to technology described herein and licensed from the University of South Florida to Targacept, Inc. Because of the historical nature of this article, the authors included a number of self-citations required for a chronological discussion. &lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15132126/ Clinical and attentional effects of acute nicotine treatment in Tourette&#039;s syndrome]=== &lt;br /&gt;
*In the 14 evaluable patients with complete primary efficacy data, nicotine (compared to placebo) failed to alter symptoms at 4 hours, but counteracted [https://en.wikipedia.org/wiki/P300_(neuroscience) ERP-P300] signs of diminished attention seen 2 weeks following placebo treatment. &lt;br /&gt;
*Secondary efficacy measures, including patient self-reports and parental ratings, found nicotine to reduce complex tics and improve behaviors related to inattention.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.eurpsy.2003.11.002 PDF Version ]&lt;br /&gt;
*Citation: Howson, A. L., Batth, S., Ilivitsky, V., Boisjoli, A., Jaworski, M., Mahoney, C., &amp;amp; Knott, V. J. (2004). Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome. European Psychiatry, 19(2), 102–112. doi:10.1016/j.eurpsy.2003.11.002 &lt;br /&gt;
*Acknowledgement: This study was supported with a grant from the Tourette Syndrome Association (USA), and patient recruitment was aided by the Ottawa chapter of the Tourette Syndrome Foundation of Canada. &lt;br /&gt;
&lt;br /&gt;
===2001 [https://pubmed.ncbi.nlm.nih.gov/11681767/ Transdermal nicotine and haloperidol in Tourette&#039;s disorder: a double-blind placebo-controlled study]=== &lt;br /&gt;
*[[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Transdermal nicotine (TNP)&#039;&#039;&#039;]] was superior to placebo in reducing behavioral symptoms when patients were receiving an optimal dose of haloperidol, when the dose of haloperidol was reduced by 50%, and when the patch had been discontinued for 2 weeks. These findings confirm earlier open-label findings and suggest that combining nicotinic receptor modulation and neuroleptics could be a therapeutic option for the treatment of Tourette&#039;s disorder &lt;br /&gt;
*[https://www.researchgate.net/profile/Paul_Sanberg/publication/11670769_Transdermal_Nicotine_and_Haloperidol_in_Tourette&#039;s_Disorder/links/5be32624299bf1124fc2d86a/Transdermal-Nicotine-and-Haloperidol-in-Tourettes-Disorder.pdf PDF Version]&lt;br /&gt;
*Citation: Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette&#039;s disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep;62(9):707-14. doi: 10.4088/jcp.v62n0908. PMID: 11681767.&lt;br /&gt;
&lt;br /&gt;
===1997 [https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994 Nicotine for the treatment of Tourette&#039;s syndrome]=== &lt;br /&gt;
*Within 24 hr of the application of a single 7-mg [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TNP (nicotine patch)&#039;&#039;&#039;]], the severity and frequency of tic symptoms is significantly decreased over baseline. This response is rapid, often reaching its maximum in the first 3 hr after application of a single patch. The duration of therapeutic effect of a single 7-mg TNP is variable and may last for about l-2 weeks.&lt;br /&gt;
*Application of a 7-mg TNP to children and adolescents with [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TS&#039;&#039;&#039;]] appears to be clinically safe, with transient side effects. However, no child under 8 years of age and weighing less than 25 kg was considered for TNP treatment.&lt;br /&gt;
*[https://sci-hub.st/https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994?via%3Dihub PDF Version]&lt;br /&gt;
*Citation: Paul R. Sanberg, Archie A. Silver, R.Doug Shytle, Mary Katherine Philipp, David W. Cahill, Harold M. Fogelson, Brian J. McConville, Nicotine for the treatment of Tourette&#039;s syndrome, Pharmacology &amp;amp; Therapeutics, Volume 74, Issue 1, 1997, Pages 21-25, ISSN 0163-7258, doi.org/10.1016/S0163-7258(96)00199-4.&lt;br /&gt;
* Acknowledgements-This review was supported, in part, by grants from the Tourette Syndrome Association, The National Institute of Neurological Disease and Stroke (ROl NS 32067sOlAl) and the Smokeless Tobacco Research Council.&lt;br /&gt;
*Keywords: Nicotine; Tourette&#039;s syndrome; tics; neuropsychiatric disorders&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Gilles de la Tourette’s syndrome (TS)&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
=== 1996 [https://pubmed.ncbi.nlm.nih.gov/8973070/ Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette&#039;s syndrome]=== &lt;br /&gt;
* Sixteen Tourette&#039;s syndrome patients, aged 9 to 15 years, whose symptoms were not controlled with neuroleptics, were followed for various lengths of time after the application of one 7 mg [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine patch (TNP)&#039;&#039;&#039;]] for 24 hours. While there was a broad range in individual response, application of the TNP produced significant reductions in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Yale Global Tic Severity Scale (YGTSS)&#039;&#039;&#039;]] scores relative to baseline, with an average duration of effect lasting between 1 and 2 weeks. Side effects, for the most part, were transient.&lt;br /&gt;
*Eleven patients had greater percentage changes after the second TNP than after the first TNP&lt;br /&gt;
*[https://sci-hub.st/10.1097/00004583-199612000-00015 PDF Version]&lt;br /&gt;
*Citation: Silver AA, Shytle RD, Philipp MK, Sanberg PR. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette&#039;s syndrome. J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1631-6. doi: 10.1097/00004583-199612000-00015. PMID: 8973070.&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1643197/ The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette&#039;s disorder]=== &lt;br /&gt;
*In this study, nicotine markedly potentiated haloperidol effects in treating [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TD&#039;&#039;&#039;]], and showed lesser effects on TD when used alone.&lt;br /&gt;
*[https://sci-hub.st/10.1016/0006-3223(92)90315-q PDF Version]&lt;br /&gt;
* Citation: McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette&#039;s disorder. Biol Psychiatry. 1992 Apr 15;31(8):832-40. doi: 10.1016/0006-3223(92)90315-q. PMID: 1643197.&lt;br /&gt;
*Acknowledgements: Supported in part by grants from the Smokeless Tobacco Research Council, Inc., the Tourette Syndrome Association, and Merrell Dow Pharmaceuticals. The authors thank Roger Stuebing, B.S.M.E., M.S.I.E., and Sunny Y. Lu, M.D., Ph.D. for statistical advice and Merrell Dow Pharmaceuticals for supplying both Nicoreue® gum and placebo nicotine gum.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against Tourette&#039;s disease (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1989 [https://www.sciencedirect.com/science/article/abs/pii/002432058990444X?via%3Dihub Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders]=== &lt;br /&gt;
*Chewing nicotine gum produced striking relief from tics and other symptoms of Tourette syndrome not controlled by neuroleptic treatment alone. It appears that the use of nicotine or cannabinoids may greatly improve the clinical response to neuroleptics in motor disorders.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/0024-3205(89)90444-X PDF Version]&lt;br /&gt;
*Citation: D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman, Paul R. Sanberg, Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders, Life Sciences, Volume 44, Issue 21, 1989, Pages 1521-1525, ISSN 0024-3205, doi.org/10.1016/0024-3205(89)90444-X.&lt;br /&gt;
*Acknowledgements: Supported in part by NIMH (RR 08012) and NIDA. Levonantradol and fluphenazine HCL were generous gifts from Pfizer Pharmaceuticals (Groton, Conn.) and E.R. Squibb and Sons (Princeton, N.J.), respectively.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Weight Loss / Appetite Control / Metabolism / Obesity&#039;&#039;&#039;= &lt;br /&gt;
===2024 Article [https://web.archive.org/web/20241204102835/https://tobaccoreporter.com/2024/12/03/slim-chances/ Harm reduction, smoking cessation and weight]====&lt;br /&gt;
*&amp;quot;Nicotine influences eating and weight in multiple ways, from hormones to microbiomes to taste perceptions. The bottom line: Nicotine raises the metabolic rate while also depressing appetite.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Nicotine, the principal addictive constituent of tobacco, has been shown to suppress appetite and attenuates obesity in many studies, but the underlying mechanism is not clear. &lt;br /&gt;
*Low-grade inflammation is a key feature of obesity and links obesity to insulin resistance, impaired glucose tolerance and even diabetes.&lt;br /&gt;
*Overall, these findings suggest that nicotine and specific α7nAChR agonists may be beneficial in the prevention and treatment of obesity-induced inflammation and insulin resistance. However, there is also evidence that heavy smoking affects body fat distribution that is associated with central obesity and insulin resistance. Moreover, smoking appears to aggravate insulin resistance in persons with type 2 diabetes and to impair glycemic control.&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
*Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
*Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
* When chronically taken, nicotine may result in reduction of body weight&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Suggested additions to this page&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2025: [https://pubmed.ncbi.nlm.nih.gov/39921606/ The protective effect of low-dose nicotine on ischemia stroke by maintaining the integrity of the blood-brain barrier]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://www.sciencedirect.com/science/article/abs/pii/S0303720724003022?via%3Dihub Nicotine increases hepatocyte transthyretin turnover: a possible mechanism for the protective effect of smoking on preeclampsia?]===&lt;br /&gt;
&lt;br /&gt;
===2011: [https://onlinelibrary.wiley.com/doi/10.1002/hipo.20806 Acute nicotine treatment prevents rem sleep deprivation-induced learning and memory impairment in rat]===&lt;br /&gt;
&lt;br /&gt;
===2017: [https://onlinelibrary.wiley.com/doi/10.1002/brb3.704 Nicotine-prevented learning and memory impairment in REM sleep-deprived rat is modulated by DREAM protein in the hippocampus]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://pubmed.ncbi.nlm.nih.gov/39719676/ Effect of Nicotine Replacement Therapy on Perioperative Pain Management and Opioid Requirement in Abstinent Tobacco Smokers Undergoing Spinal Fusion: A Double-blind Randomized Controlled Trial]===&lt;br /&gt;
&lt;br /&gt;
===2012: [https://pmc.ncbi.nlm.nih.gov/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1427314/full The double-edged nature of nicotine: toxicities and therapeutic potentials]===&lt;br /&gt;
&lt;br /&gt;
===2023: [https://drive.google.com/file/d/1ofdbKWq6rIBxI8vQAzjV8z-TYoacrqKB/view Electronic Cigarettes: an Overlooked Tool to Alleviate Disparities in Tobacco Use Disorder Among People with Mental Health and Substance Use Disorders]===&lt;br /&gt;
&lt;br /&gt;
===2023: [https://pubmed.ncbi.nlm.nih.gov/36947193/ Analgesic potential of transdermal nicotine patch in surgery: a systematic review and meta-analysis of randomised placebo-controlled trials]===&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36857384/ Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.] ===&lt;br /&gt;
&lt;br /&gt;
* Information on how nicotine is protective, technical. &lt;br /&gt;
* These results indicate that both the serotonergic and dopaminergic systems contribute to different aspects of PD symptomatology and that nicotine has beneficial effects on specific symptoms.&lt;br /&gt;
* Carvajal-Oliveros A, Dominguez-Baleón C, Sánchez-Díaz I, Zambrano-Tipan D, Hernández-Vargas R, Campusano JM, Narváez-Padilla V, Reynaud E. PLoS One. 2023 Mar 1;18 PMID: 36857384&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.sciencedirect.com/science/article/pii/S027869152300039X?via%3Dihub Tobacco heating system has less impact on bone metabolism than cigarette smoke]===&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849855/ Effect of nicotine on cholesterol gallstone formation in C57BL/6J mice fed on a lithogenic diet]===&lt;br /&gt;
&lt;br /&gt;
=== The following articles address the possible transmission of the SARS CoV 2 virus (and other pathogens) through vaping exhalations. We show that the latter are extremely weak transmission vehicles. ===&lt;br /&gt;
&lt;br /&gt;
* 2022: [https://link.springer.com/article/10.1007/s11356-022-20499-1 Analytic modeling and risk assessment of aerial transmission of SARS-CoV-2 virus through vaping expirations in shared micro-environments]&lt;br /&gt;
* 2021: [https://doi.org/10.3390/ijerph18041437 Aerial transmission of the SARS-CoV-2 virus through environmental e-cigarette aerosol: implications for public policies.]&lt;br /&gt;
* 2021: [http://doi.org/10.3390/app11146355 Modeling Aerial Transmission of Pathogens (Including the SARS-CoV-2 Virus) through Aerosol Emissions from E-Cigarettes.] &lt;br /&gt;
&lt;br /&gt;
=== 2022: [https://assets.researchsquare.com/files/rs-1062121/v1/fb8f5195-4cce-470f-9e09-e752fae3c931.pdf?c=1642705044 Part One: Abuse Liability of Vuse Solo Relative To Combustible Cigarettes And Nicotine Gum] ===&lt;br /&gt;
&lt;br /&gt;
=== 2014: [https://link.springer.com/chapter/10.1007/978-1-4939-1167-7_20 Nicotinic Receptors and Mental Illness] ===&lt;br /&gt;
&lt;br /&gt;
===2021: [https://pubmed.ncbi.nlm.nih.gov/34757527/ Meta-Analysis on Nicotine&#039;s Modulation of HIV-Associated Dementia]=== &lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
*Animal&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.sciencedirect.com/science/article/abs/pii/S1001841721007804 Real-time effects of nicotine exposure and withdrawal on neurotransmitter metabolism of hippocampal neuronal cells by microfluidic chip-coupled LC-MS]===&lt;br /&gt;
*mouse study&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006219.pub4/full Interventions for preventing weight gain after smoking cessation]===&lt;br /&gt;
*There was moderate‐certainty that NRT reduced weight at end of treatment and moderate‐certainty that the effect may be similar at 12 months, although the estimates are too imprecise to assess long‐term benefit.&lt;br /&gt;
&lt;br /&gt;
===2004: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
&lt;br /&gt;
* Yet few of the horrendous health effects of smoking are traceable to nicotine itself—cigarettes contain nearly 4,000 other compounds that play a role. Until recently, nicotine research has been driven primarily by nicotine&#039;s unparalleled power to keep people smoking, rather than its potential therapeutic uses.&lt;br /&gt;
* There&#039;s a cheap, common, and mostly safe drug, in daily use for centuries by hundreds of millions of people, that only lately has been investigated for its therapeutic potential for a long list of common ills. The list includes Alzheimer disease, Parkinson disease, depression and anxiety, schizophrenia, attention deficit hyperactivity disorder (ADHD), and even pain and obesity.&lt;br /&gt;
* People with depressive-spectrum disorders, schizophrenia, and adult ADHD tend to smoke heavily, which suggested to researchers that nicotine may soothe their symptoms. Common to all these disorders is a failure of attention, an inability to concentrate on particular stimuli and screen out the rest. Nicotine helps.&lt;br /&gt;
* Researchers at the National Institute on Drug Abuse have shown via functional magnetic resonance imaging that nicotine activates specific brain areas during tasks that demand attention&lt;br /&gt;
* Powledge TM (2004) Nicotine as Therapy. PLoS Biol 2(11): e404. &amp;lt;nowiki&amp;gt;https://doi.org/10.1371/journal.pbio.0020404&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]===&lt;br /&gt;
&lt;br /&gt;
===2001: [https://today.duke.edu/2001/08/mm_medicaluses.html Medical Uses for Nicotine]===&lt;br /&gt;
&lt;br /&gt;
===2021: [https://pubmed.ncbi.nlm.nih.gov/33675460/ Nicotine gum enhances visual processing in healthy nonsmokers]===&lt;br /&gt;
&lt;br /&gt;
===[https://www.researchgate.net/publication/325159226_Resolution_of_chronic_rhinitis_to_staphylococcus_aureus_in_a_non-smoker_who_started_to_use_glycerine_based_e-cigarettes_Antibacterial_effects_of_vaping Resolution of chronic rhinitis to staphylococcus aureus in a non-smoker who started to use glycerine based e-cigarettes: Antibacterial effects of vaping?]=== &lt;br /&gt;
&lt;br /&gt;
===2019: [https://medium.com/parkinsons-uk/protecting-brain-cells-the-story-of-nicotine-b3b51f5b8259 Protecting brain cells — the story of nicotine]===&lt;br /&gt;
*[https://web.archive.org/web/20221021040501/https://www.parkinsons.org.uk/nicotine-good-bad-and-ugly Nicotine - Good, Bad, Ugly]&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease]=== &lt;br /&gt;
*Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%.&lt;br /&gt;
*different website same study? [Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease|https://academic.oup.com/ije/article/46/3/872/2656164]&lt;br /&gt;
&lt;br /&gt;
===1986: [https://pubmed.ncbi.nlm.nih.gov/3786334/ Effects of nicotine on finger tapping rate in non-smokers]===&lt;br /&gt;
&lt;br /&gt;
===1996: [https://sci-hub.st/10.1093/oxfordjournals.bmb.a011533 Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious]===&lt;br /&gt;
&lt;br /&gt;
===2020 [https://n.neurology.org/content/neurology/94/20/e2132.full.pdf Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors]=== &lt;br /&gt;
&lt;br /&gt;
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
&lt;br /&gt;
=== 2021: [https://www.spektrum.de/news/kognition-nikotin-gegen-neuropsychiatrische-erkrankungen/1924141 Kognition: Nikotin gegen neuropsychiatrische Erkrankungen] (German)  &#039;Cognition: nicotine versus neuropsychiatric disorders&#039; ===&lt;br /&gt;
&lt;br /&gt;
===Dr. Newhouse [http://mindstudy.org/news Mind Study]=== &lt;br /&gt;
&lt;br /&gt;
===2010 [https://pubmed.ncbi.nlm.nih.gov/20414766/ Meta-analysis of the acute effects of nicotine and smoking on human performance] and 2012 [https://n.neurology.org/content/78/2/91.short Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== &lt;br /&gt;
*Clinical studies suggest some cognitive improvements as a result of nicotine.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.dovepress.com/effectiveness-and-safety-profile-of-alternative-tobacco-and-nicotine-p-peer-reviewed-fulltext-article-JMDH Effectiveness and Safety Profile of Alternative Tobacco and Nicotine Products for Smoking Reduction and Cessation: A Systematic Review]=== &lt;br /&gt;
&lt;br /&gt;
===[https://docs.google.com/document/d/13-D2q1P0KpmZuoFBkKV4l9wUEQ-zcHfp6MAVJGoAaG4/edit?usp=sharing INNCO&#039;s List smoking cessation]=== &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Started: continue @ “Among smokers who have attempted to stop without professional support, those who use e-cigarettes are more likely to report continued abstinence than those who used a licensed NRT products [i.e., nicotine patches, gum or lozenges].”&lt;br /&gt;
https://onlinelibrary.wiley.com/doi/full/10.1111/add.12623&lt;br /&gt;
&lt;br /&gt;
===[https://twitter.com/jkelovuori/status/1413963688709664769 Go through the links in this thread]=== &lt;br /&gt;
&lt;br /&gt;
===To do: Go through the references for nicotine related studies===&lt;br /&gt;
====2020: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404387/ Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders]====&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;More Information&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*[[Special:MyLanguage/Nicotine Studies|&#039;&#039;&#039;List of researchers&#039;&#039;&#039;]] studying nicotine / tobacco harm reduction&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*If you&#039;d prefer someone else to add a study to a topic, there is a &amp;quot;topic&amp;quot; called &amp;quot;Suggested studies to add to this page&amp;quot;. You may put the link in that section for one of the regular page editors to address.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*&#039;&#039;&#039;PAGE EDITORS - Please only add Studies, Surveys, Papers in this format to keep page consistent for all viewers.&#039;&#039;&#039;&lt;br /&gt;
**Topic&lt;br /&gt;
**Note here if animal study (leave blank if not)&lt;br /&gt;
**Year (list new to old) Name of Study (In link format to the study)&lt;br /&gt;
**Brief Summary&lt;br /&gt;
**Link to PDF Version&lt;br /&gt;
**Citation&lt;br /&gt;
**Acknowledgements (funded by, helped by)&lt;br /&gt;
**Keywords&lt;br /&gt;
**Other&lt;br /&gt;
[[Category:Studies, Surveys, and Papers]]&lt;br /&gt;
[[Category:THR product]]&lt;br /&gt;
[[Category:THR Stories]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=CAPHRA&amp;diff=78776</id>
		<title>CAPHRA</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=CAPHRA&amp;diff=78776"/>
		<updated>2025-03-18T13:35:48Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: remove brackets&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[File:CAPHRA logo.png|alt=CAPHRA Logo|center|frameless|300x300px]]&lt;br /&gt;
&lt;br /&gt;
== About ==&lt;br /&gt;
The Coalition of Asia Pacific Tobacco Harm Advocates (CAPHRA) is a regional alliance of consumer tobacco harm reduction advocacy organisations.  CAPHRA is not related to, or funded by any commercial interests. It is composed of volunteer consumer advocates from the Asia Pacific Region. We hope putting forward this information would clarify any doubt as to our interests and intentions.&lt;br /&gt;
&lt;br /&gt;
== Mission statement ==&lt;br /&gt;
&#039;&#039;&#039;CAPHRA stays committed to its mission to educate, advocate and represent the right of adult alternative nicotine consumers to access and use of products that reduce harm from tobacco use.  We advocate for the rights of consumers in the Asia-Pacific region to access and use evidence-based, regulated, and properly marketed harm reduction products as a means of reducing the devastating impact of smoking-related diseases.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== Mentorship ==&lt;br /&gt;
All of our members work collaboratively through discussion, support, and mentorship for our respective countries’ consumers and together as the representative consumer voice in the Asia Pacific region.&lt;br /&gt;
&lt;br /&gt;
== Grassroots Advocacy ==&lt;br /&gt;
We endeavour to advocate for all who seek harm reduction from the deadly forms of tobacco.  We collaborate with some of the world’s leading THR experts and advocates, who freely share their knowledge and expertise, as well as mentor advocates and organisations who ask for support.&lt;br /&gt;
&lt;br /&gt;
== External Links ==&lt;br /&gt;
[https://caphraorg.net/ CAPHRA Website]&lt;br /&gt;
&lt;br /&gt;
[Mailto:admin@caphraorg.net Email Us] &lt;br /&gt;
&lt;br /&gt;
{{Stub}}&lt;br /&gt;
[[Category:THR Advocacy Group]]&lt;br /&gt;
[[Category:Consumer Advocacy Organization]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=CAPHRA&amp;diff=78771</id>
		<title>CAPHRA</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=CAPHRA&amp;diff=78771"/>
		<updated>2025-03-18T13:34:20Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: remove unneeded | char from link&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[File:CAPHRA logo.png|alt=CAPHRA Logo|center|frameless|300x300px]]&lt;br /&gt;
&lt;br /&gt;
== About ==&lt;br /&gt;
The Coalition of Asia Pacific Tobacco Harm Advocates (CAPHRA) is a regional alliance of consumer tobacco harm reduction advocacy organisations.  CAPHRA is not related to, or funded by any commercial interests. It is composed of volunteer consumer advocates from the Asia Pacific Region. We hope putting forward this information would clarify any doubt as to our interests and intentions.&lt;br /&gt;
&lt;br /&gt;
== Mission statement ==&lt;br /&gt;
&#039;&#039;&#039;CAPHRA stays committed to its mission to educate, advocate and represent the right of adult alternative nicotine consumers to access and use of products that reduce harm from tobacco use.  We advocate for the rights of consumers in the Asia-Pacific region to access and use evidence-based, regulated, and properly marketed harm reduction products as a means of reducing the devastating impact of smoking-related diseases.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== Mentorship ==&lt;br /&gt;
All of our members work collaboratively through discussion, support, and mentorship for our respective countries’ consumers and together as the representative consumer voice in the Asia Pacific region.&lt;br /&gt;
&lt;br /&gt;
== Grassroots Advocacy ==&lt;br /&gt;
We endeavour to advocate for all who seek harm reduction from the deadly forms of tobacco.  We collaborate with some of the world’s leading THR experts and advocates, who freely share their knowledge and expertise, as well as mentor advocates and organisations who ask for support.&lt;br /&gt;
&lt;br /&gt;
== External Links ==&lt;br /&gt;
[https://caphraorg.net/ CAPHRA Website]&lt;br /&gt;
&lt;br /&gt;
[[Mailto:admin@caphraorg.net Email Us]] &lt;br /&gt;
&lt;br /&gt;
{{Stub}}&lt;br /&gt;
[[Category:THR Advocacy Group]]&lt;br /&gt;
[[Category:Consumer Advocacy Organization]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=CAPHRA&amp;diff=78766</id>
		<title>CAPHRA</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=CAPHRA&amp;diff=78766"/>
		<updated>2025-03-18T13:32:56Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: typo in email lin&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[File:CAPHRA logo.png|alt=CAPHRA Logo|center|frameless|300x300px]]&lt;br /&gt;
&lt;br /&gt;
== About ==&lt;br /&gt;
The Coalition of Asia Pacific Tobacco Harm Advocates (CAPHRA) is a regional alliance of consumer tobacco harm reduction advocacy organisations.  CAPHRA is not related to, or funded by any commercial interests. It is composed of volunteer consumer advocates from the Asia Pacific Region. We hope putting forward this information would clarify any doubt as to our interests and intentions.&lt;br /&gt;
&lt;br /&gt;
== Mission statement ==&lt;br /&gt;
&#039;&#039;&#039;CAPHRA stays committed to its mission to educate, advocate and represent the right of adult alternative nicotine consumers to access and use of products that reduce harm from tobacco use.  We advocate for the rights of consumers in the Asia-Pacific region to access and use evidence-based, regulated, and properly marketed harm reduction products as a means of reducing the devastating impact of smoking-related diseases.&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
== Mentorship ==&lt;br /&gt;
All of our members work collaboratively through discussion, support, and mentorship for our respective countries’ consumers and together as the representative consumer voice in the Asia Pacific region.&lt;br /&gt;
&lt;br /&gt;
== Grassroots Advocacy ==&lt;br /&gt;
We endeavour to advocate for all who seek harm reduction from the deadly forms of tobacco.  We collaborate with some of the world’s leading THR experts and advocates, who freely share their knowledge and expertise, as well as mentor advocates and organisations who ask for support.&lt;br /&gt;
&lt;br /&gt;
== External Links ==&lt;br /&gt;
[https://caphraorg.net/ CAPHRA Website]&lt;br /&gt;
&lt;br /&gt;
[[Mailto:admin@caphraorg.net|Email Us]] &lt;br /&gt;
&lt;br /&gt;
{{Stub}}&lt;br /&gt;
[[Category:THR Advocacy Group]]&lt;br /&gt;
[[Category:Consumer Advocacy Organization]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78723</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78723"/>
		<updated>2025-03-09T16:22:03Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (likely an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thanks! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78718</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78718"/>
		<updated>2025-03-02T16:38:38Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us, thanks. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (probably an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thanks! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_therapeutic_benefits&amp;diff=78703</id>
		<title>Nicotine therapeutic benefits</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_therapeutic_benefits&amp;diff=78703"/>
		<updated>2025-02-20T12:27:27Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Added stroke heading and animal study on the protective effect of nic&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;big&amp;gt;&#039;&#039;&#039;&#039;&#039;Safer Nicotine Wiki does NOT endorse smoking for any potential therapeutic benefits. Smoking has too many severe consequences. Studies showing that fewer people who smoke end up with a specific ailment are included to show the potential benefits of the nicotine. Some of these studies show a potential benefit, not proof of a benefit. Some of the studies are animal studies, not human studies.&#039;&#039;&#039;&#039;&#039;&amp;lt;/big&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
[[File:Nic Ther Ben.png|alt=Nicotine Therapeutic benefits banner|center]]&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;big&amp;gt;&#039;&#039;&#039;Note: Some topics are subgroups under the main topic of &amp;quot;Mental Health.&amp;quot; &#039;&#039;&#039;&amp;lt;/big&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Acne&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2010 [https://ijphjournal.it/article/view/5708 Evaluation of the association between acne and smoking: systematic review and meta-analysis of cross-sectional studies]===&lt;br /&gt;
*Acne vulgaris is one of the most common skin diseases with a multifactorial pathogenesis. &lt;br /&gt;
*Our meta-analysis underlines that there is no evidence to support an association between smoking habits and acne, although in three of the good quality papers a significant protection in the current smoker was found. It necessary to be cautious in declaring that smoking may provide a protective effect in the pathogenesis of acne because the analysis was based on only a small number of studies.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.sciencedirect.com/science/article/pii/S0022202X15330153 Severe Acne Vulgaris and Tobacco Smoking in Young Men]===&lt;br /&gt;
*It is crucial to emphasize that any positive effects found must be traced to specific tobacco components that can be therapeutically used without smoking (e.g., nicotine patches or gums), to avoid any “legitimatizing” of smoking based on its beneficial effects on health.&lt;br /&gt;
*Active smokers showed a significantly lower prevalence of severe acne (0.71%) than nonsmokers (1.01%) (P=0.0078). &lt;br /&gt;
*Previous in vitro and clinical studies strongly support an association with nicotine. We suggest a trial with topical nicotine treatment for acne to further investigate this association.&lt;br /&gt;
&lt;br /&gt;
===1993 [https://academic.oup.com/ced/article-abstract/18/2/100/6629365 Does smoking influence acne?]===&lt;br /&gt;
*[https://sci-hub.se/10.1111/j.1365-2230.1993.tb00986.x PDF of full study]&lt;br /&gt;
*The findings of this study support the hypothesis that some component of cigarette smoke, possibly nicotine, has an anti‐inflammatory action on acne.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;ADD / ADHD / Attention / Cognition&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.845646/full Tobacco and ADHD: A Role of MAO-Inhibition in Nicotine Dependence and Alleviation of ADHD Symptoms]===&lt;br /&gt;
*&amp;quot;Our review of evidence supports the finding that individuals with ADHD are at greater vulnerability for both initiation and continuation of smoking (both cigarettes, e-cigarettes).&amp;quot;&lt;br /&gt;
*&amp;quot;Greater support for a “self-medication” model of ADHD and smoking includes not only nicotine but also MAO-inhibitors as dopamine agonists contained in cigarettes and e-cigarettes.&amp;quot;&lt;br /&gt;
*Taylor, M. R., Carrasco, K., Carrasco, A., &amp;amp; Basu, A. (2022). Tobacco and ADHD: A Role of MAO-Inhibition in Nicotine Dependence and Alleviation of ADHD Symptoms. Frontiers in Neuroscience, 16, 845646. https://doi.org/10.3389/fnins.2022.845646&lt;br /&gt;
*Funds for open access publication fees are contributed by the Faculty of Health, University of Canterbury and University of Canterbury library.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== &lt;br /&gt;
*Preclinical models and human studies have demonstrated that nicotine has cognitive-enhancing effects. Attention, working memory, fine motor skills and episodic memory functions are particularly sensitive to nicotine’s effects. &lt;br /&gt;
*High rates of smoking are observed among individuals with psychiatric disorders including schizophrenia, bipolar disorder, major depression, attention deficit hyperactivity disorder (ADHD) and comorbid substance use disorders (SUD). Because these psychiatric disorders are associated with various cognitive impairments, including deficits in attention, working memory, and response inhibition functions, the cognitive enhancing effects of nicotine may be especially important determinants of the initation and maintenance of smoking in this comorbid population. Growing evidence suggest that cognitive enhancing effects of nicotine may also contribute to the difficulty in quitting smoking, especially in individuals with psychiatric disorders.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/pdf/CN-16-403.pdf PDF Version]&lt;br /&gt;
*Citation: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Curr Neuropharmacol. 2018;16(4):403-414. doi: 10.2174/1570159X15666171103152136. PMID: 29110618; PMCID: PMC6018192.&lt;br /&gt;
&lt;br /&gt;
===2017: [https://www.tandfonline.com/doi/full/10.1080/10826084.2017.1334066 Causal Factors of Increased Smoking in ADHD: A Systematic Review]===&lt;br /&gt;
*One of the most striking comorbidities of ADHD is nicotine dependence. Youth diagnosed with ADHD are 2–3 times more likely to smoke than their peers without ADHD, initiate smoking earlier in life and progress more quickly and more frequently to regular use and dependence. Possible explanations for these increased risks are: (a) self-medication of ADHD symptoms with the stimulant nicotine; (b) ADHD symptoms like inattention and hyperactivity/impulsivity predispose for smoking initiation and impede smoking cessation; (c) peer pressure; and/or (d) common genetic or environmental determinants for ADHD and smoking.&lt;br /&gt;
*In contrast, the positive relation between ADHD and nicotine dependence is currently best explained by the self-medication hypothesis. This hypothesis has a clear pharmacological rationale and is supported by ample evidence, but awaits confirmation from longitudinal naturalistic studies.&lt;br /&gt;
*Citation: Jan van Amsterdam, Bauke van der Velde, Mieke Schulte &amp;amp; Wim van den Brink (2018) Causal Factors of Increased Smoking in ADHD: A Systematic Review, Substance Use &amp;amp; Misuse, 53:3, 432-445, DOI: 10.1080/10826084.2017.1334066 &lt;br /&gt;
&lt;br /&gt;
===2014: [https://www.medscape.com/viewarticle/827544_1 Adult Attention-Deficit/Hyperactivity Disorder and Nicotine Use: A Qualitative Study of Patient Perceptions]===&lt;br /&gt;
*Participants had different views about the link between cigarette smoking and ADHD. While the majority thought of nicotine as a sort of therapy, viewing smoking as a way to self-medicate symptoms of ADHD, motivations for nicotine use were also related to self-image, desire to belong to a peer-group, and a drive to undermine perceived social norms. Ultimately, these findings can be used by clinicians to improve treatment alliance and collaboration.&lt;br /&gt;
*[https://sci-hub.se/10.1186/1471-244x-14-141 Alternative Link]&lt;br /&gt;
*Citation: Liebrenz, M., Frei, A., Fisher, C. E., Gamma, A., Buadze, A., &amp;amp; Eich, D. (2014). Adult attention-deficit/hyperactivity disorder and nicotine use: a qualitative study of patient perceptions. BMC Psychiatry, 14(1). doi:10.1186/1471-244x-14-141 &lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150/ Cognitive enhancers for the treatment of ADHD]===&lt;br /&gt;
*Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, affecting approximately 8–9% of school-aged children and 4–5% of adults (Froehlich et al., 2007; Kessler et al., 2006; Visser et al., 2007). Although formally the disorder is characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity (APA, 2000), myriad phenotypic features—many of which are related to cognition broadly defined—have been shown to distinguish those with ADHD from those without the disorder.&lt;br /&gt;
*Together, these findings have led to the hypothesis that individuals with ADHD may smoke in order to alleviate requisite symptoms of the disorder and further suggest nicotine and/or nicotinic agonists can be used to improve aspects of cognitive function in these patients (McClernon and Kollins, 2008). Some support for this hypothesis has been provided by studies which have shown positive effects of nicotine on ADHD symptoms (Gehricke et al., 2009; Shytle et al., 2002) and cognitive performance (Levin et al., 1996; Potter and Newhouse, 2004) in non-smokers with ADHD. Whereas there are currently no FDA-approved nicotinic agonists to treat ADHD, laboratory and small-scale clinical trials have been conducted in recent years, and novel nicotinic pharmacotherapies are on the horizon.&lt;br /&gt;
*Citation: Bidwell LC, McClernon FJ, Kollins SH. Cognitive enhancers for the treatment of ADHD. Pharmacol Biochem Behav. 2011 Aug;99(2):262-74. doi: 10.1016/j.pbb.2011.05.002. Epub 2011 May 10. PMID: 21596055; PMCID: PMC3353150.&lt;br /&gt;
&lt;br /&gt;
===2009 [https://pubmed.ncbi.nlm.nih.gov/20025370/ Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder]===&lt;br /&gt;
*Nicotine reduced reports of ADHD symptoms by 8% and negative moods by 9%, independent of smoking status. In addition, nicotine increased cardiovascular activity during the first 3 to 6 hours after nicotine patch administration. The results support the self-medication hypothesis for nicotine in adults with ADHD and suggest that smoking cessation and prevention efforts for individuals with ADHD will need to address both the symptom reducing and mood enhancing effects of nicotine.&lt;br /&gt;
*Citation: Gehricke, J. G., Hong, N., Whalen, C. K., Steinhoff, K., &amp;amp; Wigal, T. L. (2009). Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 23(4), 644–655. https://doi.org/10.1037/a0017441&lt;br /&gt;
&lt;br /&gt;
===2009 [https://www.tandfonline.com/doi/abs/10.3109/15622970209150616 A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder]===&lt;br /&gt;
*All 10 subjects enrolled (six males, four females; mean age = 10 years, SEM = 0.8) completed the study. As assessed by the 48-item Conners Parent Rating Scale at endpoint and during the trial, there was a significantly greater reduction in ADHD symptoms on “Learning Problems” and “Hyperactivity” subfactors. Nausea, stomach ache, itching under patch and dizziness were the most frequently reported adverse effects associated with transdermal nicotine.&lt;br /&gt;
*Citation: R. Douglas Shytle, Archie A. Silver, Berney J. Wilkinson &amp;amp; Paul R. Sanberg (2002) A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder, The World Journal of Biological Psychiatry, 3:3, 150-155, DOI: 10.3109/15622970209150616&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.sciencedirect.com/science/article/abs/pii/S0091305707003048?via%3Dihub Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder]=== &lt;br /&gt;
*Non-smoking young adults with ADHD-C showed improvements in cognitive performance following nicotine administration in several domains that are central to [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ADHD&#039;&#039;&#039;]].&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.pbb.2007.09.014 PDF Version]&lt;br /&gt;
*Citation: Alexandra S. Potter, Paul A. Newhouse, Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder, Pharmacology Biochemistry and Behavior, Volume 88, Issue 4, 2008, Pages 407-417, ISSN 0091-3057, doi: 10.1016/j.pbb.2007.09.014.&lt;br /&gt;
*Acknowledgements: This work was supported by: GCRC M01-00109 and Targacept Inc.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://pmc.ncbi.nlm.nih.gov/articles/PMC2446482/ Transdermal Nicotine in Adult ADHD With Depression and Anxiety]===&lt;br /&gt;
*&amp;quot;This case report neither rules out the placebo effect, nor does it prove that transdermal nicotine is useful in managing adult ADHD with depression and anxiety. However, it does suggest that the beneficial effect of transdermal nicotine may be attributed to biobehavioral pathways common to chronic nicotine withdrawal and ADHD with depression and anxiety. Nicotine agonists and delivery systems may be new treatments for adult ADHD. Larger well-designed studies are warranted to evaluate the therapeutic potential of nicotine delivery systems in otherwise medically stable adults with ADHD accompanied by depression and anxiety. Further exploration of the nicotinic-cholinergic system may also expand our understanding of the neuropsychiatry underlying ADHD.&amp;quot;&lt;br /&gt;
*Citation: Cocores JA. Transdermal nicotine in adult ADHD with depression and anxiety. Prim Care Companion J Clin Psychiatry. 2008;10(3):253-4. doi: 10.4088/pcc.v10n0312f. PMID: 18615164; PMCID: PMC2446482.&lt;br /&gt;
*Dr. Cocores reports no financial affiliations or other relationships relevant to the subject of this letter.&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.academia.edu/2412620/Smoking_to_self_medicate_attentional_and_emotional_dysfunctions Smoking to self-medicate attentional and emotional dysfunctions]===&lt;br /&gt;
*The data from diverse studies are generally consistent with the self-medication hypothesis and suggest that individuals with ADHD may smoke to alleviate symptoms associated with attention deficit, impulsivity, and hyperactivity. More studies on larger samples are necessary to assess the differential risks for adolescent smoking initiation that are associated with ADHD subtypes and with ODD and CD comorbidities.&lt;br /&gt;
*Citation: Gehricke, J.-G., Loughlin, S., Whalen, C., Potkin, S., Fallon, J., Jamner, L., … Leslie, F. (2007). Smoking to self-medicate attentional and emotional dysfunctions. Nicotine  Tobacco Research, 9, 523–536. https://doi.org/10.1080/14622200701685039&lt;br /&gt;
&lt;br /&gt;
===2007: [https://www.academia.edu/18995031/Smoking_to_self_medicate_attentional_and_emotional_dysfunctions Smoking to self-medicate attentional and emotional dysfunctions]===&lt;br /&gt;
*(Note: Need to add summary)&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.academia.edu/17983526/The_reinforcing_effects_of_nicotine_and_stimulant_medication_in_the_everyday_lives_of_adult_smokers_with_ADHD_A_preliminary_examination The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination]===&lt;br /&gt;
*The findings suggest that smokers with ADHD experience nicotine-related reductions in ADHD symptoms during their everyday lives.&lt;br /&gt;
*Citation: Gehricke, J. G., Whalen, C., Jamner, L., Wigal, T., &amp;amp; Steinhoff, K. (2006). The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination. Nicotine  Tobacco Research, 8(1), 37–47. https://doi.org/10.1080/14622200500431619&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.sciencedirect.com/science/article/abs/pii/S0031938405005627?via%3Dihub Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits]===&lt;br /&gt;
*The results showed nicotine-induced improvement on some measures of sustained attention in the low attention group and some decrement in working memory in the high attention group, which suggests that nicotine tends to optimize rather than improve performance on cognitive tasks.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.physbeh.2005.12.011 PDF Version]&lt;br /&gt;
*Citation: D.V. Poltavski, T. Petros, Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits, Physiology &amp;amp; Behavior, Volume 87, Issue 3, 2006, Pages 614-624, ISSN 0031-9384, doi: 10.1016/j.physbeh.2005.12.011.&lt;br /&gt;
&lt;br /&gt;
===2004: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
* Yet few of the horrendous health effects of smoking are traceable to nicotine itself—cigarettes contain nearly 4,000 other compounds that play a role. Until recently, nicotine research has been driven primarily by nicotine&#039;s unparalleled power to keep people smoking, rather than its potential therapeutic uses.&lt;br /&gt;
* There&#039;s a cheap, common, and mostly safe drug, in daily use for centuries by hundreds of millions of people, that only lately has been investigated for its therapeutic potential for a long list of common ills. The list includes Alzheimer disease, Parkinson disease, depression and anxiety, schizophrenia, attention deficit hyperactivity disorder (ADHD), and even pain and obesity.&lt;br /&gt;
* People with depressive-spectrum disorders, schizophrenia, and adult ADHD tend to smoke heavily, which suggested to researchers that nicotine may soothe their symptoms. Common to all these disorders is a failure of attention, an inability to concentrate on particular stimuli and screen out the rest. Nicotine helps.&lt;br /&gt;
* Researchers at the National Institute on Drug Abuse have shown via functional magnetic resonance imaging that nicotine activates specific brain areas during tasks that demand attention&lt;br /&gt;
*Citation: Powledge TM. Nicotine as therapy. PLoS Biol. 2004 Nov;2(11):e404. doi: 10.1371/journal.pbio.0020404. Epub 2004 Nov 16. PMID: 15547644; PMCID: PMC526783&lt;br /&gt;
&lt;br /&gt;
===2003: [https://www.academia.edu/2412608/Is_There_a_Link_Between_Adolescent_Cigarette_Smoking_and_Pharmacotherapy_for_ADHD   Is There a Link Between Adolescent Cigarette Smoking and pharmacotherapy for ADHD?]===&lt;br /&gt;
*Self-report surveys, electronic diaries, and salivary cotinine all indicated that adolescents treated with pharmacotherapy for ADHD smoked less than their untreated counterparts over 2 years of high school. These convergent findings from 3 disparate indicators lend support to the self-medication hypothesis over the gateway hypothesis, although alternative explanations need further study. The findings also suggest that early treatment of psychological and behavioral problems may prevent or delay smoking initiation&lt;br /&gt;
*Citation: Whalen, C. K., Jamner, L. D., Henker, B., Gehricke, J.-G., &amp;amp; King, P. S. (2003). Is There a Link Between Adolescent Cigarette Smoking and Pharmacotherapy for ADHD? Psychology of Addictive Behaviors, 17(4), 332–335. https://doi.org/10.1037/0893-164X.17.4.332&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
*Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&lt;br /&gt;
===2001 [https://psycnet.apa.org/record/2001-14365-012 Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder.]===&lt;br /&gt;
*This small study (40 participants) provided evidence that nicotine treatment can reduce severity of attentional deficit symptoms and produce improvement on an objective computerized attention task.&lt;br /&gt;
*Citation: Levin, E. D., Conners, C. K., Silva, D., Canu, W., &amp;amp; March, J. (2001). Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Experimental and Clinical Psychopharmacology, 9(1), 83–90. https://doi.org/10.1037/1064-1297.9.1.83&lt;br /&gt;
&lt;br /&gt;
===1998 [https://pubmed.ncbi.nlm.nih.gov/9860103/ Transdermal nicotine effects on attention]=== &lt;br /&gt;
*This study shows that, in addition to reducing attentional impairment, nicotine administered via transdermal patches can improve attentiveness in normal adult non-smokers.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s002130050750 PDF Version]&lt;br /&gt;
*Citation: Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J, Rose JE. Transdermal nicotine effects on attention. Psychopharmacology (Berl). 1998 Nov;140(2):135-41. doi: 10.1007/s002130050750. PMID: 9860103&lt;br /&gt;
*Acknowledgement: The authors thank R.J. Reynolds for financial support of the project. Work on this article was partially supported by Career Science Award (K05MH0122903) to Dr. Conners and Research Scientist Development Award (K02MH0098102) to Dr. March&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/8741955/ Nicotine effects on adults with attention-deficit/hyperactivity disorder]=== &lt;br /&gt;
*Nicotine caused a significant overall nicotine-induced improvement on the CGI. This effect was significant when only the nonsmokers were considered, which indicated that it was not due merely to withdrawal relief. Nicotine caused significantly increased vigor as measured by the POMS test. Nicotine caused an overall significant reduction in reaction time (RT) on the CPT, as well as, with the smokers, a significant reduction in another index of inattention, variability in reaction time over trial blocks. Nicotine improved accuracy of time estimation and lowered variability of time-estimation response curves. Because improvements occurred among nonsmokers, the nicotine effect appears not to be merely a relief of withdrawal symptoms. It is concluded that nicotine deserves further clinical trials with ADHD.&lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02246281 PDF Version]&lt;br /&gt;
*Citation: Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996 Jan;123(1):55-63. doi: 10.1007/BF02246281. PMID: 8741955.&lt;br /&gt;
*Acknowledgement: The authors thank Dr. Allen Frances, Chairman of the Department of Psychiatry, Duke University Meidcal Center for his finanical support of the project. Work on this article was partially supported by Career Science Award (K05MH01229-03) to Dr. Conners and Research Scientist Development Award (K20MH00981-02) to Dr. March and a Young Investigator Award from the National Alliance for Research Schizophenia and Depression to Dr. Levin.&lt;br /&gt;
&lt;br /&gt;
===1996: [https://pubmed.ncbi.nlm.nih.gov/8927677/ Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)]===&lt;br /&gt;
*The present study is an acute double-blind crossover administration of nicotine and placebo with smokers (n = 6) and nonsmokers (n = 11) diagnosed with adult ADHD. The drug was delivered via a transdermal patch at a dosage of 7 mg/day for nonsmokers and 21 mg/day for smokers. Results indicate significant clinician-rated global improvement, self-rated vigor and concentration, and improved performance on chronometric measures of attention and timing accuracy. Side effects were minimal. These acute results indicate the need for a longer clinical trial and a comparison with other stimulants in adult ADHD treatment.&lt;br /&gt;
*Citation: Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67-73. PMID: 8927677.&lt;br /&gt;
&lt;br /&gt;
===Year Unknown: Article: [https://www.adxs.org/en/page/192/nicotine-as-a-medication-for-adhd Nicotine as a medication for ADHD]===&lt;br /&gt;
*Lists references&lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Aging&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.nature.com/articles/s41467-023-36543-8 Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity]===&lt;br /&gt;
*Abstract &amp;quot;Imbalances in NAD+ homeostasis have been linked to aging and various diseases. Nicotine, a metabolite of the NAD+ metabolic pathway, has been found to possess anti-inflammatory and neuroprotective properties, yet the underlying molecular mechanisms remained unknown. Here we find that, independent of nicotinic acetylcholine receptors, low-dose nicotine can restore the age-related decline of NAMPT activity through SIRT1 binding and subsequent deacetylation of NAMPT, thus increasing NAD+ synthesis. 18F-FDG PET imaging revealed that nicotine is also capable of efficiently inhibiting glucose hypermetabolism in aging male mice. Additionally, nicotine ameliorated cellular energy metabolism disorders and deferred age-related deterioration and cognitive decline by stimulating neurogenesis, inhibiting neuroinflammation, and protecting organs from oxidative stress and telomere shortening. Collectively, these findings provide evidence for a mechanism by which low-dose nicotine can activate NAD+ salvage pathways and improve age-related symptoms.&amp;quot;&lt;br /&gt;
**Citation: Yang, L., Shen, J., Liu, C. et al. Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity. Nat Commun 14, 900 (2023). https://doi.org/10.1038/s41467-023-36543-8&lt;br /&gt;
***Acknowledgement: This work was supported by grants from Shenzhen Science and Technology Program (KQTD20210811090117032), Shenzhen Key Laboratory of Viral Vectors for Biomedicine (ZDSYS20200811142401005), CAS Key Laboratory of Brain Connectome and Manipulation (2019DP173024) and Guangdong Provincial Key Laboratory of Brain Connectome and Behavior (2017B030301017).&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Akathisia&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===1997: [https://pubmed.ncbi.nlm.nih.gov/9399378/ Treatment of neuroleptic-induced akathisia with nicotine patches]===&lt;br /&gt;
*We administered 14 mg nicotine patches to 16 patients, all non-smokers, who displayed akathisia from antipsychotic drugs. On single-blind ratings, akathisia appeared significantly reduced on days when patients were wearing the patches as compared to the baseline day. These findings, if confirmed, may help to explain the high rates of tobacco use among psychotic patients, and may suggest avenues for the treatment of akathisia.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s002130050436 PDF Version]&lt;br /&gt;
**Citation: Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl). 1997 Nov;134(2):153-6. doi: 10.1007/s002130050436. PMID: 9399378.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Alcohol Use Disorder&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://onlinelibrary.wiley.com/doi/10.1111/acer.15103 Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco]===&lt;br /&gt;
*Our findings may indicate that nicotine has anti-inflammatory effects in patients with AUD.&lt;br /&gt;
**Citation: Bolstad I, Lien L, Moe JS, Pandey S, Toft H, Bramness JG. Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco. Alcohol Clin Exp Res (Hoboken). 2023 Jul;47(7):1352-1363. doi: 10.1111/acer.15103. Epub 2023 May 30. PMID: 37208927.&lt;br /&gt;
***Acknowledgement: This work was financially supported by The Research Council of Norway, grant FRIPRO 251140.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Allergies / Hayfever / Histamines&#039;&#039;&#039; (See also: Hypersensitivity Pneumonitis / Extrinsic Allergic Alveolitis)=&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203434/ Suppressive effect of environmental tobacco smoke on murine Th2 cell-mediated nasal eosinophilic inflammation]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*In this study, the effect of environmental tobacco smoke (ETS) on allergen-immunized and allergen-specific Th2 cell-transferred murine eosinophilic inflammation models and that of cigarette smoke extract (CSE) and nicotine on allergen-induced Th2 cell proliferation and interleukin (IL)-4 production were investigated.&lt;br /&gt;
*In summary, ETS suppressed allergen-induced nasal responses including NHR by inhibiting allergen-specific Th2 cell responses. Although our present findings do not deny harmful effects of cigarette smoking, nicotine as a component of ETS may be a target to treat Th2-mediated allergic diseases, including allergic rhinitis (AR).&lt;br /&gt;
**Citation: Nishimura T, Kaminuma O, Saeki M, Kitamura N, Mori A, Hiroi T. Suppressive effect of environmental tobacco smoke on murine Th2 cell-mediated nasal eosinophilic inflammation. Asia Pac Allergy. 2020 Apr 27;10(2):e18. doi: 10.5415/apallergy.2020.10.e18. PMID: 32411583; PMCID: PMC7203434.&lt;br /&gt;
***Acknowledgement: This work was supported in part by funding from the Smoking Research Foundation provided to Osamu Kaminuma.&lt;br /&gt;
&lt;br /&gt;
===2017: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440386/ Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium]===&lt;br /&gt;
*Our results suggest that smoking may be causally related to a higher risk of asthma and a slightly lower risk of hay fever. However, the adverse events associated with smoking limit its clinical significance.&lt;br /&gt;
**Citation: Skaaby T, Taylor AE, Jacobsen RK, et al. Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium. Sci Rep. 2017 May 22;7(1):2224. doi: 10.1038/s41598-017-01977-w. PMID: 28533558; PMCID: PMC5440386.&lt;br /&gt;
***Acknowledgement: This work was supported by the Medical Research Council (grant numbers: MR/J01351X/1, MC_UU_12013/6). The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk).&lt;br /&gt;
&lt;br /&gt;
===2014: [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085888 Anti-allergic role of cholinergic neuronal pathway via α7 nicotinic ACh receptors on mucosal mast cells in a murine food allergy model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*In this study, nicotine treatment significantly ameliorated FA [Food Allergy], mainly due to the suppression of upregulated mucosal immune responses via α7 nAChRs on immune cells. Therefore, the therapeutic effects of nicotine and GTS-21 on the FA model raise the possibility that a strategy for drug discovery against FA by targeting α7 nAChRs could potentially have therapeutic benefits.&lt;br /&gt;
**Citation: Yamamoto T, Kodama T, Lee J, Utsunomiya N, Hayashi S, Sakamoto H, Kuramoto H, Kadowaki M. Anti-allergic role of cholinergic neuronal pathway via α7 nicotinic ACh receptors on mucosal mast cells in a murine food allergy model. PLoS One. 2014 Jan 16;9(1):e85888. doi: 10.1371/journal.pone.0085888. PMID: 24454942; PMCID: PMC3894205.&lt;br /&gt;
&lt;br /&gt;
===2008: [https://journals.aai.org/jimmunol/article/180/11/7655/84640/Nicotine-Primarily-Suppresses-Lung-Th2-but-Not Nicotine Primarily Suppresses Lung Th2 but Not Goblet Cell and Muscle Cell Responses to Allergens]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*hese results suggest that nicotine modulates allergy/asthma primarily by suppressing eosinophil trafficking and suppressing Th2 cytokine/chemokine responses without reducing goblet cell metaplasia, mucous production, and may explain the lower risk of allergic diseases in smokers. To our knowledge this is the first direct evidence that nicotine modulates allergic responses.&lt;br /&gt;
**Citation: Neerad C. Mishra, Jules Rir-sima-ah, Raymond J. Langley, Shashi P. Singh, Juan C. Peña-Philippides, Takeshi Koga, Seddigheh Razani-Boroujerdi, Julie Hutt, Matthew Campen, K. Chul Kim, Yohannes Tesfaigzi, Mohan L. Sopori; Nicotine Primarily Suppresses Lung Th2 but Not Goblet Cell and Muscle Cell Responses to Allergens1. J Immunol 1 June 2008; 180 (11): 7655–7663. https://doi.org/10.4049/jimmunol.180.11.7655&lt;br /&gt;
***Acknowledgement: This work was supported in part by grants from the National Institutes of Health (R01-DA017003, R01-DA04208-15, and R01-DA042087S).&lt;br /&gt;
&lt;br /&gt;
===2004: [https://link.springer.com/article/10.1007/s00011-004-1249-1 The effect of nicotine on basophil histamine release]===&lt;br /&gt;
*This study has demonstrated that nicotine agonists inhibit histamine release from human basophils.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s00011-004-1249-1 PDF Full Version]&lt;br /&gt;
**Citation: Thompson-Cree, M.E.M., Stevenson, M.R., Shields, M.D. et al. The effect of nicotine on basophil histamine release. Inflamm. res. 53, 211–214 (2004). https://doi.org/10.1007/s00011-004-1249-1&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Alzheimer / Dementia / Mild Cognitive Imparement (MCI)&#039;&#039;&#039;= &lt;br /&gt;
===2013 [https://link.springer.com/article/10.1007/s12017-013-8242-1 Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these results demonstrate that nicotine prevents memory deficits and synaptic impairment induced by Aβ oligomers. In addition, nicotine improves memory in young APP/PS1 transgenic mice before extensive amyloid deposition and senile plaque development, and also in old mice where senile plaques have already formed.&lt;br /&gt;
*[https://sci-hub.st/https://link.springer.com/article/10.1007/s12017-013-8242-1 PDF Version]&lt;br /&gt;
*Citation: Inestrosa, N.C., Godoy, J.A., Vargas, J.Y. et al. Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation. Neuromol Med 15, 549–569 (2013). doi: 10.1007/s12017-013-8242-1&lt;br /&gt;
*Acknowledgements: We thank Dr. Rodrigo Varas for his help with the electrophysiological studies of the α7-nAChR. This work was supported by a grant from FONDECYT No 120156 to N.C.I; predoctoral fellowships from CONICYT to G.G.F., M.S.A. F.G.S., J.A.R. and from Fundación Gran Mariscal de Ayacucho to J.Y.V. The Basal Center of Excellence in Science and Technology CARE was funded by CONICYT/PFB 12/2007.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/ Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== &lt;br /&gt;
*The secondary outcome measures showed significant nicotine-associated improvements in attention, memory, and psychomotor speed, and improvements were seen in patient/informant ratings of cognitive impairment. &lt;br /&gt;
*Safety and tolerability for transdermal nicotine were excellent. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/pdf/znl91.pdf PDF Version]&lt;br /&gt;
*Citation: Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb. PMID: 22232050; PMCID: PMC3466669.&lt;br /&gt;
&lt;br /&gt;
===2010 [https://www.tandfonline.com/doi/abs/10.1080/13607860220126808 Nicotine&#039;s effect on neural and cognitive functioning in an aging population]=== &lt;br /&gt;
*Recent advances in nicotine research have pointed to a number of cognitive and neurological benefits that have been linked to the ingestion of nicotine.&lt;br /&gt;
*This article examines cognitive decline in the elderly and looks at nicotine&#039;s potential role in ameliorating this decline.&lt;br /&gt;
*Nicotine’s effects on cognitive functioning have shown it to increase perception, visual attention,and arousal as well as improving the speed and accuracy of motor functioning while decreasing reaction time and inhibiting declines in efficiency. In addition, research has shown nicotine to improve long-term and short-term memory, and to increase the ability to withhold inappropriate responses.&lt;br /&gt;
*Research has revealed that chronic exposure to nicotine produces an unusual up-regulation of the nicotinic receptor sites. This increase in receptor sites is thought to provide some protection against neuro-degenerative disorders such as Alzheimer’s disease.&lt;br /&gt;
*[https://sci-hub.st/10.1080/13607860220126808 PDF Version]&lt;br /&gt;
*Citation: K. N. Murray &amp;amp; N. Abeles (2002) Nicotine&#039;s effect on neural and cognitive functioning in an aging population, Aging &amp;amp; Mental Health, 6:2, 129-138, DOI: 10.1080/13607860220126808&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12436427/ Nicotinic receptors in aging and dementia]=== &lt;br /&gt;
*Nicotine and nicotinic agonists have been shown to improve cognitive function in aged or impaired subjects.&lt;br /&gt;
*Acute nicotine administration can improve performance of patients with AD on cognitive tasks, including verbal learning and memory, attention in a continuous performance task, and accuracy in a visual attention task.&lt;br /&gt;
*In addition to its ability to reverse cognitive deficits following aging, nicotine has been shown to protect against neurotoxic insult in vitro and in vivo. This suggests that nicotine has a dual effect on brain function following aging or injury, such that it can rescue function of remaining neurons, as well as saving neurons that might otherwise undergo cell death.&lt;br /&gt;
*[https://sci-hub.st/10.1002/neu.10102 PDF Version]&lt;br /&gt;
*Citation: Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol. 2002 Dec;53(4):641-55. doi: 10.1002/neu.10102. PMID: 12436427.&lt;br /&gt;
*Keywords: nAChR; neuroprotection; Alzheimer’s disease; Parkinson’s disease; acetylcholine&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
*Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Alzheimer&#039;s disease (AD)&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1410164/ Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer&#039;s disease]=== &lt;br /&gt;
*Nicotine significantly improved sustained visual attention (in both RVIP and DRMLO tasks), reaction time (in both FT and RVIP tasks), and perception (CFF task--both ascending and descending thresholds). &lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02247426 PDF Version]&lt;br /&gt;
*Citation: Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer&#039;s disease. Psychopharmacology (Berl). 1992;108(4):485-94. doi: 10.1007/BF02247426. PMID: 1410164.&lt;br /&gt;
*Acknowledgements. This research was supported by British-American Tobacco Co. Ltd. BJS thanks the Wellcome Trust and the Eleanor Peel Foundation for support. &lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in enhancement of performance, and protection against  Alzheimer&#039;s disease (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1989 [https://pubmed.ncbi.nlm.nih.gov/2597885/ The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type]=== &lt;br /&gt;
*Nicotine in patients with dementia of the Alzheimer type (DAT) produced a significant and marked improvement in discriminative sensitivity and reaction times on a computerised test of attention and information processing. Nicotine also improved the ability of DAT patients to detect a flickering light in a critical flicker fusion test. These results suggest that nicotine may be acting on cortical mechanisms involved in visual perception and attention, and support the hypothesis that acetylcholine transmission modulates vigilance and discrimination. Nicotine may therefore be of some value in treating deficits in attention and information processing in DAT patients. &lt;br /&gt;
*[https://sci-hub.st/10.1192/bjp.154.6.797 PDF Version]&lt;br /&gt;
*Citation: Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989 Jun;154:797-800. doi: 10.1192/bjp.154.6.797. PMID: 2597885.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Aphthous ulcers&#039;&#039;&#039; (See also: Behcet&#039;s disease)= &lt;br /&gt;
&lt;br /&gt;
===2015: [https://pmc.ncbi.nlm.nih.gov/articles/PMC4387635/ Use of pure nicotine for the treatment of aphthous ulcers]===&lt;br /&gt;
*The theory that nicotine is known as the protective factor is also supported by three case reports, in which aphthous ulcers were prevented or healed while the patients used nicotine replacement materials.&lt;br /&gt;
*To summarize, the use of pure nicotine in therapeutic forms, seems to be a proper alternative to treat aphthous ulcers; however, there has not been any evidence-based case-control study to prove such claim.&lt;br /&gt;
**Citation: Motamedi MR, Golestannejad Z. Use of pure nicotine for the treatment of aphthous ulcers. Dent Res J (Isfahan). 2015 Mar-Apr;12(2):197-8. PMID: 25878688; PMCID: PMC4387635.&lt;br /&gt;
&lt;br /&gt;
===2014: [https://pubmed.ncbi.nlm.nih.gov/25584320/ Recurrent aphthous ulcers among tobacco users- hospital based study]===&lt;br /&gt;
*The tobacco consumers have less frequency of aphthous ulceration compared non users.&lt;br /&gt;
**Citation: Mohamed S, Janakiram C. Recurrent aphthous ulcers among tobacco users- hospital based study. J Clin Diagn Res. 2014 Nov;8(11):ZC64-LC66. doi: 10.7860/JCDR/2014/10368.5145. Epub 2014 Nov 20. PMID: 25584320; PMCID: PMC4290331.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.sciencedirect.com/science/article/abs/pii/S0306987711001691?via%3Dihub Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis]=== &lt;br /&gt;
*In addition, nicotine or its metabolites can result in decrease of pro-inflammatory cytokines like tumor necrosis factor-α, interleukins 1 and 6, and increase of anti-inflammatory cytokine interleukin-10. Consequently, there is reduced susceptibility to RAS due to immunosuppression and/or reduction in inflammatory response.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2011.04.006 PDF Version]&lt;br /&gt;
**Citation: Subramanyam, R. V. (2011). Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis. Medical Hypotheses, 77(2), 185–187. doi:10.1016/j.mehy.2011.04.006&lt;br /&gt;
&lt;br /&gt;
===2004: [https://pubmed.ncbi.nlm.nih.gov/15370162/ The relationship between smoking cessation and mouth ulcers]===&lt;br /&gt;
*Our results confirm that mouth ulcers are a common result of stopping smoking, affecting two in five quitters. Patients should be reassured that the lesions are a result of stopping smoking and not a side-effect of smoking cessation medication.&lt;br /&gt;
**Citation: McRobbie H, Hajek P, Gillison F. The relationship between smoking cessation and mouth ulcers. Nicotine Tob Res. 2004 Aug;6(4):655-9. doi: 10.1080/14622200410001734012. PMID: 15370162.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12108762/ Minor recurrent aphthous stomatitis and smoking: an epidemiological study measuring plasma cotinine]=== &lt;br /&gt;
*This study shows that a group of RAS patients is significantly less likely to contain smokers than a matched control population, and among smokers the level of cigarette use was significantly lower in RAS patients than the control population. The perceived negative association between RAS and smoking was supported by this epidemiological study.&lt;br /&gt;
*[https://sci-hub.st/10.1034/j.1601-0825.2002.01826.x PDF Version]&lt;br /&gt;
**Citation: Atkin PA, Xu X, Thornhill MH. Minor recurrent aphthous stomatitis and smoking: an epidemiological study measuring plasma cotinine. Oral Dis. 2002 May;8(3):173-6. doi: 10.1034/j.1601-0825.2002.01826.x. PMID: 12108762.&lt;br /&gt;
&lt;br /&gt;
===2000: [https://www.nejm.org/doi/10.1056/NEJM200012143432418?url_ver=Z39.88-2003&amp;amp;rfr_id=ori%3Arid%3Acrossref.org&amp;amp;rfr_dat=cr_pub++0pubmed Nicotine Patches for Aphthous Ulcers Due to Behçet&#039;s Syndrome]=== &lt;br /&gt;
*We describe a woman with Behçet&#039;s syndrome characterized by recurrent oral and genital aphthous ulcers, severe eye involvement, and the onset of arthritis at the age of 29 years. At the age of 35 several large and extremely painful buccal aphthous ulcers developed. Therapy with a nicotine patch led to a regression of all aphthous ulcers within a few days. A month later, after the patient had stopped using the nicotine patches, four aphthous ulcers developed within a week. These ulcers rapidly regressed once she resumed using the nicotine patches.&lt;br /&gt;
*[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section)&lt;br /&gt;
**Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418&lt;br /&gt;
&lt;br /&gt;
===1992: [https://pubmed.ncbi.nlm.nih.gov/1408021/ Smokeless tobacco use prevents aphthous stomatitis]===&lt;br /&gt;
*In (contrast to cigarette smoking, however, few components other than nicotine are systemically absorbed by ST users. Thus if the mechanism that protects ST users against aphthous ulcers is systemic, then nicotine is the likely protective factor. &lt;br /&gt;
*[https://sci-hub.se/10.1016/0030-4220(92)90296-3 PDF Version]&lt;br /&gt;
**Citation: Grady D, Ernster VL, Stillman L, Greenspan J. Smokeless tobacco use prevents aphthous stomatitis. Oral Surg Oral Med Oral Pathol. 1992 Oct;74(4):463-5. doi: 10.1016/0030-4220(92)90296-3. PMID: 1408021.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://onlinelibrary.wiley.com/doi/abs/10.5694/j.1326-5377.1991.tb121180.x?sid=nlm%3Apubmed Recurrent aphthous ulcers and nicotine]=== &lt;br /&gt;
*The aim of this study was to investigate the effect of nicotine, in the form of Nicorette tablets, on aphthous ulcers in non-smoking patients. This preliminary trial shows that nicotine may have a beneficial effect on aphthous ulcers.&lt;br /&gt;
*[https://sci-hub.st/10.5694/j.1326-5377.1991.tb121180.x PDF Version]&lt;br /&gt;
**Citation: Bittoun, R. (1991), Recurrent aphthous ulcers and nicotine. Medical Journal of Australia, 154: 471-472. https://doi.org/10.5694/j.1326-5377.1991.tb121180.x&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Arthritis/Skeletal&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
==Osteoarthritis==&lt;br /&gt;
&lt;br /&gt;
===2019 [https://journals.aai.org/jimmunol/article/203/2/485/107400/Nicotine-Attenuates-Osteoarthritis-Pain-and-Matrix Nicotine Attenuates Osteoarthritis Pain and Matrix Metalloproteinase-9 Expression via the α7 Nicotinic Acetylcholine Receptor]===&lt;br /&gt;
*In conclusion, stimulation of α7-nAChRs by nicotine attenuates MIA-induced OA pain and cartilage degradation. This protective effect of nicotine can be associated with the inhibition of MMP-9 overexpression through the PI3K/Akt/NF-κB signaling pathway. Although the use of nicotine is limited by its nonspecific effects, this study provides novel evidence supporting the future development of therapeutic strategies for inflammatory diseases via the cholinergic anti-inflammatory pathway.&lt;br /&gt;
**Citation: Teng P, Liu Y, Dai Y, Zhang H, Liu WT, Hu J. Nicotine Attenuates Osteoarthritis Pain and Matrix Metalloproteinase-9 Expression via the α7 Nicotinic Acetylcholine Receptor. J Immunol. 2019 Jul 15;203(2):485-492. doi: 10.4049/jimmunol.1801513. Epub 2019 May 31. PMID: 31152077.&lt;br /&gt;
***This work was supported by grants from the National Natural Science Foundation of China (81373397, 81672218, and 81603092) and the Department of Science, Education, and Health Program of Jiangsu Province (QNRC 2016606 and QNRC 2016604).&lt;br /&gt;
&lt;br /&gt;
==Rheumatoid arthritis (collagen-induced arthritis CIA in mice)==&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.spandidos-publications.com/mmr/14/6/5057 Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Taken together, the present results indicated that nicotine‑induced activation of the CAP in mice with CIA may reduce the number of macrophages in the synovium, which may serve a role in alleviating arthritis in mice.&lt;br /&gt;
**Citation: Li S, Zhou B, Liu B, Zhou Y, Zhang H, Li T, Zuo X. Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration. Mol Med Rep. 2016 Dec;14(6):5057-5064. doi: 10.3892/mmr.2016.5904. Epub 2016 Oct 31. PMID: 27840928; PMCID: PMC5355730.&lt;br /&gt;
***Acknowledgement: The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81571602).&lt;br /&gt;
&lt;br /&gt;
===2014 [https://pubmed.ncbi.nlm.nih.gov/24313917/ Regulatory effect of nicotine on collagen-induced arthritis and on the induction and function of in vitro-cultured Th17 cells]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine stimulation attenuated signs and severity of arthritis in mice. Activation of nicotine acetylcholine receptors on in vitro-cultured Th17 cells decreased their pro-inflammatory function, which may play a potential role in alleviating arthritis in mice.&lt;br /&gt;
*[https://sci-hub.st/10.3109/14397595.2013.862352 PDF Full paper]&lt;br /&gt;
**Citation: Yang Y, Yang Y, Yang J, Xie R, Ren Y, Fan H. Regulatory effect of nicotine on collagen-induced arthritis and on the induction and function of in vitro-cultured Th17 cells. Mod Rheumatol. 2014 Sep;24(5):781-7. doi: 10.3109/14397595.2013.862352. Epub 2013 Dec 9. PMID: 24313917.&lt;br /&gt;
***Acknowledgement: This work was supported by The Shanghai Committee of Science and Technology Project, China (Grant No. 12GWZX0201,11140902900).&lt;br /&gt;
&lt;br /&gt;
===2014 [https://www.sciencedirect.com/science/article/abs/pii/S0014299914003033 Attenuation of collagen induced arthritis via suppression on Th17 response by activating cholinergic anti-inflammatory pathway with nicotine]===&lt;br /&gt;
*Activating the cholinergic anti-inflammatory pathway with nicotine can inhibit Th17 cell responses, may improve the Th1/Th2 imbalance in CIA, and provide a new justification for its application in the clinical treatment of RA.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.ejphar.2014.04.019 PDF Full paper]&lt;br /&gt;
**Citation: Wu S, Luo H, Xiao X, Zhang H, Li T, Zuo X. Attenuation of collagen induced arthritis via suppression on Th17 response by activating cholinergic anti-inflammatory pathway with nicotine. Eur J Pharmacol. 2014 Jul 15;735:97-104. doi: 10.1016/j.ejphar.2014.04.019. Epub 2014 Apr 19. PMID: 24755145.&lt;br /&gt;
***Acknowledgement: This work was supported by a grant from the National Natural Science Foundation of China, People&#039;s Republic of China [81102261] and the Innovative Research Funds for the Central South University, People&#039;s Republic of China. [CX2012B088].&lt;br /&gt;
&lt;br /&gt;
===2009 [https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.24177 Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Clinical arthritis was exacerbated by vagotomy and ameliorated by oral nicotine administration. Moreover, oral nicotine inhibited bone degradation and reduced TNFalpha expression in synovial tissue. Both IP-injected nicotine and AR-R17779 ameliorated clinical arthritis and reduced synovial inflammation. This was accompanied by a reduction of TNFalpha levels in both plasma and synovial tissue. The effect of AR-R17779 was more potent compared with that of nicotine and was associated with delayed onset of the disease as well as with protection against joint destruction.&lt;br /&gt;
**Citation: van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009 Jan;60(1):114-22. doi: 10.1002/art.24177. PMID: 19116908.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Auditory&#039;&#039;&#039; =&lt;br /&gt;
===2021 [https://www.nature.com/articles/s41598-021-92588-z Task-dependent effects of nicotine treatment on auditory performance in young-adult and elderly human nonsmokers]=== &lt;br /&gt;
*The present study evaluated acute effects of oral nicotine treatment on three auditory tasks in young adult and elderly, healthy, non-smoking individuals. All had normal hearing within the frequency range of the stimuli presented for the three tasks. Compared to pre-treatment performance, nicotine improved frequency discrimination. Compared to placebo, nicotine produced no overall effects on the two frequency related tasks, but significantly improved intensity discrimination, with more improvement obtained for those who had lower baseline performance. The present results support the hypothesis that nicotine enhances auditory processing, but this enhancement is task-dependent.&lt;br /&gt;
*[https://www.nature.com/articles/s41598-021-92588-z.pdf PDF Version]&lt;br /&gt;
*Citation: Sun, S., Kapolowicz, M.R., Richardson, M. et al. Task-dependent effects of nicotine treatment on auditory performance in young-adult and elderly human nonsmokers. Sci Rep 11, 13187 (2021). doi: 10.1038/s41598-021-92588-z&lt;br /&gt;
&lt;br /&gt;
===2019 [https://pubmed.ncbi.nlm.nih.gov/31832719/ Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers]=== &lt;br /&gt;
*Nicotine improves auditory performance in difficult listening situations. The present results support future investigation of nicotine effects in clinical populations with auditory processing deficits or reduced cholinergic activation.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s00213-019-05421-x PDF Version]&lt;br /&gt;
*Citation: Pham CQ, Kapolowicz MR, Metherate R, Zeng FG. Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers. Psychopharmacology (Berl). 2020 Mar;237(3):833-840. doi: 10.1007/s00213-019-05421-x. Epub 2019 Dec 12. PMID: 31832719; PMCID: PMC7039769.&lt;br /&gt;
*Acknowledgements: This research was supported by grants from the National Institutes of Health to FGZ (5R01DC015587), to RM (4R01-DC013200) and a pre-doctoral fellowship to CQP (UL1-TR000153).&lt;br /&gt;
*Keywords: Acetylcholinergic systems; Auditory processing; Nicotine; Selective attention; Spectral ripple discrimination; Temporal gap detection; Tone in noise detection.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Atopic Dermatitis&#039;&#039;&#039; =&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37454697/ Association of Atopic Dermatitis with Substance Use Disorders: A Case-Control Study in the All of Us Research Program.] ===&lt;br /&gt;
&lt;br /&gt;
* Joshi TP, Bancroft A, DeLeon D, Garcia D, Kunisetty B, Truong P, Kim SJ. J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01361-0. doi: 10.1016/j.jaad.2023.06.051. Online ahead of print. PMID: 37454697 No abstract available.&lt;br /&gt;
* Patients with AD, compared to controls, were more likely to use cannabis (4.4% vs 2.7%, 60 P &amp;lt;0.01), hallucinogens (3.2% vs 1.8%, P &amp;lt;0.01), opioids (3.5% vs 1.3%, P &amp;lt;0.01), and 61 stimulants (2.3% vs 1.5%, P &amp;lt;0.01) and less likely to use e-cigarettes (10.8% vs 15.6%, P &amp;lt;0.01) 62 and regular cigarettes (39.0% vs 56.0%, P &amp;lt;0.01). &lt;br /&gt;
* In multivariable analysis adjusted for age, 63 income, insurance type, race, sex, depression, and anxiety, only the associations with cannabis 64 (aOR 1.49, 95% CI 1.24-1.80), e-cigarette (aOR 0.71, 95% CI 0.65-0.77), and regular cigarette 65 use (aOR 0.65, 95% CI 0.63-0.68) persisted (Table I)&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Autism&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
=== 2020: [https://pubmed.ncbi.nlm.nih.gov/32691528/ The Role of Nicotinic Receptors in the Attenuation of Autism-Related Behaviors in a Murine BTBR T + tf/J Autistic Model] ===&lt;br /&gt;
&lt;br /&gt;
* Nicotinic receptors are distributed throughout the central and peripheral nervous system. Postmortem studies have reported that some nicotinic receptor subtypes are altered in the brains of autistic people.&lt;br /&gt;
* Recent studies have demonstrated the importance of nicotinic acetylcholine receptors (nAChRs) in the autistic behavior of BTBR T + tf/J mouse model of autism. This study was undertaken to examine the behavioral effects of targeted nAChRs using pharmacological ligands, including nicotine and mecamylamine in BTBR T + tf/J and C57BL/6J mice in a panel of behavioral tests relating to autism.&lt;br /&gt;
* Overall, the findings indicate that the pharmacological modulation of nicotinic receptors is involved in modulating core behavioral phenotypes in the BTBR T + tf/J mouse model.&lt;br /&gt;
* LAY SUMMARY: The involvement of brain nicotinic neurotransmission system plays a crucial role in regulating autism-related behavioral features. In addition, the brain of the autistic-like mouse model has a low acetylcholine level. Here, we report that nicotine, at certain doses, improved sociability and reduced repetitive behaviors in a mouse model of autism, implicating the potential therapeutic values of a pharmacological intervention targeting nicotinic receptors for autism therapy.&lt;br /&gt;
* Mouse study, may not explain human response&lt;br /&gt;
* Autism Research 2020 Aug;13(8):1311-1334  doi: 10.1002/aur.2342. Epub 2020 Jul 21.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]=== &lt;br /&gt;
*Taken together, our study provides evidence for the feasibility and tolerability of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine (TN/TNP)&#039;&#039;&#039;]] in a small sample of adults with severe [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Autism Spectrum Disorder (ASD)&#039;&#039;&#039;]] symptoms and pathological chronic aggression and irritability. &lt;br /&gt;
*Our results also suggest that TN may have a beneficial effect on aggression, irritability, and sleep in ASD, though the sample size of this study is too small to make definitive conclusions. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/pdf/nihms-950880.pdf PDF Version]&lt;br /&gt;
*Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.&lt;br /&gt;
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).&lt;br /&gt;
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Behcet&#039;s disease&#039;&#039;&#039; (See also: Aphthous ulcers)= &lt;br /&gt;
*Post on [https://healthunlocked.com/behcetsuk/posts/138632782/nicotine-and-it%E2%80%99s-effects-on-my-beh%C3%A7et%E2%80%99s-for-the-positive Behçet&#039;s UK]. A person started smoking seeking relief from the pain they suffered because of Behcet&#039;s disease.&lt;br /&gt;
&lt;br /&gt;
===2010 [https://academic.oup.com/rheumatology/article/49/3/501/1786816 Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series]=== &lt;br /&gt;
*In this report, we describe five ex-smoker [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;BD&#039;&#039;&#039;]] patients with active mucocutaneous lesions, not responsive to standard pharmacological treatments and treated with transdermal nicotine patches. Four out of five patients quickly responded to nicotine-patch therapy and experienced a complete regression of all mucocutaneous lesions within 6 months of observation.&lt;br /&gt;
**Citation: Giovanni Ciancio, Matteo Colina, Renato La Corte, Andrea Lo Monaco, Francesco De Leonardis, Francesco Trotta, Marcello Govoni, Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series, Rheumatology, Volume 49, Issue 3, March 2010, Pages 501–504, doi: 10.1093/rheumatology/kep401&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.jidonline.org/article/S0022-202X(15)33112-2/fulltext Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet&#039;s disease]===&lt;br /&gt;
*&amp;quot;In conclusion, we observed substantial inhibitory effects of CSE and nicotine on IL-8 and to a lesser extent on IL-6 release by human keratinocytes and HMEC-1 endothelial cells. These findings may explain the beneficial effect of smoking in BD, also because IL-8, and to some extent IL-6, are likely to induce pivotal proinflammatory signals in this disease (Lee et al., 1993). Nicotine may cause immunoregulation by affecting chemokine/cytokine production. This study also demonstrates the different behavior of cells in terms of cytokine release when stimulated with BD patients&#039; sera compared to those of healthy individuals. The in vitro evidence of beneficial effects of nicotine in BD is fundamental to our ongoing clinical trial with nicotine transdermal patches in BD. In addition, the detected beneficial effect of biochanin A implicates this compound as a candidate for future developments in aphthae treatment. The development of topical nicotinic cholinergic receptor subtype-specific agonists is likely to exhibit beneficial effects on skin and mucosae without inducing systemic adverse effects.&amp;quot;&lt;br /&gt;
**Citation: Kalayciyan A, Orawa H, Fimmel S, Perschel FH, González JB, Fitzner RG, Orfanos CE, Zouboulis CC. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet&#039;s disease. J Invest Dermatol. 2007 Jan;127(1):81-9. doi: 10.1038/sj.jid.5700492. Epub 2006 Sep 28. PMID: 17008886.&lt;br /&gt;
***Acknowledgement: Dr Kalayciyan was supported by a grant of the Berlin Foundation for Dermatology. The research project was supported by the Deutsches Register Morbus Adamantiades–Behçet e.V.&lt;br /&gt;
&lt;br /&gt;
===2000 [https://www.nejm.org/doi/10.1056/NEJM200012143432418?url_ver=Z39.88-2003&amp;amp;rfr_id=ori%3Arid%3Acrossref.org&amp;amp;rfr_dat=cr_pub++0pubmed Nicotine Patches for Aphthous Ulcers Due to Behçet&#039;s Syndrome]=== &lt;br /&gt;
*We describe a woman with Behçet&#039;s syndrome characterized by recurrent oral and genital aphthous ulcers, severe eye involvement, and the onset of arthritis at the age of 29 years. At the age of 35 several large and extremely painful buccal aphthous ulcers developed. Therapy with a nicotine patch led to a regression of all aphthous ulcers within a few days. A month later, after the patient had stopped using the nicotine patches, four aphthous ulcers developed within a week. These ulcers rapidly regressed once she resumed using the nicotine patches.&lt;br /&gt;
*[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section)&lt;br /&gt;
**Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Brain Injury / Disease&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2024: [https://pubmed.ncbi.nlm.nih.gov/38698493/ Nicotine inhalant via E-cigarette facilitates sensorimotor function recovery by upregulating neuronal BDNF-TrkB signalling in traumatic brain injury]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Conclusioin: &amp;quot;Post-injury chronic nicotine exposure via vaping facilitates recovery of sensorimotor function by upregulating neuroprotective mBDNF/TrkB/Akt/Erk signalling. These findings suggest potential neuroprotective properties of nicotine despite its highly addictive nature. Thus, understanding the multifaceted effects of chronic nicotine exposure on TBI-associated symptoms is crucial for paving the way for informed and properly managed therapeutic interventions.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15681815/ Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease]=== &lt;br /&gt;
*Several studies have shown that nicotine treatment can attenuate cognitive deficits produced by medial septal lesions, lesions of the nucleus basalis, and traumatic brain injury.&lt;br /&gt;
*[https://sci-hub.st/10.1196/annals.1332.019 PDF Version]&lt;br /&gt;
*Citation: Pauly JR, Charriez CM, Guseva MV, Scheff SW. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Ann N Y Acad Sci. 2004 Dec;1035:316-34. doi: 10.1196/annals.1332.019. PMID: 15681815.&lt;br /&gt;
*Acknowledgements: This work was supported by grants from the National Institutes of Health (NS42196 to J.R.P. and NS39828 to S.W.S.) and the Kentucky Tobacco Research and Development Center. We acknowledge the technical assistance of Melissa Yingling and Khaled Tanwir.&lt;br /&gt;
*KEYWORDS: nicotine; neurodegeneration; neuroprotection&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cancer / Cancer Treatments&#039;&#039;&#039;= &lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S001448272030416X?via%3Dihub Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells]=== &lt;br /&gt;
*Nicotine inhibits ovarian cancer cell ERK and p38 [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;MAPK&#039;&#039;&#039;]] signaling.&lt;br /&gt;
*Nicotine inhibits ovarian cancer proliferation and spheroid invasion.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.yexcr.2020.112167 PDF Version]&lt;br /&gt;
*Citation: Sarah J. Harmych, Jay Kumar, Mesa E. Bouni, Deborah N. Chadee, Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells, Experimental Cell Research, Volume 394, Issue 1, 2020, 112167, ISSN 0014-4827, doi: 10.1016/j.yexcr.2020.112167.&lt;br /&gt;
*Acknowledgements: This work was supported by the National Institutes of Health [R15 CA199164] and [R15 CA241898] to D.N.C. &lt;br /&gt;
*Keywords: Nicotine, Ovarian cancer, Spheroid, MAPK, Invasion&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.sciencedirect.com/science/article/abs/pii/S0014299913003270?via%3Dihub Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models]=== &lt;br /&gt;
*Nicotine significantly reduced antiviral-dependent alterations of the nociceptive threshold. &lt;br /&gt;
*Moreover, nicotine decreased neuropathic pain induced by repeated intraperitoneal administration of the anticancer agent oxaliplatin (2.4 mg/kg), lowering the hypersensitivity to mechanical and thermal stimuli. &lt;br /&gt;
*Intraperitoneal nicotine administration controls neuropathic pain evoked by traumatic or toxic nervous system alterations. These results support the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] modulation as a possible therapeutic approach to the complex, undertreated chemotherapy-induced neuropathies. &lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.ejphar.2013.04.022 PDF Version]&lt;br /&gt;
*Citation: Lorenzo Di Cesare Mannelli, Matteo Zanardelli, Carla Ghelardini, Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models, European Journal of Pharmacology, Volume 711, Issues 1–3, 2013, Pages 87-94, ISSN 0014-2999, doi: 10.1016/j.ejphar.2013.04.022.&lt;br /&gt;
*Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research.&lt;br /&gt;
*Keywords: nAChR; Dideoxycytidine; Oxaliplatin; Antiviral; Anticancer, pain, chemotherapy, nicotine, neuropathy&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cannabis / THC&#039;&#039;&#039;= &lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32034447/ Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial]=== &lt;br /&gt;
*The findings provide the first evidence that [[Special:MyLanguage/Abbreviations|NP (Nicotine Patch)]] may be able to attenuate NA (negative affect) - related withdrawal symptoms in individuals with cannabis use disorder who are not heavy users of tobacco or nicotine.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s00213-020-05476-1 PDF Version]&lt;br /&gt;
*Citation: Gilbert DG, Rabinovich NE, McDaniel JT. Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial. Psychopharmacology (Berl). 2020 May;237(5):1507-1519. doi: 10.1007/s00213-020-05476-1. Epub 2020 Feb 7. PMID: 32034447.&lt;br /&gt;
*Acknowledgement: The study was supported by NIH grant R01DA031006 awarded to David Gilbert.&lt;br /&gt;
*Keywords: Cannabis; Marijuana; Negative affect; Nicotine; Smoking; THC; Testing effect; Withdrawal symptoms.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Cardiovascular&#039;&#039;&#039; =&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/pii/S0014488624002723 Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these findings indicate that acute nicotine exposure enhances functional stroke recovery. Future studies will have to evaluate the effects of (1) chronic nicotine exposure, a clinically relevant vascular risk factor, and (2) the cessation of nicotine exposure, which is widely recommended post-stroke, but might have detrimental effects in the early stroke recovery phase.&lt;br /&gt;
**Citation: Abbaspour S, Fahanik-Babaei J, Adeli S, Hermann DM, Sardari M. Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state. Exp Neurol. 2024 Sep 13;382:114946. doi: 10.1016/j.expneurol.2024.114946. Epub ahead of print. PMID: 39278587.&lt;br /&gt;
***Funding: None&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://pubmed.ncbi.nlm.nih.gov/38529793/ Transdermal Nicotine Patch Increases the Number and Function of Endothelial Progenitor Cells in Young Healthy Nonsmokers without Adverse Hemodynamic Effects] ===&lt;br /&gt;
* This study aimed to explore the influence of TNPs on circulating EPCs with surface markers of CD34, CD133, and/or KDR, and colony-forming function plus migration activity of early EPCs derived from cultured peripheral blood mononuclear cells before and after TNP treatments in young healthy nonsmokers.&lt;br /&gt;
* PWA analyses on day 7, compared with pretreatment, did not show significant change except diastolic pressure time index, which was prolonged and implied potential vascular benefit. In conclusion, 7-day TNP treatments could be a practical strategy to enhance angiogenesis of circulating EPCs to alleviate tissue ischemia without any hemodynamic concern.&lt;br /&gt;
* Nicotine patches appear to promote blood vessel formation, without adverse effects.&lt;br /&gt;
&lt;br /&gt;
=== 2015 [https://www.nature.com/articles/srep15895 Dose-dependent protective effect of nicotine in a murine model of viral myocarditis induced by coxsackievirus B3] ===&lt;br /&gt;
&lt;br /&gt;
* The alpha 7 nicotinic acetylcholine receptor (alpha7 nAChR) was recently described as an anti-inflammatory target in various inflammatory diseases. The aim of this study was to investigate the dose-related effects of nicotine, an alpha7 nAChR agonist, in murine model of viral myocarditis.&lt;br /&gt;
* The survival rate on day 14 increased in a dose-dependent fashion and was markedly higher in the 0.2 and 0.4 mg/kg nicotine groups than in the infected untreated group.&lt;br /&gt;
* The findings suggest that alpha7 nAChR agonists may be a promising new strategy for patients with viral myocarditis.&lt;br /&gt;
* Animal study (mice)&lt;br /&gt;
* Ge Li-Sha, Zhao Jing-Lin, Chen Guang-Yi, Liu Li, Zhou De-Pu &amp;amp; Li Yue-Chun &#039;&#039;Scientific Reports&#039;&#039; volume 5, Article number: 15895 (2015) &lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Chlamydia Pneumoniae&#039;&#039;&#039;=&lt;br /&gt;
*Chlamydia pneumoniae is a type of bacteria that can cause respiratory tract infections, such as pneumonia. C. pneumoniae is one cause of community-acquired pneumonia or lung infections developed outside of a healthcare setting. However, not everyone exposed to C. pneumoniae will develop pneumonia. [https://www.cdc.gov/pneumonia/atypical/cpneumoniae/index.html Source: US CDC]&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection...&lt;br /&gt;
*Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cognitive / IQ / Memory&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10998423/ An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence] ===&lt;br /&gt;
*Conclusion: Overall, the nicotine containing products improved sustained attention and mood while reducing smoking urges, with the studied e-cigarettes having comparable effects to combustible cigarettes across the assessed cognitive parameters and mood measures. These results demonstrate the potential role of e-cigarettes to provide an acceptable alternative for combustible cigarettes among people who would otherwise continue to smoke.&lt;br /&gt;
*Citation: Harry J. Green, Olivia K. O’Shea, Jack Cotter, Helen L. Philpott, and Nik Newland. Harm Reduct J. 2024; 21: 78. Published online 2024 Apr 6. doi: 10.1186/s12954-024-00993-0 PMCID: PMC10998423&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://www.frontiersin.org/articles/10.3389/fnins.2023.1252705/full Editorial: Nicotine and its derivatives in disorders of cognition: a challenging new topic of study] ===&lt;br /&gt;
&lt;br /&gt;
* Front. Neurosci., 18 July 2023 Sec. Neurodegeneration Volume 17 - 2023 | &amp;lt;nowiki&amp;gt;https://doi.org/10.3389/fnins.2023.1252705&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
* Albert Gjedde, Department of Neuroscience, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark&lt;br /&gt;
* Nicotine is a compound of considerable interest to neuroscience, in contexts of physiology as well as pathology of brain functions related to neurotransmitter mechanisms. Nicotine is an alkaloid that exists naturally in plants such as tomatoes and potatoes, with the highest levels in the tobacco plant.&lt;br /&gt;
* In mammalian brains, nicotine has multiple actions that appear to be accidents of evolution, as no specific relation springs to mind between the functions of nicotine in plants and animals.&lt;br /&gt;
* The following discussion expands upon the three topics of biology, therapy, and possible prevention, as related to cognition, in the three reviews and the three original studies included in the collection.&lt;br /&gt;
** Conclusion: Questions remain of how nicotine treatment in normal aging should proceed, including length of treatment, dose of nicotine, handling of smokers, effects of AD risk factors, and many others. While data from studies of psychiatric and memory-impaired subjects indicate that nicotine may relieve cognitive symptoms, it is mandatory to test the benefits of nicotine in normal aging in order to fill gaps in the literature and to verify the extent to which nicotine is useful as a pharmacologic agent that prevents pathological aging.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36736944/ Nicotine&#039;s effect on cognition, a friend or foe?] ===&lt;br /&gt;
* In this review, we first introduce the beneficial effect of nicotine on cognition including attention, short-term memory and long-term memory. We next summarize the beneficial effect of nicotine on cognition under pathological conditions, including Alzheimer&#039;s disease, Parkinson&#039;s disease, Schizophrenia, Stress-induced Anxiety, Depression, and drug-induced memory impairment.&lt;br /&gt;
* We can only access the abstract, but would be interested to read the whole thing if anyone can help?&lt;br /&gt;
* Human study&lt;br /&gt;
* Qian Wang, Weihong Du, Hao Wang, Panpan Geng, Yanyun Sun, Junfang Zhang, Wei Wang, Xinchun Jin, PMID: 36736944 DOI: 10.1016/j.pnpbp.2023.110723&lt;br /&gt;
&lt;br /&gt;
=== 2021: [https://www.spandidos-publications.com/10.3892/mmr.2021.12037# Molecular insights into the benefits of nicotine on memory and cognition] ===&lt;br /&gt;
&lt;br /&gt;
* Published online on: March 25, 2021 Molecular Medicine Reports  &amp;lt;nowiki&amp;gt;https://doi.org/10.3892/mmr.2021.12037&amp;lt;/nowiki&amp;gt; Article Number: 398&lt;br /&gt;
* Author: Ahmad Alhowail&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0306452220304723?via%3Dihub Effects of Nicotine on Task Switching and Distraction in Non-smokers. An fMRI Study]=== &lt;br /&gt;
*Nicotine improves sustained attention and reduces distractor interference, promoting cognitive stability. Nicotine enhances response times without differential impact on task switching or distraction.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.neuroscience.2020.07.029 PDF Version]&lt;br /&gt;
*Citation: Stefan Ahrens, Christiane M. Thiel, Effects of Nicotine on Task Switching and Distraction in Non-smokers. An fMRI Study, Neuroscience, Volume 444, 2020, Pages 43-53, ISSN 0306-4522, doi: 10.1016/j.neuroscience.2020.07.029.&lt;br /&gt;
*Acknowledgements: This work was supported by a grant from the German Research Foundation DFG TH766/8-1.&lt;br /&gt;
*Key words: nicotine, cholinergic, cognitive control, distraction, task switching, neuroimaging&lt;br /&gt;
&lt;br /&gt;
===2019: [https://www.frontiersin.org/articles/10.3389/fnins.2018.01002/full#B5 Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review]===&lt;br /&gt;
*Nicotine lowers learning and memory impairment in some neurological disorders.&lt;br /&gt;
*Citation: Majdi, A., Kamari, F., &amp;amp; Gjedde, A. (2019). Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review. Frontiers in Neuroscience, 12. https://doi.org/10.3389/fnins.2018.01002&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== &lt;br /&gt;
*Preclinical models and human studies have demonstrated that nicotine has cognitive-enhancing effects. Attention, working memory, fine motor skills and episodic memory functions are particularly sensitive to nicotine’s effects. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/pdf/CN-16-403.pdf PDF Version]&lt;br /&gt;
*Citation: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Curr Neuropharmacol. 2018;16(4):403-414. doi: 10.2174/1570159X15666171103152136. PMID: 29110618; PMCID: PMC6018192.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2013: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/ A fresh look at tobacco harm reduction: the case for the electronic cigarette]===&lt;br /&gt;
*Smokers of any age can reap substantial health benefits by quitting. In fact, no other single public health effort is likely to achieve a benefit comparable to large-scale smoking cessation.&lt;br /&gt;
*E-cigs might be the most promising product for tobacco harm reduction to date, because, besides delivering nicotine vapour without the combustion products that are responsible for nearly all of smoking’s damaging effect, they also replace some of the rituals associated with smoking behaviour.&lt;br /&gt;
*Nicotine’s beneficial effects include correcting problems with concentration, attention and memory, as well as improving symptoms of mood impairments. Keeping such disabilities at bay right now can be much stronger motivation to continue using nicotine than any threats of diseases that may strike &lt;br /&gt;
*Nicotine’s beneficial effects can be controlled, and the detrimental effects of the smoky delivery system can be attenuated, by providing the drug via less hazardous delivery systems. Although more research is needed, e-cigs appear to be effective cigarette substitutes for inveterate smokers, and the health improvements enjoyed by switchers do not differ from those enjoyed by tobacco/nicotine abstainers.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/pdf/1477-7517-10-19.pdf PDF Version]&lt;br /&gt;
&lt;br /&gt;
===2012: [https://pubmed.ncbi.nlm.nih.gov/22503574/ The electronic-cigarette: Effects on desire to smoke, withdrawal symptoms and cognition]=== &lt;br /&gt;
*The e-cigarette can reduce desire to smoke and nicotine withdrawal symptoms 20 minutes after use.&lt;br /&gt;
*The nicotine content in this respect may be more important for males.&lt;br /&gt;
*The first study to demonstrate that the nicotine e-cigarette can improve working memory.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.addbeh.2012.03.004 PDF Version]&lt;br /&gt;
*Citation: Dawkins, L., Turner, J., Hasna, S., &amp;amp; Soar, K. (2012). The electronic-cigarette: Effects on desire to smoke, withdrawal symptoms and cognition. Addictive Behaviors, 37(8), 970–973. doi:10.1016/j.addbeh.2012.03.004 &lt;br /&gt;
*Electronic Cigarette Company (TECC) supplied the e-cigarettes and cartridges for this study. TECC had no involvement in the design or conduct of the study.&lt;br /&gt;
&lt;br /&gt;
===2003 [https://www.nature.com/articles/1300202 Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects]=== &lt;br /&gt;
*Compared to placebo, nicotine and donepezil significantly improved, while alcohol significantly impaired overall flight performance. Both cholinergic drugs showed the largest effects on flight tasks requiring sustained visual attention.&lt;br /&gt;
*[https://www.nature.com/articles/1300202.pdf PDF Version]&lt;br /&gt;
*Citation: Mumenthaler, M., Yesavage, J., Taylor, J. et al. Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects. Neuropsychopharmacol 28, 1366–1373 (2003). doi: 10.1038/sj.npp.1300202&lt;br /&gt;
*Acknowledgements: This research was supported in part by NIMH Grant 40041; NIA Grant AG17824; the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); the Alcohol Beverage Medical Research Foundation; the Swiss Foundation for Alcohol Research; the Swiss National Science Foundation; and the Medical Research Service of the Department of Veterans Affairs.&lt;br /&gt;
*Keywords: cholinergic agents, ethanol, cognition, psychomotor performance, psychopharmacology, aerospace medicine&lt;br /&gt;
&lt;br /&gt;
===1996 [https://link.springer.com/article/10.1007/BF02805972 Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers]===&lt;br /&gt;
*These results are consistent with other recent research suggesting a primary effect of nicotine in enhancing cognitive performance.&lt;br /&gt;
*Citation: Foulds, J., Stapleton, J., Swettenham, J. et al. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology 127, 31–38 (1996). https://doi.org/10.1007/BF02805972&lt;br /&gt;
&lt;br /&gt;
===1994 [https://link.springer.com/article/10.1007/BF02245346 Smoking and raven IQ]=== &lt;br /&gt;
*Nicotine has recently been shown to enhance measures of information processing speed including the decision time (DT) component of simple and choice reaction time and the string length measure of evoked potential waveform complexity. Both (DT and string length) have been previously demonstrated to correlate with performance on standard intelligence tests ([[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;IQ&#039;&#039;&#039;]]).&lt;br /&gt;
*In this experiment we used the Raven [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Advanced Progressive Matrices (APM)&#039;&#039;&#039;]] test. APM scores were significantly higher in the smoking session compared to the non-smoking session, suggesting that nicotine acts to enhance physiological processes underlying performance on intellectual tasks.&lt;br /&gt;
*[https://sci-hub.st/https://link.springer.com/article/10.1007/BF02245346 PDF Version]&lt;br /&gt;
*Citation: Stough, C., Mangan, G., Bates, T. et al. Smoking and raven IQ. Psychopharmacology 116, 382–384 (1994). doi: 10.1007/BF02245346&lt;br /&gt;
*Key words: Intelligence, APM, Nicotine, Smoking Cholinergic system&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1579636/ Nicotine as a cognitive enhancer]=== &lt;br /&gt;
*Nicotine improves attention in a wide variety of tasks in healthy volunteers. &lt;br /&gt;
*Nicotine improves immediate and longer term memory in healthy volunteers. &lt;br /&gt;
*Nicotine improves attention in patients with probable Alzheimer&#039;s Disease. &lt;br /&gt;
*While some of the memory effects of nicotine may be due to enhanced attention, others seem to be the result of improved consolidation as shown by post-trial dosing. &lt;br /&gt;
*[https://sci-hub.st/10.1016/0278-5846(92)90069-q PDF Version]&lt;br /&gt;
*Citation: Warburton DM. Nicotine as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1992 Mar;16(2):181-91. doi: 10.1016/0278-5846(92)90069-q. PMID: 1579636.&lt;br /&gt;
*Keywords: acetylcholine, Alzheimer&#039;s Disease, attention, cholinergic, memory, nicotine, scopolamine.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;COVID / Long COVID / Post-COVID Syndrome / Long-Haul COVID (SARS-CoV-2)&#039;&#039;&#039;=&lt;br /&gt;
*See Also: The Inflamation Section &lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37264452/ The controversial effect of smoking and nicotine in SARS-CoV-2 infection.] ===&lt;br /&gt;
* States the obvious: the exposure (smoke vs. nicotine and dose need to be characterised correctly).&lt;br /&gt;
* Considering that the effects of nicotine and cigarette smoke are different from each other, it is necessary to be careful in generalizing the effects of nicotine and cigarette to each other in the conducted researches. The generalization and the undifferentiation of nicotine from smoke is a significant bias. Moreover, different doses of nicotine stimulate different effects (dose-dependent response). In addition to further assessing the role of nicotine in COVID-19 infection and any other cases, a clever assessment of underlying diseases should also be considered to achieve a guideline for health providers and a personalized approach to treatment.&lt;br /&gt;
* Salehi Z, Motlagh Ghoochani BFN, Hasani Nourian Y, Jamalkandi SA, Ghanei M. Allergy Asthma Clin Immunol. 2023 Jun 1;19(1):49. doi: 10.1186/s13223-023-00797-0. PMID: 37264452 Review.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36650574/ Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?] ===&lt;br /&gt;
* Nicotine COVID/SARS-CoV-2 interaction mystery takes another turn.&lt;br /&gt;
* Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh).&lt;br /&gt;
* We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.&lt;br /&gt;
*In all four of the cases we studied, transcutaneous use of nicotine led to a near immediate improvement in symptoms and rapid restitutio ad integrum. The course of symptom improvement was as distinct as the clinical presentation of post-COVID-19 syndrome in each patient.&lt;br /&gt;
*Citation: Leitzke M. Bioelectron Med. 2023 Jan 18;9(1):2. doi: 10.1186/s42234-023-00104-7. PMID: 36650574 Free PMC article.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.nature.com/articles/s41598-023-45072-9 Treatment of 95 post-Covid patients with SSRIs]===&lt;br /&gt;
*To stick nicotine patches helps PCS (post-COVID syndrome) patients. This may be not only because nicotine is a nicotinic receptor agonist and therefore an opponent of these poisonous metabolites, but nicotine is a strong acetylcholine (ACh) agonist as well.&lt;br /&gt;
*Citation: Rus, C.P., de Vries, B.E.K., de Vries, I.E.J. et al. Treatment of 95 post-Covid patients with SSRIs. Sci Rep 13, 18599 (2023). https://doi.org/10.1038/s41598-023-45072-9&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183099/ Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials]===&lt;br /&gt;
* Studies show that the penetration of SARS-CoV-2 into upper respiratory tract, bronchial and pulmonary cells involve transmembrane receptor ACE2, which probably interacts with acetylcholine nicotinic receptors of the α7 subtype. The mechanism of the interactions remains hypothetical.&lt;br /&gt;
* Despite a relatively safe tolerance profile, transdermal nicotine therapy in non-smokers can only be used in clinical trials. There is a lack of formal assessment of the potential risk of developing a tobacco addiction. This review offers baseline data to set a transdermal nicotine protocol for non-smokers with a new purpose.&lt;br /&gt;
* Analyses of nicotine administration protocols and safety were conducted after reviewing Medline and Science Direct databases performing a search using the words [transdermal nicotine] AND [non-smoker] AND selected diseases.&lt;br /&gt;
* Excessive secondary cytokine reaction plays a role in the mortality associated with COVID. One of the hypotheses to explain the effect of nicotine on the occurrence of severe forms of COVID and death is based on the loss of the downregulation of the parasympathetic nervous system, which exerts an inhibitory effect on cytokine storm, especially in the lung and digestive tract. The α 7-type nicotinic receptors are part of this chain of reaction.&lt;br /&gt;
* B. Dautzenberg, A. Levi, M. Adler, and R. Gaillardc. Respir Med Res. 2021 Nov; 80: 100844. Published online 2021 Jun 7. doi: 10.1016/j.resmer.2021.100844 PMCID: PMC8183099 PMID: 34153704&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704168/ Does Nicotine Prevent Cytokine Storms in COVID-19?]===&lt;br /&gt;
*Case study of one individual&lt;br /&gt;
*Nicotine, an α7-nACh receptor agonist, may boost the cholinergic anti-inflammatory pathway and hinder the uncontrolled overproduction of pro-inflammatory cytokines triggered by the SARS-CoV-2 virus, which is understood to be the main pathway to poor outcomes and death in severe COVID-19.&lt;br /&gt;
*In the absence of any effective treatment for COVID-19, further research as to whether nicotine replacement offers protection against severe SAR-CoV-2 infection in smokers is clearly essential. If the mechanisms through which nicotine may interact with the virus remain speculative, the effects of route of administration, duration, dosing and frequency of use of nicotine on any such interaction are unknown. Should NRT be found to be of help in the management of COVID-19, it would be yet another strong reason to persuade smokers to switch to NRT and ultimately quit smoking.&lt;br /&gt;
*Citation: Dratcu L, Boland X. Does Nicotine Prevent Cytokine Storms in COVID-19? Cureus. 2020 Oct 28;12(10):e11220. doi: 10.7759/cureus.11220. PMID: 33269148; PMCID: PMC7704168.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300218/ Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm]===&lt;br /&gt;
*Abstract: &amp;quot;SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.&amp;quot;&lt;br /&gt;
*Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218.&lt;br /&gt;
&lt;br /&gt;
===2020: [https://www.sciencedirect.com/science/article/pii/S2214750020302924 Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system]===&lt;br /&gt;
*Nicotine could maintain or restore the function of the cholinergic anti-inflammatory system and thus control the release and activity of pro-inflammatory cytokines. This could prevent or suppress the cytokine storm. This hypothesis needs to be examined in the laboratory and the clinical setting.&lt;br /&gt;
*Citation: Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, Vantarakis A, Poulas K. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020 Apr 30;7:658-663. doi: 10.1016/j.toxrep.2020.04.012. PMID: 32355638; PMCID: PMC7192087.&lt;br /&gt;
&lt;br /&gt;
=== 2019: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679833/ Mitochondria as a possible target for nicotine action] ===&lt;br /&gt;
&lt;br /&gt;
* See also this twitter thread for detailed information on possible mechanisms. https://x.com/angryhacademic/status/1741968457296490977?s=20&lt;br /&gt;
* This review presents a comprehensive overview of the present knowledge of nicotine action on mitochondrial function. Observed effects of nicotine exposure on the mitochondrial respiratory chain, oxidative stress, calcium homeostasis, mitochondrial dynamics, biogenesis, and mitophagy are discussed, considering the context of the experimental design.&lt;br /&gt;
* The potential action of nicotine on cellular adaptation and cell survival is also examined through its interaction with mitochondria. Although a large number of studies have demonstrated the impact of nicotine on various mitochondrial activities, elucidating its mechanism of action requires further investigation.&lt;br /&gt;
* J Bioenerg Biomembr. 2019; 51(4): 259–276. Published online 2019 Jun 13. doi: 10.1007/s10863-019-09800-z PMCID: PMC6679833 PMID: 31197632&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Digestive Tract / Bowel&#039;&#039;&#039;= &lt;br /&gt;
===2024: [https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntae193/7727428 The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis]===&lt;br /&gt;
*&amp;quot;Despite different mechanisms of action, both ENDS and CCs attenuated on-going colon inflammation, enhanced healing and ameliorated recovery of injured intestines of DSS-treated mice and UC patients.&amp;quot;&lt;br /&gt;
**Citation: Kastratovic N, Markovic V, Arsenijevic A, Volarevic A, Zdravkovic N, Zdravkovic M, Brankovic M, Gmizic T, Harrell CR, Jakovljevic V, Djonov V, Volarevic V. The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis. Nicotine Tob Res. 2024 Aug 5:ntae193. doi: 10.1093/ntr/ntae193. Epub ahead of print. PMID: 39101540.&lt;br /&gt;
***Paywalled, unable to view funding/COI&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects]===&lt;br /&gt;
*Analysis of several studies - some animal.&lt;br /&gt;
*In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity.&lt;br /&gt;
**Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889&lt;br /&gt;
***Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S000927971931734X Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Conclusion: &amp;quot;Taken together, we demonstrated that nicotine inhibits apoptosis and proliferation by modulating AMPK/mTOR pathway-mediated autophagy and improves colitis severity in the DSS-induced UC mouse model. These findings provide new insights into the mechanism of nicotine treatment on UC autophagy. Further exploration of the mechanism of nicotine in autophagy and targeting factors might be considered a new approach for ulcerative colitis treatment.&amp;quot;&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.cbi.2020.108943 PDF Full paper]&lt;br /&gt;
**Citation: Gao Q, Bi P, Luo D, Guan Y, Zeng W, Xiang H, Mi Q, Yang G, Li X, Yang B. Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model. Chem Biol Interact. 2020 Feb 1;317:108943. doi: 10.1016/j.cbi.2020.108943. Epub 2020 Jan 10. PMID: 31926917.&lt;br /&gt;
***Acknowledgement: This work was supported by the Yunnan Key Laboratory of Tobacco Chemistry Project [Grant No. 2017539200340397].&lt;br /&gt;
&lt;br /&gt;
===2018 [https://academic.oup.com/jleukbio/article-abstract/104/5/1013/6935503 Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment]===&lt;br /&gt;
*Animal/Cell study&lt;br /&gt;
*These results supported our hypothesis that nicotine treatment ameliorated colitis through the suppression of MAdCAM-1 expression on the microvessels in the inflamed colon. Further investigation is warranted on the role of nicotine in the treatment of UC.&lt;br /&gt;
*[https://sci-hub.st/10.1002/JLB.3A0717-304R PDF Full paper]&lt;br /&gt;
**Citation: Maruta K, Watanabe C, Hozumi H, Kurihara C, Furuhashi H, Takajo T, Okada Y, Shirakabe K, Higashiyama M, Komoto S, Tomita K, Nagao S, Ishizuka T, Miura S, Hokari R. Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment. J Leukoc Biol. 2018 Nov;104(5):1013-1022. doi: 10.1002/JLB.3A0717-304R. Epub 2018 Jun 14. PMID: 29901817.&lt;br /&gt;
***Acknowledgement: This research was supported by grants from the National Defense Medical College, by Grants-in-aid for the Intractable Diseases Project of the Ministry of Health, Labour, and Welfare of Japan, and by Grantsin-aid for Scientific Research from the Japanese Ministry of Education (2646080).&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533410/ Novel Insights on the Effect of Nicotine in a Murine Colitis Model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Administration of low, but not high, doses of oral nicotine in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of tumor necrosis factor-α.&lt;br /&gt;
**Citation: AlSharari SD, Akbarali HI, Abdullah RA, Shahab O, Auttachoat W, Ferreira GA, White KL, Lichtman AH, Cabral GA, Damaj MI. Novel insights on the effect of nicotine in a murine colitis model. J Pharmacol Exp Ther. 2013 Jan;344(1):207-17. doi: 10.1124/jpet.112.198796. Epub 2012 Oct 31. PMID: 23115221; PMCID: PMC3533410.&lt;br /&gt;
***Acknowledgement: This work was supported by National Institutes of Health [Grants DA-019377; (to M.I.D.) and DK 046367] (to H.I.A.).&lt;br /&gt;
&lt;br /&gt;
===2012 [https://journals.physiology.org/doi/full/10.1152/ajpgi.00411.2011 Nicotine suppresses hyperexcitability of colonic sensory neurons and visceral hypersensivity in mouse model of colonic inflammation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*&amp;quot;In summary, in an acute and postinflammatory model of colitis, we demonstrated that nAChRs mediate suppression of hyperexcitability of colonic sensory. The present study also highlights the potential of in vivo treatment with nicotine towards its antinociceptive effects in colonic inflammation.&amp;quot;&lt;br /&gt;
**Citation: Abdrakhmanova GR, Kang M, Imad Damaj M, Akbarali HI. Nicotine suppresses hyperexcitability of colonic sensory neurons and visceral hypersensivity in mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol. 2012 Apr;302(7):G740-7. doi: 10.1152/ajpgi.00411.2011. Epub 2012 Jan 12. PMID: 22241859; PMCID: PMC3330777.&amp;quot;&lt;br /&gt;
***Acknowledgement: This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-046367 (to H. I. Akbarali).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
**Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
***Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.hindawi.com/journals/grp/2008/237185/ Nicotine Enemas for Active Crohn&#039;s Colitis: An Open Pilot Study]=== &lt;br /&gt;
*Smoking has a detrimental effect in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Crohn&#039;s disease (CD)&#039;&#039;&#039;]], but this may be due to factors in smoking other than nicotine. Given that transdermal nicotine benefits [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ulcerative colitis (UC)&#039;&#039;&#039;]], and there is a considerable overlap in the treatment of UC and CD, the possible beneficial effect of nicotine has been examined in patients with Crohn&#039;s colitis.&lt;br /&gt;
*In this relatively small study of patients with active Crohn&#039;s colitis, 6 mg nicotine enemas appeared to be of clinical benefit in most patients. They were well tolerated and safe.&lt;br /&gt;
*[http://downloads.hindawi.com/journals/grp/2008/237185.pdf PDF Version]&lt;br /&gt;
**Citation: J. R. Ingram, J. Rhodes, B. K. Evans, and G. A. O. Thomas, Hindawi Publishing Corporation, Gastroenterology Research and Practice, Volume 2008, Article ID 237185, 6 pages, doi:10.1155/2008/237185&lt;br /&gt;
***Acknowledgements: J. R. Ingram was supported by the Gastrointestinal Foundation Trust. SLA Pharma gave financial support to the project. The authors are indebted to Dr. J. T. Green (of Cardiff and Vale Hospitals Trust) who referred patients, and to Professor G. T. Williams (GTW) who performed all histological assessments.&lt;br /&gt;
&lt;br /&gt;
===2004 [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004722.pub2/full Transdermal nicotine for induction of remission in ulcerative colitis]=== &lt;br /&gt;
*Ulcerative colitis is largely a disease of nonsmokers and patients who have quit smoking. Randomised controlled trials were therefore developed to test the hypothesis that nicotine patches can induce remission of a flare of ulcerative colitis. This review provides evidence that transdermal nicotine is superior to placebo (fake patch) for the treatment of active ulcerative colitis.&lt;br /&gt;
*[https://sci-hub.st/https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004722.pub2/full PDF Version]&lt;br /&gt;
**Citation: McGrath, J., McDonald, J. W., &amp;amp; MacDonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004722.pub2&lt;br /&gt;
***Acknowledgements: Funding for the IBD/FBD Review Group (October 1, 2005 - September 30, 2010) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch; the Canadian Agency for Drugs and Technologies in Health (CADTH); and the CIHR Institutes of Health Services and Policy Research; Musculoskeletal Health and Arthritis; Gender and Health; Human Development, Child and Youth Health; Nutrition, Metabolism and Diabetes; and Infection and Immunity. Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12072594/ Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Conclusions: (1) Two weeks of nicotine administration leads to contrasting effects on jejunal and colonic inflammation in IL-10 -/- mice. (2) Nicotine ameliorated inflammation in the colon, which was associated with enhanced expression of two protective peptides.&lt;br /&gt;
*[https://sci-hub.st/10.1097/00042737-200206000-00005 PDF of full paper]&lt;br /&gt;
**Citation: Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. Eur J Gastroenterol Hepatol. 2002 Jun;14(6):607-14. doi: 10.1097/00042737-200206000-00005. PMID: 12072594.&lt;br /&gt;
&lt;br /&gt;
===1999 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/ Nicotine treatment for ulcerative colitis]=== &lt;br /&gt;
*No withdrawal symptoms suggesting nicotine addiction have been reported either after 4–6 weeks of therapy in short-term studies, or after a period of up to 6 months in the only long-term study available&lt;br /&gt;
*It can be concluded from these data that transdermal nicotine alone has limited efficacy in active ulcerative colitis and is ineffective as maintenance treatment. On the other hand, if administered in combination with mesalazine, nicotine is superior to placebo in promoting clinical remission of ulcerative colitis of mild to moderate degree, may represent an efficacious alternative to steroids in selected cases and, when effective, seems to exert a longer-lasting therapeutic effect than prednisone.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/pdf/bcp0048-0481.pdf PDF Version]&lt;br /&gt;
**Citation: Guslandi M. Nicotine treatment for ulcerative colitis. Br J Clin Pharmacol. 1999 Oct;48(4):481-4. doi: 10.1046/j.1365-2125.1999.00039.x. PMID: 10583016; PMCID: PMC2014383.&lt;br /&gt;
***No funding/COI information&lt;br /&gt;
&lt;br /&gt;
===1996 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2398677/ The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis.]=== &lt;br /&gt;
*Nicotine is believed to be the pharmacological ingredient of tobacco that is responsible for this beneficial deterrent of UC and several clinical trials using nicotine have demonstrated it to be an effective therapeutic agent in the treatment of ulcerative colitis. Although the aetiology of ulcerative colitis is unclear, current research using nicotine-based products has produced some interesting clues, together with the possibility of some form of therapeutic treatment based on nicotine administration.&lt;br /&gt;
*[https://sci-hub.st/10.1136/pgmj.72.854.714 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J. The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Postgrad Med J. 1996 Dec;72(854):714-8. doi: 10.1136/pgmj.72.854.714. PMID: 9015463; PMCID: PMC2398677.&lt;br /&gt;
&lt;br /&gt;
===1996: [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*Nicotine may have therapeutic uses in the treatment of ulcerative colitis.&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1994: [https://pubmed.ncbi.nlm.nih.gov/8114833/ Transdermal nicotine for active ulcerative colitis]===&lt;br /&gt;
*The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.&lt;br /&gt;
**Citation: Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994 Mar 24;330(12):811-5. doi: 10.1056/NEJM199403243301202. PMID: 8114833.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against ulcerative colitis (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Down&#039;s Syndrome&#039;&#039;&#039;= &lt;br /&gt;
===2001: [https://link.springer.com/chapter/10.1007/978-3-7091-6262-0_19 Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome]===&lt;br /&gt;
*To explore the potential for cognitive enhancement utilizing nicotinic stimulation, 8 patients with Down syndrome (aged 18.5–31 years) received placebo and a single dose of transdermal nicotine (5mg patch) over 2h in a single-blind, within-subjects repeated measures design. &lt;br /&gt;
*Neuropsychological tests exhibited improvements in digit symbol performance subtest in 4 of 8 subjects and 7 of 8 subjects in the Frankfurt Attention Inventory. These results suggest that stimulating central nicotinic receptors might have an acute cognitive benefit in young adult Down syndrome subjects.&lt;br /&gt;
*Citation: Bernert G., Sustrova M., Sovcikova E., Seidl R., Lubec G. (2001) Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome. In: Lubec G. (eds) Protein Expression in Down Syndrome Brain. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6262-0_19&lt;br /&gt;
&lt;br /&gt;
===2000 [https://pubmed.ncbi.nlm.nih.gov/11052587/ Effects of transdermal nicotine on cognitive performance in Down&#039;s syndrome]=== &lt;br /&gt;
*We investigated the effect of nicotine-agonistic stimulation with 5 mg transdermal patches, compared with placebo, on cognitive performance in five adults with the disorder. Improvements possibly related to attention and information processing were seen for Down&#039;s syndrome patients compared with healthy controls. Our preliminary findings are encouraging, although not generalizable because of small numbers. &lt;br /&gt;
*[https://sci-hub.st/10.1016/S0140-6736(00)02848-8 PDF Version]&lt;br /&gt;
*Seidl R, Tiefenthaler M, Hauser E, Lubec G. Effects of transdermal nicotine on cognitive performance in Down&#039;s syndrome. Lancet. 2000 Oct 21;356(9239):1409-10. doi: 10.1016/S0140-6736(00)02848-8. PMID: 11052587.&lt;br /&gt;
*Acknowledgements: We thank Pharmacia-Upjohn, Uppsala, Sweden, for providing transdermal nicotine patches. This study was supported by the Red Bull Company, Salzburg.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Dyskinesia&#039;&#039;&#039;=&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
*In summary, our data show that nicotine treatment decreases haloperidol-induced VCMs [vacuous chewing movements] in an established rat model of tardive dyskinesia. The demonstration that nicotine removal leads to a return of VCMs, whereas nicotine re-exposure reduced haloperidol-induced VCMs, suggests a causal relationship. These data have clinical applications for the treatment of tardive dyskinesias associated with long-term antipsychotic treatment using nicotine.&lt;br /&gt;
*Bordia T, McIntosh JM, Quik M. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. J Pharmacol Exp Ther. 2012 Mar;340(3):612-9. doi: 10.1124/jpet.111.189100. Epub 2011 Dec 5. PMID: 22144565; PMCID: PMC3286320.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Endurance / Exercise / Athletic Performance&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2024 Article: [https://web.archive.org/web/20241002001111/https://www.golfdigest.com/story/tour-pros-little-helper-does-nicotine-create-a-competitive-advantage Tour Pro’s Little Helper: Does nicotine create a competitive advantage?]===&lt;br /&gt;
*&amp;quot;In all, we talked to nearly 100 pro golfers to learn more about the popularity and usage patterns of nicotine on the major professional tours. Some told us they turn to tobacco or nicotine products for an energy boost; others say it helps them concentrate or feel relaxed. But for many, it’s just about keeping on.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.mdpi.com/1660-4601/20/2/1009 The Effect of High Nicotine Dose on Maximum Anaerobic Performance and Perceived Pain in Healthy Non-Smoking Athletes: Crossover Pilot Study]===&lt;br /&gt;
*The lower perception of pain intensity that we reported after the 8 mg nicotine dose application might be an important factor that affects performance. However, we did not report any improvement in physical performance parameters.&lt;br /&gt;
**Citation: Bartík P, Šagát P, Pyšná J, Pyšný L, Suchý J, Trubák Z, Petrů D. The Effect of High Nicotine Dose on Maximum Anaerobic Performance and Perceived Pain in Healthy Non-Smoking Athletes: Crossover Pilot Study. Int J Environ Res Public Health. 2023 Jan 5;20(2):1009. doi: 10.3390/ijerph20021009. PMID: 36673765; PMCID: PMC9859273.&lt;br /&gt;
***Acknowledgement: The authors would like to acknowledge the support of Prince Sultan University for paying the article processing charges (APC) of this publication. This study was conducted by the SSDRL research group.&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745004/ Acute Effects of Nicotine on Physiological Responses and Sport Performance in Healthy Baseball Players]===&lt;br /&gt;
*Our HRV and salivary analysis revealed that nicotine could induce endocrine and sympathetic nerve activity in healthy male baseball players who had never smoked. Compared with the placebo group, the nicotine group exhibited enhanced cognitive function (an average decrease in motor reaction time of 11.14%; an average decrease in motor reaction time of 5.72%) and baseball-hitting performance (an average increase of 34.69%), and small effect sizes were observed for these results. However, muscle strength did not increase after nicotine intake.&lt;br /&gt;
**Citation: Fang SH, Lu CC, Lin HW, Kuo KC, Sun CY, Chen YY, Chang WD. Acute Effects of Nicotine on Physiological Responses and Sport Performance in Healthy Baseball Players. Int J Environ Res Public Health. 2022 Jan 4;19(1):515. doi: 10.3390/ijerph19010515. PMID: 35010774; PMCID: PMC8745004.&lt;br /&gt;
***Acknowledgement: Study was supported by the Ministry of Science and Technology in Taiwan (No: MOST 107-2410-H-028-002-MY2 and MOST 109-2410-H-028-009-MY3).&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.tandfonline.com/doi/full/10.1186/s12970-021-00413-9 Nicotine supplementation enhances simulated game performance of archery athletes]===&lt;br /&gt;
*In summary, these results indicated that 2-mg nicotine gum supplementation enhanced cognitive function, decreased saliva α-amylase activity and HRV through stimulating the sympathetic adrenergic system. More importantly, the archery scores were significantly increased after nicotine supplementation.&lt;br /&gt;
**Citation: Hung BL, Chen LJ, Chen YY, Ou JB, Fang SH. Nicotine supplementation enhances simulated game performance of archery athletes. J Int Soc Sports Nutr. 2021 Feb 18;18(1):16. doi: 10.1186/s12970-021-00413-9. PMID: 33602279; PMCID: PMC7890628.&lt;br /&gt;
***Acknowledgement: Funded by the Taiwan Ministry of Science and Technology (MOST104–2628-H-028-001-MY2).&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5236038/ A Randomised, Placebo-Controlled, Crossover Study Investigating the Effects of Nicotine Gum on Strength, Power and Anaerobic Performance in Nicotine-Naïve, Active Males]===&lt;br /&gt;
*The present study has demonstrated that low-dose (2 mg) nicotine gum increases leg extensor torque, but counter-movement jump and anaerobic capacity during WAnT remained unchanged when compared to a placebo, whilst there were minimal effects of the 4-mg nicotine gum on the performance parameters measured. Together with our previous observation [24], these results indicate that nicotine per se can improve exercise endurance and muscular strength, something that WADA should continue to monitor alongside patterns of (mis)use.&lt;br /&gt;
**Citation: Mündel T, Machal M, Cochrane DJ, Barnes MJ. A Randomised, Placebo-Controlled, Crossover Study Investigating the Effects of Nicotine Gum on Strength, Power and Anaerobic Performance in Nicotine-Naïve, Active Males. Sports Med Open. 2017 Dec;3(1):5. doi: 10.1186/s40798-016-0074-8. Epub 2017 Jan 13. PMID: 28092056; PMCID: PMC5236038.&lt;br /&gt;
***Acknowledgement: This study was funded in part by a grant from the World Anti-Doping Agency.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/expphysiol.2006.033373 Effect of transdermal nicotine administration on exercise endurance in men]=== &lt;br /&gt;
*Nicotine improved exercise endurance by 17 ± 7%, and in the absence of any effect on the usual peripheral markers, such as ventilation, heart rate and blood metabolites, we conclude that nicotine prolongs endurance by a central mechanism that may involve nicotinic receptor activation and/or altered activity of dopaminergic pathways.&lt;br /&gt;
*[https://physoc.onlinelibrary.wiley.com/doi/pdf/10.1113/expphysiol.2006.033373 PDF Version]&lt;br /&gt;
**Citation: Mündel T, Jones DA. Effect of transdermal nicotine administration on exercise endurance in men. Exp Physiol. 2006 Jul;91(4):705-13. doi: 10.1113/expphysiol.2006.033373. Epub 2006 Apr 20. PMID: 16627574.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Eyes - Ocular - Vision&#039;&#039;&#039;=&lt;br /&gt;
==Myopia (short-sighted, near-sighted)==&lt;br /&gt;
===2024 [https://iovs.arvojournals.org/article.aspx?articleid=2800816 Administration of Nicotine Can Inhibit Myopic Growth in Animal Models]===&lt;br /&gt;
*Nicotine, administered as an intravitreal injection or topical eye drop, significantly inhibits the development of experimental myopia.&lt;br /&gt;
**Citation: Thomson K, Karouta C, Ashby R. Administration of Nicotine Can Inhibit Myopic Growth in Animal Models. Invest Ophthalmol Vis Sci. 2024 Sep 3;65(11):29. doi: 10.1167/iovs.65.11.29. PMID: 39292451; PMCID: PMC11412605.&lt;br /&gt;
***Acknowledgement: Funded by ANU Connect Ventures through a Discovery Translation Fund grant (Project ID: DTF311). &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Huntington’s Disease&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2005: [https://pubmed.ncbi.nlm.nih.gov/16140176/ Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington&#039;s disease in rats]===&lt;br /&gt;
*These results clearly showed neuroprotective effect of nicotine in experimental model of HD. The clinical relevance of these findings in HD patients remains unclear and warrants further studies.&lt;br /&gt;
*In conclusion, nicotine significantly and dose-dependently attenuated 3-NP-induced striatal lesions and behavioral deficits in rats. The protective effect of nicotine may be attributed to its ability of restoring striatal DA levels in 3-NP intoxicated rats.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.brainresbull.2005.06.024 PDF Version]&lt;br /&gt;
**Citation: Tariq M, Khan HA, Elfaki I, Al Deeb S, Al Moutaery K. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington&#039;s disease in rats. Brain Res Bull. 2005 Sep 30;67(1-2):161-8. doi: 10.1016/j.brainresbull.2005.06.024. PMID: 16140176.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Hashimoto&#039;s disease (Hashimoto thyroiditis)&#039;&#039;&#039;=&lt;br /&gt;
*[https://www.hopkinsmedicine.org/health/conditions-and-diseases/hashimotos-thyroiditis Hashimoto&#039;s Thyroiditis] &amp;quot;is when your thyroid gland becomes irritated or inflamed. Hashimoto thyroiditis is the most common type of this health problem. It may also be called chronic autoimmune thyroiditis. This thyroiditis is an autoimmune disease. It occurs when your body makes antibodies that attack the cells in your thyroid. The thyroid gland becomes overrun with white blood cells and becomes scarred. This makes the gland feel firm and rubbery. The thyroid then can’t make enough of the thyroid hormone.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2020: [https://www.endocrine-abstracts.org/ea/0070/ea0070oc8.4?_ga=2.114580999.1434360570.1735281186-102848752.1735281184 Cigarette smoking and the risk to develop symptoms of Hashimoto’s thyroiditis]===&lt;br /&gt;
*&amp;quot;In patients who had discontinued smoking at the age of 39 years or more, the diagnosis of HT was predominantly made after the discontinuation of smoking.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2013: [https://onlinelibrary.wiley.com/doi/10.1111/cen.12222 Smoking and thyroid]===&lt;br /&gt;
*&amp;quot;Smoking has distinct associations with thyroid function and size in healthy subjects. It has remarkable and contrasting associations with thyroid function in autoimmune thyroid disease (lower risk of Hashimoto&#039;s disease and higher risk of Graves’ disease) and with thyroid size in nodular disease (lower risk of thyroid carcinoma and higher risk of nontoxic goitre and multinodularity). The observed associations likely indicate causal relationships in view of consistent associations across studies, the presence of a dose–response relationship and disappearance of the associations after cessation of smoking. Which mechanisms mediate the many effects of smoking remains largely obscure. Probably, they differ between the various effects. The divergent effects of smoking on the expression of autoimmune thyroid disease are intriguing and reminiscent on the contrasting effects of smoking on inflammatory bowel disease: protective against ulcerative colitis (OR 0·41, 0·34–0·48) but risky for Crohn&#039;s disease (OR 1·61, 1·27–2·03).&amp;quot;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Hypersensitivity Pneumonitis / Extrinsic Allergic Alveolitis&#039;&#039;&#039; (See Also: Allergies/Hayfever/Histamines)=&lt;br /&gt;
*[https://www.nhlbi.nih.gov/health/hypersensitivity-pneumonitis Hypersensitivity pneumonitis] is a rare immune system disorder that affects the lungs. This disease is also called bird or pigeon fancier’s lung, farmer’s lung, hot tub lung, cheese worker&#039;s lung, Bagassosis, mushroom worker&#039;s lung, malt worker&#039;s lung, or humidifier lung. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/books/NBK499918/ Hypersensitivity pneumonitis] (HP) classified as an interstitial lung disease is characterized by a complex immunological reaction of the lung parenchyma in response to repetitive inhalation of a sensitized allergen.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/books/NBK499918/ Hypersensitivity Pneumonitis]===&lt;br /&gt;
*Cigarette smoking seems to protect from developing clinically significant HP likely due to nicotine inhibiting macrophage activation and lymphocyte proliferation. &lt;br /&gt;
*However, smokers who develop HP have been shown to have a more severe course and higher mortality.&lt;br /&gt;
**Citation: Chandra D, Cherian SV. Hypersensitivity Pneumonitis. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499918/&lt;br /&gt;
&lt;br /&gt;
===2007: [https://academic.oup.com/qjmed/article-abstract/100/4/233/2258683?redirectedFrom=fulltext Extrinsic allergic alveolitis: incidence and mortality in the general population]===&lt;br /&gt;
*We identified 271 incident cases of EAA (mean age at diagnosis 57 years, 51% male). Between 1991 and 2003, the incident rate for EAA was stable at ∼0.9 cases per 100 000 person-years. In comparison to the 1084 general population controls, patients with EAA were less likely to smoke (odds ratio 0.56, 95%CI 0.39–0.81), but had a marked increase in the risk of death (hazard ratio 2.98, 95%CI 2.05–4.33).&lt;br /&gt;
**Citation: M. Solaymani-Dodaran, J. West, C. Smith, R. Hubbard, Extrinsic allergic alveolitis: incidence and mortality in the general population, QJM: An International Journal of Medicine, Volume 100, Issue 4, April 2007, Pages 233–237, https://doi.org/10.1093/qjmed/hcm008&lt;br /&gt;
&lt;br /&gt;
===2002: [https://www.atsjournals.org/doi/10.1164/rccm.200210-1154OC Inhibitory Effect of Nicotine on Experimental Hypersensitivity Pneumonitis In Vivo and In Vitro]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Results of this study show that nicotine reduces the alveolar inflammatory response to S. rectivirgula antigen and affects some AM (stimulated with LPS or S. rectivirgula) functions in vitro. This influence could be, at least in part, responsible for the protection that smokers have against development of HP. Because nicotine is effective in the treatment of ulcerative colitis, it could also be of interest in the treatment of HP and other pulmonary inflammatory diseases.&lt;br /&gt;
**Citation: Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am J Respir Crit Care Med. 2004 Apr 15;169(8):903-9. doi: 10.1164/rccm.200210-1154OC. Epub 2003 Dec 30. PMID: 14701707.&lt;br /&gt;
&lt;br /&gt;
===1992: [https://pubmed.ncbi.nlm.nih.gov/1344064/ Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum]===&lt;br /&gt;
*It was concluded that cigarette smoking had a suppressive effect on the outbreak of SHP, but smoking caused no further suppression after the disease was established.&lt;br /&gt;
**Citation: Arima K, Ando M, Ito K, Sakata T, Yamaguchi T, Araki S, Futatsuka M. Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum. Arch Environ Health. 1992 Jul-Aug;47(4):274-8. doi: 10.1080/00039896.1992.9938361. PMID: 1344064.&lt;br /&gt;
&lt;br /&gt;
===1987: [https://pubmed.ncbi.nlm.nih.gov/3499342/ Prevalence and incidence of chronic bronchitis and farmer&#039;s lung with respect to age, sex, atopy, and smoking]===&lt;br /&gt;
*Farmer&#039;s lung was only slightly more common among atopic than among non-atopic subjects and twice as common among non-smokers as among smokers.&lt;br /&gt;
**Citation: Terho EO, Husman K, Vohlonen I. Prevalence and incidence of chronic bronchitis and farmer&#039;s lung with respect to age, sex, atopy, and smoking. Eur J Respir Dis Suppl. 1987;152:19-28. PMID: 3499342.&lt;br /&gt;
&lt;br /&gt;
===1977: [https://pmc.ncbi.nlm.nih.gov/articles/PMC470791/ Extrinsic allergic alveolitis: a disease commoner in non-smokers.]===&lt;br /&gt;
*In the literature of extrinsic allergic alveolitis non-smokers predominate in those papers in which smoking habits are recorded (Hapke et al., 1968; Schlueter et al., 1969; Schofield et al., 1976). Studies of the prevalence of precipitating antibodies against Micropolyspora faeni in farmers have shown that they are detected significantly more often in non-smokers than in smokers (Morgan et al., 1975).&lt;br /&gt;
**Citation: Warren CP. Extrinsic allergic alveolitis: a disease commoner in non-smokers. Thorax. 1977 Oct;32(5):567-9. doi: 10.1136/thx.32.5.567. PMID: 594937; PMCID: PMC470791.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Inflammation&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871277/  Effect of Nicotine on Immune System Function]===&lt;br /&gt;
*Despite the completely destructive and harmful effects of cigarette smoke, nicotine via stimulation of the α7 receptor can promote the anti-inflammatory benefits on the immune system. However, these effects depend on the concentration, and administration methods are different and sometimes contradictory. It can be used successfully to treat or inhibit autoimmune diseases. Although the exact mechanism of this treatment is unknown, it appears to involve inhibiting downstream intracellular pathways that lead to the secretion of pre-inflammatory cytokines.&lt;br /&gt;
**Citation: Mahmoudzadeh L, Abtahi Froushani SM, Ajami M, Mahmoudzadeh M. Effect of Nicotine on Immune System Function. Adv Pharm Bull. 2023 Jan;13(1):69-78. doi: 10.34172/apb.2023.008. Epub 2022 Jan 4. PMID: 36721811; PMCID: PMC9871277.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://onlinelibrary.wiley.com/doi/10.1111/acer.15103 Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco]===&lt;br /&gt;
*Our findings may indicate that nicotine has anti-inflammatory effects in patients with AUD.&lt;br /&gt;
**Citation: Bolstad I, Lien L, Moe JS, Pandey S, Toft H, Bramness JG. Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco. Alcohol Clin Exp Res (Hoboken). 2023 Jul;47(7):1352-1363. doi: 10.1111/acer.15103. Epub 2023 May 30. PMID: 37208927.&lt;br /&gt;
***Acknowledgement: This work was financially supported by The Research Council of Norway, grant FRIPRO 251140.&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects]===&lt;br /&gt;
*Analysis of several studies - some animal.&lt;br /&gt;
*In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity.&lt;br /&gt;
**Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889&lt;br /&gt;
***Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.mdpi.com/1660-4601/18/2/483/htm Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study]===&lt;br /&gt;
*HSC-2 cell viability was not impaired by nicotine at the concentrations usually observed in smokers; increased expressions of IL-8 and ICAM-1 induced by P. gingivalis LPS or TNF-α were diminished by nicotine treatment. Additionally, an inhibitory effect on β-defensin production was also demonstrated. Apart from being the usually alleged harmful substance, nicotine probably exerted a suppressive effect on inflammatory factors production in HSC-2 cells.&lt;br /&gt;
**Citation: An, N., Holl, J., Wang, X., Rausch, M. A., Andrukhov, O., &amp;amp; Rausch-Fan, X. (2021). Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study. International Journal of Environmental Research and Public Health, 18(2), 483. https://doi.org/10.3390/ijerph18020483&lt;br /&gt;
***Acknowledgement: This research was supported by the grant from Ministry of Science and Technology of China under a contract from the International Science &amp;amp; Technology Cooperation Program Foundation Nr.1019 and the National Natural Science Foundation of China (Grant No. 81500859).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704168/ Does Nicotine Prevent Cytokine Storms in COVID-19?]===&lt;br /&gt;
*Case study of one individual&lt;br /&gt;
*Nicotine, an α7-nACh receptor agonist, may boost the cholinergic anti-inflammatory pathway and hinder the uncontrolled overproduction of pro-inflammatory cytokines triggered by the SARS-CoV-2 virus, which is understood to be the main pathway to poor outcomes and death in severe COVID-19.&lt;br /&gt;
*In the absence of any effective treatment for COVID-19, further research as to whether nicotine replacement offers protection against severe SAR-CoV-2 infection in smokers is clearly essential. If the mechanisms through which nicotine may interact with the virus remain speculative, the effects of route of administration, duration, dosing and frequency of use of nicotine on any such interaction are unknown. Should NRT be found to be of help in the management of COVID-19, it would be yet another strong reason to persuade smokers to switch to NRT and ultimately quit smoking.&lt;br /&gt;
**Citation: Dratcu L, Boland X. Does Nicotine Prevent Cytokine Storms in COVID-19? Cureus. 2020 Oct 28;12(10):e11220. doi: 10.7759/cureus.11220. PMID: 33269148; PMCID: PMC7704168.&lt;br /&gt;
***Acknowledgement: All authors have declared that no financial support was received from any organization for the submitted work.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300218/ Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm]===&lt;br /&gt;
*Abstract: &amp;quot;SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.&amp;quot;&lt;br /&gt;
**Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218.&lt;br /&gt;
***Acknowledgement: This work was supported by University of Castilla-La Mancha Research Programme 2020-GRIN-28705.&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
* This study provides evidence that nicotine alters the infiltration of proinflammatory monocytes and neutrophils into the CNS of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] mice via multiple [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChRs&#039;&#039;&#039;]], including the α7 and α9 subtypes. Nicotine appears to achieve these effects by inhibiting the expression of CCL2 and CXCL2, two cytokines involved in the chemotaxis of proinflammatory monocytes and neutrophils, respectively. The use of ligands that are selective for one or both of these nAChR subtypes may offer a beneficial clinical outcome, and thus provide a valuable therapeutic strategy for neuroinflammatory disorders such as MS.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/pdf/1501613.pdf PDF Version]&lt;br /&gt;
**Citation: Jiang W, St-Pierre S, Roy P, Morley BJ, Hao J, Simard AR. Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis. J Immunol. 2016 Mar 1;196(5):2095-108. doi: 10.4049/jimmunol.1501613. Epub 2016 Jan 25. PMID: 26810225; PMCID: PMC4760232.&lt;br /&gt;
***Acknowledgements: This work was supported by grants from the Multiple Sclerosis Society of Canada (to A.R.S.), the New Brunswick Health Research Foundation (to A.R.S.), the New Brunswick Innovation Foundation (to A.R.S.), the Nebraska Tobacco Settlement Biomedical Research Fund (to B.J.M.), and the National Institutes of Health (Grant R01DC006907 to B.J.M.). Salary support was provided by the Centre de Formation Médicale du Nouveau-Brunswick (to W.J.) and the New Brunswick Innovation Foundation (to S.S-P. and P.R.).&lt;br /&gt;
*See Also - Related article: [https://mssociety.ca/research-news/article/ms-society-funded-study-shows-that-nicotine-reduces-the-invasion-of-harmful-immune-cells-into-the-brain-in-mice-with-an-ms-like-disease MS Society-funded study shows that nicotine reduces the invasion of harmful immune cells into the brain in mice with an MS-like disease]&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila and Chlamydia pneumonia infection...&lt;br /&gt;
**Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/ Novel Therapeutic Approach by Nicotine in Experimental Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Due to the proven therapeutic effect of nicotine on AD (Alzheimer’s Disease) and PD (Parkinson’s Disease), we decided to study the role of nicotine in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] as an animal model of MS. Our treatment group showed less inflammation in histopathological evaluation along with myelin sheet protection. Moreover, prevention group showed less inflammation compared with treatment group. Thus, nicotine might be recommended as a promising drug for [[Special:MyLanguage/Abbreviations|MS]] therapy.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version]&lt;br /&gt;
**Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034.&lt;br /&gt;
***Acknowledgement: No funding was provided for the preparation of this article.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/ Can nicotine use alleviate symptoms of psoriasis?]=== &lt;br /&gt;
*In light of recent data demonstrating that psoriasis is an immune-mediated disease, the possibility that novel anti-inflammatory treatments such as nicotine replacement therapy or analogues could have a beneficial effect on patients with psoriasis should be considered. This case described one such occasion in which it appeared that nicotine had a therapeutic effect on a patient’s psoriasis. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version]&lt;br /&gt;
**Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
**Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
***Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://pubmed.ncbi.nlm.nih.gov/21691078/ Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells]===&lt;br /&gt;
*In summary, we showed that nicotine could suppress TNF-α expression mainly through activation of the α7 nAChR subunit, which inhibited the MyD88/IκBα/NFκB signaling pathway in HBE16 airway epithelial cells. These findings may provide new information on the potential pharmacological effects of nicotine and nAChR in the treatment of respiratory inflammatory diseases. Further research on nicotine and nAChRs may provide more evidence for the treatment of inflammatory diseases and the development of related drugs.&lt;br /&gt;
*[https://www.karger.com/Article/Pdf/329982 PDF Version]&lt;br /&gt;
**Citation: Li, Q., Zhou, X. D., Kolosov, V. P., &amp;amp; Perelman, J. M. (2011). Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 27(5), 605–612. https://doi.org/10.1159/000329982&lt;br /&gt;
***Acknowledgement: This work was supported by the National Natural Science Foundation of China (No.81070031), and China-Russia Cooperation Research Program (81011120108).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.sciencedirect.com/science/article/abs/pii/S0306987711001691?via%3Dihub Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis]===&lt;br /&gt;
*In addition, nicotine or its metabolites can result in decrease of pro-inflammatory cytokines like tumor necrosis factor-α, interleukins 1 and 6, and increase of anti-inflammatory cytokine interleukin-10. Consequently, there is reduced susceptibility to RAS due to immunosuppression and/or reduction in inflammatory response.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2011.04.006 PDF Version]&lt;br /&gt;
**Citation: Subramanyam, R. V. (2011). Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis. Medical Hypotheses, 77(2), 185–187. doi:10.1016/j.mehy.2011.04.006&lt;br /&gt;
&lt;br /&gt;
===2008 [https://onlinelibrary.wiley.com/doi/10.1002/jnr.21901 Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Primary impact to the spinal cord results in stimulation of secondary processes that potentiate the initial trauma. Recent evidence indicates that nicotine can exert potent antioxidant and neuroprotective effects in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;spinal cord injury (SCI)&#039;&#039;&#039;]].&lt;br /&gt;
*The results of the present study indicate that [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;iNOS&#039;&#039;&#039;]] is induced in the early stages of SCI, leading to increased nitration of protein tyrosine residues and potentiation of inflammatory responses. Microglial cells appear to be the main cellular source of iNOS in SCI. In addition, nicotine-induced anti-inflammatory effects in SCI are mediated, at least in part, by the attenuation of iNOS overexpression through the receptor-mediated mechanism. This data may have significant therapeutic implications for the targeting of nicotine receptors in the treatment of compressive spinal cord trauma.&lt;br /&gt;
*[https://sci-hub.st/10.1002/jnr.21901 PDF Version]&lt;br /&gt;
**Citation: Lee, M.‐Y., Chen, L. and Toborek, M. (2009), Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J. Neurosci. Res., 87: 937-947.doi.org/10.1002/jnr.21901&lt;br /&gt;
***Acknowledgement: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693390/ Neuronal Nicotinic Alpha7 Receptors Modulate Inflammatory Cytokine Production in the Skin Following Ultraviolet Radiation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Cytokine responses to UV in mice administered chronic oral nicotine, a nAChR agonist, were reduced... These results demonstrate that nAChRα7 can participate in modulating a local pro-inflammatory response in the absence of parasympathetic innervation.&lt;br /&gt;
**Citation: Osborne-Hereford AV, Rogers SW, Gahring LC. Neuronal nicotinic alpha7 receptors modulate inflammatory cytokine production in the skin following ultraviolet radiation. J Neuroimmunol. 2008 Jan;193(1-2):130-9. doi: 10.1016/j.jneuroim.2007.10.029. PMID: 18077004; PMCID: PMC2693390.&lt;br /&gt;
***Acknowledgement: These studies were funded by NIH grants DA015148 and DA018930 (LCG), PO1 HL72903 (LCG, SWR) and the Browning Foundation of Utah.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1809735/ Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-κB phosphorylation and nuclear factor-κB transcriptional activity through nicotinic acetylcholine receptor α7]===&lt;br /&gt;
*Macrophages/monocytes and the proinflammatory mediators, such as tumour necrosis factor (TNF)-α, prostaglandin E2 (PGE2), macrophage inflammatory protein (MIP)-1α and MIP-1α, play a critical role in the progression of immunological disorders including rheumatoid arthritis, Behçet’s disease and Crohn’s disease. In addition, the nicotinic acetylcholine receptor-α7 (α7nAChR) subunit is an essential regulator of inflammation. In this study, we evaluated the expression of the α7nAChR subunit on human peripheral monocytes and the effect of nicotine on the production of these proinflammatory mediators by activated monocytes.&lt;br /&gt;
*These suppressive effects of nicotine were caused at the transcriptional level and were mediated through α7nAChR. Nicotine suppressed the phosphorylation of I-κB, and then inhibited the transcriptional activity of nuclear factor-κB. These immunosuppressive effects of nicotine may contribute to the regulation of some immune diseases.&lt;br /&gt;
*This supports the therapeutic use of nicotine in some inflammatory diseases; the NF-κB activation pathway is one of the most critical molecular targets of nicotine therapy.&lt;br /&gt;
**Citation: Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. 2006 Oct;146(1):116-23. doi: 10.1111/j.1365-2249.2006.03169.x. PMID: 16968406; PMCID: PMC1809735.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Legionella Pneumophila (Legionnaires&#039; disease)&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection...&lt;br /&gt;
*Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome&#039;&#039;&#039;=&lt;br /&gt;
*See Also: COVID (Long COVID)&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Mental Health&#039;&#039;&#039;=&lt;br /&gt;
*See subcategories below&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Anxiety&#039;&#039;&#039;== &lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Behavior Issues&#039;&#039;&#039;== &lt;br /&gt;
*See Also: ADD/ADHD above&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0028390819305003?via%3Dihub Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies]=== &lt;br /&gt;
*Human and Animal Studies&lt;br /&gt;
*Clinical trials and case series report anti-aggressive effects of nicotine. Here we argue that the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] system, the molecular basis for the global public health problem of tobacco smoking, may also be a key target for modulation of aggressive behaviors. Future research should aim to clarify which forms of aggression are most strongly affected by nAChR modulation, identify the nAChR subtypes, circuits, and neurobiological mechanisms of nicotine action, and determine whether more selective nAChR-active agents can replicate or improve the serenic effects of nicotine, especially with chronic dosing. Given the prevalence of aggressive behaviors across neuropsychiatric disorders affecting the very young to the very old, these studies have the potential to have a significant impact on public health.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.neuropharm.2019.107929 PDF Version]&lt;br /&gt;
*Citation: Alan S. Lewis, Marina R. Picciotto, Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies, Neuropharmacology, Volume 167, 2020, 107929, ISSN 0028-3908, doi: 10.1016/j.neuropharm.2019.107929.&lt;br /&gt;
*Acknowledgements: This work was supported by National Institutes of Health grants MH116339 (A.S.L.), MH077681 and DA14241 (M.R.P.).&lt;br /&gt;
*Keywords: Nicotine, Nicotinic receptor, Aggression, Aggressive behavior, Impulsivity, Acetylcholine&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]=== &lt;br /&gt;
*Taken together, our study provides evidence for the feasibility and tolerability of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine (TN/TNP)&#039;&#039;&#039;]] in a small sample of adults with severe [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Autism Spectrum Disorder (ASD)&#039;&#039;&#039;]] symptoms and pathological chronic aggression and irritability. &lt;br /&gt;
*Our results also suggest that TN may have a beneficial effect on aggression, irritability, and sleep in ASD, though the sample size of this study is too small to make definitive conclusions. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/pdf/nihms-950880.pdf PDF Version]&lt;br /&gt;
*Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.&lt;br /&gt;
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).&lt;br /&gt;
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Depression&#039;&#039;&#039;== &lt;br /&gt;
===2022: [https://onlinelibrary.wiley.com/doi/full/10.1111/add.15950 The relationship between smokeless tobacco (snus) and anxiety and depression among adults and elderly people. A comparison to smoking in the Tromsø Study]===&lt;br /&gt;
*In Norway, current snus users differ from current smokers by having a higher socio-economic status and no detectable association with anxiety and depression. This suggests that the relationship between tobacco use and anxiety and depression is associated with the administration method.&lt;br /&gt;
*Citation: Yebo Yu, Fan Yang, Mingqi Fu, Farooq Ahmed, Muhammad Shahid, Jing Guo, Relationship Between Work-Family Conflict and Depressive Symptoms Among Male Firefighters in China, Journal of Occupational &amp;amp; Environmental Medicine, 10.1097/JOM.0000000000002759, 65, 4, (337-343), (2022).&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.sciencedirect.com/science/article/abs/pii/S0376871621005676 Adolescent depression symptoms and e-cigarette progression]=== &lt;br /&gt;
*Depression symptoms predicted more rapid e-cigarette progression in adolescents.&lt;br /&gt;
*E-cigarette use was not associated with an escalation in depression symptoms.&lt;br /&gt;
*E-cigarette use was not related to the development of depression symptoms over time.&lt;br /&gt;
*Must pay to view PDF&lt;br /&gt;
*Citation: Afaf F. Moustafa, Shannon Testa, Daniel Rodriguez, Stephen Pianin, Janet Audrain-McGovern, Adolescent depression symptoms and e-cigarette progression, Drug and Alcohol Dependence, Volume 228, 2021, 109072, ISSN 0376-8716, doi.org/10.1016/j.drugalcdep.2021.109072.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2000 [https://www.sciencedirect.com/science/article/abs/pii/S0091305700002057 The Effects of Nicotine on Neural Pathways Implicated in Depression: A Factor in Nicotine Addiction?]=== &lt;br /&gt;
*It is postulated that smokers are protected from the consequences of these changes, while they continue to smoke, by the antidepressant properties of nicotine.&lt;br /&gt;
*[https://sci-hub.st/10.1016/S0091-3057(00)00205-7 PDF Version]&lt;br /&gt;
*Citation: Balfour, D. J. ., &amp;amp; Ridley, D. L. (2000). The Effects of Nicotine on Neural Pathways Implicated in Depression. Pharmacology Biochemistry and Behavior, 66(1), 79–85. doi:10.1016/s0091-3057(00)00205-7 &lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.sciencedirect.com/science/article/abs/pii/S0149763417301793 Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression]=== &lt;br /&gt;
*Nicotine improves cognitive performance in clinical and preclinical studies.&lt;br /&gt;
*Nicotine may also benefit depressive symptoms and depressive behavior.&lt;br /&gt;
*Cognitive and mood benefits may be mediated by nicotinic effect on neural networks.&lt;br /&gt;
*Nicotine’s effects on networks may reverse network changes seen in depression.&lt;br /&gt;
*Improvement to mood and cognition may particularly benefit older depressed adults.&lt;br /&gt;
*Both preclinical and clinical studies support that nicotine and other nAChR agonists can improve depressive behavior, mood, and cognitive performance. nAChR agonists also demonstrate neuropharmacologic effects that oppose the intrinsic network alterations reported in MDD. Through modulation of intrinsic functional networks, nAChR agonists may reduce depressive symptoms, enhance emotional regulation ability, and improve cognitive deficits common in LLD. For these reasons, we propose nAChR agonists as a potential novel treatment for the mood and cognitive symptoms of LLD.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.neubiorev.2017.08.018 PDF Version]&lt;br /&gt;
*Citation: Gandelman, J. A., Newhouse, P., &amp;amp; Taylor, W. D. (2018). Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression. Neuroscience &amp;amp; Biobehavioral Reviews, 84, 289–298. doi:10.1016/j.neubiorev.2017.08.0&lt;br /&gt;
*Acknowledgement: Supported by NIH grants K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://pubmed.ncbi.nlm.nih.gov/29795403/ Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder]=== &lt;br /&gt;
*In [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;MDD&#039;&#039;&#039;]], acute nicotine administration normalized both pathways to the level of healthy controls, while having no impact on healthy controls. These results indicate that nicotine normalizes dysfunctional cortico-striatal communication in unmedicated non-smokers with MDD.&lt;br /&gt;
*[https://sci-hub.st/10.1038/s41386-018-0069-x PDF Version]&lt;br /&gt;
*Citation: Janes AC, Zegel M, Ohashi K, Betts J, Molokotos E, Olson D, Moran L, Pizzagalli DA. Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder. Neuropsychopharmacology. 2018 Nov;43(12):2445-2451. doi: 10.1038/s41386-018-0069-x. Epub 2018 Apr 19. PMID: 29795403; PMCID: PMC6180119.&lt;br /&gt;
*Acknoledgements: This project was supported by the National Institute on Drug Abuse grants K10 DA029645 and K02 DA042987 (ACJ). DAP was partially supported by National Institute of Mental Health grant R37 MH068376. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer and Posit Science, for activities unrelated to the current research.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/ Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Non-Smokers with Late-Life Depression]=== &lt;br /&gt;
*[[Special:MyLanguage/Abbreviations|Late &#039;&#039;&#039;Life Depression (LLD)&#039;&#039;&#039;]] is characterized by poor antidepressant response and cognitive dysfunction. Late life depression has no currently approved treatment that improves both its mood and cognitive symptoms.&lt;br /&gt;
*We observed robust response (86.7%) and remission rates (53.3%). There was a significant decrease in MADRS (Montgomery-Asberg Depression Rating scale) over the study, with improvement seen as early as three weeks. We also observed improvement in apathy and rumination. We did not observe improvement on the CPT (Conners Continuous Performance Test), but did observe improvement in subjective cognitive performance and signals of potential drug effects on secondary cognitive measures of working memory, episodic memory, and self-referential emotional processing.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/pdf/nihms965043.pdf PDF Version]&lt;br /&gt;
*Citation: Gandelman JA, Kang H, Antal A, Albert K, Boyd BD, Conley AC, Newhouse P, Taylor WD. Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. J Clin Psychiatry. 2018 Aug 28;79(5):18m12137. doi: 10.4088/JCP.18m12137. PMID: 30192444; PMCID: PMC6129985.&lt;br /&gt;
*Acknowledgements: This research was supported by NIH grant K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. The sponsor provided funding for the study but did not influence the design or conduct of the study.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://pubmed.ncbi.nlm.nih.gov/16977477/ Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial]=== &lt;br /&gt;
*These findings suggest a role for nicotinic receptor systems in the pathophysiology of depression and that nicotinic compounds should be evaluated for treating depression symptoms.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s00213-006-0516-y PDF Version]&lt;br /&gt;
*Citation: McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006 Nov;189(1):125-33. doi: 10.1007/s00213-006-0516-y. Epub 2006 Sep 15. PMID: 16977477.&lt;br /&gt;
*Acknowledgement: This research was supported by a Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression. Dr. Rose is an inventor named on several nicotine patch patents and receives royalties from sales of certain nicotine patches.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/11995405/ Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients]=== &lt;br /&gt;
*Acute administration of nicotine patches produced rapid eye movement sleep (REM) increases in non-smoking major depressed patients as well as clinical improvement in mood. Antidepressant effect was also observed after four continuous days of nicotine administration.&lt;br /&gt;
*Citation: Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin. 2002 Jan-Feb;54(1):36-40. PMID: 11995405.&lt;br /&gt;
&lt;br /&gt;
===1999 [https://link.springer.com/article/10.1007/s002130050879 Antidepressant effects of nicotine in an animal model of depression]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Epidemiological studies indicate a high incidence of cigarette smoking among depressed individuals. Moreover, individuals with a history of depression have a much harder time giving up smoking. It has been postulated that smoking may reflect an attempt at self-medication with nicotine by these individuals.&lt;br /&gt;
*The data strongly implicate the involvement of central nicotinic receptors in the depressive characteristics of the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;FSL&#039;&#039;&#039;]] rats, and suggest that nicotinic agonists may have therapeutic benefits in depressive disorders&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1007/s002130050879 PDF Version]&lt;br /&gt;
*Citation: Tizabi, Y., Overstreet, D., Rezvani, A. et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 142, 193–199 (1999). https://doi.org/10.1007/s002130050879&lt;br /&gt;
*Acknowledgements This work was supported in part by the Department of Pharmacology, Howard University, VAMC and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.&lt;br /&gt;
*Keywords: Key words Nicotine · Nicotinic receptor · FSL and FRL rats · Animal model of depression &lt;br /&gt;
&lt;br /&gt;
===1998 [https://pubmed.ncbi.nlm.nih.gov/9592048/ A novel effect of nicotine on mood and sleep in major depression]=== &lt;br /&gt;
*Transdermal nicotine patches increased REM sleep in normal volunteers and depressed patients during 4 days of continuous administration. In addition, a significant improvement of mood was observed in depressed patients. Nicotinic mechanisms may be involved in depression.  These findings suggest that nicotine receptor activation may be important in major depression and shows for the first time that nicotine patches may be useful in the treatment of depression.&lt;br /&gt;
*[https://sci-hub.st/10.1097/00001756-199801050-00012 PDF Version]&lt;br /&gt;
*Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 1998 Jan 5;9(1):57-60. doi: 10.1097/00001756-199801050-00012. PMID: 9592048.&lt;br /&gt;
*ACKNOWLEDGEMENT: This work has been supported by the following grants: DGAPA-UNAM IN -200895 to R.J.S-P.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9746444/ Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression]=== &lt;br /&gt;
*A high frequency of cigarette smoking has been reported among individuals with major depression.&lt;br /&gt;
*Results of the visual analog scale and [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;HAM-D&#039;&#039;&#039;]] showed a significant improvement in depression after the second day of nicotine patches.&lt;br /&gt;
*Citation: Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996 Sep;57(9):387-9. PMID: 9746444.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://psycnet.apa.org/record/1996-00468-019 Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement.]=== &lt;br /&gt;
*&lt;br /&gt;
*[https://sci-hub.st/10.1037/0022-006X.64.4.791 PDF Version]&lt;br /&gt;
*Citation:&lt;br /&gt;
&lt;br /&gt;
===1995 [https://pubmed.ncbi.nlm.nih.gov/8619011/ Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients]=== &lt;br /&gt;
*The main finding of the present study was that nicotine patches induced an increase in REM sleep time in depressed patients without any other changes in sleep variables&lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02246496 PDF Version]&lt;br /&gt;
*Citation: Salín-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colín R. Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl). 1995 Oct;121(4):476-9. doi: 10.1007/BF02246496. PMID: 8619011.&lt;br /&gt;
*Acknowledgement: This work has been supported in part by FIIRESIN, Fideicomiso-UNAM (to RD-C) and DGAPA-UNAM1N203393 (to RJS-P).&lt;br /&gt;
&lt;br /&gt;
===1993 [https://jamanetwork.com/journals/jamapsychiatry/article-abstract/496026 Nicotine Dependence and Major Depression]=== &lt;br /&gt;
*There is, then, no evidence in these data that the occurrence of MDD in persons with a prior history of nicotine dependence might have been caused directly by recent persistent smoking.&lt;br /&gt;
*[https://sci-hub.st/10.1001/archpsyc.1993.01820130033006 PDF Version]&lt;br /&gt;
*Citation: Breslau N, Kilbey MM, Andreski P. Nicotine Dependence and Major Depression: New Evidence From a Prospective Investigation. Arch Gen Psychiatry. 1993;50(1):31–35. doi:10.1001/archpsyc.1993.01820130033006&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
* When chronically taken, nicotine may result in: (1) positive reinforcement, (2) negative reinforcement (mood normalization) (other issues and diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Mental Illness&#039;&#039;&#039;==&lt;br /&gt;
&lt;br /&gt;
===2022 [https://academic.oup.com/ntr/article-abstract/24/9/1405/6562456 E-Cigarette Provision to Promote Switching in Cigarette Smokers With Serious Mental Illness—A Randomized Trial]===&lt;br /&gt;
*This was the first prospective study to compare e-cigarette provision with assessments only to evaluate the appeal and impact of e-cigarettes on smoking behavior, carbon monoxide exposure, and nicotine dependence among smokers with Severe Mental Illness (SMI) who had tried but were unable to quit and were not currently interested in cessation treatment. The finding that e-cigarette provision led to significant reductions in smoking and carbon monoxide without increasing nicotine dependence has implications for reducing harm not only among the millions of smokers with SMI who struggle to quit, but also for other vulnerable smokers who cannot achieve cessation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - OCD (Obsessive Compulsive Disorder)&#039;&#039;&#039;== &lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/ Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review]=== &lt;br /&gt;
*Nicotine may ameliorate OC symptoms in severe, treatment-refractory [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;OCD&#039;&#039;&#039;]] patients. Although encouraging, these initial positive effects should be tested in large controlled studies.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/pdf/12991_2020_Article_309.pdf PDF Version]&lt;br /&gt;
*Citation: Piacentino D, Maraone A, Roselli V, Berardelli I, Biondi M, Kotzalidis GD, Pasquini M. Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review. Ann Gen Psychiatry. 2020 Sep 30;19:57. doi: 10.1186/s12991-020-00309-z. PMID: 33014119; PMCID: PMC7528475.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - PTSD (Post Traumatic Stress Disorder)&#039;&#039;&#039;== &lt;br /&gt;
===2012 [https://www.hindawi.com/journals/aps/2012/265724/ Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study]=== &lt;br /&gt;
*Smokers with PTSD report greater NA (Negative Affects) immediately prior to smoking and greater decreases in NA following smoking, and these findings are consistent with the observed patterns of brain activation in the current study. Thus, our findings provide a neurobiological basis that helps explain why individuals with PTSD are at greater risk of smoking and also experience greater difficulty quitting. The present study is not without its limitations. Our sample size was small and was predominately represented by female smokers.&lt;br /&gt;
*[https://downloads.hindawi.com/journals/aps/2012/265724.pdf PDF Version]&lt;br /&gt;
*Citation: Froeliger, B., Crowell Beckham, J., Feldman Dennis, M., Victoria Kozink, R., &amp;amp; Joseph McClernon, F. (2012). Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study. Advances in Pharmacological Sciences, 2012, 1–6. doi:10.1155/2012/265724 &lt;br /&gt;
*Acknowledgement: Department of Veterans Affairs or the National Institutes of Health.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Schizophrenia&#039;&#039;&#039;== &lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fpsyt.2022.804055/full Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence]===&lt;br /&gt;
*Nicotine administration normalized DMN hyperconnectivity in schizophrenia. We here provide direct evidence that the biological basis of nicotine dependence is different in schizophrenia and in non-schizophrenia populations. Our results suggest the high prevalence of nicotine use in schizophrenia may be an attempt to correct a network deficit known to interfere with cognition.&lt;br /&gt;
*[https://twitter.com/hbwardMD/status/1487037135299518474 Twitter thread about this study]&lt;br /&gt;
**Citation: Ward HB, Beermann A, Nawaz U, Halko MA, Janes AC, Moran LV and Brady RO Jr (2022) Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence. Front. Psychiatry 13:804055. doi: 10.3389/fpsyt.2022.804055&lt;br /&gt;
***Acknowledgement: This work was supported by NIMH R01MH116170 (RB); NIMH R01MH111868 and NIMH R01MH117063 (MH); NIDA 1K02DA042987 and NIDA K01DA029645 (AJ); NIMH K23MH110564, NARSAD Young Investigator Award, Brain and Behavior Research Foundation, Pope-Hintz Fellowship Award, McLean Hospital, Dupont-Warren Fellowship Award, and Harvard Medical School (LM); and the Sidney R. Baer, Jr. Foundation, and the Norman E. Zinberg Fellowship in Addiction Psychiatry Research, Harvard Medical School (HW).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0149763420305042?via%3Dihub The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review]=== &lt;br /&gt;
*Cognitive and early sensory alterations are core features of [https://en.wikipedia.org/wiki/Schizophrenia &#039;&#039;&#039;schizophrenia&#039;&#039;&#039;]. A single dose of nicotine can improve those features in patients. Attention domain is the most responsive to nicotine in patients. Effects vary upon type of neuropsychological assessment and nicotine intake condition.&lt;br /&gt;
*[https://sci-hub.do/10.1016/j.neubiorev.2020.07.035 PDF Version]&lt;br /&gt;
**Citation: Clément Dondé, Jérôme Brunelin, Marine Mondino, Caroline Cellard, Benjamin Rolland, Frédéric Haesebaert, The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review, Neuroscience &amp;amp; Biobehavioral Reviews, Volume 118, 2020, Pages 121-133, ISSN 0149-7634, doi: 10.1016/j.neubiorev.2020.07.035.&lt;br /&gt;
&lt;br /&gt;
=== 2017: [https://www.nature.com/articles/nm.4274 Nicotine reverses hypofrontality in animal models of addiction and schizophrenia] ===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*“Our study provides compelling biological evidence that a specific genetic variant contributes to risk for schizophrenia, defines the mechanism responsible for the effect and validates that nicotine improves that deficit,” said Jerry Stitzel, a researcher at the Institute for Behavioral Genetics (IBG) and one of four CU Boulder researchers on the study. &lt;br /&gt;
*Previous genome-wide association studies have suggested that people with a variation in a gene called CHRNA5 are more likely to have schizophrenia, but the mechanism for that association has remained unclear. People with that variant are also more likely to smoke.&lt;br /&gt;
**Citation: Fani Koukouli, Marie Rooy, Dimitrios Tziotis, Kurt A Sailor, Heidi C O&#039;Neill, Josien Levenga, Mirko Witte, Michael Nilges, Jean-Pierre Changeux, Charles A Hoeffer, Jerry A Stitzel, Boris S Gutkin, David A DiGregorio  Uwe Maskos Nature Medicine volume 23, pages347–354 (2017)&lt;br /&gt;
&lt;br /&gt;
===2017: [https://pubmed.ncbi.nlm.nih.gov/28441884/ Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging]===&lt;br /&gt;
*This brief review discusses evidence from neurophysiological and neuroimaging studies in schizophrenia patients that nicotinic agonists may effectively target dysfunctional neuronal circuits in the illness. Evidence suggests that nicotine significantly modulates a number of these circuits, although relatively few studies have used modern neuroimaging techniques (e.g. functional magnetic resonance imaging (fMRI)) to examine the effects of nicotinic drugs on disease-related neurobiology. The neuronal effects of nicotine and other nicotinic agonists in schizophrenia remain a priority for psychiatry research.&lt;br /&gt;
**Citation: Smucny J, Tregellas JR. Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging. J Psychopharmacol. 2017 Jul;31(7):801-811. doi: 10.1177/0269881117705071. Epub 2017 Apr 26. PMID: 28441884; PMCID: PMC5963521.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
**Citation: Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2009 [https://pubmed.ncbi.nlm.nih.gov/19328631/ Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications]=== &lt;br /&gt;
*The principal reason for the markedly increased rate of cigarette smoking in people with schizophrenia: tobacco cigarette smoking represents an attempt at self-medication in schizophrenia, because the additional nicotine so provided alleviates the hypofunctional sensory gating seen in this illness.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version]&lt;br /&gt;
**Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631.&lt;br /&gt;
&lt;br /&gt;
===2007: [https://pmc.ncbi.nlm.nih.gov/articles/PMC2702723/ Nicotinic Interactions with Antipsychotic Drugs, Models of Schizophrenia and Impacts on Cognitive Function]===&lt;br /&gt;
*Human and Animal study&lt;br /&gt;
*Nicotinic receptor systems in the brain are important for a variety of aspects of cognitive function impaired in schizophrenia and aggravated by antipsychotic drugs. Nicotine and selective nicotinic α7 and α4β2 agonists can significantly improve learning, memory and attention. Nicotine and nicotine agonists can reduce some of the cognitive impairments caused by some antipsychotic drugs as well as reduce cognitive impairments seen in the NMDA glutamate blockade animal model of schizophrenia.&lt;br /&gt;
**Citation: Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007 Oct 15;74(8):1182-91. doi: 10.1016/j.bcp.2007.07.019. Epub 2007 Jul 20. PMID: 17714691; PMCID: PMC2702723.&lt;br /&gt;
***Acknowledgement: Research presented was supported by a grant from the National Institute of Mental Health grant MH64494.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
**Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Movement Disorders (not diagnosis specific)&#039;&#039;&#039;= &lt;br /&gt;
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/ Role for the nicotinic cholinergic system in movement disorders; therapeutic implications]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Several [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] subtypes appear to be involved in these beneficial effects of nicotine and nAChR drugs including α4β2*, α6β2* and α7 nAChRs (the asterisk indicates the possible presence of other subunits in the receptor). Overall, the above findings, coupled with nicotine&#039;s neuroprotective effects, suggest that nAChR drugs have potential for future drug development for movement disorders.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/pdf/nihms600497.pdf PDF Version]&lt;br /&gt;
*Citation: Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. PMID: 24836728; PMCID: PMC4149916.&lt;br /&gt;
*Acknowledgements: This work was supported by grants NS59910 and NS 65851 from the National Institutes of Health.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Multiple Sclerosis - Humans / Experimental Autoimmune Encephalomyelitis (EAE) - Animals&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
* This study provides evidence that nicotine alters the infiltration of proinflammatory monocytes and neutrophils into the CNS of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] mice via multiple [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChRs&#039;&#039;&#039;]], including the α7 and α9 subtypes. Nicotine appears to achieve these effects by inhibiting the expression of CCL2 and CXCL2, two cytokines involved in the chemotaxis of proinflammatory monocytes and neutrophils, respectively. The use of ligands that are selective for one or both of these nAChR subtypes may offer a beneficial clinical outcome, and thus provide a valuable therapeutic strategy for neuroinflammatory disorders such as MS.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/pdf/1501613.pdf PDF Version]&lt;br /&gt;
**Citation: Jiang W, St-Pierre S, Roy P, Morley BJ, Hao J, Simard AR. Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis. J Immunol. 2016 Mar 1;196(5):2095-108. doi: 10.4049/jimmunol.1501613. Epub 2016 Jan 25. PMID: 26810225; PMCID: PMC4760232.&lt;br /&gt;
***Acknowledgements: This work was supported by grants from the Multiple Sclerosis Society of Canada (to A.R.S.), the New Brunswick Health Research Foundation (to A.R.S.), the New Brunswick Innovation Foundation (to A.R.S.), the Nebraska Tobacco Settlement Biomedical Research Fund (to B.J.M.), and the National Institutes of Health (Grant R01DC006907 to B.J.M.). Salary support was provided by the Centre de Formation Médicale du Nouveau-Brunswick (to W.J.) and the New Brunswick Innovation Foundation (to S.S-P. and P.R.).&lt;br /&gt;
*See Also - Related article: [https://mssociety.ca/research-news/article/ms-society-funded-study-shows-that-nicotine-reduces-the-invasion-of-harmful-immune-cells-into-the-brain-in-mice-with-an-ms-like-disease MS Society-funded study shows that nicotine reduces the invasion of harmful immune cells into the brain in mice with an MS-like disease]&lt;br /&gt;
&lt;br /&gt;
===2015 [https://pubmed.ncbi.nlm.nih.gov/25813705/ Nicotine modulates neurogenesis in the central canal during experimental autoimmune encephalomyelitis]===&lt;br /&gt;
*Amimal study&lt;br /&gt;
*We found that reduction of ependymal cell proliferation correlated with inflammation in the same area, which was relieved by the administration of nicotine. Further, increased numbers of oligodendrocytes (OLs) were observed after nicotine treatment. These findings give a new insight into the mechanism of how nicotine functions to attenuate EAE.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.neuroscience.2015.03.031 PDF Full Study]&lt;br /&gt;
**Citation: Gao Z, Nissen JC, Legakis L, Tsirka SE. Nicotine modulates neurogenesis in the central canal during experimental autoimmune encephalomyelitis. Neuroscience. 2015 Jun 25;297:11-21. doi: 10.1016/j.neuroscience.2015.03.031. Epub 2015 Mar 23. PMID: 25813705; PMCID: PMC4428965.&lt;br /&gt;
***Acknowledgement: The work was supported by NMSS PP1815, NIH R01NS42168, NIH IRACDA K12GM102778.&lt;br /&gt;
&lt;br /&gt;
===2015 [https://pubmed.ncbi.nlm.nih.gov/26209886/ Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients]===&lt;br /&gt;
*The data obtained highlight the role of α7 receptor subtype in the modulation of anti-inflammatory cytokines also in MS. Moreover the ability of nicotine to up-regulate the expression of α7 receptor subtype in RR-MS patients, indicates that nicotinic receptor stimulation may contribute to down-modulate the inflammation occurred in MS by a positive feedback control of its expression.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.intimp.2015.06.034 PDF Full paper]&lt;br /&gt;
**Citation: Reale M, Di Bari M, Di Nicola M, D&#039;Angelo C, De Angelis F, Velluto L, Tata AM. Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients. Int Immunopharmacol. 2015 Nov;29(1):152-7. doi: 10.1016/j.intimp.2015.06.034. Epub 2015 Jul 23. PMID: 26209886.&lt;br /&gt;
***Acknowledgement: This work was supported by FISM – Fondazione Italiana Sclerosi Multipla – Cod. 2013/R/25. MDB was supported by fellowship on FISM project 2013/R/25.&lt;br /&gt;
&lt;br /&gt;
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176721/ The Experimental Autoimmune Encephalomyelitis Disease Course Is Modulated by Nicotine and Other Cigarette Smoke Components]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Our results show that nicotine reduces the severity of EAE, as shown by reduced demyelination, increased body weight, and attenuated microglial activation. Nicotine administration after the development of EAE symptoms prevented further disease exacerbation, suggesting that it might be useful as an [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE/MS&#039;&#039;&#039;]] therapeutic. In contrast, the remaining components of cigarette smoke, delivered as cigarette smoke condensate (CSC), accelerated and increased adverse clinical symptoms during the early stages of EAE.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176721/pdf/pone.0107979.pdf PDF Version]&lt;br /&gt;
**Citation: Gao Z, Nissen JC, Ji K, Tsirka SE. The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS One. 2014 Sep 24;9(9):e107979. doi: 10.1371/journal.pone.0107979. PMID: 25250777; PMCID: PMC4176721.&lt;br /&gt;
***Acknowledgements: This work was supported by National Multiple Sclerosis Society awards CA1044A1 and PP181, National Aeronautics and Space Administration NNA14AB04A and National Institutes of Health R01NS42168 (ST), and National Institutes of Health K12GM102778 to JN.&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/ Novel Therapeutic Approach by Nicotine in Experimental Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Due to the proven therapeutic effect of nicotine on AD (Alzheimer’s Disease) and PD (Parkinson’s Disease), we decided to study the role of nicotine in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] as an animal model of MS. Our treatment group showed less inflammation in histopathological evaluation along with myelin sheet protection. Moreover, prevention group showed less inflammation compared with treatment group. Thus, nicotine might be recommended as a promising drug for [[Special:MyLanguage/Abbreviations|MS]] therapy.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version]&lt;br /&gt;
**Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034.&lt;br /&gt;
***Acknowledgement: No funding was provided for the preparation of this article.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Narcolepsy&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.authorea.com/doi/full/10.22541/au.162126605.51833119 The therapeutic use of medical nicotine in narcolepsy]===&lt;br /&gt;
*PDF: [https://www.researchgate.net/profile/Carolina-Diamandis/publication/351648895_The_therapeutic_use_of_medical_nicotine_in_narcolepsy/links/60aa9cb945851522bc10a4c1/The-therapeutic-use-of-medical-nicotine-in-narcolepsy.pdf The therapeutic use of nicotine in narcolepsy]&lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3311418/ Narcolepsy with Cataplexy Masked by the Use of Nicotine]===&lt;br /&gt;
*&lt;br /&gt;
&lt;br /&gt;
===2010: [https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC2823281/ A Novel Approach to Treating Morning Sleep Inertia in Narcolepsy]===&lt;br /&gt;
*&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Nicotine Used With Other Substances&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/34119664/ Nicotine and modafinil combination protects against the neurotoxicity induced by 3,4-Methylenedioxymethamphetamine in hippocampal neurons of male rats]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*The overall results indicate that nicotine and modafinil co-administration rescued brain from MDMA-induced neurotoxicity. We suggest that nicotine and modafinil combination therapy could be considered as a possible treatment to reduce the neurological disorders induced by MDMA. (Note: AKA ecstasy)&lt;br /&gt;
*Citation: Kowsari G, Mehrabi S, Soleimani Asl S, Pourhamzeh M, Mousavizadeh K, Mehdizadeh M. Nicotine and modafinil combination protects against the neurotoxicity induced by 3,4-Methylenedioxymethamphetamine in hippocampal neurons of male rats. J Chem Neuroanat. 2021 Jun 10;116:101986. doi: 10.1016/j.jchemneu.2021.101986. Epub ahead of print. PMID: 34119664.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Oral / Jaw&#039;&#039;&#039;= &lt;br /&gt;
===2021: [https://www.mdpi.com/1660-4601/18/2/483/htm Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study]===&lt;br /&gt;
*HSC-2 cell viability was not impaired by nicotine at the concentrations usually observed in smokers; increased expressions of IL-8 and ICAM-1 induced by P. gingivalis LPS or TNF-α were diminished by nicotine treatment. Additionally, an inhibitory effect on β-defensin production was also demonstrated. Apart from being the usually alleged harmful substance, nicotine probably exerted a suppressive effect on inflammatory factors production in HSC-2 cells.&lt;br /&gt;
*Acknowledgement: This research was supported by the grant from Ministry of Science and Technology of China under a contract from the International Science &amp;amp; Technology Cooperation Program Foundation Nr.1019 and the National Natural Science Foundation of China (Grant No. 81500859).&lt;br /&gt;
*Citation: An, N., Holl, J., Wang, X., Rausch, M. A., Andrukhov, O., &amp;amp; Rausch-Fan, X. (2021). Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study. International Journal of Environmental Research and Public Health, 18(2), 483. https://doi.org/10.3390/ijerph18020483&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32381373/ Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial]=== &lt;br /&gt;
*The positive findings in the present study in surgeries performed under local anaesthesia are in agreement with data from systematic reviews that have reported the effectiveness of nicotine in the control of postoperative pain following surgery under general anaesthesia.&lt;br /&gt;
*This study establishes a new prevention and treatment modality regarding pain, [https://en.wikipedia.org/wiki/Edema oedema], and [https://en.wikipedia.org/wiki/Trismus trismus] in a versatile, convenient, safe, and effective form, thereby minimizing gastrointestinal and cardiovascular disorders caused by the use of anti-inflammatory drugs in third molar surgeries.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.ijom.2019.08.013 PDF Version]&lt;br /&gt;
*Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373.&lt;br /&gt;
*Acknowledgements: Funding - CAPES, Ministry of Education, Brazil&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444372/ Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program]===&lt;br /&gt;
*The results of this study confirm that chewing the tested nicotine replacement gum as recommended in a ‘real world’ active smoking cessation program produces a statistically significant change in the parameter of whitening as measured by change from baseline versus the negative control (Microtab) following 6 weeks in a smoking cessation programme. The Vita® Shade Guide (the secondary outcome measure) supported the trend of stain improvement. These results support the efficacy of the tested nicotine replacement gum in stain reduction, in arresting the progression of tooth stain and in shade lightening.&lt;br /&gt;
*Acknowledgement: The study was fully funded by McNeil AB who is the manufacturer of the test and control products. It was designed by McNeil AB in consultation with HW and DOM. The study was run, participants recruited, smoking cessation intervention administered and data collected by the team of research staff at the Oral Health Services Research Centre at University College Cork under the leadership of HW with consultant input from DOM. RK carried out the clinical examinations but was blinded to intervention allocation. The data were analysed by McNeil AB with input from HW and DOM. The study was externally monitored by MDS Pharma Services, UK and conducted to ICH GCP standards. The data were interpreted by HW, DOM and RK. The manuscript was drafted by HW with editorial comment from the other authors. HW decided to submit the manuscript for publication.&lt;br /&gt;
*Citation: Whelton H, Kingston R, O&#039;Mullane D, Nilsson F. Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program. BMC Oral Health. 2012 Jun 13;12:13. doi: 10.1186/1472-6831-12-13. PMID: 22695211; PMCID: PMC3444372.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pain / Analgesic&#039;&#039;&#039;= &lt;br /&gt;
===2023: [https://pubmed.ncbi.nlm.nih.gov/37132069/ Effect of perioperative high-dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study]===&lt;br /&gt;
*Perioperative high-dose nicotine replacement therapy may help to relieve postoperative pain among male smoking-abstinent patients undergoing abdominal surgery.&lt;br /&gt;
**Citation: Zhu C, Bi Y, Wei K, Tao K, Hu L, Lu Z. Effect of perioperative high-dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study. Addiction. 2023 Aug;118(8):1579-1585. doi: 10.1111/add.16224. Epub 2023 May 19. PMID: 37132069.&lt;br /&gt;
***Acknowledgement: Shanghai Municipal Science and Technology Commission. Grant Number: 17411960400&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.mdpi.com/1424-8247/16/12/1665 The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis]===&lt;br /&gt;
*Conclusion: These results help to clarify the mixed outcomes of trials and may ultimately inform the treatment of pain. We observed that acute nicotine administration prolonged the laboratory-induced pain threshold and tolerance time and may mildly relieve postoperative pain. In addition, long-term tobacco smoking may have a nociceptive effect on different types of chronic pain. More research is needed to determine the anti-nociceptive effects of nicotine in humans, and to understand the optimal timing, dose, and method of delivery of nicotine.&lt;br /&gt;
**Citation: Luo Y, Yang Y, Schneider C, Balle T. The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2023; 16(12):1665. https://doi.org/10.3390/ph16121665&lt;br /&gt;
***Acknowledgement: This work was funded by the Australian Research Council LP160100560.&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.sciencedirect.com/science/article/abs/pii/S0014299923000298?via%3Dihub Nicotine suppresses central post-stroke pain via facilitation of descending noradrenergic neuron through activation of orexinergic neuron]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine-induced antinociception was inhibited by intrathecal pre-treatment with yohimbine, an α2 adrenergic receptor antagonist. These results indicated that nicotine may suppress BCAO-induced mechanical hypersensitivity through the activation of the descending pain control system via orexin neurons.&lt;br /&gt;
**Citation: Nakamoto, K., Matsuura, W., &amp;amp; Tokuyama, S. (2023). Nicotine suppresses central post-stroke pain via facilitation of descending noradrenergic neuron through activation of orexinergic neuron. European journal of pharmacology, 175518. Advance online publication. https://doi.org/10.1016/j.ejphar.2023.175518&lt;br /&gt;
***Acknowledgement: This work was supported by the Smoking Research Foundation (FP01807092).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32381373/ Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial]=== &lt;br /&gt;
*The positive findings in the present study in surgeries performed under local anaesthesia are in agreement with data from systematic reviews that have reported the effectiveness of nicotine in the control of postoperative pain following surgery under general anaesthesia.&lt;br /&gt;
*This study establishes a new prevention and treatment modality regarding pain, oedema, and trismus in a versatile, convenient, safe, and effective form, thereby minimizing gastrointestinal and cardiovascular disorders caused by the use of anti-inflammatory drugs in third molar surgeries.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.ijom.2019.08.013 PDF Version]&lt;br /&gt;
**Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373.&lt;br /&gt;
***Acknowledgements: Funding - CAPES, Ministry of Education, Brazil&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912401/ Acute Analgesic Effects of Nicotine and Tobacco in Humans: A Meta-Analysis]=== &lt;br /&gt;
*Pain and tobacco smoking are both highly prevalent and comorbid conditions, current smoking has been associated with more severe chronic pain and physical impairment, and acute nicotine-induced analgesia could make smoking more rewarding and harder to give up.&lt;br /&gt;
*Moderation analyses further revealed that acute analgesic effects may be achieved regardless of nicotine delivery method, current smoking status, pain induction modality, study design, or control condition, and that such effects may be more robust among men than women.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912401/pdf/nihms-774195.pdf PDF Version]&lt;br /&gt;
**Citation: Ditre JW, Heckman BW, Zale EL, Kosiba JD, Maisto SA. Acute analgesic effects of nicotine and tobacco in humans: a meta-analysis. Pain. 2016;157(7):1373-1381. doi:10.1097/j.pain.0000000000000572 (viewed Oct 5, 2021)&lt;br /&gt;
***Acknowledgement: This research was supported by NIH Grant Nos. R21DA034285 and R21DA038204 awarded to Joseph W. Ditre, NIH Grant Nos. F31DA033058 and T32DA007288 awarded to Bryan W. Heckman, NIH Grant No. F31DA039628 awarded to Emily L. Zale, and NIH Grant No. 2K05 AA16928 awarded to Stephen A. Maisto.&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.sciencedirect.com/science/article/abs/pii/S0014299913003270?via%3Dihub Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models]=== &lt;br /&gt;
*Nicotine significantly reduced antiviral-dependent alterations of the nociceptive threshold. &lt;br /&gt;
*Moreover, nicotine decreased neuropathic pain induced by repeated intraperitoneal administration of the anticancer agent oxaliplatin (2.4 mg/kg), lowering the hypersensitivity to mechanical and thermal stimuli. &lt;br /&gt;
*Intraperitoneal nicotine administration controls neuropathic pain evoked by traumatic or toxic nervous system alterations. These results support the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] modulation as a possible therapeutic approach to the complex, undertreated chemotherapy-induced neuropathies. &lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.ejphar.2013.04.022 PDF Version]&lt;br /&gt;
**Citation: Lorenzo Di Cesare Mannelli, Matteo Zanardelli, Carla Ghelardini, Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models, European Journal of Pharmacology, Volume 711, Issues 1–3, 2013, Pages 87-94, ISSN 0014-2999, doi: 10.1016/j.ejphar.2013.04.022.&lt;br /&gt;
***Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://journals.lww.com/ejanaesthesiology/Fulltext/2011/08000/Randomised_trial_of_intranasal_nicotine_and.7.aspx Randomised trial of intranasal nicotine and postoperative pain, nausea and vomiting in non-smoking women]=== &lt;br /&gt;
*Intraoperative use of intranasal nicotine has a sustained opioid-sparing effect in non-smoking women undergoing gynaecological procedures and is associated with a higher frequency of nausea. &lt;br /&gt;
*[https://sci-hub.st/10.1097/EJA.0b013e328344d998 PDF Version]&lt;br /&gt;
*Citation: Jankowski, Christopher J.; Weingarten, Toby N.; Martin, David P.; Whalen, Francis X.; Gebhart, John B.; Liedl, Lavonne M.; Danielson, David R.; Nadeau, Ashley M.; Schroeder, Darrell R.; Warner, David O.; Sprung, Juraj Randomised trial of intranasal nicotine and postoperative pain, nausea and vomiting in non-smoking women, European Journal of Anaesthesiology (EJA): August 2011 - Volume 28 - Issue 8 - p 585-591 doi: 10.1097/EJA.0b013e328344d998&lt;br /&gt;
*Acknowledgements: The present work was supported solely by the Department of Anesthesiology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://journals.lww.com/anesthesia-analgesia/Fulltext/2008/09000/Transdermal_Nicotine_for_Analgesia_After_Radical.48.aspx Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy]=== &lt;br /&gt;
*The preoperative application of a 7 mg nicotine patch resulted in a significant reduction in postoperative opioid consumption in nonsmoking men undergoing [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;RRP&#039;&#039;&#039;]] in this study. Its use was generally well tolerated, but the maximum nausea scores were higher in patients who received nicotine.&lt;br /&gt;
*[https://sci-hub.se/10.1213/ane.0b013e31816f2616# PDF Version]&lt;br /&gt;
*Citation: Habib, Ashraf S., MBBCh, MSc, FRCA*; White, William D., MPH*; El Gasim, Magdi A., MD*; Saleh, Gamal, MD*; Polascik, Thomas J., MD†; Moul, Judd W., MD†; Gan, Tong J., MB, FRCA* Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy, Anesthesia &amp;amp; Analgesia: September 2008 - Volume 107 - Issue 3 - p 999-1004 doi: 10.1213/ane.0b013e31816f2616&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12131122/ Isoflurane hyperalgesia is modulated by nicotinic inhibition]=== &lt;br /&gt;
*Animal study&lt;br /&gt;
*Female mice had significant [https://en.wikipedia.org/wiki/Hyperalgesia hyperalgesia] from [https://en.wikipedia.org/wiki/Isoflurane isoflurane]. Nicotine administration prevented isoflurane-induced hyperalgesia without altering the antinociception produced by higher isoflurane concentrations.&lt;br /&gt;
**Citation: Flood P, Sonner JM, Gong D, Coates KM. Isoflurane hyperalgesia is modulated by nicotinic inhibition. Anesthesiology. 2002 Jul;97(1):192-8. doi: 10.1097/00000542-200207000-00027. PMID: 12131122.&lt;br /&gt;
***Acknowledgement: 1P01GM47818/GM/NIGMS NIH HHS/United States, K08GM00695/GM/NIGMS NIH HHS/United States&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Parkinson Disease&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/abs/pii/S0967586824003849 The effect of a nicotine-rich diet with/without redistribution of dietary protein on motor indices in patients with Parkinson&#039;s disease: A randomized clinical trial]===&lt;br /&gt;
*The results of our study indicated that nicotine consumption in an isocaloric diet, while preventing a decrease in anthropometric indices, leads to improvements in motor indices and a reduction in alpha-synuclein levels. Additional and larger controlled trials are required to validate these findings.&lt;br /&gt;
**Citation: Lorvand Amiri H, Hassan Javanbakht M, Mohammad Baghbanian S, Parsaeian M. The effect of a nicotine-rich diet with/without redistribution of dietary protein on motor indices in patients with Parkinson&#039;s disease: A randomized clinical trial. J Clin Neurosci. 2024 Sep 30;129:110845. doi: 10.1016/j.jocn.2024.110845. Epub ahead of print. PMID: 39353253.&lt;br /&gt;
***Acknowledgement: This work was supported by the Tehran University of Medical Sciences. (Project No. 53161).&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://pubmed.ncbi.nlm.nih.gov/38430248/ Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson&#039;s disease] ===&lt;br /&gt;
*Animal study (worms with humanised neurons)&lt;br /&gt;
*This study examines whether nicotine helps transgenic C. elegans PD models. According to numerous studies, nicotine enhances synaptic plasticity and dopaminergic neuronal survival. Upgrades UPS pathways, increases autophagy, and decreases oxidative stress and mitochondrial dysfunction.&lt;br /&gt;
*At 100, 150, and 200 µM nicotine levels, worms showed reduced α-Syn aggregation, repaired DA neurotoxicity after 6-OHDA intoxication, increased lifetime, and reduced lipofuscin accumulation. Furthermore, nicotine triggered autophagy and UPS. &lt;br /&gt;
*We revealed nicotine&#039;s potential as a UPS and autophagy activator to prevent PD and other neurodegenerative diseases.&lt;br /&gt;
*&#039;&#039;Note: highly technical brain biochemistry, appears to be important however (ed.)&#039;&#039; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586504/ Paper on the UPS and it&#039;s purpose] for info.&lt;br /&gt;
**Citation: Ullah I, Uddin S, Zhao L, Wang X, Li H. Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson&#039;s disease. Exp Brain Res. 2024 Apr;242(4):971-986. doi: 10.1007/s00221-023-06765-9. Epub 2024 Mar 2. PMID: 38430248.&lt;br /&gt;
***Acknowledgement: This study was supported by the Special International Cooperation Project of the Ministry of Science and Technology (2012DFA30480); National Natural Science Foundation of China (No. 81403145); Natural Science Foundation of Gansu Province (No. 20JR10RA602); Fundamental Research Funds for the Central Universities of China (lzujbky—2017-206, lzujbky-2018-136); Science and Technology Cooperation Program of Gansu Academy of Sciences (grant number 2019HZ-02); Program of Lanzhou Science and Technology Foundation (Grant number 2010-1-154). Major science and technology project of Gansu province (23ZDFA013), Natural Science Foundation of Gansu province (20JR10RA602).&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://www.frontiersin.org/articles/10.3389/fnagi.2023.1223310/full Changes in smoking, alcohol consumption, and the risk of Parkinson’s disease] ===&lt;br /&gt;
*A total of 3,931,741 patients were included.&lt;br /&gt;
*Compared to the sustained non-smokers, sustained light smokers, sustained moderate smokers, and sustained heavy smokers had a lower risk of PD. &lt;br /&gt;
*Compared to those who sustained non-drinking, sustained light drinkers, sustained moderate drinkers, and sustained heavy drinkers showed decreased risk of PD. &lt;br /&gt;
*Among non-drinkers, those who started drinking to a light level were at decreased risk of PD. Among non-smoking and non-drinking participants, those who initiated smoking only, drinking only, and both smoking and drinking showed decreased risk of PD.&lt;br /&gt;
*Smoking is associated with decreased risk of PD with a dose–response relationship. Alcohol consumption at a light level may also be associated with decreased risk of PD. Further studies are warranted to find the possible mechanisms for the protective effects of smoking and drinking on PD, which may present insights into the etiology of PD.&lt;br /&gt;
**Citation: Jung SY, Chun S, Cho EB, Han K, Yoo J, Yeo Y, Yoo JE, Jeong SM, Min JH, Shin DW. Changes in smoking, alcohol consumption, and the risk of Parkinson&#039;s disease. Front Aging Neurosci. 2023 Sep 13;15:1223310. doi: 10.3389/fnagi.2023.1223310. PMID: 37771519; PMCID: PMC10525683.&lt;br /&gt;
***Acknowledgement: J-HM received a grant from the National Research Foundation of Korea and SMC Research and Development Grant. J-HM has lectured, consulted, and received Honoria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Sanofi Genzyme, Teva-Handok, UCB, Samsung Bioepis, Mitsubishi Tanabe Pharma, and Roche.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36817162/ Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson&#039;s disease.] ===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine (Nic) has previously been proven to reduce neurodegeneration in the models of Parkinson&#039;s disease (PD). The present study is intended to investigate the detailed mechanisms related to the potential neuroprotective effects of Nic in vivo.&lt;br /&gt;
*In summary, Nic pretreatment ameliorates MPTP-induced dyskinesia and anxiety-like behavior in mice with PD. Nic was found to alleviate neuroapoptosis by improving nigrostriatal dopaminergic damage, reducing the accumulation of pathological p-α-syn, and inhibiting microglia activation and pro-inflammatory factor expression in the substantia nigra and striatal regions of mice brain under MPTP stimulation. These neuroprotective effects of Nic may be achieved by modulating the JNK and ERK signaling pathways in the nigrostriatal system, which was further confirmed by the pretreatment of 5-MOP to decline the brain metabolic activity of Nic.&lt;br /&gt;
**Citation: Ruan S, Xie J, Wang L, Guo L, Li Y, Fan W, Ji R, Gong Z, Xu Y, Mao J, Xie J. Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson&#039;s disease. Front Pharmacol. 2023 Feb 2;14:1088957. doi: 10.3389/fphar.2023.1088957. PMID: 36817162; PMCID: PMC9932206.&lt;br /&gt;
***Acknowledgement: This study received funding from the National Science Foundation of China (Grant No. 32072344, 82101506, 32272455), the Scientific and Technological Project of Henan Province of China (Grant No. 182102310157) and the Scientific and Technological Project of China Tobacco Jiangsu Industrial Co., Ltd. (No. H202002). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Authors JX, RJ, and ZG were employed by China Tobacco Jiangsu Industrial Co., Ltd.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://jamanetwork.com/journals/jamaneurology/article-abstract/2805037 Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune]===&lt;br /&gt;
*“Parkinson disease risk was substantially lower among Black veterans and EVER-SMOKERS (OR 0.49, 95% CI: 0.40-0.61).&lt;br /&gt;
**Citation: Goldman SM, Weaver FM, Stroupe KT, Cao L, Gonzalez B, Colletta K, Brown EG, Tanner CM. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. JAMA Neurol. 2023 Jul 1;80(7):673-681. doi: 10.1001/jamaneurol.2023.1168. PMID: 37184848; PMCID: PMC10186205.&lt;br /&gt;
***Acknowledgement: This research was supported by clinical science research and development merit award I01 CX002040-01 from the US Department of Veterans Affairs. Support for Veterans Administration (VA)/Centers for Medicare &amp;amp; Medicaid Services data was from the US Department of Veterans Affairs, VA Health Services Research and Development Service, and project numbers SDR 02-237 and 98-004 from the VA Information Resource Center. Dr Weaver reported receiving grants from the Edward Hines, Jr VA Hospital during the conduct of the study and outside the submitted work. Dr Brown reported receiving grants from the Michael J. Fox Foundation and the National Institute on Aging and personal fees from Gateway Consulting, LLC, outside the submitted work. Dr Tanner reported receiving personal fees from Lundbeck Pharma, CNS Ratings, Adamas, Cadent, and Evidera; serving on advisory boards for Kyowa Kirin, Acorda, Australia Parkinson’s Mission; serving on a clinical trial steering committee for Jazz Pharmaceuticals/Cavion; and receiving grants from the National Institutes of Health, Biogen Idec, Parkinson Foundation, Michael J. Fox Foundation, Department of Defense Parkinson’s Research Program, Roche, Genentech, BioElectron, and Gateway Institute for Brain Research, LLC, outside the submitted work. No other disclosures were reported.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602090/ Butyrate Protects and Synergizes with Nicotine against Iron- and Manganese-induced Toxicities in Cell Culture]===&lt;br /&gt;
*Preprint, not peer-reviewed.&lt;br /&gt;
*In summary, our results not only support neuroprotective effects of nicotine and butyrate in countering Fe and Mn toxicities but indicate a synergistic protection by combination of the two. Moreover, distinct mechanisms of action for each metal, i.e., nicotinic receptor for nicotine and FA3R for butyrate are indicated. Further exploitation of mechanisms of action of butyrate and nicotine may provide novel targets for metal toxicities and/or amelioration of neurodegenerative diseases.&lt;br /&gt;
**Citation: Tizabi Y, Getachew B, Aschner M. Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases. Res Sq [Preprint]. 2023 Oct 5:rs.3.rs-3389904. doi: 10.21203/rs.3.rs-3389904/v1. Update in: Neurotox Res. 2023 Dec 14;42(1):3. doi: 10.1007/s12640-023-00682-z. PMID: 37886507; PMCID: PMC10602090.&lt;br /&gt;
***Acknowledgement: Supported in part by: NIH/NIAAA R03 AA022479 and NIH/NIGMS (2 SO6 GM08016‐39) (YT), and NIEHS R01ES10563 and R01ES07331 (MA).&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.nature.com/articles/s41598-021-88910-4 Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels]===&lt;br /&gt;
*Insect study&lt;br /&gt;
*In conclusion our data show that the PD model by expression of Sph-1 in dopaminergic neurons provides a good opportunity to study the early prodromal stages of PD, while also the late onset symptoms such as neurodegeneration and motor impairment in aged animals. On the other hand, working on this animal model has allowed us to advance on the therapeutic effects of nicotine treatment over several PD-linked features. The protective effect of nicotine appears to be specific for the genotype predisposed to develop a parkinsonian phenotype and provide a hint on the idea that nicotine treatment even in later stages of the disease could be beneficial to patients. Our findings provide new ideas that contribute to a better understanding on the mechanisms underlying the positive effects of nicotine in PD.&lt;br /&gt;
**Citation: Carvajal-Oliveros, A., Domínguez-Baleón, C., Zárate, R.V. et al. Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Sci Rep 11, 9579 (2021). https://doi.org/10.1038/s41598-021-88910-4&lt;br /&gt;
***Acknowledgement: This work was supported by the CONACyT (Grant Number 255478) and by DGAPA-PAPIIT (Grant Number IN206517).&lt;br /&gt;
&lt;br /&gt;
=== 2020: [https://n.neurology.org/content/94/20/e2132 Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors] === &lt;br /&gt;
*In contrast to previous suggestions, the present report demonstrates a causally protective effect of current smoking on the risk of PD, which may provide insights into the etiology of PD.&lt;br /&gt;
**Citation: Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, Peto R. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology. 2020 May 19;94(20):e2132-e2138. doi: 10.1212/WNL.0000000000009437. Epub 2020 May 5. PMID: 32371450; PMCID: PMC7526668.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://academic.oup.com/ajcn/advance-article-abstract/doi/10.1093/ajcn/nqaa186/5876214?redirectedFrom=fulltext Dietary nicotine intake and risk of Parkinson disease: a prospective study]=== &lt;br /&gt;
*At 26 year follow-up, women with greater dietary nicotine intake had a lower risk of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Parkinson Disease (PD)&#039;&#039;&#039;]] than those with lower intake. Dietary nicotine intake was calculated based on consumption of peppers, tomatoes, processed tomatoes, potatoes, and tea. &lt;br /&gt;
*[https://sci-hub.st/10.1093/ajcn/nqaa186 PDF Version]&lt;br /&gt;
**Citation: Chaoran Ma, Samantha Molsberry, Yanping Li, Michael Schwarzschild, Alberto Ascherio, Xiang Gao, Dietary nicotine intake and risk of Parkinson disease: a prospective study, The American Journal of Clinical Nutrition, Volume 112, Issue 4, October 2020, Pages 1080–1087, doi: 10.1093/ajcn/nqaa186&lt;br /&gt;
***Acknowledgements: Supported by National Institute of Neurological Disorders and Stroke at the NIH grant 1R03NS093245-01A1 (to XG). The Nurses’ Health Study is supported by the NIH through grant UM1 CA186107. The Health Professionals Follow-up Study cohort is supported by the NIH through grant U01 CA167552.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-018-0625-y Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*The reduced prevalence of Parkinson’s disease in tobacco users is a fascinating phenomenon that is not understood. This study suggests a mechanistic explanation for how tobacco users are protected from Parkinson’s and how the tobacco component nicotine confers neuroprotection; more specifically, nicotine suppresses SIRT6 which confers resistance to neuron and cell death. Few effective treatments exist that prevent neuron death for those suffering from Parkinson’s and other neurodegenerative disorders. The identification of SIRT6 as potentially pathogenic and as a therapeutic target for suppression opens a novel line of research for the treatment of neurodegeneration.&lt;br /&gt;
**Citation: Nicholatos, J.W., Francisco, A.B., Bender, C.A. et al. Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6. acta neuropathol commun 6, 120 (2018). https://doi.org/10.1186/s40478-018-0625-y&lt;br /&gt;
***Acknowledgement: S.L. and J.W.N. were in part supported by a grant from American Federation for Aging Research (AFAR, grant # 2015–030). S.L. received seed grant funding from the Cornell University Center for Vertebrate Genomics. J.W.N. was supported by a Glenn/AFAR Scholarship for Research in the Biology of Aging.&lt;br /&gt;
&lt;br /&gt;
===2017 [https://academic.oup.com/ije/article/46/3/872/2656164 Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease]===&lt;br /&gt;
*Non-smoking men who used snus had a 60% lower risk of Parkinson’s disease compared with never snus users.&lt;br /&gt;
**Citation: Yang F, Pedersen NL, Ye W, Liu Z, Norberg M, Forsgren L, Trolle Lagerros Y, Bellocco R, Alfredsson L, Knutsson A, Jansson JH, Wennberg P, Galanti MR, Lager ACJ, Araghi M, Lundberg M, Magnusson C, Wirdefeldt K. Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease. Int J Epidemiol. 2017 Jun 1;46(3):872-880. doi: 10.1093/ije/dyw294. PMID: 27940486.&lt;br /&gt;
***Acknowledgement: This work was supported by the Swedish Research Council (grant number 521-2013-2488 to N.L.P.) and the regional agreement on medical training and clinical research between Stockholm County Council and Karolinska Institutet (Y.T.L.).&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
**Author/Acknowledgements: Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2046219/ Nicotinic receptors as CNS targets for Parkinson’s disease]=== &lt;br /&gt;
*Human and animal references&lt;br /&gt;
*Analyzes results showing that chronic nicotine treatment improved striatal integrity and function.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2046219/pdf/nihms32016.pdf PDF Version]&lt;br /&gt;
**Citation: Quik M, Bordia T, O&#039;Leary K. Nicotinic receptors as CNS targets for Parkinson&#039;s disease. Biochem Pharmacol. 2007 Oct 15;74(8):1224-34. doi: 10.1016/j.bcp.2007.06.015. Epub 2007 Jun 17. PMID: 17631864; PMCID: PMC2046219.&lt;br /&gt;
***Acknowledgements: This work was supported by NIH grants NS42091 and NS47162.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*Nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Parkinson&#039;s Disease&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against &#039;&#039;&#039;Parkinson&#039;s Disease&#039;&#039;&#039; (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pemphigus Vulgaris&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2001: [https://pubmed.ncbi.nlm.nih.gov/11737449/ Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire]===&lt;br /&gt;
*The risk for pemphigus vulgaris was lower for ex-smokers and current smokers than for patients who had never smoked.&lt;br /&gt;
*The beneficial effect of smoking on pemphigus might be explained by its effect on the immune system. &lt;br /&gt;
**Citation: Brenner S, Tur E, Shapiro J, Ruocco V, D&#039;Avino M, Ruocco E, Tsankov N, Vassileva S, Drenovska K, Brezoev P, Barnadas MA, Gonzalez MJ, Anhalt G, Nousari H, Ramos-e-Silva M, Pinto KT, Miranda MF. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol. 2001 Sep;40(9):562-9. doi: 10.1046/j.1365-4362.2001.01266.x. Erratum in: Int J Dermatol. 2003 Sep;42(9):760. Silva MR [corrected to Ramos-e-Silva M]. PMID: 11737449.&lt;br /&gt;
&lt;br /&gt;
===2000: [https://jamanetwork.com/journals/jamadermatology/fullarticle/189739 A Case of Pemphigus Vulgaris Improved by Cigarette Smoking]===&lt;br /&gt;
*The patient reported an inverse relationship between smoking and pemphigus flares. He observed a worsening of the pemphigus when he stopped smoking. Nicotine patches were prescribed, but he began smoking cigarettes again instead. On average, he smokes 15 cigarettes per day. One week after he began smoking again, his pemphigus rapidly started to clear.&lt;br /&gt;
**Citation: Mehta JN, Martin AG. A case of pemphigus vulgaris improved by cigarette smoking. Arch Dermatol. 2000 Jan;136(1):15-7. doi: 10.1001/archderm.136.1.15. PMID: 10632179.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Psoriasis&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/ Can nicotine use alleviate symptoms of psoriasis?]=== &lt;br /&gt;
*In light of recent data demonstrating that psoriasis is an immune-mediated disease, the possibility that novel anti-inflammatory treatments such as nicotine replacement therapy or analogues could have a beneficial effect on patients with psoriasis should be considered. This case described one such occasion in which it appeared that nicotine had a therapeutic effect on a patient’s psoriasis. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version]&lt;br /&gt;
**Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pyoderma Gangrenosum&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15204166/ Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream]=== &lt;br /&gt;
*Two patients with pyoderma gangrenosum treated with topical nicotine 0.5% w/w cetamacrogol formula A cream are described here, both of whom had dramatic clinical resolution of their pyoderma gangrenosum.&lt;br /&gt;
*[https://scihubtw.tw/10.1080/09546630310019364 PDF Version]&lt;br /&gt;
**Citations:Patel GK, Rhodes JR, Evans B, Holt PJ. Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream. J Dermatolog Treat. 2004 Apr;15(2):122-5. doi: 10.1080/09546630310019364. PMID: 15204166.&lt;br /&gt;
&lt;br /&gt;
===1998 [https://jamanetwork.com/journals/jamadermatology/fullarticle/189304?fbclid=IwAR33gpEktRMf2Q0v5Btl9C5E8gmXw-ZP8_gDFt6sebxUBpXE_WfVt-o-mSw Nicotine for Pyoderma Gangrenosum]=== &lt;br /&gt;
*Herein we describe a patient with pyoderma gangrenosum who responded twice to topical nicotine within 4 weeks and 3 months, respectively, without any adverse effects.&lt;br /&gt;
*[https://scholar.google.com/scholar_url?url=https://jamanetwork.com/journals/jamadermatology/articlepdf/189304/dce8005.pdf&amp;amp;hl=en&amp;amp;sa=T&amp;amp;oi=ucasa&amp;amp;ct=ufr&amp;amp;ei=Z2aqX4SnOc2rywTPj5aYDw&amp;amp;scisig=AAGBfm1pz6ffl3a23G__I3APgBLpY6Cofw PDF Version]&lt;br /&gt;
**Citation: Wolf R, Ruocco V. Nicotine for Pyoderma Gangrenosum. Arch Dermatol. 1998;134(9):1071–1072. doi:10.1001/archderm.134.9.1071&lt;br /&gt;
&lt;br /&gt;
===1995 [https://pubmed.ncbi.nlm.nih.gov/8537562/ Successful treatment of pyoderma gangrenosum with nicotine chewing gum]=== &lt;br /&gt;
*We used nicotine chewing gum for the treatment of pyoderma gangrenosum with remarkable results. We strongly suggest that nicotine chewing gum may not only be beneficial in treating pyoderma gangrenosum but may also be useful in treating other skin disorders with prominent neutrophilic infiltrations such as Behcet&#039;s disease, Sweet disease, allergic vasculitis, and recurrent oral aphthae, the last of which is known to respond to smoking.&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1346-8138.1995.tb03904.x PDF Version]&lt;br /&gt;
**Citation: Kanekura T, Kanzaki T. Successful treatment of pyoderma gangrenosum with nicotine chewing gum. J Dermatol. 1995 Sep;22(9):704-5. doi: 10.1111/j.1346-8138.1995.tb03904.x. PMID: 8537562.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sarcoidosis&#039;&#039;&#039;= &lt;br /&gt;
===2021 [https://journal.chestnet.org/article/S0012-3692(21)01282-4/fulltext Promise of Nicotine as a Treatment for Pulmonary Sarcoidosis]=== &lt;br /&gt;
===2021 [https://journal.chestnet.org/article/S0012-3692(21)00962-4/fulltext A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis]===&lt;br /&gt;
*Nicotine treatment was well tolerated in patients with active pulmonary sarcoidosis, and the preliminary findings of this pilot study suggest that it may reduce disease progression, based on FVC.&lt;br /&gt;
**Citation: A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis, Crouser, Elliott D. et al. CHEST, Volume 160, Issue 4, 1340 - 1349&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journal.chestnet.org/article/S0012-3692(13)60095-1/fulltext Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis]=== &lt;br /&gt;
*The immune phenotype of patients with symptomatic [[wikipedia:Sarcoidosis|&#039;&#039;&#039;sarcoidosis&#039;&#039;&#039;]] treated with nicotine closely resembled that of asymptomatic patients, supporting the notion that nicotine treatment may be beneficial in this patient population.&lt;br /&gt;
*[https://www.researchgate.net/profile/Mark_Julian/publication/230645268_Nicotine_Treatment_Improves_TLR2_and_TLR9_Responsiveness_in_Active_Pulmonary_Sarcoidosis/links/556ca4af08aeab77722318be/Nicotine-Treatment-Improves-TLR2-and-TLR9-Responsiveness-in-Active-Pulmonary-Sarcoidosis.pdf PDF Version]&lt;br /&gt;
**Citation: Mark W. Julian, MS; Guohong Shao, MD; Larry S. Schlesinger, MD; Qin Huang, MD; David G. Cosmar, BA; Nitin Y. Bhatt, MD; Daniel A. Culver, MD, FCCP; Robert P. Baughman, MD, FCCP; Karen L. Wood, MD, FCCP; and Elliott D. Crouser, MD - ORIGINAL RESEARCH DIFFUSE LUNG DISEASE| VOLUME 143, ISSUE 2, P461-470, FEBRUARY 01, 2013, DOI 10.1378/chest.12-0383&lt;br /&gt;
***Acknowledgements: This work was supported by the American Thoracic Society and the Foundation for Sarcoidosis Research. © 2013 American College of Chest Physicians&lt;br /&gt;
&lt;br /&gt;
===1988:[https://thorax.bmj.com/content/43/7/516.abstract Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.]===&lt;br /&gt;
*These finding support the possibility that smokers, particularly those with a prominent accumulation of alveolar macrophages in the lower respiratory tract, may be less likely to develop sarcoidosis.&lt;br /&gt;
**Citation: Valeyre D, Soler P, Clerici C, et alSmoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.Thorax 1988;43:516-524.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Seizures / Epilepsy&#039;&#039;&#039;=&lt;br /&gt;
*See also:&lt;br /&gt;
**Video: News 5: [https://www.youtube.com/watch?v=Ztvf45coKZk Nicotine Stops Seizures]&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.neurology.org/doi/10.1212/WNL.0000000000209790/ Pearls &amp;amp; Oy-sters: Exquisite Response of Sleep-Related Hypermotor Epilepsy to a Nicotine Patch]===&lt;br /&gt;
*&amp;quot;Sleep-related hypermotor epilepsy (SHE), previously known as nocturnal frontal lobe epilepsy, is characterized by brief (&amp;lt;2 minutes) seizures with abrupt onset and offset and stereotyped focal or generalized hypermotor events occurring predominantly (but not exclusively) from sleep.&amp;quot;&lt;br /&gt;
*&amp;quot;Our case highlights that there may be mechanisms by which nicotine assists with seizure cessation in specific populations of individuals with SHE.&amp;quot;&lt;br /&gt;
**Citation: Nam S, Von Stein EL, Meador KJ, Levy RJ, Gallentine W, Li Y. Pearls &amp;amp; Oy-sters: Exquisite Response of Sleep-Related Hypermotor Epilepsy to a Nicotine Patch. Neurology. 2024 Oct 8;103(7):e209790. doi: 10.1212/WNL.0000000000209790. Epub 2024 Sep 9. PMID: 39250747; PMCID: PMC11385953.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/34763266/ Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients]=== &lt;br /&gt;
*This is the hitherto largest observational study supporting a favorable effect of nicotine in this specific seizure disorder. Better seizure control from transdermal nicotine compared to only day-time consumption suggests benefit from exposure throughout the night. According to current clinical experience, patients with uncontrolled ADSHE harboring relevant mutations should be offered precision treatment with transdermal nicotine.&lt;br /&gt;
**Citation: Brodtkorb E, Myren-Svelstad S, Knudsen-Baas KM, Nakken KO, Spigset O. Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients. Epilepsy Res. 2021 Oct 25;178:106792. doi: 10.1016/j.eplepsyres.2021.106792. Epub ahead of print. PMID: 34763266.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.pedneur.com/article/S0887-8994(21)00147-8/fulltext Nicotine patch improved autosomal dominant sleep-related hypermotor epilepsy]=== &lt;br /&gt;
*Nevertheless, the two siblings reported here add to the small number of pediatric case reports regarding the successful use of nicotine patches in ADSHE.&lt;br /&gt;
*Journal Pre-Proof [https://www.pedneur.com/action/showPdf?pii=S0887-8994%2821%2900147-8 PDF Version]&lt;br /&gt;
**Citation: Nguyen SM, Deering L, Nelson GT, McDaniel SS, Nicotine patch improved autosomal dominant sleep-related hypermotor epilepsy, Pediatric Neurology (2021), doi:10.1016/j.pediatrneurol.2021.07.006.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/33284031/ Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]===&lt;br /&gt;
*&amp;quot;Genetic variants of the neuronal nicotinic acetylcholine receptor (nAChR) cause autosomal dominant sleep-related hypermotor epilepsy. Approximately 30% of autosomal dominant sleep-related hypermotor epilepsy patients are medically intractable.&amp;quot;&lt;br /&gt;
*&amp;quot;Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants. We propose consideration of transdermal nicotine treatment in intractable epilepsy with known nAChR variants as an experimental therapy.&amp;quot;&lt;br /&gt;
**Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/33284031/ Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]===&lt;br /&gt;
*&amp;quot;Four patients were prescribed nicotine patches for intractable seizures. Three of 4 patients had a clinical response, with &amp;gt;50% seizure reduction.&amp;quot;&lt;br /&gt;
*&amp;quot;Conclusions: Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants.&amp;quot;&lt;br /&gt;
**Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32097883/  Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy]===&lt;br /&gt;
*&amp;quot;Results: A striking seizure reduction was reported soon after treatment onset. Hypermotor seizures disappeared; only sporadic arousals, sometimes with minor motor elements, were observed. Psychometric testing documented improvement in cognitive domains such as visuospatial ability, processing speed, memory, and some areas of executive functions.&amp;quot;&lt;br /&gt;
**Citation: Lossius K, de Saint Martin A, Myren-Svelstad S, Bjørnvold M, Minken G, Seegmuller C, Valenti Hirsch MP, Chelly J, Steinlein O, Picard F, Brodtkorb E. Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy. Epilepsy Behav. 2020 Apr;105:106944. doi: 10.1016/j.yebeh.2020.106944. Epub 2020 Feb 22. PMID: 32097883.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.dovepress.com/sleep-related-hypermotor-epilepsy-prevalence-impact-and-management-str-peer-reviewed-fulltext-article-NSS Sleep-related hypermotor epilepsy: prevalence, impact and management strategies]===&lt;br /&gt;
*&amp;quot;Seizure frequency improved in a single patient with refractory ADSHE after nicotine transdermal patches treatment.(108) The favorable effect of nicotine on seizure frequency was also described in 9 of 22 patients from two European ADSHE families carrying CHRNA4 mutations.(109) Considering the role of the cholinergic system in arousal regulatory processes, these observations suggested a possible link between nicotine defect, alteration of arousal regulation and seizures in SHE/ADSHE patients. However, despite the reported positive effect of nicotine in reducing seizure frequency, a case–control family study, did not find a higher tendency to smoke tobacco in SHE patients and their relatives compared with the control cases.(110)&lt;br /&gt;
**Citation: Menghi V, Bisulli F, Tinuper P, Nobili L. Sleep-related hypermotor epilepsy: prevalence, impact and management strategies. Nat Sci Sleep. 2018 Oct 10;10:317-326. doi: 10.2147/NSS.S152624. PMID: 30349413; PMCID: PMC6186898.&lt;br /&gt;
&lt;br /&gt;
===2015 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433466/ Pearls &amp;amp; Oy-sters: A case of refractory nocturnal seizures]===&lt;br /&gt;
*&amp;quot;Due to frequent seizures, there was a paucity of slow-wave sleep and complete absence of REM sleep. On the second day of her hospital admission, a 7-mg nicotine patch was applied about 2–3 hours before bedtime. There was almost complete resolution of clinical and electrical events. The duration of slow-wave sleep increased and REM sleep was recorded. The next morning, the patient felt refreshed and less anxious.&amp;quot;&lt;br /&gt;
**Citation: Pavlakis PP, Douglass LM. Pearls &amp;amp; Oysters: A case of refractory nocturnal seizures: Putting out fires without smoke. Neurology. 2015 May 5;84(18):e134-6. doi: 10.1212/WNL.0000000000001539. PMID: 25941204; PMCID: PMC4433466.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2012.03715.x Resolution of epileptic encephalopathy following treatment with transdermal nicotine]=== &lt;br /&gt;
*We report resolution of an epileptic encephalopathy by administration of transdermal nicotine patches in an adolescent with severe nonlesional refractory frontal lobe epilepsy. The 18.5‐year‐old female patient had refractory epilepsy from the age of 11. Recurrent electroencephalography (EEG) recordings showed mostly generalized activity, albeit with right frontal predominance. Almost all antiepileptic medications failed to provide benefit. She developed an encephalopathic state with cognitive decline. The nonlesional frontal lobe epilepsy and a family history of a cousin with nocturnal epilepsy with frontal origin suggested genetic etiology. Transdermal nicotine patches brought complete resolution of the seizures, normalization of the EEG, and a significant improvement in her thinking process and speech organization. Sequencing of the CHRNB2 and CHRNA4 genes did not detect a mutation. Transdermal nicotine patches should be considered in severe pharmacoresistant frontal lobe epilepsy.&lt;br /&gt;
*[https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2012.03715.x PDF Version]&lt;br /&gt;
**Citation: Zerem, A., Nishri, D., Yosef, Y., Blumkin, L., Lev, D., Leshinsky‐Silver, E., Kivity, S. and Lerman‐Sagie, T. (2013), Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia, 54: e13-e15. doi: 10.1111/j.1528-1167.2012.03715.x&lt;br /&gt;
&lt;br /&gt;
===2006 [https://pubmed.ncbi.nlm.nih.gov/16931165/ Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy]===&lt;br /&gt;
*&amp;quot;This study indicates that nicotine consumption is an environmental factor that, in many patients with ADNFLE, may influence susceptibility to seizures. A detailed account of tobacco habits should be part of the history. Transdermal nicotine should be considered in pharmacoresistant cases.&amp;quot;&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.yebeh.2006.07.008 PDF Full study]&lt;br /&gt;
**Citation: Brodtkorb E, Picard F. Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy. Epilepsy Behav. 2006 Nov;9(3):515-20. doi: 10.1016/j.yebeh.2006.07.008. Epub 2006 Aug 22. PMID: 16931165.&lt;br /&gt;
&lt;br /&gt;
===2003 [https://onlinelibrary.wiley.com/doi/full/10.1046/j.1528-1157.2003.58102.x-i1?sid=nlm%3Apubmed Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study]=== &lt;br /&gt;
*In this individual with refractory [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ADNFLE&#039;&#039;&#039;]], nicotine had a therapeutic effect on seizures, and it may be useful to others with this disorder.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1046/j.1528-1157.2003.58102.x-i1 PDF Version]&lt;br /&gt;
**Citation: Willoughby, J.O., Pope, K.J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study. Epilepsia, 44: 1238-1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sepsis/Septic/endotoxemia/infection&#039;&#039;&#039;=&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/pii/S0014488624002723 Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these findings indicate that acute nicotine exposure enhances functional stroke recovery. Future studies will have to evaluate the effects of (1) chronic nicotine exposure, a clinically relevant vascular risk factor, and (2) the cessation of nicotine exposure, which is widely recommended post-stroke, but might have detrimental effects in the early stroke recovery phase.&lt;br /&gt;
**Citation: Abbaspour S, Fahanik-Babaei J, Adeli S, Hermann DM, Sardari M. Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state. Exp Neurol. 2024 Sep 13;382:114946. doi: 10.1016/j.expneurol.2024.114946. Epub ahead of print. PMID: 39278587.&lt;br /&gt;
***Funding: None&lt;br /&gt;
&lt;br /&gt;
===2014 [https://academic.oup.com/jid/article/209/10/1668/855517#78932729 Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*In conclusion, stimulation of α7nAChR by nicotine improves mortality rates and MODS during sepsis. This protective effect of nicotine can be associated with the inhibition of TLR4 overexpression through the PI3K/Akt signaling pathway. Although the therapeutic potential of nicotine is still limited by its nonspecific effects, this study may provide an impetus for further development of therapeutic strategies for modifying the cholinergic antiinflammatory pathway in the treatment of various inflammatory diseases.&lt;br /&gt;
**Citation: Kim TH, Kim SJ, Lee SM. Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation. J Infect Dis. 2014 May 15;209(10):1668-77. doi: 10.1093/infdis/jit669. Epub 2013 Dec 1. Erratum in: J Infect Dis. 2015 Mar 1;211(5):851. doi: 10.1093/infdis/jiu824. PMID: 24298024.&lt;br /&gt;
***Acknowledgement: This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Information and Communication Technologies (ICT) and Future Planning (NRF-2013R1A1A3008145).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://pubmed.ncbi.nlm.nih.gov/20805763/ Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*The results suggested that both carbachol and nicotine play a role in the anti-inflammatory process and organ function protection through the α7 subunit of nicotinic cholinergic receptor.&lt;br /&gt;
*[https://sci-hub.st/10.1097/TA.0b013e3181e9732d PDF Full Paper]&lt;br /&gt;
**Citation: Zhou G, Hu S, Lv Y, Song Q, Zou X, Sheng Z. Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide. J Trauma. 2011 Jul;71(1):157-62. doi: 10.1097/TA.0b013e3181e9732d. PMID: 20805763.&lt;br /&gt;
***Acknowledgement: From the Laboratory of Shock and Organ Dysfunction (G.Z., S.H., Y.L., Q.S., X.Z., Z.S.), Burn Institute, the First Hospital Affiliated to the People’s Liberation Army General Hospital, Beijing, China.&lt;br /&gt;
&lt;br /&gt;
===2005 [https://academic.oup.com/jid/article/191/12/2138/842542 The Cholinergic Anti-Inflammatory Pathway Regulates the Host Response during Septic Peritonitis]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*&amp;quot;Initial cytokine release during septic peritonitis was enhanced after previous vagotomy and was decreased after nicotine pretreatment, independently of the integrity of the vagus nerve. Further study established that vagotomy before septic peritonitis resulted in an enhanced influx of neutrophils and a marked increase in proinflammatory cytokine levels and liver damage. Conversely, nicotine pretreatment strongly decreased cell influx, proinflammatory cytokine levels, and liver damage, whereas bacterial clearance and survival were impaired.&amp;quot;&lt;br /&gt;
**Citation: van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, van der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis. 2005 Jun 15;191(12):2138-48. doi: 10.1086/430323. Epub 2005 May 10. PMID: 15898001.&lt;br /&gt;
***Acknowledgement: Financial support: Academic Medical Center, Amsterdam, The Netherlands. Potential conflicts of interest: K.J.T. is cofounder of Critical Therapeutics Inc., a pharmaceutical company developing potential future treatment modalities based on the cholinergic anti-inflammatory pathway.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sleep Apnea&#039;&#039;&#039;= &lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against sleep apnea (other diseases / issues mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1985: [https://pubmed.ncbi.nlm.nih.gov/3965253/ Nicotine: a different approach to treatment of obstructive sleep apnea]===&lt;br /&gt;
*Reduced upper airway muscle activity may contribute to the occurrence of obstructive apneas during sleep. There is no uniformly successful treatment of these apneas, and it is possible that agents which increase upper airway muscle activity could reduce the occurrence of obstruction during sleep. Nicotine, a known stimulant of breathing, also increases the activity of muscles which dilate the upper airway proportionally more than it does ventilation. Hence, we evaluated the effect of nicotine on apneas during the first two hours of sleep in eight patients with sleep apnea syndrome. It was concluded that nicotine reduces apneas during the early hours of sleep, and this effect may be caused by its stimulating action on upper airway muscles.&lt;br /&gt;
*[https://sci-hub.se/10.1378/chest.87.1.11 PDF Version]&lt;br /&gt;
**Citation: Gothe B, Strohl KP, Levin S, Cherniack NS. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest. 1985 Jan;87(1):11-7. doi: 10.1378/chest.87.1.11. PMID: 3965253.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Smoking Cessation / Preventing Relapse&#039;&#039;&#039;= &lt;br /&gt;
===Resource Doc: [https://docs.google.com/document/d/13-D2q1P0KpmZuoFBkKV4l9wUEQ-zcHfp6MAVJGoAaG4/edit?usp=sharing INNCO - Myth of the month:  Ecigs and snus don’t help smokers quit]=== &lt;br /&gt;
*Links and conclusions of studies formatted to fit the character limits on Twitter&lt;br /&gt;
&lt;br /&gt;
===[https://safernicotine.wiki/mediawiki/index.php/Myth:_Alternative_nicotine_products_don%27t_help_people_stop_smoking Myth: Alternative nicotine products don&#039;t help people stop smoking]=== &lt;br /&gt;
*This wiki page shows over 70 studies demonstrating these products help people stop smoking.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Spinal Cord Injury&#039;&#039;&#039;= &lt;br /&gt;
===2008 [https://onlinelibrary.wiley.com/doi/10.1002/jnr.21901 Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Primary impact to the spinal cord results in stimulation of secondary processes that potentiate the initial trauma. Recent evidence indicates that nicotine can exert potent antioxidant and neuroprotective effects in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;spinal cord injury (SCI)&#039;&#039;&#039;]].&lt;br /&gt;
*The results of the present study indicate that [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;iNOS&#039;&#039;&#039;]] is induced in the early stages of SCI, leading to increased nitration of protein tyrosine residues and potentiation of inflammatory responses. Microglial cells appear to be the main cellular source of iNOS in SCI. In addition, nicotine-induced anti-inflammatory effects in SCI are mediated, at least in part, by the attenuation of iNOS overexpression through the receptor-mediated mechanism. This data may have significant therapeutic implications for the targeting of nicotine receptors in the treatment of compressive spinal cord trauma.&lt;br /&gt;
*[https://sci-hub.st/10.1002/jnr.21901 PDF Version]&lt;br /&gt;
*Citation: Lee, M.‐Y., Chen, L. and Toborek, M. (2009), Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J. Neurosci. Res., 87: 937-947.doi.org/10.1002/jnr.21901&lt;br /&gt;
*Acknowledgements: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation.&lt;br /&gt;
*Key words: spinal cord injury; nicotine; neuronal nicotinic receptors; oxidative stress; inflammatory responses; nitric oxide synthase&lt;br /&gt;
&lt;br /&gt;
= Stroke =&lt;br /&gt;
&lt;br /&gt;
=== 2025: &#039;&#039;&#039;[https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntaf034/8005730?redirectedFrom=fulltext&amp;amp;login=false The protective effect of low-dose nicotine on ischemia stroke by maintaining the integrity of the blood-brain barrier]&#039;&#039;&#039; ===&lt;br /&gt;
&lt;br /&gt;
* Animal study (mice)&lt;br /&gt;
* These results demonstrate that nicotine treatment could alleviates the IS-compromised integrity of BBB by regulating the Wnt signal pathway through α7 nAChR.&lt;br /&gt;
* The study demonstrates that nicotine at low concentrations exerts neuro-protective effects by supporting the integrity of BBB and subsequent endothelial viability after ischemic stroke.&lt;br /&gt;
* Qianqian Pang, Xinyang Yan, Zheng Chen, Liang Yun, Jiang Qian, Zeyi Dong, Miao Wang, Wei Deng, Yao Fu, Tao Hai, Zhichao Chen, Xianfang Rong: Nicotine &amp;amp; Tobacco Research, ntaf034, &amp;lt;nowiki&amp;gt;https://doi.org/10.1093/ntr/ntaf034&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Tourette&#039;s Syndrome&#039;&#039;&#039;= &lt;br /&gt;
===2012 [https://pubmed.ncbi.nlm.nih.gov/22776623/ Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette&#039;s, depression, and beyond]=== &lt;br /&gt;
* The article presents a mini-review of studies on TS and depression over the past 25 years.&lt;br /&gt;
* It summarizes the studies on the behavioral biology of the basal ganglia and its neurotransmitters.&lt;br /&gt;
* It describes research with TS patients to evaluate the therapeutics of nicotine and mecamylamine.&lt;br /&gt;
* [https://sci-hub.se/10.1016/j.physbeh.2012.06.023 PDF Version]&lt;br /&gt;
*Citation: Sanberg, P. R., Vindrola-Padros, C., &amp;amp; Shytle, R. D. (2012). Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette’s, depression, and beyond. Physiology &amp;amp; Behavior, 107(5), 801–808. doi:10.1016/j.physbeh.2012.06.023 &lt;br /&gt;
*Acknowledgement: Paul R. Sanberg and R. Douglas Shytle are inventors on patents related to technology described herein and licensed from the University of South Florida to Targacept, Inc. Because of the historical nature of this article, the authors included a number of self-citations required for a chronological discussion. &lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15132126/ Clinical and attentional effects of acute nicotine treatment in Tourette&#039;s syndrome]=== &lt;br /&gt;
*In the 14 evaluable patients with complete primary efficacy data, nicotine (compared to placebo) failed to alter symptoms at 4 hours, but counteracted [https://en.wikipedia.org/wiki/P300_(neuroscience) ERP-P300] signs of diminished attention seen 2 weeks following placebo treatment. &lt;br /&gt;
*Secondary efficacy measures, including patient self-reports and parental ratings, found nicotine to reduce complex tics and improve behaviors related to inattention.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.eurpsy.2003.11.002 PDF Version ]&lt;br /&gt;
*Citation: Howson, A. L., Batth, S., Ilivitsky, V., Boisjoli, A., Jaworski, M., Mahoney, C., &amp;amp; Knott, V. J. (2004). Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome. European Psychiatry, 19(2), 102–112. doi:10.1016/j.eurpsy.2003.11.002 &lt;br /&gt;
*Acknowledgement: This study was supported with a grant from the Tourette Syndrome Association (USA), and patient recruitment was aided by the Ottawa chapter of the Tourette Syndrome Foundation of Canada. &lt;br /&gt;
&lt;br /&gt;
===2001 [https://pubmed.ncbi.nlm.nih.gov/11681767/ Transdermal nicotine and haloperidol in Tourette&#039;s disorder: a double-blind placebo-controlled study]=== &lt;br /&gt;
*[[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Transdermal nicotine (TNP)&#039;&#039;&#039;]] was superior to placebo in reducing behavioral symptoms when patients were receiving an optimal dose of haloperidol, when the dose of haloperidol was reduced by 50%, and when the patch had been discontinued for 2 weeks. These findings confirm earlier open-label findings and suggest that combining nicotinic receptor modulation and neuroleptics could be a therapeutic option for the treatment of Tourette&#039;s disorder &lt;br /&gt;
*[https://www.researchgate.net/profile/Paul_Sanberg/publication/11670769_Transdermal_Nicotine_and_Haloperidol_in_Tourette&#039;s_Disorder/links/5be32624299bf1124fc2d86a/Transdermal-Nicotine-and-Haloperidol-in-Tourettes-Disorder.pdf PDF Version]&lt;br /&gt;
*Citation: Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette&#039;s disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep;62(9):707-14. doi: 10.4088/jcp.v62n0908. PMID: 11681767.&lt;br /&gt;
&lt;br /&gt;
===1997 [https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994 Nicotine for the treatment of Tourette&#039;s syndrome]=== &lt;br /&gt;
*Within 24 hr of the application of a single 7-mg [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TNP (nicotine patch)&#039;&#039;&#039;]], the severity and frequency of tic symptoms is significantly decreased over baseline. This response is rapid, often reaching its maximum in the first 3 hr after application of a single patch. The duration of therapeutic effect of a single 7-mg TNP is variable and may last for about l-2 weeks.&lt;br /&gt;
*Application of a 7-mg TNP to children and adolescents with [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TS&#039;&#039;&#039;]] appears to be clinically safe, with transient side effects. However, no child under 8 years of age and weighing less than 25 kg was considered for TNP treatment.&lt;br /&gt;
*[https://sci-hub.st/https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994?via%3Dihub PDF Version]&lt;br /&gt;
*Citation: Paul R. Sanberg, Archie A. Silver, R.Doug Shytle, Mary Katherine Philipp, David W. Cahill, Harold M. Fogelson, Brian J. McConville, Nicotine for the treatment of Tourette&#039;s syndrome, Pharmacology &amp;amp; Therapeutics, Volume 74, Issue 1, 1997, Pages 21-25, ISSN 0163-7258, doi.org/10.1016/S0163-7258(96)00199-4.&lt;br /&gt;
* Acknowledgements-This review was supported, in part, by grants from the Tourette Syndrome Association, The National Institute of Neurological Disease and Stroke (ROl NS 32067sOlAl) and the Smokeless Tobacco Research Council.&lt;br /&gt;
*Keywords: Nicotine; Tourette&#039;s syndrome; tics; neuropsychiatric disorders&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Gilles de la Tourette’s syndrome (TS)&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
=== 1996 [https://pubmed.ncbi.nlm.nih.gov/8973070/ Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette&#039;s syndrome]=== &lt;br /&gt;
* Sixteen Tourette&#039;s syndrome patients, aged 9 to 15 years, whose symptoms were not controlled with neuroleptics, were followed for various lengths of time after the application of one 7 mg [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine patch (TNP)&#039;&#039;&#039;]] for 24 hours. While there was a broad range in individual response, application of the TNP produced significant reductions in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Yale Global Tic Severity Scale (YGTSS)&#039;&#039;&#039;]] scores relative to baseline, with an average duration of effect lasting between 1 and 2 weeks. Side effects, for the most part, were transient.&lt;br /&gt;
*Eleven patients had greater percentage changes after the second TNP than after the first TNP&lt;br /&gt;
*[https://sci-hub.st/10.1097/00004583-199612000-00015 PDF Version]&lt;br /&gt;
*Citation: Silver AA, Shytle RD, Philipp MK, Sanberg PR. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette&#039;s syndrome. J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1631-6. doi: 10.1097/00004583-199612000-00015. PMID: 8973070.&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1643197/ The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette&#039;s disorder]=== &lt;br /&gt;
*In this study, nicotine markedly potentiated haloperidol effects in treating [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TD&#039;&#039;&#039;]], and showed lesser effects on TD when used alone.&lt;br /&gt;
*[https://sci-hub.st/10.1016/0006-3223(92)90315-q PDF Version]&lt;br /&gt;
* Citation: McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette&#039;s disorder. Biol Psychiatry. 1992 Apr 15;31(8):832-40. doi: 10.1016/0006-3223(92)90315-q. PMID: 1643197.&lt;br /&gt;
*Acknowledgements: Supported in part by grants from the Smokeless Tobacco Research Council, Inc., the Tourette Syndrome Association, and Merrell Dow Pharmaceuticals. The authors thank Roger Stuebing, B.S.M.E., M.S.I.E., and Sunny Y. Lu, M.D., Ph.D. for statistical advice and Merrell Dow Pharmaceuticals for supplying both Nicoreue® gum and placebo nicotine gum.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against Tourette&#039;s disease (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1989 [https://www.sciencedirect.com/science/article/abs/pii/002432058990444X?via%3Dihub Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders]=== &lt;br /&gt;
*Chewing nicotine gum produced striking relief from tics and other symptoms of Tourette syndrome not controlled by neuroleptic treatment alone. It appears that the use of nicotine or cannabinoids may greatly improve the clinical response to neuroleptics in motor disorders.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/0024-3205(89)90444-X PDF Version]&lt;br /&gt;
*Citation: D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman, Paul R. Sanberg, Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders, Life Sciences, Volume 44, Issue 21, 1989, Pages 1521-1525, ISSN 0024-3205, doi.org/10.1016/0024-3205(89)90444-X.&lt;br /&gt;
*Acknowledgements: Supported in part by NIMH (RR 08012) and NIDA. Levonantradol and fluphenazine HCL were generous gifts from Pfizer Pharmaceuticals (Groton, Conn.) and E.R. Squibb and Sons (Princeton, N.J.), respectively.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Weight Loss / Appetite Control / Metabolism / Obesity&#039;&#039;&#039;= &lt;br /&gt;
===2024 Article [https://web.archive.org/web/20241204102835/https://tobaccoreporter.com/2024/12/03/slim-chances/ Harm reduction, smoking cessation and weight]====&lt;br /&gt;
*&amp;quot;Nicotine influences eating and weight in multiple ways, from hormones to microbiomes to taste perceptions. The bottom line: Nicotine raises the metabolic rate while also depressing appetite.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Nicotine, the principal addictive constituent of tobacco, has been shown to suppress appetite and attenuates obesity in many studies, but the underlying mechanism is not clear. &lt;br /&gt;
*Low-grade inflammation is a key feature of obesity and links obesity to insulin resistance, impaired glucose tolerance and even diabetes.&lt;br /&gt;
*Overall, these findings suggest that nicotine and specific α7nAChR agonists may be beneficial in the prevention and treatment of obesity-induced inflammation and insulin resistance. However, there is also evidence that heavy smoking affects body fat distribution that is associated with central obesity and insulin resistance. Moreover, smoking appears to aggravate insulin resistance in persons with type 2 diabetes and to impair glycemic control.&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
*Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
*Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
* When chronically taken, nicotine may result in reduction of body weight&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Suggested additions to this page&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2025: [https://pubmed.ncbi.nlm.nih.gov/39921606/ The protective effect of low-dose nicotine on ischemia stroke by maintaining the integrity of the blood-brain barrier]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://www.sciencedirect.com/science/article/abs/pii/S0303720724003022?via%3Dihub Nicotine increases hepatocyte transthyretin turnover: a possible mechanism for the protective effect of smoking on preeclampsia?]===&lt;br /&gt;
&lt;br /&gt;
===2011: [https://onlinelibrary.wiley.com/doi/10.1002/hipo.20806 Acute nicotine treatment prevents rem sleep deprivation-induced learning and memory impairment in rat]===&lt;br /&gt;
&lt;br /&gt;
===2017: [https://onlinelibrary.wiley.com/doi/10.1002/brb3.704 Nicotine-prevented learning and memory impairment in REM sleep-deprived rat is modulated by DREAM protein in the hippocampus]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://pubmed.ncbi.nlm.nih.gov/39719676/ Effect of Nicotine Replacement Therapy on Perioperative Pain Management and Opioid Requirement in Abstinent Tobacco Smokers Undergoing Spinal Fusion: A Double-blind Randomized Controlled Trial]===&lt;br /&gt;
&lt;br /&gt;
===2012: [https://pmc.ncbi.nlm.nih.gov/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1427314/full The double-edged nature of nicotine: toxicities and therapeutic potentials]===&lt;br /&gt;
&lt;br /&gt;
===2023: [https://drive.google.com/file/d/1ofdbKWq6rIBxI8vQAzjV8z-TYoacrqKB/view Electronic Cigarettes: an Overlooked Tool to Alleviate Disparities in Tobacco Use Disorder Among People with Mental Health and Substance Use Disorders]===&lt;br /&gt;
&lt;br /&gt;
===2023: [https://pubmed.ncbi.nlm.nih.gov/36947193/ Analgesic potential of transdermal nicotine patch in surgery: a systematic review and meta-analysis of randomised placebo-controlled trials]===&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36857384/ Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.] ===&lt;br /&gt;
&lt;br /&gt;
* Information on how nicotine is protective, technical. &lt;br /&gt;
* These results indicate that both the serotonergic and dopaminergic systems contribute to different aspects of PD symptomatology and that nicotine has beneficial effects on specific symptoms.&lt;br /&gt;
* Carvajal-Oliveros A, Dominguez-Baleón C, Sánchez-Díaz I, Zambrano-Tipan D, Hernández-Vargas R, Campusano JM, Narváez-Padilla V, Reynaud E. PLoS One. 2023 Mar 1;18 PMID: 36857384&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.sciencedirect.com/science/article/pii/S027869152300039X?via%3Dihub Tobacco heating system has less impact on bone metabolism than cigarette smoke]===&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849855/ Effect of nicotine on cholesterol gallstone formation in C57BL/6J mice fed on a lithogenic diet]===&lt;br /&gt;
&lt;br /&gt;
=== The following articles address the possible transmission of the SARS CoV 2 virus (and other pathogens) through vaping exhalations. We show that the latter are extremely weak transmission vehicles. ===&lt;br /&gt;
&lt;br /&gt;
* 2022: [https://link.springer.com/article/10.1007/s11356-022-20499-1 Analytic modeling and risk assessment of aerial transmission of SARS-CoV-2 virus through vaping expirations in shared micro-environments]&lt;br /&gt;
* 2021: [https://doi.org/10.3390/ijerph18041437 Aerial transmission of the SARS-CoV-2 virus through environmental e-cigarette aerosol: implications for public policies.]&lt;br /&gt;
* 2021: [http://doi.org/10.3390/app11146355 Modeling Aerial Transmission of Pathogens (Including the SARS-CoV-2 Virus) through Aerosol Emissions from E-Cigarettes.] &lt;br /&gt;
&lt;br /&gt;
=== 2022: [https://assets.researchsquare.com/files/rs-1062121/v1/fb8f5195-4cce-470f-9e09-e752fae3c931.pdf?c=1642705044 Part One: Abuse Liability of Vuse Solo Relative To Combustible Cigarettes And Nicotine Gum] ===&lt;br /&gt;
&lt;br /&gt;
=== 2014: [https://link.springer.com/chapter/10.1007/978-1-4939-1167-7_20 Nicotinic Receptors and Mental Illness] ===&lt;br /&gt;
&lt;br /&gt;
===2021: [https://pubmed.ncbi.nlm.nih.gov/34757527/ Meta-Analysis on Nicotine&#039;s Modulation of HIV-Associated Dementia]=== &lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
*Animal&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.sciencedirect.com/science/article/abs/pii/S1001841721007804 Real-time effects of nicotine exposure and withdrawal on neurotransmitter metabolism of hippocampal neuronal cells by microfluidic chip-coupled LC-MS]===&lt;br /&gt;
*mouse study&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006219.pub4/full Interventions for preventing weight gain after smoking cessation]===&lt;br /&gt;
*There was moderate‐certainty that NRT reduced weight at end of treatment and moderate‐certainty that the effect may be similar at 12 months, although the estimates are too imprecise to assess long‐term benefit.&lt;br /&gt;
&lt;br /&gt;
===2004: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
&lt;br /&gt;
* Yet few of the horrendous health effects of smoking are traceable to nicotine itself—cigarettes contain nearly 4,000 other compounds that play a role. Until recently, nicotine research has been driven primarily by nicotine&#039;s unparalleled power to keep people smoking, rather than its potential therapeutic uses.&lt;br /&gt;
* There&#039;s a cheap, common, and mostly safe drug, in daily use for centuries by hundreds of millions of people, that only lately has been investigated for its therapeutic potential for a long list of common ills. The list includes Alzheimer disease, Parkinson disease, depression and anxiety, schizophrenia, attention deficit hyperactivity disorder (ADHD), and even pain and obesity.&lt;br /&gt;
* People with depressive-spectrum disorders, schizophrenia, and adult ADHD tend to smoke heavily, which suggested to researchers that nicotine may soothe their symptoms. Common to all these disorders is a failure of attention, an inability to concentrate on particular stimuli and screen out the rest. Nicotine helps.&lt;br /&gt;
* Researchers at the National Institute on Drug Abuse have shown via functional magnetic resonance imaging that nicotine activates specific brain areas during tasks that demand attention&lt;br /&gt;
* Powledge TM (2004) Nicotine as Therapy. PLoS Biol 2(11): e404. &amp;lt;nowiki&amp;gt;https://doi.org/10.1371/journal.pbio.0020404&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]===&lt;br /&gt;
&lt;br /&gt;
===2001: [https://today.duke.edu/2001/08/mm_medicaluses.html Medical Uses for Nicotine]===&lt;br /&gt;
&lt;br /&gt;
===2021: [https://pubmed.ncbi.nlm.nih.gov/33675460/ Nicotine gum enhances visual processing in healthy nonsmokers]===&lt;br /&gt;
&lt;br /&gt;
===[https://www.researchgate.net/publication/325159226_Resolution_of_chronic_rhinitis_to_staphylococcus_aureus_in_a_non-smoker_who_started_to_use_glycerine_based_e-cigarettes_Antibacterial_effects_of_vaping Resolution of chronic rhinitis to staphylococcus aureus in a non-smoker who started to use glycerine based e-cigarettes: Antibacterial effects of vaping?]=== &lt;br /&gt;
&lt;br /&gt;
===2019: [https://medium.com/parkinsons-uk/protecting-brain-cells-the-story-of-nicotine-b3b51f5b8259 Protecting brain cells — the story of nicotine]===&lt;br /&gt;
*[https://web.archive.org/web/20221021040501/https://www.parkinsons.org.uk/nicotine-good-bad-and-ugly Nicotine - Good, Bad, Ugly]&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease]=== &lt;br /&gt;
*Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%.&lt;br /&gt;
*different website same study? [Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease|https://academic.oup.com/ije/article/46/3/872/2656164]&lt;br /&gt;
&lt;br /&gt;
===1986: [https://pubmed.ncbi.nlm.nih.gov/3786334/ Effects of nicotine on finger tapping rate in non-smokers]===&lt;br /&gt;
&lt;br /&gt;
===1996: [https://sci-hub.st/10.1093/oxfordjournals.bmb.a011533 Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious]===&lt;br /&gt;
&lt;br /&gt;
===2020 [https://n.neurology.org/content/neurology/94/20/e2132.full.pdf Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors]=== &lt;br /&gt;
&lt;br /&gt;
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
&lt;br /&gt;
=== 2021: [https://www.spektrum.de/news/kognition-nikotin-gegen-neuropsychiatrische-erkrankungen/1924141 Kognition: Nikotin gegen neuropsychiatrische Erkrankungen] (German)  &#039;Cognition: nicotine versus neuropsychiatric disorders&#039; ===&lt;br /&gt;
&lt;br /&gt;
===Dr. Newhouse [http://mindstudy.org/news Mind Study]=== &lt;br /&gt;
&lt;br /&gt;
===2010 [https://pubmed.ncbi.nlm.nih.gov/20414766/ Meta-analysis of the acute effects of nicotine and smoking on human performance] and 2012 [https://n.neurology.org/content/78/2/91.short Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== &lt;br /&gt;
*Clinical studies suggest some cognitive improvements as a result of nicotine.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.dovepress.com/effectiveness-and-safety-profile-of-alternative-tobacco-and-nicotine-p-peer-reviewed-fulltext-article-JMDH Effectiveness and Safety Profile of Alternative Tobacco and Nicotine Products for Smoking Reduction and Cessation: A Systematic Review]=== &lt;br /&gt;
&lt;br /&gt;
===[https://docs.google.com/document/d/13-D2q1P0KpmZuoFBkKV4l9wUEQ-zcHfp6MAVJGoAaG4/edit?usp=sharing INNCO&#039;s List smoking cessation]=== &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Started: continue @ “Among smokers who have attempted to stop without professional support, those who use e-cigarettes are more likely to report continued abstinence than those who used a licensed NRT products [i.e., nicotine patches, gum or lozenges].”&lt;br /&gt;
https://onlinelibrary.wiley.com/doi/full/10.1111/add.12623&lt;br /&gt;
&lt;br /&gt;
===[https://twitter.com/jkelovuori/status/1413963688709664769 Go through the links in this thread]=== &lt;br /&gt;
&lt;br /&gt;
===To do: Go through the references for nicotine related studies===&lt;br /&gt;
====2020: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404387/ Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders]====&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;More Information&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*[[Special:MyLanguage/Nicotine Studies|&#039;&#039;&#039;List of researchers&#039;&#039;&#039;]] studying nicotine / tobacco harm reduction&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*If you&#039;d prefer someone else to add a study to a topic, there is a &amp;quot;topic&amp;quot; called &amp;quot;Suggested studies to add to this page&amp;quot;. You may put the link in that section for one of the regular page editors to address.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*&#039;&#039;&#039;PAGE EDITORS - Please only add Studies, Surveys, Papers in this format to keep page consistent for all viewers.&#039;&#039;&#039;&lt;br /&gt;
**Topic&lt;br /&gt;
**Note here if animal study (leave blank if not)&lt;br /&gt;
**Year (list new to old) Name of Study (In link format to the study)&lt;br /&gt;
**Brief Summary&lt;br /&gt;
**Link to PDF Version&lt;br /&gt;
**Citation&lt;br /&gt;
**Acknowledgements (funded by, helped by)&lt;br /&gt;
**Keywords&lt;br /&gt;
**Other&lt;br /&gt;
[[Category:Studies, Surveys, and Papers]]&lt;br /&gt;
[[Category:THR product]]&lt;br /&gt;
[[Category:THR Stories]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=SLT&amp;diff=78699</id>
		<title>SLT</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=SLT&amp;diff=78699"/>
		<updated>2025-02-18T19:54:38Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Fix broken cat links&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[File:SmokelessTobaccoProducts.png|alt=Examples of common smokeless tobacco, includes loose tobacco, snus, dissolvable tobacco, plug tobacco  |thumb|Examples of common smokeless tobacco]]&lt;br /&gt;
&lt;br /&gt;
== Smokeless tobacco, usually abbreviated as SLT ==&lt;br /&gt;
&lt;br /&gt;
=== Definition. ===&lt;br /&gt;
Smokeless tobacco is a tobacco product that is used by means other than smoking. In other words, this type of tobacco is not burned, its consumption  does not involve  combustion.&lt;br /&gt;
&lt;br /&gt;
The consumption SLT involves chewing, sniffing, or placing the product between gum and the cheek or lip. They are produced in various forms, such as snuff, snus, chewing tobacco and Dissolvables (lozenges, sticks, strips, orbs)&lt;br /&gt;
&lt;br /&gt;
A significant  proportion  of SLT s are considered  safer than combustion  cigarettes  because  they eliminate over 4000 various compounds, most of which are hazardous carcinogens.&lt;br /&gt;
&lt;br /&gt;
SLTs can be a great answer  to the public  healthcare if well integrated in the public  health system. &lt;br /&gt;
&lt;br /&gt;
It is important  to note that because of the ban of such saffer alternatives in some countries gives rise to a &amp;quot;black market&amp;quot; where illicit and unregulated SLTs are sold.  &lt;br /&gt;
&lt;br /&gt;
See also [[Smokeless Tobacco - Pouches (not snus)]] and [[Smokeless Tobacco - HnB]] for other types of smokeless tobacco products.  &lt;br /&gt;
&lt;br /&gt;
=== Risk to health ===&lt;br /&gt;
Smoking is uniquely deadly as a delivery mechanism for nicotine, some risk undoubtedly remains with smokeless products, and there may be considerable variation between products, sometimes with the same name, or that appear almost identical.  &lt;br /&gt;
&lt;br /&gt;
Please see the following blog post for details regarding some of these.  &lt;br /&gt;
&lt;br /&gt;
[https://rodutobaccotruth.blogspot.com/2016/07/is-snus-safer-than-dip-or-chewhealth.html Is Snus Safer Than Dip or Chew? Health Effects of All Are Close to Zero] Note: that this relates only to american products mentioned in the blog post.  &lt;br /&gt;
&lt;br /&gt;
* There are essentially no differences in risk for any of these diseases in the Swedish and American studies.&lt;br /&gt;
* New research on the relative safety of American dip/chew products indicates that smokeless users who had never smoked showed no significant risks for numerous diseases.&lt;br /&gt;
* In summary, American dip/chew and Swedish snus are indistinguishable with respect to health impact.  Smokers who switch to any of these products can make smoking history.&lt;br /&gt;
In a press release 16 March 2023 [https://www.fda.gov/news-events/press-announcements/fda-authorizes-copenhagen-classic-snuff-be-marketed-modified-risk-tobacco-product FDA Authorizes Copenhagen Classic Snuff to be Marketed as a Modified Risk Tobacco Product]&lt;br /&gt;
&lt;br /&gt;
* FDA authorized U.S. Smokeless Tobacco Company (USSTC) to market its Copenhagen Classic Snuff, a loose moist smokeless tobacco product, as a modified risk tobacco product (MRTP).&lt;br /&gt;
* This product is a pre-existing tobacco product that has been marketed in the U.S. for years without modified risk information.&lt;br /&gt;
* This action now allows the product to be marketed as a modified risk tobacco product with the claim: “IF YOU SMOKE, CONSIDER THIS: Switching completely to this product from cigarettes reduces risk of lung cancer.”&lt;br /&gt;
&lt;br /&gt;
Please note that other products listed in the table below may be significantly more risky, information on the relative risks and those compared to smoking are not easily available.&lt;br /&gt;
&lt;br /&gt;
==== Possible advantages ====&lt;br /&gt;
Many of these products are likely to have lower risks than smoking, however it is not known how much less for many. &lt;br /&gt;
&lt;br /&gt;
Products such as Snus, and to an extent American smokeless have more information available, some are known to be very much less risky than smoking. &lt;br /&gt;
&lt;br /&gt;
Smokeless products present less danger to bystanders since they are combustion thus smoke free. &lt;br /&gt;
&lt;br /&gt;
Smokeless products are unlikely to cause respiratory problems or lung cancer, but may have increased risk of other cancer, such as throat and mouth.  &lt;br /&gt;
&lt;br /&gt;
==== Possible disadvantages ====&lt;br /&gt;
Little information is available for some products, and many of these products may contain toxic or carcinogenic compounds. &lt;br /&gt;
&lt;br /&gt;
Some products may have a greater risk of oral, nasal and throat cancer than smoking. However they are unlikely to directly cause lung cancer. &lt;br /&gt;
&lt;br /&gt;
They can vary widely and will depend on factors such as curing and treatment of tobacco, some additives might also be problematic.&lt;br /&gt;
&lt;br /&gt;
Even the tobacco free versions of these products may have risks, possibly greater risk, it is suggested to research elsewhere for such issues. &lt;br /&gt;
&lt;br /&gt;
=== Types of smokeless tobacco ===&lt;br /&gt;
&lt;br /&gt;
==== Snus ====&lt;br /&gt;
[[Snus]], a product that originated in Sweden, is moist snuff that comes packaged in small pouches and is often flavored. This product does not produce excess saliva like other forms of smokeless tobacco, making it spit-less. Please follow the link to the page detailing the product for full information. &lt;br /&gt;
&lt;br /&gt;
==== Chewing tobacco (“chew”) ====&lt;br /&gt;
Chewing tobacco is available in loose leaves, plugs, or twists of tobacco, and is placed between the cheek and gum or teeth. Examples of chewing tobacco include Red Man and Levi Garrett.&lt;br /&gt;
&lt;br /&gt;
This opinion piece is interesting as it looks at the risk and how to reduce it: &lt;br /&gt;
&lt;br /&gt;
[https://theprint.in/opinion/no-gutkha-zarda-or-khaini-is-safe-but-heres-how-their-cancer-causing-risk-can-be-reduced/1966957/ No gutkha, zarda, or khaini is ‘safe’. But here’s how their cancer-causing risk can be reduced] (The Print India article)&lt;br /&gt;
&lt;br /&gt;
* Many of the cancer causing chemicals are produced by curing or bacterial growth and fermentation of the product, either intentional or during transit or storage. &lt;br /&gt;
* It may allow local products to be made with a much lower risk, by eliminating the fermentation and curing processes that result in carcinogens.&lt;br /&gt;
&lt;br /&gt;
==== Snuff ====&lt;br /&gt;
Snuff is finely ground tobacco packaged in cans or pouches, which can be sold dry (powdered form that is sniffed) or moist (placed between the lower lip or cheek and gum) and is sometimes used in teabag-like pouches. Popular brands of moist snuff are Copenhagen and Skoal.&lt;br /&gt;
&lt;br /&gt;
==== Dissolvable tobacco ====&lt;br /&gt;
Dissolvable tobacco is another spit-less, frequently flavored tobacco product that is finely milled and dissolves orally. Ariva and Stonewall are some of the dissolvable products on the market.&lt;br /&gt;
&lt;br /&gt;
=== Non tobacco smokeless nicotine ===&lt;br /&gt;
&lt;br /&gt;
==== Pituri Bush ([[w:Duboisia hopwoodii|Wikipedia:Duboisia Hopwoodii]]) ====&lt;br /&gt;
Aboriginal people have used plants both as a bushfood and bush medicine for centuries.  Scientists have shown considerable interest in this particular bush and their reports from the 19th century said that they had observed Aboriginal men chewing pituri to give wisdom, feel brave in the face of  warfare and allowed them to walk hundreds of kilometres in the desert without thinking about the need for food or water. This bush also has hallucinogenic properties.&lt;br /&gt;
&lt;br /&gt;
The Pituri bush, used by the Aborigines as a bush medicine, grows to around 2.5mtrs. and is classified as a clonal shrub ie not propagated by seed.&lt;br /&gt;
&lt;br /&gt;
TRADITIONAL USE: Leaves, flowers and flowering stalks are highly valued by the Aborigines as chewing tobacco with nicotine and nor-nicotine content being up to 25% of the dry weight of plant material. Pituri is the term used by the Aborigines for the ball of chewing tobacco. Pituri is prepared by drying and powdering the leaves of the nicotine plant and mixing with ash from a variety of different specially selected species. It is rolled up into quids (balls) that are 6cm long and 1.5cm in diameter and then chewed. The mixing of the alkaloid ash with the plant material renders the alkaloids more available when chewed and ingested. When it is not chewed it is put behind the ear like bubblegum. The chewed tobacco is used as a token of friendship, of which it has taken on the significance of a social event. More information here: [https://prehistoricdrugs.wordpress.com/2011/09/03/the-aboriginal-drug-pituri-2/ The Aboriginal Drug Pituri] (prehistoricdrugs)&lt;br /&gt;
&lt;br /&gt;
An early account of the effects when smoked in a pipe: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1276357/?page=1 The Alkaloid of Pituri obtained from &#039;&#039;Duboisia hopwoodii&#039;&#039;] Biochem J. 1911; 5(5): 193–206. doi: 10.1042/bj0050193&lt;br /&gt;
&lt;br /&gt;
=== Non tobacco/nicotine products ===&lt;br /&gt;
Some of the products listed below may not always contain tobacco, or only optionally contain it. It is worth noting that some of these may be harmful without tobacco, it can not be assumed a product without tobacco is safe, or that the tobacco free version is safer. &lt;br /&gt;
&lt;br /&gt;
=== Table of available SLT products and where available details of ingredients ===&lt;br /&gt;
{| class=&amp;quot;wikitable mw-collapsible&amp;quot;&lt;br /&gt;
|+&lt;br /&gt;
!Product Name&lt;br /&gt;
!Region&lt;br /&gt;
!Mode of use&lt;br /&gt;
!Form&lt;br /&gt;
!Ingredients/additives &lt;br /&gt;
|-&lt;br /&gt;
|Gundi (kadapan)&lt;br /&gt;
|India&lt;br /&gt;
|C, IN&lt;br /&gt;
|Tobacco (coarsely powdered)&lt;br /&gt;
|Coriander seeds, other spices, and aromatic, resinous oils&lt;br /&gt;
|-&lt;br /&gt;
|Hogesoppu (leaf tobacco)&lt;br /&gt;
|India&lt;br /&gt;
|C, IN&lt;br /&gt;
|Unprocessed tobacco bundled in long strands&lt;br /&gt;
|None&lt;br /&gt;
|-&lt;br /&gt;
|Kaddipudi&lt;br /&gt;
|India&lt;br /&gt;
|C, IN&lt;br /&gt;
|Powdered sticks of raw tobacco stalks and petioles&lt;br /&gt;
|Sometimes molasses and water&lt;br /&gt;
|-&lt;br /&gt;
|Kiwam (qiwam, kimam)&lt;br /&gt;
|Pakistan, Nepal, India, Bangladesh&lt;br /&gt;
|C, H, IN&lt;br /&gt;
|Tobacco (boiled) &lt;br /&gt;
|Spices (cardamom, saffron, and/or aniseed), additives such as musk, and may contain silver flecks&lt;br /&gt;
|-&lt;br /&gt;
|Loose leaf&lt;br /&gt;
|United States&lt;br /&gt;
|C, H, S&lt;br /&gt;
|Tobacco leaves (air-cured)&lt;br /&gt;
|Sugar and/or licorice and other sweeteners&lt;br /&gt;
|-&lt;br /&gt;
|Mishri (masheri, misri)&lt;br /&gt;
|India&lt;br /&gt;
|A, D, S&lt;br /&gt;
|Tobacco (toasted, powdered)&lt;br /&gt;
|None&lt;br /&gt;
|-&lt;br /&gt;
|Moist snuff (low pH)&lt;br /&gt;
|South Africa, United States, Canada, Mexico&lt;br /&gt;
|H, S&lt;br /&gt;
|Tobacco (fermented, air or fire-cured)&lt;br /&gt;
|Flavorings (spices, essential oils, extracts), sweeteners, inorganic salts, humectants, preservatives&lt;br /&gt;
|-&lt;br /&gt;
|Neffa&lt;br /&gt;
|Algeria, Libya, Tunisia&lt;br /&gt;
|N&lt;br /&gt;
|Tobacco (dry)&lt;br /&gt;
|None&lt;br /&gt;
|-&lt;br /&gt;
|Tobacco chewing gum&lt;br /&gt;
|Gam, Japan&lt;br /&gt;
|C&lt;br /&gt;
|Tobacco (finely ground)&lt;br /&gt;
|Chewing gum base, xylitol&lt;br /&gt;
|-&lt;br /&gt;
|Pattiwalla without lime&lt;br /&gt;
|India&lt;br /&gt;
|C, IN&lt;br /&gt;
|Tobacco (sundried, flaked) &lt;br /&gt;
|None&lt;br /&gt;
|-&lt;br /&gt;
|Plug &lt;br /&gt;
|United States&lt;br /&gt;
|C, H, S&lt;br /&gt;
|Tobacco leaves&lt;br /&gt;
|Licorice, sweeteners&lt;br /&gt;
|-&lt;br /&gt;
|Red toothpowder (lal dant manjan)&lt;br /&gt;
|India&lt;br /&gt;
|A, D&lt;br /&gt;
|Tobacco (powdered)&lt;br /&gt;
|Herbs, flavorings. Additional plant-related ingredients such as ginger, pepper, and camphor, among others, may be used.&lt;br /&gt;
|-&lt;br /&gt;
|Snus (low pH)&lt;br /&gt;
|South Africa, United States, Canada, Brazil, Sweden, Norway, Finland, Denmark, Iceland&lt;br /&gt;
|H&lt;br /&gt;
|Tobacco (heat-treated, pasteurized)&lt;br /&gt;
|Sodium carbonate, moisturizers, salt (sodium chloride), sweeteners, flavorings, water&lt;br /&gt;
|-&lt;br /&gt;
|Tapkeer (bajjar, dry snuff)&lt;br /&gt;
|India &lt;br /&gt;
|A, H, N &lt;br /&gt;
|Tobacco (fermented, fire-cured)&lt;br /&gt;
|Flavorings may be added.&lt;br /&gt;
|-&lt;br /&gt;
|Tobacco leaf &lt;br /&gt;
|India, Bangladesh, Myanmar, Bhutan&lt;br /&gt;
|C, IN &lt;br /&gt;
|Tobacco leaves (dry)&lt;br /&gt;
|None&lt;br /&gt;
|-&lt;br /&gt;
|Tumbaco &lt;br /&gt;
|Congo &lt;br /&gt;
|N&lt;br /&gt;
|Tobacco (dry)&lt;br /&gt;
|None&lt;br /&gt;
|-&lt;br /&gt;
|Twist&lt;br /&gt;
|United States&lt;br /&gt;
|C, H&lt;br /&gt;
|Tobacco (dark and air-cured leaf)&lt;br /&gt;
|Tobacco leaf extracts and sometimes sweetener or flavorings&lt;br /&gt;
|-&lt;br /&gt;
|Watery tobacco&lt;br /&gt;
|Myanmar &lt;br /&gt;
|G&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Water&lt;br /&gt;
|-&lt;br /&gt;
|Zarda&lt;br /&gt;
|Yemen, India, Bangladesh, Myanmar, Nepal, Bhutan&lt;br /&gt;
|C, IN &lt;br /&gt;
|Tobacco &lt;br /&gt;
|Slaked lime or other alkaline agents, spices, vegetable dyes, and sometimes areca nut and/or silver flecks&lt;br /&gt;
|-&lt;br /&gt;
|Chimó &lt;br /&gt;
|Venezuela, Columbia&lt;br /&gt;
|H, S&lt;br /&gt;
|Tobacco leaf &lt;br /&gt;
|Baking soda (sodium bicarbonate), brown sugar, ashes from the Mamón tree (Meliccoca bijuga), and vanilla and anisette flavoring. Ingredients vary by region. &lt;br /&gt;
|-&lt;br /&gt;
|Creamy snuff&lt;br /&gt;
|India&lt;br /&gt;
|A&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Clove oil, glycerin, spearmint, menthol, camphor, water&lt;br /&gt;
|-&lt;br /&gt;
|Dissolvables&lt;br /&gt;
|United States&lt;br /&gt;
|DI, H, S&lt;br /&gt;
|Ground tobacco pressed into tablets, strips, or sticks&lt;br /&gt;
|Binders, humectants, sweeteners, colorings, preservatives, alkaline agents, flavorings&lt;br /&gt;
|-&lt;br /&gt;
|Dry snuff &lt;br /&gt;
|South Africa, Nigeria, Canada, United States, Germany&lt;br /&gt;
|H, N, S&lt;br /&gt;
|Tobacco (fermented, firecured&lt;br /&gt;
|Flavoring, alkaline agents&lt;br /&gt;
|-&lt;br /&gt;
|Ghana traditional snuff (tawa)&lt;br /&gt;
|Ghana&lt;br /&gt;
|H, N&lt;br /&gt;
|Tobacco leaves (dry)&lt;br /&gt;
|Saltpeter (potassium nitrate), ashes&lt;br /&gt;
|-&lt;br /&gt;
|Gudakhu/ Gudakha&lt;br /&gt;
|India&lt;br /&gt;
|A, H&lt;br /&gt;
|Tobacco (powdered)&lt;br /&gt;
|Molasses, red soil, slaked lime&lt;br /&gt;
|-&lt;br /&gt;
|Gul&lt;br /&gt;
|India, Bangladesh &lt;br /&gt;
|A, D&lt;br /&gt;
|Pyrolysed tobacco leaves&lt;br /&gt;
|Sugar or molasses, alkaline modifiers, and other unknown ingredients&lt;br /&gt;
|-&lt;br /&gt;
|Iqmik&lt;br /&gt;
|United States (Alaska) &lt;br /&gt;
|C&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Tree fungus ash (also known as punk, araq, or buluq ash) or other ash derived from burning driftwood or willow bushes&lt;br /&gt;
|-&lt;br /&gt;
|Khaini &lt;br /&gt;
|India, Bangladesh, Nepal, Bhutan&lt;br /&gt;
|S, H, C &lt;br /&gt;
|Tobacco &lt;br /&gt;
|Slaked lime paste and sometimes areca nut&lt;br /&gt;
|-&lt;br /&gt;
|Maras &lt;br /&gt;
|Turkey&lt;br /&gt;
|A &lt;br /&gt;
|Sun-dried tobacco&lt;br /&gt;
|Ashes from oak, walnut, or grapevine&lt;br /&gt;
|-&lt;br /&gt;
|Moist snuff (high pH) &lt;br /&gt;
|South Africa, United States, Canada, Mexico&lt;br /&gt;
|H, S&lt;br /&gt;
|Tobacco (fermented, air or fire-cured)&lt;br /&gt;
|Flavorings (spices, essential oils, extracts), sweeteners, inorganic salts, humectants, preservatives&lt;br /&gt;
|-&lt;br /&gt;
|Nass (naswar)&lt;br /&gt;
|South Africa, Pakistan, Iran, Afghanistan, United Arab Emirates, Turkmenistan&lt;br /&gt;
|C, H, S&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Nass: ash, cotton or sesame oil, water, and sometimes lime or gum Naswar: slaked lime, ash, indigo (or other coloring agent), oil, water, and sometimes flavorings such as cardamom and menthol&lt;br /&gt;
|-&lt;br /&gt;
|Nasway (nasvay)&lt;br /&gt;
|Uzbekistan, Kyrgyzstan&lt;br /&gt;
|H, S&lt;br /&gt;
|Tobacco leaves (sun and heat-dried)&lt;br /&gt;
|Tobacco leaves, slaked lime, water, and sometimes ash from tree bark, butter or oil, flavorings, or coloring agents&lt;br /&gt;
|-&lt;br /&gt;
|Nigerian traditional snuff (taaba)&lt;br /&gt;
|Nigeria, Cameroon, Senegal, Chad, Uganda&lt;br /&gt;
|H, N, S&lt;br /&gt;
|Tobacco (dry, fermented)&lt;br /&gt;
|Natron (a mixture of sodium bicarbonate and sodium chloride)&lt;br /&gt;
|-&lt;br /&gt;
|Pituri&lt;br /&gt;
|Australia&lt;br /&gt;
|H, N, S&lt;br /&gt;
|Duboisia hopwodii&lt;br /&gt;
|mixed with ash of a certain Acacia&lt;br /&gt;
|-&lt;br /&gt;
|Shammah&lt;br /&gt;
|Algeria, Saudi Arabia, Yemen&lt;br /&gt;
|H, S&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Slaked lime, ash, black pepper, oil, flavorings, and bombosa (sodium carbonate)&lt;br /&gt;
|-&lt;br /&gt;
|Snus (high pH)&lt;br /&gt;
|South Africa AMR: United States, Canada, Brazil, Sweden, Norway, Finland, Denmark, Iceland&lt;br /&gt;
|H&lt;br /&gt;
|Tobacco (heat-treated, pasteurized)&lt;br /&gt;
|Sodium carbonate, moisturizers, salt (sodium chloride), sweeteners, flavorings, water&lt;br /&gt;
|-&lt;br /&gt;
|Tobacco water (tuiber)&lt;br /&gt;
|India &lt;br /&gt;
|G, H&lt;br /&gt;
|Tobacco smoke&lt;br /&gt;
|Water, alkaline agents&lt;br /&gt;
|-&lt;br /&gt;
|Toombak&lt;br /&gt;
|Sudan&lt;br /&gt;
|H, N, S&lt;br /&gt;
|Tobacco (fermented, sun-dried)&lt;br /&gt;
|Atrun (sodium bicarbonate)&lt;br /&gt;
|-&lt;br /&gt;
|Traditional South African snuff (snuif)&lt;br /&gt;
|South Africa, Lesotho, Swaziland&lt;br /&gt;
|&lt;br /&gt;
|Tobacco leaf (sun-dried)&lt;br /&gt;
|Ash from local plants (e.g., amaranthus, aloe vera leaves)&lt;br /&gt;
|-&lt;br /&gt;
|Betel quid (paan)&lt;br /&gt;
|Pakistan, United Arab Emirates, India, Sri Lanka, Bangladesh, Myanmar, Thailand, Indonesia, Nepal, Maldives, Lao Democratic People’s Republic, Palau, Cambodia, Malaysia, Vietnam, Federal States of Micronesia &lt;br /&gt;
|C, H&lt;br /&gt;
|Tobacco. Other smokeless tobacco products may be used such as kiwam and zarda.&lt;br /&gt;
|Areca nut, slaked lime, betel leaf, and often catechu. Other ingredients vary regionally: cardamom, saffron, cloves, aniseed, turmeric, mustard, sweeteners&lt;br /&gt;
|-&lt;br /&gt;
|Dohra &lt;br /&gt;
|India&lt;br /&gt;
|C&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Areca nut, slaked lime or other alkaline agents, and other ingredients such as catechu, peppermint, cardamom&lt;br /&gt;
|-&lt;br /&gt;
|Gutka&lt;br /&gt;
|Pakistan, India, Bangladesh, Nepal, Myanmar, Sri Lanka&lt;br /&gt;
|C, H&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Areca nut, slaked lime or other alkaline agents, catechu, sweeteners, and flavorings&lt;br /&gt;
|-&lt;br /&gt;
|Kharra&lt;br /&gt;
|India&lt;br /&gt;
|C&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Areca nut, lime, and catechu&lt;br /&gt;
|-&lt;br /&gt;
|Mainpuri (kapoori)&lt;br /&gt;
|India&lt;br /&gt;
|C, H, IN&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Slaked lime or other alkaline agents, areca nut, camphor, and other spices&lt;br /&gt;
|-&lt;br /&gt;
|Mawa SE&lt;br /&gt;
|India&lt;br /&gt;
|C&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Slaked lime, areca nut&lt;br /&gt;
|-&lt;br /&gt;
|Tombol (bitter tombol)&lt;br /&gt;
|Middle East&lt;br /&gt;
|C, H&lt;br /&gt;
|Tobacco &lt;br /&gt;
|Areca nut (fofal), slaked lime, noura, betel leaf (tombol leaf), catechu, and flavorings such as clove oil, cardamom, or herbal medicine&lt;br /&gt;
|-&lt;br /&gt;
|Tombol (sweet tombol)&lt;br /&gt;
|Yemen &lt;br /&gt;
|C, H&lt;br /&gt;
|Tobacco &lt;br /&gt;
|Areca nut (fofal), slaked lime, noura, betel leaf (tombol leaf), catechu, and sweeteners such as coconut&lt;br /&gt;
|-&lt;br /&gt;
|Caffeinated moist snuff&lt;br /&gt;
|United States&lt;br /&gt;
|H&lt;br /&gt;
|Tobacco (fermented, air or fire-cured&lt;br /&gt;
|Caffeine, flavorings (spices, essential oils, extracts), sweeteners, inorganic salts, humectants, preservatives, ginseng, B and C vitamins&lt;br /&gt;
|-&lt;br /&gt;
|Rapé and NuNu&lt;br /&gt;
|Brazil&lt;br /&gt;
|N&lt;br /&gt;
|Tobacco leaf (dried)&lt;br /&gt;
|One or more ingredients: tonka bean, clove, cinnamon powder, camphor, Peruvian cocoa, cassava, ashes from select trees&lt;br /&gt;
|-&lt;br /&gt;
|Tombol with khat&lt;br /&gt;
|Yemen&lt;br /&gt;
|C, IN&lt;br /&gt;
|Tobacco&lt;br /&gt;
|Areca nut (fofal), slaked lime, noura, betel leaf (tombol leaf), catechu, and khat&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
Key to mode of use abbreviations: A=Applied gums C = Chewed D = Dentifrice DI = Dissolves G = Gargled H = Held in mouth IN = Ingredient N = Nasal use S = Sucked&lt;br /&gt;
&lt;br /&gt;
== Scientific studies and papers ==&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/38051542/ Heterogeneity of Harmful Constituent Profiles in Smokeless Tobacco Products from Five African Countries] ===&lt;br /&gt;
&lt;br /&gt;
* Chem Res Toxicol. 2023 Dec 5. doi: 10.1021/acs.chemrestox.3c00181. Online ahead of print.&lt;br /&gt;
* Francisco Gomez, Olalekan Ayo-Yusuf, Katrina Yershova, Vipin Jain, Aleksandra Alcheva, Dorothy K Hatsukami, Mark Parascandola , Irina Stepanov&lt;br /&gt;
* Manufactured and custom-made SLT products were purchased from five African countries (South Africa, Uganda, Mauritania, Nigeria, and Zambia) using a standard approach for sample collection, labeling, and storage. Moisture content, pH, total and unprotonated (biologically available) nicotine, five tobacco-specific &#039;&#039;N&#039;&#039;-nitrosamines (TSNA), 10 polycyclic aromatic hydrocarbons (PAH), five metals and metalloids (As, Cd, Cr, Ni, and Pb), nitrate, and nitrite were analyzed.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37560082/ Death, Disability, and Premature Life Years Lost Due to Cigarettes, Bidis, and Smokeless Tobacco in India: A Comparative Assessment.] ===&lt;br /&gt;
&lt;br /&gt;
* A total of 33 studies were included. PAF [population attributable fraction] was calculated for oral and lung cancer as well as ischemic heart disease (IHD) due to cigarettes, oral and lung cancer, IHD, and chronic obstructive pulmonary disease due to bidi, and oral and stomach cancer and IHD due to SLT. &lt;br /&gt;
* Cigarettes resulted in 8.4 million DALYs, 8.26 million YLLs, and 341 thousand deaths; Bidis led to 11.7 million DALYs, 10.7 million YLLs, and 478 thousand deaths (83 million users combined)&lt;br /&gt;
* SLTs accounted for 4.38 million DALYs, 4.3 million YLLs, and 171 thousand deaths annually (191 million smokeless users)&lt;br /&gt;
* I would be very time consuming to assess if they have properly attributed death and disease to these tobacco-use risks.  It is complicated by the wide range of other risks that afflict, especially the poor and rural populations. Thus their number will be used as is, further analysis welcome:&lt;br /&gt;
** Some normalising for population and user numbers would be helpful in giving a rough proxy for relative risk. In 2020, India had 274 million adult tobacco users, of which 83 million were smokers (cigarettes and bidis) and the (rest (191 m) were smokeless users (WHO data for 2020). Just using simple division: smoking = 242 DALY/100,000 users SLT = 23 DALY/100,000 users.&lt;br /&gt;
** Obviously, massive caveats apply to this.  But a crude first approximation suggests an &#039;&#039;&#039;order of magnitude&#039;&#039;&#039; difference in risks between Indian smoking and smokeless use. It would be better for smokers to switch to smokeless, even the toxic traditional South Asian recipes.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37264008/ Physical and chemical characterization of smokeless tobacco products in India.] ===&lt;br /&gt;
&lt;br /&gt;
* The products in question are better described as traditional recipes that contain tobacco (and much else).  That doesn&#039;t inhibit the authors from drawing conclusions that range far beyond the products and geography of their study and chiming in with something about flavours, as that is the happening thing now.&lt;br /&gt;
&lt;br /&gt;
* Needs reading as it may help differentiate the risk of some Indian SLT&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36738817/ Sudanese smokeless tobacco (Toombak) users harbour significantly altered long-term cortisol body production.] ===&lt;br /&gt;
&lt;br /&gt;
* The effect on body cortisol response over a retrospective period in users of this product has not been previously explored. In addition, the psycho-dependency level distributed amongst users of Toombak has also not been analysed to date.&lt;br /&gt;
&lt;br /&gt;
* FTND - ST scores ranged from 4-9, with 85% of Toombak users reflecting high levels of psycho-dependency (score&amp;gt;5) and nicotine tolerance.&lt;br /&gt;
* Cortisol body release in Sudanese smokeless tobacco users was found to be significantly altered. While low cortisol levels do lead to anxiolytic effects, long-term, this can allow for an increased susceptibility to low cortisol associated diseases. (Unfortunately there is no discussion on the possibility that this might be an overall positive regarding anxiety, and no information on what these diseases might be. ed.)&lt;br /&gt;
&lt;br /&gt;
References&lt;br /&gt;
&lt;br /&gt;
# https://truthinitiative.org/research-resources/traditional-tobacco-products/smokeless-tobacco-facts-stats-and-regulations&lt;br /&gt;
# https://cancercontrol.cancer.gov/brp/tcrb/smokeless-tobacco&lt;br /&gt;
# https://www.outbackchef.com.au/pituri-bush-bush-medicine-native-hallucinogenic/&lt;br /&gt;
# https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685874/&lt;br /&gt;
&lt;br /&gt;
[[:Category:THR product]]&lt;br /&gt;
[[:Category:Smoking cessation]]&lt;br /&gt;
[[:Category:Smoking]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78640</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78640"/>
		<updated>2025-02-14T13:08:46Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (probably an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices including ohm&#039;s law. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thanks! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78614</id>
		<title>File:Letter minister for health 11th Feb 2025.pdf</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78614"/>
		<updated>2025-02-11T11:55:31Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Richardpruen uploaded a new version of File:Letter minister for health 11th Feb 2025.pdf&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Letter minister for health 11th Feb 2025&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78609</id>
		<title>File:Letter minister for health 11th Feb 2025.pdf</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78609"/>
		<updated>2025-02-11T10:52:02Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Richardpruen uploaded a new version of File:Letter minister for health 11th Feb 2025.pdf&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Letter minister for health 11th Feb 2025&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78604</id>
		<title>File:Letter minister for health 11th Feb 2025.pdf</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78604"/>
		<updated>2025-02-11T10:49:19Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Richardpruen uploaded a new version of File:Letter minister for health 11th Feb 2025.pdf&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Letter minister for health 11th Feb 2025&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=UserWiki:Richardpruen&amp;diff=78599</id>
		<title>UserWiki:Richardpruen</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=UserWiki:Richardpruen&amp;diff=78599"/>
		<updated>2025-02-11T10:45:39Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: add draft letter&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;__TOC__&lt;br /&gt;
&lt;br /&gt;
{{#babel: en-N | de-2 }}&lt;br /&gt;
&lt;br /&gt;
= The Site admin =&lt;br /&gt;
&lt;br /&gt;
Richard Pruen &lt;br /&gt;
&lt;br /&gt;
Electrical and electronic engineer&lt;br /&gt;
&lt;br /&gt;
Favorite band: [https://www.rush.com/band/ Rush]&lt;br /&gt;
&lt;br /&gt;
Why spend so much time on this? It’s a fact that nicotine harm reduction (vaping and Snus) saved my life, this is my way to pay that forward, and pass along information on safer nicotine. &lt;br /&gt;
&lt;br /&gt;
Running a site from the ground up, has proved interesting and worthwhile. Some of the things I have learned about Linux, and configuration of software for servers is only stuff you learn by doing. &lt;br /&gt;
&lt;br /&gt;
I suspect the site will stick around, at least as long as it is required to provide links and info.&lt;br /&gt;
&lt;br /&gt;
I might well put more info of my vaping / thr story here soon, this is just a test edit. &lt;br /&gt;
&lt;br /&gt;
More test edit, and added some features, like babel to indicate users languages.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Site admin at Safer nicotine wiki.&lt;br /&gt;
[[File:2020-10-28-092657.jpg|thumb|Richard Pruen]]&lt;br /&gt;
&lt;br /&gt;
=ABOUT=&lt;br /&gt;
&lt;br /&gt;
Ecig user since 2008, consumer advocate for vaping and THR  #VapingSavedMyLife #VapingSavesLives&lt;br /&gt;
&lt;br /&gt;
Twitter [http://twitter.com/pruenrichard @pruenrichard]&lt;br /&gt;
&lt;br /&gt;
Below are letters and documents sent in advocacy efforts as a record and should anyone wish to use them for ideas. These are my efforts and do not necessarily reflect the views of the wiki or other users.&lt;br /&gt;
&lt;br /&gt;
[[File:FDA comment.pdf|thumb|alt=Comment on R-U FDA review |Comment on R-U FDA review ]]&lt;br /&gt;
&lt;br /&gt;
[[File:My response TGA request for comment.pdf|thumb|alt=My response TGA request for comment|My response TGA request for comment]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email to appg vaping 28th Feb 2023.pdf|thumb|alt=Hi Mark,  I am a consumer advocate for vaping, and do not use disposables beyond experimenting to see what they are like. I am also an engineer.  I have worked in the vaping industry previously testing against the standards for vaping products, and owned a now closed company BTC Battery Testing LTD (closed 2016).  Currently I care for my mother who suffers vascular dementia, and as such volunteer my spare time to the cause of THR.  The disposable vaping problem is not an easy one, because the product is in demand, a black market will form. A black market will be less regulated, even less concerned with the environment, and have no reuse or recycling plan, due to there being no incentives. Please see the situation in Australia if you have any doubts.  I would suggest the following rule changes to start. All disposable devices should be rechargeable, and either contain enough liquid to last the lifetime of the atomiser (roughly 15-20ml), or be required to have a fill method (there are many ways to do this, including community &#039;hacks&#039; that are available on the internet). If a refilling method was designed in, the extra cost is minimal to include a bung or device to allow re-fill). This would mean the atomiser is used for it&#039;s lifetime, and the battery recharged and used for much longer. Waste reduction by 1/10 (assuming 2ml  devices now, 10 such would be replaced by a single 20ml device)   My preferred solution is rechargeable and large capacity, for the following reasons. Large size, it becomes difficult to conceal a device with 20ml capacity, this will help reduce stealth use. As the lifetime is greater, plus content, the initial outlay will be higher putting the devices out of the purchacing power of youth, and doing so without adding to the cost per puff for the legitimate smoker wanting safer options.  Smaller re-fillable and rechargeable devices have many of the same advantages, but remain easy to hide, and lower price. That might be problematic.  This would depend on the lifting of the 2ml tank size, for a sealed for life device requiring tools to open, the 2 ml tank provides no protection to anyone. Even for refillable devices, in reality it increases fiddle and numbers of re-fills, and provides little protection (if any). Indeed it may be that the most dangerous time for ecigs is during filling, where child proof caps are removed etc, it might be argued that larger tanks would reduce risky refilling operations and be safer. At least a quick &#039;thought experiment&#039; says that is quite possible and warrants further investigation.  I have further suggestions, and would be happy to help if you would like, this is simply a start.  I would imagine manufacturers will be reluctant to see rules that force them to be responsible about waste, disposables are highly profitable and allow walking away from disposal and environmental costs. This should be addressed however. As a consumer my thoughts are &#039;oh dear how very sad&#039; but I am sure they will still manage to find a way to make a profit.  Thanks for your time  |Email to APPG Vaping 28th Feb 2023 ]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter to PM.pdf|thumb|alt=I heard your comment regarding the targeting of youth by possibly &#039;big tobacco&#039;, the vaping industry or some perceived, yet non-existent morph of the two. The same points are being made in the US, you are being fed a line Sir!  I am a vaping consumer myself, well aware as an early adopter of vaping (2008), more than 15 years ago, that youth are not targeted. I have seen the industry develop flavours for adults to use, it gives the edge to make a complete switch, dissociating from the taste of tobacco. It is unfortunate that there is no flavour puberty, humans&#039; basic taste preference is developed early, so targeting adults only is sadly not possible.  Please see the graph linked here, showing the insanity of youth targeting, it just doesn&#039;t make any sense. https://safernicotine.wiki/mediawiki/index.php/Old_farts_vaping (this uses US data, the UK numbers are lower).  I suggest you run things by someone who understands vaping and harm reduction before making a comment, to save embarrassment|Letter to PM re: Youth vaping]]&lt;br /&gt;
&lt;br /&gt;
[[File:Lord Markham letter.pdf|thumb|alt=Subject: Smoking Harm Reduction: support safer alternatives – save lives  Dear Lord Markham,   I am sure you are aware that vaping has been a great success in reducing smoking, the NHS finding that with support 2/3 smokers successfully stop smoking with e-cigs. This is vastly more effective than NRT products that at best where 6% successful. Sweden has had longer with Snus as a harm reduction product, thus are looking at becoming effectively smoke free (&amp;lt; 5% smokers) this year or next.  I see worrying signs in the media, and with the WHO both seem to be extremely hostile to vaping, when in fact it is doing immense good, not to mention saving the NHS vast sums (smoking is the leading cause of cancer) in preventing cancer and smoking related disease. A cancer prevented will require no detection, diagnosis or treatment; a triple saving in cost to the NHS and public.  I would like to make my view known and hope you would support it, that the UK must hold it’s nerve, it must stay true to the scientific evidence from the Royal Collage Physicians, NHS Smokefree, Cochrane etc as detailed in the reports commissioned by PHE/OHID. We must also be aware of the situation in Australia where effective prohibition (the recommendation of the WHO) has been tried, and as predicted by myself and many others, seems to have resulted in an illicit market, with worse figures for youth uptake of smoking. Youth smoking in the UK, NZ and USA where vaping is available have all fallen (in the USA youth vaping became popular as a result youth smoking became all but non existent (&amp;lt;1% regular smokers).  While youth vaping is not desirable, it remains more desirable than youth smoking, an important point to remember. Vaping is unlikely to result in deaths, open system vaping provides and off ramp in lowering nicotine and stopping (not so for smoking). If youth take up smoking and continue, then it is known at least half will die early because of it. This is also complicated by the fact that nicotine provides therapeutic benefits, thus I would like you to see this single link https://safernicotine.wiki/mediawiki/index.php/Nicotine_therapeutic_benefits it contains a lot of information, but it is important I feel to consider the benefits of safer sources of nicotine, without the harms of smoking. The following is my personal story, I do not insist you read it beyond knowing vaping saved my life.  I am primarily a user of Electronic Cigarettes, and of Snus, as well as tobacco free nicotine pouches. I am also a consumer advocate for Tobacco Harm Reduction products (hereafter referred to as THR) for the simple reason that I firmly believe these products saved my life, and have a desire to pass that opportunity on to other smokers, many of whom will not be aware.   I started vaping in 2008, primarily to vape where I could not smoke, I had no intention of giving up smoking, I had already tried every available method, some several times to no effect, and had given up any hope of stopping. However by early 2009 I discovered by happy accident, that I had not bought any tobacco for several weeks (at least 4) and thus had gained some funds budgeted for, but not spent. Unlike most folks who give up smoking I have no firm quit date, and don’t recall any difficulty in slowly switching from a vastly harmful product to a vastly safer one. The exact opposite of previous quit attempts. I learned on internet forums that this is not uncommon with vaping, but never happens to my knowledge with NRT. As part of my advocacy work I run the site https://safernicotine.wiki the intention to provide a repository of information on THR and links to science, resources for advocates, policy makers, doctors and indeed anyone interested in reducing the harm caused by smoking.  I am not paid in any way for my advocacy, and in fact pay for the bandwidth and time required to maintain the site. Much of the content is provided by volunteers around the world.  Please do not hesitate to contact me if you would like any further information, including the vast database of knowledge contained in the wiki site, or any assistance using the site.  Sincerely    Richard Pruen|Lord Markham letter]]&lt;br /&gt;
&lt;br /&gt;
[[File:My response NZ request for comment.pdf|thumb|alt=Submitted to Proposal to clarify how nicotine levels for vaping products are expressed in the Smokefree Environments and Regulated Products Regulations 2021 Submitted on 2023-06-14 23:07:05 Your details 1 What is your name? Name: Richard Pruen 2 What is your email address? Email: richard@pruen.co.uk 3 Are you submitting on behalf of an organisation? Yes If so, what is your organisation?: Safer Nicotine wiki 4 What ethnicity/ethnicities do you identify with? Other European, Not applicable (eg, I&#039;m submitting of behalf of an organisation or group) 5 What Iwi do you affiliate to? What Iwi do you affiliate to?: 6 I am, or I represent, the following category or categories (select all that apply) Other (please specify) Other: Citizen science project (wikipedia clone on tobacco harm reduction) Proposal questions 7 Do you agree with our proposal to set the maximum allowable nicotine concentration at 28.5mg/mL for reusable vaping products that contain nicotine salts? No 8 Please explain your reasoning. If No, please explain.: Based on the available science, the limit should be set at a level that provides protection from poisoning, while allowing sufficient for a heavy smoker to DIY mix liquid that will satisfy their needs. Having reviewed the recent science, it is only nicotine concentrations at or above 100mg/ml that have resulted in very few fatal poisonings with orally ingested nicotine. Concentrations below 80mg/ml have as far as can be found, never resulted in death or serious harm. Therefore a limit of 75mg/ml would provide protection from poisoning while being high enough to allow DIY mixing of liquid to suit a low-power pod vaping device, which would satisfy even a heavy smoker. This provides maximum safety in that 75mg/ml will cause the body to vomit before damaging amounts of nicotine can be ingested. Even suicide attempts by simply drinking the liquid would fail. Yet allows even heavy smokers to obtain sufficient nicotine, and thus switch more easily to a vastly safer product. 9 Is there anything else you would like to tell us at this time? Is there anything else you would like to tell us at this time?: Issues have been found with the UK limit of 20mg/ml, heavy smokers find switching difficult, this requires the use of a nicotine patch and vaping, which significantly increases friction to switching, this costs the lives of smokers who would otherwise stop smoking. The UK 20mg limit was based on poor science (an estimated LD50 based on one scientist&#039;s self-administration of nicotine IV) and the assumption that all the ingested nicotine would be instantly absorbed. Looking at real data and better LD50 data gives a better understanding. Declarations and privacy 10 Publishing submissions You may publish this submission 11 Do you have commercial interests? I do not have any commercial interests in smoked tobacco or other regulated products (vaping products, other notifiable products) 12 Commercially sensitive information This submission does not contain commercially sensitive information 13 Protection from commercial and other vested interests of the tobacco industry Please provide details of any tobacco company links or vested interests below.: No links to any industry, government, or commercial interest of any kind, and no funding from any tobacco or vaping industry nor taxes or fees collected from tobacco or other companies. All funding is from the individual volunteers who contribute to the project.|My response NZ request for comment.pdf]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter Steve Barclay 6th jul.pdf|thumb|alt=Subject: Health Select Committee meeting on Vaping   Dear Steve Barclay,  I am a consumer advocate, with no ties to industry at present (for full details see the APPG letter linked below).  I note that industry was present at this meeting but no one representing consumers of the product, why was this? As the people most likely to be impacted, why are we not included? I have further comments below and a suggestion to include at least one consumer org.  Vaping is less dependence forming than smoking, science says so. See:  https://safernicotine.wiki/mediawiki/index.php/ENDS_Public_Health#Dependence_(Addiction,_Abuse)_vs_Harm_/_Harm_Reduction_-_Ecigs_and_Nicotine   Youth brain harms are reversible and only found in rats. Human youth smokers never experienced such harms. A huge number of people smoked in the 60s-80s, many from a young age the population is huge, any effect would have been seen (yes, people have looked, negative research is rarely published, but nothing was found). I can however provide evidence in the form of quotes from experts in tobacco and nicotine, please feel free to request such information.   No UK legal vape delivers more nicotine than a cigarette, some of the illegal disposables do and are attractive to hardened smokers. Legal vapes should be allowed to use more than 20 mg/ml, see also my letter to APPG Vaping on the 28th Feb this year https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb_2023.pdf . The US Juul product (containing 58 mg salt nicotine) produces blood plasma concentrations lower than a cigarette, but closer to the same level (This is why it worked so well in adults who smoke). Estimating that all nicotine is absorbed by the vaper by the amount exhaled is flawed, nicotine is destroyed by heating and oxidation while in the device and vapour. Cigarettes are delivering 1-2 mg per cigarette, but start out with 250 mg per pack of 20 (delivering only 20-40 mg to the user). Far better to stick with measured blood plasma levels in comparison to cigarettes, since this data is available.  e.g. https://pubmed.ncbi.nlm.nih.gov/33486526/  I Agree with points on advertising to children, industry should not target the product at them, but targeting their smoking parents is absolutely going to save lives. Children must be told the truth, the product is not for them, but might mean they do not lose their parents to cancer. We know with absolute certainty that vaping is safer than smoking, there is no doubt; the only doubt is the magnitude of the difference (the lowest estimate 60% the highest 99.5%, current science says 95%+ and is climbing each year, as well as gaining certainty).  Was it necessary to brow-beat the industry representatives? They where asked if they targeted children, and responded that they did not, with good reasons for the answer, including that the owner of one business wanted to help existing smokers, as vaping helped him, not gain youth customers.   I have not seen legitimate businesses from the UK targeting underage users, that has been rouge overseas traders, and some Chinese companies.  Those selling genuinely child appealing products or advertising to youth on social media, where any influence can be had, since they are not UK based, then yes, they should be stopped as far as possible.   Taxation is not going to help, illicit markets will avoid the tax and make the environmental situation worse, as well a safety. The illicit market exploded in Australia with 90% of the 1.1 million vapers buying from the illicit market.  Flavours targeted at adults, including their memories of sweets available when they where young. Human flavour preference is done by age 2 approximately, targeting flavours at youth is not actually reasonable, humans like nice flavours. Please see: https://safernicotine.wiki/mediawiki/index.php/ENDS_Cardiovascular_System#Flavors_(Flavours)  The illicit market vapes are not regulated and may contain contaminants, this is not a surprise, and would suggest that regulation that works to reduce the illicit trade (not increase it) would be beneficial.   The loophole that allows giving vapes to kids (not selling them) is not used, no reputable company does this, or would do so. It is actually a complete non issue, since no one does it. I have never heard of this, and I asked and no one else has either. Please can you forward to me the data that shows this is happening, and where? As advocates we would like to know of problems, and if possible help, thanks for your assistance.   Popcorn lung is not caused by vaping see: https://safernicotine.wiki/mediawiki/index.php/ENDS_Flavors including the risk of inhaling flavours. No regulated UK product contains the chemical, it is banned. Another reason not to expand the black market, unregulated products would not be tested for banned flavours. That this was brought up, and seriously considered shows that the ministers failed to research the subject. You should include a purely user organisation such as the UK Charity NNA (New Nicotine Alliance) https://nnalliance.org/ , they have no industry affiliation and work for the users of the product. You might also consider INNCO (International Network Nicotine Consumer Organizations) https://innco.org/    As a user of these products; I would request MPs be better informed, before considering legislation that could impact my health, thank you!  If you want to price youngsters out of the market without detriment to adult smokers see the letter to APPG vaping mentioned above. It contains some ideas that would reduce waste 10 fold, and increase the initial outlay without increasing cost per puff, a win for the environment and adult smokers with less spending power.   Yours sincerely,     Richard Pruen  Cc: APPG-Vaping   P.S.   I await your reply with the requested information, including reasoning for not including representatives of consumers in the enquiry. I would also like to know if the MPs where briefed on vaping or the vaping industry, if so by whom?|Letter Steve Barclay 6th JUL]]&lt;br /&gt;
&lt;br /&gt;
[[File:TGA consult 8-sept-2023 my response.pdf|thumb|alt=Response ID ANON-EJTE-W3QH-B Submitted to Proposed reforms to the regulation of vapes Submitted on 2023-09-08 21:15:44 Survey contents Privacy and your personal information I consent to the TGA collecting the information requested in this survey about me, including any sensitive information, for the purposes indicated above. Agree: Yes Acknowledgement I agree. Yes.: Yes Introduction 1 What is your name? Name: Richard Pruen 2 What is your email address? Email: richard@pruen.co.uk 3 What is your organisation name? Organisation name or N/A: n/a 4 Please choose a stakeholder group that best describes you or your organisation. Others* *If other, please specify:: Consumer 5 Which best describes your response? I am responding as an individual. 6 Are you an authorised prescriber? No (please go to next page Conflicts of interest (actual or perceived) 1 Have you or your organisation ever received services, assistance or support (whether monetary or non-monetary in nature) from the tobacco industry and/or e-cigarette industry? If this scenario applies to you or your organisation, please provide relevant details in the textbox. Yes If you have selected yes, please provide details here. Otherwise, please state &#039;Not Applicable&#039;:: I owned a company testing electronic cigarettes for compliance with UK and other standards, as well as carried out investigations of failures including battery failure. I also worked on R&amp;amp;D and provided consulting services on for example battery protection circuits, chargers etc. Payment was from user fees for testing, government agencies (trading standards), trade associations, and sometimes individuals or companies carrying out due diligence testing or failure mode analysis. Ended 2016 since then I have been a consumer only and have not received any funding from any company (of any sort), government agency, or researchinstitution. 2 Have you or your organisation ever provided services, assistance or support (whether monetary or non-monetary in nature) to the tobacco industry and/or the e-cigarette industry? If this scenario applies to you or your organisation, please provide further information in the textbox. Yes If you have selected &#039;yes&#039;, please provide details here. Otherwise, please state &#039;Not Applicable&#039;: I assisted in writing standards for UK vaping products (PAS 54115 A guide for the importation and sale of electronic cigarettes and directly related products, with product safety testing methods) and proposed an IEEE standard project number P2800. Several sampling machines were supplied to others testing electronic cigarettes, and other custom test equipment, the supplied equipment presumably used to carry out tests on electronic cigarettes as designed. As academic and test houses purchased this equipment it is assumed this was paid for by test fees, or grants to carry out tests on electronic cigarettes, again possibly linked to taxes etc from tobacco and or electronic cigarette sales. The same funding source as government agencies, politicians and others working in the field. Again since 2016 I have been a consumer only. Proposal 1 -Restrictions on importation, manufacture and supply of all vapes . 1 Do you support the proposed approach to ban disposable single use vapes absolutely and all other vapes, except those for legitimate therapeutic use in compliance with the TG Act? No 2 How would you anticipate industry and consumers to respond to a ban on the importation, manufacture and supply of non-therapeutic vapes? * Please provide answer here. : Demand will remain, along with the risk of vaping being seen as cool because it is something disallowed. The tightening of rules is unlikely to be enforceable, so illicit supply will continue to be the primary supply to the population. The population know vaping is safer than smoking, thus it will be very difficult to curb demand. Prohibiting drugs such as cocaine and cannabis fails, vaping prohibition will almost certainly follow the same pattern. 3 Do you support removal of the personal importation scheme exception for vapes? If not, what would be the impact on you? No (* if not, what would be the impact on you?) * What would be the impact on you?: Vaping products that are acceptable and usable are likely to only be available via illicit sales, and criminal gangs. Particularly as research shows flavours to be vital for the prevention of release to smoking. These products will not be tested or regulated in any way, importing allows users who have a prescription to import what they need to stay smoke-free, thus not relapse to smoking and potentially death. Importantly importing from somewhere with a regulated legal market, they can be sure of the quality and contents of the products they buy. The one-size-fits-all approved vapes that consumers will find at pharmacy outlets is unlikely to be effective since most of the features that make an effective substitute for cigarettes will be regulated out. 4 Do you agree with the proposal to retain a traveller’s exemption, including the proposed limits? Yes 5 Do you support the proposed approach to prohibiting the advertisement of all vapes (subject to limited exceptions)? No 6 [If applicable] Suppliers, what part of supply chain do you occupy? Not applicable * Other -specify your role in supply chain.: Consumer 6 (a) What proportion of your sales volumes is attributable to vape sales [i.e. quantity of vapes sold]? Please provide details here: (or mark Not applicable).: N/A6 (b) What proportion of your sales revenue is attributable to vape sales [i.e. revenue earned from sales]? Please provide details here: (or mark Not applicable).: N/A 6 (c) What impact would the proposed measures have on your sales volumes? Please provide details here: (or mark Not applicable).: not a vendor, none 6 (d) What impact would the proposed measures have on your sales revenues? Please provide details here: (or mark Not applicable).: none not a vendor 6 (e) What proportion of your vapes sales is attributable to disposable single use vapes versus refillable products? Please provide details here: (or mark Not applicable).: not a vendor 6 (f) How would restricting the importation, manufacture and supply of disposable single use, and non-therapeutic, vapes in Australia impact you? Please provide details here: (or mark Not applicable).: not a vendor N/A 6 (g) How much stock do you have in Australia currently and how long would it take to sell that stock? Please provide details here: (or mark Not applicable).: not a vendor N/A 6 (h) What would be the cost to you if you were required to dispose or otherwise move on existing stock? Please provide details here: (or mark Not applicable).: N/A Proposal 2 -Changes to market accessibility requirements, including better regulation of device components. 7 Do you support the approach to require a pre-market notification of compliance with TGO 110? No 8 [If applicable] For suppliers of therapeutic vapes, what impact would the proposed notification system have on your supply model and what transition period would you require to comply with the new notification requirement? Please provide details here: (or mark Not applicable).: not a vendor 9 Do you support the proposed access to vapes under the SAS C notification system? No 9 (a) What impact would this pathway have on facilitating patient access to therapeutic vapes? Please provide details here: (or mark Not applicable).: Vaping works in the rest of the world as a product substitute, providing a safer alternative to a deadly (cigarettes) product. In the UK and NZ smoking decline has accelerated significantly past that in Australia, due to the adoption of consumer vaping, slightly less so in the US where the regulator is not so certain. The prescription model in Australia has failed, smoking has not continued to decline and may have increased possibly. Vaping is also higher in Australian youth than UK and NZ, the current policy has backfired and should be reversed. It is absolutely obvious at this point that unless you have unlimited resources for enforcement, the current policy is not workable, and never will be. The time has come to use what has worked elsewhere and start again.10 [If applicable] For prescribers, would the proposed new pathway likely change your approach to prescribing therapeutic vapes? How? Not a prescriber of vapes * How new pathway will change your approach to prescribing ttherapeutic vapes?: 11 [If applicable] For prescribers, which access pathway (SAS B, SAS C, or AP) would you envisage using to prescribe therapeutic vapes? Why? Not a prescriber of vapes Please tell us why: 12 [If applicable] For prescribers, would integration of SAS or AP applications or notifications into existing clinical software systems ease the administrative burden and/or encourage you to use the new pathway? Not a prescriber of vapes 13 Do you agree with the proposal to regulate both e-liquid and device components of unapproved vapes under the same part of the TG Act for simplicity? No 14 Will these changes have direct or indirect impact on you? Please provide details. Yes (please provide details below) Please provide details here:: As a consumer I want safer options to be available to me and to every person who smokes tobacco or would smoke tobacco for lack of a viable alternative. Sadly some kids will do adult things even if you try to stop them (for example drinking alcohol, unsafe sex, taking drugs, smoking) while they should not be encouraged to vape, it still offers a harm reduction if it diverts them from smoking, like it or not, this is true because safer is safer. 15 Do you require time to adjust to these requirements? If yes, how long? Yes 15 (a) How long do you require to adjust to these requirements? More than 12 months Proposal 3 - Improving quality standard for unapproved (unregistered) vapes) 16 Are the definitions of nicotine and mint flavours appropriate? If not, please provide reasons. No (* please provide reason below) * Please provide reason here.: Nicotine itself does not have a flavour, the flavour should be correctly referred to as &amp;quot;artificial tobacco flavour&amp;quot; There is no evidence that human flavour preference varies by age and none particularly that it changes at 18. It is therefore impossible to target age groups with specific flavours, thus limiting flavours on this basis has no merit whatsoever. 17 Do you agree with the proposed upper limit on the concentration of menthol in vapes? If not, please provide reasons. No (* please provide reason below) * Please provide reason here: It is trivial to add menthol to vapes, this simply encourages users to add more if they prefer, opening a can of worms and the potential for contamination or incompatible ingredients. This seem unwise for very little if any benefit. 18 [If applicable] Importers, manufacturers and suppliers, would the restrictions on flavour proposed above impact you? Not applicable 19 Do you agree with the proposal to require pharmaceutical-like packaging and presentation for vapes, e.g., vapes manufactured in black, white or grey coloured materials, predominantly white background on packaging, clear warning statements and other restrictions on labels in addition to other selective TGO 91 requirements for vapes? No (* please provide reason below)20 [If applicable] What impact will the labelling and packaging changes have on you? * Please provide detail here.: It will probably backfire, making legal products undesirable is likely to increase the number of people using illicit products, particularly if access remains easy, without enforcement that is most likely to be the case. 20 (a) How long would you need to transition your product to comply with the proposed requirements? More than 12 months 21 Do you agree with our approach to allow only permitted ingredients in vapes, instead of trying to prohibit individual chemical entities from use in e-liquids? No 22 [If applicable] Importers, manufacturers and suppliers, will your therapeutic vapes need any re-formulation or other changes to comply with the permitted ingredients and ingredient quality requirements? Not applicable 22 (a) If product re-formulation is required, how long will you need to make these changes? More than 12 months 22 (b) If product re-formulation is required, what financial or business impacts would be associated with them? Provide detail here or put &#039;Not Applicable&#039;: Not a vendor 23 Do you support applying the same regulatory controls to zero-nicotine therapeutic vapes, as for NVPs? No 24 What is the overall business cost on you to comply with a strengthened TGO 110? Please provide details here: (or mark Not applicable).: not a vendor 25 Do you agree with the proposed requirements under TGO 110 that will apply to unapproved device components of vapes? No 26 [If applicable] Suppliers, do you intend to register any vaping device on the register as an approved medical device? No (if no, why not?) If no, why not?: not a vendor 27 [If applicable] Importers, manufacturers and suppliers, are you familiar with relevant US FDA, or MHRA guidance and/or EU standards covering vaping devices? Not applicable 27 (a) Do your vapes currently comply with relevant US FDA, or MHRA guidance and/or EU standards covering vaping devices? Not applicable 27 (b) If not, what requirements do you meet? What requirements you currently comply with?: not a vendor 27 (c) How long would it take to achieve compliance with relevant standards? More than 12 months28 [If applicable] Importers, manufacturers and suppliers, are your vapes manufactured at facilities that hold relevant international standards for Quality Management Systems, such as ISO9001 or ISO 13485? Not applicable Proposal 4 - Strengthening domestic compliance and enforcement mechanisms 29 Do you have any other comments in relation to this proposal? Yes (* provide your comments below) Comments: I reiterate that Australian policy has failed, and further moves in the same direction are likely to fail. Other countries have shown much more desirable results, the best results on smoking have been where vaping has been accepted as a consumer alternative to smoking, but the prescription model, unfortunately, has proven unworkable. Realistically you should review the past responses to enquiries, select a number of people who have successfully predicted the results of current regulations, and ask them for solutions. At least they have a track record, and proven knowledge of the real world and likely outcomes. Supplementary questions 30 [If applicable] Suppliers, please confirm if you intend to continue to supply therapeutic vapes under the proposed reforms described? Not applicable * Product range : Not a vendor, but as a consumer, I can see vendors dropping out. This will benefit the criminals and gangs who supply illicit markets, more trade for them. 30 (a) How long would it take to meet the new requirements? More than 12 months 31 [If applicable] Suppliers, please confirm if you intend to register your therapeutic vapes in the next 2 years? Not applicable What guidance and/or clarity of supporting data requirements do you need from TGA: not a vendor Publication of submissions To proceed, please select from the options below how you would like the TGA to deal with your submissions: I agree to the TGA publishing my response in full. I request the TGA to consider redacting sensitive commercial information from my response before publication: No Please specify sensitive commercial inforation you want redatced :|TGA consult 8-sept-2023 my response]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter to pm 16 sept 2023.pdf|thumb|alt=Sent to The Prime Ministers office FAO The Prime Minister No10 downing street (via official contact form) 14:30 on 16th Sept 2023   Subject: The continuing debate around banning disposable vaping and flavoured vaping.  This is continuing from my note of the 25th May 2023, I hear worrying noises around an outright ban on disposable vapes. As a consumer myself, who would surely be dead now without vaping, 15 years more smoking (I started 2008) would have seen me off, but not a user of disposables. Please however consider the following.  First; evidence from Australia where vaping is prescription only and prescriptions are hard to obtain (a de-facto ban), shows that illicit markets step in to fill demand, and have done so with the cheapest and least safe disposable devices. It is entirely probable bans here would result in more disposable vapes than less.  Second; There are disposable vapes designed for high security locations, such as prisons and mental health units, particularly secure ones. Please do not inadvertently ban a much safer than smoking option in such places, some of these people are suffering enough, and require our assistance.  Third; Prohibition is not effective, please see the situation in Australia again, the failed implementation of alcohol prohibition, and more than 6 decades of drug war. Not one of these things has reduced the supply of the substances trying to be controlled, and there is no reason to assume it will be effective for disposable or flavoured vaping.  Fourth; There are measures, some that I suggested to APPG Vaping on 28th Feb this year, the link is safernicotine.wiki/mediawiki/index.php?Title=File:Email_to_appg_vaping_28th_Feb_2023.pdf Should you wish to read it. These measures would significantly reduce the environmental impact (by a factor of 10), and place the legal devices better able to compete with illicit imports (these generally have more puffs than the UK rules currently allow), has the effect of increasing the initial cost of the device but not the cost per puff. By such changes to legal devices three main goals can be achieved   1) Compete out the illicit and illegal products that are not safety tested and approved.  2) Reduce the environmental cost, and quantity of vapes in need of recycling.  3) Reduce the affordability of such devices to young people particularly children.  Legal devices could then be mandated to contain information on refillable devices that are just as easy to use, cheaper and more environmentally responsible. Measures to drive consumers to more environmentally sound products should absolutely be considered, such as paying more initially and receiving a repayment on return for recycling. This should be done with care for unintended consequences.  I have kept this short as you are busy, but if there is any further information you would like please feel free to contact me by email richard@pruen.co.uk.  Thank you for your time.|Letter to pm 16 sept 2023]]&lt;br /&gt;
&lt;br /&gt;
[[File:NSW Consult 30 sept.pdf|thumb|alt=Vaping is a direct substitute for smoking that is able to compete with cigarettes on the open market, it is unbeatable on cost compared to subsidised NRT, and far more effective, the UK NHS find 2/3 (66%) effective with support.  With regulated vaping in UK youth: 0.5% use &amp;gt; once weekly and are never smokers (see ASHuk graph attached). Driving the product to illicit markets and criminal gangs seems to have resulted in greater access for Australian youth.  While vaping is not entirely risk-free, it is known now that it poses a fraction of the risk of smoking (please see the attached risk map). Waiting for a perfect solution that may never be found is counterproductive, the reduction in risk is known to be large that much is proven (the unknown part is, is it 90% reduction in risk or 99%, to be sure will take time)  While youth should not vape or smoke, some will end up doing both. If there is no safer alternative available they will all be smoking. It is also worth remembering dependence on nicotine while not desirable can be reversed, death is final, and it is smoking that kills.  Like it or not vaping has a built-in off-ramp. Use an open-system vape, and use the liquid you need to prevent cravings. Then slowly reduce the nicotine strength at your own pace. On reaching zero nicotine, stop. This is also ample evidence it was developed by smokers, to help stop smoking, and then to stop vaping if that is desired. Would a tobacco company ensure a way out was built in?  The population has resoundingly refused the prescription model, any of the many reasons pointed out repeatedly or all of them are to blame. They deserve a fair regulated market they can trust, if you cannot provide a better solution than criminal gangs, then that is a failure on your part. |NSW Vaping submission 30 september 2023]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter Steve Barclay 19th oct.pdf|thumb|alt=Subject: ‘Ton of bricks’ regulation of vaping and flavours   Dear Steve Barclay,  I am a consumer advocate, with no ties to industry at present (for full details see my previous letter).  I await your reply to my last letter on 6th July, with the requested information, including reasoning for not including representatives of consumers in the enquiry. I would also like to know if the MPs where briefed on vaping or the vaping industry, if so by whom?  The point itself is brief, two short paragraphs.  After your comments on regulations, I would like to draw your attention to the following peer reviewed paper https://www.mdpi.com/1660-4601/20/20/6936 this strongly suggests that young people are being diverted from smoking, vaping is at least 95% safer than them smoking, thus while not ideal vaping reduces harm. Dependence to nicotine is also not ideal, but only 0.5% youth regularly use vapes who did not first smoke. Meanwhile you risk stopping millions of adult smokers switching to vapes by eliminating flavours, these are an important thing for adults. Please read this from Clive Bates (ex ASH Director) https://clivebates.com/documents/FlavoursBriefingV1July2022.pdf. You should of course ban candyfloss and sweet flavoured alcohol, as such flavours are aimed only at children?   One last point Vaping is already illegal for children, if the existing rules cannot be enforced, then further legislation will presumably not be enforced either, how would that help?   Yours sincerely,     Richard Pruen|Letter Steve Barclay 19th oct]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter to cop 10 repersentitives.pdf|thumb|alt=Subject: COP 10 WHO FCTC    Dear Rosanna O’Connor,  I am a consumer advocate for vaping, and do not use disposables beyond experimenting to see what they are like. I am also an engineer. I have worked in the vaping industry previously testing compliance with the standards for vaping products, and owned a now closed company BTC Battery Testing LTD (closed 2016). Currently I care for my mother who suffers vascular dementia, and as such volunteer my spare time to the cause of Tobacco Harm Reduction.  I believe that consumers should be present at the COP 10 meeting, it is consumers who have the most to gain from stopping the use of combustible tobacco, and the lived experience of trying to do so. Many millions have found a way to eliminate almost all the risk via THR products. The phrase ‘Nothing about us without us’ springs to mind. Why then are the public and press excluded. I would like to see the proceedings live streamed, so those effected can see what is being done. In no way could this effect the discussions, thus is reasonable transparency. I would like an answer regarding the possibility, please.   Many countries already found harm reduction useful, critical even. Be that low risk Snus (Sweden has the lowest cancer rate in Europe, and will be smoking free this year (&amp;gt;5%)). Vaping that the UK NHS finds almost 66% effective with support, as stated on their website. New Zealand has seen similar results, especially in native populations, reducing disparities. Japan has seen huge drops in cigarette sales due to reduced harm heated tobacco products.  Please see the letter from the Lancet from Robert Beaglehole and Ruth Bonita. They were both senior officials at WHO and are now at the University of Auckland. Robert was formerly Director of the Department of Chronic Disease and Health Promotion at WHO. Ruth was formerly the Director of Surveillance in the Noncommunicable Disease Cluster at WHO.  I wish to add my support for their recommendations, the article is attached (also link here https://doi.org/10.1016/S0140-6736(24)00140-5) please make sure these points are discussed at the COP 10 meeting.   Yours sincerely,     Richard Pruen  P.S Please ensure the representatives listed on the next page can discuss before the metting and forward more widely if you agree with the sentiment.   Katherine Sands Tobacco Control Team Leader Department for Health and Social Care  Martin Dockrell Tobacco Control Programme Lead Department for Health and Social Care  Alison Walker Senior Tobacco Control Policy Lead Department of Health and Social Care  Esther Lawrence Deputy Head of Global Health UK Mission to the UN, Geneva  Please find attached a letter from   [THELANCET-D-24-00371] S0140-6736(24)00140-5|Letter to cop 10 representatives]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter PM 16th Feb 2024-draft.pdf|thumb|alt=Subject: The ban on disposable cigarettes   Dear Prime Minister,  I am a consumer advocate for vaping (15 years and vaper for 16), and do not use disposables beyond experimenting to see what they are like. I am also an engineer. I have worked in the vaping industry previously testing against the standards for vaping products, and owned a now closed company BTC Battery Testing LTD (closed 2016). Currently I care for my mother who suffers vascular dementia, and as such volunteer my spare time to the cause of THR.  Regarding the subject. Might I remind you that Australia has already taken this path, over 50 fire bombings, at least 3 gang style murders, and a rampant illegal trade has resulted.  I am aware you have children, and they are potentially at the age to start experimenting with adult products. The prohibitionist faction may have played on this, and convinced you that a ban is enforceable, sadly if Australia cannot do it, the proximity of Europe means less chance here.  This is simply being realistic. The best, perhaps only, way to control the illicit trade to to make sure there is a legal trade that makes it less profitable,the US abandoned alcohol prohibition in favour of this.    Please however remain focused on preventing harm, having the only source of disposable vapes (sorry to say this but it is true) that your children could possibly buy, being from a ‘dealer’ who might supply other illicit substances, that is not safer! At least if they are from a shop selling tested, safe devices, then that is a huge reduction in harm already, avoiding interaction with drug dealers. I would prefer the shop followed the law, but as we know not everyone will. Your children might also sample smoking, especially if they sensibly avoid illicit substance dealers, this too is not exactly a win, smoking being deadly and carcinogenic.   You are not the only one being pressured, please see the tweet linked here:  https://x.com/ASHNZ2025/status/1757930273751363892?s=20  “Disappointing that @HealthCoA lump ASH in with tobacco industry in an OIA request rather than ask us. Is a smear campaign coming our way? On the record ASH has no $$ or COI with tobacco, vape, alcohol, gambling, pharmaceutical, retail, food, or billionaire philanthropist” &amp;lt;a letter from the NZ government is attached to the tweet&amp;gt;  I apologise for the somewhat robust and direct letter, but I feel you are about to make a huge mistake. I would regret it on behalf of current cigarette smokers, some of whom will die, and those who return to smoking because they use a banned product, some of those too will die. Meanwhile it will not help your children, or anyone else&#039;s to drive all sales to illicit/criminal markets.  Please see the attached graph, so far regular use is not high and may be displacing cigarettes, sensible regulations to keep it that way, those would be welcome.  A few truths to bear in mind:   Infrequent trial use isn’t the best indicator of dependence, vaping doesn’t kill children nor is it likely ever to do so, smoking cigarettes does kill adults, reasonable regulation results in overall lowest harm.    I would like to hear your thoughts, I will be happy to provide evidence to support what I have said, if required for any point please let me know.  Thank you for your time, and please do not take this lightly!  Yours sincerely,  Richard Pruen |Letter PM 16th Feb 2024-draft]]&lt;br /&gt;
&lt;br /&gt;
[[File:For Attention APPG Smoking and health.pdf|thumb|alt=Dear Rt. Hon. Bob Blackman,  I am contacting you as you are the contact for APPG Smoking and Health. There have been worrying sudden changes in government policy, primarily related to vaping and talk of taxes and bans on a vastly safer product, vaping, that has been successfully displacing smoking.  Please see my previous letter to APPG vaping on why the disposable ban is likely to backfire; simply put, it will hand the entire market to illicit sales (these are already a problem, with oversized and higher-than-legal nicotine content). Illegal sales will likely increase sales to youth since they are already ignoring the law, and the situation in Australia with more than 50 fire bombings and three murders so far in the &#039;Nicotine turf wars&#039; might be repeated here.  As per my letter above, the best way to deal with illegal disposables is to have the legal market out-compete them; at least shops and retailers have fixed premises, and trading standards can take action if they don&#039;t follow the law. It is much harder to police some bloke at the pub or other informal sales. You also lose out on VAT charged on legal sales.  Whatever you think about vaping, it saved my life; I started 16 years ago, very early when it was a new thing, and since then, there has been a vast amount of science (some good, some sadly terrible). Last week, 51 peer-reviewed papers and over 8,000 total papers were published. By now, vaping/nicotine is likely the most studied consumer drug ever. I had an MRI 15 years vaping (stopping smoking) of my head and upper torso. The doctors were able to confirm all the smoking damage had healed, and on explicitly asking if they could see any sign I vape, they could not (despite having found previously healed fractured ribs). Such experiences are not uncommon. A list of links to approximately 100,000 people reporting in their own words how vaping helped them.   Tobacco control has a problem; please do not let that upset the government&#039;s plans to help people stop smoking with the best available harm-reduced product to date. The NHS finds it 2/3 (66%) effective, far better than NRT at around 15% with the same support (easily found on their vaping to stop smoking web page).  Please ensure that the UK policy isn&#039;t derailed by click bait media, or the following:   Extract from Clive Bates (former director ASH) essay:Tobacco Control&#039;s Nervous Breakdown     Fourth, the existential threat to the tobacco control complex. The public discussion of the emerging landscape of low-risk consumer products seldom focuses on the interest group that is most vulnerable to disruption: the mainstream of tobacco control. It is a complex of interests comprising nonprofit activists, academics, medical and health societies, major institutions (such as the World Health Organization or the U.S. Food and Drug Administration), philanthropists and research-funding bodies. The problem for the mainstream of tobacco control is that without serious harm, the whole movement loses its purpose and its reason to exist. When it comes to low-risk alternatives to smoking, this complex is profoundly confronted by the threat of having nothing to control, no case for intervention and no reason to be. It is a powerful incumbent interest group challenged by new technology, new suppliers and new consumer confidence. As a result, the mainstream of this interest group has rejected tobacco harm reduction as a strategy for addressing its own notional goals of reducing death and disease from tobacco use. Instead, it has mounted a rear-guard defense based on a range of strategies, including the following: Falsely implying that noncombustible products are no less risky than cigarettes, that data is too uncertain or short-term, or asserting that reduced risk is no more than a marketing claim of tobacco companies. Asserting that harm reduction is merely a commercial strategy of tobacco companies. The aim here is to attach the reputational baggage of “Big Tobacco” to these new developments. Yet, many independent experts support tobacco harm reduction, and it is good if tobacco companies adopt a business model aligned with reducing health impacts. Excluding or stigmatizing contrarian opinions and creating sealed bubbles open to groupthink. The WHO Framework Convention on Tobacco Control has taken this to new extremes. Shifting emphasis to problematize nicotine rather than the “tar” of cigarette smoke that is the cause of nearly all tobacco-related disease. We are hearing more about “addiction” and less about cancer. Yet, a dependence only meets the definition of addiction if there is serious net harm to the user. A relentless focus on the supposed interests of children without recognizing that would-be smokers among adolescents also benefit from low-risk products and that the demand for nicotine has persisted across generations for hundreds of years. Young people have an interest in the health of the significant adults in their lives as carers, breadwinners and role models. Pressing for prohibitions or equivalent regulation to cigarettes, often with manipulation of language to imply equivalent risk, for example, by stating that heated-tobacco products produce “smoke” or that all tobacco products should be treated the same even though they have very different risks. A blunt refusal to face trade-offs (for example, between the interests of youth and adults) or unintended consequences (for example, increases in smoking) arising from favored policy positions. I have watched on in horror as the leadership in tobacco control, albeit with many honorable exceptions, has dogmatically denied and suppressed the opportunity to radically reshape the recreational nicotine market to cause vastly reduced harm and avoid hundreds of millions of premature deaths. It looks like a nervous breakdown is developing in tobacco control in response to profound disruptive innovation. I doubt they will survive it.  See also my Letter PM 16th Feb 2024 particularly the graph that shows frequent youth use is not increasing, trials and infrequent use have, for perspective however, vaping has been far less popular and less harmful than youth drinking.  Please do what you can to ensure legislation is well thought out, measured and does not result in people being forced back to deadly smoking. Thank you for your time and urgent attention!|Email APPG Smoking and health-4 March 2024]]&lt;br /&gt;
&lt;br /&gt;
[[File:Letter sec state health and social care 14 March 2024.pdf|thumb|alt=Subject: Youth vaping    Please see the above graph, so far regular use (greater than once a week) is not high and may be displacing cigarettes, cigarettes are the worlds most deadly consumer product. Infrequent and trial use (once in 30 days, or ever use) while undesirable does not lead to dependence, only those in the graph above can possibly be ‘hooked’, but not all will be.   I do not think young people should be encouraged to vape, but I would like to know your answer to one question, please.  If a young person is determined to use nicotine, would you advise them to smoke cigarettes instead of safer alternatives, and a what age should harm reduction products like vaping be made available.  I look forward to receiving your answer. Please feel free to ask others what they think should be done.  Personally I feel the situation in Sweden is close to the best balance, accepting some use of low risk Snus, in order to reduce the uptake of deadly smoking. This will take effect far faster than the generational tobacco ban, Sweden will be a non smoking nation this year, although nicotine use remains, they have the lowest cancer rate in Europe. The UK can easily and quickly achieve the same with vaping. I note also Sweden reduced the tax on Snus to accelerate uptake.  Yours sincerely,  Richard Pruen|Letter sec state health and social care 14 March 2024]]&lt;br /&gt;
[[File:Letter sec state health and social care 11 May 2024.pdf|thumb|alt=Subject: Tobacco and vapes bill Dear Victoria Atkins,  I am contacting you as a vaping consumer, and advocate for saving lives, vaping saved my life (happy to share medical records to prove that) and I aim to pass that on to as many as possible, I am not paid in any way by anyone to do so.  I was disturbed to hear some of the testimony given in parliament, much of the information was incorrect, or deliberately misleading. This is not good enough when debating a serious matter of health, accurate and science backed information is critical to saving lives.  I would like an answer to the following question: What was the reason to justify excluding stakeholders, the users of vaping products, other safer tobacco products, and even people who smoke?  User funded charities such as New Nicotine Alliance, who take no money from the tobacco or vaping industry should have been consulted. Users themselves or NNA would have been able to counter some of the poor information given and also to provide a view from those directly affected by the legislation being discussed.    Much of the information could have been corrected, quickly and easily. The main issues with the unopposed debate (no stakeholder representative, or consideration given to stakeholders, it seems); the conflation of illegal/criminal imports of untested and illegal drug products, and legal UK nicotine vaping; the lack of separation between the independent vaping industry and tobacco multinationals (they are not the same thing); the potential to harm the UK government stop to swap scheme (saving lives of people who smoke now, not a future population, years from now)… I could go on, but others like UK Vaping Industry Association have pointed out the issues, no need for a repeat.  My most important question; What is being done to ensure that stakeholders are heard, and the users of these products are not swept aside? Particularly what is being done to ensure false/misleading statements are not made to parliament by the experts, or that at least someone is included on behalf of users to set the record straight?  I look forward to your responses.   Yours sincerely,  Richard Pruen|Letter sec state health and social care 11 May 2024]]&lt;br /&gt;
&lt;br /&gt;
[[File:Draft redact address letter PM 8th Jul 2024.pdf|thumb|alt=Subject: The ban on disposable cigarettes / vaping in general&lt;br /&gt;
Dear Prime Minister,&lt;br /&gt;
I am a consumer advocate for vaping (15 years and a vaper for 16), and I do not use disposables beyond experimenting to see what they are like. I am also an engineer. I have previously worked in the vaping industry, testing against the standards for vaping products, and owned a now-closed company, BTC Battery Testing LTD (closed 2016). I am a consumer now and take no money from any industry, charity, or government scheme. Currently, I care for my mother, who suffers from vascular dementia, and as such, I volunteer my spare time to the cause of THR. I also advocate for smoking cessation in sufferers of severe mental health conditions. ASH UK funds the group, but I do not take any payment for my time. Regarding the subject. Might I remind you that Australia has already taken this path? An effective ban, over 80 fire bombings, at least three gang-style murders, and a rampant illegal trade have resulted? It simply won’t work. The prohibitionist faction has played on children starting using these products, and may have convinced you that a ban is enforceable; sadly, if Australia cannot do it, the proximity of Europe means less chance here. I am simply being realistic. The best, perhaps only, way to control the illicit trade is to make sure there is a legal trade that makes it less profitable; the US abandoned alcohol prohibition in favour of this. Please, however, remain focused on preventing harm; having the only source of disposable vapes (sorry to say this, but it is true) that adolescents could buy, being from a ‘dealer’ who might supply other illicit substances, is not safer! At least if they are from a shop selling tested, safe devices, then that is a vast reduction in harm already, avoiding interaction with drug dealers. I prefer every shop to follow the law, but as we know, not everyone will. Adolescents might also sample smoking, especially if they sensibly avoid illicit substance dealers; this, too, is not exactly a win, smoking being deadly and carcinogenic. Those diverted from cigarettes face a much lower risk of cancer and other smoking-related diseases. It is a fact that zero deaths have been caused by vaping a regulated nicotine product; among around 82 million users worldwide, the EVALI deaths all resulted from an illegal trade in THC vaping in the US (different chemistry and devices, incompatible with nicotine vapes). I favour regulations to encourage the use of rechargeable vapes. However, even disposables can be recycled; these are far superior to cigarette filters; filter tips are nearly impossible to recycle and will be in the environment for years. Exceptions should be made for disabled people (unable to fill or use pods) in secure mental health care/prisons; here, disposable tamper-resistant devices are safer. However, legislation should favour the refillable and reusable vapes that are most environmentally sound; disposables can be discouraged without a ban. Please see the graph. So far, regular use is not high and may be displacing cigarettes. Sensible regulations to keep it that way would be welcome. A few truths to bear in mind: The use of the word ‘children’ is a deliberate tactic to tug on heart strings, more correctly teens particularly adolescents are at risk from experimenting with vapes and other adult things, harm reduction still applies, beer is safer than vodka, vapes are vastly safer than cigarettes. Infrequent trial use isn’t the best indicator of dependence (once in 30 days), better is once a week or more. To risk dependence you need to be regularly vaping. The harm from vaping is low enough it is right to argue against the use of addiction, since the DSM-5 definition requires significant harm, dependence is more correct because it can be hard to stop. Vaping allows users to taper nicotine so less than cigarettes. Millions of lives are at stake, billions of pounds the NHS spend on cancer and other smoking related treatments that could be eliminated, smoking is the leading cause of preventable death, vaping regulated nicotine products, zero deaths in 20 years. The less popular you make vaping, the more popular smoking will become, they are substitutes. When you ban things; illicit markets form, they have no reason to follow age of sale or other rules, this risks making things worse not better (Australia demonstrates this). The generational ban while it sounds good, kicks the can into the future, vaping is reducing smoking right now, and more effort is required to target older adults, they are the ones facing smoking related diseases imminently, switching them to vapes is a huge immediate benefit the generational ban could never deliver. I would like to hear your thoughts, I will be happy to provide evidence to support what I have said, if required for any point please let me know. You promised your government would work for us, and would look after our health and well-being, here is a way to prove you will listen, many lives can be saved.  If there is one single study I think most important: Comparison of biomarkers of exposure among US adult smokers, users of electronic nicotine delivery systems, dual users and nonusers, 2018–2019. For every harmful or potentially harmful compound, vapers look exactly like non-users. Thank you for your time, I have tried to be brief as you must be busy, but welcome questions should you have any.  Yours sincerely, Richard Pruen P.S. My story: Why I do this? I started vaping in 2008 when it was relatively new, I had at this point given up trying to stop smoking, having tried everything. I intended to vape where I was unable to smoke. To my surprise in March of 2009 I discovered I had money budgeted for cigarettes that was unspent, this was how I discovered I had accidentally given up smoking. In 2010 I watched my father die from cancer, smoking 20/day didn’t help, although as a firefighter there is occupational risk also. My health improved substantially over the first 5 years, and at 15 years vaping I had an MRI due to aortic aneurysms running in the family (my father had one repaired), my lungs where those of a non smoker, doctors where unable to find any sign I vape. Put simply vaping saved my life and I would like pass that forward, partly in memory of my father, he was a firefighter and lived to save lives.  |draft letter to new PM for 8th JUL]]&lt;br /&gt;
[[File:Draft redact address letter wes sweeting 15th Jul 2024.pdf|thumb|alt=Subject: Tobacco and vapes bill&lt;br /&gt;
Dear Wes Sweeting,&lt;br /&gt;
&lt;br /&gt;
I am contacting you as a vaping consumer and advocate for saving lives; vaping saved my life (I am happy to share medical records to prove that), and I aim to pass that on to as many as possible. I am not paid in any way by anyone to do so. I have worked in the vaping industry, helping to develop standards and testing against them (I ran BTC battery testing until 2016). This was good for consumer safety, but the industry did not necessarily favour it. I am also part of a group funded by ASH advocating for smoking cessation in people living with severe mental illness; 40% smoke cigarettes, double the national number. &lt;br /&gt;
&lt;br /&gt;
I was disturbed to hear some of the testimony given in parliament, mainly by the previous government. Much of the information was incorrect or deliberately misleading. You must do better when debating a serious health matter; accurate and science-backed information is critical to saving lives. You should be using the research OHID paid for using taxpayers&#039; money, not anecdotal (often second-hand) accounts from teaching staff or parents frightened by the media (more on that below).&lt;br /&gt;
 &lt;br /&gt;
Before proceeding with further legislation, you must pause and ensure stakeholders (particularly end users) are appropriately consulted. Without accurate and proper information, bad legislation will result, like Australia and the prescription model (now dropped, and pharmacy only, also likely to fail)  Will Australia&#039;s tightened prescription system reduce nicotine vaping among young people? wiley.com and others show the policy failed, and instead 90% supply was from illegal sales controlled by organised crime. At the time of writing this, there have been more than 80 fire-bombings, three murders, and many gang ‘turf-wars’ in Australia. We do not need to bring that here. &lt;br /&gt;
&lt;br /&gt;
Sadly, there is a lot of misinformation being pushed in the media regarding children using these products; the use of ‘children’ is deceptive, even using the over-wide definitions that are often cited; children are not the population at risk. Sales are already illegal to those under 18; advertising to such age groups is also banned, and advertising is generally restricted. Please see my letter to the PM available from my wiki user page (direct link) https://safernicotine.wiki/mediawiki/index.php/File:Draft_redact_address_letter_PM_8th_Jul_2024.pdf. Adolescents are the population who might take up vaping, they might also take up smoking (far more deadly), or experiment with other adult things. It is a part of growing up, and if you prevent the less harmful options, adolescents will probably do more risky things.&lt;br /&gt;
 &lt;br /&gt;
I agree that you should keep a close eye on frequent vaping among adolescents; thankfully, that remains low and does not show worrying trends (please see the graph in the letter to PM above). Experimentation with vaping is preferable to cigarettes, and still, too many are starting to smoke tobacco. Vaping is unlikely to cause deaths, at least, unlike tobacco, and has (with open devices) the off-ramp of tapering nicotine slowly (around a third of folks quitting smoking with vapes also stop vaping this way; see ONS data).&lt;br /&gt;
 &lt;br /&gt;
It is essential to accept the vastly lower risk when considering legislation that will steer adolescents in a particular direction. Assuming they will do extra homework if they can’t experiment is faulty. They will likely do something more risky instead, such as alcohol. Alcohol, for example, results in accidents, intoxication and deaths. This is sadly human nature, and harm reduction at least keeps the risks as low as possible.&lt;br /&gt;
It is also vital to ensure that illicit vapes and illegal sales are kept to a minimum; buying vapes from ‘dealers’ opens all manner of unwanted possibilities, including other more harmful illegal drugs being offered. Thus, great care is needed to avoid a ban on a product type resulting in supply shifting to criminal-controlled illicit sales. There is already too much of this with over-strength/over-capacity disposable vapes; outright bans on disposables will make this far worse. This will require some subtlety and care in regulations to address the issue. Instead of a ban, having the price include the cost of disassembly recovery and recycling might better direct sales to refillable and, thus, much more environmentally friendly devices. The extra complexity of using a pod device is slight, so a small nudge is likely required for most consumers to shift to a more environmentally responsible product. You need to consider things carefully before doing anything and look at the unintended consequences that might occur.  &lt;br /&gt;
 &lt;br /&gt;
In only five years, New Zealand halved its smoking rate (now approaching 5%). https://www.scoop.co.nz/stories/WO2407/S00138/caphra-calls-on-asia-pacific-governments-to-allow-sale-of-oral-nicotine-products.htm The government there promoted vaping more than the UK government. For comparison, Canada taxes and does not promote vaping, and the smoking rate has remained stable. Sweden recently reduced the tax on Snus in a bid to increase switching (they are about to drop below 5% also) and has had great success with a THR product in Snus.&lt;br /&gt;
 &lt;br /&gt;
In Sweden, the use of nicotine is about the same as in the EU as a whole, but the rates of cancer are lower, particularly in men, since they switched earlier, and the trend is now apparent in the data. It is worth looking at Sweden because it has had a harm-reduction product for a long time, and trends and population data are readily available. It is obvious that nicotine is not a problem; it is combusted tobacco, particularly cigarettes; switching existing users to safer products is the priority; you can save vast numbers of lives and treatment costs. I suggest you research the history of THR in Sweden, allowing users to initiate nicotine use with a safer product works; they have the lowest cancer rates in the EU by a good margin. &lt;br /&gt;
&lt;br /&gt;
It is essential to be honest when looking at nicotine; it has benefits for some people; for ADHD, it is an effective treatment. I can help with other things, schizophrenia and depression. There is a list of peer-reviewed science here: https://safernicotine.wiki/mediawiki/index.php/Nicotine_therapeutic_benefits. Not to mention that every military in the world included nicotine in rations and snuff for submariners (since smoking was not possible due to hydrogen from batteries); they would not have gone to such expense if it was not beneficial to highly stressed young soldiers. These reasons mean that some people will use nicotine, so safer options are a win. Nicotine cannot be eradicated as some would wish. Trying to do so will result in uncontrolled illegal sales and crime (please see Australia if you have any doubts). To do the right thing and reduce harm as far as possible, you must look at all this and do your best. There is no clear path; there are always unintended consequences (thankfully, safer nicotine products are very non-deadly compared to cigarettes, so the remaining risk equates to being dependent (this happens with caffeine/coffee/energy drinks with little fuss)). So you have a chance to do what is right by the people you work for, and the NHS, even if it doesn’t fit entirely with popular opinion (partly due to worldwide campaigns by Mike Bloomberg and associated NGOs, they were caught trying to influence government https://mb.com.ph/2021/08/30/local-anti-vaping-groups-also-received-millions-of-grant-money-from-bloomberg/ Bloomberg has also stated “I don’t care if vapes are safer. I want them shut down no matter what” Public health heavyweights and scientists alike have offered to present evidence proving the good from vaping/THR, but have been ignored (repeatedly), Bloomberg’s view seems based not on data, but ideology.&lt;br /&gt;
&lt;br /&gt;
Needless to say, the tobacco and vapes bill is generational prohibition; by the modelling done, it will not do anything until it restricts sales (2040 before results are seen); it risks creating an illegal market and other prohibition-related problems; we can look to Australia to see the sorts of things to expect. Getting vapes out to older adult cigarette users will give results from day one; as soon as someone switches to vaping, the risk of cancer and disease begins to fall. That relieves pressure for treatment from the NHS, which can only be good.&lt;br /&gt;
&lt;br /&gt;
As I see it, you need to stop and take a hard look at the sin tax (it will put folks off switching and give the impression vapes are as bad as smoking) and the tobacco and vapes bill, then it shouldn’t be challenging to find something better. I think vapes should remain tax-free to encourage switching. However, users might put up with a small amount to improve enforcement of underage sales and illegal vapes. (Though there are things that can be done to reduce the waste from disposables by a factor of 10) some ideas in this letter https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb_2023.pdf&lt;br /&gt;
&lt;br /&gt;
One last point, the UN considers harm reduction for drug users to be a human right, and nicotine is a drug. This means that because harm reduction options exist, all with vastly lower risk than cigarettes, you must try to make them available to those at risk from the more harmful combusted tobacco.  &lt;br /&gt;
Please feel free to ask questions. I will always try to help if possible. Likewise, if you require evidence to support anything I have said, please ask. Alternatively, you can verify with your own research if you wish. Yours sincerely,Richard Pruen|Draft letter Wes Sweeting]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email 6th sept DHSC reply.pdf|thumb|alt=Sirs, Please find my reply inline in answer to your comments below. It is rather long, but a great deal of misinformation needs correcting.   On Fri, 2024-09-06 at 10:51 +0000, Department of Health and Social Care wrote:   Our ref: DE-1524319   Dear Mr Pruen,   Thank you for your correspondence of 5 August about vaping. I have been asked to reply.  I appreciate your concerns.  The Government recognises the role that vapes can play as a smoking quit aid and it is not its intention to restrict the accessibility of vapes to adults in the upcoming Bill.  Any measures brought forward through the upcoming Bill will be designed to curb youth vaping whilst having a minimal impact on adult vapers. The number of children vaping has tripled in the last three years, with one in five having used a vape in 2023, and the Government’s aim is to stop future generations from becoming hooked on nicotine.   Regarding the number vaping, very small number tripled is a very small number, for comparison please see the following graph (30 day use for various places) this includes a lot of experimental use that does not lead to dependence, and is sadly a part of growing up, adolescents try adult things (including alcohol at higher rates than vaping, causing deaths). Vaping won&#039;t cause any deaths at least, unlike cigarettes (few but fires do happen).    As can be seen the rates of infrequent use are the lowest in the UK, and highest in Australia (excluding the blip in the USA). I do not believe this is a coincidence, it reflects the regulation and illegal sales, the UK and Australia being at opposite extremes.  Here in the UK vaping is regulated and most sales are legal, from shops that have every reason to restrict sales to adolescents. In Australia the product is illegal without prescription, and 92% of the supply is via illegal sales, leading to firebombings and gang warfare. Illegal sales have every incentive to break the law, and sell to anyone with the cash. Illegal products are entirely unregulated.  We need to remain in control of sales, since it is working, the UK has the lowest use among adolescents. Changes risk sending more sales to the illegal market, and reducing control over sales. This will have the opposite effect to the one you intend and result in more sales being illegal and thus more sales to underage.  More enforcement of the existing rules, and work to reduce illegal sales would be welcome, and I suggest more useful than further restrictions in remaining in control.        Absolutely do not follow Australia, that method/type of control is proven a failure.     In the data above from ASH, we can see that 0.8% young people are vaping regularly having not also been a smoker, vaping is vastly safer than smoking, diverting them from cigarettes is a highly positive outcome.  Given the data, and we must rely on data and facts here, all but 0.8% are diverted from cigarettes, and that means virtually no smoking naive youth are going on to regularly vape. This quite near to the ideal situation, changes in legislation that might make this worse (by increasing illegal sales) should be avoided.  If it is working, don&#039;t fix it?   While it is certainly true that adults prefer fruit and sweet flavours, many flavours on the market are overly appealing to children.Evidence shows that children are attracted to the fruit and sweet flavours of vapes, both in their taste and smell, as well as how they are described. Many flavours have attractive wording and names that entice children to try vaping, such as ‘gummy bear’ and ‘rainbow burst’.  Nonsense, gummy bears are a sweet from my childhood, they may exist still, but I would buy that, I contest that is targeted at memories of adults. You might have more information on this, you should speak to the actual consumers of the product before jumping to easy sounding conclusions. New Nicotine Alliance are a charity funded exclusively by consumers and represent them, they would be a great point of contact. A consumer only org eliminates possible issues with manufacturer or even tobacco company influence.    The Government is aware that vape flavours are an important consideration for adult smokers when seeking to quit smoking and it will carefully consider any restrictions to avoid unintended consequences. The primary purpose of the Tobacco and Vapes Bill is to reduce smoking rates by bringing forward a generational ban on the sale of tobacco, making it an offence for anyone to sell tobacco products to anyone born on or after 1 January 2009. This policy is not being implemented for vapes because the health advice is clear that vaping is less harmful than smoking; however, vaping is not risk-free and nor is the consumption of nicotine.  https://x.com/JonathanFoulds/status/1829195343780819169    The tobacco part of the bill is irrelevant according to this, and economists everywhere, cigarettes are going away. By the time the generational ban has any effect, there will have been no uptake of smoking for some years, and thankfully that will result in faster reductions in death and disease. The Generational ban is too slow, no effect for more than 20 years, but thankfully, THR (tobacco harm reduction) will have more effect and way faster, it has already begun as above.      Nicotinecauses addiction rapidly and can increase the risk of developing conditions such as cardiovascular disease, gastrointestinal disorder and more rapid development of some cancers. Giving up nicotine is very difficult, and withdrawal symptoms can include cravings, irritability, anxiety, trouble concentrating, headaches and other mental symptoms. Evidence also suggests that the brain in adolescence is more sensitive to the effects of nicotine, so there could be additional risks for young people. That is why it is vital that vapes are only used as a smoking cessation tool.    Vapes are an effective quit tool for smokers, particularly when combined with behavioural support. Therefore, it is important that vapes remain accessible to adult smokers. The Government remains fully committed to the Swap to Stop scheme, which involves swapping cigarettes for vapes.    This part is shocking, and awful both at the same time. The misinformation presented to government is terrible. There is no good evidence that nicotine outside smoking increases the risk of cardiovascular disease, in fact long term studies in Sweden show nicotine from Snus is not associated with increase in cardiovascular risk, nor with any sort of cancer. Since Snus has been popular for a long time the evidence is based on studies of the actual population, much more reliable than e.g. extrapolation from cell or animal studies.  Would you provide the source of this disinformation (Cardiovascular desease, gastrointestinal desease, cancer risk), and who presented it, please? This is important, the government needs true and up to date information, and sources of poor/disinformation need to be tackled.   Further there is good evidence that nicotine can treat some gastrointestinal problems, please may I have the source for your claim it is a cause. I present some peer reviewed papers below, none are industry funded. I can present more if you would like?   https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntae193/7727428 &amp;quot;Despite different mechanisms of action, both ENDS and CCs attenuated on-going colon inflammation, enhanced healing and ameliorated recovery of injured intestines of DSS-treated mice and UC patients.&amp;quot; Citation: Kastratovic N, Markovic V, Arsenijevic A, Volarevic A, Zdravkovic N, Zdravkovic M, Brankovic M, Gmizic T, Harrell CR, Jakovljevic V, Djonov V, Volarevic V. The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis. Nicotine Tob Res. 2024 Aug 5:ntae193. doi: 10.1093/ntr/ntae193. Epub ahead of print. PMID: 39101540.  https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Analysis of several studies - some animal. In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity. Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889 Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.  https://www.hindawi.com/journals/grp/2008/237185/ Smoking has a detrimental effect in Crohn&#039;s disease (CD), but this may be due to factors in smoking other than nicotine. Given that transdermal nicotine benefits ulcerative colitis (UC), and there is a considerable overlap in the treatment of UC and CD, the possible beneficial effect of nicotine has been examined in patients with Crohn&#039;s colitis. In this relatively small study of patients with active Crohn&#039;s colitis, 6 mg nicotine enemas appeared to be of clinical benefit in most patients. They were well tolerated and safe. PDF Version Citation: J. R. Ingram, J. Rhodes, B. K. Evans, and G. A. O. Thomas, Hindawi Publishing Corporation, Gastroenterology Research and Practice, Volume 2008, Article ID 237185, 6 pages, doi:10.1155/2008/237185 Acknowledgements: J. R. Ingram was supported by the Gastrointestinal Foundation Trust. SLA Pharma gave financial support to the project. The authors are indebted to Dr. J. T. Green (of Cardiff and Vale Hospitals Trust) who referred patients, and to Professor G. T. Williams (GTW) who performed all histological assessments.   Regarding nicotine addiction, the DSM requires significant harm as well as the difficulty in stopping use, the safer forms of nicotine do not pose sufficient risk/harm by that definition. Tobacco when smoked certainly does pose sufficient risk, thus addiction is justified. Loss of autonomy is not sufficient harm, though it does require consideration, if it where caffine in coffee would be addictive, not the more reasonable dependency forming.  For the dependency of nicotine, your information appears out of date, I will deffer to Karl Fagerstrom, world leading expert and inventor of the most used dependency test for nicotine.   Karl Fagerstrom | 14 December 2013 &amp;quot;We used to believe that nicotine is very dependence producing, but the evidence suggests that there are a number of problems with this statement. For example, animals do not self-administer nicotine as readily as they do other dependence producing drugs such as amphetamine, cocaine, and heroin (Villegier et al. 2003); nicotine is a relatively weak reinforcer in human laboratory studies (Perkins et al. 2001); abstinent smokers seem to prefer a much reduced or nicotine free e-cigarette rather than other - often stronger - nicotine-containing products like gum; and although nicotine replacement treatment is an effective aid for quitting smoking, its efficacy is moderate even in doses that replace most or all nicotine from the cigarettes formerly used (Dale et al. 1995). There is very little to no evidence for the abuse of nicotine when not delivered in a tobacco vehicle.&amp;quot;  https://nicotinepolicy.net/authors/karl-fagerstrom/dependence-on-tobacco-and-nicotine/  The above link contains more information expanding on the above, with references.   The Vaping Products Duty did not form part of the previous Government’s Tobacco and Vapes Bill. Taxation is the responsibility of HM Treasury, which ran a public consultation on the proposals for the duty from 6 March to 29 May. HM Treasury and HM Revenue and Customs are currently considering responses to that consultation. There are no plans to introduce any tax changes as part of the upcoming Bill. I hope this reply is helpful.  Thank you for the reply, it remains to be seen how useful this conversation is, it depends on your willingness to accept the evidence. Evidence is changing rapidly in tobacco and nicotine, this was not always the case, for a long time tobacco was the only source of nicotine in popular use, now that has changed (for the better with safer products, mostly not from the tobacco industry of old, I would argue).    Regarding the tax, it need to be considered alongside policy, it as proposed is a &#039;sin tax&#039; and will result in significant increase in illegal sales as tax avoidance adds to profitability, thus crime and sales to youth, as well as dissuading adults who smoke cigarettes from switching to a product that is likely to save their life. I would remind you that 30% of vape sales are illegal, I have previously written to explain some ways to reduce the impact of vapes on the environment (by a significant ten fold) and at the same time allow regulated products to out-compete the illegal products (making illegal sales nonprofitable is the easiest/cheapest control). A link o my previous letter https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb_2023.pdf  Yours sincerely,   Correspondence Officer Ministerial Correspondence and Public Enquiries Department of Health and Social Care  --------------------------------------------------------------------- ----------------------------------------------------  Please do not reply to this email. To contact the Department of Health and Social Care, please visit theContact DHSC section on GOV.UK To receive news about DHSC: sign up to our monthly newsletter This e-mail and any attachments is intended only for the attention of the addressee(s). Its unauthorised use, disclosure, storage or copying is not permitted. If you are not the intended recipient, please destroy all copies and inform the sender by return e-mail. Any views expressed in this message are not necessarily those of the Department of Health and Social Care. Please note: Incoming and outgoing email messages are routinely monitored for compliance with our policy on the use of electronic communications.  --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|reply from DHSC and reply sent]]&lt;br /&gt;
&lt;br /&gt;
[[File:20240908122716 FAO- Wes Streeting, Potential risk reductions.pdf|thumb|alt=Dear Wes Streeting,  Given the abundance of poor information circulating in Parliament, I thought I should provide an easy to understand example of what a 95% reduction is risk product can do to cancer rates. Unlike the modelling and assumptions that appear to prop up the tobacco and vapes bill, I will provide real population data from Sweden (they started using a harm reduction strategy with snus years ago, enough that real world data is available).    You can verify these graphs by visiting https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Main_Page  The use of nicotine in Sweden is roughly the EU average at 22%, but much of that is a product that is similar in risk to vaping, snus is also 95% or better less risky than cigarettes. Sweden in allowing some uptake by young people has seen the reductions above, snus has substituted for a much more harmful product and overall risk has fallen dramatically as seen above. The &#039;not without risk&#039; aspect of nicotine and vaping is massively overplayed, it is certainly less risky than alcohol.      As you can see above so far the UK has avoided the surge in adolescent vaping seen elsewhere, there has been a rise, but according to the latest ASH data 0.8% of frequent (&amp;gt; once per week) users are tobacco naive, so most of the increase is diversion from smoking (a good thing since if you never inhale tobacco smoke, it cannot harm you).   This begs the question; if it seems to be working, why fix it? Further restrictions will drive the product to illegal sales, and like has been seen in Australia, that results in more sales to youth, and less access for adults, exactly the opposite of the desired outcome. We already have an illegal market in oversized/over strength products roughly 30% of the market, changes will cause it to step up and supply more if it becomes profitable. Big hint here that the proposed &#039;sin tax&#039; on nicotine is guaranteed to increase illegal sales. Is the tax take in the short term favourable, with the increase in illegal sales it will prompt, compared to maximising the savings to the NHS? I would strongly suggest not!  Extending the swap to stop scheme, particularly to target older cigarette users will have a huge effect on the NHS, reductions like those in the Sweden graph above, would save more than 500 million a year (up to 1 billion, if we can match Sweden in 50% reduction in lung cancer). https://www.brunel.ac.uk/news-and-events/news/articles/How-much-could-the-NHS-save-if-people-had-healthier-lifestyles-Hundreds-of-millions-according-to-research#:~:text=One%20of%20my%20studies%20indicates,mouth%20cancer%20and%20heart%20disease.  The reduction would help cut waiting lists by 2029 as you have promised, especially if targeting the older at risk population with swap to stop. The tobacco part of the tobacco and vapes bill, that won&#039;t have had any effect by that point, and it is likely by the time it does the cigarette market will have collapsed/changed beyond recognition.    I am not sure about it collapsing, but it is becoming obvious that big changes are afoot, and it will not be good for Big Tobacco of old.  I would like to ask you to be cautious of changing regulations that we already have, and that appear to be working. Also to ensure that any further measures are well though out. The tobacco generational ban, I don&#039;t think will do any vast harm at least, it might have been a really good idea if implemented 20 years ago.  I would also draw your attention to this regarding misinformation https://safernicotine.wiki/mediawiki/index.php/File:Email_6th_sept_DHSC_reply.pdf  I have to wonder if misinformation on vaping is from tobacco companies, since as above vaping is doing a number on them? It seems this misinformation is stated without evidence usually or highly speculative evidence (rodent studies that are unsupported by the real world data). However I am happy to provide evidence for what I have said, and welcome any questions you may have, please feel free to ask.  Thank you for your time.   --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|Email FAO- Wes Streeting, Potential risk reductions]]&lt;br /&gt;
&lt;br /&gt;
[[File:APPG for Responsible Vaping Call for Evidence Form - 10 October 2024.pdf|thumb|alt=APPG for Responsible Vaping Inquiry on Vaping – Autumn 2024 CALL FOR EVIDENCE Those wishing to submit evidence to the inquiry should use this form. Submissions should be sent by email to info@responsiblevapingappg.org by 31 October 2024. Responses to individual questions should be kept to 500 words. Supporting information and evidence will also be accepted (see section 6). The APPG for Responsible Vaping is committed to transparency. The names of those organisations providing evidence, together with their submission, will be acknowledged in the final report and made available on the APPG for Responsible Vaping website. Personal information will not be released. All information gathered will be treated in accordance with the APPG’s GDPR policies. The APPG for Responsible Vaping has no links, connections or other engagement with the tobacco industry. If any tobacco company provides a submission to the APPG inquiry, as per guidance on requirements of article 5.3 of the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC), it will not be considered. About your organisation Q. Please provide your name and the name of the organisation that you are representing including contact details. Please indicate if you are responding in a personal capacity. I am representing myself as a consumer Q. Please outline your organisation’s field of interest/area of expertise in vaping including the relevant sector you represent e.g. public health, retail, manufacturer, regulator etc. I am a consumer of vaping products, I wish to present a consumer view Key Lines of Inquiry 1. The health impact of vaping including current application and usage 1a. Please provide comment and evidence to show the health impact of vaping including how, when and by whom such products are used, and their effectiveness or otherwise. Vaping provides a vastly safer alternative to combustible tobacco, both for current cigarette users, and for anyone who would start using riskier forms of tobacco. 1b. How should the government and others in public health treat vaping as part of the Smoke Free 2030 strategy and other health interventions? Vaping has a vastly lower and different risk profile to tobacco, the rules for tobacco are suitable for tobacco only (due to the extreme harm, and long lead time to that harm). Vaping must be treated separately and law must reflect the fact that it is at least twenty times safer than cigarettes. The risk is actually substantially lower, given use over 15 years has shown little problem. Vaping is capable of displacing cigarettes from the market, this has already begun.1c. And what are the barriers to this happening at present and in the future? focus on the generational ban as the go to policy, this will not do anything in time for the 2030 strategy, and the vapes part of it needs to avoid preventing switching, and any further restrictions favour expanding the illegal market. 2. Challenges facing the vape sector, including youth access and the environment 2a. How should we tackle issues relating to youth vaping? Please provide details of your experiences and supporting evidence including examples of effective interventions or other work, including from other sectors or countries. What else should the government, regulators, retail and vape sectors be doing in this regard and what does an effective strategy look like? Youth are already prevented from legally purchasing vapes, and the uptake of regular use &amp;gt; 1 time a week is 0.8% and not trending quickly in any direction. Keeping legal vapes on the market and available more freely than illegal ones is key, illegal vapes will only be sold if profitable, the cheapest control for illegal sales is to have legal products that prevent illegal products being profitable. Vaping is at least 20 times safer than cigarettes, and has an off ramp in tapering, while use is undesirable, it is still very much better than cigarettes for those determined to use nicotine. 2b. How should we tackle issues relating to the environmental impact of vaping. Please provide comment and evidence on the effectiveness of the current environmental legislative regime, such as the WEEE Directive, whether this is fit for purpose or what changes need to occur. I wrote to APPGVaping before with some ideas here is the letter from 28th feb 2023 this would also help suppress the illegal oversize devices, and reduce waste by a factor of ten times. https://safernicotine.wiki/mediawiki/index.php/File:Email_to_appg_vaping_28th_Feb _2023.pdf 2c. What other measures or schemes could be considered to improve the environmental impact of vaping? Is there, for example, a need to consider innovative take-back schemes together with financial penalties or incentives on the consumer, retailer and manufacturer, and what is the role for government and regulators? disposables should be discouraged, having a rewarded return scheme, and improving the design. For example I released a metal free pod that the part thrown away is entirely safe to throw away, the two tiny graphite contacts are the only parts that do not biodegrade quickly https://x.com/PruenRichard/status/1729128256329154749 It is dedicated to public domain so anyone can use for any purpose. 2d. Will the government’s likely proposal to ban single use or disposable vapes be beneficial in tackling youth vaping and the environmental impact of vaping? Are there potential consequences that need to be understood and explored? Please explain and evidence yourcomments. No it will likely drive all disposable sales to illegal markets (30% is already oversized/strength disposables) This will result in easier availability to underage due to no age of sale law being followed and greater risk due to untested products. This needs to be considered, a ban will increase danger. 2e. How can challenges relating to the growth of the illicit vape market be addressed and what role is there for government, regulators, law enforcement, retail, vape manufacturers etc? The regulated legal market is the best way to ensure it is not profitable to sell illegally, this has zero cost to implement. Ensure legal products are desirable and useable enough and there is no profit in illegal products. 2f. In recent years, there has been a significant increase among smokers believing that vaping is as harmful as tobacco use. Why has this come about, what are the risks with this and how can such misconceptions be addressed and corrected? Media focus on harms. This needs media and facts targeted particularly at older adults to get them facts and encourage then to switch as soon as possible. There is no other policy that can reach the most at risk population, older adults facing smoking related issues, the sooner they switch the better. 3. The economic impact of vaping towards public health, retail sector and wider economy 3a. What evidence can you share that highlights the economic impact of vaping, both positive and negative, towards the various sectors listed above. Having it be cheaper for the consumer is another reason to switch, the risk reduction is enormous so a large incentive is warrented to incentivise switching. 3b. What impact will the government’s likely course of legislative action (proposed ban on single-use vapes, banning advertising and branding as well as potential restrictions on vape flavours and retail display) on vaping have on the economic impact of vaping? Youth regular vaping is 0.8% and it might reduce that to 0.5% at best, meanwhile it will prevent many adults from switching, the adults still smoking face death 50% of the time. None of the youth starting will face death from vaping in the short or medium term, and unlikely to face death in the long term. The youth gain little for a lot of adult death. An annoying dependence VS 50% chance of death, these need to be weighted properly. 4. Proposed government legislative measures including flavours, packaging, display, excise and a ban on certain vaping products 4a. Please comment on the government’s likely proposed measures for regulating the vapesector including a ban on single-use vapes and a graduated excise regime – please indicate where you support or oppose such steps and your views on their likely consequences. as above the risk to youth and adults must be propperly considered. The risk of increasing illegal sales as well, it can be seen from Australia that demand exists and supply will meet it. Far better legal regulated vapes than illegasl ones. Flavours are vital for adults and any youth determined to try vapes will use whatever is available, it is unlikely to change the decision they make. 4b. Please comment on the government’s potential measures around packaging, display and flavours – please indicate where you support or oppose such steps including your views on their likely consequences (the APPG recognises that the government is still to publish full details around a number of these measures). Packaging/flavours should be no more restricted than the far worse alcohol, or other adult goods, if age of sale is acceptable for alcohol, and yet deaths occur in under 18s then a product without deaths and unlikely in the extreme to cause any, it doesn’t make logical sense. one puff in 30 days but 0.8% regular use indicates vapes are not as sticky as cigarettes, as most trials do not proceed to regular use. Risk reduction, because risk elimination is not possible. 4c. What are the risks, if any, to achieving the government’s Smoke Free 2030 ambition with its likely course of legislative action? The potential to increase the share of illegal sales, thus increasing availabity to youth, while causing adults to thing vaping is as harmful as cigarettes. Restrictions have a huge potential to cause harm, and little to do good on a whole population basis. 5. Better regulating the vape sector in the UK 5a. Please set out what in your view what would constitute a better regulated vape sector, with reference to examples from other sectors or countries. Where available, provide evidence to highlight how a particular route or measure has achieved its goals in delivering better regulation and the desired outcome. This could include responsibilities for government, regulators, retail and manufactures and both legislative and non-legislative routes. The existing rules are not too bad, they have led to the lowest youth vaping in the world and no spike in use as seen in the USA. Better enforcement of age of sale and keeping the illigal market suppressd, it would be very easy to do worse than continue as things are. 5b. Would a licensing scheme for vaping provide a better regulated sector and how could such a model work? Please provide any evidence to substantiate your comments including examples from other sectors or countries, and what would specifically need to occur to make this a feasible &amp;amp; effective scheme? 500 words No vapes should be available wherever cigarettes are available and with preferably less restrictions. The existing laws are good as they are, slightly favouring display of vapes over tobacco. Restrictions on vapes will make tobaccomore appealing in comparison, and tobacco is 20 times worse. 6. Other 6a. Please use this space to set out any other information or comments that you like to submit that you do not feel have been adequately covered by the above. Respondents can also submit an attachment. 500 words general supporting evidence attached Youth vaping is well under control and there are no sudden or worying trends or fad use. This is possibly as good as it gets, more restrictions are lilkey to make things worse (increasing illegal markets) Regular use very low and has been the same for several years|Response to APPG call for evidence]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email-response-reply-DHSC-26-oct-2024-draft2.pdf.pdf|thumb|alt=Thank you for the reply, please find my response inline.   On Thu, 2024-10-24 at 17:26 +0000, Department of Health and Social Care wrote: &amp;gt; Our ref: DE-1529395 &amp;lt;cut&amp;gt;  We also remain fully committed to our Swap to Stop scheme, which sees up to one million adult smokers being encouraged to ‘swap to stop’, swapping cigarettes for vapes under the national scheme – the first of its kind in the world.   Very glad to hear this, as suggested before I hope you would consider putting extra focus on reaching older cigarette users, they are the group most directly facing health harms, and the generational ban does nothing for them ever. The possibility exists to eliminate a huge amount of disease and death. With savings to the NHS year on year because cancer treatments are expensive.   On the subject of the tobacco and vapes bill, I don&#039;t see the big rush the likes of ASHuk promote, by the time the legislation has any effect the 2030 smoke free deadline will have passed. IMHO it is better to take the time and get it right, than to rush through damaging regulations. Clive Bates provides good reasons here: https://clivebates.com/uk-tobacco-and-vapes-bill-a-misfire-and-a-backfire/    In addition, NHS programmes delivering nicotine replacement therapy are helping thousands of adults each year to live healthier lives with adult smoking rates dropping by more than half in the last three decades.  Good, the more low risk options available the more likely people will find an acceptable one, and thus not die.   Whilst vapes can be an effective quit aid for adult smokers, we are concerned about the worrying rise in vaping among children, and there are legitimate concerns about the unknown long-term harms from vaping.  There has not been a significant rise in regular use of vapes (once a week or more) certainly nothing sudden or panic worthy. The Please see this graph:      With 20 years of use, biomarker data, 16 years of popular use mostly in ex cigarette users, you are vastly overstating the remaining risk. Vaping is not likely to cause cancer of any kind (cancer potential 0.004% of smoking, a robust body of evidence https://safernicotine.wiki/mediawiki/index.php/Nicotine_-_Myth_-_Nicotine_Causes_Cancer)   At this stage any possible risks are sure to be minor, the type that may cause discomfort or be annoying, but extremely unlikely to be life threatening. Science has moved on since cigarettes where found harmful, there is also real world population data from Sweden on reduced risk products and the effect. No need for modelling, there has been enough time to see the results in the eurobarometer.     Vapes can do the same in the UK, or legalise Snus and copy Sweden, either way would work. As long as the you do not ban the good, while trying to achieve the perfect (resulting the disaster of more cigarettes). Ideally legalise Suns alongside vapes and transition those who will not vape to that, and cut deaths faster.  Disposable vapes play a significant role in driving youth vaping with 54 per cent of current vapers aged 11-to-17 in Great Britain using them. They are easily available, cheaply priced and come in enticing colours and flavours. Additionally, they cause significant environmental harm with five million disposable vapes being either littered or thrown away in general waste every week. Given the level of environmental harm, the Department for Environment, Food and Rural Affairs is reviewing proposals to restrict the sale and supply of disposable vapes and will shortly outline its plans. Reusable and refillable products will remain available to help support smokers to switch and we do not have any plans to restrict vapes, for instance, to prescription only channels.  There is absolutely no reason to punish the thousands of adults who will be put off from vaping, for 54% of 0.8% (youth vapers who never used cigarettes). Half of those adults not switching will die, while the youth will need to taper off nicotine using refillable vapes built in off ramp, cigarettes do not have that.  Meanwhile according to NHS digital 2022 (graph below) 8% of 11-16 year old&#039;s have been drunk 3 or more times, vape are very effectively kept out of young peoples hands compared to that. There is no mass moral panic about alcohol, alcohol is far more deadly than vapes  You need to sort priorities out, because the evidence doesn&#039;t support the focus on vapes.      Enforcement of our regulations is vital. This is why we will ensure that the Tobacco and Vapes Bill contains new powers for trading standards, to take more immediate action to prevent the sale of vape to children and stop illicit products.  That is great, underage sales need to be kept low, so does the illegal sale of unregulated vapes.  In addition to local enforcement action, we are also providing £3million of funding over two years for Operation Joseph to reduce the sale of illegal vapes and nicotine containing vapes to under 18s. Operation Jospeh has been increasing funding at ports to ensure trading standards can conduct large seizures of illicit vapes before they enter the country.  Great, but ensuring a legal market of products people want and find acceptable will mean illegal sales are unprofitable, there is also no cost to the government to enforce that. Restricting adults choices of flavours and full plain packaging will result in demand, the proposed sin tax will increase profitability, Australia at the time of writing has had 130 firebombings in the vapes turf war, do not bring that sort of insanity here, learn from their mistakes.  Marketing is already restricted, and no reputable company targets underage users, they would be boycotted out of existence by consumers because they will not put up with youth targeting (I have seen this several times and it is very effective).  Any genuinely youth appealing marketing or packaging can be dealt with under existing rules against advertising the product. It is while consumers are on side you can rely on this, if like Australia restrictions mean the public support the illegal market, then things will go badly here, just like Australia.   I also worry the focus on vaping will detract from youth alcohol and drug prevention. Both these cause significant deaths, vaping doesn&#039;t even intoxicate, nor will it cause young people to die.   The Department has previously published a call for evidence, a policy paper and a response to the public consultation on tobacco and vaping measures. All of these contain published links to evidence the Government has used in formulating policy and are relevant to many of the points you have raised. In addition to this, we work closely with organisations such as Action on Smoking and Health, public health bodies, academics, local organisations and other relevant parties to ensure that policy is based on the most reliable evidence.  With respect it would be best to rely more heavily on the reports that where done for OHID, and less on hearsay or anecdotal evidence that may be brought up in parliament. Views should be heard, but must never take precedence over a report based on evidence and backed by science.   We will be undertaking further consultations before the introduction of vaping regulations once the Tobacco and Vapes Bill has completed its parliamentary stages, and I would encourage you to respond to those consultations when they launch.   Yes thank you. You can be sure I will be taking part in such consultations where possible. I am however just a consumer and care for my Mum who has vascular dementia,   I hope this reply is helpful.   Yes thank you, it makes it clear that risk is not an easy concept, and I hope the information presented helps to provide better perspective. Please feel free to ask any questions I will do my best to clarify any points or provide extra evidence if needed.   Yours sincerely,   Correspondence Officer Ministerial Correspondence and Public Enquiries Department of Health and Social Care   --------------------------------------------------------------------- ----------------------------------------------------  Please do not reply to this email. To contact the Department of Health and Social Care, please visit theContact DHSC section on GOV.UK  To receive news about DHSC: sign up to our monthly newsletter     This e-mail and any attachments is intended only for the attention of the addressee(s). Its unauthorised use, disclosure, storage or copying is not permitted. If you are not the intended recipient, please destroy all copies and inform the sender by return e-mail. Any views expressed in this message are not necessarily those of the Department of Health and Social Care. Please note: Incoming and outgoing email messages are routinely monitored for compliance with our policy on the use of electronic communications.  --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|Email response to DHSC draft 2]]&lt;br /&gt;
&lt;br /&gt;
[[File:Email-dhsc-20-nov-2024.pdf|thumb|alt=Hi folks,  Since the government promised to be evidence led, I thought this new evidence was vital for vaping policy.  In this paper the authors examined respiratory symptoms in e-cigarette users without a history of smoking from the VERITAS cohort. While vapers reported slightly more frequent symptoms than non-vapers on the Respiratory Symptom Experience Scale, the difference was not clinically significant. Disposable e-cigarettes were the most common device type, with fruit flavors preferred by most users.  https://www.nature.com/articles/s41598-024-80221-8  The VERITAS cohort https://veritascohort.coehar.org/ aims to provide long term data on vaping in never cigarette users &amp;lt;100 cigarettes in their life, and is important because most vapers are past cigarette smokers and significant confounding exists due to this.  The first data above shows &#039;the difference between groups was not clinically significant&#039;, further proof that in the long term, vaping is vastly safer than smoking, and the effects on non-smokers are tiny, not clinically significant.  It is vital that you factor this information into policy because adults who are convinced not to switch face death 50% of the time. Adolescent nicotine use is falling, and if they do use any product, then smoking should be the least available to them, as it is the most harmful. Vaping in adolescents is lower than alcohol use, and alcohol is far more toxic in both the short and long term.  The current age of sale laws means the UK has the lowest regular use of vapes in underage in the world; we should keep doing that, but be aware that there is little harm from vaping when you compare that to the death faced by cigarette smokers.  The tax and ban policy will not work; it will lead to illegal markets, just like Australia has seen; once control is lost, it will be harder to regain. Sweden, on the other hand, did not reduce nicotine use, which is average for the EU, but has seen reductions in smoking-related diseases and cancer. They have also achieved the smoke-free goal 17 years early:    The UK will reduce death and disease more rapidly being more like Sweden than like Australia.  I would like you to focus on reducing death and disease quickly, and without sacrificing the older cigarettes smoking population, this is possible, if Sweden can do it, so can the UK.   Thank for your time.  --  Richard Pruen &amp;lt;richard@pruen.co.uk&amp;gt;|Email to DHSC 20 nov 2024]]&lt;br /&gt;
&lt;br /&gt;
DRAFT: [[File:Letter minister for health 11th Feb 2025.pdf|thumb|alt=Subject: Ongoing Vaping Policy Dear Ashley Dalton,  I am contacting you as a vaping consumer and advocate for saving lives; vaping saved my life (I am happy to share medical records to prove that), and I aim to pass that on to as many as possible. I am not paid in any way by anyone to do so. I have worked in the vaping industry, helping to develop standards and testing against them (I ran BTC battery testing until 2016). This was good for consumer safety, but the industry did not necessarily favour it. I am also part of a group funded by ASH advocating for smoking cessation in people living with severe mental illness; 40% smoke cigarettes, double the national number.  I was disturbed to hear some of the testimony given in parliament. Much of the information was incorrect or deliberately misleading. You must do better when debating a serious health matter; accurate and science-backed information is critical to saving lives. You should use the research OHID paid for using taxpayers&#039; money, not anecdotal (often second-hand) accounts from teaching staff or parents frightened by the media. Consumers are not represented; I would ask you to consider involving NNA (New Nicotine Alliance) as they are a consumer-only group that is not funded by the industry. info@nnalliance.org Charity Registration Number: 1160481. It seems fair since UKVIA (industry trade association) and tobacco control NGOs were involved, but there was no one for consumers.    Sadly, the media is almost all negative and presents harm because that sells papers; the truth is that in 12 years of monitoring by the MHRA yellow card early warning system, not one single disease/symptom has been detected as linked to vaping nicotine. There have been less than 20 admissions to hospital per year, and none fatal, compared to 15 per day for household cleaners (some sadly fatal).    I agree that you should keep a close eye on frequent vaping among adolescents; thankfully, that remains low and does not show worrying trends (see graphs below). Experimentation with vaping is preferable to cigarettes, and still, too many are starting to smoke tobacco. Unlike tobacco, vaping is unlikely to cause deaths since 20 years of study shows no such issue. Vaping has (with open devices) the off-ramp of tapering nicotine slowly (around a third of folks quitting smoking with vapes also stop vaping this way; see ONS data that you must have access to).   It is essential to accept the vastly lower risk from vaping when considering legislation that will steer adolescents in a particular direction. Assuming they will do extra homework if they can’t experiment is faulty. They will likely do something more risky instead, such as alcohol. Alcohol, for example, results in accidents, intoxication and deaths. This is sadly human nature, and harm reduction at least keeps the risks as low as possible. It is also vital to ensure that illicit vapes and illegal tobacco sales are kept to a minimum; buying vapes from ‘dealers’ opens all manner of unwanted possibilities, including other more harmful illegal drugs offered at the same time. Thus, great care is needed to avoid a ban on a product type resulting in supply shifting to criminal-controlled illicit sales. Australia is a perfect example of open gang war and fire bombings. A legally regulated market that renders illegal supply unprofitable is the best solution; there is no enforcement cost in that case, and consumers should be protected against entirely unregulated products.    In Sweden, the use of nicotine is about the same as in the EU as a whole, but the rates of cancer are lower, particularly in men, since they switched earlier, and the trend is now apparent in the data. It is worth looking at Sweden because it has had a harm-reduction product for a long time, and trends and population data are readily available. It is obvious that nicotine is not the problem; combusted tobacco is the killer, particularly cigarettes; switching existing users to safer products is the priority; you can save vast numbers of lives and treatment costs.   I suggest you research the history of THR in Sweden, allowing users to initiate nicotine use with a safer product works; they have the lowest cancer rates in the EU by a good margin. (see the following graphs) The UK can still do the same with vaping by not restricting it too much.     Yours sincerely,  Richard Pruen|Letter minister for health 11th Feb 2025]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78594</id>
		<title>File:Letter minister for health 11th Feb 2025.pdf</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=File:Letter_minister_for_health_11th_Feb_2025.pdf&amp;diff=78594"/>
		<updated>2025-02-11T10:43:38Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Letter minister for health 11th Feb 2025&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_therapeutic_benefits&amp;diff=78544</id>
		<title>Nicotine therapeutic benefits</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_therapeutic_benefits&amp;diff=78544"/>
		<updated>2025-02-05T09:56:35Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: /* Cardiovascular */ Add myocarditis treatment paper&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;big&amp;gt;&#039;&#039;&#039;&#039;&#039;Safer Nicotine Wiki does NOT endorse smoking for any potential therapeutic benefits. Smoking has too many severe consequences. Studies showing that fewer people who smoke end up with a specific ailment are included to show the potential benefits of the nicotine. Some of these studies show a potential benefit, not proof of a benefit. Some of the studies are animal studies, not human studies.&#039;&#039;&#039;&#039;&#039;&amp;lt;/big&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
[[File:Nic Ther Ben.png|alt=Nicotine Therapeutic benefits banner|center]]&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;big&amp;gt;&#039;&#039;&#039;Note: Some topics are subgroups under the main topic of &amp;quot;Mental Health.&amp;quot; &#039;&#039;&#039;&amp;lt;/big&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Acne&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2010 [https://ijphjournal.it/article/view/5708 Evaluation of the association between acne and smoking: systematic review and meta-analysis of cross-sectional studies]===&lt;br /&gt;
*Acne vulgaris is one of the most common skin diseases with a multifactorial pathogenesis. &lt;br /&gt;
*Our meta-analysis underlines that there is no evidence to support an association between smoking habits and acne, although in three of the good quality papers a significant protection in the current smoker was found. It necessary to be cautious in declaring that smoking may provide a protective effect in the pathogenesis of acne because the analysis was based on only a small number of studies.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.sciencedirect.com/science/article/pii/S0022202X15330153 Severe Acne Vulgaris and Tobacco Smoking in Young Men]===&lt;br /&gt;
*It is crucial to emphasize that any positive effects found must be traced to specific tobacco components that can be therapeutically used without smoking (e.g., nicotine patches or gums), to avoid any “legitimatizing” of smoking based on its beneficial effects on health.&lt;br /&gt;
*Active smokers showed a significantly lower prevalence of severe acne (0.71%) than nonsmokers (1.01%) (P=0.0078). &lt;br /&gt;
*Previous in vitro and clinical studies strongly support an association with nicotine. We suggest a trial with topical nicotine treatment for acne to further investigate this association.&lt;br /&gt;
&lt;br /&gt;
===1993 [https://academic.oup.com/ced/article-abstract/18/2/100/6629365 Does smoking influence acne?]===&lt;br /&gt;
*[https://sci-hub.se/10.1111/j.1365-2230.1993.tb00986.x PDF of full study]&lt;br /&gt;
*The findings of this study support the hypothesis that some component of cigarette smoke, possibly nicotine, has an anti‐inflammatory action on acne.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;ADD / ADHD / Attention / Cognition&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== &lt;br /&gt;
*Preclinical models and human studies have demonstrated that nicotine has cognitive-enhancing effects. Attention, working memory, fine motor skills and episodic memory functions are particularly sensitive to nicotine’s effects. &lt;br /&gt;
*High rates of smoking are observed among individuals with psychiatric disorders including schizophrenia, bipolar disorder, major depression, attention deficit hyperactivity disorder (ADHD) and comorbid substance use disorders (SUD). Because these psychiatric disorders are associated with various cognitive impairments, including deficits in attention, working memory, and response inhibition functions, the cognitive enhancing effects of nicotine may be especially important determinants of the initation and maintenance of smoking in this comorbid population. Growing evidence suggest that cognitive enhancing effects of nicotine may also contribute to the difficulty in quitting smoking, especially in individuals with psychiatric disorders.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/pdf/CN-16-403.pdf PDF Version]&lt;br /&gt;
*Citation: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Curr Neuropharmacol. 2018;16(4):403-414. doi: 10.2174/1570159X15666171103152136. PMID: 29110618; PMCID: PMC6018192.&lt;br /&gt;
&lt;br /&gt;
===2017: [https://www.tandfonline.com/doi/full/10.1080/10826084.2017.1334066 Causal Factors of Increased Smoking in ADHD: A Systematic Review]===&lt;br /&gt;
*One of the most striking comorbidities of ADHD is nicotine dependence. Youth diagnosed with ADHD are 2–3 times more likely to smoke than their peers without ADHD, initiate smoking earlier in life and progress more quickly and more frequently to regular use and dependence. Possible explanations for these increased risks are: (a) self-medication of ADHD symptoms with the stimulant nicotine; (b) ADHD symptoms like inattention and hyperactivity/impulsivity predispose for smoking initiation and impede smoking cessation; (c) peer pressure; and/or (d) common genetic or environmental determinants for ADHD and smoking.&lt;br /&gt;
*In contrast, the positive relation between ADHD and nicotine dependence is currently best explained by the self-medication hypothesis. This hypothesis has a clear pharmacological rationale and is supported by ample evidence, but awaits confirmation from longitudinal naturalistic studies.&lt;br /&gt;
*Citation: Jan van Amsterdam, Bauke van der Velde, Mieke Schulte &amp;amp; Wim van den Brink (2018) Causal Factors of Increased Smoking in ADHD: A Systematic Review, Substance Use &amp;amp; Misuse, 53:3, 432-445, DOI: 10.1080/10826084.2017.1334066 &lt;br /&gt;
&lt;br /&gt;
===2014: [https://www.medscape.com/viewarticle/827544_1 Adult Attention-Deficit/Hyperactivity Disorder and Nicotine Use: A Qualitative Study of Patient Perceptions]===&lt;br /&gt;
*Participants had different views about the link between cigarette smoking and ADHD. While the majority thought of nicotine as a sort of therapy, viewing smoking as a way to self-medicate symptoms of ADHD, motivations for nicotine use were also related to self-image, desire to belong to a peer-group, and a drive to undermine perceived social norms. Ultimately, these findings can be used by clinicians to improve treatment alliance and collaboration.&lt;br /&gt;
*[https://sci-hub.se/10.1186/1471-244x-14-141 Alternative Link]&lt;br /&gt;
*Citation: Liebrenz, M., Frei, A., Fisher, C. E., Gamma, A., Buadze, A., &amp;amp; Eich, D. (2014). Adult attention-deficit/hyperactivity disorder and nicotine use: a qualitative study of patient perceptions. BMC Psychiatry, 14(1). doi:10.1186/1471-244x-14-141 &lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150/ Cognitive enhancers for the treatment of ADHD]===&lt;br /&gt;
*Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, affecting approximately 8–9% of school-aged children and 4–5% of adults (Froehlich et al., 2007; Kessler et al., 2006; Visser et al., 2007). Although formally the disorder is characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity (APA, 2000), myriad phenotypic features—many of which are related to cognition broadly defined—have been shown to distinguish those with ADHD from those without the disorder.&lt;br /&gt;
*Together, these findings have led to the hypothesis that individuals with ADHD may smoke in order to alleviate requisite symptoms of the disorder and further suggest nicotine and/or nicotinic agonists can be used to improve aspects of cognitive function in these patients (McClernon and Kollins, 2008). Some support for this hypothesis has been provided by studies which have shown positive effects of nicotine on ADHD symptoms (Gehricke et al., 2009; Shytle et al., 2002) and cognitive performance (Levin et al., 1996; Potter and Newhouse, 2004) in non-smokers with ADHD. Whereas there are currently no FDA-approved nicotinic agonists to treat ADHD, laboratory and small-scale clinical trials have been conducted in recent years, and novel nicotinic pharmacotherapies are on the horizon.&lt;br /&gt;
*Citation: Bidwell LC, McClernon FJ, Kollins SH. Cognitive enhancers for the treatment of ADHD. Pharmacol Biochem Behav. 2011 Aug;99(2):262-74. doi: 10.1016/j.pbb.2011.05.002. Epub 2011 May 10. PMID: 21596055; PMCID: PMC3353150.&lt;br /&gt;
&lt;br /&gt;
===2009 [https://pubmed.ncbi.nlm.nih.gov/20025370/ Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder]===&lt;br /&gt;
*Nicotine reduced reports of ADHD symptoms by 8% and negative moods by 9%, independent of smoking status. In addition, nicotine increased cardiovascular activity during the first 3 to 6 hours after nicotine patch administration. The results support the self-medication hypothesis for nicotine in adults with ADHD and suggest that smoking cessation and prevention efforts for individuals with ADHD will need to address both the symptom reducing and mood enhancing effects of nicotine.&lt;br /&gt;
*Citation: Gehricke, J. G., Hong, N., Whalen, C. K., Steinhoff, K., &amp;amp; Wigal, T. L. (2009). Effects of transdermal nicotine on symptoms, moods, and cardiovascular activity in the everyday lives of smokers and nonsmokers with attention-deficit/hyperactivity disorder. Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors, 23(4), 644–655. https://doi.org/10.1037/a0017441&lt;br /&gt;
&lt;br /&gt;
===2009 [https://www.tandfonline.com/doi/abs/10.3109/15622970209150616 A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder]===&lt;br /&gt;
*All 10 subjects enrolled (six males, four females; mean age = 10 years, SEM = 0.8) completed the study. As assessed by the 48-item Conners Parent Rating Scale at endpoint and during the trial, there was a significantly greater reduction in ADHD symptoms on “Learning Problems” and “Hyperactivity” subfactors. Nausea, stomach ache, itching under patch and dizziness were the most frequently reported adverse effects associated with transdermal nicotine.&lt;br /&gt;
*Citation: R. Douglas Shytle, Archie A. Silver, Berney J. Wilkinson &amp;amp; Paul R. Sanberg (2002) A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder, The World Journal of Biological Psychiatry, 3:3, 150-155, DOI: 10.3109/15622970209150616&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.sciencedirect.com/science/article/abs/pii/S0091305707003048?via%3Dihub Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder]=== &lt;br /&gt;
*Non-smoking young adults with ADHD-C showed improvements in cognitive performance following nicotine administration in several domains that are central to [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ADHD&#039;&#039;&#039;]].&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.pbb.2007.09.014 PDF Version]&lt;br /&gt;
*Citation: Alexandra S. Potter, Paul A. Newhouse, Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder, Pharmacology Biochemistry and Behavior, Volume 88, Issue 4, 2008, Pages 407-417, ISSN 0091-3057, doi: 10.1016/j.pbb.2007.09.014.&lt;br /&gt;
*Acknowledgements: This work was supported by: GCRC M01-00109 and Targacept Inc.&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.academia.edu/2412620/Smoking_to_self_medicate_attentional_and_emotional_dysfunctions Smoking to self-medicate attentional and emotional dysfunctions]===&lt;br /&gt;
*The data from diverse studies are generally consistent with the self-medication hypothesis and suggest that individuals with ADHD may smoke to alleviate symptoms associated with attention deficit, impulsivity, and hyperactivity. More studies on larger samples are necessary to assess the differential risks for adolescent smoking initiation that are associated with ADHD subtypes and with ODD and CD comorbidities.&lt;br /&gt;
*Citation: Gehricke, J.-G., Loughlin, S., Whalen, C., Potkin, S., Fallon, J., Jamner, L., … Leslie, F. (2007). Smoking to self-medicate attentional and emotional dysfunctions. Nicotine  Tobacco Research, 9, 523–536. https://doi.org/10.1080/14622200701685039&lt;br /&gt;
&lt;br /&gt;
===2007: [https://www.academia.edu/18995031/Smoking_to_self_medicate_attentional_and_emotional_dysfunctions Smoking to self-medicate attentional and emotional dysfunctions]===&lt;br /&gt;
*(Note: Need to add summary)&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.academia.edu/17983526/The_reinforcing_effects_of_nicotine_and_stimulant_medication_in_the_everyday_lives_of_adult_smokers_with_ADHD_A_preliminary_examination The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination]===&lt;br /&gt;
*The findings suggest that smokers with ADHD experience nicotine-related reductions in ADHD symptoms during their everyday lives.&lt;br /&gt;
*Citation: Gehricke, J. G., Whalen, C., Jamner, L., Wigal, T., &amp;amp; Steinhoff, K. (2006). The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination. Nicotine  Tobacco Research, 8(1), 37–47. https://doi.org/10.1080/14622200500431619&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.sciencedirect.com/science/article/abs/pii/S0031938405005627?via%3Dihub Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits]===&lt;br /&gt;
*The results showed nicotine-induced improvement on some measures of sustained attention in the low attention group and some decrement in working memory in the high attention group, which suggests that nicotine tends to optimize rather than improve performance on cognitive tasks.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.physbeh.2005.12.011 PDF Version]&lt;br /&gt;
*Citation: D.V. Poltavski, T. Petros, Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits, Physiology &amp;amp; Behavior, Volume 87, Issue 3, 2006, Pages 614-624, ISSN 0031-9384, doi: 10.1016/j.physbeh.2005.12.011.&lt;br /&gt;
&lt;br /&gt;
===2003: [https://www.academia.edu/2412608/Is_There_a_Link_Between_Adolescent_Cigarette_Smoking_and_Pharmacotherapy_for_ADHD   Is There a Link Between Adolescent Cigarette Smoking and pharmacotherapy for ADHD?]===&lt;br /&gt;
*Self-report surveys, electronic diaries, and salivary cotinine all indicated that adolescents treated with pharmacotherapy for ADHD smoked less than their untreated counterparts over 2 years of high school. These convergent findings from 3 disparate indicators lend support to the self-medication hypothesis over the gateway hypothesis, although alternative explanations need further study. The findings also suggest that early treatment of psychological and behavioral problems may prevent or delay smoking initiation&lt;br /&gt;
*Citation: Whalen, C. K., Jamner, L. D., Henker, B., Gehricke, J.-G., &amp;amp; King, P. S. (2003). Is There a Link Between Adolescent Cigarette Smoking and Pharmacotherapy for ADHD? Psychology of Addictive Behaviors, 17(4), 332–335. https://doi.org/10.1037/0893-164X.17.4.332&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
*Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&lt;br /&gt;
===2001 [https://psycnet.apa.org/record/2001-14365-012 Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder.]===&lt;br /&gt;
*This small study (40 participants) provided evidence that nicotine treatment can reduce severity of attentional deficit symptoms and produce improvement on an objective computerized attention task.&lt;br /&gt;
*Citation: Levin, E. D., Conners, C. K., Silva, D., Canu, W., &amp;amp; March, J. (2001). Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Experimental and Clinical Psychopharmacology, 9(1), 83–90. https://doi.org/10.1037/1064-1297.9.1.83&lt;br /&gt;
&lt;br /&gt;
===1998 [https://pubmed.ncbi.nlm.nih.gov/9860103/ Transdermal nicotine effects on attention]=== &lt;br /&gt;
*This study shows that, in addition to reducing attentional impairment, nicotine administered via transdermal patches can improve attentiveness in normal adult non-smokers.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s002130050750 PDF Version]&lt;br /&gt;
*Citation: Levin ED, Conners CK, Silva D, Hinton SC, Meck WH, March J, Rose JE. Transdermal nicotine effects on attention. Psychopharmacology (Berl). 1998 Nov;140(2):135-41. doi: 10.1007/s002130050750. PMID: 9860103&lt;br /&gt;
*Acknowledgement: The authors thank R.J. Reynolds for financial support of the project. Work on this article was partially supported by Career Science Award (K05MH0122903) to Dr. Conners and Research Scientist Development Award (K02MH0098102) to Dr. March&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/8741955/ Nicotine effects on adults with attention-deficit/hyperactivity disorder]=== &lt;br /&gt;
*Nicotine caused a significant overall nicotine-induced improvement on the CGI. This effect was significant when only the nonsmokers were considered, which indicated that it was not due merely to withdrawal relief. Nicotine caused significantly increased vigor as measured by the POMS test. Nicotine caused an overall significant reduction in reaction time (RT) on the CPT, as well as, with the smokers, a significant reduction in another index of inattention, variability in reaction time over trial blocks. Nicotine improved accuracy of time estimation and lowered variability of time-estimation response curves. Because improvements occurred among nonsmokers, the nicotine effect appears not to be merely a relief of withdrawal symptoms. It is concluded that nicotine deserves further clinical trials with ADHD.&lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02246281 PDF Version]&lt;br /&gt;
*Citation: Levin ED, Conners CK, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 1996 Jan;123(1):55-63. doi: 10.1007/BF02246281. PMID: 8741955.&lt;br /&gt;
*Acknowledgement: The authors thank Dr. Allen Frances, Chairman of the Department of Psychiatry, Duke University Meidcal Center for his finanical support of the project. Work on this article was partially supported by Career Science Award (K05MH01229-03) to Dr. Conners and Research Scientist Development Award (K20MH00981-02) to Dr. March and a Young Investigator Award from the National Alliance for Research Schizophenia and Depression to Dr. Levin.&lt;br /&gt;
&lt;br /&gt;
===1996: [https://pubmed.ncbi.nlm.nih.gov/8927677/ Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)]===&lt;br /&gt;
*The present study is an acute double-blind crossover administration of nicotine and placebo with smokers (n = 6) and nonsmokers (n = 11) diagnosed with adult ADHD. The drug was delivered via a transdermal patch at a dosage of 7 mg/day for nonsmokers and 21 mg/day for smokers. Results indicate significant clinician-rated global improvement, self-rated vigor and concentration, and improved performance on chronometric measures of attention and timing accuracy. Side effects were minimal. These acute results indicate the need for a longer clinical trial and a comparison with other stimulants in adult ADHD treatment.&lt;br /&gt;
*Citation: Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, Rose JE, March J. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacol Bull. 1996;32(1):67-73. PMID: 8927677.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Aging&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.nature.com/articles/s41467-023-36543-8 Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity]===&lt;br /&gt;
*Abstract &amp;quot;Imbalances in NAD+ homeostasis have been linked to aging and various diseases. Nicotine, a metabolite of the NAD+ metabolic pathway, has been found to possess anti-inflammatory and neuroprotective properties, yet the underlying molecular mechanisms remained unknown. Here we find that, independent of nicotinic acetylcholine receptors, low-dose nicotine can restore the age-related decline of NAMPT activity through SIRT1 binding and subsequent deacetylation of NAMPT, thus increasing NAD+ synthesis. 18F-FDG PET imaging revealed that nicotine is also capable of efficiently inhibiting glucose hypermetabolism in aging male mice. Additionally, nicotine ameliorated cellular energy metabolism disorders and deferred age-related deterioration and cognitive decline by stimulating neurogenesis, inhibiting neuroinflammation, and protecting organs from oxidative stress and telomere shortening. Collectively, these findings provide evidence for a mechanism by which low-dose nicotine can activate NAD+ salvage pathways and improve age-related symptoms.&amp;quot;&lt;br /&gt;
**Citation: Yang, L., Shen, J., Liu, C. et al. Nicotine rebalances NAD+ homeostasis and improves aging-related symptoms in male mice by enhancing NAMPT activity. Nat Commun 14, 900 (2023). https://doi.org/10.1038/s41467-023-36543-8&lt;br /&gt;
***Acknowledgement: This work was supported by grants from Shenzhen Science and Technology Program (KQTD20210811090117032), Shenzhen Key Laboratory of Viral Vectors for Biomedicine (ZDSYS20200811142401005), CAS Key Laboratory of Brain Connectome and Manipulation (2019DP173024) and Guangdong Provincial Key Laboratory of Brain Connectome and Behavior (2017B030301017).&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Akathisia&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===1997: [https://pubmed.ncbi.nlm.nih.gov/9399378/ Treatment of neuroleptic-induced akathisia with nicotine patches]===&lt;br /&gt;
*We administered 14 mg nicotine patches to 16 patients, all non-smokers, who displayed akathisia from antipsychotic drugs. On single-blind ratings, akathisia appeared significantly reduced on days when patients were wearing the patches as compared to the baseline day. These findings, if confirmed, may help to explain the high rates of tobacco use among psychotic patients, and may suggest avenues for the treatment of akathisia.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s002130050436 PDF Version]&lt;br /&gt;
**Citation: Anfang MK, Pope HG Jr. Treatment of neuroleptic-induced akathisia with nicotine patches. Psychopharmacology (Berl). 1997 Nov;134(2):153-6. doi: 10.1007/s002130050436. PMID: 9399378.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Alcohol Use Disorder&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://onlinelibrary.wiley.com/doi/10.1111/acer.15103 Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco]===&lt;br /&gt;
*Our findings may indicate that nicotine has anti-inflammatory effects in patients with AUD.&lt;br /&gt;
**Citation: Bolstad I, Lien L, Moe JS, Pandey S, Toft H, Bramness JG. Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco. Alcohol Clin Exp Res (Hoboken). 2023 Jul;47(7):1352-1363. doi: 10.1111/acer.15103. Epub 2023 May 30. PMID: 37208927.&lt;br /&gt;
***Acknowledgement: This work was financially supported by The Research Council of Norway, grant FRIPRO 251140.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Allergies / Hayfever / Histamines&#039;&#039;&#039; (See also: Hypersensitivity Pneumonitis / Extrinsic Allergic Alveolitis)=&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203434/ Suppressive effect of environmental tobacco smoke on murine Th2 cell-mediated nasal eosinophilic inflammation]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*In this study, the effect of environmental tobacco smoke (ETS) on allergen-immunized and allergen-specific Th2 cell-transferred murine eosinophilic inflammation models and that of cigarette smoke extract (CSE) and nicotine on allergen-induced Th2 cell proliferation and interleukin (IL)-4 production were investigated.&lt;br /&gt;
*In summary, ETS suppressed allergen-induced nasal responses including NHR by inhibiting allergen-specific Th2 cell responses. Although our present findings do not deny harmful effects of cigarette smoking, nicotine as a component of ETS may be a target to treat Th2-mediated allergic diseases, including allergic rhinitis (AR).&lt;br /&gt;
**Citation: Nishimura T, Kaminuma O, Saeki M, Kitamura N, Mori A, Hiroi T. Suppressive effect of environmental tobacco smoke on murine Th2 cell-mediated nasal eosinophilic inflammation. Asia Pac Allergy. 2020 Apr 27;10(2):e18. doi: 10.5415/apallergy.2020.10.e18. PMID: 32411583; PMCID: PMC7203434.&lt;br /&gt;
***Acknowledgement: This work was supported in part by funding from the Smoking Research Foundation provided to Osamu Kaminuma.&lt;br /&gt;
&lt;br /&gt;
===2017: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440386/ Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium]===&lt;br /&gt;
*Our results suggest that smoking may be causally related to a higher risk of asthma and a slightly lower risk of hay fever. However, the adverse events associated with smoking limit its clinical significance.&lt;br /&gt;
**Citation: Skaaby T, Taylor AE, Jacobsen RK, et al. Investigating the causal effect of smoking on hay fever and asthma: a Mendelian randomization meta-analysis in the CARTA consortium. Sci Rep. 2017 May 22;7(1):2224. doi: 10.1038/s41598-017-01977-w. PMID: 28533558; PMCID: PMC5440386.&lt;br /&gt;
***Acknowledgement: This work was supported by the Medical Research Council (grant numbers: MR/J01351X/1, MC_UU_12013/6). The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk).&lt;br /&gt;
&lt;br /&gt;
===2014: [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085888 Anti-allergic role of cholinergic neuronal pathway via α7 nicotinic ACh receptors on mucosal mast cells in a murine food allergy model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*In this study, nicotine treatment significantly ameliorated FA [Food Allergy], mainly due to the suppression of upregulated mucosal immune responses via α7 nAChRs on immune cells. Therefore, the therapeutic effects of nicotine and GTS-21 on the FA model raise the possibility that a strategy for drug discovery against FA by targeting α7 nAChRs could potentially have therapeutic benefits.&lt;br /&gt;
**Citation: Yamamoto T, Kodama T, Lee J, Utsunomiya N, Hayashi S, Sakamoto H, Kuramoto H, Kadowaki M. Anti-allergic role of cholinergic neuronal pathway via α7 nicotinic ACh receptors on mucosal mast cells in a murine food allergy model. PLoS One. 2014 Jan 16;9(1):e85888. doi: 10.1371/journal.pone.0085888. PMID: 24454942; PMCID: PMC3894205.&lt;br /&gt;
&lt;br /&gt;
===2008: [https://journals.aai.org/jimmunol/article/180/11/7655/84640/Nicotine-Primarily-Suppresses-Lung-Th2-but-Not Nicotine Primarily Suppresses Lung Th2 but Not Goblet Cell and Muscle Cell Responses to Allergens]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*hese results suggest that nicotine modulates allergy/asthma primarily by suppressing eosinophil trafficking and suppressing Th2 cytokine/chemokine responses without reducing goblet cell metaplasia, mucous production, and may explain the lower risk of allergic diseases in smokers. To our knowledge this is the first direct evidence that nicotine modulates allergic responses.&lt;br /&gt;
**Citation: Neerad C. Mishra, Jules Rir-sima-ah, Raymond J. Langley, Shashi P. Singh, Juan C. Peña-Philippides, Takeshi Koga, Seddigheh Razani-Boroujerdi, Julie Hutt, Matthew Campen, K. Chul Kim, Yohannes Tesfaigzi, Mohan L. Sopori; Nicotine Primarily Suppresses Lung Th2 but Not Goblet Cell and Muscle Cell Responses to Allergens1. J Immunol 1 June 2008; 180 (11): 7655–7663. https://doi.org/10.4049/jimmunol.180.11.7655&lt;br /&gt;
***Acknowledgement: This work was supported in part by grants from the National Institutes of Health (R01-DA017003, R01-DA04208-15, and R01-DA042087S).&lt;br /&gt;
&lt;br /&gt;
===2004: [https://link.springer.com/article/10.1007/s00011-004-1249-1 The effect of nicotine on basophil histamine release]===&lt;br /&gt;
*This study has demonstrated that nicotine agonists inhibit histamine release from human basophils.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s00011-004-1249-1 PDF Full Version]&lt;br /&gt;
**Citation: Thompson-Cree, M.E.M., Stevenson, M.R., Shields, M.D. et al. The effect of nicotine on basophil histamine release. Inflamm. res. 53, 211–214 (2004). https://doi.org/10.1007/s00011-004-1249-1&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Alzheimer / Dementia / Mild Cognitive Imparement (MCI)&#039;&#039;&#039;= &lt;br /&gt;
===2013 [https://link.springer.com/article/10.1007/s12017-013-8242-1 Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these results demonstrate that nicotine prevents memory deficits and synaptic impairment induced by Aβ oligomers. In addition, nicotine improves memory in young APP/PS1 transgenic mice before extensive amyloid deposition and senile plaque development, and also in old mice where senile plaques have already formed.&lt;br /&gt;
*[https://sci-hub.st/https://link.springer.com/article/10.1007/s12017-013-8242-1 PDF Version]&lt;br /&gt;
*Citation: Inestrosa, N.C., Godoy, J.A., Vargas, J.Y. et al. Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers Through α7-Nicotinic Acetylcholine Receptor Activation. Neuromol Med 15, 549–569 (2013). doi: 10.1007/s12017-013-8242-1&lt;br /&gt;
*Acknowledgements: We thank Dr. Rodrigo Varas for his help with the electrophysiological studies of the α7-nAChR. This work was supported by a grant from FONDECYT No 120156 to N.C.I; predoctoral fellowships from CONICYT to G.G.F., M.S.A. F.G.S., J.A.R. and from Fundación Gran Mariscal de Ayacucho to J.Y.V. The Basal Center of Excellence in Science and Technology CARE was funded by CONICYT/PFB 12/2007.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/ Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== &lt;br /&gt;
*The secondary outcome measures showed significant nicotine-associated improvements in attention, memory, and psychomotor speed, and improvements were seen in patient/informant ratings of cognitive impairment. &lt;br /&gt;
*Safety and tolerability for transdermal nicotine were excellent. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466669/pdf/znl91.pdf PDF Version]&lt;br /&gt;
*Citation: Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb. PMID: 22232050; PMCID: PMC3466669.&lt;br /&gt;
&lt;br /&gt;
===2010 [https://www.tandfonline.com/doi/abs/10.1080/13607860220126808 Nicotine&#039;s effect on neural and cognitive functioning in an aging population]=== &lt;br /&gt;
*Recent advances in nicotine research have pointed to a number of cognitive and neurological benefits that have been linked to the ingestion of nicotine.&lt;br /&gt;
*This article examines cognitive decline in the elderly and looks at nicotine&#039;s potential role in ameliorating this decline.&lt;br /&gt;
*Nicotine’s effects on cognitive functioning have shown it to increase perception, visual attention,and arousal as well as improving the speed and accuracy of motor functioning while decreasing reaction time and inhibiting declines in efficiency. In addition, research has shown nicotine to improve long-term and short-term memory, and to increase the ability to withhold inappropriate responses.&lt;br /&gt;
*Research has revealed that chronic exposure to nicotine produces an unusual up-regulation of the nicotinic receptor sites. This increase in receptor sites is thought to provide some protection against neuro-degenerative disorders such as Alzheimer’s disease.&lt;br /&gt;
*[https://sci-hub.st/10.1080/13607860220126808 PDF Version]&lt;br /&gt;
*Citation: K. N. Murray &amp;amp; N. Abeles (2002) Nicotine&#039;s effect on neural and cognitive functioning in an aging population, Aging &amp;amp; Mental Health, 6:2, 129-138, DOI: 10.1080/13607860220126808&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12436427/ Nicotinic receptors in aging and dementia]=== &lt;br /&gt;
*Nicotine and nicotinic agonists have been shown to improve cognitive function in aged or impaired subjects.&lt;br /&gt;
*Acute nicotine administration can improve performance of patients with AD on cognitive tasks, including verbal learning and memory, attention in a continuous performance task, and accuracy in a visual attention task.&lt;br /&gt;
*In addition to its ability to reverse cognitive deficits following aging, nicotine has been shown to protect against neurotoxic insult in vitro and in vivo. This suggests that nicotine has a dual effect on brain function following aging or injury, such that it can rescue function of remaining neurons, as well as saving neurons that might otherwise undergo cell death.&lt;br /&gt;
*[https://sci-hub.st/10.1002/neu.10102 PDF Version]&lt;br /&gt;
*Citation: Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol. 2002 Dec;53(4):641-55. doi: 10.1002/neu.10102. PMID: 12436427.&lt;br /&gt;
*Keywords: nAChR; neuroprotection; Alzheimer’s disease; Parkinson’s disease; acetylcholine&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
*Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Alzheimer&#039;s disease (AD)&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1410164/ Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer&#039;s disease]=== &lt;br /&gt;
*Nicotine significantly improved sustained visual attention (in both RVIP and DRMLO tasks), reaction time (in both FT and RVIP tasks), and perception (CFF task--both ascending and descending thresholds). &lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02247426 PDF Version]&lt;br /&gt;
*Citation: Jones GM, Sahakian BJ, Levy R, Warburton DM, Gray JA. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer&#039;s disease. Psychopharmacology (Berl). 1992;108(4):485-94. doi: 10.1007/BF02247426. PMID: 1410164.&lt;br /&gt;
*Acknowledgements. This research was supported by British-American Tobacco Co. Ltd. BJS thanks the Wellcome Trust and the Eleanor Peel Foundation for support. &lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in enhancement of performance, and protection against  Alzheimer&#039;s disease (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1989 [https://pubmed.ncbi.nlm.nih.gov/2597885/ The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type]=== &lt;br /&gt;
*Nicotine in patients with dementia of the Alzheimer type (DAT) produced a significant and marked improvement in discriminative sensitivity and reaction times on a computerised test of attention and information processing. Nicotine also improved the ability of DAT patients to detect a flickering light in a critical flicker fusion test. These results suggest that nicotine may be acting on cortical mechanisms involved in visual perception and attention, and support the hypothesis that acetylcholine transmission modulates vigilance and discrimination. Nicotine may therefore be of some value in treating deficits in attention and information processing in DAT patients. &lt;br /&gt;
*[https://sci-hub.st/10.1192/bjp.154.6.797 PDF Version]&lt;br /&gt;
*Citation: Sahakian B, Jones G, Levy R, Gray J, Warburton D. The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry. 1989 Jun;154:797-800. doi: 10.1192/bjp.154.6.797. PMID: 2597885.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Aphthous ulcers&#039;&#039;&#039; (See also: Behcet&#039;s disease)= &lt;br /&gt;
&lt;br /&gt;
===2015: [https://pmc.ncbi.nlm.nih.gov/articles/PMC4387635/ Use of pure nicotine for the treatment of aphthous ulcers]===&lt;br /&gt;
*The theory that nicotine is known as the protective factor is also supported by three case reports, in which aphthous ulcers were prevented or healed while the patients used nicotine replacement materials.&lt;br /&gt;
*To summarize, the use of pure nicotine in therapeutic forms, seems to be a proper alternative to treat aphthous ulcers; however, there has not been any evidence-based case-control study to prove such claim.&lt;br /&gt;
**Citation: Motamedi MR, Golestannejad Z. Use of pure nicotine for the treatment of aphthous ulcers. Dent Res J (Isfahan). 2015 Mar-Apr;12(2):197-8. PMID: 25878688; PMCID: PMC4387635.&lt;br /&gt;
&lt;br /&gt;
===2014: [https://pubmed.ncbi.nlm.nih.gov/25584320/ Recurrent aphthous ulcers among tobacco users- hospital based study]===&lt;br /&gt;
*The tobacco consumers have less frequency of aphthous ulceration compared non users.&lt;br /&gt;
**Citation: Mohamed S, Janakiram C. Recurrent aphthous ulcers among tobacco users- hospital based study. J Clin Diagn Res. 2014 Nov;8(11):ZC64-LC66. doi: 10.7860/JCDR/2014/10368.5145. Epub 2014 Nov 20. PMID: 25584320; PMCID: PMC4290331.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.sciencedirect.com/science/article/abs/pii/S0306987711001691?via%3Dihub Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis]=== &lt;br /&gt;
*In addition, nicotine or its metabolites can result in decrease of pro-inflammatory cytokines like tumor necrosis factor-α, interleukins 1 and 6, and increase of anti-inflammatory cytokine interleukin-10. Consequently, there is reduced susceptibility to RAS due to immunosuppression and/or reduction in inflammatory response.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2011.04.006 PDF Version]&lt;br /&gt;
**Citation: Subramanyam, R. V. (2011). Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis. Medical Hypotheses, 77(2), 185–187. doi:10.1016/j.mehy.2011.04.006&lt;br /&gt;
&lt;br /&gt;
===2004: [https://pubmed.ncbi.nlm.nih.gov/15370162/ The relationship between smoking cessation and mouth ulcers]===&lt;br /&gt;
*Our results confirm that mouth ulcers are a common result of stopping smoking, affecting two in five quitters. Patients should be reassured that the lesions are a result of stopping smoking and not a side-effect of smoking cessation medication.&lt;br /&gt;
**Citation: McRobbie H, Hajek P, Gillison F. The relationship between smoking cessation and mouth ulcers. Nicotine Tob Res. 2004 Aug;6(4):655-9. doi: 10.1080/14622200410001734012. PMID: 15370162.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12108762/ Minor recurrent aphthous stomatitis and smoking: an epidemiological study measuring plasma cotinine]=== &lt;br /&gt;
*This study shows that a group of RAS patients is significantly less likely to contain smokers than a matched control population, and among smokers the level of cigarette use was significantly lower in RAS patients than the control population. The perceived negative association between RAS and smoking was supported by this epidemiological study.&lt;br /&gt;
*[https://sci-hub.st/10.1034/j.1601-0825.2002.01826.x PDF Version]&lt;br /&gt;
**Citation: Atkin PA, Xu X, Thornhill MH. Minor recurrent aphthous stomatitis and smoking: an epidemiological study measuring plasma cotinine. Oral Dis. 2002 May;8(3):173-6. doi: 10.1034/j.1601-0825.2002.01826.x. PMID: 12108762.&lt;br /&gt;
&lt;br /&gt;
===2000: [https://www.nejm.org/doi/10.1056/NEJM200012143432418?url_ver=Z39.88-2003&amp;amp;rfr_id=ori%3Arid%3Acrossref.org&amp;amp;rfr_dat=cr_pub++0pubmed Nicotine Patches for Aphthous Ulcers Due to Behçet&#039;s Syndrome]=== &lt;br /&gt;
*We describe a woman with Behçet&#039;s syndrome characterized by recurrent oral and genital aphthous ulcers, severe eye involvement, and the onset of arthritis at the age of 29 years. At the age of 35 several large and extremely painful buccal aphthous ulcers developed. Therapy with a nicotine patch led to a regression of all aphthous ulcers within a few days. A month later, after the patient had stopped using the nicotine patches, four aphthous ulcers developed within a week. These ulcers rapidly regressed once she resumed using the nicotine patches.&lt;br /&gt;
*[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section)&lt;br /&gt;
**Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418&lt;br /&gt;
&lt;br /&gt;
===1992: [https://pubmed.ncbi.nlm.nih.gov/1408021/ Smokeless tobacco use prevents aphthous stomatitis]===&lt;br /&gt;
*In (contrast to cigarette smoking, however, few components other than nicotine are systemically absorbed by ST users. Thus if the mechanism that protects ST users against aphthous ulcers is systemic, then nicotine is the likely protective factor. &lt;br /&gt;
*[https://sci-hub.se/10.1016/0030-4220(92)90296-3 PDF Version]&lt;br /&gt;
**Citation: Grady D, Ernster VL, Stillman L, Greenspan J. Smokeless tobacco use prevents aphthous stomatitis. Oral Surg Oral Med Oral Pathol. 1992 Oct;74(4):463-5. doi: 10.1016/0030-4220(92)90296-3. PMID: 1408021.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://onlinelibrary.wiley.com/doi/abs/10.5694/j.1326-5377.1991.tb121180.x?sid=nlm%3Apubmed Recurrent aphthous ulcers and nicotine]=== &lt;br /&gt;
*The aim of this study was to investigate the effect of nicotine, in the form of Nicorette tablets, on aphthous ulcers in non-smoking patients. This preliminary trial shows that nicotine may have a beneficial effect on aphthous ulcers.&lt;br /&gt;
*[https://sci-hub.st/10.5694/j.1326-5377.1991.tb121180.x PDF Version]&lt;br /&gt;
**Citation: Bittoun, R. (1991), Recurrent aphthous ulcers and nicotine. Medical Journal of Australia, 154: 471-472. https://doi.org/10.5694/j.1326-5377.1991.tb121180.x&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Arthritis/Skeletal&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
==Osteoarthritis==&lt;br /&gt;
&lt;br /&gt;
===2019 [https://journals.aai.org/jimmunol/article/203/2/485/107400/Nicotine-Attenuates-Osteoarthritis-Pain-and-Matrix Nicotine Attenuates Osteoarthritis Pain and Matrix Metalloproteinase-9 Expression via the α7 Nicotinic Acetylcholine Receptor]===&lt;br /&gt;
*In conclusion, stimulation of α7-nAChRs by nicotine attenuates MIA-induced OA pain and cartilage degradation. This protective effect of nicotine can be associated with the inhibition of MMP-9 overexpression through the PI3K/Akt/NF-κB signaling pathway. Although the use of nicotine is limited by its nonspecific effects, this study provides novel evidence supporting the future development of therapeutic strategies for inflammatory diseases via the cholinergic anti-inflammatory pathway.&lt;br /&gt;
**Citation: Teng P, Liu Y, Dai Y, Zhang H, Liu WT, Hu J. Nicotine Attenuates Osteoarthritis Pain and Matrix Metalloproteinase-9 Expression via the α7 Nicotinic Acetylcholine Receptor. J Immunol. 2019 Jul 15;203(2):485-492. doi: 10.4049/jimmunol.1801513. Epub 2019 May 31. PMID: 31152077.&lt;br /&gt;
***This work was supported by grants from the National Natural Science Foundation of China (81373397, 81672218, and 81603092) and the Department of Science, Education, and Health Program of Jiangsu Province (QNRC 2016606 and QNRC 2016604).&lt;br /&gt;
&lt;br /&gt;
==Rheumatoid arthritis (collagen-induced arthritis CIA in mice)==&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.spandidos-publications.com/mmr/14/6/5057 Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Taken together, the present results indicated that nicotine‑induced activation of the CAP in mice with CIA may reduce the number of macrophages in the synovium, which may serve a role in alleviating arthritis in mice.&lt;br /&gt;
**Citation: Li S, Zhou B, Liu B, Zhou Y, Zhang H, Li T, Zuo X. Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration. Mol Med Rep. 2016 Dec;14(6):5057-5064. doi: 10.3892/mmr.2016.5904. Epub 2016 Oct 31. PMID: 27840928; PMCID: PMC5355730.&lt;br /&gt;
***Acknowledgement: The present study was supported by a grant from the National Natural Science Foundation of China (grant no. 81571602).&lt;br /&gt;
&lt;br /&gt;
===2014 [https://pubmed.ncbi.nlm.nih.gov/24313917/ Regulatory effect of nicotine on collagen-induced arthritis and on the induction and function of in vitro-cultured Th17 cells]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine stimulation attenuated signs and severity of arthritis in mice. Activation of nicotine acetylcholine receptors on in vitro-cultured Th17 cells decreased their pro-inflammatory function, which may play a potential role in alleviating arthritis in mice.&lt;br /&gt;
*[https://sci-hub.st/10.3109/14397595.2013.862352 PDF Full paper]&lt;br /&gt;
**Citation: Yang Y, Yang Y, Yang J, Xie R, Ren Y, Fan H. Regulatory effect of nicotine on collagen-induced arthritis and on the induction and function of in vitro-cultured Th17 cells. Mod Rheumatol. 2014 Sep;24(5):781-7. doi: 10.3109/14397595.2013.862352. Epub 2013 Dec 9. PMID: 24313917.&lt;br /&gt;
***Acknowledgement: This work was supported by The Shanghai Committee of Science and Technology Project, China (Grant No. 12GWZX0201,11140902900).&lt;br /&gt;
&lt;br /&gt;
===2014 [https://www.sciencedirect.com/science/article/abs/pii/S0014299914003033 Attenuation of collagen induced arthritis via suppression on Th17 response by activating cholinergic anti-inflammatory pathway with nicotine]===&lt;br /&gt;
*Activating the cholinergic anti-inflammatory pathway with nicotine can inhibit Th17 cell responses, may improve the Th1/Th2 imbalance in CIA, and provide a new justification for its application in the clinical treatment of RA.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.ejphar.2014.04.019 PDF Full paper]&lt;br /&gt;
**Citation: Wu S, Luo H, Xiao X, Zhang H, Li T, Zuo X. Attenuation of collagen induced arthritis via suppression on Th17 response by activating cholinergic anti-inflammatory pathway with nicotine. Eur J Pharmacol. 2014 Jul 15;735:97-104. doi: 10.1016/j.ejphar.2014.04.019. Epub 2014 Apr 19. PMID: 24755145.&lt;br /&gt;
***Acknowledgement: This work was supported by a grant from the National Natural Science Foundation of China, People&#039;s Republic of China [81102261] and the Innovative Research Funds for the Central South University, People&#039;s Republic of China. [CX2012B088].&lt;br /&gt;
&lt;br /&gt;
===2009 [https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.24177 Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Clinical arthritis was exacerbated by vagotomy and ameliorated by oral nicotine administration. Moreover, oral nicotine inhibited bone degradation and reduced TNFalpha expression in synovial tissue. Both IP-injected nicotine and AR-R17779 ameliorated clinical arthritis and reduced synovial inflammation. This was accompanied by a reduction of TNFalpha levels in both plasma and synovial tissue. The effect of AR-R17779 was more potent compared with that of nicotine and was associated with delayed onset of the disease as well as with protection against joint destruction.&lt;br /&gt;
**Citation: van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, Tak PP. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum. 2009 Jan;60(1):114-22. doi: 10.1002/art.24177. PMID: 19116908.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Auditory&#039;&#039;&#039; =&lt;br /&gt;
===2021 [https://www.nature.com/articles/s41598-021-92588-z Task-dependent effects of nicotine treatment on auditory performance in young-adult and elderly human nonsmokers]=== &lt;br /&gt;
*The present study evaluated acute effects of oral nicotine treatment on three auditory tasks in young adult and elderly, healthy, non-smoking individuals. All had normal hearing within the frequency range of the stimuli presented for the three tasks. Compared to pre-treatment performance, nicotine improved frequency discrimination. Compared to placebo, nicotine produced no overall effects on the two frequency related tasks, but significantly improved intensity discrimination, with more improvement obtained for those who had lower baseline performance. The present results support the hypothesis that nicotine enhances auditory processing, but this enhancement is task-dependent.&lt;br /&gt;
*[https://www.nature.com/articles/s41598-021-92588-z.pdf PDF Version]&lt;br /&gt;
*Citation: Sun, S., Kapolowicz, M.R., Richardson, M. et al. Task-dependent effects of nicotine treatment on auditory performance in young-adult and elderly human nonsmokers. Sci Rep 11, 13187 (2021). doi: 10.1038/s41598-021-92588-z&lt;br /&gt;
&lt;br /&gt;
===2019 [https://pubmed.ncbi.nlm.nih.gov/31832719/ Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers]=== &lt;br /&gt;
*Nicotine improves auditory performance in difficult listening situations. The present results support future investigation of nicotine effects in clinical populations with auditory processing deficits or reduced cholinergic activation.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s00213-019-05421-x PDF Version]&lt;br /&gt;
*Citation: Pham CQ, Kapolowicz MR, Metherate R, Zeng FG. Nicotine enhances auditory processing in healthy and normal-hearing young adult nonsmokers. Psychopharmacology (Berl). 2020 Mar;237(3):833-840. doi: 10.1007/s00213-019-05421-x. Epub 2019 Dec 12. PMID: 31832719; PMCID: PMC7039769.&lt;br /&gt;
*Acknowledgements: This research was supported by grants from the National Institutes of Health to FGZ (5R01DC015587), to RM (4R01-DC013200) and a pre-doctoral fellowship to CQP (UL1-TR000153).&lt;br /&gt;
*Keywords: Acetylcholinergic systems; Auditory processing; Nicotine; Selective attention; Spectral ripple discrimination; Temporal gap detection; Tone in noise detection.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Atopic Dermatitis&#039;&#039;&#039; =&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37454697/ Association of Atopic Dermatitis with Substance Use Disorders: A Case-Control Study in the All of Us Research Program.] ===&lt;br /&gt;
&lt;br /&gt;
* Joshi TP, Bancroft A, DeLeon D, Garcia D, Kunisetty B, Truong P, Kim SJ. J Am Acad Dermatol. 2023 Jul 14:S0190-9622(23)01361-0. doi: 10.1016/j.jaad.2023.06.051. Online ahead of print. PMID: 37454697 No abstract available.&lt;br /&gt;
* Patients with AD, compared to controls, were more likely to use cannabis (4.4% vs 2.7%, 60 P &amp;lt;0.01), hallucinogens (3.2% vs 1.8%, P &amp;lt;0.01), opioids (3.5% vs 1.3%, P &amp;lt;0.01), and 61 stimulants (2.3% vs 1.5%, P &amp;lt;0.01) and less likely to use e-cigarettes (10.8% vs 15.6%, P &amp;lt;0.01) 62 and regular cigarettes (39.0% vs 56.0%, P &amp;lt;0.01). &lt;br /&gt;
* In multivariable analysis adjusted for age, 63 income, insurance type, race, sex, depression, and anxiety, only the associations with cannabis 64 (aOR 1.49, 95% CI 1.24-1.80), e-cigarette (aOR 0.71, 95% CI 0.65-0.77), and regular cigarette 65 use (aOR 0.65, 95% CI 0.63-0.68) persisted (Table I)&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Autism&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
=== 2020: [https://pubmed.ncbi.nlm.nih.gov/32691528/ The Role of Nicotinic Receptors in the Attenuation of Autism-Related Behaviors in a Murine BTBR T + tf/J Autistic Model] ===&lt;br /&gt;
&lt;br /&gt;
* Nicotinic receptors are distributed throughout the central and peripheral nervous system. Postmortem studies have reported that some nicotinic receptor subtypes are altered in the brains of autistic people.&lt;br /&gt;
* Recent studies have demonstrated the importance of nicotinic acetylcholine receptors (nAChRs) in the autistic behavior of BTBR T + tf/J mouse model of autism. This study was undertaken to examine the behavioral effects of targeted nAChRs using pharmacological ligands, including nicotine and mecamylamine in BTBR T + tf/J and C57BL/6J mice in a panel of behavioral tests relating to autism.&lt;br /&gt;
* Overall, the findings indicate that the pharmacological modulation of nicotinic receptors is involved in modulating core behavioral phenotypes in the BTBR T + tf/J mouse model.&lt;br /&gt;
* LAY SUMMARY: The involvement of brain nicotinic neurotransmission system plays a crucial role in regulating autism-related behavioral features. In addition, the brain of the autistic-like mouse model has a low acetylcholine level. Here, we report that nicotine, at certain doses, improved sociability and reduced repetitive behaviors in a mouse model of autism, implicating the potential therapeutic values of a pharmacological intervention targeting nicotinic receptors for autism therapy.&lt;br /&gt;
* Mouse study, may not explain human response&lt;br /&gt;
* Autism Research 2020 Aug;13(8):1311-1334  doi: 10.1002/aur.2342. Epub 2020 Jul 21.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]=== &lt;br /&gt;
*Taken together, our study provides evidence for the feasibility and tolerability of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine (TN/TNP)&#039;&#039;&#039;]] in a small sample of adults with severe [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Autism Spectrum Disorder (ASD)&#039;&#039;&#039;]] symptoms and pathological chronic aggression and irritability. &lt;br /&gt;
*Our results also suggest that TN may have a beneficial effect on aggression, irritability, and sleep in ASD, though the sample size of this study is too small to make definitive conclusions. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/pdf/nihms-950880.pdf PDF Version]&lt;br /&gt;
*Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.&lt;br /&gt;
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).&lt;br /&gt;
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Behcet&#039;s disease&#039;&#039;&#039; (See also: Aphthous ulcers)= &lt;br /&gt;
*Post on [https://healthunlocked.com/behcetsuk/posts/138632782/nicotine-and-it%E2%80%99s-effects-on-my-beh%C3%A7et%E2%80%99s-for-the-positive Behçet&#039;s UK]. A person started smoking seeking relief from the pain they suffered because of Behcet&#039;s disease.&lt;br /&gt;
&lt;br /&gt;
===2010 [https://academic.oup.com/rheumatology/article/49/3/501/1786816 Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series]=== &lt;br /&gt;
*In this report, we describe five ex-smoker [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;BD&#039;&#039;&#039;]] patients with active mucocutaneous lesions, not responsive to standard pharmacological treatments and treated with transdermal nicotine patches. Four out of five patients quickly responded to nicotine-patch therapy and experienced a complete regression of all mucocutaneous lesions within 6 months of observation.&lt;br /&gt;
**Citation: Giovanni Ciancio, Matteo Colina, Renato La Corte, Andrea Lo Monaco, Francesco De Leonardis, Francesco Trotta, Marcello Govoni, Nicotine-patch therapy on mucocutaneous lesions of Behçet’s disease: a case series, Rheumatology, Volume 49, Issue 3, March 2010, Pages 501–504, doi: 10.1093/rheumatology/kep401&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.jidonline.org/article/S0022-202X(15)33112-2/fulltext Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet&#039;s disease]===&lt;br /&gt;
*&amp;quot;In conclusion, we observed substantial inhibitory effects of CSE and nicotine on IL-8 and to a lesser extent on IL-6 release by human keratinocytes and HMEC-1 endothelial cells. These findings may explain the beneficial effect of smoking in BD, also because IL-8, and to some extent IL-6, are likely to induce pivotal proinflammatory signals in this disease (Lee et al., 1993). Nicotine may cause immunoregulation by affecting chemokine/cytokine production. This study also demonstrates the different behavior of cells in terms of cytokine release when stimulated with BD patients&#039; sera compared to those of healthy individuals. The in vitro evidence of beneficial effects of nicotine in BD is fundamental to our ongoing clinical trial with nicotine transdermal patches in BD. In addition, the detected beneficial effect of biochanin A implicates this compound as a candidate for future developments in aphthae treatment. The development of topical nicotinic cholinergic receptor subtype-specific agonists is likely to exhibit beneficial effects on skin and mucosae without inducing systemic adverse effects.&amp;quot;&lt;br /&gt;
**Citation: Kalayciyan A, Orawa H, Fimmel S, Perschel FH, González JB, Fitzner RG, Orfanos CE, Zouboulis CC. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behçet&#039;s disease. J Invest Dermatol. 2007 Jan;127(1):81-9. doi: 10.1038/sj.jid.5700492. Epub 2006 Sep 28. PMID: 17008886.&lt;br /&gt;
***Acknowledgement: Dr Kalayciyan was supported by a grant of the Berlin Foundation for Dermatology. The research project was supported by the Deutsches Register Morbus Adamantiades–Behçet e.V.&lt;br /&gt;
&lt;br /&gt;
===2000 [https://www.nejm.org/doi/10.1056/NEJM200012143432418?url_ver=Z39.88-2003&amp;amp;rfr_id=ori%3Arid%3Acrossref.org&amp;amp;rfr_dat=cr_pub++0pubmed Nicotine Patches for Aphthous Ulcers Due to Behçet&#039;s Syndrome]=== &lt;br /&gt;
*We describe a woman with Behçet&#039;s syndrome characterized by recurrent oral and genital aphthous ulcers, severe eye involvement, and the onset of arthritis at the age of 29 years. At the age of 35 several large and extremely painful buccal aphthous ulcers developed. Therapy with a nicotine patch led to a regression of all aphthous ulcers within a few days. A month later, after the patient had stopped using the nicotine patches, four aphthous ulcers developed within a week. These ulcers rapidly regressed once she resumed using the nicotine patches.&lt;br /&gt;
*[https://sci-hub.st/10.1056/NEJM200012143432418 PDF Version] (Note: Need to scroll down to the correct section)&lt;br /&gt;
**Citation: Philippe Scheid, M.D., Abraham Bohadana, M.D., Yves Martinet, M.D., Ph.D., Université Henri Poincaré, 54500 Nancy-Vandoeuvre, France, December 14, 2000, N Engl J Med 2000; 343:1816-1817, DOI: 10.1056/NEJM200012143432418&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Brain Injury / Disease&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2024: [https://pubmed.ncbi.nlm.nih.gov/38698493/ Nicotine inhalant via E-cigarette facilitates sensorimotor function recovery by upregulating neuronal BDNF-TrkB signalling in traumatic brain injury]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Conclusioin: &amp;quot;Post-injury chronic nicotine exposure via vaping facilitates recovery of sensorimotor function by upregulating neuroprotective mBDNF/TrkB/Akt/Erk signalling. These findings suggest potential neuroprotective properties of nicotine despite its highly addictive nature. Thus, understanding the multifaceted effects of chronic nicotine exposure on TBI-associated symptoms is crucial for paving the way for informed and properly managed therapeutic interventions.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15681815/ Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease]=== &lt;br /&gt;
*Several studies have shown that nicotine treatment can attenuate cognitive deficits produced by medial septal lesions, lesions of the nucleus basalis, and traumatic brain injury.&lt;br /&gt;
*[https://sci-hub.st/10.1196/annals.1332.019 PDF Version]&lt;br /&gt;
*Citation: Pauly JR, Charriez CM, Guseva MV, Scheff SW. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Ann N Y Acad Sci. 2004 Dec;1035:316-34. doi: 10.1196/annals.1332.019. PMID: 15681815.&lt;br /&gt;
*Acknowledgements: This work was supported by grants from the National Institutes of Health (NS42196 to J.R.P. and NS39828 to S.W.S.) and the Kentucky Tobacco Research and Development Center. We acknowledge the technical assistance of Melissa Yingling and Khaled Tanwir.&lt;br /&gt;
*KEYWORDS: nicotine; neurodegeneration; neuroprotection&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cancer / Cancer Treatments&#039;&#039;&#039;= &lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S001448272030416X?via%3Dihub Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells]=== &lt;br /&gt;
*Nicotine inhibits ovarian cancer cell ERK and p38 [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;MAPK&#039;&#039;&#039;]] signaling.&lt;br /&gt;
*Nicotine inhibits ovarian cancer proliferation and spheroid invasion.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.yexcr.2020.112167 PDF Version]&lt;br /&gt;
*Citation: Sarah J. Harmych, Jay Kumar, Mesa E. Bouni, Deborah N. Chadee, Nicotine inhibits MAPK signaling and spheroid invasion in ovarian cancer cells, Experimental Cell Research, Volume 394, Issue 1, 2020, 112167, ISSN 0014-4827, doi: 10.1016/j.yexcr.2020.112167.&lt;br /&gt;
*Acknowledgements: This work was supported by the National Institutes of Health [R15 CA199164] and [R15 CA241898] to D.N.C. &lt;br /&gt;
*Keywords: Nicotine, Ovarian cancer, Spheroid, MAPK, Invasion&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.sciencedirect.com/science/article/abs/pii/S0014299913003270?via%3Dihub Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models]=== &lt;br /&gt;
*Nicotine significantly reduced antiviral-dependent alterations of the nociceptive threshold. &lt;br /&gt;
*Moreover, nicotine decreased neuropathic pain induced by repeated intraperitoneal administration of the anticancer agent oxaliplatin (2.4 mg/kg), lowering the hypersensitivity to mechanical and thermal stimuli. &lt;br /&gt;
*Intraperitoneal nicotine administration controls neuropathic pain evoked by traumatic or toxic nervous system alterations. These results support the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] modulation as a possible therapeutic approach to the complex, undertreated chemotherapy-induced neuropathies. &lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.ejphar.2013.04.022 PDF Version]&lt;br /&gt;
*Citation: Lorenzo Di Cesare Mannelli, Matteo Zanardelli, Carla Ghelardini, Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models, European Journal of Pharmacology, Volume 711, Issues 1–3, 2013, Pages 87-94, ISSN 0014-2999, doi: 10.1016/j.ejphar.2013.04.022.&lt;br /&gt;
*Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research.&lt;br /&gt;
*Keywords: nAChR; Dideoxycytidine; Oxaliplatin; Antiviral; Anticancer, pain, chemotherapy, nicotine, neuropathy&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cannabis / THC&#039;&#039;&#039;= &lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32034447/ Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial]=== &lt;br /&gt;
*The findings provide the first evidence that [[Special:MyLanguage/Abbreviations|NP (Nicotine Patch)]] may be able to attenuate NA (negative affect) - related withdrawal symptoms in individuals with cannabis use disorder who are not heavy users of tobacco or nicotine.&lt;br /&gt;
*[https://sci-hub.se/10.1007/s00213-020-05476-1 PDF Version]&lt;br /&gt;
*Citation: Gilbert DG, Rabinovich NE, McDaniel JT. Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial. Psychopharmacology (Berl). 2020 May;237(5):1507-1519. doi: 10.1007/s00213-020-05476-1. Epub 2020 Feb 7. PMID: 32034447.&lt;br /&gt;
*Acknowledgement: The study was supported by NIH grant R01DA031006 awarded to David Gilbert.&lt;br /&gt;
*Keywords: Cannabis; Marijuana; Negative affect; Nicotine; Smoking; THC; Testing effect; Withdrawal symptoms.&lt;br /&gt;
&lt;br /&gt;
= &#039;&#039;&#039;Cardiovascular&#039;&#039;&#039; =&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/pii/S0014488624002723 Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these findings indicate that acute nicotine exposure enhances functional stroke recovery. Future studies will have to evaluate the effects of (1) chronic nicotine exposure, a clinically relevant vascular risk factor, and (2) the cessation of nicotine exposure, which is widely recommended post-stroke, but might have detrimental effects in the early stroke recovery phase.&lt;br /&gt;
**Citation: Abbaspour S, Fahanik-Babaei J, Adeli S, Hermann DM, Sardari M. Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state. Exp Neurol. 2024 Sep 13;382:114946. doi: 10.1016/j.expneurol.2024.114946. Epub ahead of print. PMID: 39278587.&lt;br /&gt;
***Funding: None&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://pubmed.ncbi.nlm.nih.gov/38529793/ Transdermal Nicotine Patch Increases the Number and Function of Endothelial Progenitor Cells in Young Healthy Nonsmokers without Adverse Hemodynamic Effects] ===&lt;br /&gt;
* This study aimed to explore the influence of TNPs on circulating EPCs with surface markers of CD34, CD133, and/or KDR, and colony-forming function plus migration activity of early EPCs derived from cultured peripheral blood mononuclear cells before and after TNP treatments in young healthy nonsmokers.&lt;br /&gt;
* PWA analyses on day 7, compared with pretreatment, did not show significant change except diastolic pressure time index, which was prolonged and implied potential vascular benefit. In conclusion, 7-day TNP treatments could be a practical strategy to enhance angiogenesis of circulating EPCs to alleviate tissue ischemia without any hemodynamic concern.&lt;br /&gt;
* Nicotine patches appear to promote blood vessel formation, without adverse effects.&lt;br /&gt;
&lt;br /&gt;
=== 2015 [https://www.nature.com/articles/srep15895 Dose-dependent protective effect of nicotine in a murine model of viral myocarditis induced by coxsackievirus B3] ===&lt;br /&gt;
&lt;br /&gt;
* The alpha 7 nicotinic acetylcholine receptor (alpha7 nAChR) was recently described as an anti-inflammatory target in various inflammatory diseases. The aim of this study was to investigate the dose-related effects of nicotine, an alpha7 nAChR agonist, in murine model of viral myocarditis.&lt;br /&gt;
* The survival rate on day 14 increased in a dose-dependent fashion and was markedly higher in the 0.2 and 0.4 mg/kg nicotine groups than in the infected untreated group.&lt;br /&gt;
* The findings suggest that alpha7 nAChR agonists may be a promising new strategy for patients with viral myocarditis.&lt;br /&gt;
* Animal study (mice)&lt;br /&gt;
* Ge Li-Sha, Zhao Jing-Lin, Chen Guang-Yi, Liu Li, Zhou De-Pu &amp;amp; Li Yue-Chun &#039;&#039;Scientific Reports&#039;&#039; volume 5, Article number: 15895 (2015) &lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Chlamydia Pneumoniae&#039;&#039;&#039;=&lt;br /&gt;
*Chlamydia pneumoniae is a type of bacteria that can cause respiratory tract infections, such as pneumonia. C. pneumoniae is one cause of community-acquired pneumonia or lung infections developed outside of a healthcare setting. However, not everyone exposed to C. pneumoniae will develop pneumonia. [https://www.cdc.gov/pneumonia/atypical/cpneumoniae/index.html Source: US CDC]&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection...&lt;br /&gt;
*Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Cognitive / IQ / Memory&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10998423/ An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence] ===&lt;br /&gt;
*Conclusion: Overall, the nicotine containing products improved sustained attention and mood while reducing smoking urges, with the studied e-cigarettes having comparable effects to combustible cigarettes across the assessed cognitive parameters and mood measures. These results demonstrate the potential role of e-cigarettes to provide an acceptable alternative for combustible cigarettes among people who would otherwise continue to smoke.&lt;br /&gt;
*Citation: Harry J. Green, Olivia K. O’Shea, Jack Cotter, Helen L. Philpott, and Nik Newland. Harm Reduct J. 2024; 21: 78. Published online 2024 Apr 6. doi: 10.1186/s12954-024-00993-0 PMCID: PMC10998423&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://www.frontiersin.org/articles/10.3389/fnins.2023.1252705/full Editorial: Nicotine and its derivatives in disorders of cognition: a challenging new topic of study] ===&lt;br /&gt;
&lt;br /&gt;
* Front. Neurosci., 18 July 2023 Sec. Neurodegeneration Volume 17 - 2023 | &amp;lt;nowiki&amp;gt;https://doi.org/10.3389/fnins.2023.1252705&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
* Albert Gjedde, Department of Neuroscience, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark&lt;br /&gt;
* Nicotine is a compound of considerable interest to neuroscience, in contexts of physiology as well as pathology of brain functions related to neurotransmitter mechanisms. Nicotine is an alkaloid that exists naturally in plants such as tomatoes and potatoes, with the highest levels in the tobacco plant.&lt;br /&gt;
* In mammalian brains, nicotine has multiple actions that appear to be accidents of evolution, as no specific relation springs to mind between the functions of nicotine in plants and animals.&lt;br /&gt;
* The following discussion expands upon the three topics of biology, therapy, and possible prevention, as related to cognition, in the three reviews and the three original studies included in the collection.&lt;br /&gt;
** Conclusion: Questions remain of how nicotine treatment in normal aging should proceed, including length of treatment, dose of nicotine, handling of smokers, effects of AD risk factors, and many others. While data from studies of psychiatric and memory-impaired subjects indicate that nicotine may relieve cognitive symptoms, it is mandatory to test the benefits of nicotine in normal aging in order to fill gaps in the literature and to verify the extent to which nicotine is useful as a pharmacologic agent that prevents pathological aging.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36736944/ Nicotine&#039;s effect on cognition, a friend or foe?] ===&lt;br /&gt;
* In this review, we first introduce the beneficial effect of nicotine on cognition including attention, short-term memory and long-term memory. We next summarize the beneficial effect of nicotine on cognition under pathological conditions, including Alzheimer&#039;s disease, Parkinson&#039;s disease, Schizophrenia, Stress-induced Anxiety, Depression, and drug-induced memory impairment.&lt;br /&gt;
* We can only access the abstract, but would be interested to read the whole thing if anyone can help?&lt;br /&gt;
* Human study&lt;br /&gt;
* Qian Wang, Weihong Du, Hao Wang, Panpan Geng, Yanyun Sun, Junfang Zhang, Wei Wang, Xinchun Jin, PMID: 36736944 DOI: 10.1016/j.pnpbp.2023.110723&lt;br /&gt;
&lt;br /&gt;
=== 2021: [https://www.spandidos-publications.com/10.3892/mmr.2021.12037# Molecular insights into the benefits of nicotine on memory and cognition] ===&lt;br /&gt;
&lt;br /&gt;
* Published online on: March 25, 2021 Molecular Medicine Reports  &amp;lt;nowiki&amp;gt;https://doi.org/10.3892/mmr.2021.12037&amp;lt;/nowiki&amp;gt; Article Number: 398&lt;br /&gt;
* Author: Ahmad Alhowail&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0306452220304723?via%3Dihub Effects of Nicotine on Task Switching and Distraction in Non-smokers. An fMRI Study]=== &lt;br /&gt;
*Nicotine improves sustained attention and reduces distractor interference, promoting cognitive stability. Nicotine enhances response times without differential impact on task switching or distraction.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.neuroscience.2020.07.029 PDF Version]&lt;br /&gt;
*Citation: Stefan Ahrens, Christiane M. Thiel, Effects of Nicotine on Task Switching and Distraction in Non-smokers. An fMRI Study, Neuroscience, Volume 444, 2020, Pages 43-53, ISSN 0306-4522, doi: 10.1016/j.neuroscience.2020.07.029.&lt;br /&gt;
*Acknowledgements: This work was supported by a grant from the German Research Foundation DFG TH766/8-1.&lt;br /&gt;
*Key words: nicotine, cholinergic, cognitive control, distraction, task switching, neuroimaging&lt;br /&gt;
&lt;br /&gt;
===2019: [https://www.frontiersin.org/articles/10.3389/fnins.2018.01002/full#B5 Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review]===&lt;br /&gt;
*Nicotine lowers learning and memory impairment in some neurological disorders.&lt;br /&gt;
*Citation: Majdi, A., Kamari, F., &amp;amp; Gjedde, A. (2019). Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review. Frontiers in Neuroscience, 12. https://doi.org/10.3389/fnins.2018.01002&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== &lt;br /&gt;
*Preclinical models and human studies have demonstrated that nicotine has cognitive-enhancing effects. Attention, working memory, fine motor skills and episodic memory functions are particularly sensitive to nicotine’s effects. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/pdf/CN-16-403.pdf PDF Version]&lt;br /&gt;
*Citation: Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. Curr Neuropharmacol. 2018;16(4):403-414. doi: 10.2174/1570159X15666171103152136. PMID: 29110618; PMCID: PMC6018192.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2013: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/ A fresh look at tobacco harm reduction: the case for the electronic cigarette]===&lt;br /&gt;
*Smokers of any age can reap substantial health benefits by quitting. In fact, no other single public health effort is likely to achieve a benefit comparable to large-scale smoking cessation.&lt;br /&gt;
*E-cigs might be the most promising product for tobacco harm reduction to date, because, besides delivering nicotine vapour without the combustion products that are responsible for nearly all of smoking’s damaging effect, they also replace some of the rituals associated with smoking behaviour.&lt;br /&gt;
*Nicotine’s beneficial effects include correcting problems with concentration, attention and memory, as well as improving symptoms of mood impairments. Keeping such disabilities at bay right now can be much stronger motivation to continue using nicotine than any threats of diseases that may strike &lt;br /&gt;
*Nicotine’s beneficial effects can be controlled, and the detrimental effects of the smoky delivery system can be attenuated, by providing the drug via less hazardous delivery systems. Although more research is needed, e-cigs appear to be effective cigarette substitutes for inveterate smokers, and the health improvements enjoyed by switchers do not differ from those enjoyed by tobacco/nicotine abstainers.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850892/pdf/1477-7517-10-19.pdf PDF Version]&lt;br /&gt;
&lt;br /&gt;
===2012: [https://pubmed.ncbi.nlm.nih.gov/22503574/ The electronic-cigarette: Effects on desire to smoke, withdrawal symptoms and cognition]=== &lt;br /&gt;
*The e-cigarette can reduce desire to smoke and nicotine withdrawal symptoms 20 minutes after use.&lt;br /&gt;
*The nicotine content in this respect may be more important for males.&lt;br /&gt;
*The first study to demonstrate that the nicotine e-cigarette can improve working memory.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.addbeh.2012.03.004 PDF Version]&lt;br /&gt;
*Citation: Dawkins, L., Turner, J., Hasna, S., &amp;amp; Soar, K. (2012). The electronic-cigarette: Effects on desire to smoke, withdrawal symptoms and cognition. Addictive Behaviors, 37(8), 970–973. doi:10.1016/j.addbeh.2012.03.004 &lt;br /&gt;
*Electronic Cigarette Company (TECC) supplied the e-cigarettes and cartridges for this study. TECC had no involvement in the design or conduct of the study.&lt;br /&gt;
&lt;br /&gt;
===2003 [https://www.nature.com/articles/1300202 Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects]=== &lt;br /&gt;
*Compared to placebo, nicotine and donepezil significantly improved, while alcohol significantly impaired overall flight performance. Both cholinergic drugs showed the largest effects on flight tasks requiring sustained visual attention.&lt;br /&gt;
*[https://www.nature.com/articles/1300202.pdf PDF Version]&lt;br /&gt;
*Citation: Mumenthaler, M., Yesavage, J., Taylor, J. et al. Psychoactive Drugs and Pilot Performance: A Comparison of Nicotine, Donepezil, and Alcohol Effects. Neuropsychopharmacol 28, 1366–1373 (2003). doi: 10.1038/sj.npp.1300202&lt;br /&gt;
*Acknowledgements: This research was supported in part by NIMH Grant 40041; NIA Grant AG17824; the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); the Alcohol Beverage Medical Research Foundation; the Swiss Foundation for Alcohol Research; the Swiss National Science Foundation; and the Medical Research Service of the Department of Veterans Affairs.&lt;br /&gt;
*Keywords: cholinergic agents, ethanol, cognition, psychomotor performance, psychopharmacology, aerospace medicine&lt;br /&gt;
&lt;br /&gt;
===1996 [https://link.springer.com/article/10.1007/BF02805972 Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers]===&lt;br /&gt;
*These results are consistent with other recent research suggesting a primary effect of nicotine in enhancing cognitive performance.&lt;br /&gt;
*Citation: Foulds, J., Stapleton, J., Swettenham, J. et al. Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology 127, 31–38 (1996). https://doi.org/10.1007/BF02805972&lt;br /&gt;
&lt;br /&gt;
===1994 [https://link.springer.com/article/10.1007/BF02245346 Smoking and raven IQ]=== &lt;br /&gt;
*Nicotine has recently been shown to enhance measures of information processing speed including the decision time (DT) component of simple and choice reaction time and the string length measure of evoked potential waveform complexity. Both (DT and string length) have been previously demonstrated to correlate with performance on standard intelligence tests ([[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;IQ&#039;&#039;&#039;]]).&lt;br /&gt;
*In this experiment we used the Raven [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Advanced Progressive Matrices (APM)&#039;&#039;&#039;]] test. APM scores were significantly higher in the smoking session compared to the non-smoking session, suggesting that nicotine acts to enhance physiological processes underlying performance on intellectual tasks.&lt;br /&gt;
*[https://sci-hub.st/https://link.springer.com/article/10.1007/BF02245346 PDF Version]&lt;br /&gt;
*Citation: Stough, C., Mangan, G., Bates, T. et al. Smoking and raven IQ. Psychopharmacology 116, 382–384 (1994). doi: 10.1007/BF02245346&lt;br /&gt;
*Key words: Intelligence, APM, Nicotine, Smoking Cholinergic system&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1579636/ Nicotine as a cognitive enhancer]=== &lt;br /&gt;
*Nicotine improves attention in a wide variety of tasks in healthy volunteers. &lt;br /&gt;
*Nicotine improves immediate and longer term memory in healthy volunteers. &lt;br /&gt;
*Nicotine improves attention in patients with probable Alzheimer&#039;s Disease. &lt;br /&gt;
*While some of the memory effects of nicotine may be due to enhanced attention, others seem to be the result of improved consolidation as shown by post-trial dosing. &lt;br /&gt;
*[https://sci-hub.st/10.1016/0278-5846(92)90069-q PDF Version]&lt;br /&gt;
*Citation: Warburton DM. Nicotine as a cognitive enhancer. Prog Neuropsychopharmacol Biol Psychiatry. 1992 Mar;16(2):181-91. doi: 10.1016/0278-5846(92)90069-q. PMID: 1579636.&lt;br /&gt;
*Keywords: acetylcholine, Alzheimer&#039;s Disease, attention, cholinergic, memory, nicotine, scopolamine.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;COVID / Long COVID / Post-COVID Syndrome / Long-Haul COVID (SARS-CoV-2)&#039;&#039;&#039;=&lt;br /&gt;
*See Also: The Inflamation Section &lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37264452/ The controversial effect of smoking and nicotine in SARS-CoV-2 infection.] ===&lt;br /&gt;
* States the obvious: the exposure (smoke vs. nicotine and dose need to be characterised correctly).&lt;br /&gt;
* Considering that the effects of nicotine and cigarette smoke are different from each other, it is necessary to be careful in generalizing the effects of nicotine and cigarette to each other in the conducted researches. The generalization and the undifferentiation of nicotine from smoke is a significant bias. Moreover, different doses of nicotine stimulate different effects (dose-dependent response). In addition to further assessing the role of nicotine in COVID-19 infection and any other cases, a clever assessment of underlying diseases should also be considered to achieve a guideline for health providers and a personalized approach to treatment.&lt;br /&gt;
* Salehi Z, Motlagh Ghoochani BFN, Hasani Nourian Y, Jamalkandi SA, Ghanei M. Allergy Asthma Clin Immunol. 2023 Jun 1;19(1):49. doi: 10.1186/s13223-023-00797-0. PMID: 37264452 Review.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36650574/ Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?] ===&lt;br /&gt;
* Nicotine COVID/SARS-CoV-2 interaction mystery takes another turn.&lt;br /&gt;
* Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially. This explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, characterizing post-COVID-19 syndrome. The agonist ligand nicotine shows an up to 30-fold higher affinity to nACHRs than acetylcholine (ACh).&lt;br /&gt;
* We therefore hypothesize that this molecule could displace the virus from nAChR attachment and pave the way for unimpaired cholinergic signal transmission. Treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application, we witnessed improvements ranging from immediate and substantial to complete remission in a matter of days.&lt;br /&gt;
*In all four of the cases we studied, transcutaneous use of nicotine led to a near immediate improvement in symptoms and rapid restitutio ad integrum. The course of symptom improvement was as distinct as the clinical presentation of post-COVID-19 syndrome in each patient.&lt;br /&gt;
*Citation: Leitzke M. Bioelectron Med. 2023 Jan 18;9(1):2. doi: 10.1186/s42234-023-00104-7. PMID: 36650574 Free PMC article.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.nature.com/articles/s41598-023-45072-9 Treatment of 95 post-Covid patients with SSRIs]===&lt;br /&gt;
*To stick nicotine patches helps PCS (post-COVID syndrome) patients. This may be not only because nicotine is a nicotinic receptor agonist and therefore an opponent of these poisonous metabolites, but nicotine is a strong acetylcholine (ACh) agonist as well.&lt;br /&gt;
*Citation: Rus, C.P., de Vries, B.E.K., de Vries, I.E.J. et al. Treatment of 95 post-Covid patients with SSRIs. Sci Rep 13, 18599 (2023). https://doi.org/10.1038/s41598-023-45072-9&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183099/ Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials]===&lt;br /&gt;
* Studies show that the penetration of SARS-CoV-2 into upper respiratory tract, bronchial and pulmonary cells involve transmembrane receptor ACE2, which probably interacts with acetylcholine nicotinic receptors of the α7 subtype. The mechanism of the interactions remains hypothetical.&lt;br /&gt;
* Despite a relatively safe tolerance profile, transdermal nicotine therapy in non-smokers can only be used in clinical trials. There is a lack of formal assessment of the potential risk of developing a tobacco addiction. This review offers baseline data to set a transdermal nicotine protocol for non-smokers with a new purpose.&lt;br /&gt;
* Analyses of nicotine administration protocols and safety were conducted after reviewing Medline and Science Direct databases performing a search using the words [transdermal nicotine] AND [non-smoker] AND selected diseases.&lt;br /&gt;
* Excessive secondary cytokine reaction plays a role in the mortality associated with COVID. One of the hypotheses to explain the effect of nicotine on the occurrence of severe forms of COVID and death is based on the loss of the downregulation of the parasympathetic nervous system, which exerts an inhibitory effect on cytokine storm, especially in the lung and digestive tract. The α 7-type nicotinic receptors are part of this chain of reaction.&lt;br /&gt;
* B. Dautzenberg, A. Levi, M. Adler, and R. Gaillardc. Respir Med Res. 2021 Nov; 80: 100844. Published online 2021 Jun 7. doi: 10.1016/j.resmer.2021.100844 PMCID: PMC8183099 PMID: 34153704&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704168/ Does Nicotine Prevent Cytokine Storms in COVID-19?]===&lt;br /&gt;
*Case study of one individual&lt;br /&gt;
*Nicotine, an α7-nACh receptor agonist, may boost the cholinergic anti-inflammatory pathway and hinder the uncontrolled overproduction of pro-inflammatory cytokines triggered by the SARS-CoV-2 virus, which is understood to be the main pathway to poor outcomes and death in severe COVID-19.&lt;br /&gt;
*In the absence of any effective treatment for COVID-19, further research as to whether nicotine replacement offers protection against severe SAR-CoV-2 infection in smokers is clearly essential. If the mechanisms through which nicotine may interact with the virus remain speculative, the effects of route of administration, duration, dosing and frequency of use of nicotine on any such interaction are unknown. Should NRT be found to be of help in the management of COVID-19, it would be yet another strong reason to persuade smokers to switch to NRT and ultimately quit smoking.&lt;br /&gt;
*Citation: Dratcu L, Boland X. Does Nicotine Prevent Cytokine Storms in COVID-19? Cureus. 2020 Oct 28;12(10):e11220. doi: 10.7759/cureus.11220. PMID: 33269148; PMCID: PMC7704168.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300218/ Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm]===&lt;br /&gt;
*Abstract: &amp;quot;SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.&amp;quot;&lt;br /&gt;
*Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218.&lt;br /&gt;
&lt;br /&gt;
===2020: [https://www.sciencedirect.com/science/article/pii/S2214750020302924 Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system]===&lt;br /&gt;
*Nicotine could maintain or restore the function of the cholinergic anti-inflammatory system and thus control the release and activity of pro-inflammatory cytokines. This could prevent or suppress the cytokine storm. This hypothesis needs to be examined in the laboratory and the clinical setting.&lt;br /&gt;
*Citation: Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, Vantarakis A, Poulas K. Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol Rep. 2020 Apr 30;7:658-663. doi: 10.1016/j.toxrep.2020.04.012. PMID: 32355638; PMCID: PMC7192087.&lt;br /&gt;
&lt;br /&gt;
=== 2019: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679833/ Mitochondria as a possible target for nicotine action] ===&lt;br /&gt;
&lt;br /&gt;
* See also this twitter thread for detailed information on possible mechanisms. https://x.com/angryhacademic/status/1741968457296490977?s=20&lt;br /&gt;
* This review presents a comprehensive overview of the present knowledge of nicotine action on mitochondrial function. Observed effects of nicotine exposure on the mitochondrial respiratory chain, oxidative stress, calcium homeostasis, mitochondrial dynamics, biogenesis, and mitophagy are discussed, considering the context of the experimental design.&lt;br /&gt;
* The potential action of nicotine on cellular adaptation and cell survival is also examined through its interaction with mitochondria. Although a large number of studies have demonstrated the impact of nicotine on various mitochondrial activities, elucidating its mechanism of action requires further investigation.&lt;br /&gt;
* J Bioenerg Biomembr. 2019; 51(4): 259–276. Published online 2019 Jun 13. doi: 10.1007/s10863-019-09800-z PMCID: PMC6679833 PMID: 31197632&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Digestive Tract / Bowel&#039;&#039;&#039;= &lt;br /&gt;
===2024: [https://academic.oup.com/ntr/advance-article-abstract/doi/10.1093/ntr/ntae193/7727428 The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis]===&lt;br /&gt;
*&amp;quot;Despite different mechanisms of action, both ENDS and CCs attenuated on-going colon inflammation, enhanced healing and ameliorated recovery of injured intestines of DSS-treated mice and UC patients.&amp;quot;&lt;br /&gt;
**Citation: Kastratovic N, Markovic V, Arsenijevic A, Volarevic A, Zdravkovic N, Zdravkovic M, Brankovic M, Gmizic T, Harrell CR, Jakovljevic V, Djonov V, Volarevic V. The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis. Nicotine Tob Res. 2024 Aug 5:ntae193. doi: 10.1093/ntr/ntae193. Epub ahead of print. PMID: 39101540.&lt;br /&gt;
***Paywalled, unable to view funding/COI&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects]===&lt;br /&gt;
*Analysis of several studies - some animal.&lt;br /&gt;
*In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity.&lt;br /&gt;
**Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889&lt;br /&gt;
***Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S000927971931734X Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Conclusion: &amp;quot;Taken together, we demonstrated that nicotine inhibits apoptosis and proliferation by modulating AMPK/mTOR pathway-mediated autophagy and improves colitis severity in the DSS-induced UC mouse model. These findings provide new insights into the mechanism of nicotine treatment on UC autophagy. Further exploration of the mechanism of nicotine in autophagy and targeting factors might be considered a new approach for ulcerative colitis treatment.&amp;quot;&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.cbi.2020.108943 PDF Full paper]&lt;br /&gt;
**Citation: Gao Q, Bi P, Luo D, Guan Y, Zeng W, Xiang H, Mi Q, Yang G, Li X, Yang B. Nicotine-induced autophagy via AMPK/mTOR pathway exerts protective effect in colitis mouse model. Chem Biol Interact. 2020 Feb 1;317:108943. doi: 10.1016/j.cbi.2020.108943. Epub 2020 Jan 10. PMID: 31926917.&lt;br /&gt;
***Acknowledgement: This work was supported by the Yunnan Key Laboratory of Tobacco Chemistry Project [Grant No. 2017539200340397].&lt;br /&gt;
&lt;br /&gt;
===2018 [https://academic.oup.com/jleukbio/article-abstract/104/5/1013/6935503 Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment]===&lt;br /&gt;
*Animal/Cell study&lt;br /&gt;
*These results supported our hypothesis that nicotine treatment ameliorated colitis through the suppression of MAdCAM-1 expression on the microvessels in the inflamed colon. Further investigation is warranted on the role of nicotine in the treatment of UC.&lt;br /&gt;
*[https://sci-hub.st/10.1002/JLB.3A0717-304R PDF Full paper]&lt;br /&gt;
**Citation: Maruta K, Watanabe C, Hozumi H, Kurihara C, Furuhashi H, Takajo T, Okada Y, Shirakabe K, Higashiyama M, Komoto S, Tomita K, Nagao S, Ishizuka T, Miura S, Hokari R. Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment. J Leukoc Biol. 2018 Nov;104(5):1013-1022. doi: 10.1002/JLB.3A0717-304R. Epub 2018 Jun 14. PMID: 29901817.&lt;br /&gt;
***Acknowledgement: This research was supported by grants from the National Defense Medical College, by Grants-in-aid for the Intractable Diseases Project of the Ministry of Health, Labour, and Welfare of Japan, and by Grantsin-aid for Scientific Research from the Japanese Ministry of Education (2646080).&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533410/ Novel Insights on the Effect of Nicotine in a Murine Colitis Model]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Administration of low, but not high, doses of oral nicotine in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of tumor necrosis factor-α.&lt;br /&gt;
**Citation: AlSharari SD, Akbarali HI, Abdullah RA, Shahab O, Auttachoat W, Ferreira GA, White KL, Lichtman AH, Cabral GA, Damaj MI. Novel insights on the effect of nicotine in a murine colitis model. J Pharmacol Exp Ther. 2013 Jan;344(1):207-17. doi: 10.1124/jpet.112.198796. Epub 2012 Oct 31. PMID: 23115221; PMCID: PMC3533410.&lt;br /&gt;
***Acknowledgement: This work was supported by National Institutes of Health [Grants DA-019377; (to M.I.D.) and DK 046367] (to H.I.A.).&lt;br /&gt;
&lt;br /&gt;
===2012 [https://journals.physiology.org/doi/full/10.1152/ajpgi.00411.2011 Nicotine suppresses hyperexcitability of colonic sensory neurons and visceral hypersensivity in mouse model of colonic inflammation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*&amp;quot;In summary, in an acute and postinflammatory model of colitis, we demonstrated that nAChRs mediate suppression of hyperexcitability of colonic sensory. The present study also highlights the potential of in vivo treatment with nicotine towards its antinociceptive effects in colonic inflammation.&amp;quot;&lt;br /&gt;
**Citation: Abdrakhmanova GR, Kang M, Imad Damaj M, Akbarali HI. Nicotine suppresses hyperexcitability of colonic sensory neurons and visceral hypersensivity in mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol. 2012 Apr;302(7):G740-7. doi: 10.1152/ajpgi.00411.2011. Epub 2012 Jan 12. PMID: 22241859; PMCID: PMC3330777.&amp;quot;&lt;br /&gt;
***Acknowledgement: This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-046367 (to H. I. Akbarali).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
**Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
***Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.hindawi.com/journals/grp/2008/237185/ Nicotine Enemas for Active Crohn&#039;s Colitis: An Open Pilot Study]=== &lt;br /&gt;
*Smoking has a detrimental effect in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Crohn&#039;s disease (CD)&#039;&#039;&#039;]], but this may be due to factors in smoking other than nicotine. Given that transdermal nicotine benefits [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ulcerative colitis (UC)&#039;&#039;&#039;]], and there is a considerable overlap in the treatment of UC and CD, the possible beneficial effect of nicotine has been examined in patients with Crohn&#039;s colitis.&lt;br /&gt;
*In this relatively small study of patients with active Crohn&#039;s colitis, 6 mg nicotine enemas appeared to be of clinical benefit in most patients. They were well tolerated and safe.&lt;br /&gt;
*[http://downloads.hindawi.com/journals/grp/2008/237185.pdf PDF Version]&lt;br /&gt;
**Citation: J. R. Ingram, J. Rhodes, B. K. Evans, and G. A. O. Thomas, Hindawi Publishing Corporation, Gastroenterology Research and Practice, Volume 2008, Article ID 237185, 6 pages, doi:10.1155/2008/237185&lt;br /&gt;
***Acknowledgements: J. R. Ingram was supported by the Gastrointestinal Foundation Trust. SLA Pharma gave financial support to the project. The authors are indebted to Dr. J. T. Green (of Cardiff and Vale Hospitals Trust) who referred patients, and to Professor G. T. Williams (GTW) who performed all histological assessments.&lt;br /&gt;
&lt;br /&gt;
===2004 [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004722.pub2/full Transdermal nicotine for induction of remission in ulcerative colitis]=== &lt;br /&gt;
*Ulcerative colitis is largely a disease of nonsmokers and patients who have quit smoking. Randomised controlled trials were therefore developed to test the hypothesis that nicotine patches can induce remission of a flare of ulcerative colitis. This review provides evidence that transdermal nicotine is superior to placebo (fake patch) for the treatment of active ulcerative colitis.&lt;br /&gt;
*[https://sci-hub.st/https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004722.pub2/full PDF Version]&lt;br /&gt;
**Citation: McGrath, J., McDonald, J. W., &amp;amp; MacDonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd004722.pub2&lt;br /&gt;
***Acknowledgements: Funding for the IBD/FBD Review Group (October 1, 2005 - September 30, 2010) has been provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch; the Canadian Agency for Drugs and Technologies in Health (CADTH); and the CIHR Institutes of Health Services and Policy Research; Musculoskeletal Health and Arthritis; Gender and Health; Human Development, Child and Youth Health; Nutrition, Metabolism and Diabetes; and Infection and Immunity. Miss Ila Stewart has provided support for the IBD/FBD Review Group through the Olive Stewart Fund.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12072594/ Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Conclusions: (1) Two weeks of nicotine administration leads to contrasting effects on jejunal and colonic inflammation in IL-10 -/- mice. (2) Nicotine ameliorated inflammation in the colon, which was associated with enhanced expression of two protective peptides.&lt;br /&gt;
*[https://sci-hub.st/10.1097/00042737-200206000-00005 PDF of full paper]&lt;br /&gt;
**Citation: Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. Eur J Gastroenterol Hepatol. 2002 Jun;14(6):607-14. doi: 10.1097/00042737-200206000-00005. PMID: 12072594.&lt;br /&gt;
&lt;br /&gt;
===1999 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/ Nicotine treatment for ulcerative colitis]=== &lt;br /&gt;
*No withdrawal symptoms suggesting nicotine addiction have been reported either after 4–6 weeks of therapy in short-term studies, or after a period of up to 6 months in the only long-term study available&lt;br /&gt;
*It can be concluded from these data that transdermal nicotine alone has limited efficacy in active ulcerative colitis and is ineffective as maintenance treatment. On the other hand, if administered in combination with mesalazine, nicotine is superior to placebo in promoting clinical remission of ulcerative colitis of mild to moderate degree, may represent an efficacious alternative to steroids in selected cases and, when effective, seems to exert a longer-lasting therapeutic effect than prednisone.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014383/pdf/bcp0048-0481.pdf PDF Version]&lt;br /&gt;
**Citation: Guslandi M. Nicotine treatment for ulcerative colitis. Br J Clin Pharmacol. 1999 Oct;48(4):481-4. doi: 10.1046/j.1365-2125.1999.00039.x. PMID: 10583016; PMCID: PMC2014383.&lt;br /&gt;
***No funding/COI information&lt;br /&gt;
&lt;br /&gt;
===1996 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2398677/ The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis.]=== &lt;br /&gt;
*Nicotine is believed to be the pharmacological ingredient of tobacco that is responsible for this beneficial deterrent of UC and several clinical trials using nicotine have demonstrated it to be an effective therapeutic agent in the treatment of ulcerative colitis. Although the aetiology of ulcerative colitis is unclear, current research using nicotine-based products has produced some interesting clues, together with the possibility of some form of therapeutic treatment based on nicotine administration.&lt;br /&gt;
*[https://sci-hub.st/10.1136/pgmj.72.854.714 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J. The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Postgrad Med J. 1996 Dec;72(854):714-8. doi: 10.1136/pgmj.72.854.714. PMID: 9015463; PMCID: PMC2398677.&lt;br /&gt;
&lt;br /&gt;
===1996: [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*Nicotine may have therapeutic uses in the treatment of ulcerative colitis.&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1994: [https://pubmed.ncbi.nlm.nih.gov/8114833/ Transdermal nicotine for active ulcerative colitis]===&lt;br /&gt;
*The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.&lt;br /&gt;
**Citation: Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994 Mar 24;330(12):811-5. doi: 10.1056/NEJM199403243301202. PMID: 8114833.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against ulcerative colitis (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Down&#039;s Syndrome&#039;&#039;&#039;= &lt;br /&gt;
===2001: [https://link.springer.com/chapter/10.1007/978-3-7091-6262-0_19 Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome]===&lt;br /&gt;
*To explore the potential for cognitive enhancement utilizing nicotinic stimulation, 8 patients with Down syndrome (aged 18.5–31 years) received placebo and a single dose of transdermal nicotine (5mg patch) over 2h in a single-blind, within-subjects repeated measures design. &lt;br /&gt;
*Neuropsychological tests exhibited improvements in digit symbol performance subtest in 4 of 8 subjects and 7 of 8 subjects in the Frankfurt Attention Inventory. These results suggest that stimulating central nicotinic receptors might have an acute cognitive benefit in young adult Down syndrome subjects.&lt;br /&gt;
*Citation: Bernert G., Sustrova M., Sovcikova E., Seidl R., Lubec G. (2001) Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome. In: Lubec G. (eds) Protein Expression in Down Syndrome Brain. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6262-0_19&lt;br /&gt;
&lt;br /&gt;
===2000 [https://pubmed.ncbi.nlm.nih.gov/11052587/ Effects of transdermal nicotine on cognitive performance in Down&#039;s syndrome]=== &lt;br /&gt;
*We investigated the effect of nicotine-agonistic stimulation with 5 mg transdermal patches, compared with placebo, on cognitive performance in five adults with the disorder. Improvements possibly related to attention and information processing were seen for Down&#039;s syndrome patients compared with healthy controls. Our preliminary findings are encouraging, although not generalizable because of small numbers. &lt;br /&gt;
*[https://sci-hub.st/10.1016/S0140-6736(00)02848-8 PDF Version]&lt;br /&gt;
*Seidl R, Tiefenthaler M, Hauser E, Lubec G. Effects of transdermal nicotine on cognitive performance in Down&#039;s syndrome. Lancet. 2000 Oct 21;356(9239):1409-10. doi: 10.1016/S0140-6736(00)02848-8. PMID: 11052587.&lt;br /&gt;
*Acknowledgements: We thank Pharmacia-Upjohn, Uppsala, Sweden, for providing transdermal nicotine patches. This study was supported by the Red Bull Company, Salzburg.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Dyskinesia&#039;&#039;&#039;=&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
*In summary, our data show that nicotine treatment decreases haloperidol-induced VCMs [vacuous chewing movements] in an established rat model of tardive dyskinesia. The demonstration that nicotine removal leads to a return of VCMs, whereas nicotine re-exposure reduced haloperidol-induced VCMs, suggests a causal relationship. These data have clinical applications for the treatment of tardive dyskinesias associated with long-term antipsychotic treatment using nicotine.&lt;br /&gt;
*Bordia T, McIntosh JM, Quik M. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. J Pharmacol Exp Ther. 2012 Mar;340(3):612-9. doi: 10.1124/jpet.111.189100. Epub 2011 Dec 5. PMID: 22144565; PMCID: PMC3286320.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Endurance / Exercise / Athletic Performance&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2024 Article: [https://web.archive.org/web/20241002001111/https://www.golfdigest.com/story/tour-pros-little-helper-does-nicotine-create-a-competitive-advantage Tour Pro’s Little Helper: Does nicotine create a competitive advantage?]===&lt;br /&gt;
*&amp;quot;In all, we talked to nearly 100 pro golfers to learn more about the popularity and usage patterns of nicotine on the major professional tours. Some told us they turn to tobacco or nicotine products for an energy boost; others say it helps them concentrate or feel relaxed. But for many, it’s just about keeping on.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.mdpi.com/1660-4601/20/2/1009 The Effect of High Nicotine Dose on Maximum Anaerobic Performance and Perceived Pain in Healthy Non-Smoking Athletes: Crossover Pilot Study]===&lt;br /&gt;
*The lower perception of pain intensity that we reported after the 8 mg nicotine dose application might be an important factor that affects performance. However, we did not report any improvement in physical performance parameters.&lt;br /&gt;
**Citation: Bartík P, Šagát P, Pyšná J, Pyšný L, Suchý J, Trubák Z, Petrů D. The Effect of High Nicotine Dose on Maximum Anaerobic Performance and Perceived Pain in Healthy Non-Smoking Athletes: Crossover Pilot Study. Int J Environ Res Public Health. 2023 Jan 5;20(2):1009. doi: 10.3390/ijerph20021009. PMID: 36673765; PMCID: PMC9859273.&lt;br /&gt;
***Acknowledgement: The authors would like to acknowledge the support of Prince Sultan University for paying the article processing charges (APC) of this publication. This study was conducted by the SSDRL research group.&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745004/ Acute Effects of Nicotine on Physiological Responses and Sport Performance in Healthy Baseball Players]===&lt;br /&gt;
*Our HRV and salivary analysis revealed that nicotine could induce endocrine and sympathetic nerve activity in healthy male baseball players who had never smoked. Compared with the placebo group, the nicotine group exhibited enhanced cognitive function (an average decrease in motor reaction time of 11.14%; an average decrease in motor reaction time of 5.72%) and baseball-hitting performance (an average increase of 34.69%), and small effect sizes were observed for these results. However, muscle strength did not increase after nicotine intake.&lt;br /&gt;
**Citation: Fang SH, Lu CC, Lin HW, Kuo KC, Sun CY, Chen YY, Chang WD. Acute Effects of Nicotine on Physiological Responses and Sport Performance in Healthy Baseball Players. Int J Environ Res Public Health. 2022 Jan 4;19(1):515. doi: 10.3390/ijerph19010515. PMID: 35010774; PMCID: PMC8745004.&lt;br /&gt;
***Acknowledgement: Study was supported by the Ministry of Science and Technology in Taiwan (No: MOST 107-2410-H-028-002-MY2 and MOST 109-2410-H-028-009-MY3).&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.tandfonline.com/doi/full/10.1186/s12970-021-00413-9 Nicotine supplementation enhances simulated game performance of archery athletes]===&lt;br /&gt;
*In summary, these results indicated that 2-mg nicotine gum supplementation enhanced cognitive function, decreased saliva α-amylase activity and HRV through stimulating the sympathetic adrenergic system. More importantly, the archery scores were significantly increased after nicotine supplementation.&lt;br /&gt;
**Citation: Hung BL, Chen LJ, Chen YY, Ou JB, Fang SH. Nicotine supplementation enhances simulated game performance of archery athletes. J Int Soc Sports Nutr. 2021 Feb 18;18(1):16. doi: 10.1186/s12970-021-00413-9. PMID: 33602279; PMCID: PMC7890628.&lt;br /&gt;
***Acknowledgement: Funded by the Taiwan Ministry of Science and Technology (MOST104–2628-H-028-001-MY2).&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5236038/ A Randomised, Placebo-Controlled, Crossover Study Investigating the Effects of Nicotine Gum on Strength, Power and Anaerobic Performance in Nicotine-Naïve, Active Males]===&lt;br /&gt;
*The present study has demonstrated that low-dose (2 mg) nicotine gum increases leg extensor torque, but counter-movement jump and anaerobic capacity during WAnT remained unchanged when compared to a placebo, whilst there were minimal effects of the 4-mg nicotine gum on the performance parameters measured. Together with our previous observation [24], these results indicate that nicotine per se can improve exercise endurance and muscular strength, something that WADA should continue to monitor alongside patterns of (mis)use.&lt;br /&gt;
**Citation: Mündel T, Machal M, Cochrane DJ, Barnes MJ. A Randomised, Placebo-Controlled, Crossover Study Investigating the Effects of Nicotine Gum on Strength, Power and Anaerobic Performance in Nicotine-Naïve, Active Males. Sports Med Open. 2017 Dec;3(1):5. doi: 10.1186/s40798-016-0074-8. Epub 2017 Jan 13. PMID: 28092056; PMCID: PMC5236038.&lt;br /&gt;
***Acknowledgement: This study was funded in part by a grant from the World Anti-Doping Agency.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/expphysiol.2006.033373 Effect of transdermal nicotine administration on exercise endurance in men]=== &lt;br /&gt;
*Nicotine improved exercise endurance by 17 ± 7%, and in the absence of any effect on the usual peripheral markers, such as ventilation, heart rate and blood metabolites, we conclude that nicotine prolongs endurance by a central mechanism that may involve nicotinic receptor activation and/or altered activity of dopaminergic pathways.&lt;br /&gt;
*[https://physoc.onlinelibrary.wiley.com/doi/pdf/10.1113/expphysiol.2006.033373 PDF Version]&lt;br /&gt;
**Citation: Mündel T, Jones DA. Effect of transdermal nicotine administration on exercise endurance in men. Exp Physiol. 2006 Jul;91(4):705-13. doi: 10.1113/expphysiol.2006.033373. Epub 2006 Apr 20. PMID: 16627574.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Eyes - Ocular - Vision&#039;&#039;&#039;=&lt;br /&gt;
==Myopia (short-sighted, near-sighted)==&lt;br /&gt;
===2024 [https://iovs.arvojournals.org/article.aspx?articleid=2800816 Administration of Nicotine Can Inhibit Myopic Growth in Animal Models]===&lt;br /&gt;
*Nicotine, administered as an intravitreal injection or topical eye drop, significantly inhibits the development of experimental myopia.&lt;br /&gt;
**Citation: Thomson K, Karouta C, Ashby R. Administration of Nicotine Can Inhibit Myopic Growth in Animal Models. Invest Ophthalmol Vis Sci. 2024 Sep 3;65(11):29. doi: 10.1167/iovs.65.11.29. PMID: 39292451; PMCID: PMC11412605.&lt;br /&gt;
***Acknowledgement: Funded by ANU Connect Ventures through a Discovery Translation Fund grant (Project ID: DTF311). &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Huntington’s Disease&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2005: [https://pubmed.ncbi.nlm.nih.gov/16140176/ Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington&#039;s disease in rats]===&lt;br /&gt;
*These results clearly showed neuroprotective effect of nicotine in experimental model of HD. The clinical relevance of these findings in HD patients remains unclear and warrants further studies.&lt;br /&gt;
*In conclusion, nicotine significantly and dose-dependently attenuated 3-NP-induced striatal lesions and behavioral deficits in rats. The protective effect of nicotine may be attributed to its ability of restoring striatal DA levels in 3-NP intoxicated rats.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.brainresbull.2005.06.024 PDF Version]&lt;br /&gt;
**Citation: Tariq M, Khan HA, Elfaki I, Al Deeb S, Al Moutaery K. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington&#039;s disease in rats. Brain Res Bull. 2005 Sep 30;67(1-2):161-8. doi: 10.1016/j.brainresbull.2005.06.024. PMID: 16140176.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Hashimoto&#039;s disease (Hashimoto thyroiditis)&#039;&#039;&#039;=&lt;br /&gt;
*[https://www.hopkinsmedicine.org/health/conditions-and-diseases/hashimotos-thyroiditis Hashimoto&#039;s Thyroiditis] &amp;quot;is when your thyroid gland becomes irritated or inflamed. Hashimoto thyroiditis is the most common type of this health problem. It may also be called chronic autoimmune thyroiditis. This thyroiditis is an autoimmune disease. It occurs when your body makes antibodies that attack the cells in your thyroid. The thyroid gland becomes overrun with white blood cells and becomes scarred. This makes the gland feel firm and rubbery. The thyroid then can’t make enough of the thyroid hormone.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2020: [https://www.endocrine-abstracts.org/ea/0070/ea0070oc8.4?_ga=2.114580999.1434360570.1735281186-102848752.1735281184 Cigarette smoking and the risk to develop symptoms of Hashimoto’s thyroiditis]===&lt;br /&gt;
*&amp;quot;In patients who had discontinued smoking at the age of 39 years or more, the diagnosis of HT was predominantly made after the discontinuation of smoking.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2013: [https://onlinelibrary.wiley.com/doi/10.1111/cen.12222 Smoking and thyroid]===&lt;br /&gt;
*&amp;quot;Smoking has distinct associations with thyroid function and size in healthy subjects. It has remarkable and contrasting associations with thyroid function in autoimmune thyroid disease (lower risk of Hashimoto&#039;s disease and higher risk of Graves’ disease) and with thyroid size in nodular disease (lower risk of thyroid carcinoma and higher risk of nontoxic goitre and multinodularity). The observed associations likely indicate causal relationships in view of consistent associations across studies, the presence of a dose–response relationship and disappearance of the associations after cessation of smoking. Which mechanisms mediate the many effects of smoking remains largely obscure. Probably, they differ between the various effects. The divergent effects of smoking on the expression of autoimmune thyroid disease are intriguing and reminiscent on the contrasting effects of smoking on inflammatory bowel disease: protective against ulcerative colitis (OR 0·41, 0·34–0·48) but risky for Crohn&#039;s disease (OR 1·61, 1·27–2·03).&amp;quot;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Hypersensitivity Pneumonitis / Extrinsic Allergic Alveolitis&#039;&#039;&#039; (See Also: Allergies/Hayfever/Histamines)=&lt;br /&gt;
*[https://www.nhlbi.nih.gov/health/hypersensitivity-pneumonitis Hypersensitivity pneumonitis] is a rare immune system disorder that affects the lungs. This disease is also called bird or pigeon fancier’s lung, farmer’s lung, hot tub lung, cheese worker&#039;s lung, Bagassosis, mushroom worker&#039;s lung, malt worker&#039;s lung, or humidifier lung. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/books/NBK499918/ Hypersensitivity pneumonitis] (HP) classified as an interstitial lung disease is characterized by a complex immunological reaction of the lung parenchyma in response to repetitive inhalation of a sensitized allergen.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/books/NBK499918/ Hypersensitivity Pneumonitis]===&lt;br /&gt;
*Cigarette smoking seems to protect from developing clinically significant HP likely due to nicotine inhibiting macrophage activation and lymphocyte proliferation. &lt;br /&gt;
*However, smokers who develop HP have been shown to have a more severe course and higher mortality.&lt;br /&gt;
**Citation: Chandra D, Cherian SV. Hypersensitivity Pneumonitis. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499918/&lt;br /&gt;
&lt;br /&gt;
===2007: [https://academic.oup.com/qjmed/article-abstract/100/4/233/2258683?redirectedFrom=fulltext Extrinsic allergic alveolitis: incidence and mortality in the general population]===&lt;br /&gt;
*We identified 271 incident cases of EAA (mean age at diagnosis 57 years, 51% male). Between 1991 and 2003, the incident rate for EAA was stable at ∼0.9 cases per 100 000 person-years. In comparison to the 1084 general population controls, patients with EAA were less likely to smoke (odds ratio 0.56, 95%CI 0.39–0.81), but had a marked increase in the risk of death (hazard ratio 2.98, 95%CI 2.05–4.33).&lt;br /&gt;
**Citation: M. Solaymani-Dodaran, J. West, C. Smith, R. Hubbard, Extrinsic allergic alveolitis: incidence and mortality in the general population, QJM: An International Journal of Medicine, Volume 100, Issue 4, April 2007, Pages 233–237, https://doi.org/10.1093/qjmed/hcm008&lt;br /&gt;
&lt;br /&gt;
===2002: [https://www.atsjournals.org/doi/10.1164/rccm.200210-1154OC Inhibitory Effect of Nicotine on Experimental Hypersensitivity Pneumonitis In Vivo and In Vitro]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Results of this study show that nicotine reduces the alveolar inflammatory response to S. rectivirgula antigen and affects some AM (stimulated with LPS or S. rectivirgula) functions in vitro. This influence could be, at least in part, responsible for the protection that smokers have against development of HP. Because nicotine is effective in the treatment of ulcerative colitis, it could also be of interest in the treatment of HP and other pulmonary inflammatory diseases.&lt;br /&gt;
**Citation: Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am J Respir Crit Care Med. 2004 Apr 15;169(8):903-9. doi: 10.1164/rccm.200210-1154OC. Epub 2003 Dec 30. PMID: 14701707.&lt;br /&gt;
&lt;br /&gt;
===1992: [https://pubmed.ncbi.nlm.nih.gov/1344064/ Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum]===&lt;br /&gt;
*It was concluded that cigarette smoking had a suppressive effect on the outbreak of SHP, but smoking caused no further suppression after the disease was established.&lt;br /&gt;
**Citation: Arima K, Ando M, Ito K, Sakata T, Yamaguchi T, Araki S, Futatsuka M. Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum. Arch Environ Health. 1992 Jul-Aug;47(4):274-8. doi: 10.1080/00039896.1992.9938361. PMID: 1344064.&lt;br /&gt;
&lt;br /&gt;
===1987: [https://pubmed.ncbi.nlm.nih.gov/3499342/ Prevalence and incidence of chronic bronchitis and farmer&#039;s lung with respect to age, sex, atopy, and smoking]===&lt;br /&gt;
*Farmer&#039;s lung was only slightly more common among atopic than among non-atopic subjects and twice as common among non-smokers as among smokers.&lt;br /&gt;
**Citation: Terho EO, Husman K, Vohlonen I. Prevalence and incidence of chronic bronchitis and farmer&#039;s lung with respect to age, sex, atopy, and smoking. Eur J Respir Dis Suppl. 1987;152:19-28. PMID: 3499342.&lt;br /&gt;
&lt;br /&gt;
===1977: [https://pmc.ncbi.nlm.nih.gov/articles/PMC470791/ Extrinsic allergic alveolitis: a disease commoner in non-smokers.]===&lt;br /&gt;
*In the literature of extrinsic allergic alveolitis non-smokers predominate in those papers in which smoking habits are recorded (Hapke et al., 1968; Schlueter et al., 1969; Schofield et al., 1976). Studies of the prevalence of precipitating antibodies against Micropolyspora faeni in farmers have shown that they are detected significantly more often in non-smokers than in smokers (Morgan et al., 1975).&lt;br /&gt;
**Citation: Warren CP. Extrinsic allergic alveolitis: a disease commoner in non-smokers. Thorax. 1977 Oct;32(5):567-9. doi: 10.1136/thx.32.5.567. PMID: 594937; PMCID: PMC470791.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Inflammation&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871277/  Effect of Nicotine on Immune System Function]===&lt;br /&gt;
*Despite the completely destructive and harmful effects of cigarette smoke, nicotine via stimulation of the α7 receptor can promote the anti-inflammatory benefits on the immune system. However, these effects depend on the concentration, and administration methods are different and sometimes contradictory. It can be used successfully to treat or inhibit autoimmune diseases. Although the exact mechanism of this treatment is unknown, it appears to involve inhibiting downstream intracellular pathways that lead to the secretion of pre-inflammatory cytokines.&lt;br /&gt;
**Citation: Mahmoudzadeh L, Abtahi Froushani SM, Ajami M, Mahmoudzadeh M. Effect of Nicotine on Immune System Function. Adv Pharm Bull. 2023 Jan;13(1):69-78. doi: 10.34172/apb.2023.008. Epub 2022 Jan 4. PMID: 36721811; PMCID: PMC9871277.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://onlinelibrary.wiley.com/doi/10.1111/acer.15103 Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco]===&lt;br /&gt;
*Our findings may indicate that nicotine has anti-inflammatory effects in patients with AUD.&lt;br /&gt;
**Citation: Bolstad I, Lien L, Moe JS, Pandey S, Toft H, Bramness JG. Inflammatory cytokines in alcohol use disorder patients are lower in smokers and users of smokeless tobacco. Alcohol Clin Exp Res (Hoboken). 2023 Jul;47(7):1352-1363. doi: 10.1111/acer.15103. Epub 2023 May 30. PMID: 37208927.&lt;br /&gt;
***Acknowledgement: This work was financially supported by The Research Council of Norway, grant FRIPRO 251140.&lt;br /&gt;
&lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fimmu.2022.826889/full Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects]===&lt;br /&gt;
*Analysis of several studies - some animal.&lt;br /&gt;
*In general, nicotine is beneficial in ulcerative colitis; in particular, nicotine transdermal patches or nicotine enemas have shown significantly improved histological and global clinical scores of colitis, inhibited pro-inflammatory cytokines in macrophages, and induced protective autophagy to maintain intestinal barrier integrity.&lt;br /&gt;
**Citation: Zhang W, Lin H, Zou M, Yuan Q, Huang Z, Pan X and Zhang W (2022) Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. Front. Immunol. 13:826889. doi: 10.3389/fimmu.2022.826889&lt;br /&gt;
***Acknowledgements: This work was supported by the National Natural Science Foundation of China (grant number 81903319), Natural Science Foundation of Guangdong Province of China (grant number 2021A1515011220), Administration of Traditional Chinese Medicine of Guangdong Province of China (grant number 20211008), Special Fund for Young Core Scientists of Agriculture Science (grant number R2019YJ-QG001), Special Fund for Scientific Innovation Strategy—Construction of High-Level Academy of Agriculture Science (grant number R2018YJ-YB3002), Top Young Talents of Guangdong Hundreds of Millions of Projects of China (grant number 87316004), the foundation of director of Crops Research Institute, Guangdong Academy of Agricultural Sciences (grant number 202205) and Outstanding Young Scholar of Double Hundred Talents of Jinan University of China.&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.mdpi.com/1660-4601/18/2/483/htm Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study]===&lt;br /&gt;
*HSC-2 cell viability was not impaired by nicotine at the concentrations usually observed in smokers; increased expressions of IL-8 and ICAM-1 induced by P. gingivalis LPS or TNF-α were diminished by nicotine treatment. Additionally, an inhibitory effect on β-defensin production was also demonstrated. Apart from being the usually alleged harmful substance, nicotine probably exerted a suppressive effect on inflammatory factors production in HSC-2 cells.&lt;br /&gt;
**Citation: An, N., Holl, J., Wang, X., Rausch, M. A., Andrukhov, O., &amp;amp; Rausch-Fan, X. (2021). Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study. International Journal of Environmental Research and Public Health, 18(2), 483. https://doi.org/10.3390/ijerph18020483&lt;br /&gt;
***Acknowledgement: This research was supported by the grant from Ministry of Science and Technology of China under a contract from the International Science &amp;amp; Technology Cooperation Program Foundation Nr.1019 and the National Natural Science Foundation of China (Grant No. 81500859).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704168/ Does Nicotine Prevent Cytokine Storms in COVID-19?]===&lt;br /&gt;
*Case study of one individual&lt;br /&gt;
*Nicotine, an α7-nACh receptor agonist, may boost the cholinergic anti-inflammatory pathway and hinder the uncontrolled overproduction of pro-inflammatory cytokines triggered by the SARS-CoV-2 virus, which is understood to be the main pathway to poor outcomes and death in severe COVID-19.&lt;br /&gt;
*In the absence of any effective treatment for COVID-19, further research as to whether nicotine replacement offers protection against severe SAR-CoV-2 infection in smokers is clearly essential. If the mechanisms through which nicotine may interact with the virus remain speculative, the effects of route of administration, duration, dosing and frequency of use of nicotine on any such interaction are unknown. Should NRT be found to be of help in the management of COVID-19, it would be yet another strong reason to persuade smokers to switch to NRT and ultimately quit smoking.&lt;br /&gt;
**Citation: Dratcu L, Boland X. Does Nicotine Prevent Cytokine Storms in COVID-19? Cureus. 2020 Oct 28;12(10):e11220. doi: 10.7759/cureus.11220. PMID: 33269148; PMCID: PMC7704168.&lt;br /&gt;
***Acknowledgement: All authors have declared that no financial support was received from any organization for the submitted work.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300218/ Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm]===&lt;br /&gt;
*Abstract: &amp;quot;SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.&amp;quot;&lt;br /&gt;
**Citation: Gonzalez-Rubio J, Navarro-Lopez C, Lopez-Najera E, Lopez-Najera A, Jimenez-Diaz L, Navarro-Lopez JD, Najera A. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front Immunol. 2020 Jun 11;11:1359. doi: 10.3389/fimmu.2020.01359. PMID: 32595653; PMCID: PMC7300218.&lt;br /&gt;
***Acknowledgement: This work was supported by University of Castilla-La Mancha Research Programme 2020-GRIN-28705.&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
* This study provides evidence that nicotine alters the infiltration of proinflammatory monocytes and neutrophils into the CNS of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] mice via multiple [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChRs&#039;&#039;&#039;]], including the α7 and α9 subtypes. Nicotine appears to achieve these effects by inhibiting the expression of CCL2 and CXCL2, two cytokines involved in the chemotaxis of proinflammatory monocytes and neutrophils, respectively. The use of ligands that are selective for one or both of these nAChR subtypes may offer a beneficial clinical outcome, and thus provide a valuable therapeutic strategy for neuroinflammatory disorders such as MS.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/pdf/1501613.pdf PDF Version]&lt;br /&gt;
**Citation: Jiang W, St-Pierre S, Roy P, Morley BJ, Hao J, Simard AR. Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis. J Immunol. 2016 Mar 1;196(5):2095-108. doi: 10.4049/jimmunol.1501613. Epub 2016 Jan 25. PMID: 26810225; PMCID: PMC4760232.&lt;br /&gt;
***Acknowledgements: This work was supported by grants from the Multiple Sclerosis Society of Canada (to A.R.S.), the New Brunswick Health Research Foundation (to A.R.S.), the New Brunswick Innovation Foundation (to A.R.S.), the Nebraska Tobacco Settlement Biomedical Research Fund (to B.J.M.), and the National Institutes of Health (Grant R01DC006907 to B.J.M.). Salary support was provided by the Centre de Formation Médicale du Nouveau-Brunswick (to W.J.) and the New Brunswick Innovation Foundation (to S.S-P. and P.R.).&lt;br /&gt;
*See Also - Related article: [https://mssociety.ca/research-news/article/ms-society-funded-study-shows-that-nicotine-reduces-the-invasion-of-harmful-immune-cells-into-the-brain-in-mice-with-an-ms-like-disease MS Society-funded study shows that nicotine reduces the invasion of harmful immune cells into the brain in mice with an MS-like disease]&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila and Chlamydia pneumonia infection...&lt;br /&gt;
**Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/ Novel Therapeutic Approach by Nicotine in Experimental Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Due to the proven therapeutic effect of nicotine on AD (Alzheimer’s Disease) and PD (Parkinson’s Disease), we decided to study the role of nicotine in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] as an animal model of MS. Our treatment group showed less inflammation in histopathological evaluation along with myelin sheet protection. Moreover, prevention group showed less inflammation compared with treatment group. Thus, nicotine might be recommended as a promising drug for [[Special:MyLanguage/Abbreviations|MS]] therapy.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version]&lt;br /&gt;
**Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034.&lt;br /&gt;
***Acknowledgement: No funding was provided for the preparation of this article.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/ Can nicotine use alleviate symptoms of psoriasis?]=== &lt;br /&gt;
*In light of recent data demonstrating that psoriasis is an immune-mediated disease, the possibility that novel anti-inflammatory treatments such as nicotine replacement therapy or analogues could have a beneficial effect on patients with psoriasis should be considered. This case described one such occasion in which it appeared that nicotine had a therapeutic effect on a patient’s psoriasis. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version]&lt;br /&gt;
**Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
**Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
***Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://pubmed.ncbi.nlm.nih.gov/21691078/ Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells]===&lt;br /&gt;
*In summary, we showed that nicotine could suppress TNF-α expression mainly through activation of the α7 nAChR subunit, which inhibited the MyD88/IκBα/NFκB signaling pathway in HBE16 airway epithelial cells. These findings may provide new information on the potential pharmacological effects of nicotine and nAChR in the treatment of respiratory inflammatory diseases. Further research on nicotine and nAChRs may provide more evidence for the treatment of inflammatory diseases and the development of related drugs.&lt;br /&gt;
*[https://www.karger.com/Article/Pdf/329982 PDF Version]&lt;br /&gt;
**Citation: Li, Q., Zhou, X. D., Kolosov, V. P., &amp;amp; Perelman, J. M. (2011). Nicotine reduces TNF-α expression through a α7 nAChR/MyD88/NF-ĸB pathway in HBE16 airway epithelial cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 27(5), 605–612. https://doi.org/10.1159/000329982&lt;br /&gt;
***Acknowledgement: This work was supported by the National Natural Science Foundation of China (No.81070031), and China-Russia Cooperation Research Program (81011120108).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://www.sciencedirect.com/science/article/abs/pii/S0306987711001691?via%3Dihub Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis]===&lt;br /&gt;
*In addition, nicotine or its metabolites can result in decrease of pro-inflammatory cytokines like tumor necrosis factor-α, interleukins 1 and 6, and increase of anti-inflammatory cytokine interleukin-10. Consequently, there is reduced susceptibility to RAS due to immunosuppression and/or reduction in inflammatory response.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2011.04.006 PDF Version]&lt;br /&gt;
**Citation: Subramanyam, R. V. (2011). Occurrence of recurrent aphthous stomatitis only on lining mucosa and its relationship to smoking – A possible hypothesis. Medical Hypotheses, 77(2), 185–187. doi:10.1016/j.mehy.2011.04.006&lt;br /&gt;
&lt;br /&gt;
===2008 [https://onlinelibrary.wiley.com/doi/10.1002/jnr.21901 Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Primary impact to the spinal cord results in stimulation of secondary processes that potentiate the initial trauma. Recent evidence indicates that nicotine can exert potent antioxidant and neuroprotective effects in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;spinal cord injury (SCI)&#039;&#039;&#039;]].&lt;br /&gt;
*The results of the present study indicate that [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;iNOS&#039;&#039;&#039;]] is induced in the early stages of SCI, leading to increased nitration of protein tyrosine residues and potentiation of inflammatory responses. Microglial cells appear to be the main cellular source of iNOS in SCI. In addition, nicotine-induced anti-inflammatory effects in SCI are mediated, at least in part, by the attenuation of iNOS overexpression through the receptor-mediated mechanism. This data may have significant therapeutic implications for the targeting of nicotine receptors in the treatment of compressive spinal cord trauma.&lt;br /&gt;
*[https://sci-hub.st/10.1002/jnr.21901 PDF Version]&lt;br /&gt;
**Citation: Lee, M.‐Y., Chen, L. and Toborek, M. (2009), Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J. Neurosci. Res., 87: 937-947.doi.org/10.1002/jnr.21901&lt;br /&gt;
***Acknowledgement: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693390/ Neuronal Nicotinic Alpha7 Receptors Modulate Inflammatory Cytokine Production in the Skin Following Ultraviolet Radiation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*Cytokine responses to UV in mice administered chronic oral nicotine, a nAChR agonist, were reduced... These results demonstrate that nAChRα7 can participate in modulating a local pro-inflammatory response in the absence of parasympathetic innervation.&lt;br /&gt;
**Citation: Osborne-Hereford AV, Rogers SW, Gahring LC. Neuronal nicotinic alpha7 receptors modulate inflammatory cytokine production in the skin following ultraviolet radiation. J Neuroimmunol. 2008 Jan;193(1-2):130-9. doi: 10.1016/j.jneuroim.2007.10.029. PMID: 18077004; PMCID: PMC2693390.&lt;br /&gt;
***Acknowledgement: These studies were funded by NIH grants DA015148 and DA018930 (LCG), PO1 HL72903 (LCG, SWR) and the Browning Foundation of Utah.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1809735/ Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-κB phosphorylation and nuclear factor-κB transcriptional activity through nicotinic acetylcholine receptor α7]===&lt;br /&gt;
*Macrophages/monocytes and the proinflammatory mediators, such as tumour necrosis factor (TNF)-α, prostaglandin E2 (PGE2), macrophage inflammatory protein (MIP)-1α and MIP-1α, play a critical role in the progression of immunological disorders including rheumatoid arthritis, Behçet’s disease and Crohn’s disease. In addition, the nicotinic acetylcholine receptor-α7 (α7nAChR) subunit is an essential regulator of inflammation. In this study, we evaluated the expression of the α7nAChR subunit on human peripheral monocytes and the effect of nicotine on the production of these proinflammatory mediators by activated monocytes.&lt;br /&gt;
*These suppressive effects of nicotine were caused at the transcriptional level and were mediated through α7nAChR. Nicotine suppressed the phosphorylation of I-κB, and then inhibited the transcriptional activity of nuclear factor-κB. These immunosuppressive effects of nicotine may contribute to the regulation of some immune diseases.&lt;br /&gt;
*This supports the therapeutic use of nicotine in some inflammatory diseases; the NF-κB activation pathway is one of the most critical molecular targets of nicotine therapy.&lt;br /&gt;
**Citation: Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. 2006 Oct;146(1):116-23. doi: 10.1111/j.1365-2249.2006.03169.x. PMID: 16968406; PMCID: PMC1809735.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Legionella Pneumophila (Legionnaires&#039; disease)&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]===&lt;br /&gt;
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection...&lt;br /&gt;
*Citation: D&#039;Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., &amp;amp; Clark, G. C. (2013). Targeting the &amp;quot;cytokine storm&amp;quot; for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome&#039;&#039;&#039;=&lt;br /&gt;
*See Also: COVID (Long COVID)&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Mental Health&#039;&#039;&#039;=&lt;br /&gt;
*See subcategories below&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Anxiety&#039;&#039;&#039;== &lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Behavior Issues&#039;&#039;&#039;== &lt;br /&gt;
*See Also: ADD/ADHD above&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0028390819305003?via%3Dihub Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies]=== &lt;br /&gt;
*Human and Animal Studies&lt;br /&gt;
*Clinical trials and case series report anti-aggressive effects of nicotine. Here we argue that the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] system, the molecular basis for the global public health problem of tobacco smoking, may also be a key target for modulation of aggressive behaviors. Future research should aim to clarify which forms of aggression are most strongly affected by nAChR modulation, identify the nAChR subtypes, circuits, and neurobiological mechanisms of nicotine action, and determine whether more selective nAChR-active agents can replicate or improve the serenic effects of nicotine, especially with chronic dosing. Given the prevalence of aggressive behaviors across neuropsychiatric disorders affecting the very young to the very old, these studies have the potential to have a significant impact on public health.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.neuropharm.2019.107929 PDF Version]&lt;br /&gt;
*Citation: Alan S. Lewis, Marina R. Picciotto, Regulation of aggressive behaviors by nicotinic acetylcholine receptors: Animal models, human genetics, and clinical studies, Neuropharmacology, Volume 167, 2020, 107929, ISSN 0028-3908, doi: 10.1016/j.neuropharm.2019.107929.&lt;br /&gt;
*Acknowledgements: This work was supported by National Institutes of Health grants MH116339 (A.S.L.), MH077681 and DA14241 (M.R.P.).&lt;br /&gt;
*Keywords: Nicotine, Nicotinic receptor, Aggression, Aggressive behavior, Impulsivity, Acetylcholine&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/ An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder]=== &lt;br /&gt;
*Taken together, our study provides evidence for the feasibility and tolerability of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine (TN/TNP)&#039;&#039;&#039;]] in a small sample of adults with severe [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Autism Spectrum Disorder (ASD)&#039;&#039;&#039;]] symptoms and pathological chronic aggression and irritability. &lt;br /&gt;
*Our results also suggest that TN may have a beneficial effect on aggression, irritability, and sleep in ASD, though the sample size of this study is too small to make definitive conclusions. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394231/pdf/nihms-950880.pdf PDF Version]&lt;br /&gt;
*Citation: Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG. An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. 2018 Aug;48(8):2748-2757. doi: 10.1007/s10803-018-3536-7. PMID: 29536216; PMCID: PMC6394231.&lt;br /&gt;
*Acknowledgements: This work was supported by Autism Speaks grant #9699 (ASL), National Institutes of Health grants R01DA14241 and R01MH077681 (MRP), R25MH071584, T32MH019961, and T32MH14276 (ASL), and the Child Study Center Associates and the AACAP Pilot Award for General Psychiatry Residents (GIvS).&lt;br /&gt;
*Keywords: Nicotine; nicotinic acetylcholine receptor; autism spectrum disorder; aggression; irritability; adult; sleep&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Depression&#039;&#039;&#039;== &lt;br /&gt;
===2022: [https://onlinelibrary.wiley.com/doi/full/10.1111/add.15950 The relationship between smokeless tobacco (snus) and anxiety and depression among adults and elderly people. A comparison to smoking in the Tromsø Study]===&lt;br /&gt;
*In Norway, current snus users differ from current smokers by having a higher socio-economic status and no detectable association with anxiety and depression. This suggests that the relationship between tobacco use and anxiety and depression is associated with the administration method.&lt;br /&gt;
*Citation: Yebo Yu, Fan Yang, Mingqi Fu, Farooq Ahmed, Muhammad Shahid, Jing Guo, Relationship Between Work-Family Conflict and Depressive Symptoms Among Male Firefighters in China, Journal of Occupational &amp;amp; Environmental Medicine, 10.1097/JOM.0000000000002759, 65, 4, (337-343), (2022).&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.sciencedirect.com/science/article/abs/pii/S0376871621005676 Adolescent depression symptoms and e-cigarette progression]=== &lt;br /&gt;
*Depression symptoms predicted more rapid e-cigarette progression in adolescents.&lt;br /&gt;
*E-cigarette use was not associated with an escalation in depression symptoms.&lt;br /&gt;
*E-cigarette use was not related to the development of depression symptoms over time.&lt;br /&gt;
*Must pay to view PDF&lt;br /&gt;
*Citation: Afaf F. Moustafa, Shannon Testa, Daniel Rodriguez, Stephen Pianin, Janet Audrain-McGovern, Adolescent depression symptoms and e-cigarette progression, Drug and Alcohol Dependence, Volume 228, 2021, 109072, ISSN 0376-8716, doi.org/10.1016/j.drugalcdep.2021.109072.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2000 [https://www.sciencedirect.com/science/article/abs/pii/S0091305700002057 The Effects of Nicotine on Neural Pathways Implicated in Depression: A Factor in Nicotine Addiction?]=== &lt;br /&gt;
*It is postulated that smokers are protected from the consequences of these changes, while they continue to smoke, by the antidepressant properties of nicotine.&lt;br /&gt;
*[https://sci-hub.st/10.1016/S0091-3057(00)00205-7 PDF Version]&lt;br /&gt;
*Citation: Balfour, D. J. ., &amp;amp; Ridley, D. L. (2000). The Effects of Nicotine on Neural Pathways Implicated in Depression. Pharmacology Biochemistry and Behavior, 66(1), 79–85. doi:10.1016/s0091-3057(00)00205-7 &lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.sciencedirect.com/science/article/abs/pii/S0149763417301793 Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression]=== &lt;br /&gt;
*Nicotine improves cognitive performance in clinical and preclinical studies.&lt;br /&gt;
*Nicotine may also benefit depressive symptoms and depressive behavior.&lt;br /&gt;
*Cognitive and mood benefits may be mediated by nicotinic effect on neural networks.&lt;br /&gt;
*Nicotine’s effects on networks may reverse network changes seen in depression.&lt;br /&gt;
*Improvement to mood and cognition may particularly benefit older depressed adults.&lt;br /&gt;
*Both preclinical and clinical studies support that nicotine and other nAChR agonists can improve depressive behavior, mood, and cognitive performance. nAChR agonists also demonstrate neuropharmacologic effects that oppose the intrinsic network alterations reported in MDD. Through modulation of intrinsic functional networks, nAChR agonists may reduce depressive symptoms, enhance emotional regulation ability, and improve cognitive deficits common in LLD. For these reasons, we propose nAChR agonists as a potential novel treatment for the mood and cognitive symptoms of LLD.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.neubiorev.2017.08.018 PDF Version]&lt;br /&gt;
*Citation: Gandelman, J. A., Newhouse, P., &amp;amp; Taylor, W. D. (2018). Nicotine and networks: Potential for enhancement of mood and cognition in late-life depression. Neuroscience &amp;amp; Biobehavioral Reviews, 84, 289–298. doi:10.1016/j.neubiorev.2017.08.0&lt;br /&gt;
*Acknowledgement: Supported by NIH grants K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://pubmed.ncbi.nlm.nih.gov/29795403/ Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder]=== &lt;br /&gt;
*In [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;MDD&#039;&#039;&#039;]], acute nicotine administration normalized both pathways to the level of healthy controls, while having no impact on healthy controls. These results indicate that nicotine normalizes dysfunctional cortico-striatal communication in unmedicated non-smokers with MDD.&lt;br /&gt;
*[https://sci-hub.st/10.1038/s41386-018-0069-x PDF Version]&lt;br /&gt;
*Citation: Janes AC, Zegel M, Ohashi K, Betts J, Molokotos E, Olson D, Moran L, Pizzagalli DA. Nicotine normalizes cortico-striatal connectivity in non-smoking individuals with major depressive disorder. Neuropsychopharmacology. 2018 Nov;43(12):2445-2451. doi: 10.1038/s41386-018-0069-x. Epub 2018 Apr 19. PMID: 29795403; PMCID: PMC6180119.&lt;br /&gt;
*Acknoledgements: This project was supported by the National Institute on Drug Abuse grants K10 DA029645 and K02 DA042987 (ACJ). DAP was partially supported by National Institute of Mental Health grant R37 MH068376. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Pfizer and Posit Science, for activities unrelated to the current research.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/ Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Non-Smokers with Late-Life Depression]=== &lt;br /&gt;
*[[Special:MyLanguage/Abbreviations|Late &#039;&#039;&#039;Life Depression (LLD)&#039;&#039;&#039;]] is characterized by poor antidepressant response and cognitive dysfunction. Late life depression has no currently approved treatment that improves both its mood and cognitive symptoms.&lt;br /&gt;
*We observed robust response (86.7%) and remission rates (53.3%). There was a significant decrease in MADRS (Montgomery-Asberg Depression Rating scale) over the study, with improvement seen as early as three weeks. We also observed improvement in apathy and rumination. We did not observe improvement on the CPT (Conners Continuous Performance Test), but did observe improvement in subjective cognitive performance and signals of potential drug effects on secondary cognitive measures of working memory, episodic memory, and self-referential emotional processing.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129985/pdf/nihms965043.pdf PDF Version]&lt;br /&gt;
*Citation: Gandelman JA, Kang H, Antal A, Albert K, Boyd BD, Conley AC, Newhouse P, Taylor WD. Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression. J Clin Psychiatry. 2018 Aug 28;79(5):18m12137. doi: 10.4088/JCP.18m12137. PMID: 30192444; PMCID: PMC6129985.&lt;br /&gt;
*Acknowledgements: This research was supported by NIH grant K24 MH110598 and CTSA award UL1TR000445 from the National Center for Advancing Translational Sciences. The sponsor provided funding for the study but did not influence the design or conduct of the study.&lt;br /&gt;
&lt;br /&gt;
===2006 [https://pubmed.ncbi.nlm.nih.gov/16977477/ Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial]=== &lt;br /&gt;
*These findings suggest a role for nicotinic receptor systems in the pathophysiology of depression and that nicotinic compounds should be evaluated for treating depression symptoms.&lt;br /&gt;
*[https://sci-hub.st/10.1007/s00213-006-0516-y PDF Version]&lt;br /&gt;
*Citation: McClernon FJ, Hiott FB, Westman EC, Rose JE, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006 Nov;189(1):125-33. doi: 10.1007/s00213-006-0516-y. Epub 2006 Sep 15. PMID: 16977477.&lt;br /&gt;
*Acknowledgement: This research was supported by a Young Investigator Award from the National Alliance for Research on Schizophrenia and Depression. Dr. Rose is an inventor named on several nicotine patch patents and receives royalties from sales of certain nicotine patches.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/11995405/ Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients]=== &lt;br /&gt;
*Acute administration of nicotine patches produced rapid eye movement sleep (REM) increases in non-smoking major depressed patients as well as clinical improvement in mood. Antidepressant effect was also observed after four continuous days of nicotine administration.&lt;br /&gt;
*Citation: Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin. 2002 Jan-Feb;54(1):36-40. PMID: 11995405.&lt;br /&gt;
&lt;br /&gt;
===1999 [https://link.springer.com/article/10.1007/s002130050879 Antidepressant effects of nicotine in an animal model of depression]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Epidemiological studies indicate a high incidence of cigarette smoking among depressed individuals. Moreover, individuals with a history of depression have a much harder time giving up smoking. It has been postulated that smoking may reflect an attempt at self-medication with nicotine by these individuals.&lt;br /&gt;
*The data strongly implicate the involvement of central nicotinic receptors in the depressive characteristics of the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;FSL&#039;&#039;&#039;]] rats, and suggest that nicotinic agonists may have therapeutic benefits in depressive disorders&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1007/s002130050879 PDF Version]&lt;br /&gt;
*Citation: Tizabi, Y., Overstreet, D., Rezvani, A. et al. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 142, 193–199 (1999). https://doi.org/10.1007/s002130050879&lt;br /&gt;
*Acknowledgements This work was supported in part by the Department of Pharmacology, Howard University, VAMC and Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.&lt;br /&gt;
*Keywords: Key words Nicotine · Nicotinic receptor · FSL and FRL rats · Animal model of depression &lt;br /&gt;
&lt;br /&gt;
===1998 [https://pubmed.ncbi.nlm.nih.gov/9592048/ A novel effect of nicotine on mood and sleep in major depression]=== &lt;br /&gt;
*Transdermal nicotine patches increased REM sleep in normal volunteers and depressed patients during 4 days of continuous administration. In addition, a significant improvement of mood was observed in depressed patients. Nicotinic mechanisms may be involved in depression.  These findings suggest that nicotine receptor activation may be important in major depression and shows for the first time that nicotine patches may be useful in the treatment of depression.&lt;br /&gt;
*[https://sci-hub.st/10.1097/00001756-199801050-00012 PDF Version]&lt;br /&gt;
*Salín-Pascual RJ, Drucker-Colín R. A novel effect of nicotine on mood and sleep in major depression. Neuroreport. 1998 Jan 5;9(1):57-60. doi: 10.1097/00001756-199801050-00012. PMID: 9592048.&lt;br /&gt;
*ACKNOWLEDGEMENT: This work has been supported by the following grants: DGAPA-UNAM IN -200895 to R.J.S-P.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9746444/ Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression]=== &lt;br /&gt;
*A high frequency of cigarette smoking has been reported among individuals with major depression.&lt;br /&gt;
*Results of the visual analog scale and [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;HAM-D&#039;&#039;&#039;]] showed a significant improvement in depression after the second day of nicotine patches.&lt;br /&gt;
*Citation: Salín-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996 Sep;57(9):387-9. PMID: 9746444.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://psycnet.apa.org/record/1996-00468-019 Depression and smoking cessation: Characteristics of depressed smokers and effects of nicotine replacement.]=== &lt;br /&gt;
*&lt;br /&gt;
*[https://sci-hub.st/10.1037/0022-006X.64.4.791 PDF Version]&lt;br /&gt;
*Citation:&lt;br /&gt;
&lt;br /&gt;
===1995 [https://pubmed.ncbi.nlm.nih.gov/8619011/ Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients]=== &lt;br /&gt;
*The main finding of the present study was that nicotine patches induced an increase in REM sleep time in depressed patients without any other changes in sleep variables&lt;br /&gt;
*[https://sci-hub.st/10.1007/BF02246496 PDF Version]&lt;br /&gt;
*Citation: Salín-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colín R. Effects of transderman nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl). 1995 Oct;121(4):476-9. doi: 10.1007/BF02246496. PMID: 8619011.&lt;br /&gt;
*Acknowledgement: This work has been supported in part by FIIRESIN, Fideicomiso-UNAM (to RD-C) and DGAPA-UNAM1N203393 (to RJS-P).&lt;br /&gt;
&lt;br /&gt;
===1993 [https://jamanetwork.com/journals/jamapsychiatry/article-abstract/496026 Nicotine Dependence and Major Depression]=== &lt;br /&gt;
*There is, then, no evidence in these data that the occurrence of MDD in persons with a prior history of nicotine dependence might have been caused directly by recent persistent smoking.&lt;br /&gt;
*[https://sci-hub.st/10.1001/archpsyc.1993.01820130033006 PDF Version]&lt;br /&gt;
*Citation: Breslau N, Kilbey MM, Andreski P. Nicotine Dependence and Major Depression: New Evidence From a Prospective Investigation. Arch Gen Psychiatry. 1993;50(1):31–35. doi:10.1001/archpsyc.1993.01820130033006&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
* When chronically taken, nicotine may result in: (1) positive reinforcement, (2) negative reinforcement (mood normalization) (other issues and diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Mental Illness&#039;&#039;&#039;==&lt;br /&gt;
&lt;br /&gt;
===2022 [https://academic.oup.com/ntr/article-abstract/24/9/1405/6562456 E-Cigarette Provision to Promote Switching in Cigarette Smokers With Serious Mental Illness—A Randomized Trial]===&lt;br /&gt;
*This was the first prospective study to compare e-cigarette provision with assessments only to evaluate the appeal and impact of e-cigarettes on smoking behavior, carbon monoxide exposure, and nicotine dependence among smokers with Severe Mental Illness (SMI) who had tried but were unable to quit and were not currently interested in cessation treatment. The finding that e-cigarette provision led to significant reductions in smoking and carbon monoxide without increasing nicotine dependence has implications for reducing harm not only among the millions of smokers with SMI who struggle to quit, but also for other vulnerable smokers who cannot achieve cessation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - OCD (Obsessive Compulsive Disorder)&#039;&#039;&#039;== &lt;br /&gt;
===2020 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/ Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review]=== &lt;br /&gt;
*Nicotine may ameliorate OC symptoms in severe, treatment-refractory [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;OCD&#039;&#039;&#039;]] patients. Although encouraging, these initial positive effects should be tested in large controlled studies.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528475/pdf/12991_2020_Article_309.pdf PDF Version]&lt;br /&gt;
*Citation: Piacentino D, Maraone A, Roselli V, Berardelli I, Biondi M, Kotzalidis GD, Pasquini M. Efficacy of nicotine administration on obsessions and compulsions in OCD: a systematic review. Ann Gen Psychiatry. 2020 Sep 30;19:57. doi: 10.1186/s12991-020-00309-z. PMID: 33014119; PMCID: PMC7528475.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - PTSD (Post Traumatic Stress Disorder)&#039;&#039;&#039;== &lt;br /&gt;
===2012 [https://www.hindawi.com/journals/aps/2012/265724/ Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study]=== &lt;br /&gt;
*Smokers with PTSD report greater NA (Negative Affects) immediately prior to smoking and greater decreases in NA following smoking, and these findings are consistent with the observed patterns of brain activation in the current study. Thus, our findings provide a neurobiological basis that helps explain why individuals with PTSD are at greater risk of smoking and also experience greater difficulty quitting. The present study is not without its limitations. Our sample size was small and was predominately represented by female smokers.&lt;br /&gt;
*[https://downloads.hindawi.com/journals/aps/2012/265724.pdf PDF Version]&lt;br /&gt;
*Citation: Froeliger, B., Crowell Beckham, J., Feldman Dennis, M., Victoria Kozink, R., &amp;amp; Joseph McClernon, F. (2012). Effects of Nicotine on Emotional Reactivity in PTSD and Non-PTSD Smokers: Results of a Pilot fMRI Study. Advances in Pharmacological Sciences, 2012, 1–6. doi:10.1155/2012/265724 &lt;br /&gt;
*Acknowledgement: Department of Veterans Affairs or the National Institutes of Health.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==&#039;&#039;&#039;Mental Health - Schizophrenia&#039;&#039;&#039;== &lt;br /&gt;
===2022 [https://www.frontiersin.org/articles/10.3389/fpsyt.2022.804055/full Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence]===&lt;br /&gt;
*Nicotine administration normalized DMN hyperconnectivity in schizophrenia. We here provide direct evidence that the biological basis of nicotine dependence is different in schizophrenia and in non-schizophrenia populations. Our results suggest the high prevalence of nicotine use in schizophrenia may be an attempt to correct a network deficit known to interfere with cognition.&lt;br /&gt;
*[https://twitter.com/hbwardMD/status/1487037135299518474 Twitter thread about this study]&lt;br /&gt;
**Citation: Ward HB, Beermann A, Nawaz U, Halko MA, Janes AC, Moran LV and Brady RO Jr (2022) Evidence for Schizophrenia-Specific Pathophysiology of Nicotine Dependence. Front. Psychiatry 13:804055. doi: 10.3389/fpsyt.2022.804055&lt;br /&gt;
***Acknowledgement: This work was supported by NIMH R01MH116170 (RB); NIMH R01MH111868 and NIMH R01MH117063 (MH); NIDA 1K02DA042987 and NIDA K01DA029645 (AJ); NIMH K23MH110564, NARSAD Young Investigator Award, Brain and Behavior Research Foundation, Pope-Hintz Fellowship Award, McLean Hospital, Dupont-Warren Fellowship Award, and Harvard Medical School (LM); and the Sidney R. Baer, Jr. Foundation, and the Norman E. Zinberg Fellowship in Addiction Psychiatry Research, Harvard Medical School (HW).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0149763420305042?via%3Dihub The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review]=== &lt;br /&gt;
*Cognitive and early sensory alterations are core features of [https://en.wikipedia.org/wiki/Schizophrenia &#039;&#039;&#039;schizophrenia&#039;&#039;&#039;]. A single dose of nicotine can improve those features in patients. Attention domain is the most responsive to nicotine in patients. Effects vary upon type of neuropsychological assessment and nicotine intake condition.&lt;br /&gt;
*[https://sci-hub.do/10.1016/j.neubiorev.2020.07.035 PDF Version]&lt;br /&gt;
**Citation: Clément Dondé, Jérôme Brunelin, Marine Mondino, Caroline Cellard, Benjamin Rolland, Frédéric Haesebaert, The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review, Neuroscience &amp;amp; Biobehavioral Reviews, Volume 118, 2020, Pages 121-133, ISSN 0149-7634, doi: 10.1016/j.neubiorev.2020.07.035.&lt;br /&gt;
&lt;br /&gt;
=== 2017: [https://www.nature.com/articles/nm.4274 Nicotine reverses hypofrontality in animal models of addiction and schizophrenia] ===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*“Our study provides compelling biological evidence that a specific genetic variant contributes to risk for schizophrenia, defines the mechanism responsible for the effect and validates that nicotine improves that deficit,” said Jerry Stitzel, a researcher at the Institute for Behavioral Genetics (IBG) and one of four CU Boulder researchers on the study. &lt;br /&gt;
*Previous genome-wide association studies have suggested that people with a variation in a gene called CHRNA5 are more likely to have schizophrenia, but the mechanism for that association has remained unclear. People with that variant are also more likely to smoke.&lt;br /&gt;
**Citation: Fani Koukouli, Marie Rooy, Dimitrios Tziotis, Kurt A Sailor, Heidi C O&#039;Neill, Josien Levenga, Mirko Witte, Michael Nilges, Jean-Pierre Changeux, Charles A Hoeffer, Jerry A Stitzel, Boris S Gutkin, David A DiGregorio  Uwe Maskos Nature Medicine volume 23, pages347–354 (2017)&lt;br /&gt;
&lt;br /&gt;
===2017: [https://pubmed.ncbi.nlm.nih.gov/28441884/ Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging]===&lt;br /&gt;
*This brief review discusses evidence from neurophysiological and neuroimaging studies in schizophrenia patients that nicotinic agonists may effectively target dysfunctional neuronal circuits in the illness. Evidence suggests that nicotine significantly modulates a number of these circuits, although relatively few studies have used modern neuroimaging techniques (e.g. functional magnetic resonance imaging (fMRI)) to examine the effects of nicotinic drugs on disease-related neurobiology. The neuronal effects of nicotine and other nicotinic agonists in schizophrenia remain a priority for psychiatry research.&lt;br /&gt;
**Citation: Smucny J, Tregellas JR. Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging. J Psychopharmacol. 2017 Jul;31(7):801-811. doi: 10.1177/0269881117705071. Epub 2017 Apr 26. PMID: 28441884; PMCID: PMC5963521.&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
**Citation: Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2009 [https://pubmed.ncbi.nlm.nih.gov/19328631/ Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications]=== &lt;br /&gt;
*The principal reason for the markedly increased rate of cigarette smoking in people with schizophrenia: tobacco cigarette smoking represents an attempt at self-medication in schizophrenia, because the additional nicotine so provided alleviates the hypofunctional sensory gating seen in this illness.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version]&lt;br /&gt;
**Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631.&lt;br /&gt;
&lt;br /&gt;
===2007: [https://pmc.ncbi.nlm.nih.gov/articles/PMC2702723/ Nicotinic Interactions with Antipsychotic Drugs, Models of Schizophrenia and Impacts on Cognitive Function]===&lt;br /&gt;
*Human and Animal study&lt;br /&gt;
*Nicotinic receptor systems in the brain are important for a variety of aspects of cognitive function impaired in schizophrenia and aggravated by antipsychotic drugs. Nicotine and selective nicotinic α7 and α4β2 agonists can significantly improve learning, memory and attention. Nicotine and nicotine agonists can reduce some of the cognitive impairments caused by some antipsychotic drugs as well as reduce cognitive impairments seen in the NMDA glutamate blockade animal model of schizophrenia.&lt;br /&gt;
**Citation: Levin ED, Rezvani AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007 Oct 15;74(8):1182-91. doi: 10.1016/j.bcp.2007.07.019. Epub 2007 Jul 20. PMID: 17714691; PMCID: PMC2702723.&lt;br /&gt;
***Acknowledgement: Research presented was supported by a grant from the National Institute of Mental Health grant MH64494.&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]===&lt;br /&gt;
*For development of nicotinic treatments we are fortunate to have a well characterized lead compound, nicotine. Transdermal nicotine patches offer a way to deliver measured doses of nicotine in a considerably safer fashion than the more traditional means of administration, tobacco smoking. We have found that transdermal nicotine significantly improves attentional function in people with Alzheimer&#039;s disease, schizophrenia or ADHD as well as normal nonsmoking adults.&lt;br /&gt;
**Citation: Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):423-31. doi: 10.2174/1568007023339102. PMID: 12769614.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Movement Disorders (not diagnosis specific)&#039;&#039;&#039;= &lt;br /&gt;
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/ Role for the nicotinic cholinergic system in movement disorders; therapeutic implications]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Several [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] subtypes appear to be involved in these beneficial effects of nicotine and nAChR drugs including α4β2*, α6β2* and α7 nAChRs (the asterisk indicates the possible presence of other subunits in the receptor). Overall, the above findings, coupled with nicotine&#039;s neuroprotective effects, suggest that nAChR drugs have potential for future drug development for movement disorders.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149916/pdf/nihms600497.pdf PDF Version]&lt;br /&gt;
*Citation: Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014 Oct;144(1):50-9. doi: 10.1016/j.pharmthera.2014.05.004. Epub 2014 May 14. PMID: 24836728; PMCID: PMC4149916.&lt;br /&gt;
*Acknowledgements: This work was supported by grants NS59910 and NS 65851 from the National Institutes of Health.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Multiple Sclerosis - Humans / Experimental Autoimmune Encephalomyelitis (EAE) - Animals&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2016 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/ Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
* This study provides evidence that nicotine alters the infiltration of proinflammatory monocytes and neutrophils into the CNS of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] mice via multiple [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChRs&#039;&#039;&#039;]], including the α7 and α9 subtypes. Nicotine appears to achieve these effects by inhibiting the expression of CCL2 and CXCL2, two cytokines involved in the chemotaxis of proinflammatory monocytes and neutrophils, respectively. The use of ligands that are selective for one or both of these nAChR subtypes may offer a beneficial clinical outcome, and thus provide a valuable therapeutic strategy for neuroinflammatory disorders such as MS.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760232/pdf/1501613.pdf PDF Version]&lt;br /&gt;
**Citation: Jiang W, St-Pierre S, Roy P, Morley BJ, Hao J, Simard AR. Infiltration of CCR2+Ly6Chigh Proinflammatory Monocytes and Neutrophils into the Central Nervous System Is Modulated by Nicotinic Acetylcholine Receptors in a Model of Multiple Sclerosis. J Immunol. 2016 Mar 1;196(5):2095-108. doi: 10.4049/jimmunol.1501613. Epub 2016 Jan 25. PMID: 26810225; PMCID: PMC4760232.&lt;br /&gt;
***Acknowledgements: This work was supported by grants from the Multiple Sclerosis Society of Canada (to A.R.S.), the New Brunswick Health Research Foundation (to A.R.S.), the New Brunswick Innovation Foundation (to A.R.S.), the Nebraska Tobacco Settlement Biomedical Research Fund (to B.J.M.), and the National Institutes of Health (Grant R01DC006907 to B.J.M.). Salary support was provided by the Centre de Formation Médicale du Nouveau-Brunswick (to W.J.) and the New Brunswick Innovation Foundation (to S.S-P. and P.R.).&lt;br /&gt;
*See Also - Related article: [https://mssociety.ca/research-news/article/ms-society-funded-study-shows-that-nicotine-reduces-the-invasion-of-harmful-immune-cells-into-the-brain-in-mice-with-an-ms-like-disease MS Society-funded study shows that nicotine reduces the invasion of harmful immune cells into the brain in mice with an MS-like disease]&lt;br /&gt;
&lt;br /&gt;
===2015 [https://pubmed.ncbi.nlm.nih.gov/25813705/ Nicotine modulates neurogenesis in the central canal during experimental autoimmune encephalomyelitis]===&lt;br /&gt;
*Amimal study&lt;br /&gt;
*We found that reduction of ependymal cell proliferation correlated with inflammation in the same area, which was relieved by the administration of nicotine. Further, increased numbers of oligodendrocytes (OLs) were observed after nicotine treatment. These findings give a new insight into the mechanism of how nicotine functions to attenuate EAE.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.neuroscience.2015.03.031 PDF Full Study]&lt;br /&gt;
**Citation: Gao Z, Nissen JC, Legakis L, Tsirka SE. Nicotine modulates neurogenesis in the central canal during experimental autoimmune encephalomyelitis. Neuroscience. 2015 Jun 25;297:11-21. doi: 10.1016/j.neuroscience.2015.03.031. Epub 2015 Mar 23. PMID: 25813705; PMCID: PMC4428965.&lt;br /&gt;
***Acknowledgement: The work was supported by NMSS PP1815, NIH R01NS42168, NIH IRACDA K12GM102778.&lt;br /&gt;
&lt;br /&gt;
===2015 [https://pubmed.ncbi.nlm.nih.gov/26209886/ Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients]===&lt;br /&gt;
*The data obtained highlight the role of α7 receptor subtype in the modulation of anti-inflammatory cytokines also in MS. Moreover the ability of nicotine to up-regulate the expression of α7 receptor subtype in RR-MS patients, indicates that nicotinic receptor stimulation may contribute to down-modulate the inflammation occurred in MS by a positive feedback control of its expression.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.intimp.2015.06.034 PDF Full paper]&lt;br /&gt;
**Citation: Reale M, Di Bari M, Di Nicola M, D&#039;Angelo C, De Angelis F, Velluto L, Tata AM. Nicotinic receptor activation negatively modulates pro-inflammatory cytokine production in multiple sclerosis patients. Int Immunopharmacol. 2015 Nov;29(1):152-7. doi: 10.1016/j.intimp.2015.06.034. Epub 2015 Jul 23. PMID: 26209886.&lt;br /&gt;
***Acknowledgement: This work was supported by FISM – Fondazione Italiana Sclerosi Multipla – Cod. 2013/R/25. MDB was supported by fellowship on FISM project 2013/R/25.&lt;br /&gt;
&lt;br /&gt;
===2014 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176721/ The Experimental Autoimmune Encephalomyelitis Disease Course Is Modulated by Nicotine and Other Cigarette Smoke Components]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Our results show that nicotine reduces the severity of EAE, as shown by reduced demyelination, increased body weight, and attenuated microglial activation. Nicotine administration after the development of EAE symptoms prevented further disease exacerbation, suggesting that it might be useful as an [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE/MS&#039;&#039;&#039;]] therapeutic. In contrast, the remaining components of cigarette smoke, delivered as cigarette smoke condensate (CSC), accelerated and increased adverse clinical symptoms during the early stages of EAE.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176721/pdf/pone.0107979.pdf PDF Version]&lt;br /&gt;
**Citation: Gao Z, Nissen JC, Ji K, Tsirka SE. The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS One. 2014 Sep 24;9(9):e107979. doi: 10.1371/journal.pone.0107979. PMID: 25250777; PMCID: PMC4176721.&lt;br /&gt;
***Acknowledgements: This work was supported by National Multiple Sclerosis Society awards CA1044A1 and PP181, National Aeronautics and Space Administration NNA14AB04A and National Institutes of Health R01NS42168 (ST), and National Institutes of Health K12GM102778 to JN.&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/ Novel Therapeutic Approach by Nicotine in Experimental Model of Multiple Sclerosis]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Due to the proven therapeutic effect of nicotine on AD (Alzheimer’s Disease) and PD (Parkinson’s Disease), we decided to study the role of nicotine in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;EAE&#039;&#039;&#039;]] as an animal model of MS. Our treatment group showed less inflammation in histopathological evaluation along with myelin sheet protection. Moreover, prevention group showed less inflammation compared with treatment group. Thus, nicotine might be recommended as a promising drug for [[Special:MyLanguage/Abbreviations|MS]] therapy.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659034/pdf/icns_10_4_20.pdf PDF Version]&lt;br /&gt;
**Citation: Naddafi F, Reza Haidari M, Azizi G, Sedaghat R, Mirshafiey A. Novel therapeutic approach by nicotine in experimental model of multiple sclerosis. Innov Clin Neurosci. 2013 Apr;10(4):20-5. PMID: 23696955; PMCID: PMC3659034.&lt;br /&gt;
***Acknowledgement: No funding was provided for the preparation of this article.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Narcolepsy&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.authorea.com/doi/full/10.22541/au.162126605.51833119 The therapeutic use of medical nicotine in narcolepsy]===&lt;br /&gt;
*PDF: [https://www.researchgate.net/profile/Carolina-Diamandis/publication/351648895_The_therapeutic_use_of_medical_nicotine_in_narcolepsy/links/60aa9cb945851522bc10a4c1/The-therapeutic-use-of-medical-nicotine-in-narcolepsy.pdf The therapeutic use of nicotine in narcolepsy]&lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3311418/ Narcolepsy with Cataplexy Masked by the Use of Nicotine]===&lt;br /&gt;
*&lt;br /&gt;
&lt;br /&gt;
===2010: [https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC2823281/ A Novel Approach to Treating Morning Sleep Inertia in Narcolepsy]===&lt;br /&gt;
*&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Nicotine Used With Other Substances&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/34119664/ Nicotine and modafinil combination protects against the neurotoxicity induced by 3,4-Methylenedioxymethamphetamine in hippocampal neurons of male rats]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*The overall results indicate that nicotine and modafinil co-administration rescued brain from MDMA-induced neurotoxicity. We suggest that nicotine and modafinil combination therapy could be considered as a possible treatment to reduce the neurological disorders induced by MDMA. (Note: AKA ecstasy)&lt;br /&gt;
*Citation: Kowsari G, Mehrabi S, Soleimani Asl S, Pourhamzeh M, Mousavizadeh K, Mehdizadeh M. Nicotine and modafinil combination protects against the neurotoxicity induced by 3,4-Methylenedioxymethamphetamine in hippocampal neurons of male rats. J Chem Neuroanat. 2021 Jun 10;116:101986. doi: 10.1016/j.jchemneu.2021.101986. Epub ahead of print. PMID: 34119664.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Oral / Jaw&#039;&#039;&#039;= &lt;br /&gt;
===2021: [https://www.mdpi.com/1660-4601/18/2/483/htm Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study]===&lt;br /&gt;
*HSC-2 cell viability was not impaired by nicotine at the concentrations usually observed in smokers; increased expressions of IL-8 and ICAM-1 induced by P. gingivalis LPS or TNF-α were diminished by nicotine treatment. Additionally, an inhibitory effect on β-defensin production was also demonstrated. Apart from being the usually alleged harmful substance, nicotine probably exerted a suppressive effect on inflammatory factors production in HSC-2 cells.&lt;br /&gt;
*Acknowledgement: This research was supported by the grant from Ministry of Science and Technology of China under a contract from the International Science &amp;amp; Technology Cooperation Program Foundation Nr.1019 and the National Natural Science Foundation of China (Grant No. 81500859).&lt;br /&gt;
*Citation: An, N., Holl, J., Wang, X., Rausch, M. A., Andrukhov, O., &amp;amp; Rausch-Fan, X. (2021). Potential Suppressive Effect of Nicotine on the Inflammatory Response in Oral Epithelial Cells: An In Vitro Study. International Journal of Environmental Research and Public Health, 18(2), 483. https://doi.org/10.3390/ijerph18020483&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32381373/ Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial]=== &lt;br /&gt;
*The positive findings in the present study in surgeries performed under local anaesthesia are in agreement with data from systematic reviews that have reported the effectiveness of nicotine in the control of postoperative pain following surgery under general anaesthesia.&lt;br /&gt;
*This study establishes a new prevention and treatment modality regarding pain, [https://en.wikipedia.org/wiki/Edema oedema], and [https://en.wikipedia.org/wiki/Trismus trismus] in a versatile, convenient, safe, and effective form, thereby minimizing gastrointestinal and cardiovascular disorders caused by the use of anti-inflammatory drugs in third molar surgeries.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.ijom.2019.08.013 PDF Version]&lt;br /&gt;
*Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373.&lt;br /&gt;
*Acknowledgements: Funding - CAPES, Ministry of Education, Brazil&lt;br /&gt;
&lt;br /&gt;
===2012 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444372/ Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program]===&lt;br /&gt;
*The results of this study confirm that chewing the tested nicotine replacement gum as recommended in a ‘real world’ active smoking cessation program produces a statistically significant change in the parameter of whitening as measured by change from baseline versus the negative control (Microtab) following 6 weeks in a smoking cessation programme. The Vita® Shade Guide (the secondary outcome measure) supported the trend of stain improvement. These results support the efficacy of the tested nicotine replacement gum in stain reduction, in arresting the progression of tooth stain and in shade lightening.&lt;br /&gt;
*Acknowledgement: The study was fully funded by McNeil AB who is the manufacturer of the test and control products. It was designed by McNeil AB in consultation with HW and DOM. The study was run, participants recruited, smoking cessation intervention administered and data collected by the team of research staff at the Oral Health Services Research Centre at University College Cork under the leadership of HW with consultant input from DOM. RK carried out the clinical examinations but was blinded to intervention allocation. The data were analysed by McNeil AB with input from HW and DOM. The study was externally monitored by MDS Pharma Services, UK and conducted to ICH GCP standards. The data were interpreted by HW, DOM and RK. The manuscript was drafted by HW with editorial comment from the other authors. HW decided to submit the manuscript for publication.&lt;br /&gt;
*Citation: Whelton H, Kingston R, O&#039;Mullane D, Nilsson F. Randomized controlled trial to evaluate tooth stain reduction with nicotine replacement gum during a smoking cessation program. BMC Oral Health. 2012 Jun 13;12:13. doi: 10.1186/1472-6831-12-13. PMID: 22695211; PMCID: PMC3444372.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pain / Analgesic&#039;&#039;&#039;= &lt;br /&gt;
===2023: [https://pubmed.ncbi.nlm.nih.gov/37132069/ Effect of perioperative high-dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study]===&lt;br /&gt;
*Perioperative high-dose nicotine replacement therapy may help to relieve postoperative pain among male smoking-abstinent patients undergoing abdominal surgery.&lt;br /&gt;
**Citation: Zhu C, Bi Y, Wei K, Tao K, Hu L, Lu Z. Effect of perioperative high-dose transdermal nicotine patch on pain sensitivity among male abstinent tobacco smokers undergoing abdominal surgery: A randomized controlled pilot study. Addiction. 2023 Aug;118(8):1579-1585. doi: 10.1111/add.16224. Epub 2023 May 19. PMID: 37132069.&lt;br /&gt;
***Acknowledgement: Shanghai Municipal Science and Technology Commission. Grant Number: 17411960400&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.mdpi.com/1424-8247/16/12/1665 The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis]===&lt;br /&gt;
*Conclusion: These results help to clarify the mixed outcomes of trials and may ultimately inform the treatment of pain. We observed that acute nicotine administration prolonged the laboratory-induced pain threshold and tolerance time and may mildly relieve postoperative pain. In addition, long-term tobacco smoking may have a nociceptive effect on different types of chronic pain. More research is needed to determine the anti-nociceptive effects of nicotine in humans, and to understand the optimal timing, dose, and method of delivery of nicotine.&lt;br /&gt;
**Citation: Luo Y, Yang Y, Schneider C, Balle T. The Anti-Nociceptive Effects of Nicotine in Humans: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2023; 16(12):1665. https://doi.org/10.3390/ph16121665&lt;br /&gt;
***Acknowledgement: This work was funded by the Australian Research Council LP160100560.&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.sciencedirect.com/science/article/abs/pii/S0014299923000298?via%3Dihub Nicotine suppresses central post-stroke pain via facilitation of descending noradrenergic neuron through activation of orexinergic neuron]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine-induced antinociception was inhibited by intrathecal pre-treatment with yohimbine, an α2 adrenergic receptor antagonist. These results indicated that nicotine may suppress BCAO-induced mechanical hypersensitivity through the activation of the descending pain control system via orexin neurons.&lt;br /&gt;
**Citation: Nakamoto, K., Matsuura, W., &amp;amp; Tokuyama, S. (2023). Nicotine suppresses central post-stroke pain via facilitation of descending noradrenergic neuron through activation of orexinergic neuron. European journal of pharmacology, 175518. Advance online publication. https://doi.org/10.1016/j.ejphar.2023.175518&lt;br /&gt;
***Acknowledgement: This work was supported by the Smoking Research Foundation (FP01807092).&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32381373/ Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial]=== &lt;br /&gt;
*The positive findings in the present study in surgeries performed under local anaesthesia are in agreement with data from systematic reviews that have reported the effectiveness of nicotine in the control of postoperative pain following surgery under general anaesthesia.&lt;br /&gt;
*This study establishes a new prevention and treatment modality regarding pain, oedema, and trismus in a versatile, convenient, safe, and effective form, thereby minimizing gastrointestinal and cardiovascular disorders caused by the use of anti-inflammatory drugs in third molar surgeries.&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.ijom.2019.08.013 PDF Version]&lt;br /&gt;
**Citation: Landim FS, Laureano Filho JR, Nascimento J, do Egito Vasconcelos BC. Effectiveness of nicotine patch for the control of pain, oedema, and trismus following third molar surgery: a randomized clinical trial. Int J Oral Maxillofac Surg. 2020 Nov;49(11):1508-1517. doi: 10.1016/j.ijom.2019.08.013. Epub 2020 May 4. PMID: 32381373.&lt;br /&gt;
***Acknowledgements: Funding - CAPES, Ministry of Education, Brazil&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912401/ Acute Analgesic Effects of Nicotine and Tobacco in Humans: A Meta-Analysis]=== &lt;br /&gt;
*Pain and tobacco smoking are both highly prevalent and comorbid conditions, current smoking has been associated with more severe chronic pain and physical impairment, and acute nicotine-induced analgesia could make smoking more rewarding and harder to give up.&lt;br /&gt;
*Moderation analyses further revealed that acute analgesic effects may be achieved regardless of nicotine delivery method, current smoking status, pain induction modality, study design, or control condition, and that such effects may be more robust among men than women.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912401/pdf/nihms-774195.pdf PDF Version]&lt;br /&gt;
**Citation: Ditre JW, Heckman BW, Zale EL, Kosiba JD, Maisto SA. Acute analgesic effects of nicotine and tobacco in humans: a meta-analysis. Pain. 2016;157(7):1373-1381. doi:10.1097/j.pain.0000000000000572 (viewed Oct 5, 2021)&lt;br /&gt;
***Acknowledgement: This research was supported by NIH Grant Nos. R21DA034285 and R21DA038204 awarded to Joseph W. Ditre, NIH Grant Nos. F31DA033058 and T32DA007288 awarded to Bryan W. Heckman, NIH Grant No. F31DA039628 awarded to Emily L. Zale, and NIH Grant No. 2K05 AA16928 awarded to Stephen A. Maisto.&lt;br /&gt;
&lt;br /&gt;
===2013 [https://www.sciencedirect.com/science/article/abs/pii/S0014299913003270?via%3Dihub Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models]=== &lt;br /&gt;
*Nicotine significantly reduced antiviral-dependent alterations of the nociceptive threshold. &lt;br /&gt;
*Moreover, nicotine decreased neuropathic pain induced by repeated intraperitoneal administration of the anticancer agent oxaliplatin (2.4 mg/kg), lowering the hypersensitivity to mechanical and thermal stimuli. &lt;br /&gt;
*Intraperitoneal nicotine administration controls neuropathic pain evoked by traumatic or toxic nervous system alterations. These results support the [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;nAChR&#039;&#039;&#039;]] modulation as a possible therapeutic approach to the complex, undertreated chemotherapy-induced neuropathies. &lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/j.ejphar.2013.04.022 PDF Version]&lt;br /&gt;
**Citation: Lorenzo Di Cesare Mannelli, Matteo Zanardelli, Carla Ghelardini, Nicotine is a pain reliever in trauma- and chemotherapy-induced neuropathy models, European Journal of Pharmacology, Volume 711, Issues 1–3, 2013, Pages 87-94, ISSN 0014-2999, doi: 10.1016/j.ejphar.2013.04.022.&lt;br /&gt;
***Acknowledgements: This work was supported by the Italian Ministry of Instruction, University and Research.&lt;br /&gt;
&lt;br /&gt;
===2011 [https://journals.lww.com/ejanaesthesiology/Fulltext/2011/08000/Randomised_trial_of_intranasal_nicotine_and.7.aspx Randomised trial of intranasal nicotine and postoperative pain, nausea and vomiting in non-smoking women]=== &lt;br /&gt;
*Intraoperative use of intranasal nicotine has a sustained opioid-sparing effect in non-smoking women undergoing gynaecological procedures and is associated with a higher frequency of nausea. &lt;br /&gt;
*[https://sci-hub.st/10.1097/EJA.0b013e328344d998 PDF Version]&lt;br /&gt;
*Citation: Jankowski, Christopher J.; Weingarten, Toby N.; Martin, David P.; Whalen, Francis X.; Gebhart, John B.; Liedl, Lavonne M.; Danielson, David R.; Nadeau, Ashley M.; Schroeder, Darrell R.; Warner, David O.; Sprung, Juraj Randomised trial of intranasal nicotine and postoperative pain, nausea and vomiting in non-smoking women, European Journal of Anaesthesiology (EJA): August 2011 - Volume 28 - Issue 8 - p 585-591 doi: 10.1097/EJA.0b013e328344d998&lt;br /&gt;
*Acknowledgements: The present work was supported solely by the Department of Anesthesiology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.&lt;br /&gt;
&lt;br /&gt;
===2008 [https://journals.lww.com/anesthesia-analgesia/Fulltext/2008/09000/Transdermal_Nicotine_for_Analgesia_After_Radical.48.aspx Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy]=== &lt;br /&gt;
*The preoperative application of a 7 mg nicotine patch resulted in a significant reduction in postoperative opioid consumption in nonsmoking men undergoing [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;RRP&#039;&#039;&#039;]] in this study. Its use was generally well tolerated, but the maximum nausea scores were higher in patients who received nicotine.&lt;br /&gt;
*[https://sci-hub.se/10.1213/ane.0b013e31816f2616# PDF Version]&lt;br /&gt;
*Citation: Habib, Ashraf S., MBBCh, MSc, FRCA*; White, William D., MPH*; El Gasim, Magdi A., MD*; Saleh, Gamal, MD*; Polascik, Thomas J., MD†; Moul, Judd W., MD†; Gan, Tong J., MB, FRCA* Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy, Anesthesia &amp;amp; Analgesia: September 2008 - Volume 107 - Issue 3 - p 999-1004 doi: 10.1213/ane.0b013e31816f2616&lt;br /&gt;
&lt;br /&gt;
===2002 [https://pubmed.ncbi.nlm.nih.gov/12131122/ Isoflurane hyperalgesia is modulated by nicotinic inhibition]=== &lt;br /&gt;
*Animal study&lt;br /&gt;
*Female mice had significant [https://en.wikipedia.org/wiki/Hyperalgesia hyperalgesia] from [https://en.wikipedia.org/wiki/Isoflurane isoflurane]. Nicotine administration prevented isoflurane-induced hyperalgesia without altering the antinociception produced by higher isoflurane concentrations.&lt;br /&gt;
**Citation: Flood P, Sonner JM, Gong D, Coates KM. Isoflurane hyperalgesia is modulated by nicotinic inhibition. Anesthesiology. 2002 Jul;97(1):192-8. doi: 10.1097/00000542-200207000-00027. PMID: 12131122.&lt;br /&gt;
***Acknowledgement: 1P01GM47818/GM/NIGMS NIH HHS/United States, K08GM00695/GM/NIGMS NIH HHS/United States&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Parkinson Disease&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/abs/pii/S0967586824003849 The effect of a nicotine-rich diet with/without redistribution of dietary protein on motor indices in patients with Parkinson&#039;s disease: A randomized clinical trial]===&lt;br /&gt;
*The results of our study indicated that nicotine consumption in an isocaloric diet, while preventing a decrease in anthropometric indices, leads to improvements in motor indices and a reduction in alpha-synuclein levels. Additional and larger controlled trials are required to validate these findings.&lt;br /&gt;
**Citation: Lorvand Amiri H, Hassan Javanbakht M, Mohammad Baghbanian S, Parsaeian M. The effect of a nicotine-rich diet with/without redistribution of dietary protein on motor indices in patients with Parkinson&#039;s disease: A randomized clinical trial. J Clin Neurosci. 2024 Sep 30;129:110845. doi: 10.1016/j.jocn.2024.110845. Epub ahead of print. PMID: 39353253.&lt;br /&gt;
***Acknowledgement: This work was supported by the Tehran University of Medical Sciences. (Project No. 53161).&lt;br /&gt;
&lt;br /&gt;
=== 2024: [https://pubmed.ncbi.nlm.nih.gov/38430248/ Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson&#039;s disease] ===&lt;br /&gt;
*Animal study (worms with humanised neurons)&lt;br /&gt;
*This study examines whether nicotine helps transgenic C. elegans PD models. According to numerous studies, nicotine enhances synaptic plasticity and dopaminergic neuronal survival. Upgrades UPS pathways, increases autophagy, and decreases oxidative stress and mitochondrial dysfunction.&lt;br /&gt;
*At 100, 150, and 200 µM nicotine levels, worms showed reduced α-Syn aggregation, repaired DA neurotoxicity after 6-OHDA intoxication, increased lifetime, and reduced lipofuscin accumulation. Furthermore, nicotine triggered autophagy and UPS. &lt;br /&gt;
*We revealed nicotine&#039;s potential as a UPS and autophagy activator to prevent PD and other neurodegenerative diseases.&lt;br /&gt;
*&#039;&#039;Note: highly technical brain biochemistry, appears to be important however (ed.)&#039;&#039; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586504/ Paper on the UPS and it&#039;s purpose] for info.&lt;br /&gt;
**Citation: Ullah I, Uddin S, Zhao L, Wang X, Li H. Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson&#039;s disease. Exp Brain Res. 2024 Apr;242(4):971-986. doi: 10.1007/s00221-023-06765-9. Epub 2024 Mar 2. PMID: 38430248.&lt;br /&gt;
***Acknowledgement: This study was supported by the Special International Cooperation Project of the Ministry of Science and Technology (2012DFA30480); National Natural Science Foundation of China (No. 81403145); Natural Science Foundation of Gansu Province (No. 20JR10RA602); Fundamental Research Funds for the Central Universities of China (lzujbky—2017-206, lzujbky-2018-136); Science and Technology Cooperation Program of Gansu Academy of Sciences (grant number 2019HZ-02); Program of Lanzhou Science and Technology Foundation (Grant number 2010-1-154). Major science and technology project of Gansu province (23ZDFA013), Natural Science Foundation of Gansu province (20JR10RA602).&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://www.frontiersin.org/articles/10.3389/fnagi.2023.1223310/full Changes in smoking, alcohol consumption, and the risk of Parkinson’s disease] ===&lt;br /&gt;
*A total of 3,931,741 patients were included.&lt;br /&gt;
*Compared to the sustained non-smokers, sustained light smokers, sustained moderate smokers, and sustained heavy smokers had a lower risk of PD. &lt;br /&gt;
*Compared to those who sustained non-drinking, sustained light drinkers, sustained moderate drinkers, and sustained heavy drinkers showed decreased risk of PD. &lt;br /&gt;
*Among non-drinkers, those who started drinking to a light level were at decreased risk of PD. Among non-smoking and non-drinking participants, those who initiated smoking only, drinking only, and both smoking and drinking showed decreased risk of PD.&lt;br /&gt;
*Smoking is associated with decreased risk of PD with a dose–response relationship. Alcohol consumption at a light level may also be associated with decreased risk of PD. Further studies are warranted to find the possible mechanisms for the protective effects of smoking and drinking on PD, which may present insights into the etiology of PD.&lt;br /&gt;
**Citation: Jung SY, Chun S, Cho EB, Han K, Yoo J, Yeo Y, Yoo JE, Jeong SM, Min JH, Shin DW. Changes in smoking, alcohol consumption, and the risk of Parkinson&#039;s disease. Front Aging Neurosci. 2023 Sep 13;15:1223310. doi: 10.3389/fnagi.2023.1223310. PMID: 37771519; PMCID: PMC10525683.&lt;br /&gt;
***Acknowledgement: J-HM received a grant from the National Research Foundation of Korea and SMC Research and Development Grant. J-HM has lectured, consulted, and received Honoria from Bayer Schering Pharma, Merck Serono, Biogen Idec, Sanofi Genzyme, Teva-Handok, UCB, Samsung Bioepis, Mitsubishi Tanabe Pharma, and Roche.&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36817162/ Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson&#039;s disease.] ===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Nicotine (Nic) has previously been proven to reduce neurodegeneration in the models of Parkinson&#039;s disease (PD). The present study is intended to investigate the detailed mechanisms related to the potential neuroprotective effects of Nic in vivo.&lt;br /&gt;
*In summary, Nic pretreatment ameliorates MPTP-induced dyskinesia and anxiety-like behavior in mice with PD. Nic was found to alleviate neuroapoptosis by improving nigrostriatal dopaminergic damage, reducing the accumulation of pathological p-α-syn, and inhibiting microglia activation and pro-inflammatory factor expression in the substantia nigra and striatal regions of mice brain under MPTP stimulation. These neuroprotective effects of Nic may be achieved by modulating the JNK and ERK signaling pathways in the nigrostriatal system, which was further confirmed by the pretreatment of 5-MOP to decline the brain metabolic activity of Nic.&lt;br /&gt;
**Citation: Ruan S, Xie J, Wang L, Guo L, Li Y, Fan W, Ji R, Gong Z, Xu Y, Mao J, Xie J. Nicotine alleviates MPTP-induced nigrostriatal damage through modulation of JNK and ERK signaling pathways in the mice model of Parkinson&#039;s disease. Front Pharmacol. 2023 Feb 2;14:1088957. doi: 10.3389/fphar.2023.1088957. PMID: 36817162; PMCID: PMC9932206.&lt;br /&gt;
***Acknowledgement: This study received funding from the National Science Foundation of China (Grant No. 32072344, 82101506, 32272455), the Scientific and Technological Project of Henan Province of China (Grant No. 182102310157) and the Scientific and Technological Project of China Tobacco Jiangsu Industrial Co., Ltd. (No. H202002). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. Authors JX, RJ, and ZG were employed by China Tobacco Jiangsu Industrial Co., Ltd.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://jamanetwork.com/journals/jamaneurology/article-abstract/2805037 Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune]===&lt;br /&gt;
*“Parkinson disease risk was substantially lower among Black veterans and EVER-SMOKERS (OR 0.49, 95% CI: 0.40-0.61).&lt;br /&gt;
**Citation: Goldman SM, Weaver FM, Stroupe KT, Cao L, Gonzalez B, Colletta K, Brown EG, Tanner CM. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune. JAMA Neurol. 2023 Jul 1;80(7):673-681. doi: 10.1001/jamaneurol.2023.1168. PMID: 37184848; PMCID: PMC10186205.&lt;br /&gt;
***Acknowledgement: This research was supported by clinical science research and development merit award I01 CX002040-01 from the US Department of Veterans Affairs. Support for Veterans Administration (VA)/Centers for Medicare &amp;amp; Medicaid Services data was from the US Department of Veterans Affairs, VA Health Services Research and Development Service, and project numbers SDR 02-237 and 98-004 from the VA Information Resource Center. Dr Weaver reported receiving grants from the Edward Hines, Jr VA Hospital during the conduct of the study and outside the submitted work. Dr Brown reported receiving grants from the Michael J. Fox Foundation and the National Institute on Aging and personal fees from Gateway Consulting, LLC, outside the submitted work. Dr Tanner reported receiving personal fees from Lundbeck Pharma, CNS Ratings, Adamas, Cadent, and Evidera; serving on advisory boards for Kyowa Kirin, Acorda, Australia Parkinson’s Mission; serving on a clinical trial steering committee for Jazz Pharmaceuticals/Cavion; and receiving grants from the National Institutes of Health, Biogen Idec, Parkinson Foundation, Michael J. Fox Foundation, Department of Defense Parkinson’s Research Program, Roche, Genentech, BioElectron, and Gateway Institute for Brain Research, LLC, outside the submitted work. No other disclosures were reported.&lt;br /&gt;
&lt;br /&gt;
===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602090/ Butyrate Protects and Synergizes with Nicotine against Iron- and Manganese-induced Toxicities in Cell Culture]===&lt;br /&gt;
*Preprint, not peer-reviewed.&lt;br /&gt;
*In summary, our results not only support neuroprotective effects of nicotine and butyrate in countering Fe and Mn toxicities but indicate a synergistic protection by combination of the two. Moreover, distinct mechanisms of action for each metal, i.e., nicotinic receptor for nicotine and FA3R for butyrate are indicated. Further exploitation of mechanisms of action of butyrate and nicotine may provide novel targets for metal toxicities and/or amelioration of neurodegenerative diseases.&lt;br /&gt;
**Citation: Tizabi Y, Getachew B, Aschner M. Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases. Res Sq [Preprint]. 2023 Oct 5:rs.3.rs-3389904. doi: 10.21203/rs.3.rs-3389904/v1. Update in: Neurotox Res. 2023 Dec 14;42(1):3. doi: 10.1007/s12640-023-00682-z. PMID: 37886507; PMCID: PMC10602090.&lt;br /&gt;
***Acknowledgement: Supported in part by: NIH/NIAAA R03 AA022479 and NIH/NIGMS (2 SO6 GM08016‐39) (YT), and NIEHS R01ES10563 and R01ES07331 (MA).&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.nature.com/articles/s41598-021-88910-4 Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels]===&lt;br /&gt;
*Insect study&lt;br /&gt;
*In conclusion our data show that the PD model by expression of Sph-1 in dopaminergic neurons provides a good opportunity to study the early prodromal stages of PD, while also the late onset symptoms such as neurodegeneration and motor impairment in aged animals. On the other hand, working on this animal model has allowed us to advance on the therapeutic effects of nicotine treatment over several PD-linked features. The protective effect of nicotine appears to be specific for the genotype predisposed to develop a parkinsonian phenotype and provide a hint on the idea that nicotine treatment even in later stages of the disease could be beneficial to patients. Our findings provide new ideas that contribute to a better understanding on the mechanisms underlying the positive effects of nicotine in PD.&lt;br /&gt;
**Citation: Carvajal-Oliveros, A., Domínguez-Baleón, C., Zárate, R.V. et al. Nicotine suppresses Parkinson’s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Sci Rep 11, 9579 (2021). https://doi.org/10.1038/s41598-021-88910-4&lt;br /&gt;
***Acknowledgement: This work was supported by the CONACyT (Grant Number 255478) and by DGAPA-PAPIIT (Grant Number IN206517).&lt;br /&gt;
&lt;br /&gt;
=== 2020: [https://n.neurology.org/content/94/20/e2132 Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors] === &lt;br /&gt;
*In contrast to previous suggestions, the present report demonstrates a causally protective effect of current smoking on the risk of PD, which may provide insights into the etiology of PD.&lt;br /&gt;
**Citation: Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, Peto R. Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology. 2020 May 19;94(20):e2132-e2138. doi: 10.1212/WNL.0000000000009437. Epub 2020 May 5. PMID: 32371450; PMCID: PMC7526668.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://academic.oup.com/ajcn/advance-article-abstract/doi/10.1093/ajcn/nqaa186/5876214?redirectedFrom=fulltext Dietary nicotine intake and risk of Parkinson disease: a prospective study]=== &lt;br /&gt;
*At 26 year follow-up, women with greater dietary nicotine intake had a lower risk of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Parkinson Disease (PD)&#039;&#039;&#039;]] than those with lower intake. Dietary nicotine intake was calculated based on consumption of peppers, tomatoes, processed tomatoes, potatoes, and tea. &lt;br /&gt;
*[https://sci-hub.st/10.1093/ajcn/nqaa186 PDF Version]&lt;br /&gt;
**Citation: Chaoran Ma, Samantha Molsberry, Yanping Li, Michael Schwarzschild, Alberto Ascherio, Xiang Gao, Dietary nicotine intake and risk of Parkinson disease: a prospective study, The American Journal of Clinical Nutrition, Volume 112, Issue 4, October 2020, Pages 1080–1087, doi: 10.1093/ajcn/nqaa186&lt;br /&gt;
***Acknowledgements: Supported by National Institute of Neurological Disorders and Stroke at the NIH grant 1R03NS093245-01A1 (to XG). The Nurses’ Health Study is supported by the NIH through grant UM1 CA186107. The Health Professionals Follow-up Study cohort is supported by the NIH through grant U01 CA167552.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-018-0625-y Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*The reduced prevalence of Parkinson’s disease in tobacco users is a fascinating phenomenon that is not understood. This study suggests a mechanistic explanation for how tobacco users are protected from Parkinson’s and how the tobacco component nicotine confers neuroprotection; more specifically, nicotine suppresses SIRT6 which confers resistance to neuron and cell death. Few effective treatments exist that prevent neuron death for those suffering from Parkinson’s and other neurodegenerative disorders. The identification of SIRT6 as potentially pathogenic and as a therapeutic target for suppression opens a novel line of research for the treatment of neurodegeneration.&lt;br /&gt;
**Citation: Nicholatos, J.W., Francisco, A.B., Bender, C.A. et al. Nicotine promotes neuron survival and partially protects from Parkinson’s disease by suppressing SIRT6. acta neuropathol commun 6, 120 (2018). https://doi.org/10.1186/s40478-018-0625-y&lt;br /&gt;
***Acknowledgement: S.L. and J.W.N. were in part supported by a grant from American Federation for Aging Research (AFAR, grant # 2015–030). S.L. received seed grant funding from the Cornell University Center for Vertebrate Genomics. J.W.N. was supported by a Glenn/AFAR Scholarship for Research in the Biology of Aging.&lt;br /&gt;
&lt;br /&gt;
===2017 [https://academic.oup.com/ije/article/46/3/872/2656164 Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease]===&lt;br /&gt;
*Non-smoking men who used snus had a 60% lower risk of Parkinson’s disease compared with never snus users.&lt;br /&gt;
**Citation: Yang F, Pedersen NL, Ye W, Liu Z, Norberg M, Forsgren L, Trolle Lagerros Y, Bellocco R, Alfredsson L, Knutsson A, Jansson JH, Wennberg P, Galanti MR, Lager ACJ, Araghi M, Lundberg M, Magnusson C, Wirdefeldt K. Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease. Int J Epidemiol. 2017 Jun 1;46(3):872-880. doi: 10.1093/ije/dyw294. PMID: 27940486.&lt;br /&gt;
***Acknowledgement: This work was supported by the Swedish Research Council (grant number 521-2013-2488 to N.L.P.) and the regional agreement on medical training and clinical research between Stockholm County Council and Karolinska Institutet (Y.T.L.).&lt;br /&gt;
&lt;br /&gt;
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]===&lt;br /&gt;
*Nicotine is used for a number of reasons. In human studies, acute administration of nicotine can have positive effects on cognitive processes, such as improving attention, fine motor coordination, concentration, memory, speed of information processing, and alleviation of boredom or drowsiness. Some nicotine users benefit from self-medication effects for alleviation of stress, anxiety, depression, and other mental health and medical conditions, including schizophrenia and Parkinson’s Disease. Nicotine also reverses cognitive deficits caused by withdrawal. It is not clear if chronic use of nicotine enhances cognitive function.&lt;br /&gt;
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population.&lt;br /&gt;
**Author/Acknowledgements: Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner&lt;br /&gt;
&lt;br /&gt;
===2007 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2046219/ Nicotinic receptors as CNS targets for Parkinson’s disease]=== &lt;br /&gt;
*Human and animal references&lt;br /&gt;
*Analyzes results showing that chronic nicotine treatment improved striatal integrity and function.&lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2046219/pdf/nihms32016.pdf PDF Version]&lt;br /&gt;
**Citation: Quik M, Bordia T, O&#039;Leary K. Nicotinic receptors as CNS targets for Parkinson&#039;s disease. Biochem Pharmacol. 2007 Oct 15;74(8):1224-34. doi: 10.1016/j.bcp.2007.06.015. Epub 2007 Jun 17. PMID: 17631864; PMCID: PMC2046219.&lt;br /&gt;
***Acknowledgements: This work was supported by NIH grants NS42091 and NS47162.&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*Nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Parkinson&#039;s Disease&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
**Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against &#039;&#039;&#039;Parkinson&#039;s Disease&#039;&#039;&#039; (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pemphigus Vulgaris&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2001: [https://pubmed.ncbi.nlm.nih.gov/11737449/ Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire]===&lt;br /&gt;
*The risk for pemphigus vulgaris was lower for ex-smokers and current smokers than for patients who had never smoked.&lt;br /&gt;
*The beneficial effect of smoking on pemphigus might be explained by its effect on the immune system. &lt;br /&gt;
**Citation: Brenner S, Tur E, Shapiro J, Ruocco V, D&#039;Avino M, Ruocco E, Tsankov N, Vassileva S, Drenovska K, Brezoev P, Barnadas MA, Gonzalez MJ, Anhalt G, Nousari H, Ramos-e-Silva M, Pinto KT, Miranda MF. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol. 2001 Sep;40(9):562-9. doi: 10.1046/j.1365-4362.2001.01266.x. Erratum in: Int J Dermatol. 2003 Sep;42(9):760. Silva MR [corrected to Ramos-e-Silva M]. PMID: 11737449.&lt;br /&gt;
&lt;br /&gt;
===2000: [https://jamanetwork.com/journals/jamadermatology/fullarticle/189739 A Case of Pemphigus Vulgaris Improved by Cigarette Smoking]===&lt;br /&gt;
*The patient reported an inverse relationship between smoking and pemphigus flares. He observed a worsening of the pemphigus when he stopped smoking. Nicotine patches were prescribed, but he began smoking cigarettes again instead. On average, he smokes 15 cigarettes per day. One week after he began smoking again, his pemphigus rapidly started to clear.&lt;br /&gt;
**Citation: Mehta JN, Martin AG. A case of pemphigus vulgaris improved by cigarette smoking. Arch Dermatol. 2000 Jan;136(1):15-7. doi: 10.1001/archderm.136.1.15. PMID: 10632179.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Psoriasis&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/ Can nicotine use alleviate symptoms of psoriasis?]=== &lt;br /&gt;
*In light of recent data demonstrating that psoriasis is an immune-mediated disease, the possibility that novel anti-inflammatory treatments such as nicotine replacement therapy or analogues could have a beneficial effect on patients with psoriasis should be considered. This case described one such occasion in which it appeared that nicotine had a therapeutic effect on a patient’s psoriasis. &lt;br /&gt;
*[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325452/pdf/0580404.pdf PDF Version]&lt;br /&gt;
**Citation: Staples J, Klein D. Can nicotine use alleviate symptoms of psoriasis? Can Fam Physician. 2012 Apr;58(4):404-8. PMID: 22611606; PMCID: PMC3325452.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Pyoderma Gangrenosum&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15204166/ Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream]=== &lt;br /&gt;
*Two patients with pyoderma gangrenosum treated with topical nicotine 0.5% w/w cetamacrogol formula A cream are described here, both of whom had dramatic clinical resolution of their pyoderma gangrenosum.&lt;br /&gt;
*[https://scihubtw.tw/10.1080/09546630310019364 PDF Version]&lt;br /&gt;
**Citations:Patel GK, Rhodes JR, Evans B, Holt PJ. Successful treatment of pyoderma gangrenosum with topical 0.5% nicotine cream. J Dermatolog Treat. 2004 Apr;15(2):122-5. doi: 10.1080/09546630310019364. PMID: 15204166.&lt;br /&gt;
&lt;br /&gt;
===1998 [https://jamanetwork.com/journals/jamadermatology/fullarticle/189304?fbclid=IwAR33gpEktRMf2Q0v5Btl9C5E8gmXw-ZP8_gDFt6sebxUBpXE_WfVt-o-mSw Nicotine for Pyoderma Gangrenosum]=== &lt;br /&gt;
*Herein we describe a patient with pyoderma gangrenosum who responded twice to topical nicotine within 4 weeks and 3 months, respectively, without any adverse effects.&lt;br /&gt;
*[https://scholar.google.com/scholar_url?url=https://jamanetwork.com/journals/jamadermatology/articlepdf/189304/dce8005.pdf&amp;amp;hl=en&amp;amp;sa=T&amp;amp;oi=ucasa&amp;amp;ct=ufr&amp;amp;ei=Z2aqX4SnOc2rywTPj5aYDw&amp;amp;scisig=AAGBfm1pz6ffl3a23G__I3APgBLpY6Cofw PDF Version]&lt;br /&gt;
**Citation: Wolf R, Ruocco V. Nicotine for Pyoderma Gangrenosum. Arch Dermatol. 1998;134(9):1071–1072. doi:10.1001/archderm.134.9.1071&lt;br /&gt;
&lt;br /&gt;
===1995 [https://pubmed.ncbi.nlm.nih.gov/8537562/ Successful treatment of pyoderma gangrenosum with nicotine chewing gum]=== &lt;br /&gt;
*We used nicotine chewing gum for the treatment of pyoderma gangrenosum with remarkable results. We strongly suggest that nicotine chewing gum may not only be beneficial in treating pyoderma gangrenosum but may also be useful in treating other skin disorders with prominent neutrophilic infiltrations such as Behcet&#039;s disease, Sweet disease, allergic vasculitis, and recurrent oral aphthae, the last of which is known to respond to smoking.&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1346-8138.1995.tb03904.x PDF Version]&lt;br /&gt;
**Citation: Kanekura T, Kanzaki T. Successful treatment of pyoderma gangrenosum with nicotine chewing gum. J Dermatol. 1995 Sep;22(9):704-5. doi: 10.1111/j.1346-8138.1995.tb03904.x. PMID: 8537562.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sarcoidosis&#039;&#039;&#039;= &lt;br /&gt;
===2021 [https://journal.chestnet.org/article/S0012-3692(21)01282-4/fulltext Promise of Nicotine as a Treatment for Pulmonary Sarcoidosis]=== &lt;br /&gt;
===2021 [https://journal.chestnet.org/article/S0012-3692(21)00962-4/fulltext A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis]===&lt;br /&gt;
*Nicotine treatment was well tolerated in patients with active pulmonary sarcoidosis, and the preliminary findings of this pilot study suggest that it may reduce disease progression, based on FVC.&lt;br /&gt;
**Citation: A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis, Crouser, Elliott D. et al. CHEST, Volume 160, Issue 4, 1340 - 1349&lt;br /&gt;
&lt;br /&gt;
===2013 [https://journal.chestnet.org/article/S0012-3692(13)60095-1/fulltext Nicotine Treatment Improves Toll-Like Receptor 2 and Toll-Like Receptor 9 Responsiveness in Active Pulmonary Sarcoidosis]=== &lt;br /&gt;
*The immune phenotype of patients with symptomatic [[wikipedia:Sarcoidosis|&#039;&#039;&#039;sarcoidosis&#039;&#039;&#039;]] treated with nicotine closely resembled that of asymptomatic patients, supporting the notion that nicotine treatment may be beneficial in this patient population.&lt;br /&gt;
*[https://www.researchgate.net/profile/Mark_Julian/publication/230645268_Nicotine_Treatment_Improves_TLR2_and_TLR9_Responsiveness_in_Active_Pulmonary_Sarcoidosis/links/556ca4af08aeab77722318be/Nicotine-Treatment-Improves-TLR2-and-TLR9-Responsiveness-in-Active-Pulmonary-Sarcoidosis.pdf PDF Version]&lt;br /&gt;
**Citation: Mark W. Julian, MS; Guohong Shao, MD; Larry S. Schlesinger, MD; Qin Huang, MD; David G. Cosmar, BA; Nitin Y. Bhatt, MD; Daniel A. Culver, MD, FCCP; Robert P. Baughman, MD, FCCP; Karen L. Wood, MD, FCCP; and Elliott D. Crouser, MD - ORIGINAL RESEARCH DIFFUSE LUNG DISEASE| VOLUME 143, ISSUE 2, P461-470, FEBRUARY 01, 2013, DOI 10.1378/chest.12-0383&lt;br /&gt;
***Acknowledgements: This work was supported by the American Thoracic Society and the Foundation for Sarcoidosis Research. © 2013 American College of Chest Physicians&lt;br /&gt;
&lt;br /&gt;
===1988:[https://thorax.bmj.com/content/43/7/516.abstract Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.]===&lt;br /&gt;
*These finding support the possibility that smokers, particularly those with a prominent accumulation of alveolar macrophages in the lower respiratory tract, may be less likely to develop sarcoidosis.&lt;br /&gt;
**Citation: Valeyre D, Soler P, Clerici C, et alSmoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease.Thorax 1988;43:516-524.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Seizures / Epilepsy&#039;&#039;&#039;=&lt;br /&gt;
*See also:&lt;br /&gt;
**Video: News 5: [https://www.youtube.com/watch?v=Ztvf45coKZk Nicotine Stops Seizures]&lt;br /&gt;
&lt;br /&gt;
===2024 [https://www.neurology.org/doi/10.1212/WNL.0000000000209790/ Pearls &amp;amp; Oy-sters: Exquisite Response of Sleep-Related Hypermotor Epilepsy to a Nicotine Patch]===&lt;br /&gt;
*&amp;quot;Sleep-related hypermotor epilepsy (SHE), previously known as nocturnal frontal lobe epilepsy, is characterized by brief (&amp;lt;2 minutes) seizures with abrupt onset and offset and stereotyped focal or generalized hypermotor events occurring predominantly (but not exclusively) from sleep.&amp;quot;&lt;br /&gt;
*&amp;quot;Our case highlights that there may be mechanisms by which nicotine assists with seizure cessation in specific populations of individuals with SHE.&amp;quot;&lt;br /&gt;
**Citation: Nam S, Von Stein EL, Meador KJ, Levy RJ, Gallentine W, Li Y. Pearls &amp;amp; Oy-sters: Exquisite Response of Sleep-Related Hypermotor Epilepsy to a Nicotine Patch. Neurology. 2024 Oct 8;103(7):e209790. doi: 10.1212/WNL.0000000000209790. Epub 2024 Sep 9. PMID: 39250747; PMCID: PMC11385953.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/34763266/ Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients]=== &lt;br /&gt;
*This is the hitherto largest observational study supporting a favorable effect of nicotine in this specific seizure disorder. Better seizure control from transdermal nicotine compared to only day-time consumption suggests benefit from exposure throughout the night. According to current clinical experience, patients with uncontrolled ADSHE harboring relevant mutations should be offered precision treatment with transdermal nicotine.&lt;br /&gt;
**Citation: Brodtkorb E, Myren-Svelstad S, Knudsen-Baas KM, Nakken KO, Spigset O. Precision treatment with nicotine in autosomal dominant sleep-related hypermotor epilepsy (ADSHE): An observational study of clinical outcome and serum cotinine levels in 17 patients. Epilepsy Res. 2021 Oct 25;178:106792. doi: 10.1016/j.eplepsyres.2021.106792. Epub ahead of print. PMID: 34763266.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.pedneur.com/article/S0887-8994(21)00147-8/fulltext Nicotine patch improved autosomal dominant sleep-related hypermotor epilepsy]=== &lt;br /&gt;
*Nevertheless, the two siblings reported here add to the small number of pediatric case reports regarding the successful use of nicotine patches in ADSHE.&lt;br /&gt;
*Journal Pre-Proof [https://www.pedneur.com/action/showPdf?pii=S0887-8994%2821%2900147-8 PDF Version]&lt;br /&gt;
**Citation: Nguyen SM, Deering L, Nelson GT, McDaniel SS, Nicotine patch improved autosomal dominant sleep-related hypermotor epilepsy, Pediatric Neurology (2021), doi:10.1016/j.pediatrneurol.2021.07.006.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://pubmed.ncbi.nlm.nih.gov/33284031/ Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]===&lt;br /&gt;
*&amp;quot;Genetic variants of the neuronal nicotinic acetylcholine receptor (nAChR) cause autosomal dominant sleep-related hypermotor epilepsy. Approximately 30% of autosomal dominant sleep-related hypermotor epilepsy patients are medically intractable.&amp;quot;&lt;br /&gt;
*&amp;quot;Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants. We propose consideration of transdermal nicotine treatment in intractable epilepsy with known nAChR variants as an experimental therapy.&amp;quot;&lt;br /&gt;
**Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031.&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/33284031/ Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants]===&lt;br /&gt;
*&amp;quot;Four patients were prescribed nicotine patches for intractable seizures. Three of 4 patients had a clinical response, with &amp;gt;50% seizure reduction.&amp;quot;&lt;br /&gt;
*&amp;quot;Conclusions: Treatment with a nicotine patch can be an effective therapy in epilepsy patients with nAChR gene variants.&amp;quot;&lt;br /&gt;
**Citation: Fox J, Thodeson DM, Dolce AM. Nicotine: A Targeted Therapy for Epilepsy Due to nAChR Gene Variants. J Child Neurol. 2021 Apr;36(5):371-377. doi: 10.1177/0883073820974851. Epub 2020 Dec 7. PMID: 33284031&lt;br /&gt;
&lt;br /&gt;
===2020 [https://pubmed.ncbi.nlm.nih.gov/32097883/  Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy]===&lt;br /&gt;
*&amp;quot;Results: A striking seizure reduction was reported soon after treatment onset. Hypermotor seizures disappeared; only sporadic arousals, sometimes with minor motor elements, were observed. Psychometric testing documented improvement in cognitive domains such as visuospatial ability, processing speed, memory, and some areas of executive functions.&amp;quot;&lt;br /&gt;
**Citation: Lossius K, de Saint Martin A, Myren-Svelstad S, Bjørnvold M, Minken G, Seegmuller C, Valenti Hirsch MP, Chelly J, Steinlein O, Picard F, Brodtkorb E. Remarkable effect of transdermal nicotine in children with CHRNA4-related autosomal dominant sleep-related hypermotor epilepsy. Epilepsy Behav. 2020 Apr;105:106944. doi: 10.1016/j.yebeh.2020.106944. Epub 2020 Feb 22. PMID: 32097883.&lt;br /&gt;
&lt;br /&gt;
===2018 [https://www.dovepress.com/sleep-related-hypermotor-epilepsy-prevalence-impact-and-management-str-peer-reviewed-fulltext-article-NSS Sleep-related hypermotor epilepsy: prevalence, impact and management strategies]===&lt;br /&gt;
*&amp;quot;Seizure frequency improved in a single patient with refractory ADSHE after nicotine transdermal patches treatment.(108) The favorable effect of nicotine on seizure frequency was also described in 9 of 22 patients from two European ADSHE families carrying CHRNA4 mutations.(109) Considering the role of the cholinergic system in arousal regulatory processes, these observations suggested a possible link between nicotine defect, alteration of arousal regulation and seizures in SHE/ADSHE patients. However, despite the reported positive effect of nicotine in reducing seizure frequency, a case–control family study, did not find a higher tendency to smoke tobacco in SHE patients and their relatives compared with the control cases.(110)&lt;br /&gt;
**Citation: Menghi V, Bisulli F, Tinuper P, Nobili L. Sleep-related hypermotor epilepsy: prevalence, impact and management strategies. Nat Sci Sleep. 2018 Oct 10;10:317-326. doi: 10.2147/NSS.S152624. PMID: 30349413; PMCID: PMC6186898.&lt;br /&gt;
&lt;br /&gt;
===2015 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433466/ Pearls &amp;amp; Oy-sters: A case of refractory nocturnal seizures]===&lt;br /&gt;
*&amp;quot;Due to frequent seizures, there was a paucity of slow-wave sleep and complete absence of REM sleep. On the second day of her hospital admission, a 7-mg nicotine patch was applied about 2–3 hours before bedtime. There was almost complete resolution of clinical and electrical events. The duration of slow-wave sleep increased and REM sleep was recorded. The next morning, the patient felt refreshed and less anxious.&amp;quot;&lt;br /&gt;
**Citation: Pavlakis PP, Douglass LM. Pearls &amp;amp; Oysters: A case of refractory nocturnal seizures: Putting out fires without smoke. Neurology. 2015 May 5;84(18):e134-6. doi: 10.1212/WNL.0000000000001539. PMID: 25941204; PMCID: PMC4433466.&lt;br /&gt;
&lt;br /&gt;
===2012 [https://onlinelibrary.wiley.com/doi/full/10.1111/j.1528-1167.2012.03715.x Resolution of epileptic encephalopathy following treatment with transdermal nicotine]=== &lt;br /&gt;
*We report resolution of an epileptic encephalopathy by administration of transdermal nicotine patches in an adolescent with severe nonlesional refractory frontal lobe epilepsy. The 18.5‐year‐old female patient had refractory epilepsy from the age of 11. Recurrent electroencephalography (EEG) recordings showed mostly generalized activity, albeit with right frontal predominance. Almost all antiepileptic medications failed to provide benefit. She developed an encephalopathic state with cognitive decline. The nonlesional frontal lobe epilepsy and a family history of a cousin with nocturnal epilepsy with frontal origin suggested genetic etiology. Transdermal nicotine patches brought complete resolution of the seizures, normalization of the EEG, and a significant improvement in her thinking process and speech organization. Sequencing of the CHRNB2 and CHRNA4 genes did not detect a mutation. Transdermal nicotine patches should be considered in severe pharmacoresistant frontal lobe epilepsy.&lt;br /&gt;
*[https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1528-1167.2012.03715.x PDF Version]&lt;br /&gt;
**Citation: Zerem, A., Nishri, D., Yosef, Y., Blumkin, L., Lev, D., Leshinsky‐Silver, E., Kivity, S. and Lerman‐Sagie, T. (2013), Resolution of epileptic encephalopathy following treatment with transdermal nicotine. Epilepsia, 54: e13-e15. doi: 10.1111/j.1528-1167.2012.03715.x&lt;br /&gt;
&lt;br /&gt;
===2006 [https://pubmed.ncbi.nlm.nih.gov/16931165/ Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy]===&lt;br /&gt;
*&amp;quot;This study indicates that nicotine consumption is an environmental factor that, in many patients with ADNFLE, may influence susceptibility to seizures. A detailed account of tobacco habits should be part of the history. Transdermal nicotine should be considered in pharmacoresistant cases.&amp;quot;&lt;br /&gt;
*[https://sci-hub.se/10.1016/j.yebeh.2006.07.008 PDF Full study]&lt;br /&gt;
**Citation: Brodtkorb E, Picard F. Tobacco habits modulate autosomal dominant nocturnal frontal lobe epilepsy. Epilepsy Behav. 2006 Nov;9(3):515-20. doi: 10.1016/j.yebeh.2006.07.008. Epub 2006 Aug 22. PMID: 16931165.&lt;br /&gt;
&lt;br /&gt;
===2003 [https://onlinelibrary.wiley.com/doi/full/10.1046/j.1528-1157.2003.58102.x-i1?sid=nlm%3Apubmed Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study]=== &lt;br /&gt;
*In this individual with refractory [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;ADNFLE&#039;&#039;&#039;]], nicotine had a therapeutic effect on seizures, and it may be useful to others with this disorder.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1046/j.1528-1157.2003.58102.x-i1 PDF Version]&lt;br /&gt;
**Citation: Willoughby, J.O., Pope, K.J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study. Epilepsia, 44: 1238-1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sepsis/Septic/endotoxemia/infection&#039;&#039;&#039;=&lt;br /&gt;
===2024 [https://www.sciencedirect.com/science/article/pii/S0014488624002723 Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*Taken together, these findings indicate that acute nicotine exposure enhances functional stroke recovery. Future studies will have to evaluate the effects of (1) chronic nicotine exposure, a clinically relevant vascular risk factor, and (2) the cessation of nicotine exposure, which is widely recommended post-stroke, but might have detrimental effects in the early stroke recovery phase.&lt;br /&gt;
**Citation: Abbaspour S, Fahanik-Babaei J, Adeli S, Hermann DM, Sardari M. Acute nicotine exposure attenuates neurological deficits, ischemic injury and brain inflammatory responses and restores hippocampal long-term potentiation in ischemic stroke followed by lipopolysaccharide-induced sepsis-like state. Exp Neurol. 2024 Sep 13;382:114946. doi: 10.1016/j.expneurol.2024.114946. Epub ahead of print. PMID: 39278587.&lt;br /&gt;
***Funding: None&lt;br /&gt;
&lt;br /&gt;
===2014 [https://academic.oup.com/jid/article/209/10/1668/855517#78932729 Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation]===&lt;br /&gt;
*Animal study&lt;br /&gt;
*In conclusion, stimulation of α7nAChR by nicotine improves mortality rates and MODS during sepsis. This protective effect of nicotine can be associated with the inhibition of TLR4 overexpression through the PI3K/Akt signaling pathway. Although the therapeutic potential of nicotine is still limited by its nonspecific effects, this study may provide an impetus for further development of therapeutic strategies for modifying the cholinergic antiinflammatory pathway in the treatment of various inflammatory diseases.&lt;br /&gt;
**Citation: Kim TH, Kim SJ, Lee SM. Stimulation of the α7 nicotinic acetylcholine receptor protects against sepsis by inhibiting Toll-like receptor via phosphoinositide 3-kinase activation. J Infect Dis. 2014 May 15;209(10):1668-77. doi: 10.1093/infdis/jit669. Epub 2013 Dec 1. Erratum in: J Infect Dis. 2015 Mar 1;211(5):851. doi: 10.1093/infdis/jiu824. PMID: 24298024.&lt;br /&gt;
***Acknowledgement: This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Information and Communication Technologies (ICT) and Future Planning (NRF-2013R1A1A3008145).&lt;br /&gt;
&lt;br /&gt;
===2011 [https://pubmed.ncbi.nlm.nih.gov/20805763/ Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*The results suggested that both carbachol and nicotine play a role in the anti-inflammatory process and organ function protection through the α7 subunit of nicotinic cholinergic receptor.&lt;br /&gt;
*[https://sci-hub.st/10.1097/TA.0b013e3181e9732d PDF Full Paper]&lt;br /&gt;
**Citation: Zhou G, Hu S, Lv Y, Song Q, Zou X, Sheng Z. Carbachol alleviates rat cytokine release and organ dysfunction induced by lipopolysaccharide. J Trauma. 2011 Jul;71(1):157-62. doi: 10.1097/TA.0b013e3181e9732d. PMID: 20805763.&lt;br /&gt;
***Acknowledgement: From the Laboratory of Shock and Organ Dysfunction (G.Z., S.H., Y.L., Q.S., X.Z., Z.S.), Burn Institute, the First Hospital Affiliated to the People’s Liberation Army General Hospital, Beijing, China.&lt;br /&gt;
&lt;br /&gt;
===2005 [https://academic.oup.com/jid/article/191/12/2138/842542 The Cholinergic Anti-Inflammatory Pathway Regulates the Host Response during Septic Peritonitis]===&lt;br /&gt;
*Animal Study&lt;br /&gt;
*&amp;quot;Initial cytokine release during septic peritonitis was enhanced after previous vagotomy and was decreased after nicotine pretreatment, independently of the integrity of the vagus nerve. Further study established that vagotomy before septic peritonitis resulted in an enhanced influx of neutrophils and a marked increase in proinflammatory cytokine levels and liver damage. Conversely, nicotine pretreatment strongly decreased cell influx, proinflammatory cytokine levels, and liver damage, whereas bacterial clearance and survival were impaired.&amp;quot;&lt;br /&gt;
**Citation: van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, van der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis. 2005 Jun 15;191(12):2138-48. doi: 10.1086/430323. Epub 2005 May 10. PMID: 15898001.&lt;br /&gt;
***Acknowledgement: Financial support: Academic Medical Center, Amsterdam, The Netherlands. Potential conflicts of interest: K.J.T. is cofounder of Critical Therapeutics Inc., a pharmaceutical company developing potential future treatment modalities based on the cholinergic anti-inflammatory pathway.&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Sleep Apnea&#039;&#039;&#039;= &lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against sleep apnea (other diseases / issues mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
**Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
***Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1985: [https://pubmed.ncbi.nlm.nih.gov/3965253/ Nicotine: a different approach to treatment of obstructive sleep apnea]===&lt;br /&gt;
*Reduced upper airway muscle activity may contribute to the occurrence of obstructive apneas during sleep. There is no uniformly successful treatment of these apneas, and it is possible that agents which increase upper airway muscle activity could reduce the occurrence of obstruction during sleep. Nicotine, a known stimulant of breathing, also increases the activity of muscles which dilate the upper airway proportionally more than it does ventilation. Hence, we evaluated the effect of nicotine on apneas during the first two hours of sleep in eight patients with sleep apnea syndrome. It was concluded that nicotine reduces apneas during the early hours of sleep, and this effect may be caused by its stimulating action on upper airway muscles.&lt;br /&gt;
*[https://sci-hub.se/10.1378/chest.87.1.11 PDF Version]&lt;br /&gt;
**Citation: Gothe B, Strohl KP, Levin S, Cherniack NS. Nicotine: a different approach to treatment of obstructive sleep apnea. Chest. 1985 Jan;87(1):11-7. doi: 10.1378/chest.87.1.11. PMID: 3965253.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Smoking Cessation / Preventing Relapse&#039;&#039;&#039;= &lt;br /&gt;
===Resource Doc: [https://docs.google.com/document/d/13-D2q1P0KpmZuoFBkKV4l9wUEQ-zcHfp6MAVJGoAaG4/edit?usp=sharing INNCO - Myth of the month:  Ecigs and snus don’t help smokers quit]=== &lt;br /&gt;
*Links and conclusions of studies formatted to fit the character limits on Twitter&lt;br /&gt;
&lt;br /&gt;
===[https://safernicotine.wiki/mediawiki/index.php/Myth:_Alternative_nicotine_products_don%27t_help_people_stop_smoking Myth: Alternative nicotine products don&#039;t help people stop smoking]=== &lt;br /&gt;
*This wiki page shows over 70 studies demonstrating these products help people stop smoking.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Spinal Cord Injury&#039;&#039;&#039;= &lt;br /&gt;
===2008 [https://onlinelibrary.wiley.com/doi/10.1002/jnr.21901 Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury]=== &lt;br /&gt;
*Animal Study&lt;br /&gt;
*Primary impact to the spinal cord results in stimulation of secondary processes that potentiate the initial trauma. Recent evidence indicates that nicotine can exert potent antioxidant and neuroprotective effects in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;spinal cord injury (SCI)&#039;&#039;&#039;]].&lt;br /&gt;
*The results of the present study indicate that [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;iNOS&#039;&#039;&#039;]] is induced in the early stages of SCI, leading to increased nitration of protein tyrosine residues and potentiation of inflammatory responses. Microglial cells appear to be the main cellular source of iNOS in SCI. In addition, nicotine-induced anti-inflammatory effects in SCI are mediated, at least in part, by the attenuation of iNOS overexpression through the receptor-mediated mechanism. This data may have significant therapeutic implications for the targeting of nicotine receptors in the treatment of compressive spinal cord trauma.&lt;br /&gt;
*[https://sci-hub.st/10.1002/jnr.21901 PDF Version]&lt;br /&gt;
*Citation: Lee, M.‐Y., Chen, L. and Toborek, M. (2009), Nicotine attenuates iNOS expression and contributes to neuroprotection in a compressive model of spinal cord injury. J. Neurosci. Res., 87: 937-947.doi.org/10.1002/jnr.21901&lt;br /&gt;
*Acknowledgements: This work was supported in part by the Philip Morris External Research Program and the Kentucky Science and Engineering Foundation.&lt;br /&gt;
*Key words: spinal cord injury; nicotine; neuronal nicotinic receptors; oxidative stress; inflammatory responses; nitric oxide synthase&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Tourette&#039;s Syndrome&#039;&#039;&#039;= &lt;br /&gt;
===2012 [https://pubmed.ncbi.nlm.nih.gov/22776623/ Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette&#039;s, depression, and beyond]=== &lt;br /&gt;
* The article presents a mini-review of studies on TS and depression over the past 25 years.&lt;br /&gt;
* It summarizes the studies on the behavioral biology of the basal ganglia and its neurotransmitters.&lt;br /&gt;
* It describes research with TS patients to evaluate the therapeutics of nicotine and mecamylamine.&lt;br /&gt;
* [https://sci-hub.se/10.1016/j.physbeh.2012.06.023 PDF Version]&lt;br /&gt;
*Citation: Sanberg, P. R., Vindrola-Padros, C., &amp;amp; Shytle, R. D. (2012). Translating laboratory discovery to the clinic: From nicotine and mecamylamine to Tourette’s, depression, and beyond. Physiology &amp;amp; Behavior, 107(5), 801–808. doi:10.1016/j.physbeh.2012.06.023 &lt;br /&gt;
*Acknowledgement: Paul R. Sanberg and R. Douglas Shytle are inventors on patents related to technology described herein and licensed from the University of South Florida to Targacept, Inc. Because of the historical nature of this article, the authors included a number of self-citations required for a chronological discussion. &lt;br /&gt;
&lt;br /&gt;
===2004 [https://pubmed.ncbi.nlm.nih.gov/15132126/ Clinical and attentional effects of acute nicotine treatment in Tourette&#039;s syndrome]=== &lt;br /&gt;
*In the 14 evaluable patients with complete primary efficacy data, nicotine (compared to placebo) failed to alter symptoms at 4 hours, but counteracted [https://en.wikipedia.org/wiki/P300_(neuroscience) ERP-P300] signs of diminished attention seen 2 weeks following placebo treatment. &lt;br /&gt;
*Secondary efficacy measures, including patient self-reports and parental ratings, found nicotine to reduce complex tics and improve behaviors related to inattention.&lt;br /&gt;
*[https://sci-hub.st/10.1016/j.eurpsy.2003.11.002 PDF Version ]&lt;br /&gt;
*Citation: Howson, A. L., Batth, S., Ilivitsky, V., Boisjoli, A., Jaworski, M., Mahoney, C., &amp;amp; Knott, V. J. (2004). Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome. European Psychiatry, 19(2), 102–112. doi:10.1016/j.eurpsy.2003.11.002 &lt;br /&gt;
*Acknowledgement: This study was supported with a grant from the Tourette Syndrome Association (USA), and patient recruitment was aided by the Ottawa chapter of the Tourette Syndrome Foundation of Canada. &lt;br /&gt;
&lt;br /&gt;
===2001 [https://pubmed.ncbi.nlm.nih.gov/11681767/ Transdermal nicotine and haloperidol in Tourette&#039;s disorder: a double-blind placebo-controlled study]=== &lt;br /&gt;
*[[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Transdermal nicotine (TNP)&#039;&#039;&#039;]] was superior to placebo in reducing behavioral symptoms when patients were receiving an optimal dose of haloperidol, when the dose of haloperidol was reduced by 50%, and when the patch had been discontinued for 2 weeks. These findings confirm earlier open-label findings and suggest that combining nicotinic receptor modulation and neuroleptics could be a therapeutic option for the treatment of Tourette&#039;s disorder &lt;br /&gt;
*[https://www.researchgate.net/profile/Paul_Sanberg/publication/11670769_Transdermal_Nicotine_and_Haloperidol_in_Tourette&#039;s_Disorder/links/5be32624299bf1124fc2d86a/Transdermal-Nicotine-and-Haloperidol-in-Tourettes-Disorder.pdf PDF Version]&lt;br /&gt;
*Citation: Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, McConville B, Sanberg PR. Transdermal nicotine and haloperidol in Tourette&#039;s disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep;62(9):707-14. doi: 10.4088/jcp.v62n0908. PMID: 11681767.&lt;br /&gt;
&lt;br /&gt;
===1997 [https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994 Nicotine for the treatment of Tourette&#039;s syndrome]=== &lt;br /&gt;
*Within 24 hr of the application of a single 7-mg [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TNP (nicotine patch)&#039;&#039;&#039;]], the severity and frequency of tic symptoms is significantly decreased over baseline. This response is rapid, often reaching its maximum in the first 3 hr after application of a single patch. The duration of therapeutic effect of a single 7-mg TNP is variable and may last for about l-2 weeks.&lt;br /&gt;
*Application of a 7-mg TNP to children and adolescents with [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TS&#039;&#039;&#039;]] appears to be clinically safe, with transient side effects. However, no child under 8 years of age and weighing less than 25 kg was considered for TNP treatment.&lt;br /&gt;
*[https://sci-hub.st/https://www.sciencedirect.com/science/article/abs/pii/S0163725896001994?via%3Dihub PDF Version]&lt;br /&gt;
*Citation: Paul R. Sanberg, Archie A. Silver, R.Doug Shytle, Mary Katherine Philipp, David W. Cahill, Harold M. Fogelson, Brian J. McConville, Nicotine for the treatment of Tourette&#039;s syndrome, Pharmacology &amp;amp; Therapeutics, Volume 74, Issue 1, 1997, Pages 21-25, ISSN 0163-7258, doi.org/10.1016/S0163-7258(96)00199-4.&lt;br /&gt;
* Acknowledgements-This review was supported, in part, by grants from the Tourette Syndrome Association, The National Institute of Neurological Disease and Stroke (ROl NS 32067sOlAl) and the Smokeless Tobacco Research Council.&lt;br /&gt;
*Keywords: Nicotine; Tourette&#039;s syndrome; tics; neuropsychiatric disorders&lt;br /&gt;
&lt;br /&gt;
===1996 [https://pubmed.ncbi.nlm.nih.gov/9006184/ Does nicotine have beneficial effects in the treatment of certain diseases?]=== &lt;br /&gt;
*nicotine may have therapeutic uses in the treatment of [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Gilles de la Tourette’s syndrome (TS)&#039;&#039;&#039;]].&lt;br /&gt;
*Drug companies have often refused to fund legitimate and valid research into the potential therapeutic use of nicotine owing to its association with smoking and its image of an abusable drug. Many in the health profession fail to acknowledge the evidence which suggests that nicotine may have potential therapeutic value.&lt;br /&gt;
*[https://sci-hub.st/10.12968/bjon.1996.5.19.1195 PDF Version]&lt;br /&gt;
*Citation: Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996 Oct 24-Nov 13;5(19):1195-202. doi: 10.12968/bjon.1996.5.19.1195. PMID: 9006184.&lt;br /&gt;
&lt;br /&gt;
=== 1996 [https://pubmed.ncbi.nlm.nih.gov/8973070/ Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette&#039;s syndrome]=== &lt;br /&gt;
* Sixteen Tourette&#039;s syndrome patients, aged 9 to 15 years, whose symptoms were not controlled with neuroleptics, were followed for various lengths of time after the application of one 7 mg [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;transdermal nicotine patch (TNP)&#039;&#039;&#039;]] for 24 hours. While there was a broad range in individual response, application of the TNP produced significant reductions in [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;Yale Global Tic Severity Scale (YGTSS)&#039;&#039;&#039;]] scores relative to baseline, with an average duration of effect lasting between 1 and 2 weeks. Side effects, for the most part, were transient.&lt;br /&gt;
*Eleven patients had greater percentage changes after the second TNP than after the first TNP&lt;br /&gt;
*[https://sci-hub.st/10.1097/00004583-199612000-00015 PDF Version]&lt;br /&gt;
*Citation: Silver AA, Shytle RD, Philipp MK, Sanberg PR. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette&#039;s syndrome. J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1631-6. doi: 10.1097/00004583-199612000-00015. PMID: 8973070.&lt;br /&gt;
&lt;br /&gt;
===1992 [https://pubmed.ncbi.nlm.nih.gov/1643197/ The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette&#039;s disorder]=== &lt;br /&gt;
*In this study, nicotine markedly potentiated haloperidol effects in treating [[Special:MyLanguage/Abbreviations|&#039;&#039;&#039;TD&#039;&#039;&#039;]], and showed lesser effects on TD when used alone.&lt;br /&gt;
*[https://sci-hub.st/10.1016/0006-3223(92)90315-q PDF Version]&lt;br /&gt;
* Citation: McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette&#039;s disorder. Biol Psychiatry. 1992 Apr 15;31(8):832-40. doi: 10.1016/0006-3223(92)90315-q. PMID: 1643197.&lt;br /&gt;
*Acknowledgements: Supported in part by grants from the Smokeless Tobacco Research Council, Inc., the Tourette Syndrome Association, and Merrell Dow Pharmaceuticals. The authors thank Roger Stuebing, B.S.M.E., M.S.I.E., and Sunny Y. Lu, M.D., Ph.D. for statistical advice and Merrell Dow Pharmaceuticals for supplying both Nicoreue® gum and placebo nicotine gum.&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
*When chronically taken, nicotine may result in: protection against Tourette&#039;s disease (other diseases mentioned in study)&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF Version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&lt;br /&gt;
===1989 [https://www.sciencedirect.com/science/article/abs/pii/002432058990444X?via%3Dihub Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders]=== &lt;br /&gt;
*Chewing nicotine gum produced striking relief from tics and other symptoms of Tourette syndrome not controlled by neuroleptic treatment alone. It appears that the use of nicotine or cannabinoids may greatly improve the clinical response to neuroleptics in motor disorders.&lt;br /&gt;
*[https://sci-hub.st/https://doi.org/10.1016/0024-3205(89)90444-X PDF Version]&lt;br /&gt;
*Citation: D.E. Moss, Patricia Z. Manderscheid, S.P. Montgomery, Andrew B. Norman, Paul R. Sanberg, Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of tourette syndrome and other motor disorders, Life Sciences, Volume 44, Issue 21, 1989, Pages 1521-1525, ISSN 0024-3205, doi.org/10.1016/0024-3205(89)90444-X.&lt;br /&gt;
*Acknowledgements: Supported in part by NIMH (RR 08012) and NIDA. Levonantradol and fluphenazine HCL were generous gifts from Pfizer Pharmaceuticals (Groton, Conn.) and E.R. Squibb and Sons (Princeton, N.J.), respectively.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Weight Loss / Appetite Control / Metabolism / Obesity&#039;&#039;&#039;= &lt;br /&gt;
===2024 Article [https://web.archive.org/web/20241204102835/https://tobaccoreporter.com/2024/12/03/slim-chances/ Harm reduction, smoking cessation and weight]====&lt;br /&gt;
*&amp;quot;Nicotine influences eating and weight in multiple ways, from hormones to microbiomes to taste perceptions. The bottom line: Nicotine raises the metabolic rate while also depressing appetite.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
===2011 [https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-9-129 Anti-inflammatory effects of nicotine in obesity and ulcerative colitis]===&lt;br /&gt;
*Nicotine, the principal addictive constituent of tobacco, has been shown to suppress appetite and attenuates obesity in many studies, but the underlying mechanism is not clear. &lt;br /&gt;
*Low-grade inflammation is a key feature of obesity and links obesity to insulin resistance, impaired glucose tolerance and even diabetes.&lt;br /&gt;
*Overall, these findings suggest that nicotine and specific α7nAChR agonists may be beneficial in the prevention and treatment of obesity-induced inflammation and insulin resistance. However, there is also evidence that heavy smoking affects body fat distribution that is associated with central obesity and insulin resistance. Moreover, smoking appears to aggravate insulin resistance in persons with type 2 diabetes and to impair glycemic control.&lt;br /&gt;
*Much work remains in terms of understanding the anti-inflammatory effects of nicotine in obesity-related inflammation and ulcerative colitis. However, it is now known that the α7nAChR plays a major role in the anti-inflammatory effects of nicotine and nicotine attenuates inflammation in both obesity and ulcerative colitis. Since the inflammatory response is an integral process in both obesity and ulcerative colitis, controlling the inflammatory response could ameliorate tissue damage.&lt;br /&gt;
*Acknowledgement: This development of this work was supported by the Global Neuroscience Initiative Foundation (GNIF).&lt;br /&gt;
*Citation: Lakhan, S.E., Kirchgessner, A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 9, 129 (2011). https://doi.org/10.1186/1479-5876-9-129&lt;br /&gt;
&lt;br /&gt;
===1991 [https://pubmed.ncbi.nlm.nih.gov/1859921/ Beneficial effects of nicotine]=== &lt;br /&gt;
* When chronically taken, nicotine may result in reduction of body weight&lt;br /&gt;
*[https://sci-hub.st/10.1111/j.1360-0443.1991.tb01810.x PDF version]&lt;br /&gt;
*Citation: Jarvik ME. Beneficial effects of nicotine. Br J Addict. 1991 May;86(5):571-5. doi: 10.1111/j.1360-0443.1991.tb01810.x. PMID: 1859921.&lt;br /&gt;
*Acknowledgement: Supported by U. C. Tobacco-related Disease program, grant # RT87 and a grant from the John D. and Catherine T. MacArthur Foundation.&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;Suggested additions to this page&#039;&#039;&#039;=&lt;br /&gt;
&lt;br /&gt;
===2024: [https://www.sciencedirect.com/science/article/abs/pii/S0303720724003022?via%3Dihub Nicotine increases hepatocyte transthyretin turnover: a possible mechanism for the protective effect of smoking on preeclampsia?]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://pubmed.ncbi.nlm.nih.gov/39719676/ Effect of Nicotine Replacement Therapy on Perioperative Pain Management and Opioid Requirement in Abstinent Tobacco Smokers Undergoing Spinal Fusion: A Double-blind Randomized Controlled Trial]===&lt;br /&gt;
&lt;br /&gt;
===2012: [https://pmc.ncbi.nlm.nih.gov/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
&lt;br /&gt;
===2024: [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1427314/full The double-edged nature of nicotine: toxicities and therapeutic potentials]===&lt;br /&gt;
&lt;br /&gt;
===2023: [https://drive.google.com/file/d/1ofdbKWq6rIBxI8vQAzjV8z-TYoacrqKB/view Electronic Cigarettes: an Overlooked Tool to Alleviate Disparities in Tobacco Use Disorder Among People with Mental Health and Substance Use Disorders]===&lt;br /&gt;
&lt;br /&gt;
===2023: [https://pubmed.ncbi.nlm.nih.gov/36947193/ Analgesic potential of transdermal nicotine patch in surgery: a systematic review and meta-analysis of randomised placebo-controlled trials]===&lt;br /&gt;
&lt;br /&gt;
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/36857384/ Parkinsonian phenotypes induced by Synphilin-1 expression are differentially contributed by serotonergic and dopaminergic circuits and suppressed by nicotine treatment.] ===&lt;br /&gt;
&lt;br /&gt;
* Information on how nicotine is protective, technical. &lt;br /&gt;
* These results indicate that both the serotonergic and dopaminergic systems contribute to different aspects of PD symptomatology and that nicotine has beneficial effects on specific symptoms.&lt;br /&gt;
* Carvajal-Oliveros A, Dominguez-Baleón C, Sánchez-Díaz I, Zambrano-Tipan D, Hernández-Vargas R, Campusano JM, Narváez-Padilla V, Reynaud E. PLoS One. 2023 Mar 1;18 PMID: 36857384&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.sciencedirect.com/science/article/pii/S027869152300039X?via%3Dihub Tobacco heating system has less impact on bone metabolism than cigarette smoke]===&lt;br /&gt;
&lt;br /&gt;
===2023 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849855/ Effect of nicotine on cholesterol gallstone formation in C57BL/6J mice fed on a lithogenic diet]===&lt;br /&gt;
&lt;br /&gt;
=== The following articles address the possible transmission of the SARS CoV 2 virus (and other pathogens) through vaping exhalations. We show that the latter are extremely weak transmission vehicles. ===&lt;br /&gt;
&lt;br /&gt;
* 2022: [https://link.springer.com/article/10.1007/s11356-022-20499-1 Analytic modeling and risk assessment of aerial transmission of SARS-CoV-2 virus through vaping expirations in shared micro-environments]&lt;br /&gt;
* 2021: [https://doi.org/10.3390/ijerph18041437 Aerial transmission of the SARS-CoV-2 virus through environmental e-cigarette aerosol: implications for public policies.]&lt;br /&gt;
* 2021: [http://doi.org/10.3390/app11146355 Modeling Aerial Transmission of Pathogens (Including the SARS-CoV-2 Virus) through Aerosol Emissions from E-Cigarettes.] &lt;br /&gt;
&lt;br /&gt;
=== 2022: [https://assets.researchsquare.com/files/rs-1062121/v1/fb8f5195-4cce-470f-9e09-e752fae3c931.pdf?c=1642705044 Part One: Abuse Liability of Vuse Solo Relative To Combustible Cigarettes And Nicotine Gum] ===&lt;br /&gt;
&lt;br /&gt;
=== 2014: [https://link.springer.com/chapter/10.1007/978-1-4939-1167-7_20 Nicotinic Receptors and Mental Illness] ===&lt;br /&gt;
&lt;br /&gt;
===2021: [https://pubmed.ncbi.nlm.nih.gov/34757527/ Meta-Analysis on Nicotine&#039;s Modulation of HIV-Associated Dementia]=== &lt;br /&gt;
&lt;br /&gt;
===2012: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286320/ Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats]===&lt;br /&gt;
*Animal&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.sciencedirect.com/science/article/abs/pii/S1001841721007804 Real-time effects of nicotine exposure and withdrawal on neurotransmitter metabolism of hippocampal neuronal cells by microfluidic chip-coupled LC-MS]===&lt;br /&gt;
*mouse study&lt;br /&gt;
&lt;br /&gt;
===2021: [https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006219.pub4/full Interventions for preventing weight gain after smoking cessation]===&lt;br /&gt;
*There was moderate‐certainty that NRT reduced weight at end of treatment and moderate‐certainty that the effect may be similar at 12 months, although the estimates are too imprecise to assess long‐term benefit.&lt;br /&gt;
&lt;br /&gt;
===2004: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
&lt;br /&gt;
* Yet few of the horrendous health effects of smoking are traceable to nicotine itself—cigarettes contain nearly 4,000 other compounds that play a role. Until recently, nicotine research has been driven primarily by nicotine&#039;s unparalleled power to keep people smoking, rather than its potential therapeutic uses.&lt;br /&gt;
* There&#039;s a cheap, common, and mostly safe drug, in daily use for centuries by hundreds of millions of people, that only lately has been investigated for its therapeutic potential for a long list of common ills. The list includes Alzheimer disease, Parkinson disease, depression and anxiety, schizophrenia, attention deficit hyperactivity disorder (ADHD), and even pain and obesity.&lt;br /&gt;
* People with depressive-spectrum disorders, schizophrenia, and adult ADHD tend to smoke heavily, which suggested to researchers that nicotine may soothe their symptoms. Common to all these disorders is a failure of attention, an inability to concentrate on particular stimuli and screen out the rest. Nicotine helps.&lt;br /&gt;
* Researchers at the National Institute on Drug Abuse have shown via functional magnetic resonance imaging that nicotine activates specific brain areas during tasks that demand attention&lt;br /&gt;
* Powledge TM (2004) Nicotine as Therapy. PLoS Biol 2(11): e404. &amp;lt;nowiki&amp;gt;https://doi.org/10.1371/journal.pbio.0020404&amp;lt;/nowiki&amp;gt;&lt;br /&gt;
&lt;br /&gt;
===2021: [https://link.springer.com/article/10.1007/s12640-021-00375-5 Novel Pharmacotherapies in Parkinson’s Disease]===&lt;br /&gt;
&lt;br /&gt;
===2001: [https://today.duke.edu/2001/08/mm_medicaluses.html Medical Uses for Nicotine]===&lt;br /&gt;
&lt;br /&gt;
===2021: [https://pubmed.ncbi.nlm.nih.gov/33675460/ Nicotine gum enhances visual processing in healthy nonsmokers]===&lt;br /&gt;
&lt;br /&gt;
===[https://www.researchgate.net/publication/325159226_Resolution_of_chronic_rhinitis_to_staphylococcus_aureus_in_a_non-smoker_who_started_to_use_glycerine_based_e-cigarettes_Antibacterial_effects_of_vaping Resolution of chronic rhinitis to staphylococcus aureus in a non-smoker who started to use glycerine based e-cigarettes: Antibacterial effects of vaping?]=== &lt;br /&gt;
&lt;br /&gt;
===2019: [https://medium.com/parkinsons-uk/protecting-brain-cells-the-story-of-nicotine-b3b51f5b8259 Protecting brain cells — the story of nicotine]===&lt;br /&gt;
*[https://web.archive.org/web/20221021040501/https://www.parkinsons.org.uk/nicotine-good-bad-and-ugly Nicotine - Good, Bad, Ugly]&lt;br /&gt;
&lt;br /&gt;
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson&#039;s disease]=== &lt;br /&gt;
*Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%.&lt;br /&gt;
*different website same study? [Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease|https://academic.oup.com/ije/article/46/3/872/2656164]&lt;br /&gt;
&lt;br /&gt;
===1986: [https://pubmed.ncbi.nlm.nih.gov/3786334/ Effects of nicotine on finger tapping rate in non-smokers]===&lt;br /&gt;
&lt;br /&gt;
===1996: [https://sci-hub.st/10.1093/oxfordjournals.bmb.a011533 Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious]===&lt;br /&gt;
&lt;br /&gt;
===2020 [https://n.neurology.org/content/neurology/94/20/e2132.full.pdf Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors]=== &lt;br /&gt;
&lt;br /&gt;
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===&lt;br /&gt;
&lt;br /&gt;
=== 2021: [https://www.spektrum.de/news/kognition-nikotin-gegen-neuropsychiatrische-erkrankungen/1924141 Kognition: Nikotin gegen neuropsychiatrische Erkrankungen] (German)  &#039;Cognition: nicotine versus neuropsychiatric disorders&#039; ===&lt;br /&gt;
&lt;br /&gt;
===Dr. Newhouse [http://mindstudy.org/news Mind Study]=== &lt;br /&gt;
&lt;br /&gt;
===2010 [https://pubmed.ncbi.nlm.nih.gov/20414766/ Meta-analysis of the acute effects of nicotine and smoking on human performance] and 2012 [https://n.neurology.org/content/78/2/91.short Nicotine treatment of mild cognitive impairment A 6-month double-blind pilot clinical trial]=== &lt;br /&gt;
*Clinical studies suggest some cognitive improvements as a result of nicotine.&lt;br /&gt;
&lt;br /&gt;
===2021 [https://www.dovepress.com/effectiveness-and-safety-profile-of-alternative-tobacco-and-nicotine-p-peer-reviewed-fulltext-article-JMDH Effectiveness and Safety Profile of Alternative Tobacco and Nicotine Products for Smoking Reduction and Cessation: A Systematic Review]=== &lt;br /&gt;
&lt;br /&gt;
===[https://docs.google.com/document/d/13-D2q1P0KpmZuoFBkKV4l9wUEQ-zcHfp6MAVJGoAaG4/edit?usp=sharing INNCO&#039;s List smoking cessation]=== &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Started: continue @ “Among smokers who have attempted to stop without professional support, those who use e-cigarettes are more likely to report continued abstinence than those who used a licensed NRT products [i.e., nicotine patches, gum or lozenges].”&lt;br /&gt;
https://onlinelibrary.wiley.com/doi/full/10.1111/add.12623&lt;br /&gt;
&lt;br /&gt;
===[https://twitter.com/jkelovuori/status/1413963688709664769 Go through the links in this thread]=== &lt;br /&gt;
&lt;br /&gt;
===To do: Go through the references for nicotine related studies===&lt;br /&gt;
====2020: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404387/ Allosterism of Nicotinic Acetylcholine Receptors: Therapeutic Potential for Neuroinflammation Underlying Brain Trauma and Degenerative Disorders]====&lt;br /&gt;
&lt;br /&gt;
=&#039;&#039;&#039;More Information&#039;&#039;&#039;= &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*[[Special:MyLanguage/Nicotine Studies|&#039;&#039;&#039;List of researchers&#039;&#039;&#039;]] studying nicotine / tobacco harm reduction&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*If you&#039;d prefer someone else to add a study to a topic, there is a &amp;quot;topic&amp;quot; called &amp;quot;Suggested studies to add to this page&amp;quot;. You may put the link in that section for one of the regular page editors to address.&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
*&#039;&#039;&#039;PAGE EDITORS - Please only add Studies, Surveys, Papers in this format to keep page consistent for all viewers.&#039;&#039;&#039;&lt;br /&gt;
**Topic&lt;br /&gt;
**Note here if animal study (leave blank if not)&lt;br /&gt;
**Year (list new to old) Name of Study (In link format to the study)&lt;br /&gt;
**Brief Summary&lt;br /&gt;
**Link to PDF Version&lt;br /&gt;
**Citation&lt;br /&gt;
**Acknowledgements (funded by, helped by)&lt;br /&gt;
**Keywords&lt;br /&gt;
**Other&lt;br /&gt;
[[Category:Studies, Surveys, and Papers]]&lt;br /&gt;
[[Category:THR product]]&lt;br /&gt;
[[Category:THR Stories]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78385</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=78385"/>
		<updated>2025-01-26T16:45:19Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (probably an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was initially supposed to be a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thanks! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=77846</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=77846"/>
		<updated>2025-01-01T15:43:24Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (probably an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). &lt;br /&gt;
&lt;br /&gt;
See Also: &#039;&#039;&#039;[[snw:index.php/Nicotine_/_THR_-_Statements_from_Experts|Commentary from experts]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thanks! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=77844</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=77844"/>
		<updated>2024-12-31T19:28:18Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|left|frameless|100x100px|Newspaper icon]]&lt;br /&gt;
&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (probably an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). See Also: &#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Experts Commentary from experts]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thanks! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar PV with battery storage.|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=77723</id>
		<title>Main Page</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=Main_Page&amp;diff=77723"/>
		<updated>2024-12-29T15:34:01Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: Test edit&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;languages/&amp;gt;&lt;br /&gt;
&amp;lt;translate&amp;gt;&lt;br /&gt;
[[File:98944120-A897-4072-B461-4423B907E527-snw.png|alt=The safer nicotine wiki logo, a book open in a library, and a computer screen showing the nicotine molecule|center|thumb|Safer nicotine Wiki logo]]&lt;br /&gt;
&lt;br /&gt;
== Information on Tobacco Harm Reduction (THR), Nicotine, and safer alternatives to using combustible cigarettes ==&lt;br /&gt;
We aim to provide information for interested members of the public (remember you are the &#039;public&#039; in public health). This might include consumers, scientists and researchers, health workers, medical doctors, regulators, and journalists. Most of the time papers link directly to the original science, often on government servers, we aim to provide useful summaries/comment where possible as a guide, we encourage you to read the full paper if you wish.  &lt;br /&gt;
== Finding Balance ==&lt;br /&gt;
In 2021, the American Journal of Public Health published the paper &amp;quot;[https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2021.306416 Balancing Consideration of the Risks and Benefits of E-Cigarettes].&amp;quot; It was written by 15 past presidents of the Society for Nicotine and Tobacco Research (SRNT). SRNT is the main global professional society for researchers who focus on nicotine and tobacco. Its mission is &amp;quot;...to stimulate the generation and dissemination of new knowledge concerning nicotine in all its manifestations - from molecular to societal.&amp;quot; The paper discussed the contentious debate about tobacco harm reduction, with a focus on e-cigarettes. &lt;br /&gt;
&lt;br /&gt;
Around the world, limits are being placed on people who use THR products to help themselves stop smoking. There are many reasons for over-regulating and outright banning reduced-risk products. They include a moral panic over youth use, a false belief that THR products are a gateway to smoking, stigma about using nicotine, misinformation, click-bait media articles, and science riddled with methodological flaws (To learn more about these issues, please search this website). This is adversely affecting people&#039;s ability to save their own lives and improve their health by quitting smoking or preventing a return to smoking. &lt;br /&gt;
&lt;br /&gt;
If after exploring the Safer Nicotine Wiki you feel compelled to help consumers in their efforts to have access to safer alternatives to combustible tobacco, please see our [https://safernicotine.wiki/mediawiki/index.php/Advocating_For_Tobacco_Harm_Reduction &#039;&#039;&#039;Advocating For Tobacco Harm Reduction&#039;&#039;&#039;] page, which contains calls to action you can assist with. While some of our volunteers may fill an advocacy role outside of their efforts on the Safer Nicotine Wiki, we do not participate in or endorse/oppose any regulations as a group. It is outside our mission. We&#039;re here for educational purposes only. That information may include studies showing the outcomes of some regulations because it is always important to look at the goals and tradeoffs of any policy. &lt;br /&gt;
&lt;br /&gt;
== [[Tobacco Harm Reduction News]] ==&lt;br /&gt;
[[File:Noun Newspaper 154015.svg|frameless|150x150px|Newspaper icon|left]]&lt;br /&gt;
==== The Latest News on THR, Vaping and Safer Nicotine ====&lt;br /&gt;
[[Tobacco Harm Reduction News|Here]] you will find the latest news and links to news about all nicotine products, regulations, and etc.  &lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
&amp;lt;br&amp;gt;&lt;br /&gt;
----&lt;br /&gt;
__TOC__&lt;br /&gt;
&lt;br /&gt;
== How to explore: ==&amp;lt;!--T:20--&amp;gt;&lt;br /&gt;
See the [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]], or use the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] (Tip: add ~ to the end of e.g. colour~ to find alternate (international) spellings) or the search box in the top right corner.&lt;br /&gt;
&lt;br /&gt;
There is also a list of [[:Category:FAQ Question|&#039;&#039;&#039;FAQ Questions&#039;&#039;&#039;]] that may be interesting. And a [[:Category:FAQ list|&#039;&#039;&#039;lists of FAQ questions from various other organizations&#039;&#039;&#039;]],&lt;br /&gt;
&lt;br /&gt;
There is this list of categories: &#039;&#039;&#039;[[Guide to Main Categories]]&#039;&#039;&#039;, find your local vaping organisation &#039;&#039;&#039;[[Links|List of orgs]]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
= What is this? = &amp;lt;!--T:6--&amp;gt;&lt;br /&gt;
This [[Wiki]] has been assembled by a team of keen volunteers, free of [[Special:MyLanguage/funding|funding]] from any industry (tobacco or otherwise) source. If you would like to contribute to the expansion and evolution of this resource, please see the how to contribute section below. Remember: respected sources only please.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:19--&amp;gt;&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please sign up for an account if you can help. We can be contacted at the email below, please include your username when contacting us. &lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:7--&amp;gt;&lt;br /&gt;
=A few important questions are answered here without having to access the main menu:=&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:8--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Safe or Safer?|Safe or Safer?]]&#039;&#039;&#039; Briefly, nothing is absolutely safe, but as the products continually evolve they become safer. [[Special:MyLanguage/Nicotine Replacement Therapy|Nicotine Replacement Therapy]] products such as [[Special:MyLanguage/Transdermal patch|patches]], [[Special:MyLanguage/Nicotine Chewing gum|gums]], [[Special:MyLanguage/Nicotine sprays|sprays]], and inhalers are substantially less than 1% as risky as smoking. Non-pharmaceutical nicotine products can also pose a fraction of the risk of smoking, e.g. [[Special:MyLanguage/Snus|Snus]] (approximately 1%), [[Special:MyLanguage/What are electronic cigarettes?| E-Cigarettes]] (less than 5%), and Heat not Burn (approximately 10%). These estimates become ever more refined as increasing numbers of research studies are published. Beyond the debate about nicotine tied to smoking and products used to quit smoking, science is also looking at potential [[Nicotine therapeutic benefits|therapeutic benefits of nicotine]].&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:9--&amp;gt;&lt;br /&gt;
Links here for debunking myths [[Special:MyLanguage/Myth Busting|Myth Busting]] provides links to info on anti nicotine claims and how to correct them.  &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Quit Aid|Quit Aid]]&#039;&#039;&#039;&lt;br /&gt;
The most frequently-used method to quit tobacco is &#039;cold turkey&#039;, i.e. unaided, but this has a greater failure rate than perhaps all others. It is very difficult to attribute a precise figure towards popular quit methods such as [[Special:MyLanguage/NRT|NRT]], [[Special:MyLanguage/Varenicline|Varenicline]] (various trade names), Allen Carr, hypnotherapy, [[Special:MyLanguage/snus|snus]] etc., as the usual medical standard of proof, the [[wikipedia:Randomized controlled trial| Randomised Controlled Trial]], doesn&#039;t really cover certain options such as [[Special:MyLanguage/e-cigarettes|e-cigarettes]] adequately (as choices of all various combinations of flavour choice, nicotine strength, and device type are impossible to include). However, [https://www.nejm.org/doi/full/10.1056/nejmoa1808779 a recent RCT] demonstrated that e-cigarettes were twice as effective as NRT for cessation (probably an underestimate of real world results). &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
Like who knew the [[Special:MyLanguage/Pez dispenser|Pez dispenser]] was a quit aid?&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:10--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Health Improvements|Health Improvements]]&#039;&#039;&#039; Virtually everyone who used a safer nicotine product to quit cigarettes completely experiences profound improvement in their health, e.g. improved breathing and cardiovascular benefits. This is possibly due to totally removing the previous inhalation of carbon monoxide from the tobacco cigarette. [[Special:MyLanguage/Asthma|Asthma]] and [[Special:MyLanguage/Copd|COPD]] patients have shown great recovery, see [[Special:MyLanguage/Health Improvements|Health Improvements]] &lt;br /&gt;
 &lt;br /&gt;
&#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Organizations Commentary from respected sources]&#039;&#039;&#039; Many governments around the world recognise that Safer Nicotine Products offer benefits, along with respected organisations such as [[Special:MyLanguage/Public Health England|Public Health England]], [[Special:MyLanguage/Royal College of Physicians|Royal College of Physicians]], [[Special:MyLanguage/Cochrane|Cochrane]], and [[Special:MyLanguage/NASEM|NASEM]] (US). See Also: &#039;&#039;&#039;[https://safernicotine.wiki/mediawiki/index.php/Nicotine_/_THR_-_Statements_from_Experts Commentary from experts]&#039;&#039;&#039;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:11--&amp;gt;&lt;br /&gt;
&#039;&#039;&#039;[[Special:MyLanguage/Cost Savings|Cost Savings]]&#039;&#039;&#039;&lt;br /&gt;
Vast savings are experienced; this is quite underappreciated by some members of the general public. It would be a gross underestimate to state that a 50% reduction in spending would be experienced by anyone who completely switches. For some users who make their own liquids and manufacture their own coils, costs can be less than 1% of what they would have incurred when smoking.  &lt;br /&gt;
&lt;br /&gt;
==== Our [[DIY]] page lists details and has links to important safety information, particularly for those new to making their own liquid. It also provides basic information on safe operation of vaping devices. ====&amp;lt;!--T:12--&amp;gt;&lt;br /&gt;
Don&#039;t forget the list of [[Special:AllPages|&#039;&#039;&#039;List of all pages&#039;&#039;&#039;]] if you can&#039;t find what you are looking for, try the [[Special:Search|&#039;&#039;&#039;Search page&#039;&#039;&#039;]] &lt;br /&gt;
&lt;br /&gt;
= How to Contribute = &amp;lt;!--T:13--&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== Find your local vaping group or organisation here: [[Links|List of Tobacco Harm Reduction and Vaping Groups, worldwide]]. ===&amp;lt;!--T:14--&amp;gt;&lt;br /&gt;
Please sign up for an account, you will need to verify your email address, you can then start editing after a short delay, please see the [[How to edit the wiki]] page for full details.  If you use a screen reader and e.g. captchas are a problem, please email us and we will accommodate where possible. &lt;br /&gt;
&lt;br /&gt;
We are looking for volunteers to translate the wiki into different languages, please [[Special:CreateAccount|sign up]] for an account, if you can help.  &lt;br /&gt;
&lt;br /&gt;
If you already have an account, you should be able to promote yourself to a translator, click the link in the sidebar menu or [[Special:TranslatorSignup|TranslatorSignup]]. To do this requires a verified email address, that you have completed some (currently 3) edits elsewhere on the site, and your account is not brand new. If you have difficulty or would like to be promoted manually, please email us at [mailto:Info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
We will accept documents if you prefer to write them in word (.doc(x)), or open document format (.odf) or PDF (.pdf). please include you name for attribution, unless you wish to remain anonymous. Please let you know any info you would like included for attribution etc. emails may be sent to the address above. We apologize, but it may take some time to add submitted information. Note: several people monitor the email address please include a ref. to any previous communication so that we can find it. Thanks! &lt;br /&gt;
&lt;br /&gt;
== Looking for something to edit? Try [[:Category:All stub articles]] for pages that need your input! == &lt;br /&gt;
Or click any red link to create that page! Try searching and if there is no page already, you can create one from the search results page. &lt;br /&gt;
&lt;br /&gt;
=Get in touch=&lt;br /&gt;
&amp;lt;!--T:15--&amp;gt;&lt;br /&gt;
Please email [mailto:info@safernicotine.wiki info@safernicotine.wiki]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--T:16--&amp;gt;&lt;br /&gt;
Please do not email asking to use our page authors work, that right is already granted by our licence CC-BY-SA, see the link at the bottom of the page.  &lt;br /&gt;
&lt;br /&gt;
Twitter [https://twitter.com/SaferWiki @SaferWiki]&lt;br /&gt;
&lt;br /&gt;
== Maintenance ==&lt;br /&gt;
&lt;br /&gt;
Please note every Sunday from 10:00 to 21:00 the site will be undergoing maintenance, disruption will be kept to a minimum but it might be slow or unavailable for a time due to database optimizations.  Thank you for understanding. &lt;br /&gt;
&amp;lt;/translate&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:Solar energy icon.png|alt=Powered by Solar icon (we also use battery storage)|left|thumb|Powered by Solar PV with battery storage.]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
	<entry>
		<id>https://safernicotine.wiki/mediawiki/index.php?title=MHRA_yellow_card&amp;diff=77668</id>
		<title>MHRA yellow card</title>
		<link rel="alternate" type="text/html" href="https://safernicotine.wiki/mediawiki/index.php?title=MHRA_yellow_card&amp;diff=77668"/>
		<updated>2024-12-18T13:27:01Z</updated>

		<summary type="html">&lt;p&gt;Richardpruen: fix cat&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;[[File:Yellow card.svg|alt=yellow card icon|thumb|yellow card icon]]&lt;br /&gt;
&lt;br /&gt;
== The MHRA ==&lt;br /&gt;
The [https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency Medicines and Healthcare products Regulatory Agency (MHRA)] is the executive Agency of the Department of Health and Social Care that acts on behalf of the Ministers to protect and promote public health and patient safety, by ensuring that healthcare products meet appropriate standards of safety, quality and efficacy. We keep watch over medicines and devices, and take necessary action to protect the public promptly if there is a problem.&lt;br /&gt;
&lt;br /&gt;
Speak to your doctor, pharmacist or to call [[Tel:111|NHS 111]] if you are worried about your health as the MHRA is unable to provide medical advice.&lt;br /&gt;
&lt;br /&gt;
== The Yellow Card scheme ==&lt;br /&gt;
The MHRA runs the Yellow Card scheme, which collects and monitors information on suspected safety concerns involving a healthcare products, like a side effect with a medicine or an adverse medical device incident. The scheme relies on voluntary reporting of problems to a healthcare product by the public (including patients, parents and carer givers) as well as from healthcare professionals. The scheme also collects suspected safety concerns involving defective (not of an acceptable quality), falsified or fake healthcare products.&lt;br /&gt;
&lt;br /&gt;
== Healthcare products ==&lt;br /&gt;
Always read the patient information leaflet, or instructions supplied with your medicine or medical device. It lists the known side effects or problems and advises you on what to do. You can report safety issues from any healthcare product to the Yellow Card scheme. Healthcare products include:&lt;br /&gt;
&lt;br /&gt;
* Medicines&lt;br /&gt;
* Vaccines&lt;br /&gt;
* Blood factor and immunoglobulin products&lt;br /&gt;
* Herbal products or complementary therapies such as homeopathies&lt;br /&gt;
* Medical devices (including software, apps and artificial intelligence)&lt;br /&gt;
* E-cigarettes including their refill containers (e-liquids)&lt;br /&gt;
&lt;br /&gt;
More information on the types of reports for these healthcare products can be found [https://yellowcard.mhra.gov.uk/resources/reporttypes here.]&lt;br /&gt;
&lt;br /&gt;
== Aims of the scheme ==&lt;br /&gt;
It is important for people to report problems experienced with healthcare products as these are used to identify issues which might not have been previously known about. The purpose of the Yellow Card scheme is to provide an early warning that the safety of a product may require more further investigation. The scheme helps the MHRA monitor the safety of all healthcare products in the UK to ensure they are acceptably safe for patients and users. Reports are used alongside other safety information and help the MHRA to take action if any trends associated to the safety or efficacy of a healthcare product are identified. The MHRA will review the issue and if necessary, take action to minimise risk and maximise benefit to the patients.&lt;br /&gt;
&lt;br /&gt;
== Latest details on E-Cigarettes ==&lt;br /&gt;
[[File:Electronic Cigarette Drug Analysis Print up to 30.09.2022.pdf|alt=Report on all adverse events reported by the yellow card scheme|none|thumb|Report on all adverse events reported by the yellow card scheme]]{{Stub}}&lt;br /&gt;
[[Category:THR Stories]]&lt;br /&gt;
[[Category:THR product]]&lt;br /&gt;
[[Category:Smoking cessation]]&lt;/div&gt;</summary>
		<author><name>Richardpruen</name></author>
	</entry>
</feed>